PT J
AU Lan, XC
   Li, J
   Zhou, GS
   Wei, W
AF Lan, Xiaochun
   Li, Jun
   Zhou, Guisheng
   Wei, Wei
TI Study on the mechanism of acupuncture combined with massage therapy in improving waist flexion range and relieving pain in patients with chronic lumbago and leg pain
SO INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE
LA English
DT Article
DE Chronic lumbago and leg pain; acupuncture; massage reduction; combination therapy; waist flexion; pain
ID low-back-pain; management; mobilization
AB This study aimed to explore the mechanism of acupuncture combined with massage reduction in improving waist flexion range and relieving pain in patients with chronic lumbago and leg pain. In total, 93 patients with chronic lumbago and leg pain in our hospital were divided into two groups according to the treatment methods. Group A received conventional drug therapy and group B received acupuncture combined with massage reduction in addition to treatment of group A. The efficacy, waist flexion range, modified Japanese Orthopaedic Association (M-JOA) score rating system for low back disorders, modified Oswestry disability index (ODI), visual analog scale (VAS), and inflammatory factors were compared before and after treatment. After treatment, the lumbar curvature, waist flexion range, M-JOA, ODI, VAS scores, tumor necrosis factor-alpha (TNF-alpha) and interleukin-6 (IL-6) in group B were superior to group A (P < 0.05). Acupuncture combined with massage reduction in patients with chronic lumbago and leg pain is beneficial to further improve the clinical efficacy.
C1 [Lan, Xiaochun; Li, Jun; Zhou, Guisheng] Guangxi Med Univ, Dept Rehabil Med, Wuming Hosp, Nanning 530199, Guangxi, Peoples R China.
   [Wei, Wei] Guangxi Med Univ, Dept Orthopaed, Wuming Hosp, 26 Yongning Rd, Nanning 530199, Guangxi, Peoples R China.
C3 Guangxi Medical University; Guangxi Medical University
RP Wei, W (corresponding author), Guangxi Med Univ, Dept Orthopaed, Wuming Hosp, 26 Yongning Rd, Nanning 530199, Guangxi, Peoples R China.
EM pjcnkj@163.com
CR Alfuth M, 2016, ORTHOPADE, V45, P579, DOI 10.1007/s00132-016-3233-1
   Almeida M, 2018, MED J AUSTRALIA, V208, P272, DOI 10.5694/mja17.01152
   Alrwaily M, 2016, PHYS THER, V96, P1057, DOI 10.2522/ptj.20150345
   Anheyer D, 2017, ANN INTERN MED, V166, P799, DOI 10.7326/M16-1997
   Baron R, 2016, EUR J PAIN, V20, P861, DOI 10.1002/ejp.838
   Cook CE, 2018, BRIT J SPORT MED, V52, P493, DOI 10.1136/bjsports-2017-098352
   Costa T, 2018, ACTA REUMATOL PORT, V43, P172
   da Silva T, 2017, J ORTHOP SPORT PHYS, V47, P305, DOI 10.2519/jospt.2017.7415
   Du SZ, 2017, PATIENT EDUC COUNS, V100, P37, DOI 10.1016/j.pec.2016.07.029
   Hartvigsen J, 2018, LANCET, V391, P2356, DOI 10.1016/S0140-6736(18)30480-X
   Jonckheer P, 2018, REV MED LIEGE, V73, P114
   Liu L, 2018, ARCH PHYS MED REHAB, V99, P144, DOI 10.1016/j.apmr.2017.06.008
   MacDonald J, 2017, JAMA PEDIATR, V171, P280, DOI 10.1001/jamapediatrics.2016.3334
   Melcher C, 2018, Z ORTHOP UNFALLCHIR, V156, P554, DOI 10.1055/a-0586-4815
   Morsley K, 2018, MUSCULOSKELET CARE, V16, P13, DOI 10.1002/msc.1193
   Nelson NL, 2016, J BODYW MOV THER, V20, P672, DOI 10.1016/j.jbmt.2016.04.018
   OSullivan PB, 2018, PHYS THER, V98, P408, DOI 10.1093/ptj/pzy022
   Pourahmadi MR, 2018, CLIN REHABIL, V32, P1289, DOI 10.1177/0269215518778321
   Puentedura EJ, 2016, PHYSIOTHER THEOR PR, V32, P408, DOI 10.1080/09593985.2016.1194663
   Sallehuddin SM, 2018, BMC WOMENS HEALTH, V18, P0, DOI 10.1186/s12905-018-0597-x
   Sanzarello I, 2016, J BACK MUSCULOSKELET, V29, P625, DOI 10.3233/BMR-160685
   Sehmbi H, 2017, GYNECOL OBSTET INVES, V82, P417, DOI 10.1159/000471764
   Shi ZJ, 2018, AM J PHYS MED REHAB, V97, P116, DOI 10.1097/PHM.0000000000000801
   Urits I, 2019, CURR PAIN HEADACHE R, V23, P0, DOI 10.1007/s11916-019-0757-1
   van Dieën JH, 2017, EXERC SPORT SCI REV, V45, P223, DOI 10.1249/JES.0000000000000121
   Will JS, 2018, AM FAM PHYSICIAN, V98, P421
   Yamato TP, 2016, SPINE, V41, P1013, DOI 10.1097/BRS.0000000000001398
   Yu Y, 2019, EXP THER MED, V18, P4363, DOI 10.3892/etm.2019.8073
NR 28
TC 0
Z9 0
U1 0
U2 10
PU E-CENTURY PUBLISHING CORP
PI MADISON
PA 40 WHITE OAKS LN, MADISON, WI 53711 USA
SN 1940-5901
EI 
J9 INT J CLIN EXP MED
JI Int. J. Clin. Exp. Med.
PD JUN 15
PY 2020
VL 13
IS 6
BP 4166
EP 4172
DI 
PG 7
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA MG5HE
UT WOS:000546062300048
DA 2026-01-16
ER

PT J
AU Ang, JY
   Bhojwani, K
   Chan, HK
   Chan, AC
AF Ang, Ju-Ying
   Bhojwani, Kavita
   Chan, Huan-Keat
   Chan, Ai-Chen
TI A Malaysian retrospective study of acupuncture-assisted anesthesia in breast lump
SO Acupuncture in medicine : journal of the British Medical Acupuncture Society
LA English
DT Journal Article
DE acupuncture; anesthesia; electroacupuncture, breast lump excision, retrospective study
AB INTRODUCTION: The objective of this retrospective study was to evaluate the  effectiveness and safety of acupuncture-assisted anesthesia (AAA) in breast lump  excision. METHODS: The medical records of all patients who underwent breast lump  excision under AAA in combination with electrical stimulation at traditional  acupuncture points in 2016 were examined. All of them (n = 17) received  electrostimulation (2-4 Hz) using single needles inserted at bilateral LI4 and  PC6. They also underwent insertion of four acupuncture needles at the lump site,  which were electrically stimulated at 30 Hz frequency. RESULTS: All surgical  procedures were successful with minimal use of analgesics and local anesthetic.  The median pain score reported was 1/10 (interquartile range (IQR) = 2/10) at the  first hour, and slightly increased to 2/10 (IQR = 2/10) between 24 and 48 h of  the surgery. No major postoperative adverse events were documented, except for  drowsiness in one case. CONCLUSION: AAA was found to be generally safe and  effective for anaesthesia and analgesia in breast lump excision. However, a  large-scale randomized controlled study is required to verify the findings.
C1 Clinical Research Centre, Hospital Raja Permaisuri Bainun, Ministry of Health, Malaysia.
   Department of Anaesthesiology and Intensive Care, Hospital Raja Permaisuri Bainun, Ministry of Health, Malaysia.
   Clinical Research Centre, Hospital Sultanah Bahiyah, Ministry of Health, Malaysia.
   Department of Surgery, Hospital Raja Permaisuri Bainun, Ministry of Health, Malaysia.
NR 0
TC 0
SN 1759-987
EI 
J9 Acupunct Med
PD JUN 17
PY 2020
VL 39
IS 1
BP 64
EP 68
DI 10.1177/0964528420920307
PG 4
WC Acupuncture Analgesia; Acupuncture Points; Adult; Aged; Aged, 80 and over; Breast Neoplasms; surgery; Electroacupuncture; Female; Humans; Malaysia; Middle Aged; Retrospective Studies
UT PubMed:32539426
PM 32539426
DA 2020-06-17
ER

PT J
AU Dommerholt, J
   Thorp, JN
   Chou, LW
   Hooks, T
AF Dommerholt, Jan
   Thorp, Jacob N
   Chou, Li-Wei
   Hooks, Todd
TI A critical overview of the current myofascial pain literature - January 2020.
SO Journal of bodywork and movement therapies
LA English
DT Editorial
DE Dry needling; Manual therapy; Myofascial pain syndrome; Trigger points
AB We are starting 2020 with 6 basic research studies, 9 review articles, 14 dry  needling/injection studies, and one manual therapy paper for a total of 30 new  papers. Topics range from studies on mechanisms, inflammatory mediators in  myofascial pain, fascia, screening, Platelet-rich plasma intramuscular  injections, and temporal summation to clinical studies on patients with  tension-type headache, chronic pelvic pain, knee osteoarthritis, plantar  fasciitis, generalized musculoskeletal pain, neck pain, breast cancer,  tendinopathies, thoracic outlet syndrome, and canine dry needling, among others.
C1 Bethesda Physiocare, Bethesda, MD, USA
   Myopain Seminars, Bethesda, MD, USA. 
   Myopain Seminars, Bethesda, MD, USA
   Charleston Southern University, North Charleston, SC, USA. 
   China Medical University, Taichung, Taiwan. 
   Myopain Seminars, Bethesda, MD, USA
   New Orleans Pelicans, New Orleans, LA, USA.
EM trhooks@hotmail.com
NR 0
TC 0
SN 1532-928
EI 
J9 J Bodyw Mov Ther
PD JUN 9
PY 2020
VL 24
IS 2
BP 213
EP 224
DI 10.1016/j.jbmt.2020.04.001
PG 11
WC Acupuncture Therapy; Animals; Dogs; Humans; Musculoskeletal Manipulations; Myofascial Pain Syndromes; therapy; Neck Pain; Trigger Points
UT PubMed:32507147
PM 32507147
DA 2020-06-09
ER

PT J
AU Contim, CLV
   Santo, FHD
   Moretto, IG
AF Venancio Contim, Carolina Lelis
   do Espirito Santo, Fatima Helena
   Moretto, Isadora Gorski
TI Applicability of auriculotherapy in cancer patients: an integrative literature review
SO REVISTA DA ESCOLA DE ENFERMAGEM DA USP
LA English
DT Review
DE Complementary Therapies; Auriculotherapy; Acupuncture; Ear; Neoplasms; Oncology Nursing; Review
ID auricular point acupressure; randomized controlled-trial; chemotherapy; constipation; sleep
AB Objective: To analyze scientific evidence in the literature on the use of auriculotherapy to relieve symptoms related to cancer and/or its treatment. Method: An integrative literature review based on: MEDLINE, CINAHL, LILACS, SCOPUS and COCHRANE in the last five years in English, Portuguese and Spanish. Inclusion criteria: primary studies with the central theme. Exclusion criteria: opinion articles, reviews and experience reports. Results: The search resulted in 435 publications, but only 11 remained after applying four selection stages. An analysis of the study designs showed that three of them (27.5%) had a high level of evidence, three (27.5%) had moderate, four (36%) had low and one (9%) had a very low level. The evaluated outcomes were related to the following symptoms: pain, constipation, nausea and vomiting, hot flashes, dyspnea, fatigue and insomnia. Moreover, 100% of the publications exposed positive effects of auriculotherapy in oncology. Conclusion: Auriculotherapy in cancer patients improves symptoms, and this practice was considered a safe and acceptable intervention. However, it is necessary to expand studies to obtain more favorable evidence since only 3 studies presented a high level of evidence.
C1 [Venancio Contim, Carolina Lelis; Moretto, Isadora Gorski] Inst Nacl Canc INCA, Rio De Janeiro, RJ, Brazil.
   [do Espirito Santo, Fatima Helena] Univ Fed Fluminense, Escola Enfermagem Aurora de Afonso Costa, Dept Enfermagem Med Cirurg, Niteroi, RJ, Brazil.
C3 National Cancer Institute (Inca); Universidade Federal Fluminense
RP Contim, CLV (corresponding author), Rua Mariz & Barros 840,Cobertura 02, BR-20270002 Rio De Janeiro, RJ, Brazil.
EM carolina.lelis@yahoo.com.br
CR Bonassa E MA, 2012, TERAPEUTICA ONCOLOGICA PARA ENFERMEIROS E FARMACEUTICOS, V4a, P0
   Costa TC, 2015, REV ESC ENFERM USP, V49, P332, DOI 10.1590/S0080-623420150000200020
   Curtinaz ML, 2017, REVISTA ESPAÇO CIÊNCIA & SAÚDE, V5, P4
   de Souza MT, 2010, EINSTEIN-SAO PAULO, V8, P102, DOI 10.1590/S1679-45082010RW1134
   do Prado JM, 2018, REV ESC ENFERM USP, V52, P0, DOI 10.1590/S1980-220X2017030403334
   Eghbali M, 2016, COMPLEMENT THER CLIN, V24, P189, DOI 10.1016/j.ctcp.2016.06.006
   Galvao TF, 2015, EPIDEMIOL SERV SAUDE, V24, P173
   Hanai A, 2016, BREAST CANCER RES TR, V155, P99, DOI 10.1007/s10549-015-3652-4
   Hughes JG, 2015, EUR J INTEGR MED, V7, P623, DOI 10.1016/j.eujim.2015.08.003
   Instituto Nacional de Cancer Jose Alencar Gomes da Silva, 2018, EST 2018 INC CANC BR, V0, P0
   Instituto Nacional de Cancer Jose Alencar Gomes da Silva, 2017, ABC CANC AB BAS CONT, V0, P0
   Kuo HC, 2018, RES NURS HEALTH, V41, P469, DOI 10.1002/nur.21885
   Li Y, 2017, J CANCER RES THER, V13, P844, DOI 10.4103/jcrt.JCRT_709_17
   Luz Madel T, 2005, PHYSIS, V15, P145
   Lyman GH, 2018, J CLIN ONCOL, V36, P2647, DOI 10.1200/JCO.2018.79.2721
   Mendes Karina Dal Sasso, 2008, TEXTO CONTEXTO - ENFERM., V17, P758
   Ministerio da Saude (BR), 2015, POL NAC PRAT INT COM, V0, P0
   Polit DF, 2019, FUNDAMENTOS DE PESQUISA EM ENFERMAGEM: AVALIACAO DE EVIDENCIAS PARA A PRATICA DA ENFERMAGEM, V0, P0
   Shin J, 2018, WESTERN J NURS RES, V40, P67, DOI 10.1177/0193945916680362
   Strong RA, 2016, J PALLIAT MED, V19, P556, DOI 10.1089/jpm.2015.0347
   Tan JY, 2014, EVID-BASED COMPL ALT, V2014, P0, DOI 10.1155/2014/506758
   Telesi Júnior Emílio, 2016, ESTUD. AV., V30, P99, DOI 10.1590/s0103-40142016.00100007
   Ursi Elizabeth Silva, 2006, REV. LATINO-AM. ENFERMAGEM, V14, P124
   Viel E, 2016, CLIMACTERIC, V19, P274, DOI 10.3109/13697137.2016.1164135
   Yeh CH, 2017, ONCOL NURS FORUM, V44, P476, DOI 10.1188/17.ONF.476-487
   Yeh CH, 2016, CANCER NURS, V39, P402, DOI 10.1097/NCC.0000000000000303
   Yeh CH, 2015, PAIN MANAG NURS, V16, P285, DOI 10.1016/j.pmn.2014.08.005
   Yeon Shin， Na, 2018, KOREAN JOURNAL OF ADULT NURSING, V0, P0
NR 28
TC 8
Z9 12
U1 2
U2 29
PU UNIV SAO PAOLO
PI CERQUERA CESAR
PA AV  DR ENEAS DE CARVALHO AGUIAR, 419, CERQUERA CESAR, SP 05403-000, BRAZIL
SN 0080-6234
EI 1980-220X
J9 REV ESC ENFERM USP
JI Rev. Esc. Enferm. USP
PD JUN 15
PY 2020
VL 54
IS 
BP 
EP 
DI 10.1590/S1980-220X2019001503609
PG 12
WC Nursing
SC Nursing
GA NK4FA
UT WOS:000566686800001
PM 32901659
DA 2026-01-16
ER

PT J
AU Tai, JB
   Hong, L
   Ma, ME
   Xu, J
   Fang, JQ
   Jiang, YQ
AF Tai, Jia-Bin
   Hong, Liang
   Ma, Meng-En
   Xu, Jia
   Fang, Jian-Qiao
   Jiang, Yi-Qian
TI Evaluation of therapeutic effect of transcutaneous electrical acupoint
SO Annals of palliative medicine
LA English
DT Journal Article
DE Transcutaneous acupoint electrical stimulation; cancerous pain; clinical research; immunity; tumor
AB BACKGROUND: This study aimed to observe the effect of transcutaneous electrical  acupoint stimulation (TEAS) on bone metastasis pain, anxiety and immune function  in cancer patients. METHODS: A total of 127 patients with bone metastasis pain  from malignant tumors were treated with TEAS or drugs. The TEAS group comprised  of 62 patients, while the drug control group comprised of 65 patients. The  differences in general indexes, baseline pain and anxiety between these two  groups were not statistically significant. RESULTS: Compared with those before  treatment, the visual analog scale (VAS) scores of patients in the TEAS group and  drug control group decreased after treatment, and the differences were  statistically significant. The degrees of pain relief after treatment were  similar between the two groups. Anxiety improved in both the TEAS group and drug  control group, and the difference between these two groups was not statistically  significant. The differences in immune indexes, B cell and CD8 between the TEAS  group and drug control group were statistically significant. TEAS treatment could  improve the declining trend of CD8 in patients. CONCLUSIONS: TEAS treatment and  drug treatment can effectively alleviate mild to moderate pain in patients, and  the efficacy of these two groups is similar. The treatment for moderate and  severe pain needs to be combined with drug treatment to achieve a control effect.  TEAS can improve the anxiety and immune function of patients, and prevent the  decrease in B cells and CD8 in patients treated with drugs alone.
C1 Internal Medicine-Oncology, Xiaoshan First Hospital Affiliated to Medical College of Hangzhou Normal University, Hangzhou, China.
   Internal Medicine-Oncology, Xiaoshan First Hospital Affiliated to Medical College of Hangzhou Normal University, Hangzhou, China.
   Internal Medicine-Oncology, Xiaoshan First Hospital Affiliated to Medical College of Hangzhou Normal University, Hangzhou, China.
   Internal Medicine-Oncology, Xiaoshan First Hospital Affiliated to Medical College of Hangzhou Normal University, Hangzhou, China.
   Zhejiang University of Traditional Chinese Medicine, Hangzhou, China.
   Internal Medicine-Oncology, Xiaoshan First Hospital Affiliated to Medical College of Hangzhou Normal University, Hangzhou, China. yiqian9988@163.com.
NR 0
TC 0
SN 2224-583
EI 
J9 Ann Palliat Med
PD SEP 22
PY 2020
VL 9
IS 5
BP 2538
EP 2544
DI 10.21037/apm-19-434
PG 6
WC Acupuncture Points; Cancer Pain; therapy; Humans; Immunity; Pain Management; Transcutaneous Electric Nerve Stimulation
UT PubMed:32954744
PM 32954744
DA 2020-09-22
ER

PT J
AU Pan, YQ
   Yong, T
   Liang, HQ
   Gen, C
   Shen, XP
   Dong, J
   Qi, C
   Qi, MM
AF Yuanqing, Pan
   Yong, Tang
   Haiqian, Liang
   Gen, Chen
   Shen, Xiping
   Dong, Jin
   Qi, Cui
   Miaomiao, Qi
TI Acupuncture for Hormone Therapy-Related Side Effects in Breast Cancer Patients: A GRADE-Assessed Systematic Review and Updated Meta-Analysis
SO INTEGRATIVE CANCER THERAPIES
LA English
DT Review
DE breast cancer; acupuncture; meta-analysis; alternative therapy; GRADE
ID myofascial trigger points; controlled-trial; hot flashes; vasomotor symptoms; applied relaxation; joint symptoms; women; electroacupuncture; fatigue; chemotherapy
AB Purpose:To determine the efficacy of acupuncture on the management of hormone therapy-related side effects in breast cancer patients.Methods:Randomized controlled trials of acupuncture versus a control or placebo in breast cancer patients that examined reductions in therapy-related side effects were retrieved from PubMed, EMBASE, Web of Science, and the Cochrane Library through April 2020. Data on patient symptoms (hot flashes, fatigue, pain, stiffness, and gastrointestinal symptoms), physical capacity, cytokines, and general psychosomatic well-being were analyzed. We evaluated and analyzed the quality of all included studies with the 5.2 Cochrane Handbook standards using Stata software (version 10.0) and Revman software (version 5.2), respectively. We assessed the risk of bias using the Cochrane Risk of Bias tool and evaluated the quality of evidence using the GRADE (Grading of Recommendations, Assessment, Development, and Evaluations) approach.Results:The pooled results suggested that acupuncture led to moderate improvements in hot flashes, fatigue, and stiffness. No significant differences were observed in pain, gastrointestinal symptoms, Kupperman index scores, Overall quality of life, tumor necrosis factor levels, and interleukin levels.Conclusions:Evidence for outcome indicators of symptom management were downgraded by the GRADE system for inconsistency, indirectness, and imprecision in the included RCTs. Nonetheless, acupuncture is a moderately appropriate alternative therapy for hormone therapy-related side effects in breast cancer patients. However, it still lacks large-sample, multicenter, prospective RCTs. Future research should focus on standardizing comparison groups and treatment methods, be at least single-blinded, assess biologic mechanisms, have adequate statistical power, and involve multiple acupuncturists.
C1 [Yuanqing, Pan; Gen, Chen] Guilin Med Univ, Campbell China Network, Guilin, Peoples R China.
   [Yong, Tang] Tianjin Med Univ, Affiliated Tumor Hosp, Tianjin, Peoples R China.
   [Haiqian, Liang] Characterist Med Ctr Chinese Peoples Armed Police, Tianjin, Peoples R China.
   [Shen, Xiping; Miaomiao, Qi] Lanzhou Univ, Lanzhou, Gansu, Peoples R China.
   [Dong, Jin] Tianjin Pingjin Hosp, Tianjin, Peoples R China.
   [Qi, Cui] Lanzhou Univ, Affiliated Hosp 1, Lanzhou, Gansu, Peoples R China.
C3 Guilin Medical University; Tianjin Medical University; Lanzhou University; Lanzhou University
RP Pan, YQ (corresponding author), Sch Humanities & Management, Dept Med Psychol, 1 Zhiyuan Rd, Guilin 541000, Peoples R China.
EM panyuanq@126.com
FU Undergraduate teaching reform project of Guangxi higher education in 2020: exploration on the cultivation of undergraduates' preclinical research reserve ability based on evidence-based medicine; Guangxi science and technology plan project (Guangxi science and technology base and special talent program): an evidence-based evaluation study of the GRADE system in the evidence system of non-drug complementary alternative medicine
CR Ali MM, 2017, J CANCER SURVIV, V11, P743, DOI 10.1007/s11764-017-0612-5
   Unknown -, 2008, STAT VERS 10 0 COMP, V0, P0
   Arif F, 2017, J ACUPUNCT MERIDIAN, V10, P155, DOI 10.1016/j.jams.2017.02.001
   Azamjah Nasrindokht, 2019, ASIAN PAC J CANCER PREV, V20, P2015, DOI 10.31557/apjcp.2019.20.7.2015
   Bao T, 2018, EUR J CANCER, V101, P12, DOI 10.1016/j.ejca.2018.06.008
   Bao T, 2013, BREAST CANCER RES TR, V138, P167, DOI 10.1007/s10549-013-2427-z
   Benson S, 2019, PAIN, V160, P1562, DOI 10.1097/j.pain.0000000000001546
   Bevers TB, 2018, J NATL COMPR CANC NE, V16, P1362, DOI 10.6004/jnccn.2018.0083
   Brunelle C, 2017, LYMPHAT RES BIOL, V15, P292, DOI 10.1089/lrb.2017.0016
   Consensus Conference NIH, 1998, JAMA, V280, P1518
   Crew Katherine D, 2007, J CANCER SURVIV, V1, P283, DOI 10.1007/s11764-007-0034-x
   Crew KD, 2010, J CLIN ONCOL, V28, P1154, DOI 10.1200/JCO.2009.23.4708
   Deng G, 2007, J CLIN ONCOL, V25, P5584, DOI 10.1200/JCO.2007.12.0774
   Frisk J, 2008, CLIMACTERIC, V11, P166, DOI 10.1080/13697130801958709
   Garland SN, 2017, MENOPAUSE, V24, P517, DOI 10.1097/GME.0000000000000779
   Greenlee H, 2017, CA-CANCER J CLIN, V67, P195, DOI 10.3322/caac.21397
   Guyatt GH, 2011, J CLIN EPIDEMIOL, V64, P1311, DOI 10.1016/j.jclinepi.2011.06.004
   Halsey EJ, 2015, ACUPUNCT MED, V33, P188, DOI 10.1136/acupmed-2014-010735
   Hamash KI, 2018, PAIN MANAG NURS, V19, P627, DOI 10.1016/j.pmn.2018.05.002
   Hershman DL, 2018, JAMA-J AM MED ASSOC, V320, P167, DOI 10.1001/jama.2018.8907
   Hervik J, 2014, SPRINGERPLUS, V3, P0, DOI 10.1186/2193-1801-3-141
   Hervik J, 2009, BREAST CANCER RES TR, V116, P311, DOI 10.1007/s10549-008-0210-3
   Higgins JPT, 2011, COCHRANE HDB SYSTEMA, V0, P0
   Johnston MF, 2011, BMC COMPLEM ALTERN M, V11, P0, DOI 10.1186/1472-6882-11-49
   Kudach C, 2018, PAIN MANAG NURS, V19, P348, DOI 10.1016/j.pmn.2017.12.002
   Lai HC, 2019, EVID-BASED COMPL ALT, V2019, P0, DOI 10.1155/2019/6173412
   Lesi G, 2016, J CLIN ONCOL, V34, P1795, DOI 10.1200/JCO.2015.63.2893
   Liljegren A, 2012, BREAST CANCER RES TR, V135, P791, DOI 10.1007/s10549-010-1283-3
   Lu Jing, 2018, ZHONGGUO ZHEN JIU, V38, P1249, DOI 10.13703/j.0255-2930.2018.11.031
   Lu WD, 2020, ONCOLOGIST, V25, P310, DOI 10.1634/theoncologist.2019-0489
   Lyman GH, 2018, J CLIN ONCOL, V36, P2647, DOI 10.1200/JCO.2018.79.2721
   Mao JJ, 2015, J CLIN ONCOL, V33, P3615, DOI 10.1200/JCO.2015.60.9412
   Mao JJ, 2014, CANCER-AM CANCER SOC, V120, P3744, DOI 10.1002/cncr.28917
   Mao JJ, 2014, EUR J CANCER, V50, P267, DOI 10.1016/j.ejca.2013.09.022
   Moher D, 2010, INT J SURG, V8, P336, DOI 10.1016/j.ijsu.2010.02.007
   Molassiotis A, 2013, ANN ONCOL, V24, P1645, DOI 10.1093/annonc/mdt034
   Nedstrand E, 2005, CLIMACTERIC, V8, P243, DOI 10.1080/13697130500118050
   Nedstrand E, 2006, J PSYCHOSOM OBST GYN, V27, P193, DOI 10.1080/01674820600724797
   Rosenberg SM, 2015, ONCOLOGIST, V20, P598, DOI 10.1634/theoncologist.2015-0007
   Shah JP, 2015, PM&R, V7, P746, DOI 10.1016/j.pmrj.2015.01.024
   SIMONS DG, 1981, PAIN, V10, P106, DOI 10.1016/0304-3959(81)90053-1
   Smith C, 2013, ACUPUNCT MED, V31, P9, DOI 10.1136/acupmed-2012-010228
   Standish LJ, 2017, INTEGR CANCER THER, V16, P85, DOI 10.1177/1534735416649034
   Tong TS, 2018, MED SCI MONITOR, V24, P2919, DOI 10.12659/MSM.909712
   Tsaras Konstantinos, 2018, ASIAN PAC J CANCER PREV, V19, P1661
   Vogel L, 2019, CAN MED ASSOC J, V191, PE1088, DOI 10.1503/cmaj.1095815
   Yao C, 2016, CURR ONCOL, V23, PE27, DOI 10.3747/co.23.2788
   Zhang H, 2017, ACUPUNCT MED, V35, P445, DOI 10.1136/acupmed-2016-011212
NR 49
TC 11
Z9 14
U1 0
U2 21
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 1534-7354
EI 1552-695X
J9 INTEGR CANCER THER
JI Integr. Cancer Ther.
PD JUL 15
PY 2020
VL 19
IS 
BP 
EP 
DI 10.1177/1534735420940394
PG 17
WC Oncology; Integrative & Complementary Medicine
SC Oncology; Integrative & Complementary Medicine
GA MV8LE
UT WOS:000556601500001
PM 32718258
DA 2026-01-16
ER

PT J
AU Chan, KY
   Lui, L
   Yu, KL
   Lau, K
   Lai, MC
   Lau, W
   Ng, B
   Zhong, LLD
   Bian, ZX
AF Chan, Kaiyin
   Lui, Louisa
   Yu, Kaling
   Lau, Kwongwai
   Lai, Manchi
   Lau, Waiwai
   Ng, Bacon
   Zhong, Linda L. D.
   Bian, Zhao-Xiang
TI The efficacy and safety of electro-acupuncture for alleviating chemotherapy-induced peripheral neuropathy in patients with coloreactal cancer: study protocol for a single-blinded, randomized sham-controlled trial
SO TRIALS
LA English
DT Article
DE Acupuncture; Chemotherapy-induced peripheral neuropathy; Oxaliplatin; Colorectal cancer
ID quality-of-life; oncology; questionnaire; acupuncture; prevention; validation
AB Background Colorectal cancer is the most common cancer in Hong Kong. Oxaliplatin-based chemotherapy is a major first-line conventional therapy for advanced and metastatic colorectal cancer. However, oxaliplatin causes chemotherapy-induced peripheral neuropathy (CIPN). Acupuncture has long been used to alleviate limb numbness in Chinese medicine. This study aims to examine the efficacy and safety of acupuncture for alleviating CIPN in patients with colorectal cancer in Hong Kong. Methods/design This is a single-blinded, randomized, sham-controlled efficacy trial. Eighty-four eligible patients, who are Hong Kong Chinese, aged >= 18 years, diagnosed with colorectal cancer and undergoing oxaliplatin-based chemotherapy, will be randomized in a ratio of 1:1 to the electro-acupuncture group or the sham-controlled group. During a 12-week treatment period, patients in the electro-acupuncture group will undergo electro-acupuncture once a week from the first cycle of chemotherapy, while patients in the control group will receive sham acupuncture, and the patients in both groups will be followed up for 12 weeks. The primary outcome measure is the Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity (FACT/GOC-Ntx) questionnaire. The secondary outcome measures include numerical rating scale (NRS) for numbness/pain, vibration and light touch sense test, the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) and Constitution of Chinese Medicine Questionnaire (CCMQ). Discussion The study will compare electro-acupuncture with sham acupuncture to explore the feasibility for electro-acupuncture in improving symptoms caused by chemotherapy-induced peripheral neuropathy.
C1 [Chan, Kaiyin; Yu, Kaling; Lau, Kwongwai; Lai, Manchi; Lau, Waiwai] Hong Kong Baptist Univ, Yan Chai Hosp, Chinese Med Clin, Training & Res Ctr,Ha Kwai Chung, Hong Kong, Peoples R China.
   [Lui, Louisa] Princess Margaret Hosp, Oncol Dept, Kwai Chung, Hong Kong, Peoples R China.
   [Ng, Bacon] Hong Kong Hosp Author, Chinese Med Dept, Kowloon, Hong Kong, Peoples R China.
   [Zhong, Linda L. D.; Bian, Zhao-Xiang] Hong Kong Baptist Univ, Hong Kong Chinese Med Clin Study Ctr, Jockey Club Sch Chinese Bldg,7 Baptist Rd, Hong Kong, Peoples R China.
   [Zhong, Linda L. D.; Bian, Zhao-Xiang] Hong Kong Baptist Univ, Sch Chinese Med, Jockey Club Sch Chinese Bldg,7 Baptist Rd, Hong Kong, Peoples R China.
C3 Hong Kong Baptist University; Hong Kong Baptist University; Hong Kong Baptist University
RP Zhong, LLD; Bian, ZX (corresponding author), Hong Kong Baptist Univ, Hong Kong Chinese Med Clin Study Ctr, Jockey Club Sch Chinese Bldg,7 Baptist Rd, Hong Kong, Peoples R China.; Zhong, LLD; Bian, ZX (corresponding author), Hong Kong Baptist Univ, Sch Chinese Med, Jockey Club Sch Chinese Bldg,7 Baptist Rd, Hong Kong, Peoples R China.
EM ldzhong@hkbu.edu.hk; bzxiang@hkbu.edu.hk
FU Hong Kong Hospital Authority Chinese Medicine Department Research Practical Training Program
CR AARONSON NK, 1993, J NATL CANCER I, V85, P365, DOI 10.1093/jnci/85.5.365
   Unknown -, 2010, CHECKLIST ITEMS STRI, V0, P0
   Brami C, 2016, CRIT REV ONCOL HEMAT, V98, P325, DOI 10.1016/j.critrevonc.2015.11.014
   Calhoun EA, 2003, INT J GYNECOL CANCER, V13, P741, DOI 10.1111/j.1525-1438.2003.13603.x
   Derksen TME, 2017, EVID-BASED COMPL ALT, V2017, P0, DOI 10.1155/2017/7916031
   Fleckenstein J, 2014, TRIALS, V15, P0, DOI 10.1186/1745-6215-15-292
   Gewandter JS, 2017, PAIN, V158, P30, DOI 10.1097/j.pain.0000000000000653
   Greenlee H, 2016, BREAST CANCER RES TR, V156, P453, DOI 10.1007/s10549-016-3759-2
   Griffith KA, 2014, J PERIPHER NERV SYST, V19, P127, DOI 10.1111/jns5.12064
   Han XY, 2017, BMC CANCER, V17, P0, DOI 10.1186/s12885-016-3037-z
   Hershman DL, 2014, J CLIN ONCOL, V32, P1941, DOI 10.1200/JCO.2013.54.0914
   Huang HQ, 2007, INT J GYNECOL CANCER, V17, P387, DOI 10.1111/j.1525-1438.2007.00794.x
   Kerckhove N, 2017, FRONT PHARMACOL, V8, P0, DOI 10.3389/fphar.2017.00086
   Lu ZX, 2017, J ALTERN COMPLEM MED, V23, P964, DOI 10.1089/acm.2017.0052
   Man SC, 2014, BMC COMPLEM ALTERN M, V14, P0, DOI 10.1186/1472-6882-14-255
   Ogawa K, 2013, EVID-BASED COMPL ALT, V2013, P0, DOI 10.1155/2013/928129
   Rostock M, 2013, EVID-BASED COMPL ALT, V2013, P0, DOI 10.1155/2013/349653
   SatoJ MM, 2017, J PHARM HLTH CARE SC, V3, P21, DOI 10.1186/s40780-017-0089-4
   Shin KM, 2013, TRIALS, V14, P0, DOI 10.1186/1745-6215-14-174
   Tofthagen C, 2013, SUPPORT CARE CANCER, V21, P3307, DOI 10.1007/s00520-013-1905-5
   Wong WD, 2014, COMPLEMENT THER MED, V22, P670, DOI 10.1016/j.ctim.2014.05.009
   Xie CC, 2013, EVID-BASED COMPL ALT, V2013, P0, DOI 10.1155/2013/251603
   XLW, 2013, JILIN J CIN MED, V5, P465
NR 24
TC 11
Z9 13
U1 2
U2 24
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 
EI 1745-6215
J9 TRIALS
JI Trials
PD JAN 9
PY 2020
VL 21
IS 1
BP 
EP 
DI 10.1186/s13063-019-3972-5
PG 9
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA KN2DB
UT WOS:000514650400005
PM 31918748
DA 2026-01-16
ER

PT J
AU Almeida, KAM
   Rocha, AP
   Carvas, N
   Nunes, ACP Jr
AF Meireles Almeida, Kleicyane Aguiar
   Rocha, Aline Pereira
   Carvas, Nelson
   Pereira Nunes Pinto, Ana Carolina
TI Rehabilitation Interventions for Shoulder Dysfunction in Patients With Head and Neck Cancer: Systematic Review and Meta-Analysis
SO PHYSICAL THERAPY
LA English
DT Review
ID quality-of-life; dissection; disability; pain; impairment; exercise; trial; index
AB Objective. Shoulder pain and dysfunction are highly prevalent after neck dissection in the treatment of head and neck cancer (HNC). They can lead to muscle weakness, limited range of motion, and shoulder tilt and pain, which can reduce patient functioning. The purpose of this study was to evaluate the effectiveness of rehabilitation interventions for shoulder dysfunction in patients with surgically treated HNC. Methods. A search of principal databases (MEDLINE, Embase, CENTRAL, LILACS, IBECS, PEDro, and SciELO) was conducted, in addition to hand searches and a search of gray literature, for all randomized clinical trials (RCTs) published before February 2020. Two authors independently selected all relevant studies. The 7 RCTs fulfilling all inclusion and exclusion criteria were assessed for risk of bias and certainty of evidence using the Cochrane Collaboration risk-of-bias tool and the Grading of Recommendations Assessment, Development and Evaluation (GRADE) tool, respectively. Results. Moderate-certainty evidence suggests that progressive resistance training is better than conventional treatment for improving pain and dysfunction in patients with HNC (pooled data from 214 participants; mean difference = -5.92; 95% CI = -11.38 to -0.45). Low-certainty evidence (data from 2 RCTs with 106 participants that could not be combined) suggests that acupuncture seems to be more effective than conventional treatment. Conclusions. Progressive resistance training is effective for improving shoulder pain and dysfunction in patients with HNC. Further high-quality RCTs are needed to examine the effectiveness of acupuncture for improving shoulder pain and dysfunction in these patients. Future studies with longer follow-up times are needed to clarify the effects of early postoperative intervention. Impact. Clinicians can have confidence that progressive resistance training in patients with surgically treated HNC is effective. Lay Summary. These study results show that people with head and neck cancer can benefit from gradually increased resistance training to reduce shoulder pain and improve function. This study will help researchers design clinical trials to determine whether treatments such as acupuncture and early physical therapy also could be effective in treating this population.
C1 [Meireles Almeida, Kleicyane Aguiar; Pereira Nunes Pinto, Ana Carolina] Univ Fed Amapa, Biol & Hlth Sci Dept, Rod Juscelino Kubitschek,Km 02 Jardim Marco Zero, BR-68903419 Macapa, AP, Brazil.
   [Rocha, Aline Pereira] Univ Fed Sao Paulo, Discipline Emergency & Evidence Based Med, Sao Paulo, Brazil.
   [Carvas, Nelson] Inst Assistencia Med Servidor Publ Estadual, Dept Phys Educ, Sao Paulo, SP, Brazil.
   [Pereira Nunes Pinto, Ana Carolina] Univ Pittsburgh, Pittsburgh, PA 15260 USA.
C3 Fundacao Universidade Federal do Amapa; Universidade Federal de Sao Paulo (UNIFESP); Instituto de Assistencia Medica ao Servidor Publico Estadual (IAMSPE); Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh
RP Nunes, ACP Jr (corresponding author), Univ Fed Amapa, Biol & Hlth Sci Dept, Rod Juscelino Kubitschek,Km 02 Jardim Marco Zero, BR-68903419 Macapa, AP, Brazil.; Nunes, ACP Jr (corresponding author), Univ Pittsburgh, Pittsburgh, PA 15260 USA.
EM anacarolinapnp@hotmail.com
CR Breckenridge JD, 2011, J PHYSIOTHER, V57, P197, DOI 10.1016/S1836-9553(11)70045-5
   Cappiello Johnny, 2007, CURR OPIN OTOLARYNGOL HEAD NECK SURG, V15, P107, DOI 10.1097/MOO.0b013e3280523ac5
   Cardoso LR, 2015, HEAD NECK-J SCI SPEC, V37, P1733, DOI 10.1002/hed.23825
   Carvalho APV, 2012, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD008693.pub2
   Chatterjee M, 2017, INDIAN JOURNAL OF PHYSIOTHERAPY AND OCCUPATIONAL THERAPY - AN INTERNATIONAL JOURNAL, V11, P57, DOI 10.5958/0973-5674.2017.00012.0
   Deganello A, 2016, LARYNGOSCOPE, V126, P1790, DOI 10.1002/lary.25921
   DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2
   Fitzmaurice C, 2017, JAMA ONCOL, V3, P524, DOI 10.1001/jamaoncol.2016.5688
   GRADEpro GDT, 2015, GRADES SOFTW SUMM FI, V0, P0
   Guyatt GH, 2008, BMJ-BRIT MED J, V336, P995, DOI 10.1136/bmj.39490.551019.BE
   Lauchlan DT, 2008, EUR J CANCER CARE, V17, P542, DOI 10.1111/j.1365-2354.2007.00862.x
   Lauchlan DT, 2011, EUR J CANCER CARE, V20, P113, DOI 10.1111/j.1365-2354.2009.01149.x
   McGarvey AC, 2014, HEAD NECK, V37, P1022
   McNeely ML, 2008, CANCER, V113, P214, DOI 10.1002/cncr.23536
   McNeely ML, 2004, HEAD NECK-J SCI SPEC, V26, P518, DOI 10.1002/hed.20010
   Nasser Mona, 2020, AM J PUBLIC HEALTH, V110, P753, DOI 10.2105/AJPH.2020.305609
   Patterson RH, 2020, OTOLARYNG HEAD NECK, V162, P296, DOI 10.1177/0194599819897265
   Pfister DG, 2010, J CLIN ONCOL, V28, P2565, DOI 10.1200/JCO.2009.26.9860
   Quan D, 1999, ORTHOPAEDIC J, V12, P45, DOI 10.1016/B978-0-7506-1183-1.50010-3
   Schmitt JS, 2004, J CLIN EPIDEMIOL, V57, P1008, DOI 10.1016/j.jclinepi.2004.02.007
   Taylor RJ, 2002, ARCH OTOLARYNGOL, V128, P44, DOI 10.1001/archotol.128.1.44
   Veyseller B, 2010, J OTOLARYNGOL-HEAD N, V39, P403, DOI 10.2310/7070.2010.090188
   Vrotsou K, 2018, QUAL LIFE RES, V27, P2217, DOI 10.1007/s11136-018-1875-7
NR 23
TC 21
Z9 26
U1 0
U2 14
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0031-9023
EI 1538-6724
J9 PHYS THER
JI Phys. Therapy
PD NOV 15
PY 2020
VL 100
IS 11
BP 1997
EP 2008
DI 10.1093/ptj/pzaa147
PG 12
WC Orthopedics; Rehabilitation
SC Orthopedics; Rehabilitation
GA OW8RE
UT WOS:000593146200012
PM 32750136
DA 2026-01-16
ER

PT J
AU Arriaga-Pizano, L
   Gómez-Jiménez, DC
   Flores-Mejía, LA
   Pérez-Cervera, Y
   Solórzano-Mata, CJ
   López-Macías, C
   Isibasi, A
   Torres-Rosas, R
AF Arriaga-Pizano, Lourdes
   Gómez-Jiménez, Daniel Cuauhtémoc
   Flores-Mejía, Luis Angel
   Pérez-Cervera, Yobana
   Solórzano-Mata, Carlos Josué
   López-Macías, Constantino
   Isibasi, Armando
   Torres-Rosas, Rafael
TI Low back pain in athletes can be controlled with acupuncture by a
SO Acupuncture in medicine : journal of the British Medical Acupuncture Society
LA English
DT Journal Article
DE acupuncture; low back pain; non-steroidal anti-inflammatory drugs; pain management; physical therapy; sports medicine
AB BACKGROUND: Activation of the sympathetic nervous system attenuates inflammation  via catecholamines. Recent evidence has shown that electroacupuncture (EA)  activates neuronal networks involved in the release of dopamine and  norepinephrine that control systemic inflammation. In muscle, catecholamines are  related to cyclic adenosine monophosphate (cAMP). This signaling molecule has  been implicated in recovery from sustained contractile activity, which may induce  muscular pain, such as that which occurs during low back pain (LBP). OBJECTIVE:  Our aim was to evaluate the effects of EA used for the control of LBP on the  activation of the sympathetic nervous system in a randomized controlled clinical  trial in athletes. METHODS: Two groups of athletes with acute or chronic low back  pain were studied. EA, sham EA and pharmacological treatment (diclofenac sodium)  were evaluated. The outcome measures included a pain score represented by a  visual analogue scale (VAS) and serum levels of catecholamines quantified by  enzyme-linked immunosorbent assay. In addition, blood was collected into chilled  heparin tubes, placed in 96-well cell culture plates and incubated with an equal  volume of Roswell Park Memorial Institute (RPMI) medium, with lipopolysaccharide  (LPS) alone or with catecholamines. Tumor necrosis factor (TNF)-α levels in the  supernatants were analyzed. RESULTS: The results indicated that the initial pain  ratings did not differ between the groups analyzed. EA induced epinephrine  secretion but not norepinephrine or dopamine secretion. Although EA and  pharmacological treatment did not differ in terms of pain relief, in vitro  epinephrine and norepinephrine reduced TNF-α production in response to LPS  stimuli. CONCLUSION: EA activates the sympathetic nervous system and induces the  release of epinephrine, which could ameliorate inflammation and protect muscular  tissue in addition to relieving pain.
C1 Unidad de Investigación Médica en Inmunoquímica, Hospital de Especialidades del Centro Médico Nacional Siglo XXI, Instituto Mexicano del Seguro Social (IMSS),Ciudad de México, Mexico.
   Escuela Nacional de Medicina y Homeopatía, Instituto Politécnico Nacional, Ciudad de México, México.
   Unidad de Investigación Médica en Inmunoquímica, Hospital de Especialidades del Centro Médico Nacional Siglo XXI, Instituto Mexicano del Seguro Social (IMSS),Ciudad de México, Mexico.
   "Laboratorio de Inmunología, Centro de Estudios en Ciencias de la Salud y la Enfermedad, Facultad de Odontología, Universidad Autónoma "Benito Juárez" deOaxaca, Oaxaca, México.
   Centro de Investigación UNAM-UABJO, Facultad de Medicina y Cirugía, Universidad 
   "Laboratorio de Inmunología, Centro de Estudios en Ciencias de la Salud y la Enfermedad, Facultad de Odontología, Universidad Autónoma "Benito Juárez" deOaxaca, Oaxaca, México.
   Centro de Investigación UNAM-UABJO, Facultad de Medicina y Cirugía, Universidad 
   Unidad de Investigación Médica en Inmunoquímica, Hospital de Especialidades del Centro Médico Nacional Siglo XXI, Instituto Mexicano del Seguro Social (IMSS),Ciudad de México, Mexico.
   Unidad de Investigación Médica en Inmunoquímica, Hospital de Especialidades del Centro Médico Nacional Siglo XXI, Instituto Mexicano del Seguro Social (IMSS),Ciudad de México, Mexico.
   "Laboratorio de Inmunología, Centro de Estudios en Ciencias de la Salud y la Enfermedad, Facultad de Odontología, Universidad Autónoma "Benito Juárez" deOaxaca, Oaxaca, México.
NR 0
TC 0
SN 1759-987
EI 
J9 Acupunct Med
PD MAY 21
PY 2020
VL 38
IS 6
BP 388
EP 395
DI 10.1177/0964528420912251
PG 7
WC Adolescent; Adult; Athletes; statistics & numerical data; Catecholamines; metabolism; Electroacupuncture; Humans; Low Back Pain; metabolism; Male; Treatment Outcome; Young Adult
UT PubMed:32429680
PM 32429680
DA 2020-05-21
ER

PT J
AU Tang, CJ
   Rong, Z
   Yang, MN
   Hong, XH
   Wang, TB
AF Tang, Cui-Juan
   Rong, Zhen
   Yang, Meng-Na
   Hong, Xiao-Hua
   Wang, Tong-Biao
TI [Rule of acupoint selection for cancer pain based on association rule and entropy
SO Zhongguo zhen jiu = Chinese acupuncture & moxibustion
LA chi
DT Journal Article
DE acupuncture; association rules; cancer pain; entropy clustering; rules of acupoint selection
AB OBJECTIVE: To analyze the rule of acupoint selection for cancer pain based on  data mining. METHODS: The published literature regarding acupuncture for cancer  pain in the recent 10 years was searched in PubMed, CNKI, VIP and Wanfang  database. The acupoint selection was summarized and analyzed by TCMISS V2.5.  RESULTS: Totally 68 literature was collected and 73 acupoint prescriptions were  included, involving 117 acupoints. These acupoints were mainly in bladder  meridian, stomach meridian, liver meridian and spleen meridian. Among them, 40  acupoints used more than 4 times were identified, and the top three acupoints  were Zusanli (ST 36, 65 times), Neiguan (PC 6, 55 times) and Taichong (LR 3, 50  times). A total of 68 acupoint combinations used more than 19 times were  identified, and the top three acupoint combinations were Zusanli (ST 36)-Neiguan  (PC 6), Taichong (LR 3)-Zusanli (ST 36) and Zusanli (ST 36)-Sanyinjiao (SP 6).  There were 103 acupoint combinations with strong association; based on the  entropy clustering algorithm, 20 new acupoint combinations and 10 new acupoint  prescriptions were obtained. CONCLUSION: The main meridians for cancer pain are  bladder meridian, stomach meridian, liver meridian and spleen meridian, with  Zusanli (ST 36), Neiguan (PC 6), Taichong (LR 3), Hegu (LI 4), Sanyinjiao (SP 6)  and ashi points as core acupoints, and regulating spleen-stomach and treating  qi-blood are the main principles.
C1 Graduate School of Guangxi University of CM, Nanning 530200, China.
   First Affiliated Hospital of Guangxi University of CM, Nanning 530000.
   Graduate School of Guangxi University of CM, Nanning 530200, China.
   Graduate School of Guangxi University of CM, Nanning 530200, China.
   First Affiliated Hospital of Guangxi University of CM, Nanning 530000.
NR 0
TC 0
SN 
EI 0255-293
J9 Zhongguo Zhen Jiu
PD APR 10
PY 2020
VL 40
IS 3
BP 331
EP 6
DI 10.13703/j.0255-2930.20190311-0001
PG -325
WC Acupuncture Points; Acupuncture Therapy; Cancer Pain; therapy; Cluster Analysis; Entropy; Humans; Meridians; Neoplasms; physiopathology
UT PubMed:32270652
PM 32270652
DA 2020-04-10
ER

PT J
AU Tai, JB
   Hong, L
   Ma, ME
   Xu, J
   Fang, JQ
   Jiang, YQ
AF Tai, Jia-Bin
   Hong, Liang
   Ma, Meng-En
   Xu, Jia
   Fang, Jian-Qiao
   Jiang, Yi-Qian
TI Evaluation of therapeutic effect of transcutaneous electrical acupoint stimulation on bone metastasis pain and its influence on immune function of patients
SO ANNALS OF PALLIATIVE MEDICINE
LA English
DT Article
DE Transcutaneous acupoint electrical stimulation; cancerous pain; tumor; immunity; clinical research
ID acupuncture
AB Background: This study aimed to observe the effect of transcutaneous electrical acupoint stimulation (TEAS) on bone metastasis pain, anxiety and immune function in cancer patients. Methods: A total of 127 patients with bone metastasis pain from malignant tumors were treated with TEAS or drugs. The TEAS group comprised of 62 patients, while the drug control group comprised of 65 patients. The differences in general indexes, baseline pain and anxiety between these two groups were not statistically significant. Results: Compared with those before treatment, the visual analog scale (VAS) scores of patients in the TEAS group and drug control group decreased after treatment, and the differences were statistically significant. The degrees of pain relief after treatment were similar between the two groups. Anxiety improved in both the TEAS group and drug control group, and the difference between these two groups was not statistically significant. The differences in immune indexes, B cell and CD8 between the TEAS group and drug control group were statistically significant. TEAS treatment could improve the declining trend of CD8 in patients. Conclusions: TEAS treatment and drug treatment can effectively alleviate mild to moderate pain in patients, and the efficacy of these two groups is similar. The treatment for moderate and severe pain needs to be combined with drug treatment to achieve a control effect. TEAS can improve the anxiety and immune function of patients, and prevent the decrease in B cells and CD8 in patients treated with drugs alone.
C1 [Tai, Jia-Bin; Hong, Liang; Ma, Meng-En; Xu, Jia; Jiang, Yi-Qian] Hangzhou Normal Univ, Internal Med Oncol, Xiaoshan Hosp 1, Med Coll, 199 Shixin South Rd, Hangzhou 311200, Peoples R China.
   [Fang, Jian-Qiao] Zhejiang Univ Tradit Chinese Med, Hangzhou, Peoples R China.
C3 Hangzhou Normal University; Zhejiang Chinese Medical University
RP Jiang, YQ (corresponding author), Hangzhou Normal Univ, Internal Med Oncol, Xiaoshan Hosp 1, Med Coll, 199 Shixin South Rd, Hangzhou 311200, Peoples R China.
EM yiqian9988@163.com
FU Hangzhou Science and technology project [20150633B53, 20171226Y82]; Hangzhou Health Planning Project [2017B16]
CR DAlessandro EG, 2022, BMJ SUPPORT PALLIAT, V12, P64, DOI 10.1136/bmjspcare-2018-001542
   Deng G, 2020, PAIN MED, V21, P636, DOI 10.1093/pm/pnz190
   Deng G, 2018, ONCOLOGY-NY, V32, P310
   Garland SN, 2019, JNCI-J NATL CANCER I, V111, P1323, DOI 10.1093/jnci/djz050
   He YH, 2020, JAMA ONCOL, V6, P271, DOI 10.1001/jamaoncol.2019.5233
   Keilani M, 2019, WIEN KLIN WOCHENSCHR, V131, P567, DOI 10.1007/s00508-019-1524-3
   Kerai S, 2014, INDIAN J ANAESTH, V58, P388, DOI 10.4103/0019-5049.138966
   Kim TH, 2019, ACUPUNCT MED, V37, P164, DOI 10.1177/0964528419832610
   Li K, 2019, CURR ONCOL, V26, PE147, DOI 10.3747/co.26.4261
   Lu WD, 2020, ONCOLOGIST, V25, P310, DOI 10.1634/theoncologist.2019-0489
   Guzmán RMMAY, 2019, COMPLEMENT THER CLIN, V36, P56, DOI 10.1016/j.ctcp.2019.05.003
   Shi Ren-Yi, 2019, ZHEN CI YAN JIU, V44, P161, DOI 10.13702/j.1000-0607.180635
   Sivanesan E, 2019, REGION ANESTH PAIN M, V44, P615, DOI 10.1136/rapm-2019-100488
   Wang JS, 2020, MEDICINE, V99, P0, DOI 10.1097/MD.0000000000019540
   Wu LL, 2017, J TRADIT CHIN MED, V37, P629
   Zayan K, 2020, NEUROMODULATION, V23, P871, DOI 10.1111/ner.13146
   Zhang CP, 2020, CHIN MED-UK, V15, P0, DOI 10.1186/s13020-020-0289-y
NR 17
TC 9
Z9 12
U1 1
U2 20
PU AME PUBLISHING COMPANY
PI SHATIN
PA FLAT-RM C 16F, KINGS WING PLAZA 1, NO 3 KWAN ST, SHATIN, HONG KONG 00000, PEOPLES R CHINA
SN 2224-5820
EI 2224-5839
J9 ANN PALLIAT MED
JI Ann. Pallliat. Med.
PD SEP 15
PY 2020
VL 9
IS 5
BP 2538
EP 2544
DI 10.21037/apm-19-434
PG 7
WC Health Care Sciences & Services
SC Health Care Sciences & Services
GA NY8YP
UT WOS:000576670500013
PM 32954744
DA 2026-01-16
ER

PT J
AU Hempen, CH
   Hummelsberger, J
AF Hempen, Carl-Hermann
   Hummelsberger, Josef
TI [Traditional Chinese medicine (TCM)-what is myth and what is the state of
SO Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz
LA ger
DT Review
DE Acupuncture; Chinese herbal medicine; Chinese medicine; Evidence; TCM
AB Traditional Chinese medicine (TCM) is the most comprehensive and widely practiced  system of medicine in the world.Originally, TCM appeared in our Western context  as an unfathomable mythological doctrine. Once the linguistic barriers had been  overcome, it became possible to understand and apply the terminological and  physiological concepts, the method of diagnosis, and the clinical findings.Since  the NIH consensus conference in 1998, our understanding of TCM has been the  subject of methodologically robust studies. We now have evidence of the efficacy  and effectiveness of acupuncture beyond its use in pain therapy and allergy  treatment. Thanks to fMRI studies, among others, we also have a better  understanding of the mechanisms underlying acupuncture.Meta-analyses and studies  also confirm the efficacy of Chinese medicinal drugs and remedies in some fields,  yet there is still extensive need for further research. But opportunities are  also emerging for new medicines and prescriptions for (accompanying) treatments  of infections, autoimmune diseases, cancer, metabolic illnesses, dermatological  disorders, and gastrointestinal diseases.To enable further evaluation of TCM, but  also to ensure an integrative, critical application in the practice of TCM, it is  vital for doctors to have thorough training. Further institutionalisation is  necessary to provide orientation and patient safety.The days of regarding TCM as  some kind of mysticism are indeed long over and it can offer real opportunities  for better patient care. In many fields, there is increasing evidence of TCM's  effectiveness, yet further comprehensive research is essential. This should be  encouraged unconditionally.
C1 Technische Universität München, Georg-Brauchle-Ring 62, 80992, München, Deutschland. ch@hempen.de.
   , München, Deutschland.
NR 0
TC 0
SN 1437-158
EI 
J9 Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz
PD APR 9
PY 2020
VL 63
IS 5
BP 570
EP 576
DI 10.1007/s00103-020-03132-9
PG 6
WC Acupuncture Therapy; Drugs, Chinese Herbal; Germany; Humans; Medicine, Chinese Traditional; methods; Pain Management; methods
UT PubMed:32266491
PM 32266491
DA 2020-04-09
ER

PT J
AU Xu, LP
   Yang, SL
   Su, SQ
   Huang, BX
   Lan, XM
   Yao, RJ
AF Xu, Li-Ping
   Yang, Shi-Lai
   Su, Shao-Qing
   Huang, Bi-Xia
   Lan, Xin-Mei
   Yao, Ru-Jie
TI Effect of wrist-ankle acupuncture therapy combined with auricular acupuncture on cancer pain: A four-parallel arm randomized controlled trial
SO COMPLEMENTARY THERAPIES IN CLINICAL PRACTICE
LA English
DT Article
DE Wrist-ankle acupuncture therapy; Auricular acupuncture; Combine therapy; Cancer pain
AB Background: Cancer pain affects the quality of life of cancer patients; therefore, various methods exist for alleviating the adverse effects caused by cancer pain. Nonpharmacological intervention is regarded as an important means of auxiliary therapy for drug treatment, with acupuncture receiving the most attention; However, there are numerous types of acupuncture therapies, including acupuncture, wrist-ankle acupuncture (WAA) and auricular acupuncture (AA). Previous studies have demonstrated that all types of acupuncture therapy can alleviate cancer pain. However, the effects and pathways of different acupuncture treatments are not similar, and it is unknown whether single therapy or combination therapy has better analgesic effects. This study aimed to examine the effect of WAA therapy combined with AA on cancer pain. Design: A randomized controlled trial. Method: A total of 160 patients were selected and randomly divided into groups A, B, C and D, with 40 patients in each group. Group A received conventional analgesia alone, with opioids administered based on the World Health Organization (WHO) 3-tiered "cancer pain ladder". Group B received WAA, in addition to the treatment received by group A. Group C received AA, in addition to the treatment received by group A. Group D received WAA combined with AA, in addition to the treatment received by group A. Analgesic effects and analgesic drug use before and 3, 5 and 7 days after treatment were observed in each group. Result: A total of 159 patients were included in the analysis. The verbal rating scale (VRS) and numeric rating scale (NRS) scores for patients who received mono-acupuncture therapy and combination therapy for 1 week were significantly different from those of the control group. Combination therapy had a stronger effect on the VRS score and a faster onset time, based on the NRS score, and the patients who received combination therapy had reduced analgesic drug use. Conclusion: WAA combined with AA can more quickly reduce pain symptoms with more lasting analgesic effects and can effectively reduce analgesic drug use.
C1 [Xu, Li-Ping] Fujian Univ Tradit Chinese Med, Nursing Dept, Affiliated Peoples Hosp 3, Fuzhou, Peoples R China.
   [Yang, Shi-Lai] Quanzhou Med Coll, Sch Nursing, Quanzhou, Peoples R China.
   [Su, Shao-Qing] Fujian Univ Tradit Chinese Med, Peoples Hosp, Fuzhou, Peoples R China.
   [Huang, Bi-Xia; Lan, Xin-Mei; Yao, Ru-Jie] Fujian Univ Tradit Chinese Med, Affiliated Peoples Hosp 3, Fuzhou, Peoples R China.
C3 Fujian University of Traditional Chinese Medicine; Fujian University of Traditional Chinese Medicine; Fujian University of Traditional Chinese Medicine
RP Xu, LP (corresponding author), Fujian Univ Tradit Chinese Med, Nursing Dept, Affiliated Peoples Hosp 3, Fuzhou, Peoples R China.; Yang, SL (corresponding author), Quanzhou Med Coll, Sch Nursing, Quanzhou, Peoples R China.
EM 785514523@qq.com; 247872083@qq.com
FU Fujian University of Traditional Chinese Medicine, China [XB2017032]; Education Department of Fujian Province [JAT171164]
CR Alimi D, 2003, J CLIN ONCOL, V21, P4120, DOI 10.1200/JCO.2003.09.011
   Chen H, 2013, PANCREATOLOGY, V13, P594, DOI 10.1016/j.pan.2013.10.007
   Chiu HY, 2017, EUR J CANCER CARE, V26, P0, DOI 10.1111/ecc.12457
   Choi TY, 2012, SUPPORT CARE CANCER, V20, P1147, DOI 10.1007/s00520-012-1432-9
   Davies A, 2013, J PAIN SYMPTOM MANAG, V46, P619, DOI 10.1016/j.jpainsymman.2012.12.009
   de Leon SP, 2004, ARCH MED RES, V35, P157, DOI 10.1016/j.arcmed.2003.07.009
   Hou PW, 2015, EVID-BASED COMPL ALT, V2015, P0, DOI 10.1155/2015/495684
   Li XH, 2017, BASIC NURSING, V0, P469
   Lyman GH, 2018, J CLIN ONCOL, V36, P2647, DOI 10.1200/JCO.2018.79.2721
   Lynch ME, 2014, J PAIN SYMPTOM MANAG, V47, P166, DOI 10.1016/j.jpainsymman.2013.02.018
   Magee D, 2019, PAIN MANAG, V9, P63, DOI 10.2217/pmt-2018-0031
   Marshall JL, 2012, J ONCOL PRACT, V8, P309, DOI 10.1200/JOP.2011.000461
   Neufeld NJ, 2017, FUTURE ONCOL, V13, P833, DOI 10.2217/fon-2016-0423
   Paley CA, 2015, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD007753.pub3
   Pergolizzi JV, 2015, PAIN PRACT, V15, P778, DOI 10.1111/papr.12253
   Pfister DG, 2010, J CLIN ONCOL, V28, P2565, DOI 10.1200/JCO.2009.26.9860
   Portenoy RK, 2012, J PAIN, V13, P438, DOI 10.1016/j.jpain.2012.01.003
   Raphael J, 2010, PAIN MED, V11, P872, DOI 10.1111/j.1526-4637.2010.00841.x
   Swarm RA, 2019, J NATL COMPR CANC NE, V17, P977, DOI 10.6004/jnccn.2019.0038
   The National Standard of the Peoples Republic of China, 2008, NOM LOC AUR POINT, V0, P0
   TISEO PJ, 1995, PAIN, V61, P47, DOI 10.1016/0304-3959(94)00148-8
   Torresan MM, 2015, EUR J ONCOL NURS, V19, P397, DOI 10.1016/j.ejon.2015.01.001
   Wang Qiong, 2017, ZHONGGUO ZHEN JIU, V37, P509, DOI 10.13703/j.0255-2930.2017.05.016
   Wu J, 2017, J TRADIT CHIN MED, V51, P48
   Zeng K, 2014, AM J CHINESE MED, V42, P289, DOI 10.1142/S0192415X14500190
   Zhang Huo-Jun, 2008, ZHONG XI YI JIE HE XUE BAO, V6, P907, DOI 10.3736/jcim20080906
   Zhang X, 2002, PRACTICAL WRIST-ANKLE ACUPUNCTURE THERAPY, V0, P0
   Zhu LB, 2014, EVID-BASED COMPL ALT, V2014, P0, DOI 10.1155/2014/261709
NR 29
TC 11
Z9 16
U1 0
U2 40
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1744-3881
EI 1873-6947
J9 COMPLEMENT THER CLIN
JI Complement. Ther. Clin. Pract.
PD MAY 15
PY 2020
VL 39
IS 
BP 
EP 
DI 10.1016/j.ctcp.2020.101170
PG 7
WC Integrative & Complementary Medicine
SC Integrative & Complementary Medicine
GA LK5JF
UT WOS:000530901500042
PM 32379695
DA 2026-01-16
ER

PT J
AU Carpena, M
   Nuñez-Estevez, B
   Soria-Lopez, A
   Simal-Gandara, J
AF Carpena, Maria
   Nunez-Estevez, Bernabe
   Soria-Lopez, Anton
   Simal-Gandara, Jesus
TI Bee Venom: An Updating Review of Its Bioactive Molecules and Its Health Applications
SO NUTRIENTS
LA English
DT Review
DE bee venom; biological properties; health applications; peptides; enzymes
ID cell degranulating peptide; apis-mellifera venom; nf-kappa-b; phospholipase a(2); signaling pathway; mouse model; in-vitro; neuroinflammatory responses; cancer cells; mcd peptide
AB Bee venom (BV) is usually associated with pain since, when humans are stung by bees, local inflammation and even an allergic reaction can be produced. BV has been traditionally used in ancient medicine and in acupuncture. It consists of a mixture of substances, principally of proteins and peptides, including enzymes as well as other types of molecules in a very low concentration. Melittin and phospholipase A2 (PLA2) are the most abundant and studied compounds of BV. Literature of the main biological activities exerted by BV shows that most studies focuses on the comprehension and test of anti-inflammatory effects and its mechanisms of action. Other properties such as antioxidant, antimicrobial, neuroprotective or antitumor effects have also been assessed, both in vitro and in vivo. Moreover, human trials are necessary to confirm those clinical applications. However, notwithstanding the therapeutic potential of BV, there are certain problems regarding its safety and the possible appearance of adverse effects. On this perspective, new approaches have been developed to avoid these complications. This manuscript is aimed at reviewing the actual knowledge on BV components and its associated biological activities as well as the latest advances on this subject.
C1 [Carpena, Maria; Nunez-Estevez, Bernabe; Soria-Lopez, Anton; Simal-Gandara, Jesus] Univ Vigo, Fac Food Sci & Technol, Analyt & Food Chem Dept, Nutr & Bromatol Grp, Ourense Campus, E-32004 Orense, Spain.
C3 Universidade de Vigo
RP Simal-Gandara, J (corresponding author), Univ Vigo, Fac Food Sci & Technol, Analyt & Food Chem Dept, Nutr & Bromatol Grp, Ourense Campus, E-32004 Orense, Spain.
EM maria.carpena.rodriguez@uvigo.es; bernabenunez16@gmail.com; antonsoria@hotmail.es; jsimal@uvigo.es
FU Programa de Cooperacion Interreg V-A Espana-Portugal (POCTEP) 2014-2020 [0181_NANOEATERS_01_E, 0377_IBERPHENOL_6_E]; Xunta de Galicia [IN852A 2018/58]; EcoChestnut Project (Erasmus + KA202); Ibero-American Program on Science and Technology (CYTED-AQUA-CIBUS) [P317RT0003]; European Union's Horizon 2020 and Based Industries Joint Undertaking (JU) [888003]
CR Abd El-Wahed AA, 2018, STUD NAT PROD CHEM, V60, P459, DOI 10.1016/B978-0-444-64181-6.00013-9
   Ahn YJ, 2016, J ETHNOPHARMACOL, V194, P774, DOI 10.1016/j.jep.2016.11.012
   Al-Ani I, 2015, PHYTOMEDICINE, V22, P245, DOI 10.1016/j.phymed.2014.11.019
   Al-Samie MAMA, 2012, INT J ADV RES TECHNO, V1, P1
   dos Santos-Pinto JRA, 2018, TOXICON, V148, P172, DOI 10.1016/j.toxicon.2018.04.029
   Badshah H, 2016, SCI REP-UK, V6, P0, DOI 10.1038/srep24493
   Bae YH, 2020, ADV DRUG DELIVER REV, V158, P4, DOI 10.1016/j.addr.2020.06.018
   Baek H, 2020, TOXINS, V12, P0, DOI 10.3390/toxins12030198
   Baek H, 2018, FRONT AGING NEUROSCI, V10, P0, DOI 10.3389/fnagi.2018.00179
   Baek YH, 2006, BRAIN RES, V1073, P305, DOI 10.1016/j.brainres.2005.12.086
   BANKS BEC, 1990, BRIT J PHARMACOL, V99, P350, DOI 10.1111/j.1476-5381.1990.tb14707.x
   BENTON AW, 1963, SCIENCE, V142, P228, DOI 10.1126/science.142.3589.228
   Bidaud I, 2020, SCI REP-UK, V10, P0, DOI 10.1038/s41598-020-66673-8
   Blank S, 2010, J IMMUNOL, V184, P5403, DOI 10.4049/jimmunol.0803709
   Boutrin MCF, 2008, EXP PARASITOL, V119, P246, DOI 10.1016/j.exppara.2008.02.002
   Buku A, 1999, PEPTIDES, V20, P415, DOI 10.1016/S0196-9781(98)00167-3
   Buku A, 2004, J PEPT SCI, V10, P313, DOI 10.1002/psc.532
   Buku A, 2001, PEPTIDES, V22, P1987, DOI 10.1016/S0196-9781(01)00538-1
   Buku A, 2001, PEPTIDES, V22, P1993, DOI 10.1016/S0196-9781(01)00542-3
   Cai M, 2015, TOXINS, V7, P846, DOI 10.3390/toxins7030846
   Silva LFCD, 2010, EUR J PHARMACOL, V626, P239, DOI 10.1016/j.ejphar.2009.09.064
   Chen J, 2010, PROG NEUROBIOL, V92, P151, DOI 10.1016/j.pneurobio.2010.06.006
   Chen M, 2017, SCI REP-UK, V7, P0, DOI 10.1038/s41598-017-16130-w
   Cherniack EP, 2018, TOXICON, V154, P74, DOI 10.1016/j.toxicon.2018.09.013
   Cho SY, 2012, PARKINSONISM RELAT D, V18, P948, DOI 10.1016/j.parkreldis.2012.04.030
   Choi S, 2019, TOXINS, V11, P0, DOI 10.3390/toxins11070396
   Chung ES, 2015, J IMMUNOL, V195, P4853, DOI 10.4049/jimmunol.1500386
   Chung ES, 2012, BRAIN BEHAV IMMUN, V26, P1322, DOI 10.1016/j.bbi.2012.08.013
   Cornara L, 2017, FRONT PHARMACOL, V8, P0, DOI 10.3389/fphar.2017.00412
   Corthésy B, 2016, ALLERGY, V71, P957, DOI 10.1111/all.12859
   Csoka AB, 2001, MATRIX BIOL, V20, P499, DOI 10.1016/S0945-053X(01)00172-X
   Dacheux M, 2019, INFECT IMMUN, V87, P0, DOI 10.1128/IAI.00556-19
   Davies J, 2019, THER ADV MUSCULOSKEL, V11, P0, DOI 10.1177/1759720X19844429
   de Alnneida-Muradian LB, 2020, J APICULT RES, V59, P1, DOI 10.1080/00218839.2020.1738135
   de Lau LML, 2004, NEUROLOGY, V63, P1240, DOI 10.1212/01.WNL.0000140706.52798.BE
   Dennis EA, 2011, CHEM REV, V111, P6130, DOI 10.1021/cr200085w
   Duchez AC, 2019, PROSTAG OTH LIPID M, V143, P0, DOI 10.1016/j.prostaglandins.2019.106340
   El-Hanoun A, 2020, PHYSIOL BEHAV, V223, P0, DOI 10.1016/j.physbeh.2020.112987
   Fenard D, 2001, MOL PHARMACOL, V60, P341, DOI 10.1124/mol.60.2.341
   Gajski G, 2013, ENVIRON TOXICOL PHAR, V36, P697, DOI 10.1016/j.etap.2013.06.009
   Grange PA, 2009, J DERMATOL SCI, V56, P106, DOI 10.1016/j.jdermsci.2009.08.001
   Grassberger M, 2013, BIOTHERAPY-HISTORY, V0, Principles and Practice: A Practical Quide to the Diagnosis and Treatment of Disease Using Living Organisms
   Grunwald T, 2006, J ALLERGY CLIN IMMUN, V117, P848, DOI 10.1016/j.jaci.2005.12.1331
   Gu H, 2020, TOXINS, V12, P0, DOI 10.3390/toxins12030195
   HAIT WN, 1985, CANCER CHEMOTH PHARM, V14, P202, DOI 10.1007/BF00258116
   Ham HJ, 2019, FRONT AGING NEUROSCI, V11, P0, DOI 10.3389/fnagi.2019.00287
   Hartmann A, 2016, PLOS ONE, V11, P0, DOI 10.1371/journal.pone.0158235
   Hellner M, 2008, EVID-BASED COMPL ALT, V5, P475, DOI 10.1093/ecam/nem052
   Heppner FL, 2015, NAT REV NEUROSCI, V16, P358, DOI 10.1038/nrn3880
   Hincha DK, 1996, BBA-BIOMEMBRANES, V1284, P162, DOI 10.1016/S0005-2736(96)00122-8
   Ho JN, 2010, MOL CANCER THER, V9, P825, DOI 10.1158/1535-7163.MCT-09-0904
   Hood JL, 2013, ANTIVIR THER, V18, P95, DOI 10.3851/IMP2346
   Hossen MS, 2017, MOLECULES, V22, P0, DOI 10.3390/molecules22010025
   Hou CS, 2014, MOL BIOL REP, V41, P8081, DOI 10.1007/s11033-014-3706-4
   Hu HY, 2006, J PHARM PHARMACOL, V58, P83, DOI 10.1211/jpp.58.1.0010
   Jakob T, 2017, ALLERGO JOURNAL, V26, P33, DOI 10.1007/S15007-017-1315-Y
   Jang MH, 2003, J PHARMACOL SCI, V91, P95, DOI 10.1254/jphs.91.95
   Jeong YJ, 2015, INT IMMUNOPHARMACOL, V25, P400, DOI 10.1016/j.intimp.2015.02.021
   Jin WL, 1999, BIOCHEMISTRY-US, V38, P14294, DOI 10.1021/bi991206j
   Jo M, 2012, TOXICOL APPL PHARM, V258, P72, DOI 10.1016/j.taap.2011.10.009
   Jung KH, 2017, TOXINS, V9, P0, DOI 10.3390/toxins9020068
   Jung SY, 2015, TOXINS, V7, P3715, DOI 10.3390/toxins7093715
   Khalil WKB, 2015, NEUROCHEM INT, V80, P79, DOI 10.1016/j.neuint.2014.11.008
   Khulan TS, 2015, J DIABETES METAB, V6, P0, DOI 10.4172/2155-6156.1000507
   Kim H, 2015, KIDNEY INT, V88, P550, DOI 10.1038/ki.2015.147
   Kim JY, 2017, INT J MOL MED, V39, P1188, DOI 10.3892/ijmm.2017.2922
   Kim KH, 2019, FRONT AGING NEUROSCI, V11, P0, DOI 10.3389/fnagi.2019.00080
   Kim SJ, 2012, EVID-BASED COMPL ALT, V2012, P0, DOI 10.1155/2012/305454
   Kim SJ, 2012, EXP MOL PATHOL, V93, P129, DOI 10.1016/j.yexmp.2012.04.003
   Kim SJ, 2011, J ATHEROSCLER THROMB, V18, P1117, DOI 10.5551/jat.8474
   Kim WH, 2017, PHARMACOL REP, V69, P1030, DOI 10.1016/j.pharep.2017.04.006
   Kitamura H, 2000, J PHARMACOL EXP THER, V293, P196
   Klocek G, 2009, BIOCHEMISTRY-US, V48, P2586, DOI 10.1021/bi802127h
   Kocyigit A, 2019, TOXICON, V161, P4, DOI 10.1016/j.toxicon.2019.02.016
   Komi DEA, 2018, CLIN REV ALLERG IMMU, V54, P386, DOI 10.1007/s12016-017-8597-4
   Kong GM, 2016, WORLD J GASTROENTERO, V22, P3186, DOI 10.3748/wjg.v22.i11.3186
   Krell R, 1996, FAO AGR SERVER B, V124, P0
   Kudo I, 2002, PROSTAG OTH LIPID M, V68-9, P3, DOI 10.1016/S0090-6980(02)00020-5
   Kumar A, 2004, J MOL MED, V82, P434, DOI 10.1007/s00109-004-0555-y
   Kwon YB, 2001, PAIN, V90, P271, DOI 10.1016/S0304-3959(00)00412-7
   LAMBEAU G, 1990, J BIOL CHEM, V265, P9526
   LAMBEAU G, 1989, J BIOL CHEM, V264, P11503
   Lamy C, 2010, J BIOL CHEM, V285, P27067, DOI 10.1074/jbc.M110.110072
   Landucci ECT, 2000, TOXICON, V38, P199, DOI 10.1016/S0041-0101(99)00143-9
   Leandro LF, 2015, AN ACAD BRAS CIENC, V87, P147, DOI 10.1590/0001-3765201520130511
   Lee C, 2017, ONCOTARGET, V8, P54951, DOI 10.18632/oncotarget.18627
   Lee G, 2016, MOLECULES, V21, P0, DOI 10.3390/molecules21050616
   Lee G, 2016, TOXINS, V8, P0, DOI 10.3390/toxins8020048
   Lee JE, 2019, J PHARMACOL SCI, V140, P26, DOI 10.1016/j.jphs.2019.03.009
   Lee J, 2018, VET IMMUNOL IMMUNOP, V200, P40, DOI 10.1016/j.vetimm.2018.04.006
   Lee JY, 2005, IN VIVO, V19, P801
   Lee KS, 2016, DEV COMP IMMUNOL, V63, P27, DOI 10.1016/j.dci.2016.05.011
   Lee MT, 2013, P NATL ACAD SCI USA, V110, P14243, DOI 10.1073/pnas.1307010110
   Lee WR, 2014, J INVEST DERMATOL, V134, P1922, DOI 10.1038/jid.2014.75
   Lee WR, 2011, TOXICOL APPL PHARM, V256, P209, DOI 10.1016/j.taap.2011.08.012
   Lee YJ, 2020, INFLAMMOPHARMACOLOGY, V28, P253, DOI 10.1007/s10787-019-00646-w
   Lee YM, 2020, J ETHNOPHARMACOL, V257, P0, DOI 10.1016/j.jep.2020.112860
   Li L, 2020, LIFE SCI, V256, P0, DOI 10.1016/j.lfs.2020.117893
   Lim HN, 2019, MOLECULES, V24, P0, DOI 10.3390/molecules24050929
   Lin L, 2017, BIOMED PHARMACOTHER, V90, P921, DOI 10.1016/j.biopha.2017.04.055
   Liu JJ, 2018, BBA-BIOMEMBRANES, V1860, P2234, DOI 10.1016/j.bbamem.2018.09.007
   Liu X, 2003, J CONTROL RELEASE, V93, P293, DOI 10.1016/j.jconrel.2003.08.019
   LOWY PH, 1971, ARCH BIOCHEM BIOPHYS, V145, P338, DOI 10.1016/0003-9861(71)90044-0
   Marcos JF, 1995, P NATL ACAD SCI USA, V92, P12466, DOI 10.1073/pnas.92.26.12466
   Markovic-Housley Z, 2000, STRUCTURE, V8, P1025, DOI 10.1016/S0969-2126(00)00511-6
   Pereira AFM, 2020, MICROB PATHOGENESIS, V141, P0, DOI 10.1016/j.micpath.2020.104011
   Matysiak J, 2011, J PHARMACEUT BIOMED, V54, P273, DOI 10.1016/j.jpba.2010.08.020
   Mcf C, 1870, MATERIALS, V13, P90
   Memariani H, 2020, APPL MICROBIOL BIOT, V104, P6513, DOI 10.1007/s00253-020-10701-0
   Memariani H, 2020, EUR J CLIN MICROBIOL, V39, P5, DOI 10.1007/s10096-019-03674-0
   Meng Y, 2012, CHINESE CHEM LETT, V23, P1161, DOI 10.1016/j.cclet.2012.09.003
   Rubio-Perez JM, 2012, SCI WORLD J, V0, P0, DOI DOI 10.1100/2012/756357
   Moga MA, 2018, MOLECULES, V23, P0, DOI 10.3390/molecules23030692
   Mohamed WA, 2019, TOXICOLOGY, V419, P11, DOI 10.1016/j.tox.2019.03.003
   Mohammadi-Rad M, 2019, RES PHARM SCI, V14, P424, DOI 10.4103/1735-5362.268203
   Mourelle D, 2014, PEPTIDES, V59, P42, DOI 10.1016/j.peptides.2014.07.004
   Mourre C, 1997, BRAIN RES, V778, P405, DOI 10.1016/S0006-8993(97)01165-7
   Nicolas JP, 1997, J BIOL CHEM, V272, P7173, DOI 10.1074/jbc.272.11.7173
   Orsolic N, 2012, CANCER METAST REV, V31, P173, DOI 10.1007/s10555-011-9339-3
   Otón T, 2019, BEST PRACT RES CL RH, V33, P0, DOI 10.1016/j.berh.2019.101477
   Ozturk AB, 2017, ALLERGOL IMMUNOPATH, V45, P473, DOI 10.1016/j.aller.2016.10.015
   PACAKOVA V, 1995, J CHROMATOGR A, V700, P187, DOI 10.1016/0021-9673(94)01170-J
   Pahl HL, 1999, ONCOGENE, V18, P6853, DOI 10.1038/sj.onc.1203239
   Palm NW, 2013, IMMUNITY, V39, P976, DOI 10.1016/j.immuni.2013.10.006
   Palma MS, 2013, HANDBOOK OF BIOLOGICALLYACTIVE PEPTIDES, Vsecond, P416
   Park HG, 2018, DEV COMP IMMUNOL, V85, P51, DOI 10.1016/j.dci.2018.04.001
   Park JH, 2015, PLOS ONE, V10, P0, DOI 10.1371/journal.pone.0126971
   Park JH, 2010, MOL CELLS, V29, P209, DOI 10.1007/s10059-010-0028-9
   Park MH, 2011, PROSTATE, V71, P801, DOI 10.1002/pros.21296
   Park SU, 2017, J NEUROL SCI, V381, P724, DOI 10.1016/j.jns.2017.08.2041
   Pascoal A, 2019, FOOD CHEM TOXICOL, V134, P0, DOI 10.1016/j.fct.2019.110864
   PECK ML, 1974, J AGR FOOD CHEM, V22, P51, DOI 10.1021/jf60191a002
   Peeler DJ, 2019, BIOMATERIALS, V192, P235, DOI 10.1016/j.biomaterials.2018.11.004
   Pucca MB, 2019, FRONT IMMUNOL, V10, P0, DOI 10.3389/fimmu.2019.01598
   Putz T, 2007, CANCER IMMUNOL IMMUN, V56, P627, DOI 10.1007/s00262-006-0220-0
   Qiao MX, 2007, INT J PHARMACEUT, V345, P116, DOI 10.1016/j.ijpharm.2007.05.056
   Qin G, 2016, MOL MED REP, V14, P57, DOI 10.3892/mmr.2016.5215
   Rady I, 2017, CANCER LETT, V402, P16, DOI 10.1016/j.canlet.2017.05.010
   Raghuraman H, 2007, BIOSCIENCE REP, V27, P189, DOI 10.1007/s10540-006-9030-z
   Samy RP, 2007, J APPL MICROBIOL, V102, P650, DOI 10.1111/j.1365-2672.2006.03161.x
   SCHUMACHER MJ, 1989, NATURE, V337, P413, DOI 10.1038/337413a0
   Shin JM, 2013, PLOS ONE, V8, P0, DOI 10.1371/journal.pone.0069380
   Shin SH, 2018, MOL MED REP, V17, P6632, DOI 10.3892/mmr.2018.8720
   Shin SH, 2017, TOXINS, V9, P0, DOI 10.3390/toxins9110348
   SHKENDEROV S, 1982, TOXICON, V20, P317, DOI 10.1016/0041-0101(82)90234-3
   Sobral F, 2016, FOOD CHEM TOXICOL, V94, P172, DOI 10.1016/j.fct.2016.06.008
   Soliman C, 2019, PLOS ONE, V14, P0, DOI 10.1371/journal.pone.0224028
   Somwongin S, 2018, TOXICON, V145, P32, DOI 10.1016/j.toxicon.2018.02.049
   Son DJ, 2007, PHARMACOL THERAPEUT, V115, P246, DOI 10.1016/j.pharmthera.2007.04.004
   Spencer E, 1999, GENE DEV, V13, P284, DOI 10.1101/gad.13.3.284
   Sun XJ, 2005, PEPTIDES, V26, P369, DOI 10.1016/j.peptides.2004.10.004
   Taketomi Y, 2013, NAT IMMUNOL, V14, P554, DOI 10.1038/ni.2586
   Tighilet B, 2019, NEUROPHARMACOLOGY, V144, P133, DOI 10.1016/j.neuropharm.2018.10.029
   Uddin M, 2016, J MICROBIOL, V54, P853
   Van Vaerenbergh M, 2013, INSECT MOL BIOL, V22, P199, DOI 10.1111/imb.12013
   Van Vaerenbergh M, 2014, J PROTEOMICS, V99, P169, DOI 10.1016/j.jprot.2013.04.039
   Vazquez-Revuelta P, 2018, J INVEST ALLERG CLIN, V28, P45, DOI 10.18176/jiaci.0202
   VICK JA, 1974, TOXICON, V12, P139, DOI 10.1016/0041-0101(74)90237-2
   VLASAK R, 1984, EUR J BIOCHEM, V145, P279, DOI 10.1111/j.1432-1033.1984.tb08549.x
   WACHINGER M, 1992, FEBS LETT, V309, P235, DOI 10.1016/0014-5793(92)80780-K
   Wang QQ, 2015, TRANSL NEURODEGENER, V4, P0, DOI 10.1186/s40035-015-0042-0
   Wehbe R, 2019, MOLECULES, V24, P0, DOI 10.3390/molecules24162997
   Welker S, 2011, BIOCHIMIE, V93, P195, DOI 10.1016/j.biochi.2010.09.012
   Yalcin M, 2009, PROSTAG LEUKOTR ESS, V81, P341, DOI 10.1016/j.plefa.2009.10.001
   Yang X, 2014, TUMOR BIOL, V35, P10443, DOI 10.1007/s13277-014-2218-0
   Ye M, 2016, EXP MOL MED, V48, P0, DOI 10.1038/emm.2016.49
   Ye M, 2016, J NEUROINFLAMM, V13, P0, DOI 10.1186/s12974-016-0476-z
   Yin DC, 2018, HEART RHYTHM, V15, P761, DOI 10.1016/j.hrthm.2018.01.016
   Yu X, 2019, NAT COMMUN, V10, P0, DOI 10.1038/s41467-019-08538-x
   Zhang H, 2014, PLOS ONE, V9, P0, DOI 10.1371/journal.pone.0095520
   Zhang S, 2018, TOXICON, V148, P64, DOI 10.1016/j.toxicon.2018.04.012
   ZIAI MR, 1990, J PHARM PHARMACOL, V42, P457, DOI 10.1111/j.2042-7158.1990.tb06595.x
NR 172
TC 125
Z9 143
U1 1
U2 50
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
SN 
EI 2072-6643
J9 NUTRIENTS
JI Nutrients
PD NOV 15
PY 2020
VL 12
IS 11
BP 
EP 
DI 10.3390/nu12113360
PG 27
WC Nutrition & Dietetics
SC Nutrition & Dietetics
GA OX6TN
UT WOS:000593694600001
PM 33142794
DA 2026-01-16
ER

PT J
AU Lopes-Júnior, LC
   Rosa, GS
   Pessanha, RM
   Schuab, SIPC
   Nunes, KZ
   Amorim, MHC
AF Lopes-Júnior, Luís Carlos
   Rosa, Gabriela Sylvestre
   Pessanha, Raphael Manhães
   Schuab, Sara Isabel Pimentel de Carvalho
   Nunes, Karolini Zuqui
   Amorim, Maria Helena Costa
TI Efficacy of the complementary therapies in the management of cancer pain in
SO Revista latino-americana de enfermagem
LA English
DT Journal Article
AB OBJECTIVE: to synthesize the knowledge and to critically evaluate the evidences  arising from randomized controlled trials on the efficacy of the complementary  therapies in the management of cancer pain in adult patients with cancer in  palliative care. METHOD: a systematic review guided by the Preferred Reporting  Items for Systematic Reviews and Meta-Analyses. The search for articles in the  MEDLINE, ISI Web of Knowledge, CENTRAL Cochrane, and PsycINFO databases, as well  as the manual search, selection of studies, data extraction, and methodological  assessment using the Cochrane Bias Risk tool were performed independently by two  reviewers. RESULTS: eight hundred and fifteen (815) studies were identified, six  of them being selected and analyzed, of which three used massage therapy, one  study used a combination of progressive muscle relaxation and guided imaging, and  another two studies used acupuncture. Most of the studies had an uncertain risk  of bias (n=4; 67%). CONCLUSION: while the evidence from the studies evaluating  the use of massage therapy or the use of progressive muscle relaxation and guided  imaging for the management of cancer pain in these patients demonstrated  significant benefits, the other two studies that evaluated the use of acupuncture  as a complementary therapy showed contradictory results, therefore, needing more  research studies to elucidate such findings.
NR 0
TC 0
SN 1518-834
EI 0104-116
J9 Rev Lat Am Enfermagem
PD OCT 8
PY 2020
VL 28
IS 
BP e3377
EP e3377
DI 10.1590/1518-8345.4213.3377
PG 1
WC Acupuncture Therapy; Adult; Cancer Pain; therapy; Complementary Therapies; Humans; Massage; Neoplasms; complications; Palliative Care
UT PubMed:33027406
PM 33027406
DA 2020-10-08
ER

PT J
AU Li, D
   Chung, G
   Kim, SK
AF Li, Daxian
   Chung, Geehoon
   Kim, Sun Kwang
TI The Involvement of Central Noradrenergic Pathway in the Analgesic Effect of Bee
SO Toxins
LA English
DT Journal Article
DE adrenergic receptor; bee venom acupuncture; chemotherapy-induced peripheral neuropathy; locus coeruleus; spinal wide dynamic range neuron; vincristine
AB Vincristine is a vinca alkaloid anti-mitotic drug with a broad spectrum of  effects on solid and hematologic cancers. The major dose-limiting factor of this  anti-cancer regimen is painful peripheral neuropathy. However, no gold-standard  analgesic option has been used clinically. In this study, we investigated the  effects and mechanism of bee venom acupuncture (BVA) to alleviate peripheral  neuropathic pain induced by repeated intraperitoneal infusions of vincristine (1  mg/kg/day, days 1-5 and 8-12) in rats. Subcutaneous injection with bee venom (BV,  1.0 mg/kg) at the ST36 acupoint ameliorated cold and mechanical hypersensitivity  (i.e., aberrant withdrawal responses in acetone drop and von Frey hair tests,  respectively). In vivo extracellular recording demonstrated that BVA inhibited  cutaneous cold (acetone) and mechanical (brush, press, and pinch)  stimuli-elicited abnormal hyperexcitation of the spinal wide dynamic range (WDR)  neurons in vincristine-treated rats. In addition, the microinjection of lidocaine  into the ipsilateral locus coeruleus or the antagonism of the spinal  α(2)-adrenergic receptors clearly reversed the effects of BVA on cold and  mechanical hypersensitivity, indicating a vital role of the descending  noradrenergic modulation in analgesia. These findings suggest that BVA could be a  potential therapeutic option for vincristine-induced peripheral neuropathy.
C1 Department of Science in Korean Medicine, Graduate School, Kyung Hee University, Seoul 02447, Korea.
   Department of Physiology, College of Korean Medicine, Kyung Hee University, Seoul 02447, Korea.
   Department of Science in Korean Medicine, Graduate School, Kyung Hee University, Seoul 02447, Korea.
   Department of Physiology, College of Korean Medicine, Kyung Hee University, Seoul 
   Department of East-West Medicine, Graduate School, Kyung Hee University, Seoul 02447, Korea.
NR 0
TC 0
SN 2072-665
EI 
J9 Toxins (Basel)
PD DEC 10
PY 2020
VL 12
IS 12
BP 
EP 
DI 10.3390/toxins12120775
PG 0
WC Acupuncture Points; Acupuncture Therapy; methods; Adrenergic Neurons; drug effects; Animals; Antineoplastic Agents, Phytogenic; toxicity; Bee Venoms; administration & dosage; Male; Microinjections; methods; Peripheral Nervous System Diseases; chemically induced; Rats; Rats, Sprague-Dawley; Vincristine; toxicity
UT PubMed:33291335
PM 33291335
DA 2020-12-10
ER

PT J
AU Liou, KT
   Mao, JJ
AF Liou, Kevin T
   Mao, Jun J
TI In reply to "could acupuncture be a treatment option for cancer patients with
SO Supportive care in cancer : official journal of the Multinational Association of
LA English
DT Letter
C1 Integrative Medicine Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, 1429 First Avenue, New York, NY, 10021, USA. liouk@mskcc.org.
   Integrative Medicine Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, 1429 First Avenue, New York, NY, 10021, USA.
NR 0
TC 0
SN 1433-733
EI 
J9 Support Care Cancer
PD OCT 29
PY 2020
VL 29
IS 1
BP 5
EP 5
DI 10.1007/s00520-020-05844-9
PG 0
WC Acupuncture Therapy; Cancer Pain; drug therapy; Humans; Neoplasms; complications; Pain Management
UT PubMed:33111181
PM 33111181
DA 2020-10-29
ER

PT J
AU Turawa, EB
   Musekiwa, A
   Rohwer, AC
AF Turawa, Eunice B.
   Musekiwa, Alfred
   Rohwer, Anke C.
TI Interventions for preventing postpartum constipation
SO COCHRANE DATABASE OF SYSTEMATIC REVIEWS
LA English
DT Review
DE Constipation [*prevention & control]; Dietary Fiber [*therapeutic use]; Laxatives [*therapeutic use]; Perineum [injuries]; *Postpartum Period; Randomized Controlled Trials as Topic; Adult; Female; Humans
ID maternal health; clinical-trial; primary repair; epidemiology; prevalence; symptoms; women
AB Background Postpartum constipation, with symptoms, such as pain or discomfort, straining, and hard stool, is a common condition affecting mothers. Haemorrhoids, pain at the episiotomy site, effects of pregnancy hormones, and haematinics used in pregnancy can increase the risk of postpartum constipation. Eating a high-fibre diet and increasing fluid intake are usually encouraged. Although laxatives are commonly used in relieving constipation, the effectiveness and safety of available interventions for preventing postpartum constipation should be ascertained. This is an update of a review first published in 2015. Objectives To evaluate the effectiveness and safety of interventions for preventing postpartum constipation. Search methods We searched Cochrane Pregnancy and Childbirth's Trials Register, and two trials registers ClinicalTrials.gov, the WHO International Clinical Trials Registry Platform (ICTRP) (7 October 2019), and screened reference lists of retrieved trials. Selection criteria We considered all randomised controlled trials (RCTs) comparing any intervention for preventing postpartum constipation versus another intervention, placebo, or no intervention in postpartum women. Interventions could include pharmacological (e.g. laxatives) and non-pharmacological interventions (e.g. acupuncture, educational and behavioural interventions). Quasi-randomised trials and cluster-RCTs were eligible for inclusion; none were identified. Trials using a cross-over design were not eligible. Data collection and analysis Two review authors independently screened the results of the search to select potentially relevant trials, extracted data, assessed risk of bias, and the certainty of the evidence, using the GRADE approach. We did not pool results in a meta-analysis, but reported them per study. Main results We included five trials (1208 postpartum mothers); three RCTs and two quasi-RCTs. Four trials compared a laxative with placebo; one compared a laxative plus a bulking agent versus the same laxative alone, in women who underwent surgical repair of third degree perineal tears. Trials were poorly reported, and four of the five trials were published over 40 years ago. We judged the risk of bias to be unclear for most domains. Overall, we found a high risk of selection and attrition bias. Laxative versus placebo We included four triaLs in this comparison. Two of the trials examined the effects of Laxatives that are no Longer used; one has been found to have carcinogenic properties (Danthron), and the other is not recommended for lactating women (Bisoxatin acetate); therefore, we did not include their results in our main findings. None of the trials included in this comparison assessed our primary outcomes: pain or straining on defecation, incidence of postpartum constipation, or quality of life; or many of our secondary outcomes. A laxative (senna) may increase the number of women having their first bowel movement within 24 hours after delivery (risk ratio (RR) 2.90, 95% confidence interval (CI) 2.24 to 3.75; 1 trial, 471 women; low-certainty evidence); may have little or no effect on the number of women having their first bowel movement on day one after delivery (RR 0.94, 95% CI 0.72 to 1.22; 1 trial, 471 women; very low-certainty evidence); may reduce the number of women having their first bowel movement on day two (RR 0.23, 95% CI 0.11 to 0.45; 1 trial, 471 women; low-certainty evidence); and day three (RR 0.05, 95% CI 0.00 to 0.89; 1 trial, 471 women; low-certainty evidence); and may have litte or no effect on the number of women having their first bowel movement on day four after delivery (RR 0.22, 95% CI 0.03 to 1.87; 1 trial, 471 women; very low-certainty evidence), but some of the evidence is very uncertain. Adverse effects were poorly reported. Low-certainty evidence suggests that the laxative (senna) may increase the number of women experiencing abdominal cramps (RR 4.23, 95% CI 1.75 to 10.19; 1 trial, 471 women). Very low-certainty evidence suggests that laxatives taken by the mother may have little or no effect on Loose stooLs in the baby (RR 0.62, 95% CI 0.16 to 2.41; 1 triaL, 281 babies); or diarrhoea (RR 2.46, 95% CI 0.23 to 26.82; 1 trial, 281 babies). Laxative plus bulking agent versus laxative only Very Low-certainty evidence from one trial (147 women) suggests no evidence of a difference between these two groups of women who underwent surgical repair of third degree perineal tears; only median and range data were reported. The trial also reported no evidence of a difference in the incidence of postpartum constipation (data not reported), but did not report on quality of life. Time to first bowel movement was reported as a median (range); very low-certainty evidence suggests little or no difference between the two groups. A laxative plus bulking agent may increase the number of women having any episode of faecal incontinence during the first 10 days postpartum (RR 1.81, 95% CI 1.01 to 3.23; 1 trial, 147 women; very low-certainty evidence). The trial did not report on adverse effects of the intervention on babies, or many of our secondary outcomes. Authors' conclusions There is insufficient evidence to make general conclusions about the effectiveness and safety of laxatives for preventing postpartum constipation. The evidence in this review was assessed as low to very low-certainty evidence, with downgrading decisions based on limitations in study design, indirectness and imprecision. We did not identify any trials assessing educational or behavioural interventions. We identified four trials that examined laxatives versus placebo, and one that examined laxatives versus laxatives plus stool bulking agents. Further, rigorous trials are needed to assess the effectiveness and safety of laxatives during the postpartum period for preventing constipation. Trials shouLd assess educationaL and behavioural interventions, and positions that enhance defecation. They should report on the primary outcomes from this review: pain or straining on defecation, incidence of postpartum constipation, quality of life, time to first bowel movement after delivery, and adverse effects caused by the intervention, such as: nausea or vomiting, pain, and flatus.
C1 [Turawa, Eunice B.] Stellenbosch Univ, Fac Med & Hlth Sci, Dept Global Hlth, Div Hlth Syst & Publ Hlth, Cape Town, South Africa.
   [Turawa, Eunice B.] South African Med Res Council, Burden Dis Res Unit, Cape Town, South Africa.
   [Musekiwa, Alfred] Stellenbosch Univ, Fac Med & Hlth Sci, Ctr Evidence Based Hlth Care, Div Epidemiol & Biostat, Cape Town, South Africa.
   [Rohwer, Anke C.] Stellenbosch Univ, Fac Med & Hlth Sci, Ctr Evidence Based Hlth Care, Cape Town, South Africa.
C3 Stellenbosch University; South African Medical Research Council; Stellenbosch University; Stellenbosch University
RP Turawa, EB (corresponding author), Stellenbosch Univ, Fac Med & Hlth Sci, Dept Global Hlth, Div Hlth Syst & Publ Hlth, Cape Town, South Africa.; Turawa, EB (corresponding author), South African Med Res Council, Burden Dis Res Unit, Cape Town, South Africa.
EM kbolanle@gmail.com
FU National Institute for Health Research (NIHR) Cochrane Review Incentive Scheme award, UK [14/175/47]; Research, Evidence and Development Initiative (READ-It) project, UK
CR Aksu S, 2017, CONTEMP NURSE, V53, P167, DOI 10.1080/10376178.2016.1258315
   Alonso-Coello P, 2005, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD004649.pub2
   Andrews Christopher N, 2011, CAN J GASTROENTEROL, V25 Suppl B, P0
   Unknown -, 2009, BMJ-BRIT MED J, V6, Pe1000097, DOI 10.1136/bmj.b2535, 10.1371/journal.pmed.1000097, 10.1371/JOURNAL.PMED.1000097
   Unknown -, 2014, DIOCTYL SULFOSUCCINA, V0, P0
   Unknown -, 2015, GRADEPRO GDT, V0, P0
   Unknown -, 2014, REVIEW MANAGER (REVMAN) VERSION 5.3, V0, P0
   Unknown -, 1998, MATERNAL AND NEWBORN HEALTH/SAFE MOTHERHOOD UNIT: POSTPARTUM CARE OF THE MOTHER AND NEWBORN: A PRACTICAL GUIDE: REPORT OF A TECHNICAL WORKING GROUP, V0, P0
   Unknown -, 2002, BREASTF MAT MED REC, V0, P0
   Balch PA, 2010, PRESCRIPTION FOR NUTRITIONAL HEALING, V0, P0
   BARTH JH, 1984, CLIN EXP DERMATOL, V9, P95, DOI 10.1111/j.1365-2230.1984.tb00763.x
   Borders N, 2006, J MIDWIFERY WOM HEAL, V51, P242, DOI 10.1016/j.jmwh.2005.10.014
   Brown S, 1998, BRIT J OBSTET GYNAEC, V105, P156, DOI 10.1111/j.1471-0528.1998.tb10045.x
   Candy B, 2011, SAO PAULO MED J, V129, P277, DOI 10.1002/14651858.CD003448.pub3
   Cappell J, 2017, MIDWIFERY, V50, P125, DOI 10.1016/j.midw.2017.04.002
   Cheng CY, 2006, J PERINAT EDUC, V15, P34, DOI 10.1624/105812406X119002
   Davies GAL, 2003, CAN J APPL PHYSIOL, V28, P329, DOI 10.1139/h03-024
   De Groot N, 2018, PLOS ONE, V13, P0, DOI 10.1371/journal.pone.0202960
   DIAMOND RA, 1968, J LANCET, V88, P16
   Drossman DA, 2016, GASTROENTEROLOGY, V150, P1262, DOI 10.1053/j.gastro.2016.02.032
   Eogan M, 2007, BJOG-INT J OBSTET GY, V114, P736, DOI 10.1111/j.1471-0528.2007.01331.x
   Fakheri RJ, 2019, J HOSP MED, V14, P110, DOI 10.12788/jhm.3124
   Gordon M, 2012, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD009118.pub2
   Gözüm S, 2005, MIDWIFERY, V21, P371, DOI 10.1016/j.midw.2005.02.005
   Higgins JP GS, 2011, COCHRANE HDB SYSTEMA, V4, P9.5.2, DOI 10.1002/9780470712184
   Higgins PDR, 2004, AM J GASTROENTEROL, V99, P750, DOI 10.1111/j.1572-0241.2004.04114.x
   Kabakian-Khasholian T, 2014, WOMEN BIRTH, V27, P15, DOI 10.1016/j.wombi.2013.02.002
   Lee-Robichaud H, 2010, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD007570.pub2
   Lewis SJ, 1997, SCAND J GASTROENTERO, V32, P920, DOI 10.3109/00365529709011203
   Lin LW, 2009, J ALTERN COMPLEM MED, V15, P1335, DOI 10.1089/acm.2008.0373
   Liu N, 2009, BMC PUBLIC HEALTH, V9, P0, DOI 10.1186/1471-2458-9-45
   MACARTHUR C, 1991, BRIT J OBSTET GYNAEC, V98, P1193, DOI 10.1111/j.1471-0528.1991.tb15386.x
   MacMillan TE, 2016, AM J MED, V129, P0, DOI 10.1016/j.amjmed.2016.04.008
   Mahony R, 2004, DIS COLON RECTUM, V47, P12, DOI 10.1007/s10350-003-0009-6
   Mahony Rhona, 2002, AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, V187, P0
   Mottola Michelle F, 2002, CURR SPORTS MED REP, V1, P362, DOI 10.1249/00149619-200212000-00010
   Mugie SM, 2011, BEST PRACT RES CL GA, V25, P3, DOI 10.1016/j.bpg.2010.12.010
   MUNDOW L, 1975, BRIT J CLIN PRACT, V29, P95
   National Institute of Health: National Institute of Diabetes and Digestive and Kidney Diseases (NIH-NIDDK), 2018, CONSTIPATION, V0, P0
   Omega Pharma Blegium NVWylaxine, 2016, SUMMARY PRODUCT CHAR, V0, P0
   Peppas G, 2008, BMC GASTROENTEROL, V8, P0, DOI 10.1186/1471-230X-8-5
   Schmidt FMQ, 2014, J WOUND OSTOMY CONT, V41, P70, DOI 10.1097/01.WON.0000438019.21229.b7
   Ramkumar D, 2005, AM J GASTROENTEROL, V100, P936, DOI 10.1111/j.1572-0241.2005.40925.x
   Romano Mattea, 2010, J PRENAT MED, V4, P22
   Rungsiprakarn Phassawan, 2015, COCHRANE DATABASE SYST REV, V0, PPCD011448, DOI 10.1002/14651858.CD011448.pub2
   Sakai T, 2015, BENEF MICROBES, V6, P253, DOI 10.3920/BM2014.0076
   Schunemann H, 2013, HDB GRADING QUALITY, V0, P0
   SHELTON MG, 1980, S AFR MED J, V57, P78
   Sunitha D, 2016, ASIAN JOURNAL OF PHARMACEUTICAL RESEARCH, V6, P205, DOI 10.5958/2231-5691.2016.00029.0
   Turawa EB, 2014, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD010273.pub2
   van Brummen HJ, 2006, INT UROGYNECOL J, V17, P224, DOI 10.1007/s00192-005-1351-0
   Xing JH, 2001, DIS COLON RECTUM, V44, P1201, DOI 10.1007/BF02234645
   ZUSPAN FP, 1960, AM J OBSTET GYNECOL, V80, P548
NR 57
TC 10
Z9 13
U1 4
U2 39
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1469-493X
EI 1361-6137
J9 COCHRANE DB SYST REV
JI Cochrane Database Syst Rev.
PD JUN 15
PY 2020
VL 0
IS 8
BP 
EP 
DI 10.1002/14651858.CD011625.pub3
PG 46
WC Medicine, General & Internal
SC General & Internal Medicine
GA NN3IF
UT WOS:000568684200041
PM 32761813
DA 2026-01-16
ER

PT J
AU Behzadmehr, R
   Dastyar, N
   Moghadam, MP
   Abavisani, M
   Moradi, M
AF Behzadmehr, Razieh
   Dastyar, Neda
   Moghadam, Mahdieh Poodineh
   Abavisani, Mahnaz
   Moradi, Mandana
TI Effect of complementary and alternative medicine interventions on cancer related
SO Complementary therapies in medicine
LA English
DT Journal Article
DE Breast neoplasm; Cancer related pain; Complementary and alternative medicine; Systematic review
AB OBJECTIVE: This systematic review aimed to evaluate the efficacy of CAM  interventions for cancer-related pain in breast cancer patients. METHODS:  Databases (PubMed, Scopus, Web of Science, and EMBASE) were searched from January  1, 2000, up to April 31, 2019, using the keywords: Complementary and alternative  medicine therapies and cancer related pain. Standard tools were used to evaluate  the quality of the studies included. RESULTS: Of the 3742 articles found, 46  articles comprising 3685 participants entered the final phase. Our results  indicate that interventions including acupuncture/acupressure, tai chi/qi gong,  hypnosis, meditation, music therapy, yoga, massage, reflexology, and Reiki  improve cancer-related pain in breast cancer patients. However, aromatherapy had  no effect on the same. CONCLUSIONS: Despite the positive effect of various CAM  interventions in reducing cancer-related pain, necessary precautions should be  adopted to use them alongside other treatments to control cancer pain in the  clinical setting.
C1 Department of Radiology, School of Medicine, Zabol University of Medical Sciences, Zabol, Iran.
   Department of Midwifery, Jiroft University of Medical Sciences, Jiroft, Iran.
   Department of Nursing, Faculty of Nursing and Midwifery, Zabol University of Medical Sciences, Zabol, Iran.
   MSc of Medical Surgical Nursing, Department of Nursing, Neyshabur University of Medical Sciences, Neyshabur, Iran.
   Clinical Pharmacy Department, School of Pharmacy, Zabol University of Medical Sciences, Zabol, Iran.
EM mmandana310@gmail.com
NR 0
TC 0
SN 1873-696
EI 
J9 Complement Ther Med
PD MAR 10
PY 2020
VL 49
IS 
BP 102318
EP 102318
DI 10.1016/j.ctim.2020.102318
PG 0
WC Breast Neoplasms; complications; Cancer Pain; etiology; Complementary Therapies; methods; Female; Humans
UT PubMed:32147038
PM 32147038
DA 2020-03-10
ER

PT J
AU Li, JL
   Liu, CZ
   Zhang, N
   Yan, CQ
   Tu, JF
   Wang, LQ
   Qi, YS
   Liu, JH
   Wang, X
AF Li, Jin-Ling
   Liu, Cun-Zhi
   Zhang, Na
   Yan, Chao-Qun
   Tu, Jian-Feng
   Wang, Li-Qiong
   Qi, You-Sheng
   Liu, Jun-Hong
   Wang, Xu
TI Neurological and psychological mechanisms of the specific and nonspecific effects of acupuncture on knee osteoarthritis: study protocol for a randomized, controlled, crossover trial
SO TRIALS
LA English
DT Article
DE Acupuncture; Functional magnetic resonance imaging; Nonspecific effect; Psychological factors; Specific effect
ID sham acupuncture; breast-cancer; hot flashes; brain; pain; scale; migraine; women; electroacupuncture; expectancy
AB Background: Acupuncture, as one of the promising non-pharmacological interventions, has been proved to be beneficial for patients. However, the magnitude of acupuncture's specific and nonspecific effects, as well as their neurological and psychological determinants, remains unclear. Therefore, this study is designed to examine the acupuncture efficacy, investigate whether the brain mechanisms between the specific and nonspecific effects of acupuncture are different, and to evaluate how psychological factors affect the acupuncture effects. Methods: This is a randomized, controlled, crossover clinical trial. A total of 60 patients with knee osteoarthritis will receive 4 weeks of acupuncture treatment and 4 weeks of sham acupuncture treatment in a random order separated by a washout period of 2 weeks. The changes in clinical characteristics based on pain-related scales will be assessed to investigate the clinical efficacy of acupuncture. Resting state functional magnetic resonance imaging (fMRI) scans will be used to identify the brain activity changes related to the specific and nonspecific effects of acupuncture. The questionnaires of psychological factors will be used to evaluate patients' psychological properties. Correlation and mediation analyses will be conducted among psychological factors, brain activity changes, and symptoms improvement to explore the neurological and psychological correlates of the acupuncture effects. Discussion: This study will concentrate on distinguishing and clarifying the specific and nonspecific effects of acupuncture. The results of this study may contribute to rationally optimize the acupuncture therapies by flexible application of the specific and nonspecific effects of acupuncture.
C1 [Li, Jin-Ling; Liu, Cun-Zhi; Zhang, Na; Yan, Chao-Qun; Tu, Jian-Feng; Wang, Li-Qiong] Beijing Univ Chinese Med, Sch Acupuncture Moxibust & Tuina, Acupuncture Res Ctr, Beijing 100029, Peoples R China.
   [Qi, You-Sheng; Liu, Jun-Hong] Nanyuan Community Hlth Serv Ctr, Beijing 100076, Peoples R China.
   [Wang, Xu] Beijing Univ Chinese Med, Sch Life Sci, Beijing 100029, Peoples R China.
C3 Beijing University of Chinese Medicine; Beijing University of Chinese Medicine
RP Wang, X (corresponding author), Beijing Univ Chinese Med, Sch Life Sci, Beijing 100029, Peoples R China.
EM wangx@bucm.edu.cn
FU Beijing Municipal Science & Technology Commission [D171100003217003]
CR Aslaksen PM, 2018, PAIN, V159, P2585, DOI 10.1097/j.pain.0000000000001370
   BELLAMY N, 1988, J RHEUMATOL, V15, P1833
   Black DS, 2012, ASSESSMENT, V19, P42, DOI 10.1177/1073191111415365
   Borsa PA, 2018, J PAIN RES, V11, P2497, DOI 10.2147/JPR.S171498
   Briggs JP, 2017, JAMA-J AM MED ASSOC, V317, P2489, DOI 10.1001/jama.2017.7214
   Brown KW, 2003, J PERS SOC PSYCHOL, V84, P822, DOI 10.1037/0022-3514.84.4.822
   Cao J, 2019, CEREB CORTEX, V29, P3220, DOI 10.1093/cercor/bhy190
   Carciofo R, 2016, PLOS ONE, V11, P0, DOI 10.1371/journal.pone.0149963
   Desmond JE, 2002, J NEUROSCI METH, V118, P115, DOI 10.1016/S0165-0270(02)00121-8
   Ee C, 2016, ANN INTERN MED, V164, P146, DOI 10.7326/M15-1380
   Egorova N, 2015, NEUROIMAGE-CLIN, V9, P430, DOI 10.1016/j.nicl.2015.09.012
   Eldridge SM, 2016, BMJ-BRIT MED J, V355, P0, DOI 10.1136/bmj.i5239
   Fox MD, 2007, NAT REV NEUROSCI, V8, P700, DOI 10.1038/nrn2201
   George SZ, 2016, ARTHRIT CARE RES, V68, P1671, DOI 10.1002/acr.22876
   Geuter S, 2017, ANNU REV NEUROSCI, V40, P167, DOI 10.1146/annurev-neuro-072116-031132
   Gollub RL, 2018, J PAIN, V19, P515, DOI 10.1016/j.jpain.2017.12.260
   GRUNBAUM A, 1986, PSYCHOL MED, V16, P19, DOI 10.1017/S0033291700002506
   Hall KT, 2015, TRENDS MOL MED, V21, P285, DOI 10.1016/j.molmed.2015.02.009
   Hershman DL, 2018, JAMA-J AM MED ASSOC, V320, P167, DOI 10.1001/jama.2018.8907
   Hinman RS, 2014, JAMA-J AM MED ASSOC, V312, P1313, DOI 10.1001/jama.2014.12660
   HOCHBERG MC, 1995, ARTHRITIS RHEUM, V38, P1541, DOI 10.1002/art.1780381104
   Kaptchuk TJ, 2010, PLOS ONE, V5, P0, DOI 10.1371/journal.pone.0015591
   Karner M, 2013, EVID-BASED COMPL ALT, V2013, P0, DOI 10.1155/2013/427265
   KELLGREN JH, 1957, ANN RHEUM DIS, V16, P494, DOI 10.1136/ard.16.4.494
   Kong J, 2018, NEUROIMAGE-CLIN, V18, P325, DOI 10.1016/j.nicl.2018.01.021
   Li ZJ, 2017, NEUROIMAGE-CLIN, V15, P367, DOI 10.1016/j.nicl.2017.05.013
   Linde K, 2010, BMC MED, V8, P0, DOI 10.1186/1741-7015-8-75
   Liu BY, 2014, MEDICINE, V93, P0, DOI 10.1097/MD.0000000000000200
   Liu JX, 2017, HUM BRAIN MAPP, V38, P4386, DOI 10.1002/hbm.23667
   Liu ZS, 2017, JAMA-J AM MED ASSOC, V317, P2493, DOI 10.1001/jama.2017.7220
   Ma YN, 2016, P NATL ACAD SCI USA, V113, P9256, DOI 10.1073/pnas.1604285113
   Mao JJ, 2015, J CLIN ONCOL, V33, P3615, DOI 10.1200/JCO.2015.60.9412
   Maria AS, 2016, CAN J PSYCHIAT, V61, P652, DOI 10.1177/0706743716639936
   Meissner K, 2013, JAMA INTERN MED, V173, P1941, DOI 10.1001/jamainternmed.2013.10391
   MELZACK R, 1987, PAIN, V30, P191, DOI 10.1016/0304-3959(87)91074-8
   Mumford JA, 2008, NEUROIMAGE, V39, P261, DOI 10.1016/j.neuroimage.2007.07.061
   Peciña M, 2013, NEUROPSYCHOPHARMACOL, V38, P639, DOI 10.1038/npp.2012.227
   Qiu K, 2016, EVID-BASED COMPL ALT, V2016, P0, DOI 10.1155/2016/3685785
   Smith CA, 2018, JAMA-J AM MED ASSOC, V319, P1990, DOI 10.1001/jama.2018.5336
   Tu YH, 2019, NEUROIMAGE-CLIN, V23, P0, DOI 10.1016/j.nicl.2019.101885
   Tubach F, 2005, ANN RHEUM DIS, V64, P29, DOI 10.1136/ard.2004.022905
   Vachon-Presseau E, 2018, NAT COMMUN, V9, P0, DOI 10.1038/s41467-018-05859-1
   Vase L, 2013, PAIN, V154, P1659, DOI 10.1016/j.pain.2013.05.008
   Vickers AJ, 2014, JAMA-J AM MED ASSOC, V311, P955, DOI 10.1001/jama.2013.285478
   Wang RS, 2017, JCI INSIGHT, V2, P0, DOI 10.1172/jci.insight.93911
   Williams CM, 2012, BRIT J SPORT MED, V46, P578, DOI 10.1136/bjsports-2012-091229
   Yan CG, 2016, NEUROINFORMATICS, V14, P339, DOI 10.1007/s12021-016-9299-4
   Younger J, 2012, CLIN TRIALS, V9, P767, DOI 10.1177/1740774512465064
   Zhang HH, 2017, ACCIDENT ANAL PREV, V103, P29, DOI 10.1016/j.aap.2017.03.016
   Zhao L, 2017, JAMA INTERN MED, V177, P508, DOI 10.1001/jamainternmed.2016.9378
NR 50
TC 4
Z9 6
U1 3
U2 31
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 
EI 1745-6215
J9 TRIALS
JI Trials
PD DEC 30
PY 2020
VL 21
IS 1
BP 
EP 
DI 10.1186/s13063-020-04908-9
PG 10
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA PB4PK
UT WOS:000596304400004
PM 33256796
DA 2026-01-16
ER

PT J
AU Lee, JH
   Cho, TJ
   Park, MG
   Kim, JH
   Song, SK
   Park, SY
   Sunwoo, YY
   Lee, I
   Park, TY
AF Lee, Jin-Hyun
   Cho, Tae Jin
   Park, Min Geun
   Kim, Ji-Hoon
   Song, Sung Kyu
   Park, Shin-Young
   Sunwoo, Yun-Young
   Lee, Ilkyun
   Park, Tae-Yong
TI Clinical study on concurrent use of electro-acupuncture or Chuna manual therapy with pregabalin for chemotherapy-induced peripheral neuropathy: safety and effectiveness (open-labeled, parallel, randomized controlled trial, assessor-blinded) A study protocol
SO MEDICINE
LA English
DT Article
DE acupuncture; chemotherapy-induced peripheral neuropathy; electroacupuncture; manual medicine; pregabalin
ID quality-of-life; american society; oncology; questionnaire; acupuncture; validation; management; survivors; patient
AB Introduction: Chemotherapy-induced peripheral neuropathy (CIPN) is one of the major side effects of chemotherapy. Its main symptoms are pain, paresthesia, and numbness. However, the mechanisms underlying the development of CIPN remain unclear and standard treatments have not been established. Recently, there has been a growing interest in various approaches to overcome the limitations of the existing treatments. This study aims to evaluate the efficacy and safety of the concurrent use of two complementary and alternative therapies: electroacupuncture (EA) and Chuna manual therapy (CMT), with pregabalin, which is the conventional pharmacotherapy for neuropathic pain. Methods/design: This is an open-label, parallel, assessor-blinded randomized controlled trial, which includes 90 patients with colorectal and breast cancer, who developed CIPN. After a 2-week preparation period, the patients are divided into three groups (pregabalin administration group, pregabalin + EA treatment group, and pregabalin + CMT treatment group), treated for approximately 5 weeks and followed-up 4 weeks after treatment. The primary outcome is assessed using the Functional Assessment of Cancer Therapy/Gynecologic Oncology Group Neurotoxicity subscale score (version 4.0) and the secondary outcome is measured using the Quality of Life Questionnaire-CIPN 20-Item Scale (version 3.0) and the quality of life questionnaire (version 3.0) developed by the European Organisation for Research and Treatment of Cancer. Moreover, exploratory efficacy and safety evaluations will be conducted based on the chemotherapy-completion rate and nerve conduction studies.
C1 [Lee, Jin-Hyun; Park, Tae-Yong] Catholic Kwandong Univ Int, Inst Integrat Med, St Marys Hosp, Simgok Ro 100gil 25, Incheon 22711, South Korea.
   [Cho, Tae Jin; Lee, Ilkyun] Catholic Kwandong Univ Int, Dept Emergency Med, St Marys Hosp, Coll Med, Incheon, South Korea.
   [Park, Min Geun; Song, Sung Kyu; Park, Shin-Young] Catholic Kwandong Univ Int, Coll Med, Dept Surg, St Marys Hosp, Incheon, South Korea.
   [Kim, Ji-Hoon] Catholic Univ Korea, Incheon St Marys Hosp, Dept Surg, Incheon, South Korea.
   [Sunwoo, Yun-Young] Iksoodang Korean Med Clin, Incheon, South Korea.
C3 Catholic Kwandong University; Catholic Kwandong University; Catholic Kwandong University; Catholic University of Korea
RP Park, TY (corresponding author), Catholic Kwandong Univ Int, Inst Integrat Med, St Marys Hosp, Simgok Ro 100gil 25, Incheon 22711, South Korea.; Lee, I (corresponding author), Catholic Kwandong Univ Int, Dept Surg, St Marys Hosp, Simgok Ro 100gil 25, South Korea 22711, South Korea.
EM iklee68@gmail.com; parktae9822@gmail.com
CR Argyriou AA, 2014, CANCER MANAG RES, V6, P135, DOI 10.2147/CMAR.S44261
   Cavaletti G, 2010, NAT REV NEUROL, V6, P657, DOI 10.1038/nrneurol.2010.160
   Cunningham JE, 2011, SUPPORT CARE CANCER, V19, P1473, DOI 10.1007/s00520-011-1231-8
   Eldridge S, 2020, TOXICOL PATHOL, V48, P190, DOI 10.1177/0192623319861937
   Gutiérrez-Gutiérrez G, 2010, CLIN TRANSL ONCOL, V12, P81, DOI 10.1007/S12094-010-0474-z
   Haryani H, 2017, ONCOL NURS FORUM, V44, PE111, DOI 10.1188/17.ONF.E111-E123
   Hershman DL, 2014, J CLIN ONCOL, V32, P1941, DOI 10.1200/JCO.2013.54.0914
   Hou S, 2018, PAIN PHYSICIAN, V21, P571, DOI 10.36076/ppj.2018.6.571
   Hu LY, 2019, CURR NEUROPHARMACOL, V17, P184, DOI 10.2174/1570159X15666170915143217
   Huang HQ, 2007, INT J GYNECOL CANCER, V17, P387, DOI 10.1111/j.1525-1438.2007.00794.x
   Kim HY, 2013, ASIAN ONCOL NURS, V13, P222, DOI 10.5388/aon.2013.13.4.222
   Kim JH, 2013, TRIALS, V14, P0, DOI 10.1186/1745-6215-14-254
   Kyriaki M, 2001, INT J CANCER, V94, P135
   Lu WD, 2018, HEMATOL ONCOL CLIN N, V32, P519, DOI 10.1016/j.hoc.2018.01.009
   Lu ZX, 2017, J ALTERN COMPLEM MED, V23, P964, DOI 10.1089/acm.2017.0052
   Oh PJ, 2018, J KOREAN ACAD NURS, V48, P123, DOI 10.4040/jkan.2018.48.2.123
   Onakpoya IJ, 2019, BMJ OPEN, V9, P0, DOI 10.1136/bmjopen-2018-023600
   Postma TJ, 2005, EUR J CANCER, V41, P1135, DOI 10.1016/j.ejca.2005.02.012
   Rao RD, 2007, CANCER-AM CANCER SOC, V110, P2110, DOI 10.1002/cncr.23008
   Seretny M, 2014, PAIN, V155, P2461, DOI 10.1016/j.pain.2014.09.020
   Tae-yong Park, 2017, THE JOURNAL OF KOREA CHUNA MANUAL MEDICINE FOR SPINE & NERVES 척추신경추나의학회지, V12, P71
   Windebank AJ, 2008, J PERIPHER NERV SYST, V13, P27, DOI 10.1111/j.1529-8027.2008.00156.x
   Wu BY, 2019, COMPLEMENT THER MED, V42, P226, DOI 10.1016/j.ctim.2018.11.022
   Yun YH, 2004, QUAL LIFE RES, V13, P863, DOI 10.1023/B:QURE.0000021692.81214.70
   Zhang SQ, 2017, J TRADIT CHIN MED, V37, P179
NR 26
TC 8
Z9 8
U1 3
U2 16
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0025-7974
EI 1536-5964
J9 MEDICINE
JI Medicine (Baltimore)
PD JAN 15
PY 2020
VL 99
IS 3
BP 
EP 
DI 10.1097/MD.0000000000018830
PG 7
WC Medicine, General & Internal
SC General & Internal Medicine
GA LB9LQ
UT WOS:000524950700068
PM 32011497
DA 2026-01-16
ER

PT J
AU Reed, EN
   Landmann, J
   Oberoi, D
   Piedalue, KAL
   Faris, P
   Carlson, LE
AF Reed, Erica Nicole
   Landmann, Jessa
   Oberoi, Devesh
   Piedalue, Katherine-Ann L.
   Faris, Peter
   Carlson, Linda E.
TI Group versus Individual Acupuncture (AP) for Cancer Pain: A Randomized Noninferiority Trial
SO EVIDENCE-BASED COMPLEMENTARY AND ALTERNATIVE MEDICINE
LA English
DT Article
ID chronic noncancer pain; sleep quality index; breast-cancer; clinical-trials; functional assessment; shortened version; social support; symptoms; therapy; sample
AB Background. A service delivery model using group acupuncture (AP) may be more cost-effective than individual AP in general, but there is little evidence to assess whether group AP is a comparable treatment in terms of efficacy to standard individual AP. The study aimed to compare the group to individual delivery of 6-week AP among cancer patients with pain. Methods. The study design was a randomized noninferiority trial of the individual (gold standard treatment) vs. group AP for cancer pain. The primary outcome was pain interference and severity, measured through the Brief Pain Inventory (BPI). Secondary outcomes included measures of mood, sleep, fatigue, and social support. Changes in outcomes from pre- to postintervention were examined using linear mixed effects modeling and noninferiority was inferred using a noninferiority margin, a difference of change between the two arms and 95% CIs. Pain interference was tested with a noninferiority margin of 1 on the BPI, while pain severity and secondary outcomes were compared using conventional statistical methods. Results. The trial included 74 participants randomly allocated to group (35) or individual (39) AP. The noninferiority hypothesis was supported for pain interference [& x4e8; - 1, Delta 1.03, 95% CI: 0.15-2.20] and severity [& x4e8; - 0.81, Delta 0.52, 95% CI:.33-1.38] as well as for mood [& x4e8; - 7.52, Delta 9.86, 95% CI: 0.85-18.86], sleep [& x4e8; - 1.65, Delta 2.60, 95% CI: 0.33-4.88], fatigue [& x4e8; 8.54, Delta - 15.57, 95% CI: 25.60-5.54], and social support [& x4e8;.26, Delta - 0.15, 95% CI: - 0.42-0.13], meaning that group AP was not inferior to individual AP treatment. Both arms evidenced statistically significant improvements across all symptoms before and after the intervention. Effect sizes for the group vs. individual AP on outcomes of pain, sleep, mood, and social support ranged from small to very large and were consistently larger in the group condition. The total average cost-per-person for group AP ($221.25) was almost half that of individual AP ($420). Conclusions. This is the first study to examine the noninferiority of group AP with the gold standard individual AP. Group AP was noninferior to individual AP for treating cancer pain and was superior in many health outcomes. Group AP is more cost-effective for alleviating cancer pain and should be considered for implementation trials.
C1 [Reed, Erica Nicole; Oberoi, Devesh; Piedalue, Katherine-Ann L.; Carlson, Linda E.] Univ Calgary, Cumming Sch Med, Div Psychosocial Oncol, Dept Oncol, Calgary, AB, Canada.
   [Landmann, Jessa] Vive Integrat Hlth Grp, 1889 45 St NW, Calgary, AB, Canada.
   [Faris, Peter] Univ Calgary, Alberta Hlth Serv AHS, Dept Analyt, Calgary, AB, Canada.
   [Faris, Peter] Univ Calgary, Dept Community Hlth Sci, Calgary, AB, Canada.
C3 University of Calgary; University of Calgary; University of Calgary
RP Carlson, LE (corresponding author), Univ Calgary, Cumming Sch Med, Div Psychosocial Oncol, Dept Oncol, Calgary, AB, Canada.
EM enreed@ucalgary.ca; jessalandmann.nd@gmail.com; devesh.oberoi@ucalgary.ca; klpiedal@ucalgary.ca; faris@ucalgary.ca; lcarlso@ucalgary.ca
FU Enbridge Research Chair in Psychosocial Oncology - Canadian Cancer Society Alberta/NWT Division; Alberta Cancer Foundation
CR Asprey A, 2012, ACUPUNCT MED, V30, P163, DOI 10.1136/acupmed-2012-010150
   Bao T, 2018, EUR J CANCER, V101, P12, DOI 10.1016/j.ejca.2018.06.008
   BARRERA M, 1990, J SOC PERS RELAT, V7, P541, DOI 10.1177/0265407590074010
   Beck SL, 2004, J PAIN SYMPTOM MANAG, V27, P140, DOI 10.1016/j.jpainsymman.2003.12.002
   Brick WG, 2016, J CLIN ONCOL, V34, P0, DOI 10.1200/JCO.2016.34.15_suppl.e21592
   Brucker PS, 2005, EVAL HEALTH PROF, V28, P192, DOI 10.1177/0163278705275341
   BUYSSE DJ, 1989, PSYCHIAT RES, V28, P193, DOI 10.1002/smll.202408771
   CELLA DF, 1993, CANCER INVEST, V11, P327, DOI 10.3109/07357909309024860
   Chao MT, 2012, J ALTERN COMPLEM MED, V18, P561, DOI 10.1089/acm.2011.0128
   Chien Tsai-Ju, 2013, J TRADIT COMPLEMENT MED, V3, P234, DOI 10.4103/2225-4110.119733
   Chiu HY, 2017, EUR J CANCER CARE, V26, P0, DOI 10.1111/ecc.12457
   Chuang E, 2018, J ALTERN COMPLEM MED, V24, P336, DOI 10.1089/acm.2017.0262
   Cleeland CS, 1994, ANNALS ACADEMY OF MEDICINE SINGAPORE, V23, P129
   Crew KD, 2010, J CLIN ONCOL, V28, P1154, DOI 10.1200/JCO.2009.23.4708
   Deandrea S, 2008, ANN ONCOL, V19, P1985, DOI 10.1093/annonc/mdn419
   Deng G, 2008, J THORAC CARDIOV SUR, V136, P1464, DOI 10.1016/j.jtcvs.2008.07.053
   Desbiens C, 2017, BREAST, V35, P8, DOI 10.1016/j.breast.2017.06.001
   DiLorenzo TA, 1999, BRIT J HEALTH PSYCH, V4, P315, DOI 10.1348/135910799168669
   Dworkin RH, 2005, PAIN, V113, P9, DOI 10.1016/j.pain.2004.09.012
   Dworkin RH, 2009, PAIN, V146, P238, DOI 10.1016/j.pain.2009.08.019
   Edlund MJ, 2014, CLIN J PAIN, V30, P557, DOI 10.1097/AJP.0000000000000021
   Furlan AD, 2006, CAN MED ASSOC J, V174, P1589, DOI 10.1503/cmaj.051528
   Guadagnoli E, 1989, PSYCHOL ASSESSMENT, V1, P150
   Gueorguieva R, 2004, ARCH GEN PSYCHIAT, V61, P310, DOI 10.1001/archpsyc.61.3.310
   Hahn Seokyung, 2012, KOREAN J PEDIATR, V55, P403, DOI 10.3345/kjp.2012.55.11.403
   Herbert MS, 2017, J PAIN, V18, P200, DOI 10.1016/j.jpain.2016.10.014
   Julious SA, 2004, STAT MED, V23, P1921, DOI 10.1002/sim.1783
   Kim J, 2010, J HEALTH PSYCHOL, V15, P543, DOI 10.1177/1359105309355338
   Kligler B, 2018, PAIN MED, V19, P393, DOI 10.1093/pm/pnx134
   Lu WD, 2013, CURR PAIN HEADACHE R, V17, P0, DOI 10.1007/s11916-013-0321-3
   Mist SD, 2018, PAIN MED, V19, P1862, DOI 10.1093/pm/pnx322
   Pfister DG, 2010, J CLIN ONCOL, V28, P2565, DOI 10.1200/JCO.2009.26.9860
   Reid-Arndt SA, 2009, J PSYCHOSOC ONCOL, V27, P415, DOI 10.1080/07347330903183117
   SHACHAM S, 1983, J PERS ASSESS, V47, P305, DOI 10.1207/s15327752jpa4703_14
   STOKES JP, 1984, AM J COMMUN PSYCHOL, V12, P53, DOI 10.1007/BF00896928
   Tittle Mary Beth, 2003, ONCOL NURS FORUM, V30, P325, DOI 10.1188/03.ONF.325-330
   Tofthagen C, 2015, J PALLIAT MED, V18, P878, DOI 10.1089/jpm.2015.0143
   van den Beuken-van Everdingen MHJ, 2016, J PAIN SYMPTOM MANAG, V51, P1070, DOI 10.1016/j.jpainsymman.2015.12.340
   Vickers AJ, 2012, ARCH INTERN MED, V172, P1444, DOI 10.1001/archinternmed.2012.3654
   Webster Kimberly, 2003, HEALTH QUAL LIFE OUTCOMES, V1, P79, DOI 10.1186/1477-7525-1-79
   White A, 2012, ACUPUNCT MED, V30, P170, DOI 10.1136/acupmed-2012-010151
   Yellen SB, 1997, J PAIN SYMPTOM MANAG, V13, P63, DOI 10.1016/S0885-3924(96)00274-6
   Zhang Y, 2012, EVID-BASED COMPL ALT, V2012, P0, DOI 10.1155/2012/710750
NR 43
TC 6
Z9 7
U1 1
U2 13
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 1741-427X
EI 1741-4288
J9 EVID-BASED COMPL ALT
JI Evid.-based Complement Altern. Med.
PD APR 13
PY 2020
VL 2020
IS 
BP 
EP 
DI 10.1155/2020/7209548
PG 12
WC Integrative & Complementary Medicine
SC Integrative & Complementary Medicine
GA LJ7LU
UT WOS:000530343100001
PM 32351602
DA 2026-01-16
ER

PT J
AU Berger, A
   Hochberg, U
   Zegerman, A
   Tellem, R
   Strauss, I
AF Berger, Assaf
   Hochberg, Uri
   Zegerman, Alexander
   Tellem, Rotem
   Strauss, Ido
TI Neurosurgical ablative procedures for intractable cancer pain
SO JOURNAL OF NEUROSURGERY
LA English
DT Article
DE ablative procedures; cordotomy; cingulotomy; mesencephalotomy; intractable; refractory cancer pain; oncology
ID punctate midline myelotomy; stereotactic mesencephalotomy; percutaneous cordotomy; management; relief; cingulotomy; prevalence; plea
AB OBJECTIVE Cancer patients suffering from severe refractory pain may benefit from targeted ablative neurosurgical procedures aimed to disconnect pain pathways in the spinal cord or the brain. These patients often present with a plethora of medical problems requiring careful consideration before surgical interventions. The authors present their experience at an interdisciplinary clinic aimed to facilitate appropriate patient selection for neurosurgical procedures, and the outcome of these interventions. METHODS This study was a retrospective review of all patients who underwent neurosurgical interventions for cancer pain in the authors' hospital between March 2015 and April 2018. All patients had advanced metastatic cancer with limited life expectancy and suffered from intractable oncological pain. RESULTS Sixty patients underwent surgery during the study period. Forty-three patients with localized pain underwent disconnection of the spinal pain pathways: 34 percutaneous-cervical and 5 open-thoracic cordotomies, 2 stereotactic mesencephalotomies, and 2 midline myelotomies. Thirty-nine of 42 patients (93%) who completed these procedures had excellent immediate postoperative pain relief. At 1 month the improvement was maintained in 30/36 patients (83%) available for follow-up. There was 1 case of hemiparesis. Twenty patients with diffuse pain underwent stereotactic cingulotomy. Nineteen of these patients reported substantial pain relief immediately after the operation. At 1 month good pain relief was maintained in 13/17 patients (76%) available for follow-up, and good pain relief was also found at 3 months in 7/11 patients (64%). There was no major morbidity or mortality. CONCLUSIONS With careful patient selection and tailoring of the appropriate procedure to the patient's pain syndrome, the authors' experience indicates that neurosurgical procedures are safe and effective in alleviating suffering in patients with intractable cancer pain.
C1 [Berger, Assaf; Strauss, Ido] Tel Aviv Med Ctr & Sch Med, Dept Neurosurg, Tel Aviv, Israel.
   [Strauss, Ido] Tel Aviv Med Ctr & Sch Med, Neuromodulat Unit, Tel Aviv, Israel.
   [Tellem, Rotem] Tel Aviv Med Ctr & Sch Med, Palliat Care Serv, Tel Aviv, Israel.
   [Hochberg, Uri] Tel Aviv Med Ctr & Sch Med, Inst Pain Med, Tel Aviv, Israel.
   [Zegerman, Alexander] Tel Aviv Med Ctr & Sch Med, Div Anesthesiol, Tel Aviv, Israel.
   [Berger, Assaf; Hochberg, Uri; Zegerman, Alexander; Tellem, Rotem; Strauss, Ido] Tel Aviv Univ, Sackler Sch Med, Tel Aviv, Israel.
C3 Tel Aviv University; Sackler Faculty of Medicine; Tel Aviv University; Sackler Faculty of Medicine; Tel Aviv University; Sackler Faculty of Medicine; Tel Aviv University; Sackler Faculty of Medicine; Tel Aviv University; Sackler Faculty of Medicine; Tel Aviv University; Sackler Faculty of Medicine
RP Strauss, I (corresponding author), Tel Aviv Univ, Tel Aviv Sourasky Med Ctr, Tel Aviv, Israel.
EM idos@tlvmc.gov.il
CR AMANO K, 1992, STEREOT FUNCT NEUROS, V59, P25, DOI 10.1159/000098913
   Unknown -, 1996, CANC PAIN REL GUID O, V0, P0
   Atkin N, 2010, J PAIN SYMPTOM MANAG, V39, P924, DOI 10.1016/j.jpainsymman.2009.09.011
   Bellini M, 2016, ANAESTH INTENSIVE TH, V48, P197, DOI 10.5603/AIT.a2014.0070
   Bendinger T, 2016, BJA EDUC, V16, P310, DOI 10.1093/bjaed/mkw014
   Breivik H, 2009, ANN ONCOL, V20, P1420, DOI 10.1093/annonc/mdp001
   Caraceni A, 1999, PAIN, V82, P263, DOI 10.1016/S0304-3959(99)00073-1
   Everdingen MHJVDBV, 2007, ANN ONCOL, V18, P1437, DOI 10.1093/annonc/mdm056
   Fountas KN, 2004, STEREOT FUNCT NEUROS, V82, P230, DOI 10.1159/000083174
   Harsh V, 2013, CURR PAIN HEADACHE R, V17, P0, DOI 10.1007/s11916-013-0331-1
   Hayashi M, 2003, STEREOT FUNCT NEUROS, V81, P75, DOI 10.1159/000075108
   Higaki N, 2015, NEUROSURGERY, V76, P249, DOI 10.1227/NEU.0000000000000593
   Honey CR, 2014, J PALLIAT MED, V17, P624, DOI 10.1089/jpm.2013.0664
   Hong D, 2007, J PAIN SYMPTOM MANAG, V33, P99, DOI 10.1016/j.jpainsymman.2006.06.012
   Ivanishvili Z, 2016, BRIT J NEUROSURG, V30, P444, DOI 10.3109/02688697.2015.1133805
   Kanpolat Y, 2009, NEUROSURGERY, V64, PS187, DOI 10.1227/01.NEU.0000335645.67282.03
   Kim DR, 2014, J KOREAN NEUROSURG S, V56, P71, DOI 10.3340/jkns.2014.56.1.71
   Konrad P, 2014, NEUROSURG CLIN N AM, V25, P699, DOI 10.1016/j.nec.2014.07.010
   KRIEGER AJ, 1974, J NEUROSURG, V40, P168, DOI 10.3171/jns.1974.40.2.0168
   Lordon Stephen P, 2002, CURR PAIN HEADACHE REP, V6, P202, DOI 10.1007/s11916-002-0036-3
   Menon JP, 2014, NEUROSURG CLIN N AM, V25, P663, DOI 10.1016/j.nec.2014.06.003
   Nagaro T, 2001, J NEUROSURG, V95, P425, DOI 10.3171/jns.2001.95.3.0425
   Nauta HJW, 1997, J NEUROSURG, V86, P538, DOI 10.3171/jns.1997.86.3.0538
   Nauta HJW, 2000, J NEUROSURG, V92, P125, DOI 10.3171/spi.2000.92.2.0125
   Raslan AM, 2008, NEUROSURGERY, V63, P226, DOI 10.1227/01.neu.0000317397.16089.f5
   Raslan AM, 2011, J NEUROSURG, V114, P155, DOI 10.3171/2010.6.JNS10119
   Ripamonti CI, 2012, ANN ONCOL, V23, P139, DOI 10.1093/annonc/mds233
   Shepherd TM, 2017, AM J NEURORADIOL, V38, P387, DOI 10.3174/ajnr.A4981
   Steel D, 2017, J NEUROSURG-PEDIATR, V20, P278, DOI 10.3171/2017.5.PEDS17119
   Strauss I, 2017, STEREOT FUNCT NEUROS, V95, P400, DOI 10.1159/000484613
   Strauss I, 2017, STEREOT FUNCT NEUROS, V95, P409, DOI 10.1159/000484614
   TASKER RR, 1992, J NEUROSURG, V76, P1052
   van den Beuken-van Everdingen MHJ, 2016, J PAIN SYMPTOM MANAG, V51, P1070, DOI 10.1016/j.jpainsymman.2015.12.340
   vandenBeukenvanEverdingen MH, 2016, J PAIN SYMPTOM MANAG, V51, P0
   Vayne-Bossert P, 2016, SUPPORT CARE CANCER, V24, P1429, DOI 10.1007/s00520-015-3047-4
   Vedantam A, 2018, NEUROSURGERY, V83, P783, DOI 10.1093/neuros/nyx549
   Vissers KCP, 2011, PAIN PRACT, V11, P453, DOI 10.1111/j.1533-2500.2011.00473.x
   Viswanathan A, 2013, NEUROSURG FOCUS, V35, P0, DOI 10.3171/2013.6.FOCUS13237
   Viswanathan A, 2013, NEUROSURG FOCUS, V35, P0, DOI 10.3171/2013.6.FOCUS13236
   Viswanathan A, 2010, STEREOT FUNCT NEUROS, V88, P374, DOI 10.1159/000319041
   Yen CP, 2005, J CLIN NEUROSCI, V12, P886, DOI 10.1016/j.jocn.2004.11.018
NR 41
TC 17
Z9 17
U1 0
U2 2
PU AMER ASSOC NEUROLOGICAL SURGEONS
PI ROLLING MEADOWS
PA 5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA
SN 0022-3085
EI 1933-0693
J9 J NEUROSURG
JI J. Neurosurg.
PD JUL 15
PY 2020
VL 133
IS 1
BP 144
EP 151
DI 10.3171/2019.2.JNS183159
PG 8
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA OK0VT
UT WOS:000584371500029
PM 31075782
DA 2026-01-16
ER

PT J
AU Hempen, CH
   Hummelsberger, J
AF Hempen, Carl-Hermann
   Hummelsberger, Josef
TI Traditional Chinese medicine (TCM)-what is myth and what is the state of evidence today?
SO BUNDESGESUNDHEITSBLATT-GESUNDHEITSFORSCHUNG-GESUNDHEITSSCHUTZ
LA German
DT Article
DE Chinese medicine; TCM; Acupuncture; Chinese herbal medicine; Evidence
ID cell lung-cancer; efficacy; quality
AB Traditional Chinese medicine (TCM) is the most comprehensive and widely practiced system of medicine in the world. Originally, TCM appeared in our Western context as an unfathomable mythological doctrine. Once the linguistic barriers had been overcome, it became possible to understand and apply the terminological and physiological concepts, the method of diagnosis, and the clinical findings. Since the NIH consensus conference in 1998, our understanding of TCM has been the subject of methodologically robust studies. We now have evidence of the efficacy and effectiveness of acupuncture beyond its use in pain therapy and allergy treatment. Thanks to fMRI studies, among others, we also have a better understanding of the mechanisms underlying acupuncture. Meta-analyses and studies also confirm the efficacy of Chinese medicinal drugs and remedies in some fields, yet there is still extensive need for further research. But opportunities are also emerging for new medicines and prescriptions for (accompanying) treatments of infections, autoimmune diseases, cancer, metabolic illnesses, dermatological disorders, and gastrointestinal diseases. To enable further evaluation of TCM, but also to ensure an integrative, critical application in the practice of TCM, it is vital for doctors to have thorough training. Further institutionalisation is necessary to provide orientation and patient safety. The days of regarding TCM as some kind of mysticism are indeed long over and it can offer real opportunities for better patient care. In many fields, there is increasing evidence of TCM's effectiveness, yet further comprehensive research is essential. This should be encouraged unconditionally.
C1 [Hempen, Carl-Hermann] Tech Univ Munich, Georg Brauchle Ring 62, D-80992 Munich, Germany.
C3 Technical University of Munich
RP Hempen, CH (corresponding author), Tech Univ Munich, Georg Brauchle Ring 62, D-80992 Munich, Germany.
EM ch@hempen.de
FU Projekt DEAL
CR Adams D, 2009, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD006348.pub2
   ALTMAN DG, 1995, BRIT MED J, V311, P485, DOI 10.1136/bmj.311.7003.485
   Unknown -, 1900, DOI 10.1002/14651858.CD002291.PUB2, V0, P0
   AWMF, 2019, LEITL THER MIGR PROP, V0, P0
   AWMF, 2018, LEITL RUCK, V0, P0
   Barton DL, 2010, SUPPORT CARE CANCER, V18, P179, DOI 10.1007/s00520-009-0642-2
   Bensky D, 2005, CHINESE HERBAL MEDICINE: MATERIA MEDICA, Vthird, P0
   Bensoussan A, 1998, JAMA-J AM MED ASSOC, V280, P1585, DOI 10.1001/jama.280.18.1585
   Cao HQ, 2013, MOD MANUF ENG, V8, P12
   Chung V-CH, 2016, MEDICINE, V95, P7
   Deng HY, 2017, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD012217.pub2
   Despeux C, 2000, GESCH CHINESISCHEN M, V0, P0
   Engelhardt Ute, 1997, CHINESISCHE DIATETIK., V0, P0
   Flower A, 2009, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD006568.pub2
   Flower A, 2015, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD010446.pub2
   Freireich EJ, 1997, ADV J MIND BODY HLTH, V13, P41
   Fruhauf H, 2005, CHINESISCHE MED KR 1, V0, P1
   Grant SJ, 2009, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD006690.pub2
   Guo HR, 2017, FRONT PHARMACOL, V8, P0, DOI 10.3389/fphar.2017.00454
   Guojia yaodian weiyuanhui, 2005, PHARM VR CHIN, V0, P0
   Hempen C-H, 2006, LEITFADEN CHINESISCH, V0, P0
   Hempen N, 2014, FORSCH KOMPLEMENTMED, V21, P401, DOI 10.1159/000369233
   Ho PK, 1997, A BRIEF HISTORY OF CHINESE MEDICINE AND ITS INFLUENCE, V0, P0
   Hu C-J, 2019, PAOZHI AUFBEREITUNG, V0, P0
   Hummelsberger J, 2006, DTSCH ARZTEBL, V103, P21
   Jing Z, 2009, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD006414.pub2
   Li XM, 2009, J ALLERGY CLIN IMMUN, V123, P297, DOI 10.1016/j.jaci.2008.12.026
   Liu JP, 2005, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD003937.pub2
   Liu JP, 2002, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD003642.PUB2
   Long XY, 2016, FRONT HUM NEUROSCI, V10, P0, DOI 10.3389/fnhum.2016.00510
   Lu G-D, 2002, CELESTIAL LANCETS HI, V0, P0
   MacDonald J, 2017, THE ACUPUNCTURE EVIDENCE PROJECT: A COMPARATIVE LITERATURE REVIEW, V0, P0
   Manheimer E, 2009, J ALTERN COMPLEM MED, V15, P1001, DOI 10.1089/acm.2008.0414
   McCulloch M, 2006, J CLIN ONCOL, V24, P419, DOI 10.1200/JCO.2005.03.6392
   Needham J, 2004, SCI CIVILISATION CHI, V0, P0
   Ni XJ, 2014, PLOS ONE, V9, P0, DOI 10.1371/journal.pone.0099377
   Porkert M, 1993, NEUES LEHRBUCH CHINE, V0, P0
   Porkert M, 1991, THEORETISCHEN GRUNDL, V0, P0
   Porkert M, 1985, SYSTEMATISCHE AKUPUN, V0, P0
   Ramsay DJ, 1998, JAMA-J AM MED ASSOC, V280, P1518
   RATHBONE J, 2005, COCHRANE DB SYST REV, V4, P0
   Scheid V, 2009, CHINESE HERBAL MEDICINE: FORMULAS AND STRATEGIES, V2nd edn, P0
   Scheid Volker, 2007, CURRENTS TRADITION C, V1st, P0
   SHEEHAN MP, 1992, LANCET, V340, P13, DOI 10.1016/0140-6736(92)92424-E
   Sun YY, 2009, ANTI-CANCER DRUG, V20, P757, DOI 10.1097/CAD.0b013e328330d95b
   Unschuld PaulU, 1985, MED CHINA HIST IDEAS, V0, P0
   Wang G, 2005, COCHRANE DB SYST REV, V1, P0
   Wayne PM, 2014, J AM GERIATR SOC, V62, P25, DOI 10.1111/jgs.12611
   Wiebrecht A, 2017, LEITFADEN CHINESISCH, V0, P0
   World Federation of Chinese Medicine Societies, 2017, UB INT STAND CHIN ME, V0, P0
   Yuan W, 2008, COCHRANE DB SYST REV, V2, P0, DOI 10.1002/14651858.CD006335.PUB2
   Zhang X, 2007, COCHRANE DATABASE SY, V1, P0
   Zhu X, 2007, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD005288.pub2
NR 53
TC 10
Z9 14
U1 5
U2 29
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 1436-9990
EI 1437-1588
J9 BUNDESGESUNDHEITSBLA
JI Bundesgesundheitsblatt-Gesund.
PD MAY 15
PY 2020
VL 63
IS 5
BP 570
EP 576
DI 10.1007/s00103-020-03132-9
EA APR 2020
PG 7
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA LI5NW
UT WOS:000524385000002
PM 32266491
DA 2026-01-16
ER

PT J
AU Yang, J
   Xu, G
   Yin, Z
   Cheng, Y
   Sun, SM
   Zheng, Q
   Chen, J
   Liang, FR
   Zhao, L
AF Yang, Jiao
   Xu, Guixing
   Yin, Zihan
   Cheng, Ying
   Sun, Sheng Ming
   Zheng, Qianhua
   Chen, Jiao
   Liang, Fan-Rong
   Zhao, Ling
TI Acupuncture for chronic cancer-related pain: a systematic review and network
SO BMJ open
LA English
DT Journal Article
DE anaesthesia in oncology; complementary medicine; pain management
AB INTRODUCTION: Chronic cancer-related pain is one of the most common excruciating  symptom that can be caused by the cancer (by the primary tumour or by metastases)  or by its treatment (surgery, chemotherapy and radiotherapy). Although multiple  clinical trials and systematic reviews have suggested that acupuncture could be  effective in treating chronic cancer-related pain, the comparative efficacy and  safety of these acupuncture methods remains unclear. We, therefore, performed  this study to evaluate and rank the efficacy and safety of different acupuncture  methods for chronic cancer-related pain. METHODS AND ANALYSIS: Seven databases  will be searched, including Cochrane Library, MEDLINE, Embase, Chinese National  Knowledge Infrastructure (CNKI), Wanfang Database, the Chongqing VIP Chinese  Science and Technology Periodical Database and Chinese Biomedical Literature  Database (CBM) from their inception to March 2020. The primary outcome is the  change of pain intensity. Bayesian network meta-analysis will be conducted using  software R3.5.1. Finally, we will use the Grading of Recommendations Assessment,  Development and Evaluation System (GRADE) to assess the quality of evidence.  ETHICS AND DISSEMINATION: Ethical approval is not required for literature-based  studies. The results will be disseminated through peer-reviewed publication.  PROSPERO REGISTRATION NUMBER: CRD42020165747.
C1 Acupuncture and Tuina School, Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan, China.
   Acupuncture and Tuina School, Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan, China.
   Acupuncture and Tuina School, Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan, China.
   Acupuncture and Tuina School, Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan, China.
   Acupuncture and Tuina School, Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan, China.
   Acupuncture and Tuina School, Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan, China.
   Acupuncture and Tuina School, Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan, China.
   Acupuncture and Tuina School, Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan, China acuresearch@126.com zhaoling@cdutcm.edu.cn.
   Acupuncture and Tuina School, Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan, China acuresearch@126.com zhaoling@cdutcm.edu.cn.
NR 0
TC 0
SN 2044-605
EI 
J9 BMJ Open
PD OCT 10
PY 2020
VL 10
IS 10
BP e039087
EP e039087
DI 10.1136/bmjopen-2020-039087
PG 1
WC Acupuncture Therapy; Bayes Theorem; Cancer Pain; etiology; Chronic Pain; etiology; Humans; Neoplasms; complications; Systematic Reviews as Topic; Network Meta-Analysis as Topic
UT PubMed:33033027
PM 33033027
DA 2020-10-10
ER

PT J
AU Yang, P
   Wang, Y
   Xiao, Y
   Ma, Q
   Ma, R
   Mi, J
   Hui, J
AF Yang, Pu
   Wang, Yuanchun
   Xiao, Yingchun
   Ma, Qiaolin
   Ma, Runhong
   Mi, Jing
   Hui, Jianrong
TI Acupuncture for opioid-induced constipation: Protocol for a systematic review and
SO Medicine
LA English
DT Journal Article
AB BACKGROUND: Opioid-induced constipation (OIC) is one of the most common  complications of analgesic therapy for cancer pain patients who suffer moderate  to severe pain. Acupuncture as an effective treatment in constipation has been  widely applied. But its efficacy has not been assessed systematically. Thus, the  purpose of this study is to provide a protocol to explore the efficacy and safety  of acupuncture for OIC. METHODS: Randomized Controlled Trials (RCTs) of  acupuncture treatment for OIC in 4 Chinese electronic databases (China National  Knowledge Infrastructure, Chinese Biological and Medical Database, China  Scientific Journal Database, Wan-Fang Data) and 3 English electronic databases  (PubMed, Embase, Cochrane Library) will be searched from their inception to  September 31, 2020. RevMan 5.3 software and Stata 14.0 software will be used for  meta-analysis, EndNote X9.2 and Cochrane Risk of Bias Tool will be used for  literature screening and quality assessment. RESULTS: This study will present an  assessment of the efficacy and safety of acupuncture treatment for OIC patients  through summarize high-quality clinical evidence. CONCLUSION: The conclusion of  our systematic review and meta-analysis may provide evidence of whether  acupuncture treatment is beneficial to patients with OIC.INPLASY registration  number: INPLASY2020100026.
C1 School of Acupuncture-Moxibustion and Tuina, Shaanxi University of Chinese Medicine, Xian.
   The Affiliated Hospital of Shaanxi University of Chinese Medicine, Xianyang, Shaanxi Province, China.
   School of Acupuncture-Moxibustion and Tuina, Shaanxi University of Chinese Medicine, Xian.
   School of Acupuncture-Moxibustion and Tuina, Shaanxi University of Chinese Medicine, Xian.
   School of Acupuncture-Moxibustion and Tuina, Shaanxi University of Chinese Medicine, Xian.
   School of Acupuncture-Moxibustion and Tuina, Shaanxi University of Chinese Medicine, Xian.
   School of Acupuncture-Moxibustion and Tuina, Shaanxi University of Chinese Medicine, Xian.
NR 0
TC 0
SN 1536-596
EI 0025-797
J9 Medicine (Baltimore)
PD DEC 9
PY 2020
VL 99
IS 49
BP e23352
EP e23352
DI 10.1097/MD.0000000000023352
PG 1
WC Acupuncture Therapy; adverse effects; Humans; Opioid-Induced Constipation; therapy; Quality of Life; Randomized Controlled Trials as Topic; Research Design; Meta-Analysis as Topic; Systematic Reviews as Topic
UT PubMed:33285714
PM 33285714
DA 2020-12-09
ER

PT J
AU Liou, KT
   Baser, R
   Romero, SAD
   Green, J
   Li, QS
   Orlow, I
   Panageas, KS
   Mao, JJ
AF Liou, Kevin T.
   Baser, Ray
   Romero, Sally A. D.
   Green, Jamie
   Li, Q. Susan
   Orlow, Irene
   Panageas, Katherine S.
   Mao, Jun J.
TI Personalized electro-acupuncture versus auricular-acupuncture comparative effectiveness (PEACE): A protocol of a randomized controlled trial for chronic musculoskeletal pain in cancer survivors
SO MEDICINE
LA English
DT Article
DE cancer; acupuncture; chronic pain; comparative effectiveness; pain management; personalized medicine
ID sleep quality index; battlefield acupuncture; hospital anxiety; information; stimulation; reliability; arthralgia; validation; expectancy; strategy
AB Introduction: Chronic pain is a leading cause of disability and remains under-treated in nearly half of patients with cancer. The opioid crisis has highlighted an urgent public health need for effective nonpharmacological pain management. Electroacupuncture (EA) and Battlefield Acupuncture (BFA) represent nonpharmacological modalities used in clinical practice to manage pain; however, their effectiveness has not been rigorously evaluated in oncology settings. Methods: We describe the design of a 3-arm, parallel, single-center, multisite randomized controlled trial that investigates EA and BFA versus usual-care wait-list control (WLC) for chronic musculoskeletal pain among 360 patients with diverse cancer types across various stages. The primary aim is to compare effects of EA and BFA versus WLC on pain, physical function, and co-morbid symptoms. The secondary aim is to examine the interaction between patient outcome expectancy and acupuncture modality (EA vs BFA) on pain reduction. The tertiary aim is to evaluate the association between genetic polymorphisms and responses to acupuncture. Patients will be randomized in a 2:2:1 ratio to EA:BFA:WLC. Acupuncture groups will receive weekly treatments over 10 weeks. WLC will receive usual care over the same evaluation period as the acupuncture groups. The primary endpoint will be the change in average pain intensity score from baseline to week 12. We will collect validated patient-reported outcomes and blood/saliva samples at multiple timepoints over 24 weeks. Discussion: Our findings will advance nonpharmacological pain management in oncology and inform personalized treatment approaches that integrate individuals' expectations and genetic biomarkers to deliver "precision" acupuncture to cancer patients with chronic pain.
C1 [Liou, Kevin T.; Green, Jamie; Li, Q. Susan; Mao, Jun J.] Mem Sloan Kettering Canc Ctr, Integrat Med Serv, Dept Med, New York, NY 10021 USA.
   [Baser, Ray; Orlow, Irene; Panageas, Katherine S.] Mem Sloan Kettering Canc Ctr, Dept Epidemiol & Biostat, New York, NY 10021 USA.
   [Romero, Sally A. D.] UC San Diego Sch Med, Dept Family Med & Publ Hlth, San Diego, CA USA.
C3 Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center
RP Mao, JJ (corresponding author), Mem Sloan Kettering Canc Ctr, Bendheim Integrat Med Ctr, 1429 First Ave, New York, NY 10021 USA.
EM maoj@mskcc.org
FU U.S. Department of Defense [W81XWH-15-1-0245]; National Institutes of Health/National Cancer Institute [P30 CA008748]; Translational and Integrative Medicine Research Fund at Memorial Sloan Kettering Cancer Center; National Cancer Institute [P30CA008748] Funding Source: NIH RePORTER
CR Aloe L, 2009, NEUROSCI LETT, V449, P173, DOI 10.1016/j.neulet.2008.11.003
   Bauml Joshua, 2014, JOURNAL OF THE NATIONAL CANCER INSTITUTE MONOGRAPHS, V0, PP302, DOI 10.1093/jncimonographs/lgu029
   Boutron I, 2008, ANN INTERN MED, V148, P295, DOI 10.7326/0003-4819-148-4-200802190-00008
   Buysse D J, 1989, PSYCHIATRY RES, V28, P193
   Cheng Xin-Nong, 1987, CHINESE ACUPUNCTURE AND MOXIBUSTION, V0, P0
   Cleeland CS, 1994, ANNALS ACADEMY OF MEDICINE SINGAPORE, V23, P129
   Colagiuri B, 2012, EVID-BASED COMPL ALT, V2012, P0, DOI 10.1155/2012/857804
   Correa DD, 2016, NEURO-ONCOLOGY, V18, P1425, DOI 10.1093/neuonc/now057
   De Gregori M, 2013, EUR J CLIN PHARMACOL, V69, P1651, DOI 10.1007/s00228-013-1523-7
   Deandrea S, 2008, ANN ONCOL, V19, P1985, DOI 10.1093/annonc/mdn419
   Diatchenko L, 2005, HUM MOL GENET, V14, P135, DOI 10.1093/hmg/ddi013
   Dmitrienko A, 2011, BIOMETRICAL J, V53, P875, DOI 10.1002/bimj.201100036
   Farrar JT, 2001, PAIN, V94, P149, DOI 10.1016/S0304-3959(01)00349-9
   Federman DG, 2018, MED ACUPUNCT, V30, P273, DOI 10.1089/acu.2018.1296
   Fox LM, 2018, AM J EMERG MED, V36, P1045, DOI 10.1016/j.ajem.2018.02.038
   Genovese TJ, 2019, PAIN MED, V20, P191, DOI 10.1093/pm/pny067
   Goertz CMH, 2006, MIL MED, V171, P1010, DOI 10.7205/MILMED.171.10.1010
   Gummesson C, 2006, BMC MUSCULOSKEL DIS, V7, P0, DOI 10.1186/1471-2474-7-44
   Hall KC, 2012, PLOS ONE, V7, P0, DOI 10.1371/journal.pone.0031600
   Han JS, 2003, TRENDS NEUROSCI, V26, P17, DOI 10.1016/S0166-2236(02)00006-1
   Harris PA, 2009, J BIOMED INFORM, V42, P377, DOI 10.1016/j.jbi.2008.08.010
   Hays RD, 2009, QUAL LIFE RES, V18, P873, DOI 10.1007/s11136-009-9496-9
   He Y, 2019, JAMA ONCOL, V0, P0
   Huang WJ, 2012, PLOS ONE, V7, P0, DOI 10.1371/journal.pone.0032960
   Hui D, 2014, J CLIN ONCOL, V32, P1640, DOI 10.1200/JCO.2013.52.2508
   Hui KKS, 2005, NEUROIMAGE, V27, P479, DOI 10.1016/j.neuroimage.2005.04.037
   Ingle JN, 2010, J CLIN ONCOL, V28, P4674, DOI 10.1200/JCO.2010.28.5064
   Kim MR, 2005, NEUROSCI LETT, V387, P17, DOI 10.1016/j.neulet.2005.07.007
   LAIRD NM, 1982, BIOMETRICS, V38, P963, DOI 10.2307/2529876
   LeBlanc M, 2014, ARCH PHYS MED REHAB, V95, P493, DOI 10.1016/j.apmr.2013.09.016
   Lee HJ, 2009, J EXP CLIN CANC RES, V28, P0, DOI 10.1186/1756-9966-28-102
   Liu GHF, 2009, STAT MED, V28, P2509, DOI 10.1002/sim.3639
   Liu MH, 2012, BREAST CANCER RES, V14, P0, DOI 10.1186/bcr3137
   Lu K, 2008, THE INTERNATIONAL JOURNAL OF BIOSTATISTICS, V4, P1, DOI 10.2202/1557-4679.1098
   Lu WD, 2008, HEMATOL ONCOL CLIN N, V22, P631, DOI 10.1016/j.hoc.2008.04.005
   MacPherson H, 2017, PAIN, V158, P784, DOI 10.1097/j.pain.0000000000000747
   MacPherson H, 2010, PLOS MED, V7, P0, DOI 10.1371/journal.pmed.1000261
   Mao Jun J, 2007, ACUPUNCT MED, V25, P158
   Mao JJ, 2007, J AM BOARD FAM MED, V20, P434, DOI 10.3122/jabfm.2007.05.060225
   Mao JJ, 2007, EXPLORE-NY, V3, P372, DOI 10.1016/j.explore.2006.12.003
   Mao JJ, 2014, CANCER-AM CANCER SOC, V120, P3744, DOI 10.1002/cncr.28917
   Mao JJ, 2014, EUR J CANCER, V50, P267, DOI 10.1016/j.ejca.2013.09.022
   Mao JJ, 2010, ALTERN THER HEALTH M, V16, P22
   Mao JJ, 2010, PRIMARY CARE, V37, P105, DOI 10.1016/j.pop.2009.09.010
   Mao JJ, 2011, J CANCER SURVIV, V5, P8, DOI 10.1007/s11764-010-0153-7
   McConnell S, 2001, ARTHRIT RHEUM-ARTHR, V45, P453, DOI 10.1002/1529-0131(200110)45:5<453::AID-ART365>3.0.CO;2-W
   Mendoza TR, 1999, CANCER-AM CANCER SOC, V85, P1186, DOI 10.1002/(SICI)1097-0142(19990301)85:5<1186::AID-CNCR24>3.0.CO;2-N
   Miller KD, 2016, CA-CANCER J CLIN, V66, P271, DOI 10.3322/caac.21349
   Mollayeva T, 2016, SLEEP MED REV, V25, P52, DOI 10.1016/j.smrv.2015.01.009
   Napadow V, 2005, HUM BRAIN MAPP, V24, P193, DOI 10.1002/hbm.20081
   Niemtzow R, 2007, MED ACUPUNCT, V19, P0
   Niemtzow R, 2018, MIL MED, V183, PE486, DOI 10.1093/milmed/usy028
   Orlow I, 2015, BRIT J DERMATOL, V172, P1081, DOI 10.1111/bjd.13467
   Orlow I, 2018, PIGM CELL MELANOMA R, V31, P0, DOI 10.1111/pcmr.12653
   Osman A, 1997, J BEHAV MED, V20, P589, DOI 10.1023/A:1025570508954
   Paice JA, 2018, ONCOLOGY-NY, V32, P386
   Reinhold T, 2014, J ALTERN COMPLEM MED, V20, P169, DOI 10.1089/acm.2012.0719
   Revicki DA, 2009, QUAL LIFE RES, V18, P783, DOI 10.1007/s11136-009-9489-8
   Ruggiero KJ, 2003, J TRAUMA STRESS, V16, P495, DOI 10.1023/A:1025714729117
   Sloan JA, 2002, MAYO CLIN PROC, V77, P479, DOI 10.4065/77.5.479
   Smith AB, 2002, PSYCHOL PSYCHOTHER-T, V75, P165, DOI 10.1348/147608302169625
   Steglitz J, 2012, TRANSL BEHAV MED, V2, P6, DOI 10.1007/s13142-012-0110-2
   TAKESHIGE C, 1991, BRAIN RES BULL, V26, P113, DOI 10.1016/0361-9230(91)90195-P
   Taylor SL, 2018, MED ACUPUNCT, V30, P252, DOI 10.1089/acu.2018.1286
   Vadivelu N, 2018, CURR PAIN HEADACHE R, V22, P0, DOI 10.1007/s11916-018-0670-z
   van den Beuken-van Everdingen MHJ, 2016, J PAIN SYMPTOM MANAG, V51, P1070, DOI 10.1016/j.jpainsymman.2015.12.340
   Vickers AJ, 2018, J PAIN, V19, P455, DOI 10.1016/j.jpain.2017.11.005
   Vickers AJ, 2012, ARCH INTERN MED, V172, P1444, DOI 10.1001/archinternmed.2012.3654
   Weathers FW, 1996, MEASUREMENT STRESS T, V0, P0, DOI DOI 10.1016/0005-7967(96)00033-2
   Weeks J, 2016, J ALTERN COMPLEM MED, V22, P947, DOI 10.1089/acm.2016.29016.jjw
   White Adrian, 2004, ACUPUNCT MED, V22, P122
   Willich SN, 2006, PAIN, V125, P107, DOI 10.1016/j.pain.2006.06.006
   Witt CM, 2009, FORSCH KOMPLEMENTMED, V16, P91, DOI 10.1159/000209315
   Yun H, 2017, J NATL CANC I MONOGR, V2017, P0
   Zhang RX, 2005, PHARMACOL BIOCHEM BE, V81, P146, DOI 10.1016/j.pbb.2005.03.002
   Zia FZ, 2017, J NATL CANC I MONOGR, V2017, P0
   ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x
   Zylla D, 2017, SUPPORT CARE CANCER, V25, P1687, DOI 10.1007/s00520-017-3614-y
NR 78
TC 16
Z9 20
U1 1
U2 16
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0025-7974
EI 1536-5964
J9 MEDICINE
JI Medicine (Baltimore)
PD MAY 22
PY 2020
VL 99
IS 21
BP 
EP 
DI 10.1097/MD.0000000000020085
PG 9
WC Medicine, General & Internal
SC General & Internal Medicine
GA MO4OT
UT WOS:000551508200030
PM 32481275
DA 2026-01-16
ER

PT J
AU Chien, A
   Yang, CC
   Chang, SC
   Jan, YM
   Yang, CH
   Hsieh, YL
AF Chien, Andy
   Yang, Chen-Chia
   Chang, Sheng-Chi
   Jan, Yi-Min
   Yang, Ching-Hsiang
   Hsieh, Yueh-Ling
TI Ultrasound Acupuncture for Oxaliplatin-induced Peripheral Neuropathy in Patients
SO PM & R : the journal of injury, function, and rehabilitation
LA English
DT Journal Article
AB BACKGROUND: Oxaliplatin is frequently used in the treatment of metastatic  colorectal cancer. However, peripheral neuropathy is a severe adverse effect of  oxaliplatin that may persist and impact quality of life. OBJECTIVE: To assess the  potential effects of ultrasound acupuncture for the alleviation of symptoms  related to oxaliplatin-induced peripheral neuropathy (OIPN) among patients with  metastatic colorectal cancer. DESIGN: Prospective cohort pilot study. SETTING:  Education and research hospital. PARTICIPANTS: Patients with a diagnosis of stage  II-IV colorectal cancer undergoing oxaliplatin-based treatment regimens who  experienced OIPN symptoms (n = 17). INTERVENTIONS: Pulsed therapeutic ultrasound  (1 MHz) at bilateral acupuncture points of PC6, PC7, BL60, and KI1 was  administered for 5 minutes per point daily for 12 days. MAIN OUTCOME  MEASUREMENTS: Pain Quality Assessment Scale (PQAS), Chemotherapy-induced  Neurotoxicity Questionnaire (CINQ), quantitative touch-detection threshold,  cold-trigger pain withdrawal latency, and quality of life (EORTC QLQ-C30) were  measured at baseline (day 0), pre-intervention (day 12, post wash-out period),  post-intervention (day 24), and final follow-up (day 54). A P value of less than  .05 was considered statistically significant. RESULTS: Scores of PQAS and CINQ  significantly improved after ultrasound acupuncture at post-intervention and  follow-up compared to both baseline and pre-intervention. Similar trends were  also observed for the quantitative sensory testing, where touch-detection  threshold significantly decreased and cold-trigger pain withdrawal latency  significantly increased after ultrasound acupuncture. Patients also showed an  improvement on quality of life outcomes as measured by QLQ-C30 post-intervention  and at follow-up. CONCLUSIONS: Ultrasound acupuncture could be an effective  intervention for OIPN symptoms for patients with colorectal cancer. However,  larger and randomized clinical trials with placebo controls are needed to confirm  such effects.
C1 Department of Physical Therapy, Graduate Institute of Rehabilitation Science, China Medical University, Taichung, Taiwan.
   Kao-An Rehabilitation and Pain Clinic, Taichung, Taiwan.
   Department of Colorectal Surgery, China Medical University Hospital, Taichung, Taiwan.
   Center for General Education, China Medical University, Taichung, Taiwan.
   Department of Physical Therapy, Graduate Institute of Rehabilitation Science, China Medical University, Taichung, Taiwan.
   Department of Physical Therapy, Graduate Institute of Rehabilitation Science, China Medical University, Taichung, Taiwan.
NR 0
TC 0
SN 1934-156
EI 
J9 PM R
PD MAR 14
PY 2020
VL 13
IS 1
BP 55
EP 65
DI 10.1002/pmrj.12361
PG 10
WC Acupuncture Therapy; Colorectal Neoplasms; drug therapy; Humans; Oxaliplatin; Peripheral Nervous System Diseases; chemically induced; Pilot Projects; Prospective Studies; Quality of Life
UT PubMed:32168417
PM 32168417
DA 2020-03-14
ER

PT J
AU Behzadmehr, R
   Dastyar, N
   Moghadam, MP
   Abavisani, M
   Moradi, M
AF Behzadmehr, Razieh
   Dastyar, Neda
   Moghadam, Mahdieh Poodineh
   Abavisani, Mahnaz
   Moradi, Mandana
TI Effect of complementary and alternative medicine interventions on cancer related pain among breast cancer patients: A systematic review
SO COMPLEMENTARY THERAPIES IN MEDICINE
LA English
DT Review
DE Complementary and alternative medicine; Cancer related pain; Breast neoplasm; Systematic review
ID quality-of-life; inhibitor-induced arthralgia; low-back-pain; mindfulness meditation; massage therapy; musculoskeletal symptoms; hypnosis intervention; stress reduction; controlled-trial; acupuncture
AB Objective: This systematic review aimed to evaluate the efficacy of CAM interventions for cancer-related pain in breast cancer patients. Methods: Databases (PubMed, Scopus, Web of Science, and EMBASE) were searched from January 1, 2000, up to April 31, 2019, using the keywords: Complementary and alternative medicine therapies and cancer related pain. Standard tools were used to evaluate the quality of the studies included. Results: Of the 3742 articles found, 46 articles comprising 3685 participants entered the final phase. Our results indicate that interventions including acupuncture/acupressure, tai chi/qi gong, hypnosis, meditation, music therapy, yoga, massage, reflexology, and Reiki improve cancer-related pain in breast cancer patients. However, aromatherapy had no effect on the same. Conclusions: Despite the positive effect of various CAM interventions in reducing cancer-related pain, necessary precautions should be adopted to use them alongside other treatments to control cancer pain in the clinical setting.
C1 [Behzadmehr, Razieh] Zabol Univ Med Sci, Sch Med, Dept Radiol, Zabol, Iran.
   [Dastyar, Neda] Jiroft Univ Med Sci, Dept Midwifery, Jiroft, Iran.
   [Moghadam, Mahdieh Poodineh] Zabol Univ Med Sci, Fac Nursing & Midwifery, Dept Nursing, Zabol, Iran.
   [Abavisani, Mahnaz] Neyshabur Univ Med Sci, Dept Nursing, Med Surg Nursing, Neyshabur, Iran.
   [Moradi, Mandana] Zabol Univ Med Sci, Sch Pharm, Clin Pharm Dept, Zabol, Iran.
RP Moradi, M (corresponding author), Zabol Univ Med Sci, Behdasht St, Zabol, Iran.
EM mmandana310@gmail.com
CR Amraoui J, 2018, JAMA NETW OPEN, V1, P0, DOI 10.1001/jamanetworkopen.2018.1164
   Unknown -, 2018, COCHRANE DATABASE SY, V0, P0, DOI DOI 10.1002/14651858.CD009290.PUB3
   Bae K, 2015, INTEGR CANCER THER, V14, P496, DOI 10.1177/1534735415596573
   Bai ZG, 2015, AM J CHINESE MED, V43, P1525, DOI 10.1142/S0192415X15500871
   Bakhtiarian A, 2008, TOXICOL MECH METHOD, V18, P581, DOI 10.1080/15376510701563779
   Ball EF, 2017, CURR OPIN OBSTET GYN, V29, P359, DOI 10.1097/GCO.0000000000000417
   Bao T, 2018, ACUPUNCT MED, V36, P80, DOI 10.1136/acupmed-2017-011435
   Beck SL, 2010, J PAIN SYMPTOM MANAG, V39, P100, DOI 10.1016/j.jpainsymman.2009.06.009
   Behzadmehr R, 2017, INT J ADV RES BIOL S, V4, P58, DOI 10.22192/ijarbs.2017.04.06.010
   Benyamin R, 2008, PAIN PHYSICIAN, V11, P0
   Berlière M, 2018, BREAST, V37, P114, DOI 10.1016/j.breast.2017.10.017
   Binns-Turner Pamela G, 2011, AANA J, V79, P0
   Bower JE, 2015, CANCER-AM CANCER SOC, V121, P1231, DOI 10.1002/cncr.29194
   Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21609
   Breivik H, 2009, ANN ONCOL, V20, P1420, DOI 10.1093/annonc/mdp001
   Büssing A, 2012, J PAIN, V13, P1, DOI 10.1016/j.jpain.2011.10.001
   Butler LD, 2009, HEALTH PSYCHOL, V28, P579, DOI 10.1037/a0016124
   Carson JW, 2007, J PAIN SYMPTOM MANAG, V33, P331, DOI 10.1016/j.jpainsymman.2006.08.009
   Chang SY, 2008, J KOREAN ACAD NURS, V38, P493, DOI 10.4040/jkan.2008.38.4.493
   Chen L, 2017, BREAST, V33, P132, DOI 10.1016/j.breast.2017.03.015
   Chien TJ, 2015, J ALTERN COMPLEM MED, V21, P251, DOI 10.1089/acm.2014.0083
   Chiu HY, 2017, EUR J CANCER CARE, V26, P0, DOI 10.1111/ecc.12457
   Clark HD, 1999, CONTROL CLIN TRIALS, V20, P448, DOI 10.1016/S0197-2456(99)00026-4
   Cramer H, 2013, CLIN J PAIN, V29, P450, DOI 10.1097/AJP.0b013e31825e1492
   Crew Katherine D, 2007, J CANCER SURVIV, V1, P283, DOI 10.1007/s11764-007-0034-x
   Crew KD, 2010, J CLIN ONCOL, V28, P1154, DOI 10.1200/JCO.2009.23.4708
   Deandrea S, 2008, ANN ONCOL, V19, P1985, DOI 10.1093/annonc/mdn419
   DiGianni LM, 2002, J CLIN ONCOL, V20, P34S, DOI 10.1200/JCO.2002.07.176
   Dion L, 2015, INTEGR MED RES, V4, P78, DOI 10.1016/j.imr.2015.04.110
   Dogan MD, 2018, COMPLEMENT THER CLIN, V31, P384, DOI 10.1016/j.ctcp.2018.02.020
   Drackley NL, 2012, CLIN J ONCOL NURS, V16, P121, DOI 10.1188/12.CJON.121-124
   Efficace F, 2006, ANN ONCOL, V17, P1698, DOI 10.1093/annonc/mdl183
   Eustachi A, 2007, BREAST CARE, V2, P209, DOI 10.1159/000105558
   Everdingen MHJVDBV, 2007, ANN ONCOL, V18, P1437, DOI 10.1093/annonc/mdm056
   Eyigor S, 2018, COMPLEMENT THER CLIN, V32, P40, DOI 10.1016/j.ctcp.2018.04.010
   Frambes D, 2017, ONCOL NURS FORUM, V44, P596, DOI 10.1188/17.ONF.596-605
   Furlan AD, 2015, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD001929.pub3
   Galantino ML, 2013, ALTERN THER HEALTH M, V19, P38
   Galantino ML, 2012, INTEGR CANCER THER, V11, P313, DOI 10.1177/1534735411413270
   Garza-Villarreal EA, 2017, PAIN PHYSICIAN, V20, P597, DOI 10.36076/ppj/2017.7.597
   Giron PS, 2016, SUPPORT CARE CANCER, V24, P2491, DOI 10.1007/s00520-015-3054-5
   Gu Q, 2018, CHINESE MED J-PEKING, V131, P829, DOI 10.4103/0366-6999.228242
   Hall H, 2016, MEDICINE, V95, P0, DOI 10.1097/MD.0000000000004723
   Halm MA, 2014, J HOLIST NURS, V32, P290, DOI 10.1177/0898010114527184
   Hernandez-Reif M, 2005, INT J NEUROSCI, V115, P495, DOI 10.1080/00207450590523080
   Hershman DL, 2018, JAMA-J AM MED ASSOC, V320, P167, DOI 10.1001/jama.2018.8907
   Hilton L, 2017, ANN BEHAV MED, V51, P199, DOI 10.1007/s12160-016-9844-2
   Holtzman S, 2013, PAIN RES MANAG, V18, P267, DOI 10.1155/2013/105919
   JBI, 2019, JBI CRIT APPR CHECKL, V0, P0
   Jensen MP, 2012, INT J CLIN EXP HYP, V60, P135, DOI 10.1080/00207144.2012.648057
   Johannsen M, 2016, J CLIN ONCOL, V34, P3390, DOI 10.1200/JCO.2015.65.0770
   Kekecs Z, 2014, ANESTH ANALG, V119, P1407, DOI 10.1213/ANE.0000000000000466
   Kim Jung T, 2006, PAIN PRACT, V6, P273, DOI 10.1111/j.1533-2500.2006.00095.x
   Kukimoto Y, 2017, PAIN MANAG NURS, V18, P378, DOI 10.1016/j.pmn.2017.09.001
   Kumar N, 2013, INDIAN J PALLIAT CAR, V19, P180, DOI 10.4103/0973-1075.121537
   Lauche R, 2013, EVID-BASED COMPL ALT, V2013, P0, DOI 10.1155/2013/635182
   Lee CE, 2017, HOLIST NURS PRACT, V31, P260, DOI 10.1097/HNP.0000000000000220
   Lee SH, 2015, INTEGR CANCER THER, V14, P297, DOI 10.1177/1534735415572885
   Lee TI, 2006, AM J CHINESE MED, V34, P37, DOI 10.1142/S0192415X06003618
   Lengacher CA, 2016, J CLIN ONCOL, V34, P2827, DOI 10.1200/JCO.2015.65.7874
   Li XM, 2011, BREAST CANCER RES TR, V128, P411, DOI 10.1007/s10549-011-1533-z
   Liberati Alessandro, 2009, PLOS MED, V6, Pe1000100, DOI 10.1371/journal.pmed.1000100
   Lindquist R, 2018, COMPLEMENTARY AND ALTERNATIVE THERAPIES IN NURSING, V8th, P0
   Listing M, 2009, PSYCHO-ONCOLOGY, V18, P1290, DOI 10.1002/pon.1508
   Loudon A, 2014, BMC COMPLEM ALTERN M, V14, P0, DOI 10.1186/1472-6882-14-214
   Louis Margaret, 2002, AM J HOSP PALLIAT CARE, V19, P381, DOI 10.1177/104990910201900607
   Lukose Nivya, 2016, NURS J INDIA, V107, P159, DOI 10.48029/nji.2016.cvii402
   Madden K, 2016, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD009356.pub3
   Mallory MJ, 2015, AM J CHINESE MED, V43, P45, DOI 10.1142/S0192415X15500032
   Mao JJ, 2009, INTEGR CANCER THER, V8, P123, DOI 10.1177/1534735409332903
   Mao JJ, 2014, EUR J CANCER, V50, P267, DOI 10.1016/j.ejca.2013.09.022
   Moghimi-Hanjani Soheila, 2015, ACTA MED IRAN, V53, P507
   Molassiotis A, 2005, ANN ONCOL, V16, P655, DOI 10.1093/annonc/mdi110
   Montgomery GH, 2007, JNCI-J NATL CANCER I, V99, P1304, DOI 10.1093/jnci/djm106
   Oh B, 2013, ACUPUNCT MED, V31, P264, DOI 10.1136/acupmed-2012-010309
   Oldenmenger WH, 2018, CANCER TREAT REV, V63, P96, DOI 10.1016/j.ctrv.2017.12.005
   Pan YQ, 2018, INTEGR CANCER THER, V17, P602, DOI 10.1177/1534735418786801
   Peppone LJ, 2015, BREAST CANCER RES TR, V150, P597, DOI 10.1007/s10549-015-3351-1
   Pittler MH, 2008, CLIN J PAIN, V24, P731, DOI 10.1097/AJP.0b013e3181759231
   Porter C, 2019, PROCEEDINGS OF 2019 SICE INTERNATIONAL SYMPOSIUM ON CONTROL SYSTEMS (SICE ISCS 2019), V0, PP1, DOI 10.23919/SICEISCS.2019.8758755
   Quinlan-Woodward J, 2016, ONCOL NURS FORUM, V43, P725, DOI 10.1188/16.ONF.725-732
   Roberts K, 2017, CRIT REV ONCOL HEMAT, V111, P66, DOI 10.1016/j.critrevonc.2017.01.010
   Rubinstein SM, 2010, EUR SPINE J, V19, P1213, DOI 10.1007/s00586-010-1356-3
   Sturgeon M, 2009, J ALTERN COMPLEM MED, V15, P373, DOI 10.1089/acm.2008.0399
   Sudarshan M, 2013, COMPLEMENT THER CLIN, V19, P227, DOI 10.1016/j.ctcp.2013.06.004
   Tarrasch R, 2018, J ALTERN COMPLEM MED, V24, P62, DOI 10.1089/acm.2017.0023
   Tefikow S, 2013, CLIN PSYCHOL REV, V33, P623, DOI 10.1016/j.cpr.2013.03.005
   Ucuzal M, 2014, PAIN MANAG NURS, V15, P458, DOI 10.1016/j.pmn.2012.03.001
   van den Beuken-van Everdingen MHJ, 2016, J PAIN SYMPTOM MANAG, V51, P1070, DOI 10.1016/j.jpainsymman.2015.12.340
   Wang K, 2018, BREAST, V42, P113, DOI 10.1016/j.breast.2018.08.105
   Wayne PM, 2018, J CANCER SURVIV, V12, P256, DOI 10.1007/s11764-017-0665-5
   Yagli NV, 2015, COMPLEMENT THER CLIN, V21, P7, DOI 10.1016/j.ctcp.2015.01.002
   Yeganeh M, 2017, COMPLEMENT THER CLIN, V27, P11, DOI 10.1016/j.ctcp.2016.11.012
   Yuan QL, 2016, SCI REP-UK, V6, P0, DOI 10.1038/srep30675
   Zaza C, 2002, J PAIN SYMPTOM MANAG, V24, P526, DOI 10.1016/S0885-3924(02)00497-9
   Zick SM, 2018, JNCI CANCER SPECT, V2, P0, DOI 10.1093/jncics/pky064
NR 102
TC 34
Z9 46
U1 1
U2 68
PU CHURCHILL LIVINGSTONE
PI EDINBURGH
PA JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE, LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND
SN 0965-2299
EI 1873-6963
J9 COMPLEMENT THER MED
JI Complement. Ther. Med.
PD MAR 15
PY 2020
VL 49
IS 
BP 
EP 
DI 10.1016/j.ctim.2020.102318
PG 12
WC Integrative & Complementary Medicine
SC Integrative & Complementary Medicine
GA LG1NY
UT WOS:000527877700053
PM 32147038
DA 2026-01-16
ER

PT J
AU Qiao, L
   Guo, MJ
   Qian, JJ
   Xu, B
   Gu, CY
   Yang, Y
AF Qiao, Li
   Guo, Mengjie
   Qian, Jinjun
   Xu, Bin
   Gu, Chunyan
   Yang, Ye
TI Research Advances on Acupuncture Analgesia
SO AMERICAN JOURNAL OF CHINESE MEDICINE
LA English
DT Article
DE Acupuncture; Moxibustion; Analgesia; Mechanism; Neurotransmitters; Review
ID muscle blood-flow; cancer-related fatigue; dorsal raphe nucleus; manual acupuncture; chinese medicine; opioid receptors; nitric-oxide; electroacupuncture; pain; rat
AB Pain is a widespread and complex symptom which causes serious emotional and social burdens to individuals and society. Most patients with pain rely heavily on over the counter (OTC) and prescription pain killers. However, there would be a number of issues that arise from the use of pain killers, in which safety and addiction are the most critical issues. For traditional Chinese medicine (TCM), pain is a result of the meridians being blocked. This could occur as a symptom of or be caused by various diseases. In this case, the key to relieve pain depends on dredging the meridian or meridians. Acupuncture has been practiced in China for over 2000 years to lessen pain. It is based on the "meridian theory". Acupuncture is being used more widely and with a growing number of people in the treatment of pain because it is safer and has fewer side effects. Along with growing use and interest in acupuncture to treat pain, more attention has been paid to the mechanism underlying its analgesic effect, which is mainly associated with the changes of neurotransmitters. In this review, we summarize and analyze the range and mechanism of acupuncture analgesia treatment.
C1 [Qiao, Li; Guo, Mengjie] Nanjing Univ Chinese Med, Affiliated Hosp 3, Nanjing 210001, Peoples R China.
   [Qiao, Li; Guo, Mengjie; Qian, Jinjun; Gu, Chunyan; Yang, Ye] Nanjing Univ Chinese Med, Sch Med & Holist Integrat Med, 138 Xianlin Rd, Nanjing 210023, Jiangsu, Peoples R China.
   [Xu, Bin; Yang, Ye] Nanjing Univ Chinese Med, Chinese Minist Educ, Key Lab Combinat Acupuncture & Chinese Mat Med, Nanjing 210023, Peoples R China.
C3 Nanjing University of Chinese Medicine; Nanjing University of Chinese Medicine; Nanjing University of Chinese Medicine
RP Gu, CY; Yang, Y (corresponding author), Nanjing Univ Chinese Med, Sch Med & Holist Integrat Med, 138 Xianlin Rd, Nanjing 210023, Jiangsu, Peoples R China.
EM guchunyan@njucm.edu.cn; yangye876@sina.com
FU National Natural Science Foundation of China [81770220, 81600177, 81670200]; Innovation Team of Six Talent Peaks Project in Jiangsu Province [TD-SWYY-015]; 2016 outstanding youth fund of Jiangsu Province [BK20160048]; Natural Science Foundation of Jiangsu Province [BK20161041]; National key research and development program-precision medicine sub-program [2016YFC0905900]; Priority Academic Program Development of Jiangsu Higher Education Institutions for Chinese Medicine
CR Burnstock G, 2009, AUTONOMIC & AUTACOID PHARMACOLOGY, V29, P63, DOI 10.1111/j.1474-8673.2009.00435.x
   Burnstock G, 2016, ADV PHARMACOL, V75, P91, DOI 10.1016/bs.apha.2015.09.001
   Chang HC, 2016, RSC POLYM CHEM SER, V18, P355
   Chen YH, 2013, EVID-BASED COMPL ALT, V2013, P0, DOI 10.1155/2013/134610
   Dai QX, 2017, NEURAL REGEN RES, V12, P228, DOI 10.4103/1673-5374.200806
   Erthal V, 2013, LASER MED SCI, V28, P1345, DOI 10.1007/s10103-012-1260-7
   Freitas RL, 2008, EXP NEUROL, V213, P410, DOI 10.1016/j.expneurol.2008.07.003
   Fu SF, 2016, CHIN J INTEGR MED, V22, P473, DOI 10.1007/s11655-015-2250-y
   Fusumada Kazutoshi, 2007, OKAJIMAS FOLIA ANATOMICA JAPONICA, V84, P1, DOI 10.2535/ofaj.84.1
   Garcia MK, 2013, J CLIN ONCOL, V31, P952, DOI 10.1200/JCO.2012.43.5818
   Goldman N, 2010, NAT NEUROSCI, V13, P883, DOI 10.1038/nn.2562
   Guo ZL, 2012, BRAIN RES, V1442, P25, DOI 10.1016/j.brainres.2012.01.006
   Hsieh CW, 2011, EVID-BASED COMPL ALT, V2011, P1, DOI 10.1155/2011/951258
   Huang C, 2002, BRAIN RES, V945, P20, DOI 10.1016/S0006-8993(02)02503-9
   Huang CP, 2013, EVID-BASED COMPL ALT, V2013, P0, DOI 10.1155/2013/312184
   Iwasaki T, 2013, EUR J PHARMACOL, V702, P149, DOI 10.1016/j.ejphar.2013.01.058
   Jan AL, 2017, EMERG MED AUSTRALAS, V29, P490, DOI 10.1111/1742-6723.12832
   Kandimalla R, 2017, J ALZHEIMERS DIS, V57, P1049, DOI 10.3233/JAD-161118
   Kim JH, 2004, BRAIN RES, V998, P230, DOI 10.1016/j.brainres.2003.11.045
   Kim W, 2013, EVID-BASED COMPL ALT, V2013, P0, DOI 10.1155/2013/436913
   Lau CH, 2016, MEDICINE, V95, P290
   Lee BH, 2015, J ACUPUNCT MERIDIAN, V8, P175, DOI 10.1016/j.jams.2015.04.001
   Li P, 2010, AUTON NEUROSCI-BASIC, V158, P13, DOI 10.1016/j.autneu.2010.05.006
   Li ZYY, 2016, SHIJIE KEXUE JISHU, V18, P395
   Li ZY, 2017, WORLD J GASTROENTERO, V23, P6220, DOI 10.3748/wjg.v23.i34.6220
   Lin JG, 2008, AM J CHINESE MED, V36, P635, DOI 10.1142/S0192415X08006107
   Lin JG, 2018, AM J CHINESE MED, V46, P55, DOI 10.1142/S0192415X18500039
   Lin YW, 2010, J INTEGR NEUROSCI, V9, P269, DOI 10.1142/S0219635210002433
   Liu J, 2017, CHINESE JOURNAL OF TRADITIONAL CHINESE MEDICINE, V35, P373, DOI 10.13193/j.issn.1673-7717.2017.02.033
   Lu KW, 2016, SCI REP-UK, V6, P0, DOI 10.1038/srep22123
   Mao HJ, 2016, CANCER-AM CANCER SOC, V122, P3667, DOI 10.1002/cncr.30189
   Nagaoka S, 2016, ACUPUNCT MED, V34, P229, DOI 10.1136/acupmed-2015-010959
   Pan H, 2018, AM J CHINESE MED, V46, P489, DOI 10.1142/S0192415X18500258
   Park JH, 2010, BRAIN RES, V1322, P24, DOI 10.1016/j.brainres.2010.02.001
   Patil S, 2016, CURR PAIN HEADACHE R, V20, P0, DOI 10.1007/s11916-016-0545-0
   Rithirangsriroj K, 2015, GYNECOL ONCOL, V136, P82, DOI 10.1016/j.ygyno.2014.10.025
   Sandberg M, 2004, EUR J PAIN, V8, P163, DOI 10.1016/S1090-3801(03)00090-9
   Seo BK, 2016, BMC COMPLEM ALTERN M, V16, P0, DOI 10.1186/s12906-016-1204-z
   Shinbara H, 2017, ACUPUNCT MED, V35, P284, DOI 10.1136/acupmed-2016-011152
   Shinbara H, 2015, ACUPUNCT MED, V33, P65, DOI 10.1136/acupmed-2014-010634
   Shirakata Y, 2016, CASE REP OPHTHAL, V7, P1, DOI 10.1159/000443322
   Staelin R, 2017, PAIN MANAG, V7, P99, DOI 10.2217/pmt-2016-0046
   Stein C, 2003, NAT MED, V9, P1003, DOI 10.1038/nm908
   Taguchi R, 2010, BRAIN RES, V1355, P97, DOI 10.1016/j.brainres.2010.08.014
   Tsuchiya M, 2007, ANESTH ANALG, V104, P301, DOI 10.1213/01.ane.0000230622.16367.fb
   Vickers AJ, 2018, J PAIN, V19, P455, DOI 10.1016/j.jpain.2017.11.005
   Wang Hong-peng, 2011, AUTOMATION & INSTRUMENTATION, V26, P1
   Wang S, 2014, EVID-BASED COMPL ALT, V2014, P0
   Wang Y, 2005, EXP NEUROL, V192, P156, DOI 10.1016/j.expneurol.2004.11.003
   Werner FM, 2017, EPILEPSY BEHAV, V71, P124, DOI 10.1016/j.yebeh.2015.01.038
   Wu SY, 2014, BMC COMPLEM ALTERN M, V14, P0, DOI 10.1186/1472-6882-14-96
   Wu YY, 2017, EXP THER MED, V14, P107, DOI 10.3892/etm.2017.4479
   Xu Y, 2018, AM J CHINESE MED, V46, P997, DOI 10.1142/S0192415X18500520
   Yang ES, 2011, PFLUG ARCH EUR J PHY, V462, P645, DOI 10.1007/s00424-011-1017-3
   Ye JJ, 2017, J PAIN RES, V10, P0, DOI 10.2147/JPR.S129287
   Yeom M, 2018, LIFE SCI, V203, P20, DOI 10.1016/j.lfs.2018.04.016
   Zhang Q, 2016, BMJ OPEN, V6, P1
   Zhang RX, 2004, BRAIN RES, V1020, P12, DOI 10.1016/j.brainres.2004.05.067
   Zhang Y, 2018, SUPPORT CARE CANCER, V26, P415, DOI 10.1007/s00520-017-3955-6
   Zhang ZJ, 2012, PLOS ONE, V7, P0, DOI 10.1371/journal.pone.0029651
   Zhao ZQ, 2008, PROG NEUROBIOL, V85, P355, DOI 10.1016/j.pneurobio.2008.05.004
   Zhou EH, 2011, WORLD J GASTROENTERO, V17, P662, DOI 10.3748/wjg.v17.i5.662
   Zhou W, 2014, J ACUPUNCT MERIDIAN, V7, P190
   [朱丽霞 Zhu Lixia], 2002, 针刺研究 ACUPUNCTURE RESEARCH, V27, P85
NR 64
TC 71
Z9 80
U1 1
U2 61
PU WORLD SCIENTIFIC PUBL CO PTE LTD
PI SINGAPORE
PA 5 TOH TUCK LINK, SINGAPORE 596224, SINGAPORE
SN 0192-415X
EI 1793-6853
J9 AM J CHINESE MED
JI Am. J. Chin. Med.
PD JUN 15
PY 2020
VL 48
IS 2
BP 245
EP 258
DI 10.1142/S0192415X20500135
PG 14
WC Integrative & Complementary Medicine; Medicine, General & Internal
SC Integrative & Complementary Medicine; General & Internal Medicine
GA LL4UY
UT WOS:000531553500001
PM 32138535
DA 2026-01-16
ER

PT J
AU He, YH
   May, BH
   Zhang, HB
AF He, Yihan
   May, Brian H.
   Zhang, Haibo
TI Association of Acupuncture and Acupressure With Improved Cancer Pain Reply
SO JAMA ONCOLOGY
LA English
DT Letter
C1 [He, Yihan; Zhang, Haibo] Guangzhou Univ Chinese Med, Guangdong Prov Acad Chinese Med Sci, Guangdong Prov Hosp Chinese Med, Affiliated Hosp 2, 111 Dade Rd, Guangzhou 510120, Guangdong, Peoples R China.
   [He, Yihan; May, Brian H.] RMIT Univ, Sch Hlth & Biomed Sci, China Australia Int Res Ctr Chinese Med, Melbourne, Vic, Australia.
C3 Guangzhou University of Chinese Medicine; Royal Melbourne Institute of Technology (RMIT)
RP Zhang, HB (corresponding author), Guangzhou Univ Chinese Med, Guangdong Prov Acad Chinese Med Sci, Guangdong Prov Hosp Chinese Med, Affiliated Hosp 2, 111 Dade Rd, Guangzhou 510120, Guangdong, Peoples R China.
EM haibozh@gzucm.edu.cn
CR Farrar JT, 2003, J PAIN SYMPTOM MANAG, V25, P406, DOI 10.1016/S0885-3924(03)00162-3
   He YH, 2020, JAMA ONCOL, V6, P271, DOI 10.1001/jamaoncol.2019.5233
   He YH, 2017, BMJ OPEN, V7, P0, DOI 10.1136/bmjopen-2017-018494
   Hershman DL, 2018, JAMA-J AM MED ASSOC, V320, P167, DOI 10.1001/jama.2018.8907
   Hjermstad MJ, 2011, J PAIN SYMPTOM MANAG, V41, P1073, DOI 10.1016/j.jpainsymman.2010.08.016
   Nasser Mona, 2020, AM J PUBLIC HEALTH, V110, P753, DOI 10.2105/AJPH.2020.305609
NR 6
TC 0
Z9 0
U1 0
U2 7
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 2374-2437
EI 2374-2445
J9 JAMA ONCOL
JI JAMA Oncol.
PD JUN 15
PY 2020
VL 6
IS 6
BP 940
EP 940
DI 10.1001/jamaoncol.2020.0640
PG 1
WC Oncology
SC Oncology
GA MA6QT
UT WOS:000542037700036
PM 32324196
DA 2026-01-16
ER

PT J
AU Wang, GX
   Deng, KF
   Liao, ZL
   Zhu, Y
   Chen, RL
AF Wang, Guo-Xiang
   Deng, Kai-Feng
   Liao, Zi-Long
   Zhu, Ying
   Chen, Ri-Lan
TI [Effect of hysteretic acupuncture on joint function and related cytokines in
SO Zhen ci yan jiu = Acupuncture research
LA chi
DT Journal Article
DE Hysteretic acupuncture; Joint function; Knee osteoarthritis; Pain; Randomized controlled trial
AB OBJECTIVE: To observe the difference of therapeutic effect between hysteretic  acupuncture and Celecoxib capsules for knee osteoarthritis(KOA), and to  investigate their effects on levels of interleukin 6(IL-6) and tumor necrosis  factor α(TNF-α) in articular fluid. METHODS: Seventy-two patients with KOA were  randomly divided into hysteretic acupuncture and me-dication groups, with 36  cases in each group. The patients of the hysteretic acupuncture group received  hysteretic acupuncture stimulation at Dubi (ST35), Neixiyan (EX-LE4), Zusanli  (ST36), Yanglingquan (GB34), Yinlingquan (SP9), Xuehai (SP10), Liangqiu (ST34)  and Heding (EX-LE2) as the main acupoints for 30 min once daily. The patients of  the medication group received oral administration of Celecoxib capsules(200 mg)  once daily. Both of the two groups were treated with 14 days as a course of  treatment, with a 2-day rest between each course of treatment, and the treatments  were conducted for 2 courses. The visual analogue scale(VAS) score of pain,  Lequesne index score, IL-6 and TNF-α level in joint fluid and the change of  traditional Chinese medicine(TCM) syndrome score were observed before and after  treatment. RESULTS: Compared with pre-treatment, the VAS score, Lequesne index  score, IL-6 and TNF-α level, and total TCM syndrome score decreased significantly  after treatment in both of the two groups (P<0.05). Hysteretic acupuncture was  more effective in reducing VAS score, Lequesne index score, IL-6 and TNF-α level  than Celecoxib capsules (P<0.05), and there was no significant difference in  total TCM syndrome score and total effective rate between the two groups(P>0.05).  No adverse events occurred in both groups during the treatment. CONCLUSION:  Hysteretic acupuncture can effectively relieve pain symptoms and improve joint  function in KOA patients. Its effect is comparable to that of oral administration  of Celecoxib capsules.
C1 Ruikang Hospital Affiliated to Guangxi University of Chinese Medicine, Nanning 530011, China.
   Graduate School of Guangxi University of Chinese Medicine, Nanning 530001.
   Ruikang Hospital Affiliated to Guangxi University of Chinese Medicine, Nanning 530011, China.
   Ruikang Hospital Affiliated to Guangxi University of Chinese Medicine, Nanning 530011, China.
   Ruikang Hospital Affiliated to Guangxi University of Chinese Medicine, Nanning 530011, China.
NR 0
TC 0
SN 
EI 1000-060
J9 Zhen Ci Yan Jiu
PD JUL 25
PY 2020
VL 45
IS 7
BP 564
EP 8
DI 10.13702/j.1000-0607.200054
PG -556
WC Acupuncture Therapy; Cytokines; Humans; Knee Joint; Osteoarthritis, Knee; Treatment Outcome
UT PubMed:32705831
PM 32705831
DA 2020-07-25
ER

PT J
AU Ni, XX
   Tian, T
   Liu, L
   Li, X
   Zhao, L
AF Ni, Xi-Xiu
   Tian, Tian
   Liu, Lu
   Li, Xiao
   Zhao, Ling
TI [Reporting quality of randomized controlled trials of acupuncture for cancer
SO Zhongguo zhen jiu = Chinese acupuncture & moxibustion
LA chi
DT Journal Article
DE Consolidated Standards for Reporting of Trials (CONSORT); Standards for Reporting Interventions in Controlled Trials of Acupuncture ; acupuncture; cancer pain; literature report quality; randomized controlled trial (RCT)
AB Based on the internationally-recognized Consolidated Standards for Reporting of  Trials (CONSORT) statement and Standards for Reporting Interventions in  Controlled Trials of Acupuncture (STRICTA), the reported quality of randomized  controlled trials (RCTs) of acupuncture for cancer pain during last 10 years were  evaluated. The RCTs of acupuncture for cancer pain were searched by computer. The  English databases included PubMed and EMbase while the Chinese databases included  CNKI, Wanfang, VIP and SinoMed. The publication date of the literature was from  March 2009 to March 2019. As a result, 22 Chinese RCTs and 13 English RCTs were  included. According to the CONSORT statement, among the Chinese studies, 1 RCT  reported primary and secondary outcomes, 8 RCTs reported randomization, none of  RCTs reported allocation concealment and blind method, and 4 RCTs reported  baseline data; among the English studies, 8 RCTs reported primary and secondary  outcomes, 8 RCTs reported randomization, 6 RCTs reported described allocation  concealment, 7 RCTs reported blind method, and 13 RCTs reported baseline data.  According to the STRICTA statement, among the Chinese studies, 17 RCTs reported  the name of acupoints, 6 RCTs reported depth of insertion, 17 RCTs reported  acupuncture response sought, and none of RCTs reported the qualifications of  acupuncturists; among the English studies, 12 RCTs reported the name of  acupoints, 7 RCTs reported depth of insertion, 8 RCTs reported acupuncture  response sought, and 7 RCTs reported the qualifications of acupuncturists. The  Chinese RCTs have more detailed description of acupuncture intervention and  theory, but not enough attention is paid to methodological description such as  randomization, blindness, data analysis. On the other hand, the English RCTs have  better description of methodology, but the description of theory and details of  acupuncture is relatively weak. It is concluded that more efforts were needed to  further improve the clinical trial design according to the CONSORT statement and  STRICTA statement to improve the quality of clinical evidence.
C1 College of Acupuncture-Moxibustion and Tuina, Chengdu University of TCM, Chengdu 610075, Sichuan Province, China.
   College of Acupuncture-Moxibustion and Tuina, Chengdu University of TCM, Chengdu 610075, Sichuan Province, China.
   College of Acupuncture-Moxibustion and Tuina, Chengdu University of TCM, Chengdu 610075, Sichuan Province, China.
   College of Acupuncture-Moxibustion and Tuina, Chengdu University of TCM, Chengdu 610075, Sichuan Province, China.
   College of Acupuncture-Moxibustion and Tuina, Chengdu University of TCM, Chengdu 610075, Sichuan Province, China.
NR 0
TC 0
SN 
EI 0255-293
J9 Zhongguo Zhen Jiu
PD JUN 17
PY 2020
VL 40
IS 6
BP 671
EP 7
DI 10.13703/j.0255-2930.20190619-k0004
PG -664
WC Acupuncture Therapy; Cancer Pain; therapy; Humans; Neoplasms; complications; Randomized Controlled Trials as Topic; standards
UT PubMed:32538022
PM 32538022
DA 2020-06-17
ER

PT J
AU Zhang, YP
   Hu, RX
   Han, M
   Lai, BY
   Liang, SB
   Chen, BJ
   Robinson, N
   Chen, K
   Liu, JP
AF Zhang, Ya-Peng
   Hu, Rui-Xue
   Han, Mei
   Lai, Bao-Yong
   Liang, Shi-Bing
   Chen, Bing-Jie
   Robinson, Nicola
   Chen, Kevin
   Liu, Jian-Ping
TI Evidence Base of Clinical Studies on Qi Gong: A Bibliometric Analysis.
SO Complementary therapies in medicine
LA English
DT Review
DE Ba Duan Jin; Bibliometric Analysis; Clinical Study; Non-drug therapy; Qigong
AB OBJECTIVE: This bibliometric study aimed to systematically and comprehensively  summarize the volume, breadth and evidence for clinical research on Qigong. And  this bibliometric analysis also can provide the evidence of this field. DESIGN:  Bibliometric analysis. METHODS: All types of primary and secondary studies on  humans were included: systematic reviews, randomized clinical trials,  non-randomized controlled clinical studies, case series and case reports. Chinese  Biomedical Literature Database, China National Knowledge Infrastructure, Chinese  Scientific Journal Database, Chinese Academic Conference Papers Database and  Chinese Dissertation Database, PubMed and the Cochrane Library were searched from  the date of inception to December 10, 2018. Bibliometric information, such as  publication information, disease/condition, Qigong intervention and research  results were extracted and analyzed. RESULTS: A total of 886 clinical studies  were identified: including 47 systematic reviews, 705 randomized clinical trials,  116 non-randomized controlled clinical studies, 12 case series and 6 case  reports. The studies were conducted in 14 countries. The top 15  diseases/conditions studied were: diabetes, chronic obstructive pulmonary  disease, hypertension, stroke, cervical spondylosis, lumbar disc herniation,  insomnia, knee osteoarthritis, low back pain, and osteoporosis, Coronary heart  disease, breast cancer, periarthritis of shoulder, depression, metabolic  syndrome. Of the various Qigong exercises reported in these 886 clinical studies,  Ba Duan Jin was the most frequently researched in 492 (55.5%) studies, followed  by Health Qigong 107 (12.1%), Dao Yin Shu 85 (9.6%), Wu Qin Xi 67 (7.6%) and Yi  Jin Jing 66 (7.4%). The most frequently used comparisons in randomized trials  were maintaining normal way of life unchanged 149 (18.1%), the remaining controls  included conventional treatment, mainly western medicine, Chinese herbal  medicine, acupuncture, health education, psychological therapy, Yoga, Tai Chi and  other non-drug therapy. The most frequently reported outcomes were physical  function, quality of life, symptoms, pain and mental health indicators.  Beneficial results from practicing Qigong were reported in 97% of studies.  CONCLUSIONS: Qigong research publications have been increasing gradually. Reports  on study types, participants, Qigong Intervention, and outcomes are diverse and  inconsistent. There is an urgent need to develop a set of reporting standards for  various interventions of Qigong. Further trials of high methodological quality  with sufficient sample size and real world studies are needed to verify the  effects of Qigong in health and disease management.
C1 Centre for Evidence Based Chinese Medicine, Beijing University of Chinese Medicine, Beijing, 100029, China
   Institute of Integrated Traditional ChineseMedicine and Western Medicine, Guangzhou Medical University, Guangzhou, China.
   Centre for Evidence Based Chinese Medicine, Beijing University of Chinese Medicine, Beijing, 100029, China
   Center of Evidence Based Traditional ChineseMedicine, Institute of Basic Research in Clinical Medicine, China Academy ofChinese Medical Sciences, China
   Institute of Integrated Traditional ChineseMedicine and Western Medicine, Guangzhou Medical University, Guangzhou, China.
   Centre for Evidence Based Chinese Medicine, Beijing University of Chinese Medicine, Beijing, 100029, China
   Institute of Integrated Traditional ChineseMedicine and Western Medicine, Guangzhou Medical University, Guangzhou, China.
   The Third Affiliated Hospital of Beijing Universality of Chinese Medicine, Beijing 100029, China
   Institute of Integrated Traditional Chinese Medicine andWestern Medicine, Guangzhou Medical University, Guangzhou, China. Electronicaddress: by_lai@126.com.
   Centre for Evidence Based Chinese Medicine, Beijing University of Chinese Medicine, Beijing, 100029, China
   College of Basic Medical Sciences, ShanxiUniversity of Traditional Chinese Medicine, Taiyuan, 030000, China
   Institute ofIntegrated Traditional Chinese Medicine and Western Medicine, Guangzhou MedicalUniversity, Guangzhou, China. 
   College of Traditional Chinese Medicine, Beijing University of Chinese Medicine, Beijing, 100029, China
   Institute of Integrated Traditional Chinese Medicine andWestern Medicine, Guangzhou Medical University, Guangzhou, China. Electronicaddress: tian8388@163.com.
   Centre for Evidence Based Chinese Medicine, Beijing University of Chinese Medicine, Beijing, 100029, China
   School of Health and Social Care, London SouthBank University, London, SE1 0AA, UK
   Institute of Integrated Traditional ChineseMedicine and Western Medicine, Guangzhou Medical University, Guangzhou, China.
   University of Maryland School of Medicine, Center for Integrative Medicine, United States
   ShenZhen University, Faculty of Physical Education, China;Institute of Integrated Traditional Chinese Medicine and Western Medicine,Guangzhou Medical University, Guangzhou, China. 
   Centre for Evidence Based Chinese Medicine, Beijing University of Chinese Medicine, Beijing, 100029, China
   Institute of Integrated Traditional ChineseMedicine and Western Medicine, Guangzhou Medical University, Guangzhou, China.
EM Liujp@bucm.edu.cn
NR 0
TC 0
SN 1873-696
EI 
J9 Complement Ther Med
PD MAY 24
PY 2020
VL 50
IS 
BP 102392
EP 102392
DI 10.1016/j.ctim.2020.102392
PG 0
WC Bibliometrics; Evidence-Based Medicine; Humans; Periodicals as Topic; Qigong
UT PubMed:32444061
PM 32444061
DA 2020-05-24
ER

PT J
AU He, Y
   May, BH
   Zhang, H
AF He, Yihan
   May, Brian H
   Zhang, Haibo
TI Association of Acupuncture and Acupressure With Improved Cancer Pain-Reply.
SO JAMA oncology
LA English
DT Letter
C1 Guangdong Provincial Hospital of Chinese Medicine, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangdong Provincial Academy ofChinese Medical Sciences, Guangzhou, Guangdong Province, China.
   China-Australia International Research Centre for Chinese Medicine, School of 
   China-Australia International Research Centre for Chinese Medicine, School of Health and Biomedical Sciences, RMIT University, Melbourne, Victoria, Australia.
   Guangdong Provincial Hospital of Chinese Medicine, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangdong Provincial Academy ofChinese Medical Sciences, Guangzhou, Guangdong Province, China.
NR 0
TC 0
SN 2374-244
EI 
J9 JAMA Oncol
PD APR 24
PY 2020
VL 6
IS 6
BP 940
EP 940
DI 10.1001/jamaoncol.2020.0640
PG 0
WC Acupressure; Acupuncture Therapy; Cancer Pain; therapy; Humans; Neoplasms; complications
UT PubMed:32324196
PM 32324196
DA 2020-04-24
ER

PT J
AU Lu, W
AF Lu, Weidong
TI Axon Degeneration and Inflammation in Neuropathy: The Role of Acupuncture.
SO Medical acupuncture
LA English
DT Journal Article
DE axon degeneration; breast cancer; electroacupuncture; inflammation; pain management acupuncture; peripheral neuropathy
AB Chemotherapy-induced peripheral neuropathy (CIPN) induces debilitating long-term  side-effects in breast cancer-survivors. This article describes some of the  more-recent research in this area including a randomized controlled pilot trial  the current author and colleagues performed to assess feasibility, safety, and  effectiveness of acupuncture for treating CIPN in this population. In this  randomized pilot trial of 40 breast-cancer survivors with CIPN after adjuvant  taxane therapy, an 8-week acupuncture intervention (versus usual care) led to a  statistically and clinically significant reduction in subjective sensory  symptoms, including neuropathic pain and paresthesia. Given the lack of effective  therapies and given the established safety profile of acupuncture, clinicians may  consider acupuncture as a treatment option for mild-to-moderate CIPN in practice.  Additional larger studies are needed to confirm these findings.
C1 Leonard P. Zakim Center for Integrative Therapies, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
NR 0
TC 0
SN 1933-659
EI 1933-658
J9 Med Acupunct
PD DEC 29
PY 2020
VL 32
IS 6
BP 398
EP 399
DI 10.1089/acu.2020.1496
PG 1
UT PubMed:33362898
PM 33362898
DA 2020-12-29
ER

PT J
AU Li, Y
   Wu, F
   Wei, J
   Lao, L
   Shen, X
AF Li, Yuan
   Wu, Fan
   Wei, Jianzi
   Lao, Lixing
   Shen, Xueyong
TI Laser Moxibustion Alleviates Knee Osteoarthritis Pain by Inhibiting Spinal
SO Photobiomodulation, photomedicine, and laser surgery
LA English
DT Journal Article
DE glial activation; knee osteoarthritis pain; laser moxibustion; neuroinflammation
AB Background: Central sensitization driven by glial activation-mediated  neuroinflammation is recognized as a key mechanism in pain processing. Laser  moxibustion using low-intensity laser irradiation of corresponding acupoints  significantly relieves knee osteoarthritis (KOA) pain. However, the underlying  mechanism of its effects on KOA pain is still not completely understood.  Objective: In this study, we aimed to investigate whether laser moxibustion could  alleviate KOA pain by inhibiting spinal glial activation and proinflammatory  cytokines upregulation in monosodium iodoacetate (MIA)-induced KOA pain in rats.  Materials and methods: Sprague-Dawley rats were divided randomly into three  groups: Saline + Sham Laser, MIA + Laser, and MIA + Sham Laser. A 10.6 μm laser  was used to irradiate ST35 (Dubi) for 10 min once every 2 days for a total of  seven applications. The paw withdrawal mechanical threshold and weight-bearing  distribution were performed to evaluate the nociceptive behaviors. Spinal  expressions of microglial marker, ionized calcium binding adaptor molecule-1  (Iba-1); astrocyte marker, glial fibrillary acidic protein (GFAP);  pro-inflammatory cytokines, tumor necrosis factor-α (TNF-α), interleukin-1β  (IL-1β), and interleukin-6 (IL-6) were measured 14 days after MIA injection.  Results: The results showed that laser moxibustion significantly reversed the  MIA-induced mechanical hyperalgesia and weight-bearing difference up to 14 days  compared with MIA + Sham Laser group (p < 0.05 or p < 0.01). Moreover, both the  protein level and immunofluorescence intensity of Iba-1 in the ipsilateral spinal  cord dorsal horn were markedly decreased in the MIA + Laser group than those in  the MIA + Sham Laser group (p < 0.01). However, there was no significant  difference in the expression of GFAP between groups (p > 0.05). In addition,  laser moxibustion decreased the upregulation of TNF-α, IL-1β, and IL-6 compared  with the MIA + Sham Laser group (p < 0.01). Conclusions: This study demonstrated  that laser moxibustion at ST35 significantly alleviated MIA-induced KOA pain  through inhibition of the microglial activation-mediated neuroinflammation, at  least partially, by suppressing the production of proinflammatory cytokines,  which may provide a potential analgesic target for KOA pain relief.
C1 School of Acupuncture-Moxibustion and Tuina, Shanghai University of Traditional Chinese Medicine, Shanghai, China.
   School of Acupuncture-Moxibustion and Tuina, Shanghai University of Traditional Chinese Medicine, Shanghai, China.
   School of Acupuncture-Moxibustion and Tuina, Shanghai University of Traditional Chinese Medicine, Shanghai, China.
   School of Acupuncture-Moxibustion and Tuina, Shanghai University of Traditional Chinese Medicine, Shanghai, China.
   School of Chinese Medicine, The University of Hong Kong, Hong Kong SAR, China.
   School of Acupuncture-Moxibustion and Tuina, Shanghai University of Traditional Chinese Medicine, Shanghai, China.
   Shanghai Research Center of Acupuncture & Meridian, Shanghai, China.
NR 0
TC 0
SN 2578-547
EI 
J9 Photobiomodul Photomed Laser Surg
PD JAN 25
PY 2020
VL 38
IS 4
BP 237
EP 243
DI 10.1089/photob.2019.4744
PG 6
WC Animals; Cytokines; metabolism; Disease Models, Animal; Iodoacetic Acid; Low-Level Light Therapy; Male; Microglia; physiology; Moxibustion; Osteoarthritis, Knee; complications; Pain; etiology; Rats; Rats, Sprague-Dawley
UT PubMed:31976816
PM 31976816
DA 2020-01-25
ER

PT J
AU Kang, SY
   Bang, SK
   Kwon, OS
   Seo, SY
   Choi, KH
   Cho, SJ
   Yoo, HS
   Lee, JS
   Kim, HW
   Ryu, Y
AF Kang, Suk-Yun
   Bang, Se Kyun
   Kwon, O. Sang
   Seo, Su-Yeon
   Choi, Kwang-Ho
   Cho, Seong Jin
   Yoo, Hwa Seung
   Lee, Jin Sun
   Kim, Hyun-Woo
   Ryu, Yeonhee
TI Treatment of electrical wrist stimulation reduces chemotherapy-induced neuropathy and ultrasound vocalization via modulation of spinal NR2B phosphorylation
SO BRAIN RESEARCH BULLETIN
LA English
DT Article
DE Chemotherapy; Docetaxel; Analgesia; Electrical stimulation; Ultrasound
ID induced peripheral neuropathy; mechanical allodynia; nerve-stimulation; laboratory rats; d-serine; pain; acupuncture; electroacupuncture; cancer; neurotoxicity
AB Docetaxel, a chemotherapeutic agent used to treat breast cancer, produces a robust painful neuropathy that is aggravated by mechanical and thermal stimuli. This study was undertaken to investigate the analgesic effects of electrical stimulation on docetaxel-induced neuropathic pain in mice and to identify associated changes in ultrasound vocalizations. Peripheral neuropathy was induced with intraperitoneally injected docetaxel (5 mg/kg) on 3 times every 2 days in male ICR mice. Electrical wrist stimulation was administered and pain behavior signs were evaluated by von Frey filaments and thermal stimulation on the hind paw. Ultrasound vocalizations were measured using ultrasound microphones, after electrical stimulation. After mice developed docetaxel-induced neuropathic pain behavior, an electrical stimulation temporarily attenuated mechanical allodynia and thermal hyperalgesia. In formalin and NMDA test, pain-induced mice showed increases in 10-30 kHz ultrasound vocalizations, but not in 30-50 and 50-80 kHz vocalizations. Treatment with docetaxel selectively increased 10-30 kHz ultrasound vocalizations, whereas electrical stimulation caused a meaningful decrease. Moreover, electrical stimulation suppressed the docetaxel-enhanced phosphorylation of the NMDA receptor NR2B subunit in the spinal dorsal horn. These results of the analgesic effect of electrical stimulation in chemotherapy-induced neuropathy could potentially provide a new method to treat and manage peripheral neuropathy in patients with cancer.
C1 [Kang, Suk-Yun; Bang, Se Kyun; Seo, Su-Yeon; Choi, Kwang-Ho; Cho, Seong Jin; Ryu, Yeonhee] KoreaInst Oriental Med, Clin Med Div, 1672 Yuseong Daero, Daejeon 34054, South Korea.
   [Yoo, Hwa Seung] Daejeon Univ, East West Canc Ctr, Dunsan Korean Med Hosp, Daejeon 35234, South Korea.
   [Lee, Jin Sun] Chungnam Natl Univ Hosp, Dept Surg, Daejeon 35015, South Korea.
   [Kim, Hyun-Woo] Chungnam Natl Univ, Dept Physiol & Med Sci, Daejeon 35015, South Korea.
   [Kwon, O. Sang] Wonkwang Univ, Coll Korean Med, Dept Meridian & Acupuncture Points, Iksan 54538, South Korea.
C3 Daejeon University; Chungnam National University; Chungnam National University Hospital; Chungnam National University; Wonkwang University
RP Ryu, Y (corresponding author), KoreaInst Oriental Med, Clin Med Div, 1672 Yuseong Daero, Daejeon 34054, South Korea.
EM sy8974@kiom.re.kr; sichosi@kiom.re.kr; logos319@wku.ac.kr; ssy1025@kiom.re.kr; ddoongho@kiom.re.kr; ipcng@kiom.re.kr; altyhs@daum.net; leejin123@daum.net; kim0827@cnu.ac.kr; yhryu@kiom.re.kr
FU Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI) - Ministry of Health & Welfare, Republic of Korea [HI15C0007]; Korea Institute of Oriental Medicine (KIOM; Daejeon, South Korea) [KSN1812181]
CR ABBADIE C, 1994, PAIN, V57, P45, DOI 10.1016/0304-3959(94)90106-6
   Bennett GJ, 2010, ONCOLOGIST, V15, P9, DOI 10.1634/theoncologist.2009-S503
   Bennett MI, 2010, J PAIN, V11, P351, DOI 10.1016/j.jpain.2009.08.002
   BLANCHARD RJ, 1991, PHYSIOL BEHAV, V50, P967, DOI 10.1016/0031-9384(91)90423-L
   Brewer JR, 2016, GYNECOL ONCOL, V140, P176, DOI 10.1016/j.ygyno.2015.11.011
   Cavaletti G, 2010, NAT REV NEUROL, V6, P657, DOI 10.1038/nrneurol.2010.160
   Cervellini I, 2010, NEUROTOX RES, V18, P151, DOI 10.1007/s12640-009-9127-9
   Cho HY, 2014, TOHOKU J EXP MED, V232, P207, DOI 10.1620/tjem.232.207
   Choi JW, 2015, AM J CHINESE MED, V43, P57, DOI 10.1142/S0192415X15500044
   Choi SR, 2017, J PAIN, V18, P415, DOI 10.1016/j.jpain.2016.12.002
   Clark AK, 2009, J NEUROSCI, V29, P6945, DOI 10.1523/JNEUROSCI.0828-09.2009
   Han JS, 2004, NEUROSCI LETT, V361, P258, DOI 10.1016/j.neulet.2003.12.019
   Han JS, 2003, TRENDS NEUROSCI, V26, P17, DOI 10.1016/S0166-2236(02)00006-1
   Hershman DL, 2014, J CLIN ONCOL, V32, P1941, DOI 10.1200/JCO.2013.54.0914
   Hong JS, 2014, CURR ONCOL, V21, P174, DOI 10.3747/co.21.1984
   Hsieh YL, 2016, ACUPUNCT MED, V34, P398, DOI 10.1136/acupmed-2016-011112
   Huang C, 2000, NEUROSCI LETT, V294, P159, DOI 10.1016/S0304-3940(00)01572-X
   Inagaki H, 2017, PHYSIOL BEHAV, V169, P189, DOI 10.1016/j.physbeh.2016.11.015
   Jaggi AS, 2012, TOXICOLOGY, V291, P1, DOI 10.1016/j.tox.2011.10.019
   Jay GW, 2014, DM-DIS MON, V60, P6, DOI 10.1016/j.disamonth.2013.12.001
   Johnson M, 2007, PAIN, V130, P157, DOI 10.1016/j.pain.2007.02.007
   Kang SY, 2011, BRAIN RES BULL, V86, P412, DOI 10.1016/j.brainresbull.2011.08.012
   Kim HW, 2008, BRAIN RES BULL, V75, P698, DOI 10.1016/j.brainresbull.2007.11.015
   Knutson B, 1998, J COMP PSYCHOL, V112, P65, DOI 10.1037/0735-7036.112.1.65
   Knutson B, 2002, PSYCHOL BULL, V128, P961, DOI 10.1037//0033-2909.128.6.961
   Ko EJ, 2017, EUR J CANCER CARE, V26, P0, DOI 10.1111/ecc.12615
   Kurejova M, 2010, MOL PAIN, V6, P0, DOI 10.1186/1744-8069-6-18
   Lim DW, 2018, INFLAMMOPHARMACOLOGY, V26, P207, DOI 10.1007/s10787-017-0389-1
   Litvin Y, 2007, BEHAV BRAIN RES, V182, P166, DOI 10.1016/j.bbr.2006.11.038
   McGinnis MY, 2003, PHYSIOL BEHAV, V80, P81, DOI 10.1016/S0031-9384(03)00227-0
   MICZEK KA, 1995, PSYCHOPHARMACOLOGY, V121, P38, DOI 10.1007/BF02245590
   Mihara Y, 2011, MOL PAIN, V7, P0, DOI 10.1186/1744-8069-7-8
   Park SB, 2013, CA-CANCER J CLIN, V63, P419, DOI 10.3322/caac.21204
   Peng P, 2012, J HUAZHONG U SCI-MED, V32, P586, DOI 10.1007/s11596-012-1001-y
   Portfors CV, 2007, J AM ASSOC LAB ANIM, V46, P28
   Qiao LN, 2017, ACUPUNCT MED, V35, P276, DOI 10.1136/acupmed-2016-011177
   Seretny M, 2014, PAIN, V155, P2461, DOI 10.1016/j.pain.2014.09.020
   Stubblefield MD, 2009, J NATL COMPR CANC NE, V7, PS1, DOI 10.6004/jnccn.2009.0078
   Takahashi N, 2010, PLOS ONE, V5, P0, DOI 10.1371/journal.pone.0014115
   Tsuzuki H, 2012, NEUROREPORT, V23, P937, DOI 10.1097/WNR.0b013e3283595726
   Ventzel L, 2016, PAIN, V157, P560, DOI 10.1097/j.pain.0000000000000404
   von Schlippe M, 2001, BRIT J CANCER, V85, P823, DOI 10.1054/bjoc.2001.2006
   Wang H, 2014, BRIT J ANAESTH, V112, P1075, DOI 10.1093/bja/aeu001
   Yeo JH, 2016, J PAIN, V17, P298, DOI 10.1016/j.jpain.2015.10.018
   Yu XD, 2017, ACUPUNCT MED, V35, P142, DOI 10.1136/acupmed-2016-011063
   Zhou Hong-Yi, 2011, EXPERT REV CLIN PHARMACOL, V4, P379
NR 46
TC 5
Z9 6
U1 0
U2 17
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0361-9230
EI 1873-2747
J9 BRAIN RES BULL
JI Brain Res. Bull.
PD SEP 15
PY 2020
VL 162
IS 
BP 237
EP 244
DI 10.1016/j.brainresbull.2020.06.016
PG 8
WC Neurosciences
SC Neurosciences & Neurology
GA MO2BR
UT WOS:000551338700025
PM 32593737
DA 2026-01-16
ER

PT J
AU Chen, T
   Zhang, WW
   Chu, YX
   Wang, YQ
AF Chen, Teng
   Zhang, Wen Wen
   Chu, Yu-Xia
   Wang, Yan-Qing
TI Acupuncture for Pain Management: Molecular Mechanisms of Action.
SO The American journal of Chinese medicine
LA English
DT Review
DE Electroacupuncture; Glial Cells; Manual Acupuncture; Pain Modulation; Review
AB Acupuncture reduces pain by activating specific areas called acupoints on the  patient's body. When these acupoints are fully activated, sensations of soreness,  numbness, fullness, or heaviness called De qi or Te qi are felt by clinicians and  patients. There are two kinds of acupuncture, manual acupuncture and  electroacupuncture (EA). Compared with non-acupoints, acupoints are easily  activated on the basis of their special composition of blood vessels, mast cells,  and nerve fibers that mediate the acupuncture signals. In the spinal cord, EA can  inhibit glial cell activation by down-regulating the chemokine CX3CL1 and  increasing the anti-inflammatory cytokine interleukin-10. This inhibits P38  mitogen-activated protein kinase and extracellular signal-regulated kinase  pathways, which are associated with microglial activation of the C-Jun N-terminal  kinase signaling pathway and subsequent astrocyte activation. The inactivation of  spinal microglia and astrocytes mediates the immediate and long-term analgesic  effects of EA, respectively. A variety of pain-related substances released by  glial cells such as the proinflammatory cytokines tumor necrosis factor [Formula:  see text], interleukin-1[Formula: see text], interleukin-6, and prostaglandins  such as prostaglandins E2 can also be reduced. The descending pain modulation  system in the brain, including the anterior cingulated cortex, the periaqueductal  gray, and the rostral ventromedial medulla, plays an important role in EA  analgesia. Multiple transmitters and modulators, including endogenous opioids,  cholecystokinin octapeptide, 5-hydroxytryptamine, glutamate, noradrenalin,  dopamine, [Formula: see text]-aminobutyric acid, acetylcholine, and orexin A, are  involved in acupuncture analgesia. Finally, the "Acupuncture [Formula: see text]"  strategy is introduced to help clinicians achieve better analgesic effects, and a  newly reported acupuncture method called acupoint catgut embedding, which injects  sutures made of absorbable materials at acupoints to achieve long-term effects,  is discussed.
C1 Department of Integrative Medicine and Neurobiology, Institutes of Integrative Medicine School of Basic Medical Sciences, Institutes of Brain Science, BrainScience Collaborative Innovation Center, State Key Laboratory of MedicalNeurobiology and MOE Frontiers Center for Brain Science, Fudan UniversityShanghai, P. R. China.
   Department of Integrative Medicine and Neurobiology, Institutes of Integrative Medicine School of Basic Medical Sciences, Institutes of Brain Science, BrainScience Collaborative Innovation Center, State Key Laboratory of MedicalNeurobiology and MOE Frontiers Center for Brain Science, Fudan UniversityShanghai, P. R. China.
   Department of Integrative Medicine and Neurobiology, Institutes of Integrative Medicine School of Basic Medical Sciences, Institutes of Brain Science, BrainScience Collaborative Innovation Center, State Key Laboratory of MedicalNeurobiology and MOE Frontiers Center for Brain Science, Fudan UniversityShanghai, P. R. China.
   Department of Integrative Medicine and Neurobiology, Institutes of Integrative Medicine School of Basic Medical Sciences, Institutes of Brain Science, BrainScience Collaborative Innovation Center, State Key Laboratory of MedicalNeurobiology and MOE Frontiers Center for Brain Science, Fudan UniversityShanghai, P. R. China.
NR 0
TC 0
SN 1793-685
EI 
J9 Am J Chin Med
PD MAY 19
PY 2020
VL 48
IS 4
BP 793
EP 811
DI 10.1142/S0192415X20500408
PG 18
WC Acupuncture Analgesia; methods; Acupuncture Points; Adrenocorticotropic Hormone; physiology; Animals; Brain; blood supply; Chemokine CX3CL1; metabolism; Cytokines; metabolism; Dopamine; physiology; Electroacupuncture; Glutamic Acid; physiology; Hemodynamics; Humans; JNK Mitogen-Activated Protein Kinases; metabolism; MAP Kinase Signaling System; physiology; Neuroglia; physiology; Neurotransmitter Agents; physiology; Norepinephrine; physiology; Opioid Peptides; physiology; Serotonin; physiology; Sincalide; physiology; Spinal Cord; cytology; gamma-Aminobutyric Acid; physiology; p38 Mitogen-Activated Protein Kinases; metabolism
UT PubMed:32420752
PM 32420752
DA 2020-05-19
ER

PT J
AU Wang, J
   Li, DL
   Tang, W
   Guo, J
   Chen, WT
   Yong, Y
   Song, W
   Yu, GJ
   Feng, R
   Yuan, L
   Fu, GQ
   Song, JG
   Fan, LH
AF Wang, Jian
   Li, Dongli
   Tang, Wei
   Guo, Jun
   Chen, Wenting
   Yong, Yue
   Song, Wei
   Yu, Guijie
   Feng, Rui
   Yuan, Lan
   Fu, Guoqiang
   Song, Jiangang
   Fan, Lihua
TI Pretreatment with transcutaneous electrical acupoint stimulation to prevent postoperative ileus in patients undergoing laparoscopic colon surgery: study protocol for a randomised controlled trial
SO BMJ OPEN
LA English
DT Article
DE transcutaneous electrical acupoint stimulation (TEAS); postoperative ileus (POI); pretreatment
ID type-1 memory cells; radical cystectomy; economic burden; acupuncture; reduction; inhibition; alvimopan; recovery; duration; cancer
AB Introduction Postoperative ileus (POI), a common complication after surgery, severely affects postoperative recovery. It is unclear whether pretreatment with transcutaneous electrical acupoint stimulation (TEAS) can improve recovery from POI. This trial will evaluate the effects of pretreatment with TEAS on POI. Methods and analysis This will be a prospective, randomised controlled trial. American Society of Anesthesiologists (ASA) physical status classification I-III level patients, aged 18-75 years and scheduled for laparoscopic colon surgery, will be included in the study. It is planned that 146 subjects will be randomised to the TEAS and sham TEAS (STEAS) groups. The groups will undergo two sessions of TEAS/STEAS daily for 3 days before surgery, with a final TEAS/STEAS treatment 30 min before anaesthesia. The primary endpoint of the study will be time to first defaecation. Secondary endpoints will include time to first flatus, time to tolerance of oral diet, GI-2 (composite outcome of time to first defaecation and time to tolerance of oral diet), time to independent walking, length of hospital stay, postoperative pain Visual Analogue Scale score on the first 3 days after surgery, analgesic requirements, complications and plasma concentrations of interferon-beta (IFN-beta), IFN-gamma, interleukin-6 (IL-6) and IL-1 beta. Multiple linear regression will be used to identify independent predictors of outcome measures. Ethics and dissemination This study has been approved by the Chinese Registered Clinical Trial Ethics Review Committee (No. ChiECRCT-20170084). The results of the trial will be published in an international peer-reviewed journal. Trial status The study was in the recruitment phase at the time of manuscript submission.
C1 [Wang, Jian; Tang, Wei; Guo, Jun; Chen, Wenting; Song, Wei; Yu, Guijie; Feng, Rui; Yuan, Lan; Fu, Guoqiang; Song, Jiangang] Shanghai Univ Tradit Chinese Med, Anesthesiol, Shuguang Hosp, Shanghai, Peoples R China.
   [Li, Dongli; Fan, Lihua] Wenzhou Med Univ, Affiliated Hosp 6, Anesthesiol, Lishui, Peoples R China.
   [Yong, Yue] Shanghai Univ Tradit Chinese Med, Res Inst Acupuncture Anesthesia, Shuguang Hosp, Shanghai, Peoples R China.
C3 Shanghai University of Traditional Chinese Medicine; Wenzhou Medical University; Shanghai University of Traditional Chinese Medicine
RP Fan, LH (corresponding author), Wenzhou Med Univ, Affiliated Hosp 6, Anesthesiol, Lishui, Peoples R China.
EM fanlihua_ls@126.com
FU National Natural Science Foundation of China [81703898, 81603702, 81603700, 81774108]; SINCH Pharmaceuticals Tech.
CR Adding LC, 2001, CARDIOVASC DRUG REV, V19, P41
   Unknown -, 2008, CHIN J INTEGR MED, V14, P61, DOI 10.1007/s11655-007-9006
   Balogun JA, 1998, DISABIL REHABIL, V20, P41, DOI 10.3109/09638289809166052
   Boelens PG, 2014, ANN SURG, V259, P649, DOI 10.1097/SLA.0000000000000288
   Bragg D, 2015, CLIN NUTR, V34, P367, DOI 10.1016/j.clnu.2015.01.016
   Bungard TJ, 1999, PHARMACOTHERAPY, V19, P416, DOI 10.1592/phco.19.6.416.31040
   Chae HD, 2016, J ALTERN COMPLEM MED, V22, P465, DOI 10.1089/acm.2015.0161
   Deng G, 2013, ANN SURG ONCOL, V20, P1164, DOI 10.1245/s10434-012-2759-7
   Dindo D, 2004, ANN SURG, V240, P205, DOI 10.17116/hirurgia2018090162
   Engel DR, 2010, NAT MED, V16, P1407, DOI 10.1038/nm.2255
   Goldstein JL, 2007, P & T, V32, P82
   Hilton WM, 2013, BJU INT, V111, P1054, DOI 10.1111/j.1464-410X.2012.11499.x
   Huang LP, 2017, TURK J MED SCI, V47, P1267, DOI 10.3906/sag-1611-35
   Iyer S, 2009, J MANAGE CARE PHARM, V15, P485, DOI 10.18553/jmcp.2009.15.6.485
   Jiang YQ, 2013, PLOS ONE, V8, P0, DOI 10.1371/journal.pone.0065756
   Koscielny A, 2011, CURR OPIN GASTROEN, V27, P509, DOI 10.1097/MOG.0b013e32834bb7d7
   Maffezzini M, 2008, SURG ONCOL, V17, P41, DOI 10.1016/j.suronc.2007.09.003
   Melis M, 2006, ARCH SURG-CHICAGO, V141, P701, DOI 10.1001/archsurg.141.7.701
   Mikkelsen HB, 1999, CELL TISSUE RES, V295, P485, DOI 10.1007/s004410051254
   Moghadamyeghaneh Z, 2016, SURG ENDOSC, V30, P603, DOI 10.1007/s00464-015-4247-1
   Ng SSM, 2013, GASTROENTEROLOGY, V144, P307, DOI 10.1053/j.gastro.2012.10.050
   Nguyen DL, 2015, ANN GASTROENTEROL, V28, P475
   Rakel B, 2010, J PAIN, V11, P230, DOI 10.1016/j.jpain.2009.07.007
   Schwarz NT, 2001, GASTROENTEROLOGY, V121, P1354, DOI 10.1053/gast.2001.29605
   Song JG, 2012, ANESTHESIOLOGY, V116, P406, DOI 10.1097/ALN.0b013e3182426ebd
   Stakenborg N, 2019, GUT, V68, P1406, DOI 10.1136/gutjnl-2018-317263
   van Bree SHW, 2014, ANN SURG, V259, P708, DOI 10.1097/SLA.0b013e318293ee55
   van Bree SHW, 2012, NAT REV GASTRO HEPAT, V9, P675, DOI 10.1038/nrgastro.2012.134
   Vather R, 2013, J GASTROINTEST SURG, V17, P962, DOI 10.1007/s11605-013-2148-y
   Vilz TO, 2016, BMJ OPEN, V6, P0, DOI 10.1136/bmjopen-2015-011014
   Wehner S, 2007, GUT, V56, P176, DOI 10.1136/gut.2005.089615
   Wehner S, 2009, GASTROENTEROLOGY, V136, P619, DOI 10.1053/j.gastro.2008.10.017
   Wolthuis AM, 2016, COLORECTAL DIS, V18, PO1, DOI 10.1111/codi.13210
   Wu ZQ, 2015, EUR SURG RES, V54, P127, DOI 10.1159/000369529
   You XM, 2015, MEDICINE, V94, P0, DOI 10.1097/MD.0000000000001968
   Zhang J, 2015, SCI REP-UK, V5, P0, DOI 10.1038/srep15503
   Zhang Q, 2014, ANAESTHESIA, V69, P832, DOI 10.1111/anae.12639
NR 37
TC 2
Z9 2
U1 2
U2 14
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 2044-6055
EI 
J9 BMJ OPEN
JI BMJ Open
PD JUN 15
PY 2020
VL 10
IS 8
BP 
EP 
DI 10.1136/bmjopen-2019-030694
PG 7
WC Medicine, General & Internal
SC General & Internal Medicine
GA NH0DY
UT WOS:000564351500026
PM 32819923
DA 2026-01-16
ER

PT J
AU Wang, B
   Lu, Z
   Huang, Y
AF Wang, Bolin
   Lu, Zhong
   Huang, Yan
TI Association of Acupuncture and Acupressure With Improved Cancer Pain.
SO JAMA oncology
LA English
DT Letter
C1 Weifang Medical University, Weifang, China.
   Department of Oncology, Affiliated Hospital of Weifang Medical University, Weifang, China.
   Department of Oncology, Affiliated Hospital of Weifang Medical University, Weifang, China.
NR 0
TC 0
SN 2374-244
EI 
J9 JAMA Oncol
PD APR 24
PY 2020
VL 6
IS 6
BP 938
EP 939
DI 10.1001/jamaoncol.2020.0619
PG 1
WC Acupressure; Acupuncture Therapy; Cancer Pain; therapy; Humans; Neoplasms; complications
UT PubMed:32324200
PM 32324200
DA 2020-04-24
ER

PT J
AU Dilaveri, CA
   Croghan, IT
   Mallory, MJ
   Dion, LJ
   Fischer, KM
   Schroeder, DR
   Martinez-Jorge, J
   Nguyen, MDT
   Fokken, SC
   Bauer, BA
   Wahner-Roedler, DL
AF Dilaveri, Christina A.
   Croghan, Ivana T.
   Mallory, Molly J.
   Dion, Liza J.
   Fischer, Karen M.
   Schroeder, Darrell R.
   Martinez-Jorge, Jorys
   Nguyen, Minh-Doan T.
   Fokken, Shawn C.
   Bauer, Brent A.
   Wahner-Roedler, Dietlind L.
TI Massage Compared with Massage Plus Acupuncture for Breast Cancer Patients Undergoing Reconstructive Surgery
SO JOURNAL OF ALTERNATIVE AND COMPLEMENTARY MEDICINE
LA English
DT Article
DE acupuncture; integrative therapy; massage; stress
ID therapy; selection; impact; bias; care; pain
AB Objectives:Integrative therapies have been incorporated increasingly into health and wellness in the United States in recent decades. Their potential benefits are under evaluation in various situations, including pain and symptom relief for cancer patients and survivors. This pilot study evaluated whether combining two integrative complementary approaches augments a patient's benefit by reducing postoperative stress, pain, anxiety, muscle tension, and fatigue compared with one integrative complementary approach alone. Design:Patients undergoing autologous tissue breast reconstruction were randomly assigned to one of two postoperative complementary alternative therapies for three consecutive days. All participants were observed for up to 3 months. Subjects:Forty-two participants were recruited from January 29, 2016 to July 11, 2018. Interventions:Twenty-one participants were randomly assigned to massage alone and 21 to massage and acupuncture. Outcome measures:Stress, anxiety, relaxation, nausea, fatigue, pain, and mood (score 0-10) were measured at enrollment before surgery and postoperative days 1, 2, and 3 before and after the intervention. Patient satisfaction was evaluated. Results:Stress decreased from baseline for both Massage-Only Group and Massage+Acupuncture Group after each treatment intervention. Change in stress score from baseline decreased significantly more in the Massage-Only Group at pretreatment and posttreatment (p = 0.03 andp = 0.04). After adjustment for baseline values, change in fatigue, anxiety, relaxation, nausea, pain, and mood scores did not differ between groups. When patients were asked whether they would recommend the study, 100% (19/19) of Massage-Only Group and 94% (17/18) of Massage+Acupuncture Group responded yes (p = 0.49). Conclusion:No additive beneficial effects were observed with addition of acupuncture to massage for pain, anxiety, relaxation, nausea, fatigue, and mood. Combined massage and acupuncture was not as effective in reducing stress as massage alone, although both groups had significant stress reduction. These findings indicate a need for larger studies to explore these therapies further.
C1 [Dilaveri, Christina A.; Croghan, Ivana T.; Mallory, Molly J.; Dion, Liza J.; Fokken, Shawn C.; Bauer, Brent A.; Wahner-Roedler, Dietlind L.] Mayo Clin, Div Gen Internal Med, 200 First St SW, Rochester, MN 55905 USA.
   [Croghan, Ivana T.; Fischer, Karen M.; Schroeder, Darrell R.] Mayo Clin, Dept Hlth Sci Res, Rochester, MN 55905 USA.
   [Croghan, Ivana T.; Fokken, Shawn C.] Mayo Clin, Dept Med Clin Res Off, Rochester, MN 55905 USA.
   [Martinez-Jorge, Jorys; Nguyen, Minh-Doan T.] Mayo Clin, Div Plast & Reconstruct Surg, Rochester, MN 55905 USA.
C3 Mayo Clinic; Mayo Clinic; Mayo Clinic; Mayo Clinic
RP Croghan, IT (corresponding author), Mayo Clin, Div Gen Internal Med, 200 First St SW, Rochester, MN 55905 USA.
EM croghan.ivana@mayo.edu
CR An LX, 2014, AM J CHINESE MED, V42, P1099, DOI 10.1142/S0192415X14500682
   Unknown -, 2020, US BREAST CANC STAT, V0, P0
   Unknown -, 2018, COMPLEMENTARY, V0, P0
   Bu Ling-xue, 2011, SHANGHAI KOU QIANG YI XUE, V20, P292
   Cassileth BR, 2004, J PAIN SYMPTOM MANAG, V28, P244, DOI 10.1016/j.jpainsymman.2003.12.016
   Cutshall Susanne M, 2010, COMPLEMENT THER CLIN PRACT, V16, P92, DOI 10.1016/j.ctcp.2009.10.006
   Dion LJ, 2016, COMPLEMENT THER CLIN, V23, P82, DOI 10.1016/j.ctcp.2015.04.005
   Drackley NL, 2012, CLIN J ONCOL NURS, V16, P121, DOI 10.1188/12.CJON.121-124
   DUNN C, 1995, J ADV NURS, V21, P34, DOI 10.1046/j.1365-2648.1995.21010034.x
   Field T, 2016, COMPLEMENT THER CLIN, V24, P19, DOI 10.1016/j.ctcp.2016.04.005
   Greenlee H, 2017, CA-CANCER J CLIN, V67, P195, DOI 10.3322/caac.21397
   Halpern SD, 2003, J CLIN EPIDEMIOL, V56, P109, DOI 10.1016/S0895-4356(02)00598-X
   Haneuse S, 2016, MED CARE, V54, PE23, DOI 10.1097/MLR.0000000000000011
   Harris PA, 2009, J BIOMED INFORM, V42, P377, DOI 10.1016/j.jbi.2008.08.010
   Hayes J, 1999, INTENSIVE CRIT CARE NURS, V15, P77, DOI 10.1016/S0964-3397(99)80003-2
   Jeong YJ, 2015, MED ACUPUNCT, V27, P206, DOI 10.1089/acu.2014.1071
   Jüni P, 2001, BMJ-BRIT MED J, V323, P42, DOI 10.1136/bmj.323.7303.42
   Kinkead B, 2018, CANCER-AM CANCER SOC, V124, P546, DOI 10.1002/cncr.31064
   Lee PLT, 2016, COMPLEMENT THER MED, V27, P87, DOI 10.1016/j.ctim.2016.06.003
   Lewis P, 1997, AM J CRIT CARE, V6, P132
   Mallory MJ, 2015, AM J CHINESE MED, V43, P45, DOI 10.1142/S0192415X15500032
   Mazor KM, 2002, HEALTH SERV RES, V37, P1403, DOI 10.1111/1475-6773.11194
   MCCORKLE R, 1974, NURS RES, V23, P125
   Mehling WE, 2007, J PAIN SYMPTOM MANAG, V33, P258, DOI 10.1016/j.jpainsymman.2006.09.016
   Quinlan-Woodward J, 2016, ONCOL NURS FORUM, V43, P725, DOI 10.1188/16.ONF.725-732
   RUCKER G, 1989, STAT MED, V8, P477, DOI 10.1002/sim.4780080411
   SAS Institute Inc, 2020, SAS STAT, V0, P0
   Schroeder S, 2017, J ACUPUNCT MERIDIAN, V10, P165, DOI 10.1016/j.jams.2017.01.002
   Smith MC, 1999, ALTERN THER HEALTH M, V5, P64
   TYLER DO, 1990, HEART LUNG, V19, P562
   Vickers AJ, 2018, J PAIN, V19, P455, DOI 10.1016/j.jpain.2017.11.005
   Wentworth Laura J, 2009, PROG CARDIOVASC NURS, V24, P155, DOI 10.1111/j.1751-7117.2009.00054.x
   Yuan W, 2019, CHINESE MED J-PEKING, V132, P707, DOI 10.1097/CM9.0000000000000123
NR 34
TC 13
Z9 16
U1 1
U2 20
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1075-5535
EI 1557-7708
J9 J ALTERN COMPLEM MED
JI J. Altern. Complement Med.
PD JUL 1
PY 2020
VL 26
IS 7
BP 602
EP 609
DI 10.1089/acm.2019.0479
PG 8
WC Integrative & Complementary Medicine
SC Integrative & Complementary Medicine
GA MK5FJ
UT WOS:000548812300006
PM 32673082
DA 2026-01-16
ER

PT J
AU Yu, ML
   Qian, JJ
   Fu, SP
   Chen, JY
   Zheng, YW
   Lu, ZG
   Lu, SF
AF Yu, Mei-ling
   Qian, Jia-jia
   Fu, Shu-ping
   Chen, Jia-ying
   Zheng, Yu-wen
   Lu, Zhi-gang
   Lu, Sheng-feng
TI Acupuncture for Cancer-Induced Bone Pain in Animal Models: A Systemic Review and Meta-Analysis
SO EVIDENCE-BASED COMPLEMENTARY AND ALTERNATIVE MEDICINE
LA English
DT Review
ID breakthrough pain; electroacupuncture; prevalence; management; mechanisms; expression
AB Background. Cancer-induced bone pain (CIBP) is a highly prevalent symptom, which afflicts vast majority of patients who suffer from cancer. The current treatment options failed to achieve satisfactory effect and the side effects were prominent. Recent randomized controlled trials (RCTs) of animal demonstrate the benefit of acupuncture for CIBP. We sought to determine if the pooled data from available RCTs supports the use of acupuncture for CIBP.Methods. A literature search for randomized controlled trials was conducted in six electronic databases from inception to May 31, 2019. Meta-analysis was performed with Review Manager 5.3 software; the publication bias was assessed by Stata 12.0 software. We used random effects model for pooling data because heterogeneity is absolute among studies to some extent.Results. Twenty-four trials were included in the review, of which 12 trials provided detailed data for meta-analyses. Preliminary evidence indicates that compared to wait list/sham group, acupuncture was effective on increasing paw withdrawal threshold (PWT) and paw withdrawal latency (PWL). Compared to medicine, acupuncture was less effective on PWT, but as effective as medicine on PWL. Acupuncture can reinforce medicine's effect on PWT and PWL. Compared to the control group, acupuncture was superior to increase body weight (BW), decrease spinal cord glial fibrillary acidic protein (GFAP), and interleukin-1 beta(IL-1 beta). Furthermore, some studies showed acupuncture delay or partially reverse morphine tolerance. Three studies found acupuncture has no effect on PWT, but 2 of them found acupuncture could enhance small dose of Celebrex's effect on CIBP.Conclusions. Acupuncture was superior to wait list/sham acupuncture on increasing PWT and has no less effect on increasing PWL compared to medicine; acupuncture improved the efficacy of drugs, increased the CIBP animals' body weight, and decreased their spinal cord GFAP and IL-1 beta. High-quality studies are necessary to confirm the results.
C1 [Yu, Mei-ling; Qian, Jia-jia; Lu, Zhi-gang] Nanjing Univ Chinese Med, Clin Med Coll 1, Nanjing 210023, Peoples R China.
   [Yu, Mei-ling; Qian, Jia-jia; Chen, Jia-ying; Zheng, Yu-wen] Nanjing Univ Chinese Med, Acupuncture & Rehabil Coll, Nanjing 210023, Peoples R China.
   [Fu, Shu-ping; Lu, Sheng-feng] Nanjing Univ Chinese Med, Key Lab Acupuncture & Med Res, Minist Educ, Nanjing 210023, Peoples R China.
   [Lu, Zhi-gang] Nanjing Univ Chinese Med, Coll Pharm, Nanjing 210023, Peoples R China.
C3 Nanjing University of Chinese Medicine; Nanjing University of Chinese Medicine; Nanjing University of Chinese Medicine; Nanjing University of Chinese Medicine
RP Lu, ZG (corresponding author), Nanjing Univ Chinese Med, Clin Med Coll 1, Nanjing 210023, Peoples R China.; Lu, SF (corresponding author), Nanjing Univ Chinese Med, Key Lab Acupuncture & Med Res, Minist Educ, Nanjing 210023, Peoples R China.; Lu, ZG (corresponding author), Nanjing Univ Chinese Med, Coll Pharm, Nanjing 210023, Peoples R China.
EM Luzg@njucm.edu.cn; lushengfeng@njucm.edu.cn
FU National Natural Science Foundation of China [81774210, 81574062]; "Six Major Talent Summit" of Jiangsu Province [YY-033]; Jiangsu Province "333 High-Level Talents Cultivating Project (2016); Qing Lan Project" of Jiangsu Province; Nursing Priority Academic Program Development of Jiangsu Higher Education Institutions [2019YSHL059, 2019YSHL046]
CR Breivik H, 2009, ANN ONCOL, V20, P1420, DOI 10.1093/annonc/mdp001
   Cai YG, 2019, CHIN J TRADIT CHIN M, V37, P137
   Caraceni A, 2012, LANCET ONCOL, V13, PE58, DOI 10.1016/S1470-2045(12)70040-2
   Chen H, 2013, PANCREATOLOGY, V13, P594, DOI 10.1016/j.pan.2013.10.007
   Dang W, 1998, J TRADIT CHIN MED, V18, P31
   Gómez MD, 2017, ADV THER, V34, P136, DOI 10.1007/s12325-016-0435-1
   Du Junying, 2015, ZHONGGUO ZHEN JIU, V35, P161
   [杜俊英 Du Junying], 2014, 中华中医药杂志 CHINA JOURNAL OF TRADITIONAL CHINESE MEDICINE AND PHARMACY, V29, P1454
   Ferguson JL, 2018, AM FAM PHYSICIAN, V98, P205
   Fu Taofang, 2017, ZHONGGUO ZHEN JIU, V37, P513, DOI 10.13703/j.0255-2930.2017.05.017
   Fu TF, 2017, J ZHEJIANG CHINESE M, V41, P447, DOI 10.16466/j.issn1005-5509.2017.06.001
   Guan JF, 2018, CHINESE J GERONTOLOG, V38, P4513
   Guan JF, 2019, J PREVENTIVE MED CHI, V37, P154
   Haugen DF, 2010, PAIN, V149, P476, DOI 10.1016/j.pain.2010.02.035
   Hershman DL, 2018, JAMA-J AM MED ASSOC, V320, P167, DOI 10.1001/jama.2018.8907
   Ho KY, 2018, ASIA-PAC J CLIN ONCO, V14, P159, DOI 10.1111/ajco.12696
   Hooijmans CR, 2014, BMC MED RES METHODOL, V14, P0, DOI 10.1186/1471-2288-14-43
   Kuai L, 2012, CHINESE ACUPUNCTURE, V32, P0
   Li X, 2010, ROLE SPINAL TOLL REC, V96, P0
   [梁宜 Liang Yi], 2018, 中华中医药杂志 CHINA JOURNAL OF TRADITIONAL CHINESE MEDICINE AND PHARMACY, V33, P4877
   Liang Y, 2018, INTEGR CANCER THER, V17, P401, DOI 10.1177/1534735417728335
   Lu QB, 2015, CJTCMP, V30, P0
   Lu QY, 2016, SHANGHAI J TRADIT CH, V50, P77
   Lu WD, 2012, MED ACUPUNCT, V24, P233, DOI 10.1089/acu.2012.0904
   Lueptow LM, 2018, FRONT NEUROSCI-SWITZ, V12, P0, DOI 10.3389/fnins.2018.00886
   Luger NM, 2002, PAIN, V99, P397, DOI 10.1016/S0304-3959(02)00102-1
   MacPherson H, 2010, PLOS MED, V7, P0, DOI 10.1371/journal.pmed.1000261
   Mao-Ying Qi-liang, 2008, ZHONG XI YI JIE HE XUE BAO, V6, P830, DOI 10.3736/jcim20080812
   Marino S, 2018, CSH PERSPECT MED, V8, P0, DOI 10.1101/cshperspect.a031286
   Menéndez L, 2003, NEUROREPORT, V14, P867, DOI 10.1097/01.wnr.0000069963.11849.af
   Mercadante S, 2015, CURR OPIN ANESTHESIO, V28, P559, DOI 10.1097/ACO.0000000000000224
   Pan Kok Long, 2010, J ORTHOP SURG (HONG KONG), V18, P55
   Qiliang MY, 2007, INVOLVEMENT SPINAL G, V129, P0
   Qin SL, 2019, CHONGQING MED J, V48, P390
   Reis-Pina P, 2017, J PAIN RES, V10, P2097, DOI 10.2147/JPR.S139715
   Shi Ren-Yi, 2019, ZHEN CI YAN JIU, V44, P161, DOI 10.13702/j.1000-0607.180635
   Sima L, 2016, EVID-BASED COMPL ALT, V2016, P0, DOI 10.1155/2016/8028474
   Sima WX, 2013, CHINESE PHYS B, V22, P0, DOI 10.1088/1674-1056/22/1/015203
   Smeester BA, 2012, EVID-BASED COMPL ALT, V2012, P0, DOI 10.1155/2012/671386
   Vermeirsch H, 2004, PHARMACOL BIOCHEM BE, V79, P243, DOI 10.1016/j.pbb.2004.07.011
   Xu LL, 2018, J CANCER RES THER, V14, P99, DOI 10.4103/jcrt.JCRT_736_17
   Zhang RX, 2008, EUR J PAIN, V12, P870, DOI 10.1016/j.ejpain.2007.12.006
   Zhang RX, 2007, ANESTH ANALG, V105, P1482, DOI 10.1213/01.ane.0000284705.34629.c5
   Zhao W, 2013, J CLINI ACUPUNCT MED, V29, P69
   Zhao WL, 2013, HEILONGJIANG U CHINE, V97, P0
NR 45
TC 1
Z9 2
U1 1
U2 14
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 1741-427X
EI 1741-4288
J9 EVID-BASED COMPL ALT
JI Evid.-based Complement Altern. Med.
PD JUL 30
PY 2020
VL 2020
IS 
BP 
EP 
DI 10.1155/2020/5606823
PG 14
WC Integrative & Complementary Medicine
SC Integrative & Complementary Medicine
GA ND3NA
UT WOS:000561809300007
PM 32802130
DA 2026-01-16
ER

PT J
AU Guo, J
   Pei, LX
   Chen, L
   Chen, H
   Gu, DM
   Xin, C
   Peng, YJ
   Sun, JH
AF Guo, Jing
   Pei, Lixia
   Chen, Lu
   Chen, Hao
   Gu, Dongmei
   Xin, Chen
   Peng, Yongjun
   Sun, Jianhua
TI Research Trends of Acupuncture Therapy on Cancer Over the Past Two Decades: A Bibliometric Analysis
SO INTEGRATIVE CANCER THERAPIES
LA English
DT Review
DE acupuncture therapy; cancer; bibliometric analysis; CiteSpace; VOSviewer
ID induced peripheral neuropathy; breast-cancer; aromatase inhibitors; palliative care; hot flashes; fatigue; electroacupuncture; chemotherapy; management; pain
AB Purpose: Acupuncture has been used for managing cancer-related symptoms. However, there are still few studies concerning the overall trends in acupuncture therapy on cancer based on bibliometric analysis. This study aims to demonstrate the current status and trends in this field over the past 2 decades. Methods: Articles were retrieved from the Web of Science from 2000 to 2019. CiteSpace was used for co-authorship network of countries/institutions, dual-map analysis, and detecting the keywords with citation bursts. VOSviewer was used to construct networks based on co-authorship and co-citation analysis of authors, and co-occurrence of keywords. Results: A total of 927 articles and reviews were included in the final analysis. The number of publications has steadily increased with some fluctuations among years. The country and institution contributing most to this field are the USA and Memorial Sloan Kettering Cancer Center. Mao JJ was the most productive author and Molassiotis A ranked first in the cited authors. The co-occurrence analysis revealed 5 clusters (including "clinical trials," "clinical studies on chemotherapy/radiation-induced symptoms," "CAM therapy for cancer," "clinical studies on vasomotor symptoms," and "systematic reviews"). Most recent keyword bursts were "neuropathic pain," "arthralgia," "prevention," "supportive care," and "integrative medicine". Conclusions: The annual publication output would increase rapidly in the next decade, which shows a promising future in this research field. Future research hotspots would focus on the role of acupuncture in neuropathic pain, arthralgia, prevention, supportive care, and integrative medicine.
C1 [Guo, Jing; Pei, Lixia; Chen, Lu; Gu, Dongmei; Xin, Chen; Peng, Yongjun; Sun, Jianhua] Nanjing Univ Chinese Med, Affiliated Hosp, 155 Hanzhong Rd, Nanjing 210029, Jiangsu, Peoples R China.
   [Chen, Hao] Nanjing Univ Chinese Med, Nanjing, Peoples R China.
C3 Nanjing University of Chinese Medicine; Nanjing University of Chinese Medicine
RP Peng, YJ; Sun, JH (corresponding author), Nanjing Univ Chinese Med, Affiliated Hosp, 155 Hanzhong Rd, Nanjing 210029, Jiangsu, Peoples R China.
EM pengyongjun2004@126.com; 377201634@qq.com
FU State Administration of Traditional Chinese Medicine "Evidence-based capacity Building Project of Traditional Chinese Medicine" [2019XZZX-ZJ008]
CR Bao T, 2018, EUR J CANCER, V101, P12, DOI 10.1016/j.ejca.2018.06.008
   Bao T, 2018, BREAST CANCER RES TR, V170, P77, DOI 10.1007/s10549-018-4743-9
   Burstein HJ, 2016, J CLIN ONCOL, V34, P1689, DOI 10.1200/JCO.2015.65.9573
   Chen CM, 2014, J ASSOC INF SCI TECH, V65, P334, DOI 10.1002/asi.22968
   Chen CM, 2006, J AM SOC INF SCI TEC, V57, P359, DOI 10.1002/asi.20317
   Chen JJ, 2012, NEURAL REGEN RES, V7, P2944, DOI 10.3969/j.issn.1673-5374.2012.36.013
   Chen L, 2017, BREAST, V33, P132, DOI 10.1016/j.breast.2017.03.015
   Chien TJ, 2019, INTEGR CANCER THER, V18, P0, DOI 10.1177/1534735419866910
   Crew KD, 2007, J CLIN ONCOL, V25, P3877, DOI 10.1200/JCO.2007.10.7573
   Garcia MK, 2018, INTEGR CANCER THER, V17, P148, DOI 10.1177/1534735416685403
   Garcia MK, 2015, CANCER-AM CANCER SOC, V121, P3948, DOI 10.1002/cncr.29630
   Garcia MK, 2013, J CLIN ONCOL, V31, P952, DOI 10.1200/JCO.2012.43.5818
   Garland SN, 2019, JNCI-J NATL CANCER I, V111, P1323, DOI 10.1093/jnci/djz050
   Greenlee H, 2017, CA-CANCER J CLIN, V67, P195, DOI 10.3322/caac.21397
   He YH, 2020, JAMA ONCOL, V6, P271, DOI 10.1001/jamaoncol.2019.5233
   Henry NL, 2012, J CLIN ONCOL, V30, P936, DOI 10.1200/JCO.2011.38.0261
   Hershman DL, 2018, JAMA-J AM MED ASSOC, V320, P167, DOI 10.1001/jama.2018.8907
   Hershman DL, 2014, J CLIN ONCOL, V32, P1941, DOI 10.1200/JCO.2013.54.0914
   Lee A, 2015, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD003281.pub4
   Lee IS, 2020, J PAIN RES, V13, P367, DOI 10.2147/JPR.S235047
   Li TF, 2019, J CHIN MED ASSOC, V82, P428, DOI 10.1097/JCMA.0000000000000093
   Liang YD, 2017, J PAIN RES, V10, P951, DOI 10.2147/JPR.S132808
   Lyman GH, 2018, J CLIN ONCOL, V36, P2647, DOI 10.1200/JCO.2018.79.2721
   Ma Y, 2016, PLOS ONE, V11, P0, DOI 10.1371/journal.pone.0168123
   Mao JJ, 2015, J CLIN ONCOL, V33, P3615, DOI 10.1200/JCO.2015.60.9412
   Mao JJ, 2014, CANCER-AM CANCER SOC, V120, P3744, DOI 10.1002/cncr.28917
   Miller KD, 2019, CA-CANCER J CLIN, V69, P363, DOI 10.3322/caac.21565
   Molassiotis A, 2013, ANN ONCOL, V24, P1645, DOI 10.1093/annonc/mdt034
   Molassiotis A, 2007, COMPLEMENT THER MED, V15, P228, DOI 10.1016/j.ctim.2006.09.009
   Molassiotis A, 2019, INTEGR CANCER THER, V18, P0, DOI 10.1177/1534735419836501
   Molassiotis A, 2012, J CLIN ONCOL, V30, P4470, DOI 10.1200/JCO.2012.41.6222
   Ng SSM, 2013, GASTROENTEROLOGY, V144, P307, DOI 10.1053/j.gastro.2012.10.050
   Pei WY, 2019, BMC COMPLEM ALTERN M, V19, P0, DOI 10.1186/s12906-019-2606-5
   Pfister DG, 2010, J CLIN ONCOL, V28, P2565, DOI 10.1200/JCO.2009.26.9860
   Siegel RL, 2020, CA-CANCER J CLIN, V70, P7
   Stute P, 2003, J PAIN SYMPTOM MANAG, V26, P1123, DOI 10.1016/j.jpainsymman.2003.04.002
   Sun F, 2012, NEURAL REGEN RES, V7, P1192, DOI 10.3969/j.issn.1673-5374.2012.15.011
   Towler P, 2013, SUPPORT CARE CANCER, V21, P2913, DOI 10.1007/s00520-013-1882-8
   van Eck NJ, 2017, SCIENTOMETRICS, V111, P1053, DOI 10.1007/s11192-017-2300-7
   van Eck NJ, 2010, SCIENTOMETRICS, V84, P523, DOI 10.1007/s11192-009-0146-3
   Wu XY, 2015, SCI REP-UK, V5, P0, DOI 10.1038/srep16776
   Zhi WI, 2018, INTEGR CANCER THER, V17, P1079, DOI 10.1177/1534735418788667
NR 42
TC 17
Z9 20
U1 1
U2 84
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 1534-7354
EI 1552-695X
J9 INTEGR CANCER THER
JI Integr. Cancer Ther.
PD NOV 15
PY 2020
VL 19
IS 
BP 
EP 
DI 10.1177/1534735420959442
PG 11
WC Oncology; Integrative & Complementary Medicine
SC Oncology; Integrative & Complementary Medicine
GA OS8NY
UT WOS:000590416800001
PM 33143477
DA 2026-01-16
ER

PT J
AU Guo, X
   Zhao, Y
   Huang, F
   Li, S
   Luo, M
   Wang, Y
   Zhang, J
   Li, L
   Zhang, Y
   Jiao, Y
   Zhao, B
   Wang, J
   Meng, H
   Zhang, Z
   Rong, P
AF Guo, Xiao
   Zhao, Yuanyuan
   Huang, Feng
   Li, Shaoyuan
   Luo, Man
   Wang, Yu
   Zhang, Jinling
   Li, Liang
   Zhang, Yue
   Jiao, Yue
   Zhao, Bin
   Wang, Junying
   Meng, Hong
   Zhang, Zhangjin
   Rong, Peijing
TI Effects of Transcutaneous Auricular Vagus Nerve Stimulation on Peripheral and
SO Neural plasticity
LA English
DT Journal Article
AB Depression and pain disorders share a high degree of comorbidity. Inflammatory  mechanisms play an important role in the pathogenesis of depression-chronic  somatic pain comorbidity. In this study, we investigated the effects of  acupuncture on blood and brain regional tumor necrosis factor alpha (TNF-α) in  rats with depression and chronic somatic pain comorbidity. Forty Sprague-Dawley  rats were randomly divided into the following 4 groups with 10 each: control,  model, model treated with transcutaneous auricular vagus nerve stimulation  (taVNS), and model treated with electroacupuncture (EA). Chronic unpredictable  mild stress (CUMS) with chronic constriction injury of the sciatic nerve (CCI)  was used to produce depression and chronic somatic pain comorbidity in the latter  3 groups. The rats of the taVNS and EA groups received, respectively, taVNS and  EA at ST 36 for 28 days. Pain intensity was measured using a mechanical  withdrawal threshold and thermal stimulation latency once biweekly. Depressive  behavior was examined using a sucrose preference test at baseline and the end of  modeling and intervention. The level of plasma TNF-α and the expression of TNF-α  in the prefrontal cortex (PFC), hippocampus, amygdala, and hypothalamus were  measured. While CUMS plus CCI produced remarkable depression-like behavior and  pain disorders, EA and taVNS significantly improved depression and reduced pain  intensity. CUMS plus CCI also resulted in a significant increase in plasma TNF-α  level and the expression in all brain regions examined compared to the intact  controls. Both EA and taVNS interventions, however, suppressed the elevated level  of TNF-α. These results suggest that EA and taVNS have antidepressant and  analgesic effects. Such effects may be associated with the suppression of  TNF-α-related neuroinflammation.
C1 Institute of Acupuncture and Moxibustion, China Academy of Chinese Medical Sciences, Beijing 100700, China.
   Department of Scientific Research Management, China Academy of Chinese Medical 
   Department of Psychiatry, First Hospital of Hebei Medical University, Shijiazhuang 050031, China.
   Institute of Acupuncture and Moxibustion, China Academy of Chinese Medical Sciences, Beijing 100700, China.
   Beijing Hospital of Traditional Chinese Medicine, Capital Medical University, 
   Institute of Acupuncture and Moxibustion, China Academy of Chinese Medical Sciences, Beijing 100700, China.
   Institute of Acupuncture and Moxibustion, China Academy of Chinese Medical Sciences, Beijing 100700, China.
   Institute of Acupuncture and Moxibustion, China Academy of Chinese Medical Sciences, Beijing 100700, China.
   Institute of Acupuncture and Moxibustion, China Academy of Chinese Medical Sciences, Beijing 100700, China.
   Institute of Acupuncture and Moxibustion, China Academy of Chinese Medical Sciences, Beijing 100700, China.
   Institute of Acupuncture and Moxibustion, China Academy of Chinese Medical Sciences, Beijing 100700, China.
   Institute of Acupuncture and Moxibustion, China Academy of Chinese Medical Sciences, Beijing 100700, China.
   Institute of Acupuncture and Moxibustion, China Academy of Chinese Medical Sciences, Beijing 100700, China.
   Institute of Acupuncture and Moxibustion, China Academy of Chinese Medical Sciences, Beijing 100700, China.
   Key Laboratory of Cosmetic, China National Light Industry, Beijing Technology and Business University, Beijing 100048, China.
   The School of Chinese Medicine, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong, China.
   Institute of Acupuncture and Moxibustion, China Academy of Chinese Medical Sciences, Beijing 100700, China.
NR 0
TC 0
SN 1687-544
EI 2090-590
J9 Neural Plast
PD NOV 5
PY 2020
VL 2020
IS 
BP 8885729
EP 8885729
DI 10.1155/2020/8885729
PG 0
WC Acupuncture Therapy; Animals; Brain; metabolism; Depression; metabolism; Male; Nociceptive Pain; metabolism; Rats, Sprague-Dawley; Transcutaneous Electric Nerve Stimulation; Tumor Necrosis Factor-alpha; metabolism; Vagus Nerve Stimulation
UT PubMed:33144854
PM 33144854
DA 2020-11-05
ER

PT J
AU Arriaga-Pizano, L
   Gómez-Jiménez, DC
   Flores-Mejía, LA
   Pérez-Cervera, Y
   Solórzano-Mata, CJ
   Lopez-Macias, C
   Isibasi, A
   Torres-Rosas, R
AF Arriaga-Pizano, Lourdes
   Cuauhtemoc Gomez-Jimenez, Daniel
   Angel Flores-Mejia, Luis
   Perez-Cervera, Yobana
   Josue Solorzano-Mata, Carlos
   Lopez-Macias, Constantino
   Isibasi, Armando
   Torres-Rosas, Rafael
TI Low back pain in athletes can be controlled with acupuncture by a catecholaminergic pathway: clinical trial
SO ACUPUNCTURE IN MEDICINE
LA English
DT Article
DE acupuncture; low back pain; non-steroidal anti-inflammatory drugs; pain management; physical therapy; sports medicine
AB Background: Activation of the sympathetic nervous system attenuates inflammation via catecholamines. Recent evidence has shown that electroacupuncture (EA) activates neuronal networks involved in the release of dopamine and norepinephrine that control systemic inflammation. In muscle, catecholamines are related to cyclic adenosine monophosphate (cAMP). This signaling molecule has been implicated in recovery from sustained contractile activity, which may induce muscular pain, such as that which occurs during low back pain (LBP). Objective: Our aim was to evaluate the effects of EA used for the control of LBP on the activation of the sympathetic nervous system in a randomized controlled clinical trial in athletes. Methods: Two groups of athletes with acute or chronic low back pain were studied. EA, sham EA and pharmacological treatment (diclofenac sodium) were evaluated. The outcome measures included a pain score represented by a visual analogue scale (VAS) and serum levels of catecholamines quantified by enzyme-linked immunosorbent assay. In addition, blood was collected into chilled heparin tubes, placed in 96-well cell culture plates and incubated with an equal volume of Roswell Park Memorial Institute (RPMI) medium, with lipopolysaccharide (LPS) alone or with catecholamines. Tumor necrosis factor (TNF)-alpha levels in the supernatants were analyzed. Results: The results indicated that the initial pain ratings did not differ between the groups analyzed. EA induced epinephrine secretion but not norepinephrine or dopamine secretion. Although EA and pharmacological treatment did not differ in terms of pain relief, in vitro epinephrine and norepinephrine reduced TNF-alpha production in response to LPS stimuli. Conclusion: EA activates the sympathetic nervous system and induces the release of epinephrine, which could ameliorate inflammation and protect muscular tissue in addition to relieving pain.
C1 [Arriaga-Pizano, Lourdes; Angel Flores-Mejia, Luis; Lopez-Macias, Constantino; Isibasi, Armando] Hosp Especialidades Ctr Med Nacl Siglo XXI, Inst Mexicano Seguro Social IMSS, Unidad Invest Med Inmunoquim, Mexico City, DF, Mexico.
   [Cuauhtemoc Gomez-Jimenez, Daniel] Inst Politecn Nacl, Escuela Nacl Med & Homeopatia, Mexico City, DF, Mexico.
   [Perez-Cervera, Yobana; Josue Solorzano-Mata, Carlos; Torres-Rosas, Rafael] Univ Autonoma Benito Juarez Oaxaca, Fac Odontol, Ctr Estudios Ciencias Salud & Enfermedad, Lab Inmunol, Oaxaca, Oaxaca, Mexico.
   [Perez-Cervera, Yobana; Josue Solorzano-Mata, Carlos] Univ Autonoma Benito Juarez Oaxaca, Fac Med & Cirugia, Ctr Invest UNAM UABJO, Oaxaca, Oaxaca, Mexico.
C3 Instituto Mexicano del Seguro Social; Instituto Politecnico Nacional - Mexico; Universidad Autonoma Benito Juarez de Oaxaca; Universidad Autonoma Benito Juarez de Oaxaca
RP Torres-Rosas, R (corresponding author), Univ Autonoma Benito Juarez Oaxaca, Div Posgrad, Fac Odontol, Ave Univ Sin Numero, Oaxaca 68120, Oaxaca, Mexico.
EM rtorres.cat@uabjo.mx
FU CONACYT Basic Science [284495]; Strengthening Program in Educational Quality 2016 & 2017 (PFCE) Grant from Secretary of Public Education (SEP)
CR Abboud J, 2017, FRONT HUM NEUROSCI, V10, P0, DOI 10.3389/fnhum.2016.00576
   Berdeaux R, 2012, AM J PHYSIOL-ENDOC M, V303, PE1, DOI 10.1152/ajpendo.00555.2011
   Brinkhaus B, 2006, ARCH INTERN MED, V166, P450
   Buch MH, 2011, CURR OPIN RHEUMATOL, V23, P245, DOI 10.1097/BOR.0b013e3283454124
   Clausen T, 2003, PHYSIOL REV, V83, P1269, DOI 10.1152/physrev.00011.2003
   da Silva MD, 2015, MOL NEUROBIOL, V51, P19, DOI 10.1007/s12035-014-8790-x
   Dehner C, 2009, J SPORT REHABIL, V18, P572, DOI 10.1123/jsr.18.4.572
   Demoulin C, 2007, JOINT BONE SPINE, V74, P9, DOI 10.1016/j.jbspin.2006.02.013
   ELFELLAH MS, 1989, BRIT J CLIN PHARMACO, V27, P31, DOI 10.1111/j.1365-2125.1989.tb05332.x
   Emrick MA, 2010, P NATL ACAD SCI USA, V107, P18712, DOI 10.1073/pnas.1012384107
   Eskinazi D P, 1996, J ALTERN COMPLEMENT MED, V2, P3, DOI 10.1089/acm.1996.2.3
   Foster NE, 2016, HEALTH TECHNOL ASSES, V20, P1, DOI 10.3310/hta20330
   GOLDFARB AH, 1989, J APPL PHYSIOL, V66, P190, DOI 10.1152/jappl.1989.66.1.190
   Goldman N, 2010, NAT NEUROSCI, V13, P883, DOI 10.1038/nn.2562
   Gorth DJ, 2015, DISCOV MED, V20, P177
   Grabovoi A N, 1999, MORFOLOGIIA, V115, P68
   Hartmann C, 2017, SHOCK, V48, P390, DOI 10.1097/SHK.0000000000000879
   Hawker GA, 2011, ARTHRIT CARE RES, V63, PS240, DOI 10.1002/acr.20543
   Jager J, 2017, MONOGR SOC RES CHILD, V82, P13, DOI 10.1111/mono.12296
   Jaumard NV, 2011, J BIOMECH ENG-T ASME, V133, P0, DOI 10.1115/1.4004493
   Ji H, 2014, MUCOSAL IMMUNOL, V7, P335, DOI 10.1038/mi.2013.52
   Kagitani F, 2010, AUTON NEUROSCI-BASIC, V157, P2, DOI 10.1016/j.autneu.2010.03.004
   Kox M, 2014, P NATL ACAD SCI USA, V111, P7379, DOI 10.1073/pnas.1322174111
   LEBARS D, 1979, PAIN, V6, P283, DOI 10.1016/0304-3959(79)90049-6
   Levy G, 2013, SHOCK, V39, P39, DOI 10.1097/SHK.0b013e31827b450d
   MELZACK R, 1984, POSTGRAD MED J, V60, P893, DOI 10.1136/pgmj.60.710.893
   Oke SL, 2009, ANN NY ACAD SCI, V1172, P172, DOI 10.1196/annals.1393.013
   POMERANZ B, 1976, LIFE SCI, V19, P1757, DOI 10.1016/0024-3205(76)90084-9
   Sbriccoli P, 2004, MUSCLE NERVE, V29, P300, DOI 10.1002/mus.10531
   SODERLING TR, 1970, J BIOL CHEM, V245, P6317
   Su TF, 2012, EUR J PAIN, V16, P624, DOI 10.1002/j.1532-2149.2011.00055.x
   Torres-Rosas R, 2014, NAT MED, V20, P291, DOI 10.1038/nm.3479
   Tsuchiya M, 2007, ANESTH ANALG, V104, P301, DOI 10.1213/01.ane.0000230622.16367.fb
   Van Westerloo DJ, 2006, GASTROENTEROLOGY, V130, P1822, DOI 10.1053/j.gastro.2006.02.022
   VANDERPOLL T, 1994, INFECT IMMUN, V62, P2046, DOI 10.1128/IAI.62.5.2046-2050.1994
   Vas J, 2012, PAIN, V153, P1883, DOI 10.1016/j.pain.2012.05.033
   Vida G, 2011, J IMMUNOL, V186, P4340, DOI 10.4049/jimmunol.1003722
   Whittle SL, 2011, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD003113.pub3
   Yu JB, 2014, MED SCI MONITOR, V20, P406, DOI 10.12659/MSM.890111
NR 39
TC 8
Z9 16
U1 1
U2 16
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 0964-5284
EI 1759-9873
J9 ACUPUNCT MED
JI Acupunct. Med.
PD DEC 15
PY 2020
VL 38
IS 6
BP 388
EP 395
DI 10.1177/0964528420912251
PG 8
WC Integrative & Complementary Medicine
SC Integrative & Complementary Medicine
GA PA8GG
UT WOS:000595867300003
PM 32429680
DA 2026-01-16
ER

PT J
AU He, YH
   Guo, XF
   May, BH
   Zhang, AL
   Liu, YH
   Lu, CJ
   Mao, JJ
   Xue, CC
   Zhang, HB
AF He, Yihan
   Guo, Xinfeng
   May, Brian H.
   Zhang, Anthony Lin
   Liu, Yihong
   Lu, Chuanjian
   Mao, Jun J.
   Xue, Charlie Changli
   Zhang, Haibo
TI Clinical Evidence for Association of Acupuncture and Acupressure With Improved Cancer Pain A Systematic Review and Meta-Analysis
SO JAMA ONCOLOGY
LA English
DT Review
ID inhibitor-induced arthralgia; breast-cancer; alternative medicine; palliative care; joint pain; management; symptoms; therapy; trials; relief
AB Question Is the use of acupuncture and acupressure associated with improved cancer pain management compared with sham intervention and/or analgesic therapy alone? Findings In this systematic review of 17 randomized clinical trials and meta-analysis of 14 trials in the current English-language and Chinese-language literature, a significant association was found between real (compared with sham) acupuncture and reduced pain, and acupuncture combined with analgesic therapy was associated with decreased analgesic use. However, heterogeneity lowered the level of certainty of the evidence. Meaning This study found a moderate level of evidence that acupuncture and/or acupressure was significantly associated with lower pain intensity in patients with cancer compared with a sham control, which suggests a potential for a combination of acupuncture and acupressure to help reduce opioid doses in patients with cancer. This systematic review and meta-analysis provides an updated synthesis of the published randomized clinical trials into the use and advantages of acupuncture and/or acupressure among patients with cancer pain. Importance Research into acupuncture and acupressure and their application for cancer pain has been growing, but the findings have been inconsistent. Objective To evaluate the existing randomized clinical trials (RCTs) for evidence of the association of acupuncture and acupressure with reduction in cancer pain. Data Sources Three English-language databases (PubMed, Embase, and CINAHL) and 4 Chinese-language biomedical databases (Chinese Biomedical Literature Database, VIP Database for Chinese Technical Periodicals, China National Knowledge Infrastructure, and Wanfang) were searched for RCTs published from database inception through March 31, 2019. Study Selection Randomized clinical trials that compared acupuncture and acupressure with a sham control, analgesic therapy, or usual care for managing cancer pain were included. Data Extraction and Synthesis Data were screened and extracted independently using predesigned forms. The quality of RCTs was appraised with the Cochrane Collaboration risk of bias tool. Random-effects modeling was used to calculate the effect sizes of included RCTs. The quality of evidence was evaluated with the Grading of Recommendations Assessment, Development and Evaluation approach. Main Outcomes and Measures The primary outcome was pain intensity measured by the Brief Pain Inventory, Numerical Rating Scale, Visual Analog Scale, or Verbal Rating Scale. Results A total of 17 RCTs (with 1111 patients) were included in the systematic review, and data from 14 RCTs (with 920 patients) were used in the meta-analysis. Seven sham-controlled RCTs (35%) were notable for their high quality, being judged to have a low risk of bias for all of their domains, and showed that real (compared with sham) acupuncture was associated with reduced pain intensity (mean difference [MD], -1.38 points; 95% CI, -2.13 to -0.64 points; I-2 = 81%). A favorable association was also seen when acupuncture and acupressure were combined with analgesic therapy in 6 RCTs for reducing pain intensity (MD, -1.44 points; 95% CI, -1.98 to -0.89; I-2 = 92%) and in 2 RCTs for reducing opioid dose (MD, -30.00 mg morphine equivalent daily dose; 95% CI, -37.5 mg to -22.5 mg). The evidence grade was moderate because of the substantial heterogeneity among studies. Conclusions and Relevance This systematic review and meta-analysis found that acupuncture and/or acupressure was significantly associated with reduced cancer pain and decreased use of analgesics, although the evidence level was moderate. This finding suggests that more rigorous trials are needed to identify the association of acupuncture and acupressure with specific types of cancer pain and to integrate such evidence into clinical care to reduce opioid use.
C1 [He, Yihan; Guo, Xinfeng; Liu, Yihong; Lu, Chuanjian; Xue, Charlie Changli; Zhang, Haibo] Guangdong Prov Acad Chinese Med Sci, Guangdong Prov Hosp Chinese Med, Guangzhou Univ Chinese Med, Affiliated Hosp 2, 111 Dade Rd, Guangzhou 510120, Guangdong, Peoples R China.
   [He, Yihan; May, Brian H.; Zhang, Anthony Lin; Xue, Charlie Changli] RMIT Univ, China Australia Int Res Ctr Chinese Med, Sch Hlth & Biomed Sci, Bundoora, Vic 3083, Australia.
   [Mao, Jun J.] Mem Sloan Kettering Canc Ctr, Integrat Med Dept, 1275 York Ave, New York, NY 10021 USA.
C3 Guangzhou University of Chinese Medicine; Royal Melbourne Institute of Technology (RMIT); Memorial Sloan Kettering Cancer Center
RP Zhang, HB (corresponding author), Guangdong Prov Acad Chinese Med Sci, Guangdong Prov Hosp Chinese Med, Guangzhou Univ Chinese Med, Affiliated Hosp 2, 111 Dade Rd, Guangzhou 510120, Guangdong, Peoples R China.; Xue, CC (corresponding author), RMIT Univ, China Australia Int Res Ctr Chinese Med, Sch Hlth & Biomed Sci, Bundoora, Vic 3083, Australia.
EM charlie.xue@rmit.edu.au; haibozh@gzucm.edu.cn
FU Specific Research Fund for TCM Science and Technology from the Guangdong Provincial Hospital of Chinese Medicine [YN2018QL04]; Traditional Chinese Medicine Bureau of Guangdong Province [20191126]; Guangdong Provincial Academy of Chinese Medical Sciences, RMIT University through the China-Australia International Research Centre for Chinese Medicine; National Cancer Institute [P30-CA008748]; National Cancer Institute [P30CA008748] Funding Source: NIH RePORTER
CR Alimi D, 2003, J CLIN ONCOL, V21, P4120, DOI 10.1200/JCO.2003.09.011
   Unknown -, 2018, NCCN CLINICAL PRACTICE GUIDELINES IN ONCOLOGY (NCCN GUIDELINESREG;): BREAST CANCER VERSION 2, V0, P0
   Unknown -, 2016, THESIS, V0, P0
   Unknown -, 2011, THESIS, V0, P0
   Unknown -, 2017, ZHEJIANG J TRADIT CH, V0, P0
   Bae K, 2015, INTEGR CANCER THER, V14, P496, DOI 10.1177/1534735415596573
   Bao T, 2013, BREAST CANCER RES TR, V138, P167, DOI 10.1007/s10549-013-2427-z
   Bardia A, 2006, J CLIN ONCOL, V24, P5457, DOI 10.1200/JCO.2006.08.3725
   Ben-Arye E, 2015, TRANSL LUNG CANCER R, V4, P630, DOI 10.3978/j.issn.2218-6751.2015.03.07
   Briggs JP, 2017, JAMA-J AM MED ASSOC, V317, P2489, DOI 10.1001/jama.2017.7214
   Carlson CL, 2016, J PAIN RES, V9, P515, DOI 10.2147/JPR.S97759
   Chalkidou K, 2012, CLIN TRIALS, V9, P436, DOI 10.1177/1740774512450097
   Chan MWC, 2017, SCI REP-UK, V7, P0, DOI 10.1038/s41598-017-03272-0
   Chao LF, 2009, BREAST CANCER RES TR, V118, P255, DOI 10.1007/s10549-009-0533-8
   Chen H, 2013, PANCREATOLOGY, V13, P594, DOI 10.1016/j.pan.2013.10.007
   Chen L, 2017, BREAST, V33, P132, DOI 10.1016/j.breast.2017.03.015
   Chien TJ, 2015, J ALTERN COMPLEM MED, V21, P251, DOI 10.1089/acm.2014.0083
   Chiu HY, 2017, EUR J CANCER CARE, V26, P0, DOI 10.1111/ecc.12457
   Choi TY, 2012, SUPPORT CARE CANCER, V20, P1147, DOI 10.1007/s00520-012-1432-9
   Chua IS, 2019, JAMA ONCOL, V5, P734, DOI 10.1001/jamaoncol.2019.0042
   Clark SD, 2019, EXPLORE-NY, V15, P61, DOI 10.1016/j.explore.2018.07.006
   Crew Katherine D, 2007, J CANCER SURVIV, V1, P283, DOI 10.1007/s11764-007-0034-x
   Crew KD, 2010, J CLIN ONCOL, V28, P1154, DOI 10.1200/JCO.2009.23.4708
   Dos Santos S, 2010, MED ACUPUNCT, V22, P81, DOI 10.1089/acu.2009.0730
   Elsayem AF, 2016, WORLD J CLIN ONCOL, V7, P227, DOI 10.5306/wjco.v7.i2.227
   Fainsinger RL, 2009, J CLIN ONCOL, V27, P585, DOI 10.1200/JCO.2008.17.1660
   Fan AY, 2017, J INTEGR MED-JIM, V15, P411, DOI 10.1016/S2095-4964(17)60378-9
   Ford I, 2016, NEW ENGL J MED, V375, P454, DOI 10.1056/NEJMra1510059
   Garcia MK, 2013, J CLIN ONCOL, V31, P952, DOI 10.1200/JCO.2012.43.5818
   Guo Z, 2015, INT J TRAD CHIN MED, V37, P371
   He YH, 2017, BMJ OPEN, V7, P0, DOI 10.1136/bmjopen-2017-018494
   Hershman DL, 2018, JAMA-J AM MED ASSOC, V320, P167, DOI 10.1001/jama.2018.8907
   Hjermstad MJ, 2011, J PAIN SYMPTOM MANAG, V41, P1073, DOI 10.1016/j.jpainsymman.2010.08.016
   Hu CQ, 2016, EVID-BASED COMPL ALT, V2016, P0, DOI 10.1155/2016/1720239
   Hui D, 2016, CANCER-AM CANCER SOC, V122, P1774, DOI 10.1002/cncr.29970
   Kaptchuk TJ, 2010, CHIN J INTEGR MED, V16, P197, DOI 10.1007/s11655-010-0197-x
   Kim K, 2018, INTEGR CANCER THER, V17, P1137, DOI 10.1177/1534735418786797
   Kim YC, 2015, CANCER MED-US, V4, P1196, DOI 10.1002/cam4.471
   Kwon JH, 2014, J CLIN ONCOL, V32, P1727, DOI 10.1200/JCO.2013.52.4827
   Lau CHY, 2016, MEDICINE, V95, P0, DOI 10.1097/MD.0000000000002901
   Lee H, 2005, EUR J PAIN, V9, P437, DOI 10.1016/j.ejpain.2004.10.004
   Lee PLT, 2016, COMPLEMENT THER MED, V27, P87, DOI 10.1016/j.ctim.2016.06.003
   Li J, 2015, CHIN J INTEGR MED, V21, P43, DOI 10.1007/s11655-014-1765-y
   Lian WL, 2014, CHIN J INTEGR MED, V20, P136, DOI 10.1007/s11655-013-1439-1
   Liou KT, 2019, PAIN MED, V20, P2060, DOI 10.1093/pm/pnz087
   Local Health Unit South-East Tuscany Department of Integrated Medicine Pitigliano Hospital Tuscany , 2018, OBM INTEGRATIVE AND COMPLEMENTARY MEDICINE, V4, P1, DOI 10.21926/obm.icm.1901006
   Macdonald Geraldine, 2012, COCHRANE DATABASE SYST REV, V0, PPCD001930, DOI 10.1002/14651858.CD001930.pub3
   MacLeod Jodi, 2017, JOURNAL OF THE NATIONAL CANCER INSTITUTE MONOGRAPHS, V0, PP46, DOI 10.1093/jncimonographs/lgx008
   MacPherson H, 2001, BMJ-BRIT MED J, V323, P486, DOI 10.1136/bmj.323.7311.486
   Mao JJ, 2018, JAMA-J AM MED ASSOC, V320, P2269, DOI 10.1001/jama.2018.16736
   Mao JJ, 2014, EUR J CANCER, V50, P267, DOI 10.1016/j.ejca.2013.09.022
   Miller KR, 2019, AM J HOSP PALLIAT ME, V36, P326, DOI 10.1177/1049909118804464
   Miller M, 2015, JAMA INTERN MED, V175, P608, DOI 10.1001/jamainternmed.2014.8071
   Neufeld NJ, 2017, FUTURE ONCOL, V13, P833, DOI 10.2217/fon-2016-0423
   Oh B, 2013, ACUPUNCT MED, V31, P264, DOI 10.1136/acupmed-2012-010309
   Pachman DR, 2012, J CLIN ONCOL, V30, P3687, DOI 10.1200/JCO.2012.41.7238
   Paley CA, 2015, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD007753.pub3
   Pan CX, 2000, J PAIN SYMPTOM MANAG, V20, P374, DOI 10.1016/S0885-3924(00)00190-1
   Peng Hao, 2010, ZHONG XI YI JIE HE XUE BAO, V8, P501
   Pfister DG, 2010, J CLIN ONCOL, V28, P2565, DOI 10.1200/JCO.2009.26.9860
   Portenoy RK, 2011, LANCET, V377, P2236, DOI 10.1016/S0140-6736(11)60236-5
   Robb KA, 2008, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD006276.pub2
   Ruela LD, 2018, REV ESC ENFERM USP, V52, P0, DOI 10.1590/S1980-220X2017040503402
   Sharfstein JM, 2019, JAMA-J AM MED ASSOC, V322, P809, DOI 10.1001/jama.2019.9794
   Shen L, 2016, J MED RES, V45, P87
   Simone CB II, 2012, CLIN J PAIN, V28, P157, DOI 10.1097/AJP.0b013e318223be30
   Sox HC, 2016, JAMA-J AM MED ASSOC, V316, P1205, DOI 10.1001/jama.2016.11409
   Swarm Robert, 2007, J NATL COMPR CANC NETW, V5, P726
   Tao WW, 2016, J PAIN SYMPTOM MANAG, V51, P728, DOI 10.1016/j.jpainsymman.2015.11.027
   Tedesco D, 2017, JAMA SURG, V152, P0, DOI 10.1001/jamasurg.2017.2872
   Tick H, 2018, EXPLORE-NY, V14, P177, DOI 10.1016/j.explore.2018.02.001
   van den Beuken-van Everdingen MHJ, 2016, J PAIN SYMPTOM MANAG, V51, P1070, DOI 10.1016/j.jpainsymman.2015.12.340
   Vickers AJ, 2014, JAMA-J AM MED ASSOC, V311, P955, DOI 10.1001/jama.2013.285478
   Vowles KE, 2015, PAIN, V156, P569, DOI 10.1097/01.j.pain.0000460357.01998.f1
   Yang GS, 2017, CANCER NURS, V40, PE26, DOI 10.1097/NCC.0000000000000409
   Yun Hyeongjun, 2017, JOURNAL OF THE NATIONAL CANCER INSTITUTE MONOGRAPHS, V0, PP29, DOI 10.1093/jncimonographs/lgx004
   Zheng Y, 2014, J LIAONING UNIV TRADIT CHIN MED, V16, P152, DOI 10.13194/j.issn.1673-842x.2014.01.055
   Zhou J, 2014, CHIN ARCH TRADIT CHIN MED, V32, P2326
   朱利楠, 2013, 中华物理医学与康复杂志 CHINESE JOURNAL OF PHYSICAL MEDICINE AND REHABILITATION, V35, P579
   Zia Farah Z, 2017, JOURNAL OF THE NATIONAL CANCER INSTITUTE MONOGRAPHS, V0, PP68, DOI 10.1093/jncimonographs/lgx005
NR 81
TC 293
Z9 340
U1 28
U2 335
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 2374-2437
EI 2374-2445
J9 JAMA ONCOL
JI JAMA Oncol.
PD FEB 15
PY 2020
VL 6
IS 2
BP 271
EP 278
DI 10.1001/jamaoncol.2019.5233
PG 8
WC Oncology
SC Oncology
GA KP0TR
UT WOS:000515957200017
PM 31855257
DA 2026-01-16
ER

PT J
AU Zhao, Q
   Zheng, SY
   Delaney, GP
   Moylan, E
   Agar, MR
   Koh, ES
   Lai, HZ
   Birling, Y
   Zhang, GS
   Wang, K
   Ma, Y
   Zhu, XS
AF Zhao, Qi
   Zheng, Suyang
   Delaney, Geoff P.
   Moylan, Eugene
   Agar, Meera R.
   Koh, Eng-Siew
   Lai, Hezheng
   Birling, Yoann
   Zhang, George Shengxi
   Wang, Kang
   Ma, Yong
   Zhu, Xiaoshu
TI Acupuncture for Cancer Related Pain: Protocol for a Pragmatic Randomised Wait-List Controlled Trial
SO INTEGRATIVE CANCER THERAPIES
LA English
DT Article
DE acupuncture; cancer related pain; pragmatic; clinical trial; complementary and alternative medicine
AB Background: Acupuncture has been proved effective for cancer related pain (CRP) in China, America and some other countries. However, there is relative lack of evidence to support the use of acupuncture for CRP in Australia. Objectives: To assess the effectiveness and safety of acupuncture for management of CRP in a real-world setting and to understand cancer patients' experience of undergoing acupuncture for CRP. Methods: A pragmatic randomised controlled trial will be conducted in South Western Sydney Local Health District (SWSLHD) in NSW, Australia. Adults with cancer related pain (n = 106) will be randomised in a 1:1 ratio to receive the acupuncture intervention up front versus after a wait list period of 4 weeks. Pain level (by Numerical Rating Scale), analgesic use, auricular acupressure frequency and adverse events will be assessed at baseline, mid-treatment and post-treatment. Expectancy on trial outcome (by Credibility and Expectancy questionnaire) will be assessed at baseline. The perspective of the participants (by an interview) will be recorded after the last intervention. Expected outcomes: We hypothesise that acupuncture will relieve cancer related pain at mid-treatment and post-treatment. We also hypothesise that few adverse events will be provoked by acupuncture.
C1 [Zhao, Qi; Wang, Kang] Beijing Univ Chinese Med, Dongzhimen Hosp, Beijing, Peoples R China.
   [Zhao, Qi; Zheng, Suyang; Lai, Hezheng; Birling, Yoann; Zhang, George Shengxi; Wang, Kang; Zhu, Xiaoshu] Western Sydney Univ, Chinese Med Ctr, Locked Bag 1797, Penrith, NSW 2751, Australia.
   [Zheng, Suyang; Ma, Yong] Nanjing Univ Chinese Med, Nanjing, Peoples R China.
   [Delaney, Geoff P.; Agar, Meera R.] Univ NSW, Sydney, NSW, Australia.
   [Moylan, Eugene; Agar, Meera R.; Koh, Eng-Siew] South Western Sydney Local Hlth Dist, Sydney, NSW, Australia.
   [Agar, Meera R.] Univ Technol Sydney, Sydney, NSW, Australia.
   [Ma, Yong] Nanjing Univ Chinese Med, Affiliated Hosp, Nanjing, Jiangsu, Peoples R China.
C3 Beijing University of Chinese Medicine; Western Sydney University; Nanjing University of Chinese Medicine; University of New South Wales Sydney; South Western Sydney Local Health District; University of Technology Sydney; Nanjing University of Chinese Medicine
RP Zhu, XS (corresponding author), Western Sydney Univ, Chinese Med Ctr, Locked Bag 1797, Penrith, NSW 2751, Australia.
EM X.Zhu@westernsydney.edu.au
FU China Scholarship Council; Postgraduate Research & Practice Innovation Program of Jiangsu Province [KYCX19_1200]
CR Anderson KC, 2000, CANCER, V88, P1929, DOI 10.1002/(SICI)1097-0142(20000415)88:8<1929::AID-CNCR23>3.3.CO;2-U
   Unknown -, 2016, NCCN CLINICAL PRACTICE GUIDELINES IN ONCOLOGY, V0, P0
   BORKOVEC TD, 1972, J BEHAV THER EXP PSY, V3, P257, DOI 10.1016/0005-7916(72)90045-6
   Braun V, 2006, QUAL RES PSYCHOL, V3, P77, DOI 10.1191/1478088706QP063OA
   Brotto LA, 2012, GYNECOL ONCOL, V125, P320, DOI 10.1016/j.ygyno.2012.01.035
   Cancer-Council-Australia, 2020, MAN AUSTR GET CANC, V0, P0
   Devilly GJ, 2000, J BEHAV THER EXP PSY, V31, P73, DOI 10.1016/S0005-7916(00)00012-4
   Dworkin RH, 2009, PAIN, V146, P238, DOI 10.1016/j.pain.2009.08.019
   Ernst E, 1999, ACUPUNCTURE - A SCIENTIFIC APPRAISAL, V0, P0
   Everdingen MHJVDBV, 2007, PAIN, V132, P312, DOI 10.1016/j.pain.2007.08.022
   Farquhar M, 2009, J PALLIAT MED, V12, P213, DOI 10.1089/jpm.2008.0267
   Filshie Jacqueline, 2006, ACUPUNCT MED, V24, P172
   Fixler M, 2012, COMPLEMENT THER CLIN PRACT, V18, P140, DOI 10.1016/j.ctcp.2012.03.003
   Gausche-Hill M, 2017, ROSEN S EMERGENCY ME, V0, P0
   GOISIS A, 1989, TUMORI J, V75, P470, DOI 10.1177/030089168907500513
   Goossens MEJB, 2005, CLIN J PAIN, V21, P18, DOI 10.1097/00002508-200501000-00003
   Green CR, 2011, CANCER-AM CANCER SOC, V117, P1994, DOI 10.1002/cncr.25761
   Harrington CB, 2010, INT J PSYCHIAT MED, V40, P163, DOI 10.2190/PM.40.2.c
   Hershman DL, 2018, JAMA-J AM MED ASSOC, V320, P167, DOI 10.1001/jama.2018.8907
   Hjermstad MJ, 2011, J PAIN SYMPTOM MANAG, V41, P1073, DOI 10.1016/j.jpainsymman.2010.08.016
   Hulley SB, 2013, DESIGNING CLIN RES, V0, P0
   JENSEN MP, 1986, PAIN, V27, P117, DOI 10.1016/0304-3959(86)90228-9
   Jin BX, 2019, WORLD J ACUPUNCT-MOX, V29, P1, DOI 10.1016/j.wjam.2019.03.003
   [金春兰 Jin Chunlan], 2005, 针刺研究 ACUPUNCTURE RESEARCH, V30, P187
   Johannsen M, 2016, J CLIN ONCOL, V34, P3390, DOI 10.1200/JCO.2015.65.0770
   Karcioglu O, 2018, AM J EMERG MED, V36, P707, DOI 10.1016/j.ajem.2018.01.008
   Kiecolt-Glaser JK, 2014, J CLIN ONCOL, V32, P1040, DOI 10.1200/JCO.2013.51.8860
   Kroenke K, 2010, J PAIN SYMPTOM MANAG, V40, P327, DOI 10.1016/j.jpainsymman.2009.12.023
   Laird BJA, 2009, PSYCHO-ONCOL, V18, P459, DOI 10.1002/pon.1431
   Latte-Naor S, 2019, J ONCOL PRACT, V15, P7, DOI 10.1200/JOP.18.00554
   Liao YH, 2017, J CANCER RES CLIN, V143, P2425, DOI 10.1007/s00432-017-2491-6
   Lopez G, 2017, MED CLIN N AM, V101, P977, DOI 10.1016/j.mcna.2017.04.011
   Lu WD, 2018, HEMATOL ONCOL CLIN N, V32, P519, DOI 10.1016/j.hoc.2018.01.009
   Lund Irene, 2006, ACUPUNCT MED, V24, P13
   Markman M, 1900, V2008, V0, P181
   May B, 2019, JAMA ONCOL, V6, P939
   Mertens VC, 2017, PAIN PRACT, V17, P902, DOI 10.1111/papr.12543
   Naik PN, 2014, MED ACUPUNCT, V26, P308, DOI 10.1089/acu.2014.1028
   National-Health-and-Medical-Research-Council, 2016, GUIDANCE: SAFETY MONITORING AND REPORTING IN CLINICAL TRIALS INVOLVING THERAPEUTIC GOODS, V0, P0
   OMahony Sean, 2010, J OPIOID MANAG, V6, P211
   Patsopoulos Nikolaos A, 2011, DIALOGUES CLIN NEUROSCI, V13, P217
   Portenoy RK, 2011, LANCET, V377, P2236, DOI 10.1016/S0140-6736(11)60236-5
   Prommer EE, 2015, CANCER CONTROL, V22, P412, DOI 10.1177/107327481502200407
   Ripamonti CI, 2012, ANN ONCOL, V23, P139, DOI 10.1093/annonc/mds233
   Rossi E, 2015, SUPPORT CARE CANCER, V23, P1795, DOI 10.1007/s00520-014-2517-4
   Satija A, 2017, INDIAN J PALLIAT CAR, V23, P468, DOI 10.4103/IJPC.IJPC_100_17
   Schenkman M, 2018, JAMA NEUROL, V75, P219, DOI 10.1001/jamaneurol.2017.3517
   Siddons HM, 2013, PSYCHO-ONCOLOGY, V22, P2186, DOI 10.1002/pon.3273
   Sun YX, 2015, REGION ANESTH PAIN M, V40, P589, DOI 10.1097/AAP.0000000000000273
   Swarm RA, 2013, J NATL COMPR CANC NE, V11, P992, DOI 10.6004/jnccn.2013.0119
   Turner BJ, 2018, J PAIN, V19, P1471, DOI 10.1016/j.jpain.2018.06.010
   Usichenko TI, 2006, ANESTH ANALG, V103, P1333, DOI 10.1213/01.ane.0000242641.13473.af
   van den Beuken-van Everdingen MHJ, 2016, J PAIN SYMPTOM MANAG, V51, P1070, DOI 10.1016/j.jpainsymman.2015.12.340
   Witt Claudia M, 2017, JOURNAL OF THE NATIONAL CANCER INSTITUTE MONOGRAPHS, V0, PP3, DOI 10.1093/jncimonographs/lgx012
   Witt CM, 2009, FORSCH KOMPLEMENTMED, V16, P91, DOI 10.1159/000209315
   Yun Hyeongjun, 2017, JOURNAL OF THE NATIONAL CANCER INSTITUTE MONOGRAPHS, V0, PP29, DOI 10.1093/jncimonographs/lgx004
   ZECH DFJ, 1995, PAIN, V63, P65, DOI 10.1016/0304-3959(95)00017-M
   Zhang H, 2018, HEBEI J TRADIT CHIN, V40, P462
NR 59
TC 3
Z9 3
U1 1
U2 18
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 1534-7354
EI 1552-695X
J9 INTEGR CANCER THER
JI Integr. Cancer Ther.
PD DEC 15
PY 2020
VL 19
IS 
BP 
EP 
DI 10.1177/1534735420976579
PG 10
WC Oncology; Integrative & Complementary Medicine
SC Oncology; Integrative & Complementary Medicine
GA PE9LE
UT WOS:000598681100001
PM 33300382
DA 2026-01-16
ER

PT J
AU Shi, GX
   Tu, JF
   Wang, TQ
   Yang, JW
   Wang, LQ
   Lin, LL
   Wang, Y
   Li, YT
   Liu, CZ
AF Shi, Guang-Xia
   Tu, Jian-Feng
   Wang, Tian-Qi
   Yang, Jing-Wen
   Wang, Li-Qiong
   Lin, Lu-Lu
   Wang, Yu
   Li, Yong-Ting
   Liu, Cun-Zhi
TI Effect of Electro-Acupuncture (EA) and Manual Acupuncture (MA) on Markers of Inflammation in Knee Osteoarthritis
SO JOURNAL OF PAIN RESEARCH
LA English
DT Article
DE knee osteoarthritis; electro-acupuncture; manual acupuncture; inflammation
ID pain; expression; cartilage; chondrocytes; modulation; outcm
AB Background: Inflammation plays a significant role in the pathogenesis of knee osteoarthritis (KOA). Although both electro-acupuncture (EA) and manual acupuncture (MA) are known to influence systemic inflammation, little is known about the potential changes in inflammation as a working mechanism of EA and MA in KOA. Methods: Data from the Acupuncture for Knee Osteoarthritis Trial (ATKOA) were used. Serum concentrations of inflammatory factors (tumor necrosis factor-alpha (TNF-alpha), interleukin-1 beta (IL-1 beta), IL-6, IL-8, IL-18, IL-4, IL-10, IL-13, IL-15, IL-17, monocyte chemotactic protein-1 (MCP-1), CC-chemokine ligand 5 (CCL5), and cartilage degradation biomarkers (matrix metalloproteinase-1 MMP-1, MMP-3, MMP-13 and cartilage oligomeric matrix protein COMP)) were measured at baseline and after 8 weeks of treatment. Clinical outcomes were valid and reliable self-reported pain and function measures for osteoarthritis using the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) and visual analogue scale (VAS) at baseline and post-treatment. Results: Both 8-weeks EA and MA significantly reduced pro-inflammatory cytokines (TNF alpha, IL-1 beta), and cartilage degradation biomarkers (MMP-3, MMP-13) significantly increased the anti-inflammatory cytokine IL-13 compared with pre-treatment (p<0.05). Further, the reduction of TNF-alpha was more significant in EA when compared to MA (p=0.046). While there was no significant difference between groups in cytokines IL-1 beta (p=0.102), MMP-3 (p=0.113), MMP-13 (p=0.623) or IL-13 (p=0.935). Moreover, in both EA and MA, the effect of acupuncture on the VAS and WOMAC function scale after 8 weeks is clinically important, although no significant differences were found between groups. Conclusion: Eight weeks of both EA and MA seem to provide improvement in pain relief and function among individuals with mild to moderate knee OA. This benefit is partly mediated by changes of major inflammatory factors TNF-alpha, IL-1 beta and IL-13.
C1 [Shi, Guang-Xia; Wang, Yu; Li, Yong-Ting] Capital Med Univ, Dept Acupuncture & Moxibust, Beijing Hosp Tradit Chinese Med, Beijing, Peoples R China.
   [Tu, Jian-Feng; Wang, Tian-Qi; Yang, Jing-Wen; Wang, Li-Qiong; Lin, Lu-Lu; Liu, Cun-Zhi] Beijing Univ Chinese Med, Sch Acupuncture Moxibust & Tuina, Beijing, Peoples R China.
C3 Capital Medical University; Beijing University of Chinese Medicine
RP Liu, CZ (corresponding author), Beijing Univ Chinese Med, Sch Acupuncture Moxibust & Tuina, Beijing, Peoples R China.
EM lcz_tg@126.com
FU The 4th Project of China Association of Science and Technology Youth Talents Enrollment Project [2018QNRC001]
CR Ahsin S, 2009, PAIN, V147, P60, DOI 10.1016/j.pain.2009.08.004
   Alaaeddine N, 2001, ARTHRITIS RHEUM-US, V44, P1633, DOI 10.1002/1529-0131(200107)44:7<1633::AID-ART286>3.0.CO;2-Z
   Berenbaum F, 2013, OSTEOARTHR CARTILAGE, V21, P16, DOI 10.1016/j.joca.2012.11.012
   Bijlsma JWJ, 2011, LANCET, V377, P2115, DOI 10.1016/S0140-6736(11)60243-2
   Corbett MS, 2013, OSTEOARTHR CARTILAGE, V21, P1290, DOI 10.1016/j.joca.2013.05.007
   Corciulo C, 2017, NAT COMMUN, V8, P0, DOI 10.1038/ncomms15019
   da Silva MD, 2015, MOL NEUROBIOL, V51, P19, DOI 10.1007/s12035-014-8790-x
   Dworkin RH, 2008, J PAIN, V9, P105, DOI 10.1016/j.jpain.2007.09.005
   Felson DT, 2006, NEW ENGL J MED, V354, P841, DOI 10.1056/NEJMcp051726
   Fernandes JC, 2002, BIORHEOLOGY, V39, P237
   Han JS, 2011, NEUROSCI BIOBEHAV R, V35, P680, DOI 10.1016/j.neubiorev.2010.08.006
   Hannan MT, 2000, J RHEUMATOL, V27, P1513
   Lin LL, 2018, CLIN REHABIL, V32, P1666, DOI 10.1177/0269215518790632
   LOTZ M, 1992, J IMMUNOL, V148, P466
   Luo F, 2008, NEUROCHEM RES, V33, P1950, DOI 10.1007/s11064-008-9692-y
   Mo YC, 2017, MEDIAT INFLAMM, V2017, P0, DOI 10.1155/2017/8369737
   Otterness IG, 2001, OSTEOARTHR CARTILAGE, V9, P224, DOI 10.1053/joca.2000.0379
   Reboul P, 1996, J CLIN INVEST, V97, P2011, DOI 10.1172/JCI118636
   Robinson WH, 2016, NAT REV RHEUMATOL, V12, P580, DOI 10.1038/nrrheum.2016.136
   Sakao K, 2008, J ORTHOP SCI, V13, P202, DOI 10.1007/s00776-008-1227-5
   Scott JL, 2010, ANN RHEUM DIS, V69, P1502, DOI 10.1136/ard.2009.119966
   Stannus OP, 2013, ANN RHEUM DIS, V72, P535, DOI 10.1136/annrheumdis-2011-201047
   Torres-Rosas R, 2014, NAT MED, V20, P291, DOI 10.1038/nm.3479
   Tubach F, 2005, ANN RHEUM DIS, V64, P29, DOI 10.1136/ard.2004.022905
   VILLIGER PM, 1992, J CLIN INVEST, V90, P488, DOI 10.1172/JCI115885
   Wang MN, 2013, ARTHRITIS RES THER, V15, P0, DOI 10.1186/ar4133
   Witt C, 2005, LANCET, V366, P136, DOI 10.1016/S0140-6736(05)66871-7
   Xu Y, 2018, AM J CHINESE MED, V46, P997, DOI 10.1142/S0192415X18500520
   Zhang RX, 2005, J ALTERN COMPLEM MED, V11, P135, DOI 10.1089/acm.2005.11.135
   Zhao ZQ, 2008, PROG NEUROBIOL, V85, P355, DOI 10.1016/j.pneurobio.2008.05.004
NR 30
TC 58
Z9 72
U1 2
U2 36
PU DOVE MEDICAL PRESS LTD
PI ALBANY
PA PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND
SN 1178-7090
EI 
J9 J PAIN RES
JI J. Pain Res.
PD JUN 15
PY 2020
VL 13
IS 
BP 2171
EP 2179
DI 10.2147/JPR.S256950
PG 9
WC Clinical Neurology
SC Neurosciences & Neurology
GA NF1DC
UT WOS:000563041200001
PM 32904642
DA 2026-01-16
ER

PT J
AU Zhong, XM
   Fang, JF
   Jiang, B
   Zhou, J
   Cai, YQ
   Liang, Y
   Fang, JQ
   Chen, F
   Du, JY
AF Zhong, Xue-Mei
   Fang, Jun-Fan
   Jiang, Bin
   Zhou, Jie
   Cai, Yang-Qian
   Liang, Yi
   Fang, Jian-Qiao
   Chen, Feng
   Du, Jun-Ying
TI [Early intervention of bone-nearby acupuncture combined with electroacupuncture
SO Zhongguo zhen jiu = Chinese acupuncture & moxibustion
LA chi
DT Journal Article
DE bone cancer pain; bone-nearby acupuncture; electroacupuncture; histone deacetylase 2 (HDAC2);μ-opioid recepter (MOR); histone deacetylase1 (HDAC1); histone dorsal root ganglia; morphine tolerance
AB OBJECTIVE: To observe the effect of early intervention of bone-nearby acupuncture  (BNA) combined with electroacupuncture (EA) on the expression of histone  deacetylase1(HDAC1), histone deacetylase 2 (HDAC2) andμ-opioid recepter (MOR) in  dorsal root ganglia (DRG) of bone cancer pain-morphine tolerance (BCP-MT) rats,  and to explore its possible mechanism. METHODS: A total of 35 SD rats were  randomized into a sham BCP group (n=6), a BCP group (n=7), a MT group (n=7), a  BNA+EA group (n=8) and a shame BNA group (n=7). Except of the sham BCP group,  cancer cell inoculation operation at left tibia was given in the other 4 groups  to establish the bone cancer pain model. In the MT group, the BNA+EA group and  the shame BNA group, intraperitoneal injection of morphine hydrochloride was  given to establish the morphine tolerance model. After the operation, bone-nearby  acupuncture combined with electroacupuncture was applied at "Zusanli" (ST 36) and  "Kunlun" (BL 60) in the BNA+EA group, with dilatational wave, 2 Hz/100 Hz in  frequency, 0.5 to 1.5 mA in intensity. Intervention in the shame BNA group was  applied at the same time and acupoints as those in the BNA+EA group, the needles  were pierced the skin without any electrical stimulation. The needles were  retained for 30 min, once a day for continuous 7 days in both BNA+EA and shame  BNA groups. Before and 10, 11, 15, 22 days after the operation, the left paw  withdrawal threshold (PWT) was measured in the 5 groups. The levels of HDAC1,  HDAC2 and MOR in DRG were detected by Western blot. RESULTS: Ten days after the  cancer cell inoculation operation, the PWT of the BCP, MT, BNA+EA and sham BNA  groups was decreased compared with the sham BCP group (P<0.01). Eleven days after  the operation, the PWT of the MT, BNA+EA and sham BNA groups was increased  compared with the BCP group (P<0.01). Twenty-two days after the operation, the  difference was no significant between the BCP group and MT group (P>0.05); the  PWT of the BNA+EA group was increased compared with the MT and sham BNA group  (P<0.01). In the BCP group, the DRG levels of HDAC1 and HDCA2 were increased,  while the level of MOR was decreased compared with the sham BCP group (P<0.05,  P<0.01). In the MT group, the DRG level of HDAC1 was increased compared with the  BCP group (P<0.05). In the BNA+EA group, the DRG level of HDAC1 was decreased  compared with the MT group and the sham BNA group (P<0.01, P<0.05), while the  level of MOR was increased (P<0.01). CONCLUSION: Early intervention of  bone-nearby acupuncture combined with electroacupuncture can relieve the morphine  tolerance in bone cancer pain rats, it may relate to down-regulating the  expression of HDAC1 and up-regulating the expression of MOR in the dorsal root  ganglia.
C1 Second Clinical Medical College, Zhejiang Chinese Medical University, Hangzhou 310053, China
   Department of Acupuncture and Moxibustion, First AffiliatedHospital of Jiaxing University, Jiaxing 314001, Zhejiang Province.
   Third Clinical Medical College, Zhejiang Chinese Medical University, Zhejiang Key Laboratory of Acupuncture and Moxibustion Neurology Research, Hangzhou 310053.
   Department of Acupuncture and Moxibustion, First Affiliated Hospital of Jiaxing University, Jiaxing 314001, Zhejiang Province.
   Third Clinical Medical College, Zhejiang Chinese Medical University, Zhejiang Key Laboratory of Acupuncture and Moxibustion Neurology Research, Hangzhou 310053.
   Third Clinical Medical College, Zhejiang Chinese Medical University, Zhejiang Key Laboratory of Acupuncture and Moxibustion Neurology Research, Hangzhou 310053.
   Third Clinical Medical College, Zhejiang Chinese Medical University, Zhejiang Key Laboratory of Acupuncture and Moxibustion Neurology Research, Hangzhou 310053.
   Third Clinical Medical College, Zhejiang Chinese Medical University, Zhejiang Key Laboratory of Acupuncture and Moxibustion Neurology Research, Hangzhou 310053.
   Second Clinical Medical College, Zhejiang Chinese Medical University, Hangzhou 310053, China
   Department of Acupuncture and Moxibustion, First AffiliatedHospital of Jiaxing University, Jiaxing 314001, Zhejiang Province.
   Third Clinical Medical College, Zhejiang Chinese Medical University, Zhejiang Key Laboratory of Acupuncture and Moxibustion Neurology Research, Hangzhou 310053.
NR 0
TC 0
SN 
EI 0255-293
J9 Zhongguo Zhen Jiu
PD APR 11
PY 2020
VL 40
IS 4
BP 405
EP 10
DI 10.13703/j.0255-2930.20190822-k0002
PG -395
WC Acupuncture Points; Animals; Bone Neoplasms; complications; Cancer Pain; therapy; Drug Tolerance; Electroacupuncture; Ganglia, Spinal; metabolism; Histone Deacetylases; metabolism; Morphine; Random Allocation; Rats; Rats, Sprague-Dawley; Receptors, Opioid, mu; metabolism
UT PubMed:32275370
PM 32275370
DA 2020-04-11
ER

PT J
AU Molassiotis, A
   Dawkins, B
   Longo, R
   Suen, LK
   Cheng, HL
   Mok, T
   Hulme, CT
   Yeo, W
AF Molassiotis, Alex
   Dawkins, Bryony
   Longo, Roberta
   Suen, Lorna Kp
   Cheng, Hui Lin
   Mok, Tony
   Hulme, Claire T
   Yeo, Winnie
TI Economic evaluation alongside a randomised controlled trial to assess the
SO Acupuncture in medicine : journal of the British Medical Acupuncture Society
LA English
DT Journal Article
DE acupuncture; chemotherapy; cost-effectiveness; peripheral neuropathy
AB OBJECTIVE: To assess the cost-effectiveness of acupuncture in the management of  chemotherapy-induced peripheral neuropathy (CIPN) in Hong Kong. METHODS: A within  trial cost-utility analysis with the primary endpoint for the economic evaluation  being the Quality Adjusted Life Year (QALY) and associated Incremental Cost  Effectiveness Ratio (ICER) over 14 weeks of treatment. A secondary  cost-effectiveness analysis was undertaken with the endpoint being change in pain  as measured on the Brief Pain Inventory (BPI). RESULTS: Eighty-seven patients  were randomised to acupuncture or usual care. Acupuncture resulted in significant  improvements in pain intensity (8- and 14-week mean changes compared to usual  care of -1.8 and -1.8, respectively), pain interference (8- and 14-week mean  changes compared to usual care of -1.5 and -0.9, respectively) and indicators of  quality of life and neurotoxicity-related symptoms. However, in the economic  evaluation there was little difference in QALYs between the two arms (mean change  0.209 and 0.200 in the acupuncture and usual care arms, respectively). Also,  costs yielded deterministic ICERs of HK$616,965.62, HK$824,083.44 and  HK$540,727.56 per QALY gained from the health care provider perspective, the  societal perspective and the patient perspective, respectively. These costs are  significantly higher than the cost-effectiveness threshold of HK$180,450 that was  used for the base case analysis. CONCLUSION: While acupuncture can improve  symptoms and quality of life indicators related to CIPN, it is unlikely to be a  cost-effective treatment for CIPN-related pain in health care systems with  limited resources. TRIAL REGISTRATION NUMBER: NCT02553863 (ClinicalTrials.gov)  post-results.
C1 School of Nursing, The Hong Kong Polytechnic University, Hung Hom, Hong Kong SAR.
   Academic Unit of Health Economics, Leeds Institute of Health Sciences, University of Leeds, Leeds, UK.
   Academic Unit of Health Economics, Leeds Institute of Health Sciences, University of Leeds, Leeds, UK.
   School of Nursing, The Hong Kong Polytechnic University, Hung Hom, Hong Kong SAR.
   School of Nursing, The Hong Kong Polytechnic University, Hung Hom, Hong Kong SAR.
   Department of Clinical Oncology, Prince of Wales Hospital, Hung Hom, Hong Kong SAR.
   Academic Unit of Health Economics, Leeds Institute of Health Sciences, University of Leeds, Leeds, UK.
   Department of Clinical Oncology, Prince of Wales Hospital, Hung Hom, Hong Kong SAR.
NR 0
TC 0
SN 1759-987
EI 
J9 Acupunct Med
PD MAY 15
PY 2020
VL 39
IS 1
BP 41
EP 52
DI 10.1177/0964528420920285
PG 11
WC Acupuncture Therapy; economics; Adult; Antineoplastic Agents; adverse effects; Cost-Benefit Analysis; Female; Hong Kong; Humans; Male; Middle Aged; Neoplasms; complications; Neuralgia; economics; Peripheral Nervous System Diseases; economics; Quality-Adjusted Life Years; Treatment Outcome
UT PubMed:32404001
PM 32404001
DA 2020-05-15
ER

PT J
AU Angelopoulou, E
   Anagnostouli, M
   Chrousos, GP
   Bougea, A
AF Angelopoulou, Efthalia
   Anagnostouli, Maria
   Chrousos, George P.
   Bougea, Anastasia
TI Massage therapy as a complementary treatment for Parkinson's disease: A Systematic Literature Review
SO COMPLEMENTARY THERAPIES IN MEDICINE
LA English
DT Review
DE Parkinson's disease (PD); Complementary and alternative medicine (CAM); Massage therapy; Non-motor symptoms; Systematic review
ID breast-cancer patients; alternative medicine; brain-development; symptoms; pain; quality; acupuncture; outpatients; serotonin; dopamine
AB Objective: There is no definite cure for Parkinson's disease (PD); therefore, the goals for symptomatic treatment are to improve quality of life and manage the motor and non-motor symptoms of the disease. Although massage is the one of the commonest used forms of complementary and alternative medicine (CAM), there is no systematically-oriented review focusing specifically on the efficacy of the different massage techniques on PD.Aim of this review was to evaluate the quality of evidence referring to massage therapy for PD. Design: A systematic search was conductedin the MEDLINE database to identify the efficacy of massage on PD between 01/01/1970 and 06/12/2019. Results: A total of 12 studies were analyzed in this systematic review. Massage therapy seems to induce relaxation in most cases, which is accompanied by biological measures involving urine stress hormones. Quality of life has been shown to be improved upon various therapeutic massage styles, involving classical whole-body therapeutic massage and reflexology. Non-motor symptoms, such as sleep disturbances, pain, fatigue, anxiety and depressive symptoms have been demonstrated to be improved upon different massage techniques, including classical deep therapeutic massage, Traditional Japanese (Anma) massage, Thai massage, neuromuscular therapy and Yin Tui Na massage. Regarding motor symptoms, classical therapeutic massage, Traditional Japanese (Anma) massage, Thai massage, and neuromuscular therapy seemed to improve motor symptoms, whereas Yin Tui Na technique combined with acupuncture was associated with worse motor scores. Conclusions: Despite the methodological concerns regarding the existing evidence, there is a wide range of safe massage techniques with beneficial effects on both motor and non-motor symptoms of PD. Longitudinal studies are needed to justify the introduction of massage therapy into clinical practice.
C1 [Angelopoulou, Efthalia; Anagnostouli, Maria; Bougea, Anastasia] Natl Kapodistrian Univ Athens, Aeginit Hosp, Fac Med, Dept Neurol 1, Athens, Greece.
   [Anagnostouli, Maria; Bougea, Anastasia] Natl Kapodistrian Univ Athens, Fac Med, Stress Management & Hlth Promot, Post Grad Course, Athens, Greece.
   [Chrousos, George P.] Natl & Kapodistrian Univ Athens, Aghia Sophia Childrens Hosp, Sch Med, Dept Pediat 1,Unit Dev & Behav Pediat, Athens, Greece.
C3 National & Kapodistrian University of Athens; National & Kapodistrian University of Athens; The Aghia Sophia Children's Hospital; National & Kapodistrian University of Athens
RP Bougea, A (corresponding author), Natl & Kapodistrian Univ Athens, Med Sch, Eginit Hosp, Dept Neurol 1,Memory & Movement Disorder Clin, Vassilisis Sophias Ave 72-74, Athens 11528, Greece.
EM annita139@yahoo.gr
CR Airosa F, 2016, J HOLIST NURS, V34, P13, DOI 10.1177/0898010115579769
   Anderson Loretta, 2019, JBI DATABASE SYSTEM REV IMPLEMENT REP, V17, P1668, DOI 10.11124/jbisrir-2017-003932
   Anselmi L, 2017, GASTROENTEROLOGY, V153, P1581, DOI 10.1053/j.gastro.2017.08.069
   Barone P, 2017, INT REV NEUROBIOL, V133, P499, DOI 10.1016/bs.im.2017.05.023
   Ben-Horin I, 2017, INTEGR CANCER THER, V16, P258, DOI 10.1177/1534735417690254
   Bereznick DE, 2002, CLIN BIOMECH, V17, P297, DOI 10.1016/S0021-9290(02)00014-3
   Bernhard FP, 2016, PLOS ONE, V11, P0, DOI 10.1371/journal.pone.0150552
   Cho KH, 2018, FRONT AGING NEUROSCI, V10, P0, DOI 10.3389/fnagi.2018.00323
   Craig LH, 2006, MOVEMENT DISORD, V21, P2127, DOI 10.1002/mds.21132
   Donley S, 2019, PARKINSONISM RELAT D, V58, P46, DOI 10.1016/j.parkreldis.2018.08.003
   Donoyama N, 2014, COMPLEMENT THER CLIN, V20, P251, DOI 10.1016/j.ctcp.2014.07.010
   Donoyama N, 2012, J ALTERN COMPLEM MED, V18, P294, DOI 10.1089/acm.2011.0148
   Duval C, 2002, J MANIP PHYSIOL THER, V25, P455, DOI 10.1067/mmt.2002.126469
   Dyson-Hudson TA, 2001, ARCH PHYS MED REHAB, V82, P1038, DOI 10.1053/apmr.2001.24888
   Eng ML, 2006, J ALTERN COMPLEM MED, V12, P395, DOI 10.1089/acm.2006.12.395
   Ferry P, 2002, POSTGRAD MED J, V78, P612, DOI 10.1136/pmj.78.924.612
   Field T, 2005, INT J NEUROSCI, V115, P1397, DOI 10.1080/00207450590956459
   Field T, 2002, JCR-J CLIN RHEUMATOL, V8, P72, DOI 10.1097/00124743-200204000-00002
   Field T, 1998, ADOLESCENCE, V33, P555
   Field T, 2006, INFANT BEHAV DEV, V29, P574, DOI 10.1016/j.infbeh.2006.07.011
   Field T, 2016, COMPLEMENT THER CLIN, V24, P19, DOI 10.1016/j.ctcp.2016.04.005
   Field T, 2014, COMPLEMENT THER CLIN, V20, P224, DOI 10.1016/j.ctcp.2014.07.002
   Finseth TA, 2015, EVID-BASED COMPL ALT, V2015, P0, DOI 10.1155/2015/874849
   Franklin NC, 2014, ARCH PHYS MED REHAB, V95, P1127, DOI 10.1016/j.apmr.2014.02.007
   George M, 2013, NURS CLIN N AM, V48, P53, DOI 10.1016/j.cnur.2012.11.002
   Green VL, 2010, EXP THER MED, V1, P97, DOI 10.3892/etm_00000018
   Guo TP, 2018, MEDICINE, V97, P0, DOI 10.1097/MD.0000000000009697
   Guzzetta A, 2009, J NEUROSCI, V29, P6042, DOI 10.1523/JNEUROSCI.5548-08.2009
   Hart S, 2001, EAT DISORD, V9, P289, DOI 10.1080/106402601753454868
   Hernandez-Reif M, 2004, J PSYCHOSOM RES, V57, P45, DOI 10.1016/S0022-3999(03)00500-2
   Hernandez -Reif M, 2002, J. BODYW. MOV. THER, V6, P177, DOI 10.1054/JBMT.2002.0282
   Ironson G, 1996, INT J NEUROSCI, V84, P205, DOI 10.3109/00207459608987266
   Jiang S, 2017, NEUROL SCI, V38, P1373, DOI 10.1007/s10072-017-2988-4
   Johns Christopher, 2010, COMPLEMENT THER CLIN PRACT, V16, P96, DOI 10.1016/j.ctcp.2009.10.003
   Juntakarn Chantip, 2017, INT J THER MASSAGE BODYWORK, V10, P3, DOI 10.3822/ijtmb.v10i2.350
   Kaptchuk TJ, 2002, ANN INTERN MED, V136, P817, DOI 10.7326/0003-4819-136-11-200206040-00011
   Kim In-Hong, 2016, J PHYS THER SCI, V28, P2703, DOI 10.1589/jpts.28.2703
   Klein Penelope, 2017, MEDICINES (BASEL), V4, P0, DOI 10.3390/medicines4040069
   Kostic VS, 2016, MOV DISORD CLIN PRAC, V3, P323, DOI 10.1002/mdc3.12343
   Kumar S, 2013, INT J GEN MED, V6, P733, DOI 10.2147/IJGM.S50243
   Lidstone Sarah Christine, 2014, HANDB EXP PHARMACOL, V225, P139, DOI 10.1007/978-3-662-44519-8_8
   Liu D, 2000, NAT NEUROSCI, V3, P799, DOI 10.1038/77702
   McClurg D, 2016, AGE AGEING, V45, P299, DOI 10.1093/ageing/afw005
   MEARA RJ, 1993, ELECTROEN CLIN NEURO, V89, P261, DOI 10.1016/0168-5597(93)90105-X
   MEARA RJ, 1992, BRAIN, V115, P1167, DOI 10.1093/brain/115.4.1167
   Mercado NM, 2017, AUSTIN NEUROL NEUROSCI, V2, P0
   Miyahara Yuka, 2018, J TRADIT COMPLEMENT MED, V8, P261, DOI 10.1016/j.jtcme.2018.01.004
   Nelson NL, 2017, AM J PHYS MED REHAB, V96, P665, DOI 10.1097/PHM.0000000000000712
   Paterson Charlotte, 2005, COMPLEMENT THER CLIN PRACT, V11, P161, DOI 10.1016/j.ctcp.2004.12.008
   Quattrone A, 2018, MOVEMENT DISORD, V33, P1213, DOI 10.1002/mds.27438
   Ratey JJ, 2011, REV NEUROSCIENCE, V22, P171, DOI 10.1515/RNS.2011.017
   Rexilius Stephanie J, 2002, ONCOL NURS FORUM, V29, PE35, DOI 10.1188/02.ONF.E35-E44
   Rizek P, 2016, CAN MED ASSOC J, V188, P1157, DOI 10.1503/cmaj.151179
   SCATTON B, 1983, BRAIN RES, V275, P321, DOI 10.1016/0006-8993(83)90993-9
   Sitte HH, 2017, EUR J NEUROSCI, V45, P1356, DOI 10.1111/ejn.13573
   Soares NM, 2019, J NEURAL TRANSM, V126, P219, DOI 10.1007/s00702-018-1947-4
   Stang A, 2010, EUR J EPIDEMIOL, V25, P603, DOI 10.1007/s10654-010-9491-z
   Stub T, 2017, BMC COMPLEM ALTERN M, V17, P0, DOI 10.1186/s12906-017-1770-8
   Suoh S, 2016, J BODYW MOV THER, V20, P364, DOI 10.1016/j.jbmt.2015.11.008
   TATTON WG, 1975, BRAIN RES, V100, P671, DOI 10.1016/0006-8993(75)90167-5
   Törnhage CJ, 2013, BMC COMPLEM ALTERN M, V13, P0, DOI 10.1186/1472-6882-13-357
   Walton-Hadlock J, 1999, AM J ACUPUNCT, V27, P31
   Wang QS, 2014, J NEUROSCI, V34, P12490, DOI 10.1523/JNEUROSCI.2238-14.2014
   Waters-Banker C, 2014, J APPL PHYSIOL, V116, P164, DOI 10.1152/japplphysiol.00573.2013
   Wen ZQ, 2012, NEURAL REGEN RES, V7, P1185, DOI 10.3969/j.issn.1673-5374.2012.15.010
   Wu JJ, 2014, COMPLEMENT THER MED, V22, P456, DOI 10.1016/j.ctim.2014.04.001
   Yu QJ, 2018, SCI REP-UK, V8, P0, DOI 10.1038/s41598-017-16790-8
NR 67
TC 24
Z9 25
U1 0
U2 30
PU CHURCHILL LIVINGSTONE
PI EDINBURGH
PA JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE, LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND
SN 0965-2299
EI 1873-6963
J9 COMPLEMENT THER MED
JI Complement. Ther. Med.
PD MAR 15
PY 2020
VL 49
IS 
BP 
EP 
DI 10.1016/j.ctim.2020.102340
PG 8
WC Integrative & Complementary Medicine
SC Integrative & Complementary Medicine
GA LG1NY
UT WOS:000527877700054
PM 32147033
DA 2026-01-16
ER

PT J
AU Chen, YQ
   Song, HH
   Chen, MY
   Xu, H
AF Chen, Yuqin
   Song, Huaihua
   Chen, Mingyu
   Xu, Hua
TI The role of acupotomy in treatment of patients with lumbar spinal stenosis A protocol for a randomized study (Publication with Expression of Concern. See vol. 104, 2025)
SO MEDICINE
LA English
DT Article; Publication with Expression of Concern
DE acupuncture; lumbar spinal stenosis; pain control; protocol
ID low-back-pain; acupuncture; guideline; diagnosis; exercise
AB Background: Currently, there is some clinical evidence supporting the use of acupuncture in alleviating pain and dysfunction in patients with lumbar spinal stenosis (LSS). However, the question of whether acupuncture could be efficacious for ageing patients remains unanswered. We designed a randomized controlled study to evaluate the safety and feasibility of acupuncture for participants with symptomatic LSS. Methods: This study is a randomized, single-blind, noninferiority trial. This clinical trial was approved by the Linyi Cancer Hospital. We received informed consent from all patients before surgery. In preparing this report, we adhered to the Consolidated Standards of Reporting Trials guidelines. We randomized consented study participants on a 1:1 ratio to one of two study groups (acupuncture and control groups) using a computer-generated list of random numbers in varying block sizes. Three outcome measures were selected to evaluate the effectiveness and safety of the treatment: visual analogue score and Oswestry disability index, and complicatins. AP Results: The hypothesis was that the acupuncture group would achieve acceptable clinical outcomes as compared to the control group in LSS.
C1 [Chen, Yuqin] Linyi Cent Hosp, Dept Rehabil, Linyi, Shandong, Peoples R China.
   [Song, Huaihua] Third Peoples Hosp Linyi, Dept Obstet & Gynecol, Linyi, Shandong, Peoples R China.
   [Chen, Mingyu] Linyi Cent Hosp, Dept Neurol, Linyi, Shandong, Peoples R China.
   [Xu, Hua] Linyi Canc Hosp, Dept Bone Oncol, Linyi, Shandong, Peoples R China.
RP Xu, H (corresponding author), Linyi Canc Hosp, Dept Bone Oncol, Linyi, Shandong, Peoples R China.
EM huaxuczyy9208@sina.com
FU National Natural Science Foundation of China [81774218]
CR Airaksinen O, 2006, EUR SPINE J, V15, PS192, DOI 10.1007/s00586-006-1072-1
   Benoist M, 2002, JOINT BONE SPINE, V69, P450, DOI 10.1016/S1297-319X(02)00429-3
   Bodack MP, 2001, CLIN ORTHOP RELAT R, V0, P144
   Burgstaller JM, 2020, SPINE PHILA PA 1976, V0, P0
   Chou R, 2007, ANN INTERN MED, V147, P478, DOI 10.7326/0003-4819-147-7-200710020-00006
   CUCKLER JM, 1985, J BONE JOINT SURG AM, V67A, P63, DOI 10.2106/00004623-198567010-00009
   Hopton AK, 2012, BMJ OPEN, V2, P0, DOI 10.1136/bmjopen-2011-000456
   Hunter RF, 2012, CLIN J PAIN, V28, P259, DOI 10.1097/AJP.0b013e3182274018
   Kim KH, 2013, COMPLEMENT THER MED, V21, P535, DOI 10.1016/j.ctim.2013.08.007
   Koes BW, 1995, PAIN, V63, P279, DOI 10.1016/0304-3959(95)00124-7
   Kreiner DS, 2013, SPINE J, V13, P734, DOI 10.1016/j.spinee.2012.11.059
   Kwon CY, 2019, MEDICINE, V98, P0, DOI 10.1097/MD.0000000000016662
   Liu LZ, 2017, CLIN REHABIL, V31, P1592, DOI 10.1177/0269215517705690
   Lurie J, 2016, BMJ-BRIT MED J, V352, P0, DOI 10.1136/bmj.h6234
   Mazanec DJ, 2002, CLEV CLIN J MED, V69, P909, DOI 10.3949/ccjm.69.11.909
   Rittenberg Joshua D, 2003, PHYS MED REHABIL CLIN N AM, V14, P111, DOI 10.1016/S1047-9651(02)00082-7
   Roelofs PDDM, 2008, SPINE, V33, P1766, DOI 10.1097/BRS.0b013e31817e69d3
   Whitman JM, 2006, SPINE, V31, P2541, DOI 10.1097/01.brs.0000241136.98159.8c
   WILLNER S, 1985, ACTA ORTHOP SCAND, V56, P40, DOI 10.3109/17453678508992977
   Xue CCL, 2008, BMC PUBLIC HEALTH, V8, P0, DOI 10.1186/1471-2458-8-105
NR 20
TC 61
Z9 63
U1 3
U2 12
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0025-7974
EI 1536-5964
J9 MEDICINE
JI Medicine (Baltimore)
PD JUL 31
PY 2020
VL 99
IS 31
BP 
EP 
DI 10.1097/MD.0000000000021444
PG 4
WC Medicine, General & Internal
SC General & Internal Medicine
GA NE6EZ
UT WOS:000562693800090
PM 32756160
DA 2026-01-16
ER

PT J
AU Wang, BL
   Lu, Z
   Huang, Y
AF Wang, Bolin
   Lu, Zhong
   Huang, Yan
TI Association of Acupuncture and Acupressure With Improved Cancer Pain
SO JAMA ONCOLOGY
LA English
DT Letter
C1 [Wang, Bolin] Weifang Med Univ, Weifang, Peoples R China.
   [Lu, Zhong; Huang, Yan] Weifang Med Univ, Affiliated Hosp, Dept Oncol, Weifang 261031, Peoples R China.
C3 Shandong Second Medical University; Shandong Second Medical University
RP Huang, Y (corresponding author), Weifang Med Univ, Affiliated Hosp, Dept Oncol, Weifang 261031, Peoples R China.
EM yanhuangdr@163.com
CR He YH, 2020, JAMA ONCOL, V6, P271, DOI 10.1001/jamaoncol.2019.5233
NR 1
TC 1
Z9 1
U1 0
U2 5
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 2374-2437
EI 2374-2445
J9 JAMA ONCOL
JI JAMA Oncol.
PD JUN 15
PY 2020
VL 6
IS 6
BP 938
EP +
DI 10.1001/jamaoncol.2020.0619
PG 5
WC Oncology
SC Oncology
GA MA6QT
UT WOS:000542037700034
PM 32324200
DA 2026-01-16
ER

PT J
AU Irman
   Helianthi, DR
AF Irman
   Helianthi, Dwi Rachma
TI The Roles of Battlefield Acupuncture and Electroacupuncture in a Patient with
SO Medical acupuncture
LA English
DT Journal Article
DE acupuncture; battlefield acupuncture; cancer pain; electroacupuncture
AB Background: Pain is one of the most-frightening complications of cancer and  disrupts quality of life. Cancer-related pain can be caused by primary cancer  itself, metastases that occur, and interventions to treat cancer. Almost all  cancer-related pain is pain with moderate-to-severe intensity. Thus,  cancer-related pain management often involves administration of opioid  analgesics. However, administration of opioid analgesics can cause side-effects  that cause new problems for these patients. Several studies have shown that  acupuncture can reduce cancer-related pain and data show that acupuncture therapy  is safe and can provide clinically meaningful improvements when used in  conjunction with standard therapy. Case: A 72-year-old female patient had pain  throughout her body since 1 month prior to before being admitted to the hospital.  She was unable to sleep at night often cried because she was unable to stand the  pain. This was reduced by morphine 3 × /day. Because of the drug's side-effects,  she slept more often during the day, could not sleep at night, and was  constipated. She also had breakthrough pain, on an average of 2-3 × /day. She had  a history of malignancy in the pleura, liver, lungs, and cervix. There was an  increase in some tumor markers. Her baseline numeric rating scale (NRS)  assessment was 4 with an oral morphine slow-release tablet 3 × 15 mg/day.  Acupuncture therapy was performed at Battlefield Acupuncture points of the right  ear and body acupuncture points (LI 4, LI 11, ST 36, SP 6, and LR 3) was treated  with 3-Hz continuous-wave electroacupuncture for 30 minutes at each session.  During this therapy, there were reductions in pain (baseline NRS 4 became 2),  need for morphine, morphine side-effects, and frequency of breakthrough pain.  There were no significant side-effects due to acupuncture. Conclusions:  Acupuncture is an effective and safe therapeutic option for reducing cancer pain  with minimal side-effects. Acupuncture can enable a reduced need for narcotic  analgesics.
C1 Department of Medical Acupuncture, Faculty of Medicine Universitas Indonesia/RSUPN Dr. Cipto Mangunkusumo, Central Jakarta, Indonesia.
   Department of Medical Acupuncture, Faculty of Medicine Universitas Indonesia/RSUPN Dr. Cipto Mangunkusumo, Central Jakarta, Indonesia.
NR 0
TC 0
SN 1933-659
EI 1933-658
J9 Med Acupunct
PD SEP 4
PY 2020
VL 32
IS 4
BP 234
EP 240
DI 10.1089/acu.2020.1423
PG 6
UT PubMed:32879650
PM 32879650
DA 2020-09-04
ER

PT J
AU Reed, EN
   Landmann, J
   Oberoi, D
   Piedalue, KL
   Faris, P
   Carlson, LE
AF Reed, Erica Nicole
   Landmann, Jessa
   Oberoi, Devesh
   Piedalue, Katherine-Ann L
   Faris, Peter
   Carlson, Linda E
TI Group versus Individual Acupuncture (AP) for Cancer Pain: A Randomized
SO Evidence-based complementary and alternative medicine : eCAM
LA English
DT Journal Article
AB BACKGROUND: A service delivery model using group acupuncture (AP) may be more  cost-effective than individual AP in general, but there is little evidence to  assess whether group AP is a comparable treatment in terms of efficacy to  standard individual AP. The study aimed to compare the group to individual  delivery of 6-week AP among cancer patients with pain. METHODS: The study design  was a randomized noninferiority trial of the individual (gold standard treatment)  vs. group AP for cancer pain. The primary outcome was pain interference and  severity, measured through the Brief Pain Inventory (BPI). Secondary outcomes  included measures of mood, sleep, fatigue, and social support. Changes in  outcomes from pre- to postintervention were examined using linear mixed effects  modeling and noninferiority was inferred using a noninferiority margin, a  difference of change between the two arms and 95% CIs. Pain interference was  tested with a noninferiority margin of 1 on the BPI, while pain severity and  secondary outcomes were compared using conventional statistical methods. RESULTS:  The trial included 74 participants randomly allocated to group (35) or individual  (39) AP. The noninferiority hypothesis was supported for pain interference  [Ө - 1, Δ 1.03, 95% CI: 0.15-2.20] and severity [Ө - 0.81, Δ 0.52, 95%  CI:.33-1.38] as well as for mood [Ө - 7.52, Δ 9.86, 95% CI: 0.85-18.86], sleep  [Ө - 1.65, Δ 2.60, 95% CI: 0.33-4.88], fatigue [Ө 8.54, Δ - 15.57, 95% CI:  25.60-5.54], and social support [Ө.26, Δ - 0.15, 95% CI:  - 0.42-0.13], meaning  that group AP was not inferior to individual AP treatment. Both arms evidenced  statistically significant improvements across all symptoms before and after the  intervention. Effect sizes for the group vs. individual AP on outcomes of pain,  sleep, mood, and social support ranged from small to very large and were  consistently larger in the group condition. The total average cost-per-person for  group AP ($221.25) was almost half that of individual AP ($420). CONCLUSIONS:  This is the first study to examine the noninferiority of group AP with the gold  standard individual AP. Group AP was noninferior to individual AP for treating  cancer pain and was superior in many health outcomes. Group AP is more  cost-effective for alleviating cancer pain and should be considered for  implementation trials.
C1 Division of Psychosocial Oncology, Department of Oncology, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada.
   Vive Integrative Health Group, 1889 45 Street NW, Calgary, AB, Canada.
   Division of Psychosocial Oncology, Department of Oncology, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada.
   Division of Psychosocial Oncology, Department of Oncology, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada.
   Department of Analytics, Alberta Health Services (AHS) and Department of Community Health Sciences, University of Calgary, Calgary, AB, Canada.
   Division of Psychosocial Oncology, Department of Oncology, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada.
NR 0
TC 0
SN 1741-428
EI 1741-427
J9 Evid Based Complement Alternat Med
PD MAY 1
PY 2020
VL 2020
IS 
BP 7209548
EP 7209548
DI 10.1155/2020/7209548
PG 0
UT PubMed:32351602
PM 32351602
DA 2020-05-01
ER

PT J
AU Alsabri, M
   Yeluru, A
   Basak, RB
AF Alsabri, Mohammed
   Yeluru, Ajitha
   Basak, Ratna B.
TI Ancillary Services in Pediatric Departments of USA
SO INDIAN PEDIATRICS
LA English
DT Article
DE Art; Clowning; Health; Hospital; Music; Pets
ID procedure-related pain; music-therapy; alternative medicine; art-therapy; children; hypnosis; cancer; complementary; chemotherapy; acupuncture
AB It is well known that prolonged hospitalizations and medical procedures have adverse psychological impact on children. Ancillary services in the pediatric departments help in mitigating stress, improve patient satisfaction, reduce procedural time, and improve the quality of life. This can be translated to measurable outcomes such as less doctor's visits, fewer symptoms, early discharge and fewer medications. Other benefits include conserving staff time and energy, thereby increasing productivity, staff retention and decreasing burnout. As more free-standing children's hospitals emerge, the ancillary services will gain more recognition and popularity to give the best patient care experience.
C1 [Alsabri, Mohammed; Yeluru, Ajitha; Basak, Ratna B.] Brookdale Univ Hosp Med Ctr, Dept Pediat, One Brookdale Plaza, New York, NY 11212 USA.
RP Basak, RB (corresponding author), Brookdale Univ Hosp Med Ctr, Dept Pediat, One Brookdale Plaza, New York, NY 11212 USA.
EM ratnabimalbasak@gmail.com
CR Abasi Z, 2011, J N KHORASAN U MED S, V3, P51, DOI 10.29252/jnkums.3.3.51
   Ali Babar, 2015, ASIAN PACIFIC JOURNAL OF TROPICAL BIOMEDICINE, V5, P601, DOI 10.1016/j.apjtb.2015.05.007
   American Academy of Pediatrics Committee on Hospital Care, 1986, HDB HOSP CAR CHILDR, V0, P0
   Unknown -, 2014, HIST AN ASS THER, V0, P0
   Unknown -, 2014, GLOBAL J HLTH SCI, V0, P0
   Unknown -, 2004, COCHRANE DB SYST REV, V0, P0
   Unknown -, 1946, PURPOSE FAMILY GUIDE, V0, P0
   Barrera ME, 2002, PSYCHO-ONCOL, V11, P379, DOI 10.1002/pon.589
   Basak RB, 2019, J PAIN SYMPTOM MANAG, V58, P735, DOI 10.1016/j.jpainsymman.2019.05.022
   Beebe A, 2010, J ALLERGY CLIN IMMUN, V126, P263, DOI 10.1016/j.jaci.2010.03.019
   Bieleninik L, 2016, PEDIATRICS, V138, P0, DOI 10.1542/peds.2016-0971
   Bremner J Douglas, 2006, DIALOGUES CLIN NEUROSCI, V8, P445
   Bustad L, 1980, ANIMALS, V0, P0, DOI 10.5749/J.CTTTT4CW
   Dain AS, 2015, J PAIN SYMPTOM MANAG, V49, P1035, DOI 10.1016/j.jpainsymman.2014.11.295
   Ernst E, 2000, B WORLD HEALTH ORGAN, V78, P252
   Gagnon Johanne, 2004, CAN ONCOL NURS J, V14, P217
   Ghetti CM, 2013, J MUSIC THER, V50, P93, DOI 10.1093/jmt/50.2.93
   Gomberg J, 2020, CLIN MED INSIGHTS-PE, V14, P0, DOI 10.1177/1179556520909376
   Grebosz-Haring K, 2018, HELIYON, V4, P0, DOI 10.1016/j.heliyon.2018.e01014
   Groenewald CB, 2017, ACAD PEDIATR, V17, P785, DOI 10.1016/j.acap.2017.02.008
   Jindal V, 2008, J PEDIAT HEMATOL ONC, V30, P431, DOI 10.1097/MPH.0b013e318165b2cc
   Kaminski M, 2002, CHILD HEALTH CARE, V31, P321, DOI 10.1207/S15326888CHC3104_5
   Kemper KJ, 2000, PEDIATRICS, V105, P941
   Knott D, 2020, J MUSIC THER, V57, P34, DOI 10.1093/jmt/thz019
   Könsgen N, 2019, SYST REV-LONDON, V8, P0, DOI 10.1186/s13643-019-1095-4
   Kong LJ, 2013, EVID-BASED COMPL ALT, V2013, P0, DOI 10.1155/2013/613279
   Längler A, 2013, COMPLEMENT THER MED, V21, PS26, DOI 10.1016/j.ctim.2012.01.005
   Landier W, 2010, J PEDIATR NURS, V25, P566, DOI 10.1016/j.pedn.2010.01.009
   Liossi C, 2003, INT J CLIN EXP HYP, V51, P4, DOI 10.1076/iceh.51.1.4.14064
   Lookabaugh S, 2018, J CHILD FAM STUD, V27, P1721, DOI 10.1007/s10826-018-1031-6
   Malchiodi CA, 1999, MEDICAL ART THERAPY WITH CHILDREN, V0, P0
   Martin L, 2018, BEHAV SCI-BASEL, V8, P0, DOI 10.3390/bs8020028
   Metzl E, 2016, CANADIAN ART THERAPY ASSOCIATION JOURNAL, V29, P3, DOI 10.1080/08322473.2016.1170496
   Michelson KN, 2018, CLIN PEDIAT EMERG ME, V83, P212
   MORGAN AH, 1979, AM J CLIN HYPN, V21, P148
   Ndao DH, 2012, PSYCHO-ONCOLOGY, V21, P247, DOI 10.1002/pon.1898
   Post-White J, 2009, J PEDIATR ONCOL NURS, V26, P16, DOI 10.1177/1043454208323295
   Reindl TK, 2006, SUPPORT CARE CANCER, V14, P172, DOI 10.1007/s00520-005-0846-z
   Richardson J, 2007, EUR J CANCER CARE, V16, P402, DOI 10.1111/j.1365-2354.2006.00736.x
   Richardson J, 2006, J PAIN SYMPTOM MANAG, V31, P70, DOI 10.1016/j.jpainsymman.2005.06.010
   Riley S, 2001, WESTERN J MED, V175, P54, DOI 10.1136/ewjm.175.1.54
   Shaw SR, 2008, PSYCHOL SCHOOLS, V45, P74, DOI 10.1002/pits.20280
   Shefer S, 2019, EUR J PEDIATR, V178, P1283, DOI 10.1007/s00431-019-03415-7
   Silva NB, 2018, PLOS ONE, V13, P0, DOI 10.1371/journal.pone.0194731
   Steinke SM, 2016, PHYSICAL DISABILITIES EDUCATION AND RELATED SERVICES, V35, P28, DOI 10.14434/pders.v35i1.20896
   Still G F, 1931, THE HISTORY OF PEDIATRICS: THE PROGRESS OF THE STUDY OF DISEASES OF CHILDREN UP TO THE END OF THE XVIIITH CENTURY, V0, P0
   Stuckey HL, 2010, AM J PUBLIC HEALTH, V100, P254, DOI 10.2105/AJPH.2008.156497
   Vanhaudenhuyse A, 2008, REV MED LIEGE, V63, P424
   Xinghua BB, 2001, ACUPUNCTURE VISIBLE, V0, P0
   Yinger OS, 2016, J MUSIC THER, V53, P336, DOI 10.1093/jmt/thw010
NR 50
TC 0
Z9 0
U1 0
U2 14
PU SPRINGER INDIA
PI NEW DELHI
PA 7TH FLOOR, VIJAYA BUILDING, 17, BARAKHAMBA ROAD, NEW DELHI, 110 001, INDIA
SN 0019-6061
EI 0974-7559
J9 INDIAN PEDIATR
JI Indian Pediatrics
PD NOV 15
PY 2020
VL 57
IS 11
BP 999
EP 1003
DI 10.1007/s13312-020-2022-4
PG 5
WC Pediatrics
SC Pediatrics
GA OT8WE
UT WOS:000591119000002
PM 33231173
DA 2026-01-16
ER

PT J
AU Shi, KJ
   Tang, Y
   He, FY
   Xiao, X
   Zhang, JY
   Jin, YX
   Wang, YX
   Zhang, Q
AF Shi, Kejin
   Tang, Ying
   He, Fengyi
   Xiao, Xiao
   Zhang, Jiayuan
   Jin, Yuxia
   Wang, Yunxia
   Zhang, Qi
TI The maintenance effect of acupuncture on the side effects of breast cancer endocrine therapy A protocol for systematic review and meta analysis
SO MEDICINE
LA English
DT Review
DE acupuncture; breast cancer; side effects; systematic review protocol
ID women; menopause; adherence; symptoms
AB Background: Breast cancer is common among women throughout the world and endocrine therapy is an established part of its treatment. But, unfortunately, this has also resulted in intolerable side effects affecting the quality of life. Acupuncture has been widely used to treat endocrine-related side effects in patients with breast cancer, but how long its effect can be maintained has not been published. The systematic review is designed to evaluate the maintenance efficacy of acupuncture for related side effects after breast cancer endocrine therapy. Methods and analysis: We will search for the following databases: PubMed, Embase, Cochrane Library, Web of Science, including China National Knowledge Infrastructure (CNKI), WanFang Data, Technology Periodical Database (VIP), and China Biology Medicine (CBM) from inception to May 2020. Two reviewers will search these databases, collect all articles, and assess the quality of studies separately, and there will be no limitations on language. The primary outcomes will be assessed using acupuncture for endocrine-related hot flashes and joint pain duration (1 month, 3 months, 6 months). Measurement tools include the Kupperman index, Brief Pain Inventory Short Form (BPI-SF), the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC), the Brief Pain Inventory-Short (BPI-SF). We will use RevMan V.5.3 for meta-analysis and employ the Grading of Recommendations Assessment, Development and Evaluation System to assess the quality of evidence. Results: This systematic review will evaluate the maintenance efficacy of acupuncture on the side effects of breast cancer endocrine therapy. Conclusion: This study will provide high-quality current evidence of how long its effect can be maintained after acupuncture for related side effects after breast cancer endocrine therapy. Ethics and dissemination: Ethical committee approval is not required for this systematic review as patient data will not be collected. This study will help to inform doctors and researchers on the duration of acupuncture treatment for endocrine-related hot flashes and joint pain. The results will be published in a peer-reviewed journal and will be disseminated in relevant conferences.
C1 [Shi, Kejin; Tang, Ying; He, Fengyi; Xiao, Xiao; Zhang, Jiayuan; Jin, Yuxia; Wang, Yunxia; Zhang, Qi] Chengdu Univ Tradit Chinese Med, Chengdu, Sichuan, Peoples R China.
C3 Chengdu University of Traditional Chinese Medicine
RP Zhang, Q (corresponding author), Chengdu Univ Tradit Chinese Med, Sch Basic Med, Chengdu 610000, Sichuan, Peoples R China.
EM zhangqicduntcm@163.com
FU National Natural Science Foundation of China [81873222]
CR Baker H, 2016, LANCET ONCOL, V17, PE275, DOI 10.1016/S1470-2045(16)30241-8
   BELLAMY N, 1988, J RHEUMATOL, V15, P1833
   Boonstra A, 2013, CANCER NURS, V36, P52, DOI 10.1097/NCC.0b013e31824a7e18
   Brauer JA, 2010, J ALTERN COMPLEM MED, V16, P183, DOI 10.1089/acm.2009.0354
   Bruce Bonnie, 2003, HEALTH QUAL LIFE OUTCOMES, V1, P20, DOI 10.1186/1477-7525-1-20
   Burstein HJ, 2019, J CLIN ONCOL, V37, P423, DOI 10.1200/JCO.18.01160
   Burstein HJ, 2014, J CLIN ONCOL, V32, P2255, DOI 10.1200/JCO.2013.54.2258
   Chien TJ, 2017, PLOS ONE, V12, P0, DOI 10.1371/journal.pone.0180918
   Cleeland CS, 1994, ANNALS ACADEMY OF MEDICINE SINGAPORE, V23, P129
   Condorelli R, 2018, EXPERT REV ANTICANC, V18, P1101, DOI 10.1080/14737140.2018.1520096
   Crew KD, 2007, J CLIN ONCOL, V25, P3877, DOI 10.1200/JCO.2007.10.7573
   Fan HGM, 2010, ANN ONCOL, V21, P983, DOI 10.1093/annonc/mdp394
   Hershman DL, 2018, JAMA-J AM MED ASSOC, V320, P167, DOI 10.1001/jama.2018.8907
   Hilditch JR, 1996, MATURITAS, V24, P161, DOI 10.1016/0378-5122(96)01038-9
   Hortobagyi GN, 2006, CLIN BREAST CANCER, V6, P391
   Lee HJ, 2009, J EXP CLIN CANC RES, V28, P0, DOI 10.1186/1756-9966-28-102
   Lesi G, 2015, J CLIN ONCOL JCO, V63, P1795
   Liberati A, 2009, ANN INTERN MED, V151, PW65, DOI 10.7326/0003-4819-151-4-200908180-00136
   Makubate B, 2013, BRIT J CANCER, V108, P1515, DOI 10.1038/bjc.2013.116
   Momenimovahed Z, 2019, BREAST CANCER-TARGET, V11, P151, DOI 10.2147/BCTT.S176070
   Niravath P, 2013, ANN ONCOL, V24, P1443, DOI 10.1093/annonc/mdt037
   Oh B, 2013, ACUPUNCT MED, V31, P264, DOI 10.1136/acupmed-2012-010309
   Pan YQ, 2018, INTEGR CANCER THER, V17, P602, DOI 10.1177/1534735418786801
   Partridge AH, 2008, J CLIN ONCOL, V26, P556, DOI 10.1200/JCO.2007.11.5451
   Savard MH, 2009, J PAIN SYMPTOM MANAG, V37, P687, DOI 10.1016/j.jpainsymman.2008.04.010
   Schneider H P, 2000, CLIMACTERIC, V3, P50, DOI 10.3109/13697130009167599
   Olid AS, 2013, MED ACUPUNCT, V25, P386, DOI 10.1089/acu.2013.0976
   Shamseer L, 2015, BMJ-BRIT MED J, V349, P0, DOI 10.1136/bmj.g7647
   Tedesco D, 2017, JAMA SURG, V152, P0, DOI 10.1001/jamasurg.2017.2872
   Zhu W, 2018, NEUROSCIENCE, V379, P281, DOI 10.1016/j.neuroscience.2018.03.029
NR 30
TC 1
Z9 1
U1 0
U2 5
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0025-7974
EI 1536-5964
J9 MEDICINE
JI Medicine (Baltimore)
PD JUN 15
PY 2020
VL 99
IS 24
BP 
EP 
DI 10.1097/MD.0000000000020567
PG 5
WC Medicine, General & Internal
SC General & Internal Medicine
GA MM0WU
UT WOS:000549881200038
PM 32541483
DA 2026-01-16
ER

PT J
AU Mao, JJ
AF Mao, Jun J
TI Oncology Acupuncture: Precision Medicine Meets Patient-Centered Care.
SO Medical acupuncture
LA English
DT Journal Article
DE acupuncture; hot flashes; insomnia; oncology; pain; precision medicine
AB The Precision Medicine Initiative of 2015, together with a growing focus on  patient-centered care, has challenged the U.S. health care system to provide the  correct treatment to the correct individual patient rather than to a collective  population. This demonstrates that acupuncture-with its history as an  individualized therapy and with growing evidence-based clinical findings-is the  ideal model for personalized medicine within oncology care. The current author  and colleagues used previously conducted oncology acupuncture trials for pain,  hot flashes, and insomnia to demonstrate that precise delivery of acupuncture  might depend on a patient's genetics. Individual preferences and perceived  evidence surrounding treatments might also factor into patient treatment choices.  Further effectiveness evidence comparing acupuncture to drugs or  cognitive-behavioral therapy provides insight on the relative benefit or harm of  each treatment, which, in turn, can help clinicians and patients to choose the  best treatment plans centered on patients' goals. To advance precision oncology  acupuncture research, appropriate biomarkers and psychologic attributes should be  incorporated into adequately powered and well-designed clinical trials to  evaluate how acupuncture can be delivered to the correct patients.
C1 Bendheim Integrative Medicine Center, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
NR 0
TC 0
SN 1933-659
EI 1933-658
J9 Med Acupunct
PD DEC 29
PY 2020
VL 32
IS 6
BP 405
EP 407
DI 10.1089/acu.2020.1501
PG 2
UT PubMed:33362901
PM 33362901
DA 2020-12-29
ER

PT J
AU Tang, Q
   Zhang, K
AF Tang, Qilin
   Zhang, Kai
TI Association of Acupuncture and Acupressure With Improved Cancer Pain.
SO JAMA oncology
LA English
DT Letter
C1 School of Basic Medical Sciences, Hebei University of Chinese Medicine, Shijiazhuang, China.
   Department of Acupuncture and Moxibustion, Tianjin Gong An Hospital, Tianjin, China.
NR 0
TC 0
SN 2374-244
EI 
J9 JAMA Oncol
PD APR 24
PY 2020
VL 6
IS 6
BP 938
EP 938
DI 10.1001/jamaoncol.2020.0616
PG 0
WC Acupressure; Acupuncture Therapy; Cancer Pain; therapy; Humans; Neoplasms; complications
UT PubMed:32324212
PM 32324212
DA 2020-04-24
ER

PT J
AU Luo, Y
   Wang, CZ
   Sawadogo, R
   Tan, T
   Yuan, CS
AF Luo, Yun
   Wang, Chong-Zhi
   Sawadogo, Richard
   Tan, Ting
   Yuan, Chun-Su
TI Effects of Herbal Medicines on Pain Management
SO AMERICAN JOURNAL OF CHINESE MEDICINE
LA English
DT Article
DE Pain; Nociception; NSAIDS; Opioids; Herbal Medicine; Chinese Medicine; Corydalis yanhusuo; Ligusticum chuanxiong; Aconitum carmichaeli; Chinese Herbal Formulation; Review
ID traditional chinese medicine; low-back-pain; panax-notoginseng; neuropathic pain; acupuncture; efficacy; bulleyaconitine; formula; disease
AB Pain is an unpleasant sensory and emotional experience in many diseases and is often caused by intense or damaging stimuli. Pain negatively affects the quality of life and increases high health expenditures. Drugs with analgesic properties are commonly used to relieve pain, but these Western medications could be overwhelmed by side effects including tolerance and addiction. Herbal medicines may provide alternative measures for pain management. In this review paper, after introduction of Chinese medicine theory and treatment modality, emphasis is placed on the application of Chinese herbs and herbal formulations in pain management. Three of the most commonly used herbs, i.e., Corydalis yanhusuo, Ligusticum chuanxiong, and Aconitum carmichaeli, are reviewed. Subsequently, using this ancient medical remedy, Chinese herbal formulation in treating common medical conditions associated with pain, such as headache/migraine, chest pain, abdominal pain, low back pain, neuropathic pain, osteoarthritis, and cancer pain, is presented. Chinese herbal medicines could be considered as a complementary and integrative approach in the modern armamentarium in combating pain.
C1 [Luo, Yun; Tan, Ting] Jiangxi Univ Tradit Chinese Med, Minist Educ, Key Lab Modern Preparat Tradit Chinese Med, Nanchang 330004, Jiangxi, Peoples R China.
   [Luo, Yun; Wang, Chong-Zhi; Sawadogo, Richard; Yuan, Chun-Su] Univ Chicago, Pritzker Sch Med, Tang Ctr Herbal Med Res, 5841 South Maryland Ave,MC 4028, Chicago, IL 60637 USA.
   [Luo, Yun; Wang, Chong-Zhi; Sawadogo, Richard; Yuan, Chun-Su] Univ Chicago, Pritzker Sch Med, Dept Anesthesia & Crit Care, 5841 South Maryland Ave,MC 4028, Chicago, IL 60637 USA.
   [Yuan, Chun-Su] Univ Chicago, Pritzker Sch Med, Comm Clin Pharmacol & Pharmacogen, Chicago, IL 60637 USA.
   [Sawadogo, Richard] Inst Hlth Sci Res, 03 BP 7192, Ouagadougou 03, Burkina Faso.
C3 Jiangxi University of Traditional Chinese Medicine; University of Chicago; University of Chicago; University of Chicago
RP Yuan, CS (corresponding author), Univ Chicago, Pritzker Sch Med, Tang Ctr Herbal Med Res, 5841 South Maryland Ave,MC 4028, Chicago, IL 60637 USA.; Yuan, CS (corresponding author), Univ Chicago, Pritzker Sch Med, Dept Anesthesia & Crit Care, 5841 South Maryland Ave,MC 4028, Chicago, IL 60637 USA.
EM cyuan@dacc.uchicago.edu
FU National Natural Science Foundation of China [81760711, 81460600, 81603274]; State Scholarship Fund of China Scholarship Council [201808360056]; Natural Science Foundation of Jiangxi Province, China [20171BAB205100, 20181BAB205080]; 111 Project from the Ministry of Education of China [B16046]; State Administration of Foreign Experts Affairs of China [B16046]; Fulbright Visiting Scholars Program from the U.S. Department of State [PS00267280]; U.S. National Institutes of Health [AT004418, 5P30DK042086]
CR Abrams J, 2005, NEW ENGL J MED, V352, P2524, DOI 10.1056/NEJMcp042317
   Bardia A, 2006, J CLIN ONCOL, V24, P5457, DOI 10.1200/JCO.2006.08.3725
   Burch R, 2018, HEADACHE, V58, P496, DOI 10.1111/head.13281
   Cai W, 2018, AM J CHINESE MED, V46, P515, DOI 10.1142/S0192415X1850026X
   Cao KG, 2016, BMC COMPLEM ALTERN M, V16, P0, DOI 10.1186/s12906-016-1321-8
   Charles A, 2017, NEW ENGL J MED, V377, P553, DOI 10.1056/NEJMcp1605502
   Chen HM, 2012, AM J CHINESE MED, V47, P1
   Chen M, 2018, ALIMENT PHARM THER, V48, P160, DOI 10.1111/apt.14817
   Chen ZJ, 2018, FOOD CHEM TOXICOL, V119, P309, DOI 10.1016/j.fct.2018.02.050
   Dai YC, 2017, MEDICINE, V96, P0, DOI 10.1097/MD.0000000000006651
   Demsie DG, 2019, J PAIN RES, V12, P1399, DOI 10.2147/JPR.S193029
   Dong PX, 2018, CHIN MED-UK, V13, P0, DOI 10.1186/s13020-018-0185-x
   Duan L, 2018, PHYTOMEDICINE, V47, P23, DOI 10.1016/j.phymed.2018.04.044
   Fan H, 2017, CLIN GASTROENTEROL H, V15, P1724, DOI 10.1016/j.cgh.2017.06.026
   Fang RM, 2018, AM J CHINESE MED, V46, P1609, DOI 10.1142/S0192415X18500829
   Feng L, 2014, AM J CHINESE MED, V42, P109, DOI 10.1142/S0192415X14500074
   Fu CH, 2012, EVID-BASED COMPL ALT, V2012, P0, DOI 10.1155/2012/967968
   Fung FY, 2015, ALTERNAT MED, V2015, P0
   Gagnier JJ, 2016, SPINE, V41, P116, DOI 10.1097/BRS.0000000000001310
   Gilron I, 2005, NEW ENGL J MED, V352, P1324, DOI 10.1056/NEJMoa042580
   Guo ZG, 2014, SCI REP-UK, V4, P0, DOI 10.1038/srep03905
   Hamaguchi T, 2017, J ALTERN COMPLEM MED, V23, P208, DOI 10.1089/acm.2016.0276
   Huang YL, 2019, AM J CHINESE MED, V47, P727, DOI 10.1142/S0192415X19500381
   Huo WW, 2018, MOL PAIN, V14, P0, DOI 10.1177/1744806918781733
   Jia W, 2006, PHYTOTHER RES, V20, P819, DOI 10.1002/ptr.1905
   Lao L, 2015, OSTEOARTHR CARTILAGE, V23, P2102, DOI 10.1016/j.joca.2015.06.007
   Lee H, 2016, MATURITAS, V86, P64, DOI 10.1016/j.maturitas.2016.01.012
   Li JH, 2015, COMPLEMENT THER MED, V23, P577, DOI 10.1016/j.ctim.2015.06.012
   Li LR, 2019, AM J CHINESE MED, V47, P495, DOI 10.1142/S0192415X19500253
   Lin JG, 2018, AM J CHINESE MED, V46, P55, DOI 10.1142/S0192415X18500039
   Liu S, 2017, J ETHNOPHARMACOL, V207, P237, DOI 10.1016/j.jep.2017.06.038
   Luan F, 2019, AM J CHINESE MED, V47, P959, DOI 10.1142/s0192415x19500502
   Luo Y, 2019, AM J CHINESE MED, V47, P1223, DOI 10.1142/S0192415X19500629
   Martyn JAJ, 2019, NEW ENGL J MED, V380, P365, DOI 10.1056/NEJMra1800222
   Moore RA, 2015, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD010794.pub2
   Pan H, 2018, AM J CHINESE MED, V46, P489, DOI 10.1142/S0192415X18500258
   Patil S, 2016, CURR PAIN HEADACHE R, V20, P0, DOI 10.1007/s11916-016-0552-1
   Peirs C, 2016, SCIENCE, V354, P578, DOI 10.1126/science.aaf8933
   Peng C, 2009, PHYTOMEDICINE, V16, P25, DOI 10.1016/j.phymed.2008.10.010
   Qi FH, 2015, BIOSCI TRENDS, V9, P16, DOI 10.5582/bst.2015.01019
   Qi Y, 2012, J EVID BASED MED, V11, P83
   Ran X, 2011, PHARM BIOL, V49, P1180, DOI 10.3109/13880209.2011.576346
   Shirazi M, 2017, J EVID-BASED INTEGR, V22, P120, DOI 10.1177/2156587216654601
   Singhuber J, 2009, J ETHNOPHARMACOL, V126, P18, DOI 10.1016/j.jep.2009.07.031
   Sommer C, 2016, SCIENCE, V354, P588, DOI 10.1126/science.aaf8935
   Straube A, 2019, J HEADACHE PAIN, V20, P0, DOI 10.1186/s10194-019-0985-0
   Sun ML, 2018, PSYCHOPHARMACOLOGY, V235, P2559, DOI 10.1007/s00213-018-4948-y
   Suzuki T, 2016, J ETHNOPHARMACOL, V186, P44, DOI 10.1016/j.jep.2016.03.056
   Takao Yumiko, 2015, KOBE J MED SCI, V61, P0
   Tomioka H, 2017, AM J CHINESE MED, V45, P1597, DOI 10.1142/S0192415X17500860
   Tsai CI, 2013, EVID-BASED COMPL ALT, V2013, P0, DOI 10.1155/2013/767498
   Viniol A, 2014, FAM PRACT, V31, P517, DOI 10.1093/fampra/cmu036
   Wang F, 2018, EVID-BASED COMPL ALT, V2018, P0, DOI 10.1155/2018/1827528
   Wang HY, 2018, AM J CHINESE MED, V46, P1387, DOI 10.1142/S0192415X18500738
   WANG L, 2016, EVID-BASED COMPL ALT, V0, P0, DOI DOI 10.1155/2016/7960503
   Wang L, 2016, PLOS ONE, V11, P0, DOI 10.1371/journal.pone.0162875
   Wang SM, 2018, AM J CHINESE MED, V46, P953, DOI 10.1142/S0192415X18500507
   Wang ZY, 2017, OXID MED CELL LONGEV, V2017, P0, DOI 10.1155/2017/7191856
   Williams ACD, 2016, PAIN, V157, P2420, DOI 10.1097/j.pain.0000000000000613
   Woolf CJ, 2010, J CLIN INVEST, V120, P3742, DOI 10.1172/JCI45178
   Wu LH, 2018, MOLECULES, V23, P0, DOI 10.3390/molecules23102585
   Xie MX, 2018, MOL PAIN, V14, P0, DOI 10.1177/1744806918797243
   Xiong W, 2018, AM J CHINESE MED, V46, P1169, DOI 10.1142/S0192415X18500611
   Xu Y, 2016, ONCOTARGET, V7, P20455, DOI 10.18632/oncotarget.7973
   Xu Y, 2018, AM J CHINESE MED, V46, P971, DOI 10.1142/s0192415x18500519
   Xu ZH, 2018, AM J CHIN MED, V0, P1
   Yeh LLL, 2007, PLOS ONE, V2, P0, DOI 10.1371/journal.pone.0000719
   Yu SY, 2015, EVID-BASED COMPL ALT, V2015, P0, DOI 10.1155/2015/694061
   Yu YN, 2014, SCI REP-UK, V4, P0, DOI 10.1038/srep07058
   Zhan JYX, 2013, PLANTA MED, V79, P533, DOI 10.1055/s-0032-1328261
   Zhang D, 2016, MEDICINE, V95, P51
   Zhang W, 2016, BMJ OPEN, V6, P0, DOI 10.1136/bmjopen-2015-008973corr1
   Zhao LX, 2014, EUR J NEUROSCI, V39, P1391, DOI 10.1111/ejn.12502
   Zhu HQ, 2015, EXP NEUROL, V273, P263, DOI 10.1016/j.expneurol.2015.09.006
   Zhu MD, 2014, BRAIN RES BULL, V109, P54, DOI 10.1016/j.brainresbull.2014.10.002
NR 75
TC 71
Z9 76
U1 5
U2 83
PU WORLD SCIENTIFIC PUBL CO PTE LTD
PI SINGAPORE
PA 5 TOH TUCK LINK, SINGAPORE 596224, SINGAPORE
SN 0192-415X
EI 1793-6853
J9 AM J CHINESE MED
JI Am. J. Chin. Med.
PD JUN 15
PY 2020
VL 48
IS 1
BP 1
EP 16
DI 10.1142/S0192415X20500019
PG 16
WC Integrative & Complementary Medicine; Medicine, General & Internal
SC Integrative & Complementary Medicine; General & Internal Medicine
GA KN9GX
UT WOS:000515156400001
PM 32054304
DA 2026-01-16
ER

PT J
AU Xue, Y
   Dai, SL
   Liang, JX
   Ji, WJ
AF Xue, Yan
   Dai, Sailin
   Liang, Jiexian
   Ji, Wenjin
TI Effect of reactive oxygen species of the psoas major muscle in complete Freund's adjuvant-induced inflammatory pain in rats
SO MOLECULAR PAIN
LA English
DT Article
DE Lower limb pain; psoas major muscle; reactive oxygen species; PBN; complete Freund's adjuvant-induced inflammatory pain
ID induced mechanical hyperalgesia; free-radicals; oxidative stress; neuropathic pain; allodynia; model; superoxide; ros; antioxidants; scavenger
AB Lower limb pain is a common clinical disease that affects millions of people worldwide. It is found in previous studies that reactive oxygen species is closely related to neuropathic, cancer, chemotherapy, and inflammatory pain, which can be relieved by reactive oxygen species scavengers. Furthermore, acupuncture or electroacupuncture on the psoas major muscle has a great effect on adjuvant-induced arthritis and lower back pain. In our study, we investigated the function of reactive oxygen species scavengers locally injecting into the ipsilateral psoas major muscle on complete Freund's adjuvant-induced inflammatory pain. Our results demonstrated that in the development of complete Freund's adjuvant-induced inflammatory pain, early local continuous application of N-tert-Butyl-alpha-phenylnitrone (PBN, 1 and 5 mg/kg/0.2 ml) on the ipsilateral psoas major muscle effectively reduced mechanical and cold hyperalgesia. However, intraperitoneal injection of PBN (1 and 5 mg/kg) or local injection of PBN (1 and 5 mg/kg/0.2 ml) into contralateral psoas major muscle, ipsilateral quadratus lumborum, and ipsilateral erector spinae showed limited effect. In the developed inflammatory pain model, local injection of PBN into the ipsilateral psoas major muscle also alleviated pain and paw edema. In addition, reactive oxygen species level increased in ipsilateral psoas major muscle at seven days after complete Freund's adjuvant injection. In general, PBN reduces complete Freund's adjuvant-evoked inflammatory pain by inhibiting reactive oxygen species in the psoas major muscle.
C1 [Xue, Yan; Liang, Jiexian] South China Univ Technol, Guangdong Prov Peoples Hosp, Guangdong Acad Med Sci,Div Anesthesiol, Sch Med,Dept Cardiovasc Surg,Guangdong Inst Cardi, 96 DongChun Rd, Guangzhou 510080, Guangdong, Peoples R China.
   [Xue, Yan; Liang, Jiexian; Ji, Wenjin] Guangdong Prov Peoples Hosp, Guangdong Acad Med Sci, Dept Anesthesiol, Guangzhou, Peoples R China.
   [Dai, Sailin] Fudan Univ, Shanghai Canc Ctr, Dept Anesthesiol, Shanghai, Peoples R China.
C3 Guangdong Academy of Medical Sciences & Guangdong General Hospital; South China University of Technology; Southern Medical University - China; Southern Medical University - China; Guangdong Academy of Medical Sciences & Guangdong General Hospital; Fudan University
RP Liang, JX (corresponding author), South China Univ Technol, Guangdong Prov Peoples Hosp, Guangdong Acad Med Sci,Div Anesthesiol, Sch Med,Dept Cardiovasc Surg,Guangdong Inst Cardi, 96 DongChun Rd, Guangzhou 510080, Guangdong, Peoples R China.
EM lijessy@msn.com
FU National Natural Science Foundation of China [81171040, 81371236]
CR Almarestani L, 2011, ARTHRITIS RHEUM-US, V63, P1573, DOI 10.1002/art.30303
   Almarestani L, 2008, MOL PAIN, V4, P0, DOI 10.1186/1744-8069-4-56
   Arbanas J, 2013, EUR SPINE J, V22, P1965, DOI 10.1007/s00586-013-2749-x
   Areti A, 2014, REDOX BIOL, V2, P289, DOI 10.1016/j.redox.2014.01.006
   Walker CIB, 2017, N-S ARCH PHARMACOL, V390, P1163, DOI 10.1007/s00210-017-1416-x
   Boettger MK, 2007, EUR J PAIN, V11, P810, DOI 10.1016/j.ejpain.2006.12.008
   CHAPLAN SR, 1994, J NEUROSCI METH, V53, P55, DOI 10.1016/0165-0270(94)90144-9
   Chen KH, 2014, CELL MOL NEUROBIOL, V34, P195, DOI 10.1007/s10571-013-0003-z
   Chen SP, 2018, MOL PAIN, V14, P0, DOI 10.1177/1744806918793232
   Chen YC, 2011, BREAKING FEM WAVES, V0, PP1, DOI 10.1057/9780230119185
   Chia KL, 2016, J INTEGR MED-JIM, V14, P128, DOI 10.1016/S2095-4964(16)60246-7
   CHOI Y, 1994, PAIN, V59, P369, DOI 10.1016/0304-3959(94)90023-X
   Chung JM, 2004, MOL INTERV, V4, P248, DOI 10.1124/mi.4.5.3
   Close GL, 2004, EUR J APPL PHYSIOL, V91, P615, DOI 10.1007/s00421-003-1012-2
   Djordjevic VB, 2004, INT REV CYTOL, V237, P57, DOI 10.1016/S0074-7696(04)37002-6
   Gao X, 2008, PAIN, V23, P1
   Gwak YS, 2013, PAIN, V154, P1699, DOI 10.1016/j.pain.2013.05.018
   Hacimuftuoglu A, 2006, BEHAV BRAIN RES, V173, P211, DOI 10.1016/j.bbr.2006.06.030
   Hamilton CB, 2015, OSTEOARTHR CARTILAGE, V23, P1178, DOI 10.1016/j.joca.2015.03.001
   Herzberg D, 2019, ANIMALS-BASEL, V9, P0, DOI 10.3390/ani9090693
   Jindong C, 2007, CHIN MED J, V87, P602
   Khalil Z, 2001, FREE RADICAL BIO MED, V31, P430, DOI 10.1016/S0891-5849(01)00597-4
   Khattab MM, 2006, EUR J PHARMACOL, V548, P167, DOI 10.1016/j.ejphar.2006.08.007
   Kim HK, 2010, ANESTHESIOLOGY, V112, P432, DOI 10.1097/ALN.0b013e3181ca31bd
   Kim HY, 2015, NEURAL PLAST, V2015, P0, DOI 10.1155/2015/293423
   Kim HY, 2008, NEUROSCI LETT, V447, P87, DOI 10.1016/j.neulet.2008.09.041
   Kim HK, 2004, PAIN, V111, P116, DOI 10.1016/j.pain.2004.06.008
   Lee DZ, 2012, PAIN, V153, P1905, DOI 10.1016/j.pain.2012.06.001
   Lee I, 2007, PAIN, V133, P9, DOI 10.1016/j.pain.2007.01.035
   Liao HY, 2017, SCI REP-UK, V7, P0, DOI 10.1038/srep42531
   Maioli NA, 2015, BRAZ J MED BIOL RES, V48, P321, DOI 10.1590/1414-431X20144187
   Nagakura Y, 2003, J PHARMACOL EXP THER, V306, P490, DOI 10.1124/jpet.103.050781
   SIEMS WG, 1995, LIFE SCI, V57, P785, DOI 10.1016/0024-3205(95)02006-5
   Singh AK, 2017, INFLAMM RES, V66, P911, DOI 10.1007/s00011-017-1072-0
   Stadtman ER, 2004, CURR MED CHEM, V11, P1105, DOI 10.2174/0929867043365341
   Thirupathi A, 2018, J PHYSIOL BIOCHEM, V74, P359, DOI 10.1007/s13105-018-0633-1
   Valko M, 2006, CHEM-BIOL INTERACT, V160, P1, DOI 10.1016/j.cbi.2005.12.009
   Valko M, 2007, INT J BIOCHEM CELL B, V39, P44, DOI 10.1016/j.biocel.2006.07.001
   Walsh NE, 2017, BRIT MED BULL, V122, P151, DOI 10.1093/bmb/ldx012
   Wang ZQ, 2004, J PHARMACOL EXP THER, V309, P869, DOI 10.1124/jpet.103.064154
   Xie WR, 2016, J NEUROSCI, V36, P8712, DOI 10.1523/JNEUROSCI.4118-15.2016
   Zhou YQ, 2018, PHARMACOL RES, V134, P305, DOI 10.1016/j.phrs.2018.07.002
   Zhou YQ, 2018, REDOX BIOL, V14, P391, DOI 10.1016/j.redox.2017.10.011
NR 43
TC 8
Z9 8
U1 0
U2 7
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 
EI 1744-8069
J9 MOL PAIN
JI Mol. Pain
PD JUN 15
PY 2020
VL 16
IS 
BP 
EP 
DI 10.1177/1744806920929246
PG 10
WC Neurosciences
SC Neurosciences & Neurology
GA ME5WI
UT WOS:000544725500001
PM 32552357
DA 2026-01-16
ER

PT J
AU Cai, DB
   Yuan, WQ
   Zheng, W
AF Cai, Dong-Bin
   Yuan, Wei-Qu
   Zheng, Wei
TI Association of Acupuncture and Acupressure With Improved Cancer Pain
SO JAMA ONCOLOGY
LA English
DT Letter
C1 [Cai, Dong-Bin; Yuan, Wei-Qu] Guangzhou Univ Chinese Med, Clin Med Coll 4, Shenzhen Tradit Chinese Med Hosp, Shenzhen, Peoples R China.
   [Zheng, Wei] Guangzhou Med Univ, Guangzhou Huiai Hosp, Affiliated Brain Hosp, 36 Mingxin Rd, Guangzhou 510000, Peoples R China.
C3 Guangzhou University of Chinese Medicine; Shenzhen Traditional Chinese Medicine Hospital; Guangzhou Medical University
RP Zheng, W (corresponding author), Guangzhou Med Univ, Guangzhou Huiai Hosp, Affiliated Brain Hosp, 36 Mingxin Rd, Guangzhou 510000, Peoples R China.
EM zhengwei0702@163.com
CR Cohen J, 1988, STAT POWER ANAL BEHA, V0, P0, DOI DOI 10.4324/9780203771587
   He YH, 2020, JAMA ONCOL, V6, P271, DOI 10.1001/jamaoncol.2019.5233
   Hershman DL, 2018, JAMA-J AM MED ASSOC, V320, P167, DOI 10.1001/jama.2018.8907
   Rahlfs V, 2019, BIOMETRICAL J, V61, P973, DOI 10.1002/bimj.201800107
   Warren JB, 2017, BRIT J CLIN PHARMACO, V83, P221, DOI 10.1111/bcp.13166
NR 5
TC 1
Z9 1
U1 0
U2 5
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 2374-2437
EI 2374-2445
J9 JAMA ONCOL
JI JAMA Oncol.
PD JUN 15
PY 2020
VL 6
IS 6
BP 939
EP 940
DI 10.1001/jamaoncol.2020.0622
PG 2
WC Oncology
SC Oncology
GA MA6QT
UT WOS:000542037700035
PM 32324193
DA 2026-01-16
ER

PT J
AU Yuanqing, P
   Yong, T
   Haiqian, L
   Gen, C
   Shen, X
   Dong, J
   Qi, C
   Miaomiao, Q
AF Yuanqing, Pan
   Yong, Tang
   Haiqian, Liang
   Gen, Chen
   Shen, Xiping
   Dong, Jin
   Qi, Cui
   Miaomiao, Qi
TI Acupuncture for Hormone Therapy-Related Side Effects in Breast Cancer Patients: A
SO Integrative cancer therapies
LA English
DT Journal Article
DE GRADE; acupuncture; alternative therapy; breast cancer; meta-analysis
AB Purpose: To determine the efficacy of acupuncture on the management of hormone  therapy-related side effects in breast cancer patients. Methods: Randomized  controlled trials of acupuncture versus a control or placebo in breast cancer  patients that examined reductions in therapy-related side effects were retrieved  from PubMed, EMBASE, Web of Science, and the Cochrane Library through April 2020.  Data on patient symptoms (hot flashes, fatigue, pain, stiffness, and  gastrointestinal symptoms), physical capacity, cytokines, and general  psychosomatic well-being were analyzed. We evaluated and analyzed the quality of  all included studies with the 5.2 Cochrane Handbook standards using Stata  software (version 10.0) and Revman software (version 5.2), respectively. We  assessed the risk of bias using the Cochrane Risk of Bias tool and evaluated the  quality of evidence using the GRADE (Grading of Recommendations, Assessment,  Development, and Evaluations) approach. Results: The pooled results suggested  that acupuncture led to moderate improvements in hot flashes, fatigue, and  stiffness. No significant differences were observed in pain, gastrointestinal  symptoms, Kupperman index scores, Overall quality of life, tumor necrosis factor  levels, and interleukin levels. Conclusions: Evidence for outcome indicators of  symptom management were downgraded by the GRADE system for inconsistency,  indirectness, and imprecision in the included RCTs. Nonetheless, acupuncture is a  moderately appropriate alternative therapy for hormone therapy-related side  effects in breast cancer patients. However, it still lacks large-sample,  multicenter, prospective RCTs. Future research should focus on standardizing  comparison groups and treatment methods, be at least single-blinded, assess  biologic mechanisms, have adequate statistical power, and involve multiple  acupuncturists.
C1 Guilin Medical University, Campbell China Network, Guilin, China.
   The Affiliated Tumor Hospital of Tianjin Medical University, Tianjin, China.
   Characteristic Medical Center of Chinese people's Armed Police Force, Tianjin, China.
   Guilin Medical University, Campbell China Network, Guilin, China.
   Lanzhou University, Gansu, China.
   Tianjin Pingjin Hospital, Tianjin, China.
   The First Affiliated Hospital of Lanzhou University, Gansu, China.
   Lanzhou University, Gansu, China.
NR 0
TC 0
SN 1552-695
EI 1534-735
J9 Integr Cancer Ther
PD JUL 29
PY 2020
VL 19
IS 
BP 1534735420940394
EP 1534735420940394
DI 10.1177/1534735420940394
PG 1
WC Acupuncture Therapy; Breast Neoplasms; drug therapy; Female; Hormones; Humans; Multicenter Studies as Topic; Prospective Studies; Quality of Life
UT PubMed:32718258
PM 32718258
DA 2020-07-29
ER

PT J
AU Almeida, KAM
   Rocha, AP
   Carvas, N
   Pinto, ACPN
AF Almeida, Kleicyane Aguiar Meireles
   Rocha, Aline Pereira
   Carvas, Nelson
   Pinto, Ana Carolina Pereira Nunes
TI Rehabilitation Interventions for Shoulder Dysfunction in Patients With Head and
SO Physical therapy
LA English
DT Journal Article
DE Cancer; Head and neck neoplasms; Physical therapy; Rehabilitation; Systematic review
AB OBJECTIVE: Shoulder pain and dysfunction are highly prevalent after neck  dissection in the treatment of head and neck cancer (HNC). They can lead to  muscle weakness, limited range of motion, and shoulder tilt and pain, which can  reduce patient functioning. The purpose of this study was to evaluate the  effectiveness of rehabilitation interventions for shoulder dysfunction in  patients with surgically treated HNC. METHODS: A search of principal databases  (MEDLINE, Embase, CENTRAL, LILACS, IBECS, PEDro, and SciELO) was conducted, in  addition to hand searches and a search of gray literature, for all randomized  clinical trials (RCTs) published before February 2020. Two authors independently  selected all relevant studies. The 7 RCTs fulfilling all inclusion and exclusion  criteria were assessed for risk of bias and certainty of evidence using the  Cochrane Collaboration risk-of-bias tool and the Grading of Recommendations  Assessment, Development and Evaluation (GRADE) tool, respectively. RESULTS:  Moderate-certainty evidence suggests that progressive resistance training is  better than conventional treatment for improving pain and dysfunction in patients  with HNC (pooled data from 214 participants; mean difference = -5.92; 95%  CI = -11.38 to -0.45). Low-certainty evidence (data from 2 RCTs with 106  participants that could not be combined) suggests that acupuncture seems to be  more effective than conventional treatment. CONCLUSIONS: Progressive resistance  training is effective for improving shoulder pain and dysfunction in patients  with HNC. Further high-quality RCTs are needed to examine the effectiveness of  acupuncture for improving shoulder pain and dysfunction in these patients. Future  studies with longer follow-up times are needed to clarify the effects of early  postoperative intervention. IMPACT: Clinicians can have confidence that  progressive resistance training in patients with surgically treated HNC is  effective. LAY SUMMARY: These study results show that people with head and neck  cancer can benefit from gradually increased resistance training to reduce  shoulder pain and improve function. This study will help researchers design  clinical trials to determine whether treatments such as acupuncture and early  physical therapy also could be effective in treating this population.
C1 Biological and Health Sciences Department, Universidade Federal do Amapá, Rod. Juscelino Kubitschek, km-02 Jardim Marco Zero, Macapá, AP, CEP 68.903-419 Brazil.
   Discipline of Emergency and Evidence-Based Medicine, Universidade Federal de São Paulo, São Paulo, Brazil.
   Department of Physical Education, Instituto de Assistência Médica ao Servidor Público Estadual, São Paulo, São Paulo, Brazil.
   Fulbright Alumna at University of Pittsburgh, Pittsburgh, Pennsylvania, USA
   Biological and Health Sciences Department, Universidade Federal do Amapá.
NR 0
TC 0
SN 1538-672
EI 
J9 Phys Ther
PD AUG 5
PY 2020
VL 100
IS 11
BP 1997
EP 2008
DI 10.1093/ptj/pzaa147
PG 11
WC Head and Neck Neoplasms; complications; Humans; Muscle Weakness; etiology; Physical Therapy Modalities; Randomized Controlled Trials as Topic; Resistance Training; Shoulder Pain; etiology
UT PubMed:32750136
PM 32750136
DA 2020-08-05
ER

PT J
AU Jacobson, KA
   Reitman, ML
AF Jacobson, Kenneth A.
   Reitman, Marc L.
TI Adenosine-Related Mechanisms in Non-Adenosine Receptor Drugs
SO CELLS
LA English
DT Review
DE adenosine receptor; nucleoside transport; CNS; inflammation; cardiovascular system; pain
ID equilibrative nucleoside transporter; increases extracellular adenosine; a(1) receptors; a(2a) receptor; reperfusion injury; aica riboside; in-vivo; inhibition; involvement; mice
AB Many ligands directly target adenosine receptors (ARs). Here we review the effects of noncanonical AR drugs on adenosinergic signaling. Non-AR mechanisms include raising adenosine levels by inhibiting adenosine transport (e.g., ticagrelor, ethanol, and cannabidiol), affecting intracellular metabolic pathways (e.g., methotrexate, nicotinamide riboside, salicylate, and 5-aminoimidazole-4-carboxamide riboside), or undetermined means (e.g., acupuncture). However, other compounds bind ARs in addition to their canonical 'on-target' activity (e.g., mefloquine). The strength of experimental support for an adenosine-related role in a drug's effects varies widely. AR knockout mice are the 'gold standard' method for investigating an AR role, but few drugs have been tested on these mice. Given the interest in AR modulation for treatment of cancer, CNS, immune, metabolic, cardiovascular, and musculoskeletal conditions, it is informative to consider AR and non-AR adenosinergic effects of approved drugs and conventional treatments.
C1 [Jacobson, Kenneth A.] NIDDK, Mol Recognit Sect, Bioorgan Chem Lab, Bethesda, MD 20892 USA.
   [Reitman, Marc L.] NIDDK, Diabet Endocrinol & Obes Branch, NIH, Bethesda, MD 20892 USA.
C3 National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)
RP Jacobson, KA (corresponding author), NIDDK, Mol Recognit Sect, Bioorgan Chem Lab, Bethesda, MD 20892 USA.
EM kennethj@niddk.nih.gov; marc.reitman@nih.gov
FU NIH (NIDDK) [ZIADK031117, ZIADK075063]; National Institute of Diabetes and Digestive and Kidney Diseases [ZIADK075063, ZIADK075062, ZIADK031117] Funding Source: NIH RePORTER
CR Allard B, 2016, CURR OPIN PHARMACOL, V29, P7, DOI 10.1016/j.coph.2016.04.001
   Alnouri MW, 2015, PURINERG SIGNAL, V11, P389, DOI 10.1007/s11302-015-9460-9
   Ameyaw Elvis Ofori, 2016, JOURNAL OF BASIC AND CLINICAL PHYSIOLOGY AND PHARMACOLOGY, V27, P557, DOI 10.1515/jbcpp-2015-0108
   Amouzadeh HR, 2019, TRANSL ONCOL, V12, P1296, DOI 10.1016/j.tranon.2019.05.018
   Antonioli HGL, 2018, THE ADENOSINE RECEPTORS, V34, P499, DOI 10.1007/978-3-319- 90808-3_20
   Antonioli L, 2007, J PHARMACOL EXP THER, V322, P435, DOI 10.1124/jpet.107.122762
   Arruda MA, 2017, FRONT PHARMACOL, V8, P0, DOI 10.3389/fphar.2017.00908
   Azimzadeh K, 2017, PHARMACEUT BIOMED RE, V3, P17, DOI 10.29252/pbr.3.3.17
   Bai YS, 2011, CLIN EXP PHARMACOL P, V38, P658, DOI 10.1111/j.1440-1681.2011.05550.x
   Barczyk K, 2010, BLOOD, V116, P446, DOI 10.1182/blood-2009-10-247106
   Baxter GF, 2002, CARDIOVASC RES, V55, P483, DOI 10.1016/S0008-6363(02)00280-8
   BLARDI P, 1993, EUR J CLIN PHARMACOL, V44, P505, DOI 10.1007/BF00315554
   Boison D, 2013, PHARMACOL REV, V65, P906, DOI 10.1124/pr.112.006361
   Borroto-Escuela DO, 2019, J NEURAL TRANSM, V126, P455, DOI 10.1007/s00702-019-01969-2
   Borroto-Escuela DO, 2018, MOL NEUROBIOL, V55, P7038, DOI 10.1007/s12035-018-0887-1
   Boss M, 2016, SCI REP-UK, V6, P0, DOI 10.1038/srep32111
   Boswell-Casteel RC, 2017, NUCLEOS NUCLEOT NUCL, V36, P7, DOI 10.1080/15257770.2016.1210805
   Braganhol E, 2007, BBA-GEN SUBJECTS, V1770, P1352, DOI 10.1016/j.bbagen.2007.06.003
   Burnstock G, 2017, FRONT PHARMACOL, V8, P0, DOI 10.3389/fphar.2017.00661
   Burstein S, 2015, BIOORGAN MED CHEM, V23, P1377, DOI 10.1016/j.bmc.2015.01.059
   Calker D, 2005, NEUROCHEM RES, V30, P1205, DOI 10.1007/s11064-005-8792-1
   Camici M, 2018, INT J MOL SCI, V19, P0, DOI 10.3390/ijms19030784
   Carlin JL, 2017, NEUROPHARMACOLOGY, V114, P101, DOI 10.1016/j.neuropharm.2016.11.026
   Carreira MC, 2006, J ENDOCRINOL, V191, P147, DOI 10.1677/joe.1.06714
   Carrier EJ, 2006, P NATL ACAD SCI USA, V103, P7895, DOI 10.1073/pnas.0511232103
   Castillo A, 2010, NEUROBIOL DIS, V37, P434, DOI 10.1016/j.nbd.2009.10.023
   Cattaneo M, 2012, THROMB HAEMOSTASIS, V108, P1031, DOI 10.1160/TH12-08-0547
   Choi DS, 2004, NAT NEUROSCI, V7, P855, DOI 10.1038/nn1288
   Cronstein BN, 1999, P NATL ACAD SCI USA, V96, P6377, DOI 10.1073/pnas.96.11.6377
   Cunha MP, 2015, PURINERG SIGNAL, V11, P215, DOI 10.1007/s11302-015-9446-7
   Drury AN, 1929, J PHYSIOL-LONDON, V68, P213, DOI 10.1113/jphysiol.1929.sp002608
   Fang T, 2017, SCI REP-UK, V7, P0, DOI 10.1038/s41598-017-12689-6
   Ferré S, 2018, FRONT NEUROSCI-SWITZ, V11, P0, DOI 10.3389/fnins.2017.00722
   Fiebich BL, 1996, GLIA, V18, P152, DOI 10.1002/(SICI)1098-1136(199610)18:2<152::AID-GLIA7>3.0.CO;2-2
   Fong M, 2010, CIRC J, V74, P181, DOI 10.1253/circj.CJ-09-0372
   Fraser CM, 1997, EUR NEUROPSYCHOPHARM, V7, P267, DOI 10.1016/S0924-977X(97)00032-1
   Fredholm BB, 2007, CELL DEATH DIFFER, V14, P1315, DOI 10.1038/sj.cdd.4402132
   FRIES JF, 1993, ARCH INTERN MED, V153, P2465, DOI 10.1001/archinte.153.21.2465
   Futatsuki T, 2018, SCI REP-UK, V8, P0, DOI 10.1038/s41598-018-21252-w
   Gadalla AE, 2004, J NEUROCHEM, V88, P1272, DOI 10.1046/j.1471-4159.2003.02253.x
   Gadangi P, 1996, J IMMUNOL, V156, P1937
   Gandhi AV, 2015, NEURON, V85, P1193, DOI 10.1016/j.neuron.2015.02.016
   Gao ZG, 2018, THE RECEPTERS, V34, P59, DOI 10.1007/978-3-319-90808-3_4
   Gillespie RJ, 2008, BIOORG MED CHEM LETT, V18, P2916, DOI 10.1016/j.bmcl.2008.03.075
   Ginés S, 2000, P NATL ACAD SCI USA, V97, P8606, DOI 10.1073/pnas.150241097
   Goldfine AB, 2013, ANN INTERN MED, V159, P1, DOI 10.7326/0003-4819-159-1-201307020-00003
   Goldman N, 2010, NAT NEUROSCI, V13, P883, DOI 10.1038/nn.2562
   GRUBER HE, 1989, CIRCULATION, V80, P1400, DOI 10.1161/01.CIR.80.5.1400
   Guieu R, 1998, KIDNEY INT, V53, P200, DOI 10.1046/j.1523-1755.1998.00727.x
   Guo ZF, 2019, NAT CHEM, V11, P254, DOI 10.1038/s41557-018-0187-4
   Haskó G, 2008, NAT REV DRUG DISCOV, V7, P759, DOI 10.1038/nrd2638
   HAWKINS M, 1988, PHARMACOL BIOCHEM BE, V30, P303, DOI 10.1016/0091-3057(88)90459-5
   Hines DJ, 2013, TRANSL PSYCHIAT, V3, P0, DOI 10.1038/tp.2012.136
   Hoffmann K, 2013, EUR J PHARMACOL, V700, P152, DOI 10.1016/j.ejphar.2012.12.003
   Hu X, 2016, CELL REP, V16, P106, DOI 10.1016/j.celrep.2016.05.080
   Hughes V, 2018, BRIT J PHARMACOL, V175, P1471, DOI 10.1111/bph.14152
   Hur KY, 2015, J DIABETES INVEST, V6, P600, DOI 10.1111/jdi.12328
   HUTCHISON AJ, 1989, J PHARMACOL EXP THER, V251, P47
   Jacobson KA, 2002, ADV EXP MED BIOL, V505, P163
   Jacobson KA, 2020, PAIN, V161, P1425, DOI 10.1097/j.pain.0000000000001857
   Kalkan S, 2018, INT J PHARMACOL, V14, P116, DOI 10.3923/ijp.2018.116.120
   KAPLAN GB, 1992, J PHARM PHARMACOL, V44, P700, DOI 10.1111/j.2042-7158.1992.tb05502.x
   Kemeny-Beke A, 2007, PHARMACOL RES, V56, P124, DOI 10.1016/j.phrs.2007.04.017
   Kim HH, 2008, ARTERIOSCL THROM VAS, V28, PS39, DOI 10.1161/ATVBAHA.107.160226
   Kim Y, 2019, KOREAN J ANESTHESIOL, V72, P60, DOI 10.4097/kja.d.18.00022
   Knowles HJ, 2019, CELLS-BASEL, V8, P0, DOI 10.3390/cells8060624
   Kowaluk EA, 2000, J PHARMACOL EXP THER, V295, P1165
   Lanaspa MA, 2012, PLOS ONE, V7, P0, DOI 10.1371/journal.pone.0048801
   Le DE, 2020, AM J PHYSIOL-HEART C, V318, PH189, DOI 10.1152/ajpheart.00217.2019
   Li RWS, 2012, J CARDIOVASC PHARM, V59, P10, DOI 10.1097/FJC.0b013e31820eb788
   Liao HY, 2017, SCI REP-UK, V7, P0, DOI 10.1038/srep42531
   Liou GI, 2008, INVEST OPHTH VIS SCI, V49, P5526, DOI 10.1167/iovs.08-2196
   Liu J, 2013, EUR J PHARMACOL, V698, P213, DOI 10.1016/j.ejphar.2012.10.042
   Liu YG, 2001, CARDIOVASC DRUG REV, V19, P369, DOI 10.1111/j.1527-3466.2001.tb00076.x
   Lobato KR, 2008, PROG NEURO-PSYCHOPH, V32, P994, DOI 10.1016/j.pnpbp.2008.01.012
   Mackey JR, 1998, DRUG RESIST UPDATE, V1, P310, DOI 10.1016/S1368-7646(98)80047-2
   Martens CR, 2018, NAT COMMUN, V9, P0, DOI 10.1038/s41467-018-03421-7
   Martins DF, 2015, J PERIPHER NERV SYST, V20, P403, DOI 10.1111/jns.12149
   Martins DF, 2015, J NEUROSCI RES, V93, P157, DOI 10.1002/jnr.23461
   Masino SA, 2011, J CLIN INVEST, V121, P2679, DOI 10.1172/JCI57813
   Mazar J, 2005, ANESTHESIOLOGY, V102, P1174, DOI 10.1097/00000542-200506000-00017
   Mediero A, 2013, TRENDS ENDOCRIN MET, V24, P290, DOI 10.1016/j.tem.2013.02.001
   Meijer P, 2009, ARTERIOSCL THROM VAS, V29, P963, DOI 10.1161/ATVBAHA.108.179622
   Mittal SPK, 2016, BBA-GEN SUBJECTS, V1860, P2377, DOI 10.1016/j.bbagen.2016.07.005
   MOSER GH, 1989, AM J PHYSIOL, V256, PC799, DOI 10.1152/ajpcell.1989.256.4.C799
   Müller CE, 2011, BBA-BIOMEMBRANES, V1808, P1290, DOI 10.1016/j.bbamem.2010.12.017
   Naassila M, 2002, J NEUROSCI, V22, P10487
   NAGY LE, 1990, J BIOL CHEM, V265, P1946
   NEWBY AC, 1984, TRENDS BIOCHEM SCI, V9, P42, DOI 10.1016/0968-0004(84)90176-2
   Nylander S, 2013, J THROMB HAEMOST, V11, P1867, DOI 10.1111/jth.12360
   Okumura T, 2016, J NEUROL SCI, V362, P106, DOI 10.1016/j.jns.2016.01.031
   Ouyang JY, 2011, J BIOL CHEM, V286, P1, DOI 10.1074/jbc.M110.121806
   Paiva M, 2009, J CARDIOVASC PHARM, V53, P373, DOI 10.1097/FJC.0b013e31819fd4e7
   Parsons WJ, 1998, MOL PHARM, V33, P441
   PHILLIS JW, 1982, COMP BIOCHEM PHYS C, V72, P179, DOI 10.1016/0306-4492(82)90082-X
   Posadzki PP, 2018, BMC MED, V16, P0, DOI 10.1186/s12916-017-1000-8
   Rena G, 2017, DIABETOLOGIA, V60, P1577, DOI 10.1007/s00125-017-4342-z
   Ribeiro A, 2012, EUR J PHARMACOL, V678, P78, DOI 10.1016/j.ejphar.2011.12.043
   Ribeiro LR, 2017, TOXICOL APPL PHARM, V317, P41, DOI 10.1016/j.taap.2016.12.021
   Rodriguez D, 2016, ACS CHEM BIOL, V11, P2763, DOI 10.1021/acschembio.6b00357
   Ruby Christina L, 2010, CURR DRUG ABUSE REV, V3, P163
   Salloum FN, 2007, J MOL CELL CARDIOL, V43, P545, DOI 10.1016/j.yjmcc.2007.08.014
   Sandner-Kiesling A, 2001, ANESTHESIOLOGY, V95, P1455, DOI 10.1097/00000542-200112000-00026
   Schmidt K, 2010, EUR HEART J, V31, P1655, DOI 10.1093/eurheartj/ehp555
   Serchov T, 2015, NEURON, V87, P549, DOI 10.1016/j.neuron.2015.07.010
   Siddiqi SM, 1996, NUCLEOS NUCLEOT, V15, P693, DOI 10.1080/07328319608002416
   Silva RL, 2019, TOXICOL APPL PHARM, V368, P63, DOI 10.1016/j.taap.2019.02.011
   Singh L, 2018, KOREAN J PHYSIOL PHA, V22, P225, DOI 10.4196/kjpp.2018.22.3.225
   Smith RG, 2005, ENDOCR REV, V26, P346, DOI 10.1210/er.2004-0019
   Stolz ED, 2016, EVID-BASED COMPL ALT, V2016, P0, DOI 10.1155/2016/5890590
   STONE TW, 1979, NATURE, V281, P227, DOI 10.1038/281227a0
   STRIESSNIG J, 1985, EUR J BIOCHEM, V150, P67, DOI 10.1111/j.1432-1033.1985.tb08989.x
   Surendra H, 2013, J MOL CELL CARDIOL, V60, P142, DOI 10.1016/j.yjmcc.2013.04.010
   SWEENEY MI, 1987, EUR J PHARMACOL, V141, P169, DOI 10.1016/0014-2999(87)90428-6
   Terasaka T, 2004, J AM CHEM SOC, V126, P34, DOI 10.1021/ja038606l
   Tian HH, 2007, BULL HOSP JT DIS, V65, P168
   Tosh DK, 2019, J MED CHEM, V62, P1502, DOI 10.1021/acs.jmedchem.8b01662
   Uzbay TI, 2007, NEUROPSYCHOPHARMACOL, V32, P412, DOI 10.1038/sj.npp.1301143
   van den Berg TNA, 2014, PLOS ONE, V9, P0, DOI 10.1371/journal.pone.0111248
   Varani K, 2017, MEDIAT INFLAMM, V2017, P0, DOI 10.1155/2017/2740963
   Vecchio EA, 2018, BRIT J PHARMACOL, V175, P4036, DOI 10.1111/bph.14337
   Vincenzi F, 2018, ORTHOPAED P, V100, P35, DOI 10.1302/1358-992X.2018.15.035
   Wan TC, 2004, 4 INT S NUCLEOSIDES, V0, P0
   Wan TC, 2019, BIOCHEM PHARMACOL, V163, P21, DOI 10.1016/j.bcp.2019.01.022
   Wang ML, 2015, SCI REP-UK, V5, P0, DOI 10.1038/srep16107
   Wessels JAM, 2006, ARTHRITIS RHEUM, V54, P2830, DOI 10.1002/art.22032
   WILLIAMS M, 1981, CAN J PHYSIOL PHARM, V59, P897, DOI 10.1139/y81-136
   Xiao CY, 2019, PLOS BIOL, V17, P0, DOI 10.1371/journal.pbio.3000161
   Zakaria ZA, 2018, PAIN RES MANAG, V2018, P0, DOI 10.1155/2018/9536406
NR 129
TC 22
Z9 23
U1 2
U2 12
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
SN 
EI 2073-4409
J9 CELLS-BASEL
JI Cells
PD APR 15
PY 2020
VL 9
IS 4
BP 
EP 
DI 10.3390/cells9040956
PG 20
WC Cell Biology
SC Cell Biology
GA LR2XW
UT WOS:000535559500167
PM 32295065
DA 2026-01-16
ER

PT J
AU Zhang, RY
   Zhu, BF
   Wang, LK
   Song, Y
   Zhao, JG
   Guo, Y
   Zhao, L
   Chen, S
AF Zhang, Rong Yi
   Zhu, Ben Fan
   Wang, Li Kui
   Song, Yang
   Zhao, Jia Gui
   Guo, Yan
   Zhao, Long
   Chen, Shi
TI Electroacupuncture alleviates inflammatory pain via adenosine suppression and its
SO Arquivos de neuro-psiquiatria
LA English
DT Journal Article
AB BACKGROUND: Acupuncture has been widely used for alleviating pain. However, its  mechanisms remain largely enigmatic. OBJECTIVE: In the present study, we focused  on whether the analgesic effect of electroacupuncture is related to its  regulation on adenosine and substance P expression. METHODS: We established  chronic inflammatory pain model in rats through a single injection of Complete  Freund's Adjuvant, and then we treated animals using daily electroacupuncture. We  applied seven bilateral sessions of electroacupuncture (ST36 and BL60, 0.5 to 1.5  mA, initial strength of 0.5 mA, increased by 0.5 mA every 10 minutes, for 30  minutes per session, one section per day) to Complete Freund's Adjuvant rats for  seven days. The analgesic effect of electroacupuncture was evaluated by measuring  paw withdrawal threshold in rats that received mechanical and thermal  stimulation. RESULTS: Daily electroacupuncture stimulation effectively increased  paw withdrawal threshold in Complete Freund's Adjuvant rats. Electroacupuncture  increased the adenosine level in zusanli. A further study showed that  electroacupuncture could decrease substance P, neurokinin-1 receptor, tumor  necrosis factor-alpha, interleukin-1β, interleukin-6 and CD68 levels in dorsal  root ganglion. Interestingly, direct injection of adenosine A1 or substance P  receptor antagonists, or dorsal nerve root transection could significantly impair  electroacupuncture induced analgesic actions in Complete Freund's Adjuvant rats  could and reduce the levels of substance P, neurokinin-1 receptor, tumor necrosis  factor-alpha, interleukin-1β, interleukin-6 and CD68. Finally, we confirmed that  direct injection of adenosine A1 receptor agonist replicated the analgesic effect  of electroacupuncture. CONCLUSION: Our results indicate regulation of  adenosine-mediated substance P secretion. Substance P-mediated pathway may be  involved in the analgesia process by electroacupuncture in rats.
C1 Anhui Medical University, The First Affiliated Hospital, Department of Pain Management, Hefei, Anhui Province, China.
   Anhui Medical University, The First Affiliated Hospital, Department of Pain Management, Hefei, Anhui Province, China.
   Anhui Medical University, The First Affiliated Hospital, Department of Pain Management, Hefei, Anhui Province, China.
   Anhui Medical University, The First Affiliated Hospital, Department of Pain Management, Hefei, Anhui Province, China.
   Anhui Medical University, The First Affiliated Hospital, Department of Pain Management, Hefei, Anhui Province, China.
   Anhui Medical University, The First Affiliated Hospital, Department of Pain Management, Hefei, Anhui Province, China.
   Anhui Medical University, The First Affiliated Hospital, Department of Pain Management, Hefei, Anhui Province, China.
   Anhui Medical University, The First Affiliated Hospital, Department of Pain Management, Hefei, Anhui Province, China.
NR 0
TC 0
SN 1678-422
EI 
J9 Arq Neuropsiquiatr
PD NOV 5
PY 2020
VL 78
IS 10
BP 617
EP 623
DI 10.1590/0004-282X20200078
PG 6
WC Adenosine; chemistry; Animals; Electroacupuncture; Pain; Rats; Rats, Sprague-Dawley; Substance P; chemistry
UT PubMed:33146290
PM 33146290
DA 2020-11-05
ER

PT J
AU Wang, XQ
   Duan, PB
   Zheng, M
   Xu, Q
   Yang, LH
   Wang, AQ
AF Wang, Xiao-Qing
   Duan, Pei-Bei
   Zheng, Man
   Xu, Qian
   Yang, Li-Hua
   Wang, A-Qin
TI Perioperative auricular acupuncture technique via intradermal needling buried for postoperative movement-evoked pain after open radical gastrectomy: Study protocol for a pilot randomized controlled trial
SO EUROPEAN JOURNAL OF INTEGRATIVE MEDICINE
LA English
DT Article
DE Gastric cancer; Movement-evoked pain; Auricular acupuncture; Intradermal needling; Study protocol; Randomized controlled trial
ID adverse events; gastric-cancer; risk-factors; management; surgery; quality
AB Introduction: Auricular acupuncture has been used for pain management but a more recent technique which buries an intradermal needle into the skin may provide longer lasting stimulation and enhance analgesia. The purpose of this study was to evaluate the efficacy and feasibility of perioperative auricular acupuncture technique via intradermal needling buried on postoperative movement-evoked pain reduction in patients with advanced gastric cancer following open radical gastrectomy. Methods: This research is a protocol for a prospective, assessor- and analyst-blinded, randomized controlled pilot trial with two parallel groups. Forty patients who undergo elective open radical gastrectomy will be recruited from 210-bed oncology surgery ward at a 2500-bed medical center between 2019/8/23 and 2020/2/20. Patients will be randomized to either the control group receiving non-invasive sham auricular acupuncture or to the experimental group receiving auricular acupuncture technique via intradermal needling buried, delivered 24 h before surgery and retained & replaced every 3 days for 6 consecutive days. A standard general anesthetic technique will be used for both groups. Rescue analgesia will be given when the VAS score is >= 4. Primary outcome measures are Functional Activity Score (FAS) and Numerical Rating Scale score (NRS) for movementevoked pain. Secondary outcome measures are NRS score for pain at rest, use of rescues analgesic, total opioid consumption, postoperative nausea and vomiting, physiological recovery Outcomes, Quality of Recovery-9 (QoR-9) and patient's satisfaction. Ethics and dissemination: This protocol has been approved by the Institutional Review Board (IRB) of the Clinical Research Centre (Affiliated Hospital of Nanjing University of Chinese Medicine, IRB No. 2019NL-032-02). In addition, the results of the preliminary study will be disseminated through peer-reviewed publications.
C1 [Wang, Xiao-Qing; Zheng, Man; Xu, Qian] Nanjing Univ Chinese Med, Jiangsu Prov Hosp Chinese Med, Affiliated Hosp, Anesthesiol & Pain Med, 155 Hanzhong Rd, Nanjing 210029, Jiangsu, Peoples R China.
   [Duan, Pei-Bei] Nanjing Univ Chinese Med, Jiangsu Prov Hosp Chinese Med, Dept Nursing, Affiliated Hosp, 155 Hanzhong Rd, Nanjing 210029, Jiangsu, Peoples R China.
   [Yang, Li-Hua] Nanjing Univ Chinese Med, Jiangsu Prov Hosp Chinese Med, Dept Oncol, Affiliated Hosp, 155 Hanzhong Rd, Nanjing 210029, Jiangsu, Peoples R China.
   [Wang, A-Qin] Nanjing Univ Chinese Med, Sch Nursing, 138 Xianlin Rd, Nanjing 210046, Jiangsu, Peoples R China.
C3 Nanjing University of Chinese Medicine; Nanjing University of Chinese Medicine; Nanjing University of Chinese Medicine; Nanjing University of Chinese Medicine
RP Zheng, M (corresponding author), Nanjing Univ Chinese Med, Jiangsu Prov Hosp Chinese Med, Affiliated Hosp, Anesthesiol & Pain Med, 155 Hanzhong Rd, Nanjing 210029, Jiangsu, Peoples R China.; Duan, PB (corresponding author), Nanjing Univ Chinese Med, Jiangsu Prov Hosp Chinese Med, Dept Nursing, Affiliated Hosp, 155 Hanzhong Rd, Nanjing 210029, Jiangsu, Peoples R China.
EM wangxiaoqing319@126.com; dpb_58@163.com; man_zheng@sina.com; xuqian36@126.com; yanglihua17@sina.com; 1078651915@qq.com
FU Affiliated Hospital of Nanjing University of Chinese Medicine [Y19074]
CR Unknown -, 2005, ACUTE PAIN MANAGEMENT PERFORMANCE MEASUREMENT TOOLKIT, V0, P0
   Argoff CE, 2014, PAIN PRACT, V14, P477, DOI 10.1111/papr.12108
   Asher GN, 2010, J ALTERN COMPLEM MED, V16, P1097, DOI 10.1089/acm.2009.0451
   Bang YJ, 2012, LANCET, V379, P315, DOI 10.1016/S0140-6736(11)61873-4
   Beloeil H, 2016, J VISC SURG, V153, PS15, DOI 10.1016/j.jchirv.2016.09.003
   Bijur PE, 2003, ACAD EMERG MED, V10, P390, DOI 10.1197/aemj.10.4.390
   Boutron I, 2008, ANN INTERN MED, V148, P295, DOI 10.7326/0003-4819-148-4-200802190-00008
   Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21609
   Breivik H, 2008, BRIT J ANAESTH, V101, P17, DOI 10.1093/bja/aen103
   Chan MTV, 2008, ANESTH ANALG, V107, P1189, DOI 10.1213/ane.0b013e318184b94e
   Chen W Q, 2018, ZHONGHUA ZHONG LIU ZA ZHI, V40, P5, DOI 10.3760/cma.j.issn.0253-3766.2018.01.002
   Chung KF, 2015, CLIN J PAIN, V31, P922, DOI 10.1097/AJP.0000000000000189
   Chung KF, 2014, ACUPUNCT MED, V32, P455, DOI 10.1136/acupmed-2014-010635
   Devin CJ, 2015, J CLIN NEUROSCI, V22, P930, DOI 10.1016/j.jocn.2015.01.003
   Dowell Deborah, 2016, JAMA, V315, P1624, DOI 10.15585/mmwr.rr6501e1
   Emanuel EJ, 2013, LANCET, V381, P1532, DOI 10.1016/S0140-6736(13)60970-8
   Coura LEF, 2011, ACUPUNCT MED, V29, P16, DOI 10.1136/aim.2010.003251
   Ferlay J, 2019, INT J CANCER, V144, P1941, DOI 10.1002/ijc.31937
   Ferlay J, 2015, INT J CANCER, V136, PE359, DOI 10.14343/jcscr.2016.4e1003
   Fletcher D, 2008, PAIN, V137, P441, DOI 10.1016/j.pain.2008.02.026
   Furuse N, 2017, MED ACUPUNCT, V29, P155, DOI 10.1089/acu.2017.1230
   Gerbershagen HJ, 2014, ANESTHESIOLOGY, V120, P1237, DOI 10.1097/ALN.0000000000000108
   Gerbershagen HJ, 2013, ANESTHESIOLOGY, V118, P934, DOI 10.1097/ALN.0b013e31828866b3
   Hamashima C, 2014, WORLD J GASTROENTERO, V20, P13767, DOI 10.3748/wjg.v20.i38.13767
   Hawker GA, 2011, ARTHRIT CARE RES, V63, PS240, DOI 10.1002/acr.20543
   Holzer A, 2011, MINERVA ANESTESIOL, V77, P298
   Karimi P, 2014, CANCER EPIDEM BIOMAR, V23, P700, DOI 10.1158/1055-9965.EPI-13-1057
   Kehlet H, 2006, LANCET, V367, P1618, DOI 10.1016/S0140-6736(06)68700-X
   Khalili G, 2013, J CLIN ANESTH, V25, P188, DOI 10.1016/j.jclinane.2012.09.004
   Lorenz KA, 2009, J AM BOARD FAM MED, V22, P291, DOI 10.3122/jabfm.2009.03.080162
   MacPherson H, 2004, QUAL SAF HEALTH CARE, V13, P349, DOI 10.1136/qshc.2003.009134
   MacPherson Hugh, 2010, J EVID BASED MED, V3, P140, DOI 10.1111/j.1756-5391.2010.01086.x
   Meissner W, 2017, DTSCH ARZTEBL INT, V114, P161, DOI 10.3238/arztebl.2017.0161
   Melchart D, 2004, ARCH INTERN MED, V164, P104, DOI 10.1001/archinte.164.1.104
   Miclescu A, 2017, SCAND J PAIN, V16, P204, DOI 10.1016/j.sjpain.2017.04.072
   Mitra S, 2018, CURR PAIN HEADACHE R, V22, P0, DOI 10.1007/s11916-018-0690-8
   Nogier R, 2014, MED ACUPUNCT, V26, P76, DOI 10.1089/acu.2014.1035
   Radnovich R, 2014, POSTGRAD MED, V126, P59, DOI 10.3810/pgm.2014.07.2784
   Schug SA, 2016, MED J AUSTRALIA, V204, P315, DOI 10.5694/mja16.00133
   Srikandarajah S, 2011, PAIN, V152, P1734, DOI 10.1016/j.pain.2011.02.008
   Tan JY, 2014, EVID-BASED COMPL ALT, V2014, P0, DOI 10.1155/2014/506758
   Usichenko TI, 2008, ANAESTHESIA, V63, P1343, DOI 10.1111/j.1365-2044.2008.05632.x
   Vincent C, 1990, COMPLEMENTARY MEDICAL RESEARCH, V4, P8
   Wan Lai-Siqi, 2013, ZHONGGUO ZHEN JIU, V33, P237
   White PF, 2010, ANESTHESIOLOGY, V112, P220, DOI 10.1097/ALN.0b013e3181c6316e
   Witt CM, 2009, FORSCH KOMPLEMENTMED, V16, P91, DOI 10.1159/000209315
   Yang XY, 2015, BRIT J ANAESTH, V115, P883, DOI 10.1093/bja/aev352
NR 49
TC 1
Z9 1
U1 1
U2 27
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1876-3820
EI 1876-3839
J9 EUR J INTEGR MED
JI Eur. J. Integr. Med.
PD JAN 15
PY 2020
VL 33
IS 
BP 
EP 
DI 10.1016/j.eujim.2019.101034
PG 7
WC Integrative & Complementary Medicine
SC Integrative & Complementary Medicine
GA LD6DP
UT WOS:000526121000024
DA 2026-01-16
ER

PT J
AU Yang, J
   Xu, GX
   Yin, ZH
   Cheng, Y
   Sun, SM
   Zheng, QH
   Chen, J
   Liang, FR
   Zhao, L
AF Yang, Jiao
   Xu, Guixing
   Yin, Zihan
   Cheng, Ying
   Sun, Sheng Ming
   Zheng, Qianhua
   Chen, Jiao
   Liang, Fan-rong
   Zhao, Ling
TI Acupuncture for chronic cancer-related pain: a systematic review and network meta-analysis protocol
SO BMJ OPEN
LA English
DT Review
DE anaesthesia in oncology; complementary medicine; pain management
ID multiple-treatments; breast-cancer; quality; prevalence; predictors; management
AB Introduction Chronic cancer-related pain is one of the most common excruciating symptom that can be caused by the cancer (by the primary tumour or by metastases) or by its treatment (surgery, chemotherapy and radiotherapy). Although multiple clinical trials and systematic reviews have suggested that acupuncture could be effective in treating chronic cancer-related pain, the comparative efficacy and safety of these acupuncture methods remains unclear. We, therefore, performed this study to evaluate and rank the efficacy and safety of different acupuncture methods for chronic cancer-related pain. Methods and analysis Seven databases will be searched, including Cochrane Library, MEDLINE, Embase, Chinese National Knowledge Infrastructure (CNKI), Wanfang Database, the Chongqing VIP Chinese Science and Technology Periodical Database and Chinese Biomedical Literature Database (CBM) from their inception to March 2020. The primary outcome is the change of pain intensity. Bayesian network meta-analysis will be conducted using software R3.5.1. Finally, we will use the Grading of Recommendations Assessment, Development and Evaluation System (GRADE) to assess the quality of evidence. Ethics and dissemination Ethical approval is not required for literature-based studies. The results will be disseminated through peer-reviewed publication. PROSPERO registration number CRD42020165747
C1 [Yang, Jiao; Xu, Guixing; Yin, Zihan; Cheng, Ying; Sun, Sheng Ming; Zheng, Qianhua; Chen, Jiao; Liang, Fan-rong; Zhao, Ling] Chengdu Univ Tradit Chinese Med, Acupuncture & Tuina Sch, Chengdu, Sichuan, Peoples R China.
C3 Chengdu University of Traditional Chinese Medicine
RP Liang, FR; Zhao, L (corresponding author), Chengdu Univ Tradit Chinese Med, Acupuncture & Tuina Sch, Chengdu, Sichuan, Peoples R China.
EM acuresearch@126.com; zhaoling@cdutcm.edu.cn
FU National Key Research and Development Program [2019YFC1709701]; National Natural Science Foundation of China [81590951, 81973962]; Project of Science and Technology Department of Sichuan Province [20ZDYF1199, 2019YFS0081]
CR American College of Chest Physicians, 2007, J ALTERN COMPLEMENT, V13, P1049, DOI 10.1089/acm.2007.0703
   Benyamin R, 2008, PAIN PHYSICIAN, V11, P0
   Brown MRD, 2014, BRIT J PAIN, V8, P139, DOI 10.1177/2049463714542605
   Burton AW, 2007, PAIN MED, V8, P189, DOI 10.1111/j.1526-4637.2006.00220.x
   Caldwell DM, 2005, BMJ-BRIT MED J, V331, P897, DOI 10.1136/bmj.331.7521.897
   Chaimani A, 2013, PLOS ONE, V8, P0, DOI 10.1371/journal.pone.0076654
   Choi TY, 2012, SUPPORT CARE CANCER, V20, P1147, DOI 10.1007/s00520-012-1432-9
   Cipriani A, 2013, ANN INTERN MED, V159, P130, DOI 10.7326/0003-4819-159-2-201307160-00008
   Deng G, 2005, CA-CANCER J CLIN, V55, P109, DOI 10.3322/canjclin.55.2.109
   Edirisinghe NP, 2019, PAIN RES MANAG, V2019, P0, DOI 10.1155/2019/5050979
   Everdingen MHJVDBV, 2007, ANN ONCOL, V18, P1437, DOI 10.1093/annonc/mdm056
   Fallon M, 2018, ANN ONCOL, V29, P166, DOI 10.1093/annonc/mdy152
   Fortner BV, 2002, J PAIN, V3, P38, DOI 10.1054/jpai.2002.27136
   Giacalone A, 2012, CANCER-AM CANCER SOC, V118, P1955, DOI 10.1002/cncr.26443
   Guyatt GH, 2011, J CLIN EPIDEMIOL, V64, P380, DOI 10.1016/j.jclinepi.2010.09.011
   Haidich AB, 2010, HIPPOKRATIA, V14, P29
   Ham OK, 2017, WESTERN J NURS RES, V39, P1547, DOI 10.1177/0193945916672663
   Hamood R, 2018, BREAST CANCER RES TR, V167, P157, DOI 10.1007/s10549-017-4485-0
   He YH, 2020, JAMA ONCOL, V6, P271, DOI 10.1001/jamaoncol.2019.5233
   Hershman DL, 2018, JAMA-J AM MED ASSOC, V320, P167, DOI 10.1001/jama.2018.8907
   Higgins Julian P T, 2011, BMJ, V343, Pd5928, DOI 10.1136/bmj.d5928
   Huang ZR, 2020, J PAIN SYMPTOM MANAG, V59, P829, DOI 10.1016/j.jpainsymman.2019.11.003
   Hutton B, 2015, ANN INTERN MED, V162, P777, DOI 10.7326/M14-2385
   Johnson JR, 2010, J PAIN SYMPTOM MANAG, V39, P167, DOI 10.1016/j.jpainsymman.2009.06.008
   Lu W, 2018, CANCER BIOTHER RADIO, V33, P176, DOI 10.1089/cbr.2017.2425
   Luce BR, 1999, HEALTH ECON, V8, P187, DOI 10.1002/(SICI)1099-1050(199905)8:3<187::AID-HEC434>3.3.CO;2-D
   MacPherson H, 2017, PAIN, V158, P784, DOI 10.1097/j.pain.0000000000000747
   Paley CA, 2015, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD007753.pub3
   Peng Hao, 2010, ZHONG XI YI JIE HE XUE BAO, V8, P501
   Portenoy RK, 2018, HEMATOL ONCOL CLIN N, V32, P371, DOI 10.1016/j.hoc.2018.01.002
   Reis-Pina P, 2017, J PAIN RES, V10, P2097, DOI 10.2147/JPR.S139715
   Richardson MA, 2000, J CLIN ONCOL, V18, P2505, DOI 10.1200/JCO.2000.18.13.2505
   Ruela LD, 2018, REV ESC ENFERM USP, V52, P0, DOI 10.1590/S1980-220X2017040503402
   Salanti G, 2014, PLOS ONE, V9, P0, DOI 10.1371/journal.pone.0099682
   Salanti G, 2012, RES SYNTH METHODS, V3, P80, DOI 10.1002/jrsm.1037
   Sanford NN, 2019, CANCER-AM CANCER SOC, V125, P4310, DOI 10.1002/cncr.32450
   Schünemann HJ, 2008, BMJ-BRIT MED J, V336, P1106, DOI 10.1136/bmj.39500.677199.AE
   Shamseer L, 2015, BMJ-BRIT MED J, V349, P0, DOI 10.1136/bmj.g7647
   Spiegelhalter DJ, 2004, BAYESIAN APPROACHES, V22, P80
   Swarm RA, 2019, JNCCN, V11, P992
   Treede RD, 2019, PAIN, V160, P19, DOI 10.1097/j.pain.0000000000001384
   Wiffen PJ, 2017, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD012592.pub2
   Zhang J, 2019, MED SCI MONITOR, V25, P1275, DOI 10.12659/MSM.912632
   Zhao L, 2019, JAMA INTERN MED, V179, P1388, DOI 10.1001/jamainternmed.2019.2407
   Zhao L, 2017, JAMA INTERN MED, V177, P508, DOI 10.1001/jamainternmed.2016.9378
NR 45
TC 1
Z9 2
U1 0
U2 17
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 2044-6055
EI 
J9 BMJ OPEN
JI BMJ Open
PD JUN 15
PY 2020
VL 10
IS 10
BP 
EP 
DI 10.1136/bmjopen-2020-039087
PG 6
WC Medicine, General & Internal
SC General & Internal Medicine
GA OI5DD
UT WOS:000583298100015
PM 33033027
DA 2026-01-16
ER

PT J
AU Schnyer, RN
   Hullender, Rubin L
AF Schnyer, Rosa N
   Hullender Rubin, Lee
TI Overcoming Barriers in Clinical Acupuncture Research: Translating Clinical
SO Medical acupuncture
LA English
DT Journal Article
DE acupuncture; chronic illness management; dose response; hypothesis-driven outcomes; interprofessional teams
AB Background: The translation of clinical practice into research presents unique  challenges. This is especially the case in evaluating the effect of interventions  in the management of chronic conditions such as pain, mental health, substance  misuse, and oncology care. Chronic complex conditions might respond to different  strategies at different points in time and may require an interdisciplinary  approach to treatment. Objectives: To define the key barriers to the design,  implementation, and evaluation of clinical trials of acupuncture that derive from  a unidirectional translational research strategy. Results: Critical challenges to  the design, implementation, and evaluation of clinical trials of acupuncture  center around four areas: (1) insufficient early phase research, (2) suboptimal  treatment protocols, (3) inadequate research questions, and 4) a narrowed  assessment of outcomes. Conclusions: By promoting research priorities that  reflect the complex nature of chronic illness, we can more clearly articulate  research questions that better reflect clinical practice, while evaluating the  impact of acupuncture in patient care. Key priorities include phase I research  funding opportunities, pragmatic trials that evaluate acupuncture embedded in  interprofessional teams, and the inclusion of hypothesis-driven secondary  outcomes.
C1 School of Nursing, University of Texas, Austin, TX, USA.
   Osher Center for Integrative Medicine, University of California, San Francisco, San Francisco, CA, USA.
NR 0
TC 0
SN 1933-659
EI 1933-658
J9 Med Acupunct
PD DEC 29
PY 2020
VL 32
IS 6
BP 388
EP 390
DI 10.1089/acu.2020.1479
PG 2
UT PubMed:33362894
PM 33362894
DA 2020-12-29
ER

PT J
AU Childress, MA
   Stuek, SJ
AF Childress, Marc A.
   Stuek, Samantha Jayne
TI Neck Pain: Initial Evaluation and Management
SO AMERICAN FAMILY PHYSICIAN
LA English
DT Article
ID low-back-pain; cervical radiculopathy; diagnostic-accuracy; epidemiology; myelopathy; population; placebo; tests
AB Neck pain is a common presenting symptom in the primary care setting and causes significant disability. The broad differential diagnosis requires an efficient but global assessment; therefore, emphasis is typically placed on red flags that can assist in the early recognition and treatment of more concerning diagnoses, such as traumatic injuries, infection, malignancy, vascular emergencies, and other inflammatory conditions. The critical element in appropriate diagnosis and management of these conditions is an accurate patient history. Physical examination findings complement and refine diagnostic cues from the history but often lack the specificity to be of value independently. Diagnostic tools such as imaging and electrodiagnostic tests have variable utility, especially in chronic or degenerative conditions. Treatment of mechanical or nonneuropathic neck pain includes short-term use of medications and possibly injections. However, long-term data for these interventions are limited. Acupuncture and other complementary and alternative therapies may be helpful in some cases. Advanced imaging and surgical evaluation may be warranted for patients with worsening neurologic function or persistent pain. (Copyright (C) 2020 American Academy of Family Physicians.)
C1 [Childress, Marc A.; Stuek, Samantha Jayne] Virginia Commonwealth Univ Fairfax Family Practic, 3650 Joseph Siewick Dr,Ste 400, Fairfax, VA 22033 USA.
RP Childress, MA (corresponding author), Virginia Commonwealth Univ Fairfax Family Practic, 3650 Joseph Siewick Dr,Ste 400, Fairfax, VA 22033 USA.
EM mchildress@ffpcs.com
CR Bono CM, 2011, SPINE J, V11, P64, DOI 10.1016/j.spinee.2010.10.023
   Bronfort G, 2012, ANN INTERN MED, V156, P1, DOI 10.7326/0003-4819-156-1-201201030-00002
   Childress MA, 2016, AM FAM PHYSICIAN, V93, P746
   Chou R, 2009, LANCET, V373, P463, DOI 10.1016/S0140-6736(09)60172-0
   Cohen SP, 2017, BMJ-BRIT MED J, V358, P0, DOI 10.1136/bmj.j3221
   Cohen SP, 2015, MAYO CLIN PROC, V90, P284, DOI 10.1016/j.mayocp.2014.09.008
   Cook C, 2009, J ORTHOP SPORT PHYS, V39, P172, DOI 10.2519/jospt.2009.2938
   Davies BM, 2018, BMJ-BRIT MED J, V360, P0, DOI 10.1136/bmj.k186
   Duehmke RM, 2017, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD003726.pub4
   Finnerup NB, 2015, LANCET NEUROL, V14, P162, DOI 10.1016/S1474-4422(14)70251-0
   Friedman BW, 2015, JAMA-J AM MED ASSOC, V314, P1572, DOI 10.1001/jama.2015.13043
   Gattie ER, 2017, JMIR RES PROTOC, V6, P0, DOI 10.2196/resprot.7980
   Ghasemi M, 2013, J RES MED SCI, V18, P0
   Grijalva RA, 2015, SPINE, V40, P475, DOI 10.1097/BRS.0000000000000794
   Gross A, 2015, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD004249.pub4
   HONET JC, 1976, ARCH PHYS MED REHAB, V57, P12
   Kroeling P, 2013, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD004251.pub5
   Laiho K, 2002, CLIN RHEUMATOL, V21, P227, DOI 10.1007/PL00011222
   Langevin P, 2011, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD008626.pub2
   Lazennec JY, 2015, ORTHOP TRAUMATOL-SUR, V101, P507, DOI 10.1016/j.otsr.2015.02.005
   Liu R, 2017, REGION ANESTH PAIN M, V42, P52, DOI 10.1097/AAP.0000000000000505
   Malmivaara A, 2003, COCHRANE DATABASE SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD004058
   Manchikanti L, 2015, PAIN PHYSICIAN, V18, PE535, DOI 10.36076/ppj.2015/18/e535
   Matsumoto M, 1998, J BONE JOINT SURG BR, V80B, P19, DOI 10.1302/0301-620X.80B1.7929
   Murray CJL, 2013, JAMA-J AM MED ASSOC, V310, P591, DOI 10.1001/jama.2013.13805
   Nouri A, 2015, SPINE, V40, PE675, DOI 10.1097/BRS.0000000000000913
   RADHAKRISHNAN K, 1994, BRAIN, V117, P325, DOI 10.1093/brain/117.2.325
   Räsänen P, 2006, J NEUROSURG-SPINE, V5, P204, DOI 10.3171/spi.2006.5.3.204
   Rubinstein SM, 2007, EUR SPINE J, V16, P307, DOI 10.1007/s00586-006-0225-6
   Smith AD, 2013, BMC MUSCULOSKEL DIS, V14, P0, DOI 10.1186/1471-2474-14-313
   Stenneberg MS, 2017, ARCH PHYS MED REHAB, V98, P1407, DOI 10.1016/j.apmr.2016.10.003
   Trinh K, 2016, COCHRANE DATABASE SY, V0, P0
   Vasseljen O, 2013, PAIN, V154, P1237, DOI 10.1016/j.pain.2013.03.032
   Young WF, 2000, AM FAM PHYSICIAN, V62, P1064
   Young WF, 2001, AM FAM PHYSICIAN, V63, P1916
NR 36
TC 31
Z9 41
U1 0
U2 8
PU AMER ACAD FAMILY PHYSICIANS
PI KANSAS CITY
PA 8880 WARD PARKWAY, KANSAS CITY, MO 64114-2797 USA
SN 0002-838X
EI 1532-0650
J9 AM FAM PHYSICIAN
JI Am. Fam. Physician
PD AUG 1
PY 2020
VL 102
IS 3
BP 150
EP 156
DI 
PG 7
WC Primary Health Care; Medicine, General & Internal
SC General & Internal Medicine
GA NM3GN
UT WOS:000567988500007
PM 32735440
DA 2026-01-16
ER

PT J
AU Bae, K
   Song, SY
AF Bae, Kyeore
   Song, Si Yeon
TI Comparison of the clinical effectiveness of treatments for aromatase inhibitor-induced arthralgia in breast cancer patients: a protocol for a systematic review and network meta-analysis
SO BMJ OPEN
LA English
DT Article
ID controlled-trial; risk-factors; joint pain; therapy; placebo; multicenter; anastrozole; symptoms; omega-3-fatty-acids; acupuncture
AB Introduction Aromatase inhibitor-induced arthralgia (AIA) is a major adverse event of aromatase inhibitors (AIs) and leads to premature discontinuation of AI therapy in breast cancer patients. The objective of this protocol for a systematic review and network meta-analysis (NMA) is to provide the methodology to compare the change in pain intensity between different AIA treatments and demonstrate the rank probabilities for different treatments by combining all available direct and indirect evidence. Methods and analysis PubMed, the Cochrane Controlled Register of Trials (CENTRAL), EMBASE, Web of Science and ClinicalTrials.gov will be searched to identify publications in English from inception to November 2019. We will include randomised controlled trials (RCTs) assessing the effects of different treatments for AIA in postmenopausal women with stage 0-III hormone receptor-positive breast cancer. The primary endpoints will be the change in patient-reported pain intensity from baseline to post-treatment. The number of adverse events will be presented as a secondary outcome. Both pairwise meta-analysis and NMA with the Frequentist approach will be conducted. We will demonstrate summary estimates with forest plots in meta-analysis and direct and mixed evidence with a ranking of the treatments as the P-score in NMA. The revised Cochrane risk-of-bias tool for randomised trials will be used to assess the methodological quality within individual RCTs. The quality of evidence will be assessed. Ethics and dissemination As this review does not involve individual patients, ethical approval is not required. The results of this systematic review and NMA will be published in a peer-reviewed journal. This review will provide valuable information on AIA therapeutic options for clinicians, health practitioners and breast cancer survivors.
C1 [Bae, Kyeore] Kwanghye Hosp, Ctr Immun & Pain, Dept Integrat Med, Seoul, South Korea.
   [Song, Si Yeon] Daejeon Univ, East West Canc Ctr, Dunsan Korean Med Hosp, Daejeon, South Korea.
C3 Daejeon University
RP Bae, K (corresponding author), Kwanghye Hosp, Ctr Immun & Pain, Dept Integrat Med, Seoul, South Korea.
EM kyeorebae@gmail.com
FU [MIMIC2019-RS07]
CR Aydiner A, 2013, BREAST, V22, P121, DOI 10.1016/j.breast.2013.01.014
   Beckwée D, 2017, SUPPORT CARE CANCER, V25, P1673, DOI 10.1007/s00520-017-3613-z
   Borenstein M, 2009, INTRODUCTION TO META-ANALYSIS, V0, PP221, DOI 10.1002/9780470743386.CH23
   Breivik H, 2008, BRIT J ANAESTH, V101, P17, DOI 10.1093/bja/aen103
   Burstein HJ, 2019, J CLIN ONCOL, V37, P423, DOI 10.1200/JCO.18.01160
   Burstein HJ, 2010, J CLIN ONCOL, V28, P3784, DOI 10.1200/JOP.000082
   Coleman RE, 2008, CANCER TREAT REV, V34, P275, DOI 10.1016/j.ctrv.2007.10.004
   Egawa C, 2016, INT J CLIN ONCOL, V21, P262, DOI 10.1007/s10147-015-0905-5
   Ferlay J, 2018, EUR J CANCER, V103, P356, DOI 10.1016/j.ejca.2018.07.005
   FOLLMANN D, 1992, J CLIN EPIDEMIOL, V45, P769, DOI 10.1016/0895-4356(92)90054-Q
   Guyatt GH, 2008, BRIT MED J, V336, P924, DOI 10.1136/bmj.39489.470347.AD
   Hadji P, 2014, ANN ONCOL, V25, P372, DOI 10.1093/annonc/mdt513
   Han JS, 2011, NEUROSCI BIOBEHAV R, V35, P680, DOI 10.1016/j.neubiorev.2010.08.006
   Henry NL, 2018, J CLIN ONCOL, V36, P326, DOI 10.1200/JCO.2017.74.6651
   Hershman DL, 2018, JAMA-J AM MED ASSOC, V320, P167, DOI 10.1001/jama.2018.8907
   Hershman DL, 2015, J CLIN ONCOL, V33, P1910, DOI 10.1200/JCO.2014.59.5595
   Hershman DL, 2010, J CLIN ONCOL, V28, P4120, DOI 10.1200/JCO.2009.25.9655
   Higgins JPT, 2011, BMJ-BRIT MED J, V343, P0, DOI 10.1136/bmj.d5928
   Hozo S, 2005, BMC MED RES METHODOL, V5, P13, DOI 10.1186/1471-2288-5-13
   International Agency for Research on Cancer, 2019, IARC CANC MORT DAT, V0, P0
   Jansen JP, 2014, VALUE HEALTH, V17, P157, DOI 10.1016/j.jval.2014.01.004
   Jung KW, 2019, CANCER RES TREAT, V51, P431, DOI 10.4143/crt.2019.139
   Kadic AJ, 2016, J CLIN EPIDEMIOL, V74, P119, DOI 10.1016/j.jclinepi.2016.01.002
   Kanematsu M, 2011, BMC CANCER, V11, P0, DOI 10.1186/1471-2407-11-436
   Karmakar M, 2017, BREAST CANCER-BASIC, V11, P1, DOI 10.1177/1178223417694520
   Kim TH, 2018, MATURITAS, V118, P29, DOI 10.1016/j.maturitas.2018.09.005
   Langevin HM, 2011, EVID-BASED COMPL ALT, V2011, P0, DOI 10.1155/2011/180805
   Li YF, 2017, EVID-BASED COMPL ALT, V2017, P0, DOI 10.1155/2017/2478565
   Linde K, 2010, FORSCH KOMPLEMENTMED, V17, P259, DOI 10.1159/000320374
   Lopez-Lopez JA, 2018, RES SYNTH METHODS, V9, P336, DOI 10.1002/jrsm.1310
   Lu G, 2004, STAT MED, V23, P3105, DOI 10.1002/sim.1875
   Lustberg MB, 2018, BREAST CANCER RES TR, V167, P709, DOI 10.1007/s10549-017-4559-z
   Mao JJ, 2009, CANCER, V115, P3631, DOI 10.1002/cncr.24419
   Menas Pamela, 2012, J ONCOL PHARM PRACT, V18, P387, DOI 10.1177/1078155211434853
   Moxley G, 2010, CLIN BREAST CANCER, V10, P144, DOI 10.3816/CBC.2010.n.019
   Nahm Nicole, 2018, ASIA PAC J CLIN ONCOL, V14, P374, DOI 10.1111/ajco.12845
   Nasser Mona, 2020, AM J PUBLIC HEALTH, V110, P753, DOI 10.2105/AJPH.2020.305609
   Paley CA, 2015, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD007753.pub3
   Polanin JR, 2016, CAMPBELL METHODS POL, V0, P0
   Puhan MA, 2014, BMJ-BRIT MED J, V349, P0, DOI 10.1136/bmj.g5630
   Roberts K, 2017, CRIT REV ONCOL HEMAT, V111, P66, DOI 10.1016/j.critrevonc.2017.01.010
   Rucker G, 2019, R PACKAGE VERSION 1.0-1, V0, P0
   Shamseer L, 2015, BMJ-BRIT MED J, V349, P0, DOI 10.1136/bmj.g7647
   Shi QL, 2013, J PAIN, V14, P290, DOI 10.1016/j.jpain.2012.11.010
   Sterne JAC, 2019, BMJ-BRIT MED J, V366, P0, DOI 10.1136/bmj.l4898
   Wan X, 2014, BMC MED RES METHODOL, V14, P0, DOI 10.1186/1471-2288-14-135
   White P, 2012, PAIN, V153, P455, DOI 10.1016/j.pain.2011.11.007
   Yang GS, 2017, CANCER NURS, V40, PE26, DOI 10.1097/NCC.0000000000000409
   Youlden Danny R, 2014, CANCER BIOLOGY MEDICINE, V11, P101, DOI 10.7497/j.issn.2095-3941.2014.02.005
   Zorzela L, 2016, BMJ-BRIT MED J, V352, P0, DOI 10.1136/bmj.i157
NR 50
TC 4
Z9 4
U1 0
U2 3
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 2044-6055
EI 
J9 BMJ OPEN
JI BMJ Open
PD MAY 15
PY 2020
VL 10
IS 5
BP 
EP 
DI 10.1136/bmjopen-2019-033461
PG 8
WC Medicine, General & Internal
SC General & Internal Medicine
GA VK5WH
UT WOS:000738373200027
PM 32371507
DA 2026-01-16
ER

PT J
AU Mazzei, LG
   Bergamaschi, CD
   Silva, MT
   Barberato, S
   Fulone, I
   Moura, MD
   Guimaraes, C
   Lopes, LC
AF Mazzei, Lauren Giustti
   Bergamaschi, Cristiane de Cassia
   Silva, Marcus Tolentino
   Barberato Filho, Silvio
   Fulone, Izabela
   Moura, Mariana Del Grossi
   Guimaraes, Caio
   Lopes, Luciane Cruz
TI Use of IMMPACT domains in clinical trials of acupuncture for chronic pain: A methodological survey
SO PLOS ONE
LA English
DT Article
ID low-back-pain; tension-type headache; core outcome domains; traditional acupuncture; knee osteoarthritis; physical function; randomized-trial; neck pain; multicenter; management
AB Acupuncture is one of the therapeutic resources used for the management of chronic pain. Variability in outcome measurements in randomized clinical trials of non-oncologic chronic pain (RCT-NOCP) generates inconsistencies in determining effects of treatments. The objective of this survey was to assess the adherence to the recommendations made by the Initiative on Methods, Measurement, and Pain Assessment in Clinical Trials (IMMPACT) in the measurement of RCT-NOCP of acupuncture. This methodological research made a systematic search for eligible studies from different sources of information. Eligible studies included those with number of patients.100, who randomized and allocated patients with chronic non-oncologic pain to be treated with acupuncture or with "sham" acupuncture, or non-acupuncture. This research included the recommendations for IMMPACT in the measurement of RCT-NOCP: presence of outcomes pain, physical function, emotional state and improvement perception of patient, the source of the outcome information pain and the tools used to measure such domains. From a total of 1,386 studies, 24 were included in this survey. Eleven studies presented low risk of bias. Pain outcome was measured in 23 studies, physical function in 22 studies, emotional state in 14 studies and improvement perception of patient in one study. As for the pain outcome, the patient was the information source in 50% of the studies. The measurement tools recommended for IMMPACT were included in eight studies (35%) that evaluated pain, one study that evaluated the emotional state (7%), and one study that evaluated the improvement perception and satisfaction of patient. It was observed that studies which did not adhere to the recommendations had more favorable results for acupuncture in the outcome pain. This study concludes that randomized clinical trials that used acupuncture to manage chronic pain failed to adhere to IMMPACT recommendations. Clinical societies and IMMPACT do not share the same recommendations. This fact reflects in the diversity of outcomes and instruments adopted in the studies, making it difficult to compare the results.
C1 [Mazzei, Lauren Giustti; Bergamaschi, Cristiane de Cassia; Silva, Marcus Tolentino; Barberato Filho, Silvio; Fulone, Izabela; Moura, Mariana Del Grossi; Guimaraes, Caio; Lopes, Luciane Cruz] Univ Sorocaba, Pharmaceut Sci Grad Program, Sorocaba, SP, Brazil.
C3 Universidade de Sorocaba
RP Lopes, LC (corresponding author), Univ Sorocaba, Pharmaceut Sci Grad Program, Sorocaba, SP, Brazil.
EM luciane.lopes@prof.uniso.br
CR Abdulla A, 2013, AGE AGEING, V42, PI1, DOI 10.1093/ageing/afs200
   Akl EA, 2012, J CLIN EPIDEMIOL, V65, P262, DOI 10.1016/j.jclinepi.2011.04.015
   Berman BM, 2004, ANN INTERN MED, V141, P901, DOI 10.7326/0003-4819-141-12-200412210-00006
   Bes A, 2013, CEPHALALGIA, V33, P629, DOI 10.1177/0333102413485658
   Blanpied Peter R, 2017, J ORTHOP SPORTS PHYS THER, V47, PA1, DOI 10.2519/jospt.2017.0302
   Borenstein M, 2010, RES SYNTH METHODS, V1, P97, DOI 10.1002/jrsm.12
   Brinkhaus B, 2006, ARCH INTERN MED, V166, P450
   Busse J, 2013, MODIFICATION COCHRAN, V0, P0
   Chen LX, 2013, JCR-J CLIN RHEUMATOL, V19, P308, DOI 10.1097/RHU.0b013e3182a21848
   Cho YJ, 2013, SPINE, V38, P549, DOI 10.1097/BRS.0b013e318275e601
   Collins NJ, 2011, ARTHRIT CARE RES, V63, PS208, DOI 10.1002/acr.20632
   CPSO, 2000, EV BAS REC MED MAN C, V0, P0
   Diener HC, 2006, LANCET NEUROL, V5, P310, DOI 10.1016/S1474-4422(06)70382-9
   Dworkin RH, 2008, J PAIN, V9, P105, DOI 10.1016/j.jpain.2007.09.005
   Dworkin RH, 2010, PAIN, V149, P177, DOI 10.1016/j.pain.2010.02.018
   Endres Heinz G, 2007, J HEADACHE PAIN, V8, P306, DOI 10.1007/s10194-007-0416-5
   Facco E, 2008, HEADACHE, V48, P398, DOI 10.1111/j.1526-4610.2007.00916.x
   Fairbanks CA, 2015, EUR J PHARMACOL, V759, P169, DOI 10.1016/j.ejphar.2015.03.049
   Foster NE, 2007, BMJ-BRIT MED J, V335, P436, DOI 10.1136/bmj.39280.509803.BE
   Guerriere DN, 2010, CAN J ANAESTH, V57, P549, DOI 10.1007/s12630-010-9306-4
   Haake M, 2007, ARCH INTERN MED, V167, P1892, DOI 10.1001/archinte.167.17.1892
   Higgins JP, 2011, COCHRANE HDB SYSTEMA, V0, P0
   Hinman RS, 2014, JAMA-J AM MED ASSOC, V312, P1313, DOI 10.1001/jama.2014.12660
   Hooten WM, 2011, NATL GUIDELINE CLEAR, V0, P112
   IASP, 1994, CLASS CHRON PAIN INT, V0, P0
   Irnich D, 2001, BMJ-BRIT MED J, V322, P1574, DOI 10.1136/bmj.322.7302.1574
   Jena S, 2008, CEPHALALGIA, V28, P969, DOI 10.1111/j.1468-2982.2008.01640.x
   KOPF AP, 2010, GUIA TRAT DOR CONT P, V0, P0
   Liang ZH, 2011, COMPLEMENT THER MED, V19, PS26, DOI 10.1016/j.ctim.2010.11.005
   Linde K, 2005, JAMA-J AM MED ASSOC, V293, P2118, DOI 10.1001/jama.293.17.2118
   Mazzei LG, 2017, BMJ OPEN, V7, P0, DOI 10.1136/bmjopen-2016-014904
   Melchart D, 2005, BMJ-BRIT MED J, V331, P376, DOI 10.1136/bmj.38512.405440.8F
   Molsberger AF, 2002, PAIN, V99, P579, DOI 10.1016/S0304-3959(02)00269-5
   Molsberger AF, 2011, DTSCH Z AKUPUNKT, V54, P35, DOI 10.1016/j.dza.2011.01.008
   Mulla SM, 2015, PAIN, V156, P1615, DOI 10.1097/j.pain.0000000000000241
   OMS, 2013, ESTR OMS MED TRAD 20, V0, P0
   Qaseem Amir, 2017, ANN INTERN MED, V166, P514, DOI 10.7326/M16-2367
   Rasu RS, 2014, J MANAG CARE SPEC PH, V20, P921, DOI 10.18553/jmcp.2014.20.9.921
   RNAO, 2013, ASS MAN PAIN REG NUR, V0, P0
   Rosenquist RW, 2010, ANESTHESIOLOGY, V112, P810, DOI 10.1097/ALN.0b013e3181c43103
   Scharf HP, 2006, ANN INTERN MED, V145, P12, DOI 10.7326/0003-4819-145-1-200607040-00005
   SIGN, 2013, MAN CHRON PAIN NAT C, V0, P0
   Taylor AM, 2016, PAIN, V157, P1836, DOI 10.1097/j.pain.0000000000000577
   Thomas KJ, 2006, BMJ-BRIT MED J, V333, P623, DOI 10.1136/bmj.38878.907361.7C
   Turk DC, 2003, PAIN, V106, P337, DOI 10.1016/j.pain.2003.08.001
   Turk DC, 2008, PAIN, V139, P485, DOI 10.1016/j.pain.2008.06.025
   Turk DC, 2006, PAIN, V125, P208, DOI 10.1016/j.pain.2006.09.028
   Vickers AJ, 2012, ARCH INTERN MED, V172, P1444, DOI 10.1001/archinternmed.2012.3654
   White P, 2004, ANN INTERN MED, V141, P911, DOI 10.7326/0003-4819-141-12-200412210-00007
   Witt C, 2005, LANCET, V366, P136, DOI 10.1016/S0140-6736(05)66871-7
   Witt CM, 2006, PAIN, V125, P98, DOI 10.1016/j.pain.2006.05.013
   Witt CM, 2006, ARTHRITIS RHEUM-US, V54, P3485, DOI 10.1002/art.22154
   Witt CM, 2006, AM J EPIDEMIOL, V164, P487, DOI 10.1093/aje/kwj224
   Yeh TS, 2014, BMC COMPLEM ALTERN M, V14, P0, DOI 10.1186/1472-6882-14-144
   Yin C, 2017, CURR OPIN ANESTHESIO, V30, P583, DOI 10.1097/ACO.0000000000000501
NR 55
TC 5
Z9 6
U1 1
U2 7
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 
EI 1932-6203
J9 PLOS ONE
JI PLoS One
PD APR 16
PY 2020
VL 15
IS 4
BP 
EP 
DI 10.1371/journal.pone.0231444
PG 21
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA LR9JM
UT WOS:000536011400047
PM 32298300
DA 2026-01-16
ER

PT J
AU Lopes, LC Jr
   Rosa, GS
   Pessanha, RM
   Schuab, SIPD
   Nunes, KZ
   Amorim, MHC
AF Lopes-Junior, Luis Carlos
   Rosa, Gabriela Sylvestre
   Pessanha, Raphael Manhaes
   de Carvalho Schuab, Sara Isabel Pimentel
   Nunes, Karolini Zuqui
   Costa Amorim, Maria Helena
TI Efficacy of the complementary therapies in the management of cancer pain in palliative care: A systematic review
SO REVISTA LATINO-AMERICANA DE ENFERMAGEM
LA English
DT Review
DE Descriptors: Complementary Therapies; Adult; Cancer Pain; Palliative Care; Oncology Nursing; Evidence-Based Nursing
ID randomized controlled-trial; aromatherapy massage; guided imagery; breast-cancer; of-life; fatigue; intervention; experiences; adolescents; relaxation
AB Objective: to synthesize the knowledge and to critically evaluate the evidences arising from randomized controlled trials on the efficacy of the complementary therapies in the management of cancer pain in adult patients with cancer in palliative care. Method: a systematic review guided by the Preferred Reporting Items for Systematic Reviews and Meta-Analyses. The search for articles in the MEDLINE, ISI Web of Knowledge, CENTRAL Cochrane, and PsycINFO databases, as well as the manual search, selection of studies, data extraction, and methodological assessment using the Cochrane Bias Risk tool were performed independently by two reviewers. Results: eight hundred and fifteen (815) studies were identified, six of them being selected and analyzed, of which three used massage therapy, one study used a combination of progressive muscle relaxation and guided imaging, and another two studies used acupuncture. Most of the studies had an uncertain risk of bias (n=4; 67%). Conclusion: while the evidence from the studies evaluating the use of massage therapy or the use of progressive muscle relaxation and guided imaging for the management of cancer pain in these patients demonstrated significant benefits, the other two studies that evaluated the use of acupuncture as a complementary therapy showed contradictory results, therefore, needing more research studies to elucidate such findings.
C1 [Lopes-Junior, Luis Carlos; Rosa, Gabriela Sylvestre; Pessanha, Raphael Manhaes; de Carvalho Schuab, Sara Isabel Pimentel; Nunes, Karolini Zuqui] Univ Fed Espirito Santo, Dept Enfermagem, Vitoria, ES, Brazil.
   [Costa Amorim, Maria Helena] Univ Fed Sao Paulo, Escola Paulista Enfermagem, Sao Paulo, SP, Brazil.
C3 Universidade Federal do Espirito Santo; Universidade Federal de Sao Paulo (UNIFESP)
RP Lopes, LC Jr (corresponding author), Univ Fed Espirito Santo, Dept Enfermagem, Vitoria, ES, Brazil.
EM lopesjr.lc@gmail.com
FU Fundacao de Amparo a Pesquisa e Inovacao do Espirito Santo (FAPES) [359/2019]
CR Abuelgasim KA, 2018, BMC COMPLEM ALTERN M, V18, P0, DOI 10.1186/s12906-018-2150-8
   Unknown -, 2023, "EVIDENCE-BASED PRACTICE IN NURSING HEALTHCARE: A GUIDE TO BEST PRACTICE." EVIDENCE-BASED PRACTICE IN NURSING AND HEALTHCARE. WOLTERS KLUWER, V0, P0
   Unknown -, 2002, NAT CANC CONTR PROGR, V0, P0
   Unknown -, 2019, CANC NURS, V0, P0, DOI DOI 10.1097/NCC.0000000000000690
   Unknown -, 2007, J SOC INTEGR ONCOL, V0, P0, DOI DOI 10.2310/7200.2007.014
   Unknown -, 2019, CANCER CYTOPATHOL, V0, P0, DOI DOI 10.3390/CANCERS11040565
   Unknown -, 2019, J EVID BASED INTEGR, V0, P0
   Baviera AF, 2019, REV LAT-AM ENFERM, V27, P0, DOI 10.1590/1518-8345.2959.3126
   Billhult A, 2001, CANCER NURS, V24, P180, DOI 10.1097/00002820-200106000-00003
   Billhult Annika, 2007, CLIN NURS RES, V16, P85, DOI 10.1177/1054773806298488
   Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21609
   Cassileth BR, 2004, J PAIN SYMPTOM MANAG, V28, P244, DOI 10.1016/j.jpainsymman.2003.12.016
   Chandwani KD, 2012, EVID-BASED COMPL ALT, V2012, P0, DOI 10.1155/2012/979213
   Dalal S, 2017, ONCOLOGIST, V22, P361, DOI 10.1634/theoncologist.2016-0277
   De Paolis G, 2019, COMPLEMENT THER CLIN, V34, P280, DOI 10.1016/j.ctcp.2018.12.014
   Deng G, 2019, CANCER J, V25, P343, DOI 10.1097/PPO.0000000000000399
   Eremin O, 2009, BREAST, V18, P17, DOI 10.1016/j.breast.2008.09.002
   Fallon M, 2018, ANN ONCOL, V29, P166, DOI 10.1093/annonc/mdy152
   Forbes K, 2011, CLIN ONCOL-UK, V23, P379, DOI 10.1016/j.clon.2011.04.016
   Freire MEM, 2018, TEXTO CONTEXTO ENFER, V27, P0, DOI 10.1590/0104-070720180005420016
   Garcia TR, 2018, CLASSIFICACAO INTERNACIONAL PARA A PRATICA DE ENFERMAGEM (CIPE), V0, P0
   Gonçalves CA, 2019, BMJ OPEN, V9, P0, DOI 10.1136/bmjopen-2018-026975
   Hernandez-Reif M, 2005, INT J NEUROSCI, V115, P495, DOI 10.1080/00207450590523080
   Higgins JPT, 2016, COCHRANE HANDBOOK FOR SYSTEMATIC REVIEWS OF INTERVENTIONS VERSION 5.1.0, V0, P0
   Ho SSM, 2017, J CLIN NURS, V26, P4519, DOI 10.1111/jocn.13784
   Hsu CH, 2019, MEDICINE, V98, P0, DOI 10.1097/MD.0000000000014720
   Instituto Nacional de Cancer Jose Alencar Gomes da Silva (BR), 2019, COORD PREV VIG EST 2, V0, P0
   Johnston MF, 2011, EVID-BASED COMPL ALT, V2011, P1, DOI 10.1093/ecam/nep236
   Kim K, 2018, INTEGR CANCER THER, V17, P1137, DOI 10.1177/1534735418786797
   Kreiner M, 2010, ACUPUNCT MED, V28, P33, DOI 10.1136/aim.2009.001735
   Kuo YH, 2018, J ALTERN COMPLEM MED, V24, P276, DOI 10.1089/acm.2016.0396
   Kutner JS, 2008, ANN INTERN MED, V149, P369, DOI 10.7326/0003-4819-149-6-200809160-00003
   Kwekkeboom KL, 2012, J PAIN SYMPTOM MANAG, V44, P810, DOI 10.1016/j.jpainsymman.2011.12.281
   Lam TY, 2017, BMC COMPLEM ALTERN M, V17, P0, DOI 10.1186/s12906-017-1838-5
   Laurant M, 2018, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD001271.pub3
   Lee SH, 2015, INTEGR CANCER THER, V14, P297, DOI 10.1177/1534735415572885
   Liberati Alessandro, 2009, PLOS MED, V6, Pe1000100, DOI 10.1371/journal.pmed.1000100
   Lopes LC, 2016, EUR J CANCER CARE, V25, P921, DOI 10.1111/ecc.12381
   Lopes LC Jr, 2018, INTEGR CANCER THER, V17, P928, DOI 10.1177/1534735418781725
   Lopes-Júnior LC, 2016, BRITISH JOURNAL OF NURSING, V25, PS12, DOI 10.12968/bjon.2016.25.10.s12
   Lopes LC Jr, 2019, BMJ OPEN, V9, P0, DOI 10.1136/bmjopen-2018-026524
   Lopes LC, 2016, REV LAT-AM ENFERM, V24, P0, DOI 10.1590/1518-8345.0647.2762
   López-Sendín N, 2012, J ALTERN COMPLEM MED, V18, P480, DOI 10.1089/acm.2011.0277
   Mendes TR, 2014, ACTA PAUL ENFERM, V27, P356
   Methley AM, 2014, BMC HEALTH SERV RES, V14, P0, DOI 10.1186/s12913-014-0579-0
   National Centre for Complementary and Alternative Medicine, 2019, COMPL ALT INT HLTH W, V0, P0
   Rhee TG, 2019, PSYCHO-ONCOLOGY, V28, P896, DOI 10.1002/pon.5039
   Nunes MDR, 2017, EUR J ONCOL NURS, V29, P39, DOI 10.1016/j.ejon.2017.05.001
   Ruela LD, 2018, REV ESC ENFERM USP, V52, P0, DOI 10.1590/S1980-220X2017040503402
   Shin ES, 2016, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD009873.pub3
   Soden K, 2004, PALLIATIVE MED, V18, P87, DOI 10.1191/0269216304pm874oa
   Uchida S, 2008, EVID-BASED COMPL ALT, V5, P145, DOI 10.1093/ecam/nem051
   Wilkie D J, 2000, HOSP J, V15, P31
   Wode K, 2019, BMC COMPLEM ALTERN M, V19, P0, DOI 10.1186/s12906-019-2452-5
   World Health Organization, 2020, CANC WHO, V0, P0
   Xavier WD, 2020, ACTA PAUL ENFERM, V33, P0, DOI 10.37689/acta-ape/2020AR0022
NR 56
TC 33
Z9 52
U1 1
U2 41
PU UNIV SAO PAULO, ESCOLA DE ENFERMAGEM DE RIBEIRAO PRETO
PI RIBEIRAO PRETO
PA AV BANDEIRANTES, 3900, RIBEIRAO PRETO, SP 14040-902  A, BRAZIL
SN 1518-8345
EI 
J9 REV LAT-AM ENFERM
JI Rev. Latino-Am. Enfermagem
PD JUN 15
PY 2020
VL 28
IS 
BP 
EP 
DI 10.1590/1518-8345.4213.3377
PG 17
WC Nursing
SC Nursing
GA NY0QL
UT WOS:000576104400001
PM 33027406
DA 2026-01-16
ER

PT J
AU Hung, HH
   Chen, WC
   Chen, YH
   Chiu, LT
   Chen, HY
AF Hung, Hao-Hsiu
   Chen, Wen-Chi
   Chen, Yung-Hsiang
   Chiu, Lu-Ting
   Chen, Huey-Yi
TI Evaluation of the efficacy of Chinese herbal medicine and acupuncture for the prevention of mental disorders in interstitial cystitis patients A nationwide population-based study
SO MEDICINE
LA English
DT Article
DE anxiety; depression; insomnia; interstitial cystitis; bladder pain syndrome; National Health Insurance Research Database; traditional Chinese medicine
ID pain syndrome/interstitial cystitis; quality-of-life; cancer type; bladder; depression; prevalence; anxiety; risk; diagnosis; symptoms
AB Traditional Chinese medicine (TCM) is commonly used for urinary symptoms in Eastern countries. Since there are few effective treatments available for patients with interstitial cystitis/bladder pain syndrome (IC/BPS), the psychological burden leads to increased healthcare-seeking behavior. Some patients may therefore seek TCM treatment for related urinary symptoms. Due to limited clinical research evaluating the effects of TCM on IC/BPS, we conducted a nationwide population-based cohort study to investigate the relationship between TCM and mental disorders among these patients. The IC/BPS cohort and its matched non-IC/BPS comparison cohort were recruited from the National Health Insurance (NHI) Research Database between 2000 and 2011. Patients with the use of Chinese herbal medicine (CHM) granules or acupuncture over 90 days per year were enrolled as the TCM users. Multivariable Cox proportional hazards models were used to evaluate the hazard ratio (HR) of mental disorders related to interstitial cystitis. The incidence of mental disorders in the 2 cohorts was assessed with Kaplan-Meier curves. A total of 1123 patients with IC/BPS and 4492 matched non-IC/BPS subjects were included in this study. The IC/BPS cohort demonstrated higher incidence rate of mental disorders than the cohort without IC/BPS (adjusted HR: 2.21, 95% confidence interval [CI]: 1.73-2.81). There was no statistically significant difference in the risk of mental disorders between IC/BPS patients with and without CHM granules or acupuncture treatment (adjusted HR: 0.99, 95% CI: 0.58-1.68). Our results indicated that CHM and acupuncture showed insignificant efficacy in the prevention of mental disorders in IC/BPS patients.
C1 [Hung, Hao-Hsiu] Asia Univ, Dept Chinese Med, Taichung, Taiwan.
   [Chen, Wen-Chi; Chen, Yung-Hsiang; Chen, Huey-Yi] Asia Univ, Grad Inst Integrated Med, Coll Chinese Med, Taichung, Taiwan.
   [Chen, Wen-Chi; Chen, Yung-Hsiang; Chen, Huey-Yi] Asia Univ, Dept Obstet & Gynecol, Taichung, Taiwan.
   [Chen, Yung-Hsiang] Asia Univ, Coll Med & Hlth Sci, Dept Psychol, Taichung, Taiwan.
   [Chiu, Lu-Ting] China Med Univ Hosp, Management Off Hlth Data, Taichung, Taiwan.
   [Chiu, Lu-Ting] China Med Univ, Coll Med, Taichung, Taiwan.
C3 Asia University Taiwan; Asia University Taiwan; Asia University Taiwan; Asia University Taiwan; China Medical University Taiwan; China Medical University Hospital - Taiwan; China Medical University Taiwan
RP Chen, HY (corresponding author), China Med Univ, 91 Hsueh Shih Rd, Taichung 40402, Taiwan.
EM d888208@ms45.hinet.net
FU Taiwan Ministry of Health and Welfare Clinical Trial Center, Taichung, Taiwan [MOHW109-TDU-B-212-114004]; MOST Clinical Trial Consortium for Stroke, Taichung, Taiwan [MOST 108-2321-B-039-003-]; Tseng-Lien Lin Foundation, Taichung, Taiwan; China Medical University, Taichung, Taiwan [DMR-109-085, CMU108-S-38]
CR Baranowski AP, 2008, EUR UROL, V53, P33, DOI 10.1016/j.eururo.2007.10.010
   Berry SH, 2011, J UROLOGY, V186, P540, DOI 10.1016/j.juro.2011.03.132
   Chuang YC, 2015, INT UROL NEPHROL, V47, P275, DOI 10.1007/s11255-014-0908-6
   Ciaramella A, 2001, PSYCHO-ONCOLOGY, V10, P156, DOI 10.1002/pon.505
   Clemens JQ, 2005, J UROLOGY, V173, P98, DOI 10.1097/01.ju.0000146114.53828.82
   Fan YH, 2008, INT J UROL, V15, P416, DOI 10.1111/j.1442-2042.2008.02020.x
   Fietta Pierluigi, 2007, ACTA BIOMED, V78, P88
   Flores-Carreras O, 2015, TRANSL ANDROL UROL, V4, P620, DOI 10.3978/j.issn.2223-4683.2015.10.11
   FORRESTER AW, 1992, INT J PSYCHIAT MED, V22, P33, DOI 10.2190/CJ9D-32C2-8CM7-FT3D
   Gotoh A, 2004, J PHARMACOL SCI, V96, P115, DOI 10.1254/jphs.FPJ03098X
   Hanno PM, 2015, J UROLOGY, V193, P1545, DOI 10.1016/j.juro.2015.01.086
   Kajiwara Mitsuru, 2008, HINYOKIKA KIYO, V54, P95
   Keller JJ, 2013, NEUROUROL URODYNAM, V32, P467, DOI 10.1002/nau.22316
   Keller JJ, 2012, BJU INT, V110, PE903, DOI 10.1111/j.1464-410X.2012.11539.x
   Konrad M, 2016, WORLD J CARDIOL, V8, P547, DOI 10.4330/wjc.v8.i9.547
   Laganà AS, 2017, INT J WOMENS HEALTH, V9, P323, DOI 10.2147/IJWH.S119729
   Lee WC, 2016, J ETHNOPHARMACOL, V184, P1, DOI 10.1016/j.jep.2015.12.026
   Linden W, 2012, J AFFECT DISORDERS, V141, P343, DOI 10.1016/j.jad.2012.03.025
   Michael YL, 2000, J UROLOGY, V164, P423, DOI 10.1016/S0022-5347(05)67376-4
   Nickel JC, 2010, J UROLOGY, V183, P167, DOI 10.1016/j.juro.2009.08.133
   OHare PG, 2013, INT UROGYNECOL J, V24, P977, DOI 10.1007/s00192-012-1966-x
   Pazin C, 2016, INT UROGYNECOL J, V27, P697, DOI 10.1007/s00192-015-2815-5
   Rothrock NE, 2002, J UROLOGY, V167, P1763, DOI 10.1016/S0022-5347(05)65195-6
   Rovner E, 2000, UROLOGY, V56, P940, DOI 10.1016/S0090-4295(00)00845-1
   Sönmez MG, 2017, GINEKOL POL, V88, P61, DOI 10.5603/GP.a2017.0013
   Thompson AE, 2016, BMC FAM PRACT, V17, P0, DOI 10.1186/s12875-016-0440-0
   Troxel WM, 2014, J CLIN SLEEP MED, V10, P1331, DOI 10.5664/jcsm.4292
   Tsai CF, 2010, NEUROUROL URODYNAM, V29, P568, DOI 10.1002/nau.20799
   Wang H, 2012, NEUROSCI RES, V72, P43, DOI 10.1016/j.neures.2011.09.007
   Watkins KE, 2011, GEN HOSP PSYCHIAT, V33, P143, DOI 10.1016/j.genhosppsych.2011.01.004
   Yagi Hiroshi, 2016, J TRADIT COMPLEMENT MED, V6, P126, DOI 10.1016/j.jtcme.2014.11.021
NR 31
TC 5
Z9 7
U1 1
U2 22
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0025-7974
EI 1536-5964
J9 MEDICINE
JI Medicine (Baltimore)
PD JUL 24
PY 2020
VL 99
IS 30
BP 
EP 
DI 10.1097/MD.0000000000021422
PG 8
WC Medicine, General & Internal
SC General & Internal Medicine
GA MY4WY
UT WOS:000558420900107
PM 32791761
DA 2026-01-16
ER

PT J
AU Liou, KT
   Baser, R
   Romero, SAD
   Green, J
   Li, QS
   Orlow, I
   Panageas, KS
   Mao, JJ
AF Liou, Kevin T
   Baser, Ray
   Romero, Sally A D
   Green, Jamie
   Li, Q Susan
   Orlow, Irene
   Panageas, Katherine S
   Mao, Jun J
TI Personalized electro-acupuncture versus auricular-acupuncture comparative
SO Medicine
LA English
DT Journal Article
AB INTRODUCTION: Chronic pain is a leading cause of disability and remains  under-treated in nearly half of patients with cancer. The opioid crisis has  highlighted an urgent public health need for effective nonpharmacological pain  management. Electroacupuncture (EA) and Battlefield Acupuncture (BFA) represent  nonpharmacological modalities used in clinical practice to manage pain; however,  their effectiveness has not been rigorously evaluated in oncology settings.  METHODS: We describe the design of a 3-arm, parallel, single-center, multisite  randomized controlled trial that investigates EA and BFA versus usual-care  wait-list control (WLC) for chronic musculoskeletal pain among 360 patients with  diverse cancer types across various stages. The primary aim is to compare effects  of EA and BFA versus WLC on pain, physical function, and co-morbid symptoms. The  secondary aim is to examine the interaction between patient outcome expectancy  and acupuncture modality (EA vs BFA) on pain reduction. The tertiary aim is to  evaluate the association between genetic polymorphisms and responses to  acupuncture. Patients will be randomized in a 2:2:1 ratio to EA:BFA:WLC.  Acupuncture groups will receive weekly treatments over 10 weeks. WLC will receive  usual care over the same evaluation period as the acupuncture groups. The primary  endpoint will be the change in average pain intensity score from baseline to week  12. We will collect validated patient-reported outcomes and blood/saliva samples  at multiple timepoints over 24 weeks. DISCUSSION: Our findings will advance  nonpharmacological pain management in oncology and inform personalized treatment  approaches that integrate individuals' expectations and genetic biomarkers to  deliver "precision" acupuncture to cancer patients with chronic pain. TRIAL  REGISTRATION: ClinicalTrials.gov Identifier: NCT02979574.
C1 Integrative Medicine Service, Department of Medicine.
   Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY.
   Department of Family Medicine and Public Health, UC San Diego School of Medicine, San Diego, CA.
   Integrative Medicine Service, Department of Medicine.
   Integrative Medicine Service, Department of Medicine.
   Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY.
   Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY.
   Integrative Medicine Service, Department of Medicine.
NR 0
TC 0
SN 1536-596
EI 0025-797
J9 Medicine (Baltimore)
PD JUN 3
PY 2020
VL 99
IS 21
BP e20085
EP e20085
DI 10.1097/MD.0000000000020085
PG 1
WC Acupuncture Therapy; methods; Adult; Cancer Survivors; Chronic Pain; therapy; Humans; Musculoskeletal Pain; therapy; Pain Management; methods; Pain Measurement; methods; Quality of Life; Randomized Controlled Trials as Topic
UT PubMed:32481275
PM 32481275
DA 2020-06-03
ER

PT J
AU Shao, YL
   Fan, LY
AF Shao, Yanlong
   Fan, Lingyu
TI Effects of acupuncture-moxibustion at Du channel combined with triamcinolone acetonide on clinical treatment efficacy and quality of life in patients with sciatica
SO INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE
LA English
DT Article
DE Sciatica; triamcinolone acetonide; acupuncture-moxibustion at Du channel; quality of life; dysfunction
ID pain
AB Objective: To investigate the effects of acupuncture-moxibustion at Du channel combined with triamcinolone acetonide (AMDCTA) on the clinical treatment efficacy and quality of life in patients with sciatica. Methods: A retrospective study was conducted on 86 patients with sciatica admitted to Tianjin Hospital from March 2018 to April 2020. According to different treatment methods, the patients were divided into an observation group (45 cases) and a control group (41 cases). The control group was treated with triamcinolone acetonide, while the observation group was treated with AMDCTA, both lasted for 3 weeks. Clinical treatment efficacy, visual analogue scale score, straight leg raising score, Oswestry dysfunction index score, 36-item short-form health survey quality of life score, serum insulin-like growth factor-1 (IGF-1) level, tumor necrosis factor-alpha (TNF-alpha) level, monocyte chemoattractant protein-1 (MCP-1) level, and the incidence of adverse reactions in both groups were compared. Results: The total effective rate of the observation group was significantly higher compared with that of the control group (P < 0.05). Visual analogue scale and Oswestry dysfunction index scores in both groups were significantly lower compared with those before treatment, and the scores of the observation group were significantly lower compared with the control group after treatment (all P < 0.05). Straight leg raising and 36-item short-form health survey quality of life scores in both groups were significantly improved compared with those before treatment, and those in the observation group were significantly higher compared with the control group after treatment (all P < 0.05). IGF-1, TNF-alpha and MCP-1 levels in both groups were significantly lower compared with those before treatment, and those levels in the observation group were lower compared with those in the control group after treatment (all P < 0.05). There was no significant difference in the incidence of adverse reactions between the two groups (P > 0.05). Conclusion: AMDCTA had a definite curative effect on sciatica, could effectively improve patients' pain, functional activity and quality of life, as well as reduce IGF-1, TNF-alpha and MCP-1 levels; revealing it is safe and reliable.
C1 [Shao, Yanlong] Tianjin Hosp, Dept Orthoped & Traumatol Integrated Tradit Chine, 406 Jiefang South Rd, Tianjin 300021, Peoples R China.
   [Fan, Lingyu] Tianjin Hosp, Dept Cardlol, Tianjin, Peoples R China.
C3 Tianjin University; Tianjin University
RP Shao, YL (corresponding author), Tianjin Hosp, Dept Orthoped & Traumatol Integrated Tradit Chine, 406 Jiefang South Rd, Tianjin 300021, Peoples R China.
EM shaoyanlongts3j@163.com
CR Adjien CK, 2018, NEUROSCIENCE &AMP MEDICINE, V09, P171, DOI 10.4236/nm.2018.94017
   Akinyemi OA, 2017, J ORTHOP SPORT PHYS, V47, P442, DOI 10.2519/jospt.2017.6877
   Bernstein IA, 2017, BMJ-BRIT MED J, V356, P0, DOI 10.1136/bmj.i6748
   Di Mattia F, 2018, J ORTHOP SPORT PHYS, V48, P436, DOI 10.2519/jospt.2018.0609
   Djuric N, 2019, SPINE, V44, PE742, DOI 10.1097/BRS.0000000000003004
   Erden B, 2019, OCUL IMMUNOL INFLAMM, V27, P1235, DOI 10.1080/09273948.2019.1620786
   Fairbank JCT, 2000, SPINE, V25, P2940, DOI 10.1097/00007632-200011150-00017
   Fjeld O, 2017, SPINE, V42, PE272, DOI 10.1097/BRS.0000000000001773
   Fjeld OR, 2020, SCAND J PAIN, V20, P69, DOI 10.1515/sjpain-2019-0112
   Gulati S, 2017, ACTA NEUROCHIR, V159, P509, DOI 10.1007/s00701-017-3077-4
   Guo JR, 2017, ANN PHARMACOTHER, V51, P1041, DOI 10.1177/1060028017722008
   Konstantinou K, 2018, SPINE J, V18, P1030, DOI 10.1016/j.spinee.2017.10.071
   Kwan Y, 2016, RHEUMATOL INT, V36, P1759, DOI 10.1007/s00296-016-3567-3
   Lord Bill A, 2003, PREHOSP DISASTER MED, V18, P353
   Ministry of Health of the Peoples Republic of China, 2002, GUID PRINC CLIN RES, V0, P164
   Moses ZB, 2017, NEUROSURGERY, V81, PN13, DOI 10.1093/neuros/nyx259
   Neurology Branch of Chinese Medical Associa, 2009, CHIN J INT MED, V48, P526
   Nwankwo BO, 2018, ORTHOPEDICS, V41, PE151, DOI 10.3928/01477447-20170918-07
   Oosterhuis T, 2019, OCCUP ENVIRON MED, V76, P772, DOI 10.1136/oemed-2019-105797
   Rasmussen-Barr E, 2017, SPINE, V42, P586, DOI 10.1097/BRS.0000000000002092
   Robertson K, 2019, JAMA NEUROL, V76, P28, DOI 10.1001/jamaneurol.2018.3077
   Sadeghian Rastin, 2019, DENT RES J (ISFAHAN), V16, P277
   Shi MX, 2002, PRACTICE OF SURG, V0, P193
   Song HP, 2019, J COSMET DERMATOL-US, V18, P874, DOI 10.1111/jocd.12690
   Woo PYM, 2019, BRIT J NEUROSURG, V33, P562, DOI 10.1080/02688697.2017.1378801
   叶建红, 2002, 中华物理医学与康复杂志 CHINESE JOURNAL OF PHYSICAL MEDICINE AND REHABILITATION, V24, P628
NR 26
TC 0
Z9 0
U1 0
U2 3
PU E-CENTURY PUBLISHING CORP
PI MADISON
PA 40 WHITE OAKS LN, MADISON, WI 53711 USA
SN 1940-5901
EI 
J9 INT J CLIN EXP MED
JI Int. J. Clin. Exp. Med.
PD JUN 15
PY 2020
VL 13
IS 12
BP 9751
EP 9759
DI 
PG 9
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA PO2SX
UT WOS:000605020700074
DA 2026-01-16
ER

PT J
AU Ahmed, A
   Thota, RS
   Bhatnagar, S
   Jain, P
   Ramanjulu, R
   Salins, N
   Chatterjee, A
   Bhattacharya, D
AF Ahmed, Arif
   Thota, Raghu S
   Bhatnagar, Sushma
   Jain, Parmanand
   Ramanjulu, Raghavendra
   Salins, Naveen
   Chatterjee, Aparna
   Bhattacharya, Dipasri
TI Indian Society for Study of Pain, Cancer Pain Special Interest Group Guidelines
SO Indian journal of palliative care
LA English
DT Journal Article
DE Acupuncture; Indian Association of Palliative Care; Indian society for study of pain; cancer pain management; cancer pain management guidelines; cancer pain special interest group; cognitive behavioural therapy; complimentary therapy
AB The Indian Society for Study of Pain (ISSP), cancer pain Special Interest Group  (SIG) guidelines on complementary therapies for cancer pain in adults provides a  structured, stepwise approach which will help to improve the management of cancer  pain and to provide the patients with a minimally acceptable quality of life. The  guidelines have been developed based on the available literature and evidence, to  suit the needs, patient population, and situations in India. A questionnaire  based on the key elements of each sub drafts addressing certain inconclusive  areas where evidence was lacking, was made available on the ISSP website and  circulated by e-mail to all the ISSP and Indian Association of Palliative Care  members. We recommend that psychological interventions, including  psychoeducation, are useful and should be considered in patients with cancer pain  and psychological distress. Furthermore, physical and complementary treatment can  be used as an adjunctive therapy for patients with cancer pain.
C1 Department of Anaesthesia, Critical Care and Pain Management, CK Birla Hospital for Women, Gurugram, Haryana, India.
   Department of Anaesthesiology, Critical Care and Pain, Tata Memorial Centre, Homi Bhabha National Institute, Mumbai, Maharashtra, India.
   Department of Onco-Anaesthesia and Palliative Medicine, Dr. B.R.A. Institute Rotary Cancer Hospital, All India Institute of Medical Sciences, New Delhi,India.
   Department of Anaesthesiology, Critical Care and Pain, Tata Memorial Centre, Homi Bhabha National Institute, Mumbai, Maharashtra, India.
   Department of Pain and Palliative Care, Cytecare Hospital, Bengaluru, Karnataka, India.
   Department of Palliative Medicine and Supportive Care, Manipal Comprehensive Cancer Care Centre, Kasturba Medical College, Manipal Academy of HigherEducation, Manipal, Karnataka, India.
   Department of Anaesthesiology, Critical Care and Pain, Tata Memorial Centre, Homi Bhabha National Institute, Mumbai, Maharashtra, India.
   Department of Anaesthesiology, Critical Care and Pain, R.G. Kar Medical College, Kolkata, West Bengal, India.
NR 0
TC 0
SN 1998-373
EI 0973-107
J9 Indian J Palliat Care
PD SEP 3
PY 2020
VL 26
IS 2
BP 198
EP 202
DI 10.4103/0973-1075.285695
PG 4
UT PubMed:32874033
PM 32874033
DA 2020-09-03
ER

PT J
AU Tao, X
   Lee, MS
   Donnelly, CR
   Ji, RR
AF Tao, Xueshu
   Lee, Michael S
   Donnelly, Christopher R
   Ji, Ru-Rong
TI Neuromodulation, Specialized Proresolving Mediators, and Resolution of Pain.
SO Neurotherapeutics : the journal of the American Society for Experimental
LA English
DT Review
DE Auricular stimulation; chemotherapy; dorsal root ganglion; fish oil; resolvin; vagus nerve stimulation
AB The current crises in opioid abuse and chronic pain call for the development of  nonopioid and nonpharmacological therapeutics for pain relief.  Neuromodulation-based approaches, such as spinal cord stimulation, dorsal root  ganglion simulation, and nerve stimulation including vagus nerve stimulation,  have shown efficacy in achieving pain control in preclinical and clinical  studies. However, the mechanisms by which neuromodulation alleviates pain are not  fully understood. Accumulating evidence suggests that neuromodulation regulates  inflammation and neuroinflammation-a localized inflammation in peripheral nerves,  dorsal root ganglia/trigeminal ganglia, and spinal cord/brain-through  neuro-immune interactions. Specialized proresolving mediators (SPMs) such as  resolvins, protectins, maresins, and lipoxins are lipid molecules produced during  the resolution phase of inflammation and exhibit multiple beneficial effects in  resolving inflammation in various animal models. Recent studies suggest that SPMs  inhibit inflammatory pain, postoperative pain, neuropathic pain, and cancer pain  in rodent models via immune, glial, and neuronal modulations. It is noteworthy  that sham surgery is sufficient to elevate resolvin levels and may serve as a  model of resolution. Interestingly, it has been shown that the vagus nerve  produces SPMs and vagus nerve stimulation (VNS) induces SPM production in vitro.  In this review, we discuss how neuromodulation such as VNS controls pain via  immunomodulation and neuro-immune interactions and highlight possible involvement  of SPMs. In particular, we demonstrate that VNS via auricular electroacupuncture  effectively attenuates chemotherapy-induced neuropathic pain. Furthermore,  auricular stimulation is able to increase resolvin levels in mice. Thus, we  propose that neuromodulation may control pain and inflammation/neuroinflammatioin  via SPMs. Finally, we discuss key questions that remain unanswered in our  understanding of how neuromodulation-based therapies provide short-term and  long-term pain relief.
C1 Center for Translational Pain Medicine, Department of Anesthesiology, Duke University Medical Center, Durham, NC, 27710, USA.
   Center for Translational Pain Medicine, Department of Anesthesiology, Duke University Medical Center, Durham, NC, 27710, USA.
   Center for Translational Pain Medicine, Department of Anesthesiology, Duke University Medical Center, Durham, NC, 27710, USA.
   Center for Translational Pain Medicine, Department of Anesthesiology, Duke University Medical Center, Durham, NC, 27710, USA. ru-rong.ji@duke.edu.
   Department of Neurobiology, Duke University Medical Center, Durham, NC, 27710, 
   Department of Cell Biology, Duke University Medical Center, Durham, NC, 27710, USA. ru-rong.ji@duke.edu.
NR 0
TC 0
SN 1878-747
EI 1933-721
J9 Neurotherapeutics
PD JUL 23
PY 2020
VL 17
IS 3
BP 886
EP 899
DI 10.1007/s13311-020-00892-9
PG 13
WC Analgesics; pharmacology; Animals; Docosahexaenoic Acids; metabolism; Humans; Inflammation Mediators; antagonists & inhibitors; Lipid Metabolism; drug effects; Lipoxins; metabolism; Neuroimmunomodulation; drug effects; Pain; metabolism; Pain Management; methods; Vagus Nerve Stimulation; methods
UT PubMed:32696274
PM 32696274
DA 2020-07-23
ER

PT J
AU Hochberg, U
   Berger, A
   Atias, M
   Tellem, R
   Strauss, I
AF Hochberg, Uri
   Berger, Asaf
   Atias, Miri
   Tellem, Rotem
   Strauss, Ido
TI Tailoring of neurosurgical ablative procedures in the management of refractory cancer pain
SO REGIONAL ANESTHESIA AND PAIN MEDICINE
LA English
DT Article
ID cordotomy; cingulotomy
AB Introduction Neurosurgical ablative procedures can offer immediate and effective pain relief for patients suffering from refractory cancer pain. However, choosing the appropriate procedure for each patient may not be straightforward and warrants an interdisciplinary approach. The purpose of the current study was to evaluate the outcome of patients with cancer who were carefully selected for neurosurgical intervention by a dedicated interdisciplinary team composed of a palliative physician and nurse practitioner, a pain specialist and a neurosurgeon. Methods A retrospective review was carried out on all patients who underwent neurosurgical ablative procedures in our institute between March 2015 and September 2019. All patients had advanced metastatic cancer with unfavorable prognosis and suffered from intractable oncological pain. Each treatment plan was devised to address the patients' specific pain syndromes. Results A total of 204 patients were examined by our service during the study period. Sixty-four patients with localized pain and nineteen patients with diffuse pain syndromes were selected for neurosurgical interventions, either targeted disconnection of the spinothalamic tract or stereotactic cingulotomy. Substantial pain relief was reported by both groups immediately (cordotomy: Numerical Rating Scale (NRS) 9 >= 1, p=0.001, cingulotomy: NRS 9 >= 2, p=0.001) and maintained along the next 3-month follow-up visits. Conclusions An interdisciplinary collaboration designated to provide neurosurgical ablative procedures among carefully selected patients could culminate in substantial relief of intractable cancer pain.
C1 [Hochberg, Uri] Tel Aviv Sourasky Med Ctr, Inst Pain Med, Div Anesthesiol, Tel Aviv, Israel.
   [Hochberg, Uri; Berger, Asaf; Tellem, Rotem; Strauss, Ido] Tel Aviv Univ, Sackler Sch Med, Tel Aviv, Israel.
   [Berger, Asaf; Atias, Miri] Tel Aviv Sourasky Med Ctr, Dept Neurosurg, Tel Aviv, Israel.
   [Tellem, Rotem] Tel Aviv Sourasky Med Ctr, Palliat Care Serv, Tel Aviv, Israel.
   [Strauss, Ido] Tel Aviv Sourasky Med Ctr, Dept Neurosurg, Neuromodulat Unit, Tel Aviv, Israel.
C3 Tel Aviv University; Sackler Faculty of Medicine; Tel Aviv Sourasky Medical Center; Tel Aviv University; Sackler Faculty of Medicine; Tel Aviv University; Sackler Faculty of Medicine; Tel Aviv Sourasky Medical Center; Tel Aviv University; Sackler Faculty of Medicine; Tel Aviv Sourasky Medical Center; Tel Aviv University; Sackler Faculty of Medicine; Tel Aviv Sourasky Medical Center
RP Hochberg, U (corresponding author), Tel Aviv Sourasky Med Ctr, Inst Pain Med, Div Anesthesiol, Tel Aviv, Israel.
EM urihochberg@hotmail.com
CR Afsharimani B, 2015, SUPPORT CARE CANCER, V23, P1473, DOI 10.1007/s00520-015-2678-9
   Unknown -, 1986, CANC PAIN REL, V0, P0
   Atkin N, 2010, J PAIN SYMPTOM MANAG, V39, P924, DOI 10.1016/j.jpainsymman.2009.09.011
   Bedard G, 2013, J PAIN SYMPTOM MANAG, V46, P192, DOI 10.1016/j.jpainsymman.2012.07.022
   Bentley JN, 2014, PAIN MED, V15, P1488, DOI 10.1111/pme.12481
   Bhatnagar S, 2015, INDIAN J PALLIAT CAR, V21, P137, DOI 10.4103/0973-1075.156466
   France BD, 2014, BMJ SUPPORT PALLIAT, V4, P19, DOI 10.1136/bmjspcare-2013-000508
   Harsh V, 2013, CURR PAIN HEADACHE R, V17, P0, DOI 10.1007/s11916-013-0331-1
   Higaki N, 2015, NEUROSURGERY, V76, P249, DOI 10.1227/NEU.0000000000000593
   Perez J, 2016, PAIN RES MANAG, V2016, P0, DOI 10.1155/2016/2157950
   Raslan AM, 2008, NEUROSURGERY, V63, P226, DOI 10.1227/01.neu.0000317397.16089.f5
   Ripamonti CI, 2012, ANN ONCOL, V23, P139, DOI 10.1093/annonc/mds233
   Russo JF, 2015, NEUROSURG FOCUS, V38, P0, DOI 10.3171/2015.3.FOCUS1543
   Sharim J, 2016, PAIN PHYSICIAN, V19, P537, DOI 10.36076/ppj/2016.19.537
   Strauss I, 2017, STEREOT FUNCT NEUROS, V95, P400, DOI 10.1159/000484613
   Strauss I, 2017, STEREOT FUNCT NEUROS, V95, P409, DOI 10.1159/000484614
   Vissers KCP, 2011, PAIN PRACT, V11, P453, DOI 10.1111/j.1533-2500.2011.00473.x
   Wager TD, 2013, NEW ENGL J MED, V368, P1388, DOI 10.1056/NEJMoa1204471
   Yoon DM, 2018, SUPPORT CARE CANCER, V26, P2023, DOI 10.1007/s00520-018-4043-2
NR 19
TC 6
Z9 7
U1 0
U2 3
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 1098-7339
EI 1532-8651
J9 REGION ANESTH PAIN M
JI Region. Anesth. Pain Med.
PD SEP 15
PY 2020
VL 45
IS 9
BP 696
EP 701
DI 10.1136/rapm-2020-101566
PG 6
WC Anesthesiology
SC Anesthesiology
GA NK9DO
UT WOS:000567029500007
PM 32699105
DA 2026-01-16
ER

PT J
AU Lee, JH
   Gang, J
   Yang, E
   Kim, W
   Jin, YH
AF Lee, Ji Hwan
   Gang, Juan
   Yang, Eunhee
   Kim, Woojin
   Jin, Young-Ho
TI Bee Venom Acupuncture Attenuates Oxaliplatin-Induced Neuropathic Pain by Modulating Action Potential Threshold in A-Fiber Dorsal Root Ganglia Neurons
SO TOXINS
LA English
DT Article
DE action potential; allodynia; bee venom acupuncture; oxaliplatin; voltage-gated sodium channel
ID sodium-channels; peripheral neuropathy; anticancer drug; neurotoxicity; mechanisms; prevention; management; cisplatin; model; na+
AB Oxaliplatin is a third-generation platinum-based chemotherapeutic drug widely used in colorectal cancer treatment. Although potent against this tumor, it can induce cold and mechanical allodynia even after a single injection. The currently used drugs to attenuate this allodynia can also cause unwanted effects, which limit their use. Bee venom acupuncture (BVA) is widely used in Korean medicine to treat pain. Although the effect of BVA on oxaliplatin-induced neuropathic pain has been addressed in many studies, its action on dorsal root ganglia (DRG) neurons has never been investigated. A single oxaliplatin injection (6 mg/kg, intraperitoneally) induced cold and mechanical allodynia, and BVA (0.1 and 1 mg/kg, subcutaneous, ST36) dose-dependently decreased allodynia in rats. On acutely dissociated lumbar 4-6 DRG neurons, 10 min application of oxaliplatin (100 mu M) shifted the voltage-dependence of sodium conductance toward negative membrane potentials in A- but not C-fibers. The resting membrane potential remained unchanged, but the action potential threshold decreased significantly compared to that of the control (p < 0.05). However, 0.1 mu g/mL of BVA administration increased the lowered action potential threshold. In conclusion, these results suggest that BVA may attenuate oxaliplatin-induced neuropathic pain by altering the action potential threshold in A-fiber DRG neurons.
C1 [Lee, Ji Hwan; Kim, Woojin] Kyung Hee Univ, Coll Korean Med, Dept Physiol, Seoul 02453, South Korea.
   [Lee, Ji Hwan; Kim, Woojin] Kyung Hee Univ, Grad Sch, Dept Sci Korean Med, Seoul 02453, South Korea.
   [Gang, Juan; Kim, Woojin] Kyung Hee Univ, Grad Sch, Dept East West Med, Seoul 02453, South Korea.
   [Yang, Eunhee; Jin, Young-Ho] Kyung Hee Univ, Coll Med, Dept Physiol, Seoul 02453, South Korea.
C3 Kyung Hee University; Kyung Hee University; Kyung Hee University; Kyung Hee University
RP Kim, W (corresponding author), Kyung Hee Univ, Coll Korean Med, Dept Physiol, Seoul 02453, South Korea.; Kim, W (corresponding author), Kyung Hee Univ, Grad Sch, Dept Sci Korean Med, Seoul 02453, South Korea.; Kim, W (corresponding author), Kyung Hee Univ, Grad Sch, Dept East West Med, Seoul 02453, South Korea.; Jin, YH (corresponding author), Kyung Hee Univ, Coll Med, Dept Physiol, Seoul 02453, South Korea.
EM mibdna@khu.ac.kr; khan2296@naver.com; dmsgmls317@gmail.com; wjkim@khu.ac.kr; jinyh@khu.ac.kr
FU National Research Foundation of Korea (NRF) - Korea government (Ministry of Science and Information and Communications Technology; MSIT) [2020R1A5A201941311]; Immune and Pain Society
CR Adelsberger H, 2000, EUR J PHARMACOL, V406, P25, DOI 10.1016/S0014-2999(00)00667-1
   Andre T, 2004, NEW ENGL J MED, V350, P2343, DOI 10.1056/NEJMoa032709
   Bennett DL, 2019, PHYSIOL REV, V99, P1079, DOI 10.1152/physrev.00052.2017
   Benoit E, 2006, GEN PHYSIOL BIOPHYS, V25, P263
   Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21609
   Cavaletti G, 2001, EUR J CANCER, V37, P2457, DOI 10.1016/S0959-8049(01)00300-8
   Cersosimo RJ, 2005, ANN PHARMACOTHER, V39, P128, DOI 10.1345/aph.1E319
   Chae HK, 2019, NUTRIENTS, V11, P0, DOI 10.3390/nu11020432
   Choi J, 2017, TOXINS, V9, P0, DOI 10.3390/toxins9110351
   Choi S, 2019, TOXINS, V11, P0, DOI 10.3390/toxins11070396
   Cummins TR, 2007, PAIN, V131, P243, DOI 10.1016/j.pain.2007.07.026
   Deuis JR, 2013, PAIN, V154, P1749, DOI 10.1016/j.pain.2013.05.032
   Eckel F, 2002, DEUT MED WOCHENSCHR, V127, P78, DOI 10.1055/s-2002-19594
   Farshchian N, 2018, CANCER CHEMOTH PHARM, V82, P787, DOI 10.1007/s00280-018-3664-y
   Frot M, 2004, PAIN, V108, P230, DOI 10.1016/j.pain.2003.11.017
   Gamelin E, 2002, SEMIN ONCOL, V29, P21, DOI 10.1053/sonc.2002.35525
   GREGG RW, 1992, J CLIN ONCOL, V10, P795, DOI 10.1200/JCO.1992.10.5.795
   Hains BC, 2005, BRAIN, V128, P2359, DOI 10.1093/brain/awh623
   Heide R, 2018, CLIN NEUROPHYSIOL, V129, P694, DOI 10.1016/j.clinph.2017.11.015
   Hershman DL, 2014, J CLIN ONCOL, V32, P1941, DOI 10.1200/JCO.2013.54.0914
   Horowitz Steven H, 2007, ANESTHESIOL CLIN, V25, P699, DOI 10.1016/j.anclin.2007.07.010
   Jacobs S, 2010, CANCER CHEMOTH PHARM, V65, P817, DOI 10.1007/s00280-009-1085-7
   Jung Y, 2017, BMC COMPLEM ALTERN M, V17, P0, DOI 10.1186/s12906-017-1556-z
   Kagiava A, 2008, NEUROTOXICOLOGY, V29, P1100, DOI 10.1016/j.neuro.2008.09.005
   Kim C, 2016, MOLECULES, V21, P0, DOI 10.3390/molecules21091253
   Kim MJ, 2017, KOREAN J PHYSIOL PHA, V21, P657, DOI 10.4196/kjpp.2017.21.6.657
   Kim W, 2020, PROCESSES, V8, P0, DOI 10.3390/pr8060680
   Kim W, 2017, INT J MOL SCI, V18, P0, DOI 10.3390/ijms18122626
   Kim W, 2016, TOXINS, V8, P0, DOI 10.3390/toxins8020033
   Lee Eun Joo, 2016, NEONATAL MEDICINE, V23, P43, DOI 10.5385/nm.2016.23.1.43
   Lee G, 2018, J PHARMACOL EXP THER, V367, P215, DOI 10.1124/jpet.118.251363
   Lee JD, 2005, EVID-BASED COMPL ALT, V2, P79, DOI 10.1093/ecam/neh070
   Lee JH, 2016, KOREAN J PHYSIOL PHA, V20, P407, DOI 10.4196/kjpp.2016.20.4.407
   Lee JH, 2014, BMC COMPLEM ALTERN M, V14, P0, DOI 10.1186/1472-6882-14-471
   Lee MS, 2008, J PAIN, V9, P289, DOI 10.1016/j.jpain.2007.11.012
   Li D, 2016, TOXINS, V8, P0, DOI 10.3390/toxins8010027
   Li D, 2015, TOXINS, V7, P2422, DOI 10.3390/toxins7072422
   Lim BS, 2013, EVID-BASED COMPL ALT, V2013, P0, DOI 10.1155/2013/369324
   Mannelli LD, 2017, NEUROPHARMACOLOGY, V121, P49, DOI 10.1016/j.neuropharm.2017.04.029
   Park SB, 2008, CURR MED CHEM, V15, P3081, DOI 10.2174/092986708786848569
   Rogers M, 2006, SEMIN CELL DEV BIOL, V17, P571, DOI 10.1016/j.semcdb.2006.10.009
   Shin BC, 2012, EUR J INTEGR MED, V4, PE271, DOI 10.1016/j.eujim.2012.02.005
   Sittl R, 2012, P NATL ACAD SCI USA, V109, P6704, DOI 10.1073/pnas.1118058109
   Smith EML, 2013, JAMA-J AM MED ASSOC, V309, P1359, DOI 10.1001/jama.2013.2813
   Son DJ, 2007, PHARMACOL THERAPEUT, V115, P246, DOI 10.1016/j.pharmthera.2007.04.004
   Song YL, 2018, J PHYSIOL BIOCHEM, V74, P207, DOI 10.1007/s13105-017-0606-9
   Soulie P, 1997, EUR J CANCER, V33, P1400, DOI 10.1016/S0959-8049(97)00122-6
   Wilson RH, 2002, J CLIN ONCOL, V20, P1767, DOI 10.1200/JCO.2002.07.056
   Yoon J, 2012, J ACUPUNCT MERIDIAN, V5, P156, DOI 10.1016/j.jams.2012.05.003
   Zhang S, 2018, TOXICON, V148, P64, DOI 10.1016/j.toxicon.2018.04.012
NR 50
TC 25
Z9 26
U1 2
U2 9
PU MDPI
PI BASEL
PA MDPI AG, Grosspeteranlage 5, CH-4052 BASEL, SWITZERLAND
SN 
EI 2072-6651
J9 TOXINS
JI Toxins
PD DEC 15
PY 2020
VL 12
IS 12
BP 
EP 
DI 10.3390/toxins12120737
PG 13
WC Food Science & Technology; Toxicology
SC Food Science & Technology; Toxicology
GA PK3HB
UT WOS:000602339500001
PM 33255279
DA 2026-01-16
ER

PT J
AU Fink, J
   Burns, J
   Moreno, ACP
   Kram, JJF
   Armstrong, M
   Chopp, S
   Maul, SJ
   Conway, N
AF Fink, Jennifer
   Burns, John
   Perez Moreno, Ana Christina
   Kram, Jessica J. F.
   Armstrong, Melissa
   Chopp, Sara
   Maul, Scott J.
   Conway, Nancy
TI A Quality Brief of an Oncological Multisite Massage and Acupuncture Therapy Program to Improve Cancer-Related Outcomes
SO JOURNAL OF ALTERNATIVE AND COMPLEMENTARY MEDICINE
LA English
DT Article
DE cancer-related symptoms; acupuncture treatment; massage treatment
ID integrative medicine
AB Objectives:Cancer treatment can present its own physical and mental challenges resulting in symptoms such as fatigue, stress, pain, nausea, and vomiting. Aurora Health Care is a large health system with 19 cancer centers. Integrative therapies such as acupuncture and massage have demonstrated success in reducing cancer-related symptoms and side effects to conventional cancer treatment and improving patient outcomes. In 2018, 15 of the 19 Aurora Cancer Clinics embedded a replicable Integrative Cancer Care closed model to provide adjuvant therapies for the best patient outcomes. This quality improvement study aimed to explore if the replicable integrative care model could demonstrate consistent outcomes for massage and acupuncture therapies aimed at symptom reduction across multiple oncology clinics. Design:Aurora Cancer Care and Aurora Integrative Medicine designed a reproducible integrative therapy service model to be embedded into the Aurora Cancer Centers. Integrative therapies within the cancer centers allow patients easy access to care before, during, or after their cancer treatment. In 2018, 15 of the 19 cancer clinics had integrative therapies available to patients with cancer. This model required unified operations, onboarding, training, competency, and clinical oversight to achieve consistent processes for consistent outcomes. Furthermore, these innovative models prioritized the following: patient access (easy and affordable); service delivery (consistent and operationalized); clinical outcomes (effective and meaningful); and caliber of clinician (competent and confident). Aurora Health Care employs massage therapists (Mts) and acupuncturists (Ats). This employment model allows for standards and program model adherence. To achieve competent and confident clinician's, MT or AT must complete a cancer treatment-focused competency training program relative to their respective profession and adherence to practice standards outlined. The training program is built on evidence-based practice, observation, direct demonstration, return demonstration, mentorship, and ongoing quality review by clinical leaders. Aurora's Integrative Cancer Care closed model of care is accessible to patients through philanthropic funds secured to underwrite the free service of MT provided during infusion treatments. Funds also provided three free AT sessions. Ongoing acupuncture therapies were provided at a low-cost group acupuncture fee at $25.00 per treatment. Acupuncture is available in group format and provided either before or after chemotherapy treatment. The free services were intended to introduce the concept of integrative therapies as a viable adjuvant option with conventional cancer care. As this model incorporates a mix of philanthropic funding and low-cost fees to offset the cost of the therapy provider, it is referred to as a "closed model" or accessible only to those patients under the care of an Aurora Cancer specialist. In 2018, 15 Aurora Cancer Clinics offered massage and 11 Aurora Cancer Clinics offered acupuncture. Patients who self-selected integrative therapies via system-employed Mts and Ats were surveyed pre/post acupuncture and MT treatments using a visual analog scale about their perceived levels of pain, stress, nausea, and neuropathy. The staff integrative clinicians collected data from patients, and post-treatment data were compiled by the Department of Integrative Medicine. Settings/Location:Aurora Cancer Centers are embedded within Aurora hospitals or free-standing clinics located throughout Wisconsin. In 2018, 15 cancer clinic locations embedded Mts, and 11 cancer clinic locations embedded Ats. Subjects:Oncology patients. Interventions:Clinical competencies were developed and applied to address indications, contraindications, and oncology-specific procedures to ensure that consistent quality of therapies was provided across sites. In 2018, Ats delivered 4367 Ats across 11 locations and Mts delivered 4197 Mts across 15 locations. During this study, the number of treatments provided was tracked versus episodic care. Outcome Measures:Pre/post AT and MT pain, stress, nausea, and neuropathy scores were recorded (0 [least] to 10 [worst]) and compared using pairedt-tests. Results:Pre/post AT scores for pain, neuropathy, stress, and nausea were all significantly different (p < 0.001). For AT, there was a reported decrease in pain, stress, and neuropathy of 61.7%, 68.8%, and 47.9%, respectively. Pre/post MT scores for pain, neuropathy, nausea, and stress were also significantly different (p < 0.001). MT was greater at reducing stress and pain, 42.5% and 34.4%, respectively. Conclusions:Across 15 cancer clinics, both AT and MT treatments consistently and significantly reduced cancer-related side effects. These findings highlight the value of conducting a larger randomized-controlled trial to further assess the impact of Oncological Multisite Massage and Acupuncture Therapy on cancer-related symptoms across multiple oncologic clinics.
C1 [Fink, Jennifer; Chopp, Sara] Univ Wisconsin, Dept Hlth Informat & Adm, 2025 East Newport Ave, Milwaukee, WI 53211 USA.
   [Burns, John; Armstrong, Melissa; Conway, Nancy] Aurora Sinai Med Ctr, Aurora Hlth Care, Dept Integrat Med, Milwaukee, WI USA.
   [Perez Moreno, Ana Christina] Aurora Hlth Care, Aurora Res Inst, Milwaukee, WI USA.
   [Kram, Jessica J. F.] Aurora Sinai Med Ctr, Aurora Hlth Care, Aurora UW Med Grp, Milwaukee, WI USA.
   [Kram, Jessica J. F.] Aurora Sinai Med Ctr, Aurora Hlth Care, Ctr Urban Populat Hlth, Milwaukee, WI USA.
   [Maul, Scott J.] Aurora Hlth Care, Dept Oncol, Milwaukee, WI USA.
C3 University of Wisconsin System; University of Wisconsin Milwaukee; University of Wisconsin System; University of Wisconsin Milwaukee
RP Fink, J (corresponding author), Univ Wisconsin, Dept Hlth Informat & Adm, 2025 East Newport Ave, Milwaukee, WI 53211 USA.
EM jtfink@uwm.edu
CR Armstrong K, 2018, SUPPORT CARE CANCER, V26, P2267, DOI 10.1007/s00520-017-4007-y
   Cassileth BR, 2004, J PAIN SYMPTOM MANAG, V28, P244, DOI 10.1016/j.jpainsymman.2003.12.016
   Deng G, 2017, J NATL CANC I MONOGR, V2017, P0
   Garcia MK, 2013, J CLIN ONCOL, V31, P952, DOI 10.1200/JCO.2012.43.5818
   Kedar A, 2012, PROG PALLIAT CARE, V20, P284, DOI 10.1179/1743291X12Y.0000000034
   Lu WD, 2013, CURR PAIN HEADACHE R, V17, P0, DOI 10.1007/s11916-013-0321-3
   Pearce A, 2017, PLOS ONE, V12, P0, DOI 10.1371/journal.pone.0184360
   Schuster L, 2018, JNP-J NURSE PRACT, V14, P276, DOI 10.1016/j.nurpra.2017.11.015
   Siegel P, 2015, EUR J INTEGR MED, V7, P23, DOI 10.1016/j.eujim.2014.11.004
   Stone JAM, 2010, CURR TREAT OPTION ON, V11, P118, DOI 10.1007/s11864-010-0128-y
NR 10
TC 14
Z9 15
U1 1
U2 16
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1075-5535
EI 1557-7708
J9 J ALTERN COMPLEM MED
JI J. Altern. Complement Med.
PD SEP 1
PY 2020
VL 26
IS 9
BP 820
EP 824
DI 10.1089/acm.2019.0371
PG 5
WC Integrative & Complementary Medicine
SC Integrative & Complementary Medicine
GA NN8AD
UT WOS:000569008100013
PM 32924553
DA 2026-01-16
ER

PT J
AU Birch, S
   Bovey, M
   Alraek, T
   Robinson, N
   Kim, TH
   Lee, MS
AF Birch, Stephen
   Bovey, Mark
   Alraek, Terje
   Robinson, Nicola
   Kim, Tae-Hun
   Lee, Myeong Soo
TI Acupuncture as a Treatment Within Integrative Health for Palliative Care: A Brief Narrative Review of Evidence and Recommendations
SO JOURNAL OF ALTERNATIVE AND COMPLEMENTARY MEDICINE
LA English
DT Review
DE acupuncture; palliative care; evidence; recommendations
ID complex interventions; alternative medicine; symptom management; safety; complementary; therapy; oncology; efficacy; dyspnea; pain
AB Background:Acupuncture is one of the fastest developing evidence bases in Complementary Medicine and is one of the leading therapies included within integrative health care. This narrative review includes two separate parts: the first is about evaluation of the current evidence status in reviews on acupuncture and the second examines and gives examples of available recommendations on acupuncture in treatment guidelines from health care experts and public health organizations recommending acupuncture as a viable treatment in patients in palliative care. Methods:Electronic searches were performed in PubMed using the terms "acupuncture" + "palliative" and adding the term "safety" to find review articles documenting safety and evidence of effectiveness of acupuncture for treatment of symptoms in palliative care patients. Treatment guidelines that recommend use of acupuncture for symptom control in palliative care were found by searching through a database currently under construction by the lead author. Results:Acupuncture shows emerging evidence for 17 indications in palliative care. Examples were found and presented of publications recommending acupuncture for treatment of symptoms for patients in palliative care from Government, public health, oncology, and medical expert sources. The most publications are in oncology, but other conditions were found and a number were found in pediatric care. Conclusions:While the evidence for use of acupuncture to treat symptoms in palliative care patients is relatively weak, the evidence base is growing. Experts worldwide are also increasingly recommending acupuncture as a treatment for symptoms in palliative care. Since acupuncture is a safe, nonpharmacological treatment but with small, clinically significant effects, these recommended uses appear as pragmatic efforts to bridge the gap of treatment options available to this patient group.
C1 [Birch, Stephen; Alraek, Terje] Kristiania Univ Coll, Sch Hlth Sci, N-0152 Oslo, Norway.
   [Bovey, Mark] British Acupuncture Council, Acupuncture Res Resource Ctr, London, England.
   [Alraek, Terje] UiT Arctic Univ Norway, Natl Res Ctr Complementary & Alternat Med, Fac Med, Dept Community Med, Tromso, Norway.
   [Robinson, Nicola] Beijing Univ Chinese Med, Ctr Evidence Based Chinese Med, Beijing, Peoples R China.
   [Kim, Tae-Hun] Kyung Hee Univ, Korean Med Hosp, Korean Med Clin Trial Ctr, Seoul, South Korea.
   [Lee, Myeong Soo] Korea Inst Oriental Med, Div Clin Med, Daejeon, South Korea.
C3 Kristiania University College; UiT The Arctic University of Tromso; Beijing University of Chinese Medicine; Kyung Hee University; Kyung Hee University Hospital; Korea Institute of Oriental Medicine (KIOM)
RP Birch, S (corresponding author), Kristiania Univ Coll, Sch Hlth Sci, N-0152 Oslo, Norway.
EM sjbirch@gmail.com
CR Adams D, 2011, PEDIATRICS, V128, PE1575, DOI 10.1542/peds.2011-1091
   Adler SR, 2019, J ALTERN COMPLEM MED, V25, P257, DOI 10.1089/acm.2019.29063.sra
   Anderson MD, 2007, PATIENT FAMILY SYMPT, V0, P0
   Unknown -, 2014, THE PALLIATIVE CARE HANDBOOK, V8A, P0
   Unknown -, 2016, RESP SYMPT PALL CAR, V0, P0
   Unknown -, 2016, PAIN MAN PALL CAR, V0, P0
   Unknown -, 1900, DOI 10.1177/1049909108322292, V0, P0
   Appleyard I, 2014, EUR J INTEGR MED, V6, P234, DOI 10.1016/j.eujim.2014.03.004
   Arbeitsgemeinschaft Gynakologische Onkologie, 2015, DIAGN TREATM PAT PRI, V0, P0
   Ben-Aharon I, 2008, J CLIN ONCOL, V26, P2396, DOI 10.1200/JCO.2007.15.5796
   Birch J, 2020, BIOL PHILOS, V35, P0, DOI 10.1007/s10539-019-9712-0
   Birch S, 2004, J ALTERN COMPLEM MED, V10, P468, DOI 10.1089/1075553041323894
   Birch S, 2018, J ALTERN COMPLEM MED, V24, P752, DOI 10.1089/acm.2018.0092
   Birch S, 2019, INTEGR MED RES, V8, P160, DOI 10.1016/j.imr.2019.05.002
   Birch Stephen, 1999, UNDERSTANDING ACUPUN, V0, P0
   Brittner M, 2016, CURR PROB PEDIATR AD, V46, P179, DOI 10.1016/j.cppeds.2015.12.005
   Cancer Council Victoria, 2019, PALL CAR, V0, P0
   Colvin L, 2006, BRIT MED J, V332, P1081, DOI 10.1136/bmj.332.7549.1081
   Cornally N, 2016, PALLIATIVE CARE FOR THE PERSON WITH DEMENTIA GUIDANCE DOCUMENT 5: PAIN ASSESSMENT AND MANAGEMENT, V0, P0
   Cracolici F, 2019, OBM INTEGRAT COMPLEM, V4, P12
   Craig Peter, 2008, BMJ, V337, Pa1655, DOI 10.1136/bmj.a1655
   Cybularz PA, 2015, MED ACUPUNCT, V27, P224, DOI 10.1089/acu.2015.1099
   Dhingra L, 2015, PAIN MED, V16, PS37, DOI 10.1111/pme.12912
   Dodd M J, 2001, ONCOL NURS FORUM, V28, P465
   Dutch Association for Pediatrics, 2013, PALL CAR CHILDR, V0, P0
   Ernst Edzard, 2010, J PAIN SYMPTOM MANAGE, V40, Pe3, DOI 10.1016/j.jpainsymman.2010.07.003
   Evans CJ, 2013, MRC GUIDANCE DEV EVA, V0, P0
   EviCore Healthcare, 2019, CLIN GUID AC SERV VE, V0, P0
   Filshie J, 2001, ACUPUNCT MED, V19, P117
   Filshie J, 2011, ACUPUNCT MED, V29, P166, DOI 10.1136/acupmed-2011-010063
   Garcia MK, 2014, CURR ONCOL REP, V16, P0, DOI 10.1007/s11912-014-0418-9
   Grande G, 2011, PALLIATIVE MED, V25, P737, DOI 10.1177/0269216311425641
   Grant SJ, 2019, INTEGR CANCER THER, V18, P0, DOI 10.1177/1534735418823266
   Hackett J, 2018, BMJ OPEN, V8, P0, DOI 10.1136/bmjopen-2018-022835
   Hepgul N, 2019, TXB PALLIATIVE CARE, V0, P1669
   Higginson IJ, 2013, BMC MED, V11, P0, DOI 10.1186/1741-7015-11-111
   Integral Cancer Center of the Netherlands, 2015, DYSPN PALL PHAS NAT, V0, P0
   Jansen K, 2018, J PAIN SYMPTOM MANAG, V55, P508, DOI 10.1016/j.jpainsymman.2017.06.010
   Janz S, 2019, ACUPUNCTURE EVIDENCE, V0, P0
   Jindal V, 2008, J PEDIAT HEMATOL ONC, V30, P431, DOI 10.1097/MPH.0b013e318165b2cc
   Kahn ST, 2005, ONCOLOGY-NY, V19, P1827
   Kamal AH, 2012, J PALLIAT MED, V15, P106, DOI 10.1089/jpm.2011.0110
   Kelly Kara M, 2009, HEMATOLOGY AM SOC HEMATOL EDUC PROGRAM, V0, PP307, DOI 10.1182/asheducation-2009.1.307
   Kim KH, 2016, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD009440.pub2
   Lau CHY, 2016, MEDICINE, V95, P0, DOI 10.1097/MD.0000000000002901
   Lian WL, 2014, CHIN J INTEGR MED, V20, P136, DOI 10.1007/s11655-013-1439-1
   Liao GS, 2013, EVID-BASED COMPL ALT, V2013, P0, DOI 10.1155/2013/437948
   Lu WD, 2008, HEMATOL ONCOL CLIN N, V22, P631, DOI 10.1016/j.hoc.2008.04.005
   Lu WD, 2010, CURR TREAT OPTION ON, V11, P141, DOI 10.1007/s11864-010-0126-0
   Lund Irene, 2006, ACUPUNCT MED, V24, P13
   Lytle CD, 1993, OVERVIEW ACUPUNCTURE, V0, P0
   Ma Y, 2016, PLOS ONE, V11, P0, DOI 10.1371/journal.pone.0168123
   MacPherson H, 2014, PLOS ONE, V9, P0, DOI 10.1371/journal.pone.0093739
   MacPherson H, 2012, J ACUPUNCT MERIDIAN, V5, P141, DOI 10.1016/j.jams.2012.05.001
   Maindet C, 2019, SUPPORT CARE CANCER, V27, P3119, DOI 10.1007/s00520-019-04829-7
   Mansky PJ, 2006, CANCER J, V12, P425, DOI 10.1097/00130404-200609000-00011
   Marchand L, 2014, ANN PALLIAT MED, V3, P160, DOI 10.3978/j.issn.2224-5820.2014.07.01
   McPhail P, 2018, EUR J CANCER CARE, V27, P0, DOI 10.1111/ecc.12802
   Miller KR, 2019, AM J HOSP PALLIAT ME, V36, P326, DOI 10.1177/1049909118804464
   Moretto EN, 2013, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD008768.pub2
   Morrison RS, 2013, CURR OPIN SUPPORT PA, V7, P201, DOI 10.1097/SPC.0b013e32836103e5
   Muecke R, 2016, INTEGR CANCER THER, V15, P10, DOI 10.1177/1534735415596423
   Multiple Sclerosis Society, 2006, MS PALL CAR GUID HLT, V0, P0
   National Cancer Institute, 2019, AC PDQ HLTH PROF VER, V0, P0
   National Comprehensive Cancer Network, 2017, PALL CAR VERS 1 2017, V0, P0
   Norval DA, 2006, CLIN GUIDE SUPPORT 2, V0, P43
   Oneschuk D, 2007, SUPPORT CARE CANCER, V15, P939, DOI 10.1007/s00520-007-0284-1
   Osman Hibah, 2018, J GLOB ONCOL, V4, P1, DOI 10.1200/JGO.18.00026
   Paley CA, 2011, EVID-BASED COMPL ALT, V2011, P1, DOI 10.1093/ecam/neq020
   Pan CX, 2000, J PAIN SYMPTOM MANAG, V20, P374, DOI 10.1016/S0885-3924(00)00190-1
   Pan-Weisz TM, 2019, PSYCHO-ONCOLOGY, V28, P11, DOI 10.1002/pon.4906
   Pediatric Oncology Group of Ontario, 2018, SYMPT MAN GUID CHILD, V0, P0
   Pineda MJ, 2012, OBSTET GYN CLIN N AM, V39, P285, DOI 10.1016/j.ogc.2012.03.001
   Raina R, 2018, HEMODIAL INT, V22, P290, DOI 10.1111/hdi.12622
   Ralston-Wilson J, 2016, J ALTERN COMPLEM MED, V22, P458, DOI 10.1089/acm.2015.0347
   Ramsay DJ, 1998, JAMA-J AM MED ASSOC, V280, P1518
   Raphael J, 2010, PAIN MED, V11, P872, DOI 10.1111/j.1526-4637.2010.00841.x
   Ring M, 2017, PRIMARY CARE, V44, P203, DOI 10.1016/j.pop.2017.02.006
   Robinson N, 2019, EUR J INTEGR MED, V32, P0, DOI 10.1016/j.eujim.2019.100997
   Runowicz CD, 2016, CA-CANCER J CLIN, V66, P44, DOI 10.3322/caac.21319
   Scarborough BM, 2018, CA-CANCER J CLIN, V68, P182, DOI 10.3322/caac.21453
   Scotté F, 2012, ONCOLOGIST, V17, P23, DOI 10.1634/theoncologist.2012-S1-23
   Seamark DA, 2007, J ROY SOC MED, V100, P225, DOI 10.1258/jrsm.100.5.225
   Shafto K, 2018, CHILDREN-BASEL, V5, P0, DOI 10.3390/children5060075
   Standish LJ, 2008, AM J HOSP PALLIAT ME, V25, P298, DOI 10.1177/1049909108315916
   Stussman BJ, 2020, J ALTERN COMPLEM MED, V26, P25, DOI 10.1089/acm.2019.0303
   Thompson LMA, 2019, ASCO POST 2019, V0, P0
   Towler P, 2013, SUPPORT CARE CANCER, V21, P2913, DOI 10.1007/s00520-013-1882-8
   Unschuld PU, 2003, HUANG DI NEI JING SU WEN: NATURE, V0, P0
   Venkatasalu MR, 2020, BMC ORAL HEALTH, V20, P0, DOI 10.1186/s12903-020-01075-w
   Vesel T, 2011, HANDBOOK OF PEDIATRIC CHRONIC PAIN: CURRENT SCIENCE AND INTEGRATIVE PRACTICE, V0, PP193, DOI 10.1007/978-1-4419-0350-1_12
   Vickers A, 2002, QUAL SAF HEALTH CARE, V11, P92, DOI 10.1136/qhc.11.1.92
   Vilela VC, 2017, SAO PAULO MED J, V135, P309, DOI 10.1590/1516-3180.2017.0092060617
   von Trott P, 2020, J PAIN SYMPTOM MANAG, V59, P327, DOI 10.1016/j.jpainsymman.2019.09.007
   Walshe C, 2011, PALLIATIVE MED, V25, P774, DOI 10.1177/0269216311419883
   Watson M, 2016, PALLIATIVE CARE GUID, V0, P0
   Wolff A, 2012, CURR PHARM DESIGN, V18, P5515, DOI 10.2174/138161212803307509
   World Health Organization, 2018, "INTEGRATING PALLIATIVE CARE AND SYMPTOM RELIEF INTO RESPONSES TO HUMANITARIAN EMERGENCIES AND CRISES: A WHO GUIDE", V0, P0
   World Health Organization, 2002, WHO DEF PALL CAR WHO, V0, P0
   World Health Organization, 2006, 3 PALL CAR PEOPL LIV, V0, P0
   Wu XL, 2015, SCI REP-UK, V5, P0, DOI 10.1038/srep11728
   Yang CS, 2015, PEDIATR RES, V78, P112, DOI 10.1038/pr.2015.91
   Yu CF, 2019, INTEGR CANCER THER, V18, P0, DOI 10.1177/1534735419829568
   Zeng YS, 2018, J PAIN SYMPTOM MANAG, V56, P781, DOI 10.1016/j.jpainsymman.2018.07.016
   Zhang CS, 2015, PLOS ONE, V10, P0, DOI 10.1371/journal.pone.0140825
   Zia Farah Z, 2017, JOURNAL OF THE NATIONAL CANCER INSTITUTE MONOGRAPHS, V0, PP68, DOI 10.1093/jncimonographs/lgx005
NR 108
TC 14
Z9 16
U1 0
U2 14
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1075-5535
EI 1557-7708
J9 J ALTERN COMPLEM MED
JI J. Altern. Complement Med.
PD SEP 1
PY 2020
VL 26
IS 9
BP 784
EP 791
DI 10.1089/acm.2020.0032
PG 8
WC Integrative & Complementary Medicine
SC Integrative & Complementary Medicine
GA NN8AD
UT WOS:000569008100008
PM 32924554
DA 2026-01-16
ER

PT J
AU Jang, S
   Ko, Y
   Sasaki, Y
   Park, S
   Jo, J
   Kang, NH
   Yoo, ES
   Park, NC
   Cho, SH
   Jang, H
   Jang, BH
   Hwang, DS
   Ko, SG
AF Jang, Soobin
   Ko, Youme
   Sasaki, Yui
   Park, Sunju
   Jo, Junyoung
   Kang, Na-Hoon
   Yoo, Eun-Sil
   Park, Nam-Chun
   Cho, Seong Hee
   Jang, Heejea
   Jang, Bo-Hyoung
   Hwang, Deok-Sang
   Ko, Seong-Gyu
TI Acupuncture as an adjuvant therapy for management of treatment-related symptoms
SO Medicine
LA English
DT Journal Article
AB BACKGROUND: Although randomized controlled trials have revealed the considerable  effectiveness of acupuncture in breast cancer patients, there have been no  studies exploring current acupuncture research trends for treatment induced  various symptoms in breast cancer patients. This review evaluated the  effectiveness of acupuncture for treatment-induced symptoms in breast cancer  patients. METHODS: We performed a systematic review and meta-analysis of the  literature regarding acupuncture to treat symptoms associated with breast cancer  therapies. The following databases were searched for relevant RCTs published  before June 2018: MEDLINE, EMBASE, the Cochrane Library, AMED, CINAHL, OASIS,  CNKI, and CiNii. RESULTS: Among the 19,483 records identified, 835 articles  remained after screening titles and abstracts. A total of 19 RCTs were included  in this qualitative synthesis. Among the studies, 8 explored climacteric  symptoms, 4 explored pain, 2 explored lymphedemas, 2 explored nausea and vomiting  and 3 investigated miscellaneous symptoms.explored miscellaneous symptoms due to  cancer treatments. Most of the studies reported that acupuncture can alleviate  various symptoms of breast cancer treatment. However, there is a lack of evidence  as to whether accupuncture can alleviate chemotherapy associated side effects  CONCLUSIONS:: Acupuncture may alleviate the treatment-related symptoms of breast  cancer; however, further studies are necessary to obtain conclusive evidence of  the effectiveness of acupuncture in treating breast cancer. REGISTRATION NUMBER:  CRD42018087813.
C1 Clinical Research Division, Korea Institute of Oriental Medicine
   1672 Yuseong-daero, Yuseong-gu, Daejeon.
   Department of Preventive Medicine, College of Korean Medicine, Kyung Hee University
   26, Kyungheedae-ro, Hoegi-dong, Dongdaemun-gu, Seoul.
   Department of Preventive Medicine, College of Korean Medicine, Kyung Hee University
   26, Kyungheedae-ro, Hoegi-dong, Dongdaemun-gu, Seoul.
   Department of Preventive Medicine, College of Korean Medicine, Daejeon University
   62 Daehak-ro, Dong-gu, Daejeon.
   Department of Korean Obstetrics and Gynecology, Conmaul Hospital of Korean Medicine, 110 Seochojungang-ro, Seocho-dong, Seocho-gu, Seoul.
   Department of Clinical Korean Medicine, Graduate School, Kyung-Hee University, 26, Kyungheedae-ro, Hoegi-dong, Dongdaemun-gu, Seoul.
   Department of Clinical Korean Medicine, Graduate School, Kyung-Hee University, 26, Kyungheedae-ro, Hoegi-dong, Dongdaemun-gu, Seoul.
   Department of Clinical Korean Medicine, Graduate School, Kyung-Hee University, 26, Kyungheedae-ro, Hoegi-dong, Dongdaemun-gu, Seoul.
   Department of Obstetrics and Gynecology, College of Korean Medicine, Dong-Shin University, 185, Geonjae-ro, Naju-si, Jeollanam-do.
   Women Cancer Center, Soram Korean medicine Hospital, 154-11, Samsung-dong, 06154, Gangnam-gu, Seoul, Republic of Korea.
   Department of Preventive Medicine, College of Korean Medicine, Kyung Hee University
   26, Kyungheedae-ro, Hoegi-dong, Dongdaemun-gu, Seoul.
   Department of Preventive Medicine, College of Korean Medicine, Daejeon University
   62 Daehak-ro, Dong-gu, Daejeon.
   Department of Preventive Medicine, College of Korean Medicine, Kyung Hee University
   26, Kyungheedae-ro, Hoegi-dong, Dongdaemun-gu, Seoul.
NR 0
TC 0
SN 1536-596
EI 0025-797
J9 Medicine (Baltimore)
PD DEC 18
PY 2020
VL 99
IS 50
BP e21820
EP e21820
DI 10.1097/MD.0000000000021820
PG 1
WC Acupuncture Therapy; methods; Adult; Aged; Aged, 80 and over; Breast Cancer Lymphedema; therapy; Breast Neoplasms; pathology; Case-Control Studies; Evaluation Studies as Topic; Female; Hot Flashes; therapy; Humans; Middle Aged; Nausea; therapy; Pain Management; methods; Randomized Controlled Trials as Topic; Vomiting; therapy
UT PubMed:33327222
PM 33327222
DA 2020-12-18
ER

PT J
AU Zhang, N
   Li, JL
   Yan, CQ
   Wang, X
   Lin, LL
   Tu, JF
   Qi, YS
   Liu, JH
   Liu, CZ
   Wang, LQ
AF Zhang, Na
   Li, Jin-Ling
   Yan, Chao-Qun
   Wang, Xu
   Lin, Lu-Lu
   Tu, Jian-Feng
   Qi, You-Sheng
   Liu, Jun-Hong
   Liu, Cun-Zhi
   Wang, Li-Qiong
TI The cerebral mechanism of the specific and nonspecific effects of acupuncture based on knee osteoarthritis: study protocol for a randomized controlled trial
SO TRIALS
LA English
DT Article
DE Specific effect; Nonspecific effect; Acupuncture; Knee osteoarthritis; Functional magnetic resonance imaging; Clinical trial
ID sham acupuncture; breast-cancer; placebo; pain; brain; women; power; fmri; electroacupuncture; regions
AB BackgroundResearch on the effect of acupuncture has been limited. Whether the effect of acupuncture is equivalent to placebo has been the focus of debate in this field. This study will explore the specific and non-specific effects of acupuncture for knee osteoarthritis (KOA) by functional magnetic resonance imaging (fMRI).Methods and designNinety participants diagnosed with KOA will be randomly divided into the acupuncture group, sham acupuncture group, and waiting list group in a ratio of 1:1:1. Except for the waiting list group, the other participants will receive acupuncture or sham acupuncture three sessions per week for 4weeks respectively. The primary outcome will be the response rate which is defined on an individual basis as at least a 2-point decrease in the numerical rating scale (NRS) of pain at the end of intervention period compared with the baseline. fMRI scans will be performed at baseline and the end of the intervention period to examine the response of various brain regions. The secondary outcomes will include the Western Ontario and McMaster Osteoarthritis Index (WOMAC), State-Trait Anxiety Scale-State Anxiety Subscale (STAI-S), and Stanford Expectations of Treatment Scale (SETS). Pearson's correlation coefficient will be performed to investigate the changes in brain activity and clinical variables.DiscussionThe results of our study will help to evaluate the specific and nonspecific effects of acupuncture combined with clinical and brain function changes based on KOA.Trial registrationChinese Clinical Trial Registry ChiCTR1900025799. Registered on 9 September 2019.
C1 [Zhang, Na] Shandong Univ Chinese Med, Sch Acupuncture Moxibust & Tuina, Jinan, Shandong, Peoples R China.
   [Zhang, Na; Li, Jin-Ling; Yan, Chao-Qun; Lin, Lu-Lu; Tu, Jian-Feng; Liu, Cun-Zhi; Wang, Li-Qiong] Beijing Univ Chinese Med, Sch Acupuncture Moxibust & Tuina, Acupuncture Res Ctr, 11 Bei San Huan Dong Lu, Beijing 100029, Peoples R China.
   [Wang, Xu] Beijing Univ Chinese Med, Sch Life Sci, Beijing, Peoples R China.
   [Qi, You-Sheng; Liu, Jun-Hong] Nanyuan Community Hlth Serv Ctr, Beijing, Peoples R China.
C3 Shandong University of Traditional Chinese Medicine; Beijing University of Chinese Medicine; Beijing University of Chinese Medicine
RP Wang, LQ (corresponding author), Beijing Univ Chinese Med, Sch Acupuncture Moxibust & Tuina, Acupuncture Res Ctr, 11 Bei San Huan Dong Lu, Beijing 100029, Peoples R China.
EM wangliqiongwork@163.com
FU Beijing Municipal Science & Technology Commission [D171100003217003]
CR Alshelh Z, 2018, NEUROIMAGE-CLIN, V17, P222, DOI 10.1016/j.nicl.2017.10.019
   Benedetti F, 2008, ANNU REV PHARMACOL, V48, P33, DOI 10.1146/annurev.pharmtox.48.113006.094711
   Bijlsma JWJ, 2011, LANCET, V377, P2115, DOI 10.1016/S0140-6736(11)60243-2
   Cao J, 2019, CEREB CORTEX, V29, P3220, DOI 10.1093/cercor/bhy190
   Chen XY, 2015, MOL PAIN, V11, P0, DOI 10.1186/s12990-015-0071-9
   Chen XY, 2014, SCI REP-UK, V4, P0, DOI 10.1038/srep06482
   Desmond JE, 2002, J NEUROSCI METH, V118, P115, DOI 10.1016/S0165-0270(02)00121-8
   Egorova N, 2015, NEUROIMAGE-CLIN, V9, P430, DOI 10.1016/j.nicl.2015.09.012
   Ernst E, 2011, PAIN, V152, P952, DOI 10.1016/j.pain.2010.12.007
   Finniss DG, 2010, LANCET, V375, P686, DOI 10.1016/S0140-6736(09)61706-2
   Furlan AD, 2005, SPINE, V30, P944, DOI 10.1097/01.brs.0000158941.21571.01
   Gabrieli JDE, 2015, NEURON, V85, P11, DOI 10.1016/j.neuron.2014.10.047
   Geuter S, 2017, ANNU REV NEUROSCI, V40, P167, DOI 10.1146/annurev-neuro-072116-031132
   Hall KT, 2015, TRENDS MOL MED, V21, P285, DOI 10.1016/j.molmed.2015.02.009
   Hershman DL, 2018, JAMA-J AM MED ASSOC, V320, P167, DOI 10.1001/jama.2018.8907
   Hinman RS, 2014, JAMA-J AM MED ASSOC, V312, P1313, DOI 10.1001/jama.2014.12660
   HOCHBERG MC, 1995, ARTHRITIS RHEUM, V38, P1541, DOI 10.1002/art.1780381104
   Karner M, 2013, EVID-BASED COMPL ALT, V2013, P0, DOI 10.1155/2013/427265
   Kong J, 2018, NEUROIMAGE-CLIN, V18, P325, DOI 10.1016/j.nicl.2018.01.021
   Linde K, 2016, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD001218.pub3
   Linde K, 2010, BMC MED, V8, P0, DOI 10.1186/1741-7015-8-75
   Linde K, 2009, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD007587
   Liu CH, 2020, BRAIN BEHAV, V10, P0, DOI 10.1002/brb3.1494
   Liu JX, 2017, HUM BRAIN MAPP, V38, P4386, DOI 10.1002/hbm.23667
   Liu ZS, 2017, JAMA-J AM MED ASSOC, V317, P2493, DOI 10.1001/jama.2017.7220
   Ma Y, 2016, PLOS ONE, V11, P0, DOI 10.1371/journal.pone.0168123
   Madsen MV, 2009, BMJ-BRIT MED J, V338, P0, DOI 10.1136/bmj.a3115
   Mao JJ, 2015, J CLIN ONCOL, V33, P3615, DOI 10.1200/JCO.2015.60.9412
   Meissner K, 2013, JAMA INTERN MED, V173, P1941, DOI 10.1001/jamainternmed.2013.10391
   Miller FG, 2008, J ROY SOC MED, V101, P222, DOI 10.1258/jrsm.2008.070466
   Mumford JA, 2008, NEUROIMAGE, V39, P261, DOI 10.1016/j.neuroimage.2007.07.061
   Murray CJL, 2012, LANCET, V380, P2197, DOI 10.1016/S0140-6736(12)61729-2
   Price DD, 2008, ANNU REV PSYCHOL, V59, P565, DOI 10.1146/annurev.psych.59.113006.095941
   Smith CA, 2018, JAMA-J AM MED ASSOC, V319, P1990, DOI 10.1001/jama.2018.5336
   Tedesco D, 2017, JAMA SURG, V152, P0, DOI 10.1001/jamasurg.2017.2872
   Tétreault P, 2018, HUM BRAIN MAPP, V39, P2210, DOI 10.1002/hbm.23999
   Tétreault P, 2016, PLOS BIOL, V14, P0, DOI 10.1371/journal.pbio.1002570
   Vachon-Presseau E, 2018, NAT COMMUN, V9, P0, DOI 10.1038/s41467-018-05859-1
   Wager TD, 2013, NEW ENGL J MED, V368, P1388, DOI 10.1056/NEJMoa1204471
   Wampold BE, 2005, J CLIN PSYCHOL, V61, P835, DOI 10.1002/jclp.20129
   Wang HY, 2018, AM J CHINESE MED, V46, P1387, DOI 10.1142/S0192415X18500738
   Williams CM, 2012, BRIT J SPORT MED, V46, P578, DOI 10.1136/bjsports-2012-091229
   Woolf AD, 2003, B WORLD HEALTH ORGAN, V81, P646
   Zhao L, 2019, JAMA INTERN MED, V179, P1388, DOI 10.1001/jamainternmed.2019.2407
   Zou K, 2016, ANN RHEUM DIS, V75, P1964, DOI 10.1136/annrheumdis-2015-208387
   Zou Y, 2019, NEURAL PLAST, V2019, P0, DOI 10.1155/2019/5047463
NR 46
TC 2
Z9 4
U1 1
U2 14
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 
EI 1745-6215
J9 TRIALS
JI Trials
PD JUN 23
PY 2020
VL 21
IS 1
BP 
EP 
DI 10.1186/s13063-020-04518-5
PG 10
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA MF9UK
UT WOS:000545682400005
PM 32576243
DA 2026-01-16
ER

PT J
AU Tao, XS
   Lee, MCS
   Donnelly, CR
   Ji, RR
AF Tao, Xueshu
   Lee, Michael S.
   Donnelly, Christopher R.
   Ji, Ru-Rong
TI Neuromodulation, Specialized Proresolving Mediators, and Resolution of Pain
SO NEUROTHERAPEUTICS
LA English
DT Review
DE Auricular stimulation; chemotherapy; dorsal root ganglion; fish oil; resolvin; vagus nerve stimulation
ID spinal-cord stimulation; vagus nerve-stimulation; pro-resolving mediators; primary sensory neurons; n-6 fatty-acids; inflammatory pain; neuropathic pain; central sensitization; electrical-stimulation; molecular-mechanisms
AB The current crises in opioid abuse and chronic pain call for the development of nonopioid and nonpharmacological therapeutics for pain relief. Neuromodulation-based approaches, such as spinal cord stimulation, dorsal root ganglion simulation, and nerve stimulation including vagus nerve stimulation, have shown efficacy in achieving pain control in preclinical and clinical studies. However, the mechanisms by which neuromodulation alleviates pain are not fully understood. Accumulating evidence suggests that neuromodulation regulates inflammation and neuroinflammation-a localized inflammation in peripheral nerves, dorsal root ganglia/trigeminal ganglia, and spinal cord/brain-through neuro-immune interactions. Specialized proresolving mediators (SPMs) such as resolvins, protectins, maresins, and lipoxins are lipid molecules produced during the resolution phase of inflammation and exhibit multiple beneficial effects in resolving inflammation in various animal models. Recent studies suggest that SPMs inhibit inflammatory pain, postoperative pain, neuropathic pain, and cancer pain in rodent models via immune, glial, and neuronal modulations. It is noteworthy that sham surgery is sufficient to elevate resolvin levels and may serve as a model of resolution. Interestingly, it has been shown that the vagus nerve produces SPMs and vagus nerve stimulation (VNS) induces SPM productionin vitro. In this review, we discuss how neuromodulation such as VNS controls pain via immunomodulation and neuro-immune interactions and highlight possible involvement of SPMs. In particular, we demonstrate that VNS via auricular electroacupuncture effectively attenuates chemotherapy-induced neuropathic pain. Furthermore, auricular stimulation is able to increase resolvin levels in mice. Thus, we propose that neuromodulation may control pain and inflammation/neuroinflammatioin via SPMs. Finally, we discuss key questions that remain unanswered in our understanding of how neuromodulation-based therapies provide short-term and long-term pain relief.
C1 [Tao, Xueshu; Lee, Michael S.; Donnelly, Christopher R.; Ji, Ru-Rong] Duke Univ, Med Ctr, Dept Anesthesiol, Ctr Translat Pain Med, Durham, NC 27710 USA.
   [Ji, Ru-Rong] Duke Univ, Med Ctr, Dept Neurobiol, Durham, NC 27710 USA.
   [Ji, Ru-Rong] Duke Univ, Med Ctr, Dept Cell Biol, Durham, NC 27710 USA.
C3 Duke University; Duke University; Duke University
RP Ji, RR (corresponding author), Duke Univ, Med Ctr, Dept Anesthesiol, Ctr Translat Pain Med, Durham, NC 27710 USA.; Ji, RR (corresponding author), Duke Univ, Med Ctr, Dept Neurobiol, Durham, NC 27710 USA.; Ji, RR (corresponding author), Duke Univ, Med Ctr, Dept Cell Biol, Durham, NC 27710 USA.
EM ru-rong.ji@duke.edu
FU Duke University; Bonica Fellowship from the International Association for the Study of Pain (IASP)
CR Allen BL, 2020, PAIN, V0, P0
   Arita M, 2005, J EXP MED, V201, P713, DOI 10.1084/jem.20042031
   Arita M, 2006, J BIOL CHEM, V281, P22847, DOI 10.1074/jbc.M603766200
   Bang S, 2010, BRIT J PHARMACOL, V161, P707, DOI 10.1111/j.1476-5381.2010.00909.x
   Bang SS, 2018, J CLIN INVEST, V128, P3568, DOI 10.1172/JCI99888
   Bannenberg G, 2010, BBA-MOL CELL BIOL L, V1801, P1260, DOI 10.1016/j.bbalip.2010.08.002
   Baral P, 2019, NAT REV IMMUNOL, V19, P433, DOI 10.1038/s41577-019-0147-2
   Barbanti P, 2015, J HEADACHE PAIN, V16, P0, DOI 10.1186/s10194-015-0542-4
   Basbaum AI, 2009, CELL, V139, P267, DOI 10.1016/j.cell.2009.09.028
   Binshtok AM, 2008, J NEUROSCI, V28, P14062, DOI 10.1523/JNEUROSCI.3795-08.2008
   Borovikova LV, 2000, NATURE, V405, P458, DOI 10.1038/35013070
   Braz J, 2014, NEURON, V82, P522, DOI 10.1016/j.neuron.2014.01.018
   Buckley CD, 2014, IMMUNITY, V40, P315, DOI 10.1016/j.immuni.2014.02.009
   Busch V, 2013, BRAIN STIMUL, V6, P202, DOI 10.1016/j.brs.2012.04.006
   Cavaletti G, 2010, NAT REV NEUROL, V6, P657, DOI 10.1038/nrneurol.2010.160
   Chen G, 2018, NEURON, V100, P1292, DOI 10.1016/j.neuron.2018.11.009
   Chen O, 2020, CURR OPIN NEUROBIOL, V62, P17, DOI 10.1016/j.conb.2019.11.006
   Chiang N, 2019, J CLIN INVEST, V129, P5294, DOI 10.1172/JCI129448
   Chiang N, 2015, J EXP MED, V212, P1203, DOI 10.1084/jem.20150225
   Chiang N, 2012, NATURE, V484, P524, DOI 10.1038/nature11042
   Chiu IM, 2012, NAT NEUROSCI, V15, P1063, DOI 10.1038/nn.3144
   Clark AK, 2010, J NEUROSCI, V30, P573, DOI 10.1523/JNEUROSCI.3295-09.2010
   Coull JAM, 2005, NATURE, V438, P1017, DOI 10.1038/nature04223
   Coull JAM, 2003, NATURE, V424, P938, DOI 10.1038/nature01868
   da Silva MD, 2015, MOL NEUROBIOL, V51, P19, DOI 10.1007/s12035-014-8790-x
   Dai WJ, 2019, EVID-BASED COMPL ALT, V2019, P0, DOI 10.1155/2019/8413576
   DIXON WJ, 1980, ANNU REV PHARMACOL, V20, P441, DOI 10.1146/annurev.pa.20.040180.002301
   Duan B, 2018, NEUROSCI BULL, V34, P186, DOI 10.1007/s12264-017-0136-z
   Duffield JS, 2006, J IMMUNOL, V177, P5902, DOI 10.4049/jimmunol.177.9.5902
   Ellis A, 2013, BRIT J ANAESTH, V111, P26, DOI 10.1093/bja/aet128
   Fang JF, 2017, BMC COMPLEM ALTERN M, V17, P0, DOI 10.1186/s12906-017-1690-7
   Fattori V, 2019, BRIT J PHARMACOL, V176, P1728, DOI 10.1111/bph.14647
   Flatters SJL, 2008, PAIN, V135, P119, DOI 10.1016/j.pain.2007.05.013
   Flatters SJL, 2004, PAIN, V109, P150, DOI 10.1016/j.pain.2004.01.029
   Fullerton JN, 2016, NAT REV DRUG DISCOV, V15, P551, DOI 10.1038/nrd.2016.39
   Gao J, 2018, J PAIN RES, V11, P1511, DOI 10.2147/JPR.S160779
   Gao YJ, 2010, PAIN, V148, P309, DOI 10.1016/j.pain.2009.11.017
   Gilroy DW, 1999, NAT MED, V5, P698, DOI 10.1038/9550
   Goadsby PJ, 2014, CEPHALALGIA, V34, P986, DOI 10.1177/0333102414524494
   Goadsby PJ, 2018, CEPHALALGIA, V38, P959, DOI 10.1177/0333102417744362
   Gold MS, 2010, NAT MED, V16, P1248, DOI 10.1038/nm.2235
   Gold MS, 1998, J NEUROSCI, V18, P10345
   Goldberg RJ, 2007, PAIN, V129, P210, DOI 10.1016/j.pain.2007.01.020
   Guan Y, 2010, ANESTHESIOLOGY, V113, P1392, DOI 10.1097/ALN.0b013e3181fcd95c
   Han JS, 2003, TRENDS NEUROSCI, V26, P17, DOI 10.1016/S0166-2236(02)00006-1
   HOKFELT T, 1994, TRENDS NEUROSCI, V17, P22, DOI 10.1016/0166-2236(94)90031-0
   Huang LA, 2011, PAIN, V152, P557, DOI 10.1016/j.pain.2010.11.021
   Huang Q, 2019, NEUROSCI BULL, V35, P527, DOI 10.1007/s12264-018-0320-9
   Hucho T, 2007, NEURON, V55, P365, DOI 10.1016/j.neuron.2007.07.008
   Inoue K, 2018, NAT REV NEUROSCI, V19, P138, DOI 10.1038/nrn.2018.2
   Ji RR, 2011, TRENDS NEUROSCI, V0, P0
   Ji RR, 2018, ANESTHESIOLOGY, V0, P0
   Ji RR, 1998, P NATL ACAD SCI USA, V95, P15635, DOI 10.1073/pnas.95.26.15635
   Ji RR, 2003, TRENDS NEUROSCI, V26, P696, DOI 10.1016/j.tins.2003.09.017
   Ji RR, 2002, NEURON, V36, P57, DOI 10.1016/S0896-6273(02)00908-X
   Ji RR, 2013, PAIN, V0, P0
   Ji RR, 2014, NAT REV DRUG DISCOV, V13, P533, DOI 10.1038/nrd4334
   Jin XC, 2006, J NEUROSCI, V26, P246, DOI 10.1523/JNEUROSCI.3858-05.2006
   Jonas WB, 2015, BMJ OPEN, V5, P0, DOI 10.1136/bmjopen-2015-009655
   Julius D, 2001, NATURE, V413, P203, DOI 10.1038/35093019
   Kawasaki Y, 2008, J NEUROSCI, V28, P5189, DOI 10.1523/JNEUROSCI.3338-07.2008
   Krishnamoorthy S, 2010, P NATL ACAD SCI USA, V107, P1660, DOI 10.1073/pnas.0907342107
   Lai NY, 2019, CELL, V0, P0
   Lange G, 2011, PAIN MED, V12, P1406, DOI 10.1111/j.1526-4637.2011.01203.x
   Latremoliere A, 2009, J PAIN, V10, P895, DOI 10.1016/j.jpain.2009.06.012
   Li Y, 2014, J PAIN, V15, P712, DOI 10.1016/j.jpain.2014.04.001
   Lim HD, 2016, PLOS ONE, V11, P0, DOI 10.1371/journal.pone.0151882
   Lu Y, 2013, J CLIN INVEST, V123, P4050, DOI 10.1172/JCI70026
   Lukiw WJ, 2010, MOL NEUROBIOL, V42, P10, DOI 10.1007/s12035-010-8126-4
   Lukiw WJ, 2005, J CLIN INVEST, V115, P2774, DOI 10.1172/JCI25420
   Luo H, 2019, CELL REP, V29, P2384, DOI 10.1016/j.celrep.2019.10.085
   Luo X, 2019, FRONT PHARMACOL, V10, P0, DOI 10.3389/fphar.2019.00745
   MAIXNER W, 1984, BRAIN RES, V298, P374, DOI 10.1016/0006-8993(84)91441-0
   Martelletti P, 2018, J HEADACHE PAIN, V19, P0, DOI 10.1186/s10194-018-0946-z
   Martini AC, 2016, J NEUROINFLAMM, V13, P0, DOI 10.1186/s12974-016-0540-8
   Matsuda M, 2019, J ANESTH, V33, P131, DOI 10.1007/s00540-018-2579-4
   MELZACK R, 1965, SCIENCE, V150, P971, DOI 10.1126/science.150.3699.971
   Miao GS, 2015, NEUROSCIENCE, V300, P10, DOI 10.1016/j.neuroscience.2015.04.060
   Milligan ED, 2003, J NEUROSCI, V23, P1026
   Mirakaj V, 2014, J EXP MED, V211, P1037, DOI 10.1084/jem.20132103
   Moore KA, 2002, J NEUROSCI, V22, P6724, DOI 10.1523/jneurosci.22-15-06724.2002
   Moreno-Duarte I, 2014, NEUROIMAGE, V85, P1003, DOI 10.1016/j.neuroimage.2013.05.097
   Napadow V, 2012, PAIN MED, V13, P777, DOI 10.1111/j.1526-4637.2012.01385.x
   Norling LV, 2016, JCI INSIGHT, V1, P0, DOI 10.1172/jci.insight.85922
   Norling LV, 2011, J IMMUNOL, V186, P5543, DOI 10.4049/jimmunol.1003865
   Norris PC, 2016, PROSTAGLANDINS LEUKO, V0, P0
   Obata K, 2005, J CLIN INVEST, V115, P2393, DOI 10.1172/JCI23437
   Oehler B, 2017, FRONT MOL NEUROSCI, V10, P0, DOI 10.3389/fnmol.2017.00242
   Oh DY, 2010, CELL, V142, P687, DOI 10.1016/j.cell.2010.07.041
   Palacios-Pelaez R, 2010, MOL NEUROBIOL, V41, P367, DOI 10.1007/s12035-010-8139-z
   Park CK, 2014, NEURON, V82, P47, DOI 10.1016/j.neuron.2014.02.011
   Park CK, 2011, J NEUROSCI, V31, P18433, DOI 10.1523/JNEUROSCI.4192-11.2011
   Park CK, 2011, J NEUROSCI, V31, P15072, DOI 10.1523/JNEUROSCI.2443-11.2011
   Patapoutian A, 2009, NAT REV DRUG DISCOV, V8, P55, DOI 10.1038/nrd2757
   Pawela CP, 2017, NEUROIMAGE, V147, P10, DOI 10.1016/j.neuroimage.2016.11.046
   Peirs C, 2016, SCIENCE, V354, P578, DOI 10.1126/science.aaf8933
   Ramsden CE, 2015, PAIN, V156, P587, DOI 10.1097/01.j.pain.0000460348.84965.47
   Ramsden CE, 2013, PAIN, V154, P2441, DOI 10.1016/j.pain.2013.07.028
   Ruscheweyh R, 2011, MOL PAIN, V7, P0, DOI 10.1186/1744-8069-7-20
   Samad TA, 2001, NATURE, V410, P471, DOI 10.1038/35068566
   Sato KL, 2014, ANESTH ANALG, V118, P464, DOI 10.1213/ANE.0000000000000047
   Serhan CN, 2019, J INTERN MED, V286, P240, DOI 10.1111/joim.12871
   Serhan CN, 2018, J IMMUNOL, V201, P3161, DOI 10.4049/jimmunol.1800806
   Serhan CN, 2014, NATURE, V510, P92, DOI 10.1038/nature13479
   Serhan CN, 2012, FASEB J, V26, P1755, DOI 10.1096/fj.11-201442
   SERHAN CN, 1984, P NATL ACAD SCI-BIOL, V81, P5335, DOI 10.1073/pnas.81.17.5335
   Shamji MF, 2017, NEUROSURGERY, V80, PS108, DOI 10.1093/neuros/nyw047
   Sisignano M, 2014, NAT REV NEUROL, V10, P694, DOI 10.1038/nrneurol.2014.211
   Sisignano M, 2012, J NEUROSCI, V32, P6364, DOI 10.1523/JNEUROSCI.5793-11.2012
   Spite M, 2009, NATURE, V461, P1287, DOI 10.1038/nature08541
   Steinberg BE, 2016, ANESTHESIOLOGY, V124, P1174, DOI 10.1097/ALN.0000000000001083
   Sulciner ML, 2018, J EXP MED, V215, P115, DOI 10.1084/jem.20170681
   Svensson CI, 2007, J EXP MED, V204, P245, DOI 10.1084/jem.20061826
   Svensson CI, 2003, J NEUROCHEM, V86, P1534, DOI 10.1046/j.1471-4159.2003.01969.x
   Tassorelli C, 2018, NEUROLOGY, V91, PE364, DOI 10.1212/WNL.0000000000005857
   Torres-Rosas R, 2014, NAT MED, V20, P291, DOI 10.1038/nm.3479
   Tracey KJ, 2002, NATURE, V420, P853, DOI 10.1038/nature01321
   Usoskin D, 2015, NAT NEUROSCI, V18, P145, DOI 10.1038/nn.3881
   Volkow ND, 2017, NEW ENGL J MED, V377, P391, DOI 10.1056/NEJMsr1706626
   Wang JC, 2017, J PAIN, V0, P0
   Wei TP, 2009, PAIN, V144, P278, DOI 10.1016/j.pain.2009.04.020
   White FA, 2005, NAT REV DRUG DISCOV, V4, P834, DOI 10.1038/nrd1852
   Woolf CJ, 2007, NEURON, V55, P353, DOI 10.1016/j.neuron.2007.07.016
   Woolf CJ, 2011, PAIN, V152, PS2, DOI 10.1016/j.pain.2010.09.030
   Xu ZZ, 2013, ANN NEUROL, V74, P490, DOI 10.1002/ana.23928
   Xu ZZ, 2013, J NEUROIMMUNE PHARM, V8, P37, DOI 10.1007/s11481-012-9394-8
   Xu ZZ, 2011, BRIT J PHARMACOL, V164, P274, DOI 10.1111/j.1476-5381.2011.01348.x
   Xu ZZ, 2010, NAT MED, V16, P592, DOI 10.1038/nm.2123
   Yang F, 2015, NEUROMODULATION, V18, P592, DOI 10.1111/ner.12341
   Yang Q, 2014, J NEUROSCI, V34, P10765, DOI 10.1523/JNEUROSCI.5316-13.2014
   Ye Y, 2018, NEUROPHARMACOLOGY, V139, P182, DOI 10.1016/j.neuropharm.2018.07.016
   Zhang LL, 2018, FRONT PHARMACOL, V9, P0, DOI 10.3389/fphar.2018.00412
   Zhang RX, 2007, ANESTH ANALG, V105, P1482, DOI 10.1213/01.ane.0000284705.34629.c5
   Zhang TC, 2015, J NEUROPHYSIOL, V114, P284, DOI 10.1152/jn.00147.2015
   Zheng Y, 2019, NEURON, V0, P0
   Zhuang ZY, 2006, J NEUROSCI, V26, P3551, DOI 10.1523/JNEUROSCI.5290-05.2006
NR 136
TC 44
Z9 50
U1 2
U2 37
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 1933-7213
EI 1878-7479
J9 NEUROTHERAPEUTICS
JI Neurotherapeutics
PD JUL 15
PY 2020
VL 17
IS 3
BP 886
EP 899
DI 10.1007/s13311-020-00892-9
EA JUL 2020
PG 14
WC Clinical Neurology; Neurosciences; Pharmacology & Pharmacy
SC Neurosciences & Neurology; Pharmacology & Pharmacy
GA OL3SN
UT WOS:000550997000001
PM 32696274
DA 2026-01-16
ER

PT J
AU Cai, DB
   Yuan, WQ
   Zheng, W
AF Cai, Dong-Bin
   Yuan, Wei-Qu
   Zheng, Wei
TI Association of Acupuncture and Acupressure With Improved Cancer Pain.
SO JAMA oncology
LA English
DT Letter
C1 Shenzhen Traditional Chinese Medicine Hospital, The Fourth Clinical Medical College, Guangzhou University of Chinese Medicine, Shenzhen, China.
   Shenzhen Traditional Chinese Medicine Hospital, The Fourth Clinical Medical College, Guangzhou University of Chinese Medicine, Shenzhen, China.
   The Affiliated Brain Hospital of Guangzhou Medical University, Guangzhou Huiai Hospital, Guangzhou, China.
NR 0
TC 0
SN 2374-244
EI 
J9 JAMA Oncol
PD APR 24
PY 2020
VL 6
IS 6
BP 939
EP 940
DI 10.1001/jamaoncol.2020.0622
PG 1
WC Acupressure; Acupuncture Therapy; Cancer Pain; therapy; Humans; Neoplasms; complications
UT PubMed:32324193
PM 32324193
DA 2020-04-24
ER

PT J
AU You, EH
AF You, Eunhea
TI Nontraditional and Home-Based Self-management Interventions in Cancer Patients With Pain A Mixed-Method Systematic Review
SO HOLISTIC NURSING PRACTICE
LA English
DT Article
DE cancer patients; nontraditional and home-based intervention; self-management
ID auricular point acupressure; randomized controlled-trial; chronic care model; oncology outpatients; analgesic treatment; clinical-trial; life; education; efficacy; fatigue
AB One or 2 decades ago, oncologists focused on only cancer treatments or acute care related to cancer. Since cancer care is considered as long-term cares, cancer patients require self-management (SM) ability or skill to manage their symptoms and daily cares. This mixed-method review is to evaluate quantitative and qualitative studies, which were conducted using non-traditional SM interventions for cancer pain based. This review also explores the process of SM in the chronic care model (CCM). PubMed, CINAHL, Scopus, and Wiley were used from 2011 to 2018. A total of 16 quantitative and 2 qualitative studies were included for this review. All interventions are divided into 3 types, which are educational and/or counseling programs, complementary and alternative medicine (CAM) therapy, and exercise. Ten of the included 16 studies were statistically significant on pain management: 3 CAM studies (100%), 1 exercise study (100%), and 6 of the 12 educational and/or counseling studies (50%). The CAM and exercise were statistically effective in improving cancer pain in the review. However, uncertainty remains regarding the strength of the evidence, due to the small number of studies included and lack of consistent methodologies. The application (5A) of SM support may help cancer patients to manage their pain.
C1 [You, Eunhea] Rutgers State Univ, Dept Nursing, 180 Univ Ave, Newark, NJ 07102 USA.
C3 Rutgers University System; Rutgers University Newark; Rutgers University New Brunswick
RP You, EH (corresponding author), Rutgers State Univ, Dept Nursing, 180 Univ Ave, Newark, NJ 07102 USA.
EM ey100@sn.rutgers.edu
CR Unknown -, 2011, REL PAIN AM BLUEPR T, V0, P0, DOI DOI 10.17226/13172
   Unknown -, 2009, KIDNEY INT, V6, P0
   Unknown -, 2018, THE CHRONIC CARE MODEL, V0, P0
   Baptista DR, 2016, DIABETOL METAB SYNDR, V8, P0, DOI 10.1186/s13098-015-0119-z
   Borneman T, 2011, J PALLIAT MED, V14, P197, DOI 10.1089/jpm.2010.0268
   Cantarero-Villanueva I, 2011, EUR J INTEGR MED, V3, PE189, DOI 10.1016/j.eujim.2011.08.001
   Chahardah-Cherik Shima MS, 2018, INT J COMMUNITY BASED NURS MIDWIFERY, V6, P65
   Coleman K, 2009, HEALTH AFFAIR, V28, P75, DOI 10.1377/hlthaff.28.1.75
   Eaton LH, 2017, CLIN J ONCOL NURS, V21, P54, DOI 10.1188/17.CJON.S3.54-70
   Garrison GM, 2016, J AM BOARD FAM MED, V29, P10, DOI 10.3122/jabfm.2016.01.150128
   Glasgow RE, 2002, ANN BEHAV MED, V24, P80, DOI 10.1207/S15324796ABM2402_04
   Greene J, 2007, ACAD MED, V82, P161, DOI 10.1097/ACM.0b013e31802d90ed
   Hammer MJ, 2015, CANCER NURS, V38, PE10, DOI 10.1097/NCC.0000000000000122
   Hardcastle SJ, 2015, FRONT PSYCHOL, V6, P0, DOI 10.3389/fpsyg.2015.00835
   Hodge FS, 2012, J CANCER SURVIV, V6, P182, DOI 10.1007/s11764-011-0209-3
   Jan A, 2015, MED ACUPUNCT, V27, P168, DOI 10.1089/acu.2015.1095
   Kim HS, 2013, SUPPORT CARE CANCER, V21, P1751, DOI 10.1007/s00520-013-1722-x
   Koller A, 2018, CANCER NURS, V41, P367, DOI 10.1097/NCC.0000000000000502
   Koller A, 2013, EUR J ONCOL NURS, V17, P284, DOI 10.1016/j.ejon.2012.08.002
   Koller A, 2012, J PAIN SYMPTOM MANAG, V44, P264, DOI 10.1016/j.jpainsymman.2011.08.015
   Kravitz RL, 2012, J PAIN SYMPTOM MANAG, V43, P874, DOI 10.1016/j.jpainsymman.2011.05.020
   Kwekkeboom KL, 2012, J PAIN SYMPTOM MANAG, V44, P810, DOI 10.1016/j.jpainsymman.2011.12.281
   Mahigir F, 2012, ASIAN PAC J CANCER P, V13, P4561, DOI 10.7314/APJCP.2012.13.9.4561
   McCorkle R, 2011, CA-CANCER J CLIN, V61, P50, DOI 10.3322/caac.20093
   Molina PE, 2013, ENDOCRINE PHYSL, V4e, P0
   National Cancer Institute, 2016, STAT OFF CANC SURV, V0, P0
   Ohlsson-Nevo E, 2016, EUR J ONCOL NURS, V21, P181, DOI 10.1016/j.ejon.2015.10.002
   Oldenmenger WH, 2011, PAIN, V152, P2632, DOI 10.1016/j.pain.2011.08.009
   Pearson M L, 2007, FINAL CONTRACT REPORT (PREPARED BY RAND HEALTH UNDER CONTRACT NO. 282-00-0005), V0, P0
   RISENDAL BC, 2015, FRONT PUBLIC HEALTH, V2, P1
   Rustoen T, 2014, CANCER NURS, V37, P34, DOI 10.1097/NCC.0b013e3182948418
   Ryan P, 2009, NURS OUTLOOK, V57, P217, DOI 10.1016/j.outlook.2008.10.004
   Schembri A, 2018, GLOSSA-UK, V3, P0, DOI 10.5334/gjgl.468
   Schumacher KL, 2014, J PAIN SYMPTOM MANAG, V48, P784, DOI 10.1016/j.jpainsymman.2013.12.247
   Slev VN, 2017, BMC PALLIAT CARE, V16, P0, DOI 10.1186/s12904-017-0238-4
   Thomas ML, 2012, ONCOL NURS FORUM, V39, P39, DOI 10.1188/12.ONF.39-49
   Vargas RB, 2007, J GEN INTERN MED, V22, P215, DOI 10.1007/s11606-006-0072-5
   Yeh CH, 2017, ONCOL NURS FORUM, V44, P476, DOI 10.1188/17.ONF.476-487
   Yeh CH, 2016, CANCER NURS, V39, P402, DOI 10.1097/NCC.0000000000000303
   Yeh CH, 2015, PAIN MANAG NURS, V16, P285, DOI 10.1016/j.pmn.2014.08.005
   Yeh CH, 2014, EVID-BASED COMPL ALT, V2014, P0, DOI 10.1155/2014/934670
   You E, 2019, PAIN MANAG NURS, V20, P17, DOI 10.1016/j.pmn.2018.07.010
NR 43
TC 5
Z9 5
U1 0
U2 17
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0887-9311
EI 1550-5138
J9 HOLIST NURS PRACT
JI Holist. Nurs. Pract.
PD MAY-JUN 15
PY 2020
VL 34
IS 3
BP 138
EP 149
DI 10.1097/HNP.0000000000000380
PG 12
WC Integrative & Complementary Medicine; Nursing
SC Integrative & Complementary Medicine; Nursing
GA LL1VX
UT WOS:000531344200002
PM 32282489
DA 2026-01-16
ER

PT J
AU Chen, Y
   Song, H
   Chen, M
   Xu, H
AF Chen, Yuqin
   Song, Huaihua
   Chen, Mingyu
   Xu, Hua
TI The role of acupotomy in treatment of patients with lumbar spinal stenosis: A
SO Medicine
LA English
DT Journal Article
AB BACKGROUND: Currently, there is some clinical evidence supporting the use of  acupuncture in alleviating pain and dysfunction in patients with lumbar spinal  stenosis (LSS). However, the question of whether acupuncture could be efficacious  for ageing patients remains unanswered. We designed a randomized controlled study  to evaluate the safety and feasibility of acupuncture for participants with  symptomatic LSS. METHODS: This study is a randomized, single-blind,  noninferiority trial. This clinical trial was approved by the Linyi Cancer  Hospital. We received informed consent from all patients before surgery. In  preparing this report, we adhered to the Consolidated Standards of Reporting  Trials guidelines. We randomized consented study participants on a 1:1 ratio to  one of two study groups (acupuncture and control groups) using a  computer-generated list of random numbers in varying block sizes. Three outcome  measures were selected to evaluate the effectiveness and safety of the treatment:  visual analogue score and Oswestry disability index, and complicatins. A P < .05  was regarded as statistically significant. RESULTS: The hypothesis was that the  acupuncture group would achieve acceptable clinical outcomes as compared to the  control group in LSS. TRIAL REGISTRATION: This study protocol was registered in  Research Registry (researchregistry5744).
C1 Department of Rehabilitation, Linyi Central Hospital.
   Department of Obstetrics and Gynecology, The third People's Hospital of Linyi.
   Department of Neurology, Linyi Central Hospital.
   Department of Bone Oncology, Linyi Cancer Hospital, Shandong, China.
NR 0
TC 0
SN 1536-596
EI 0025-797
J9 Medicine (Baltimore)
PD AUG 7
PY 2020
VL 99
IS 31
BP e21444
EP e21444
DI 10.1097/MD.0000000000021444
PG 1
WC Aged; Aged, 80 and over; Humans; Middle Aged; Acupuncture Therapy; methods; Case-Control Studies; Feasibility Studies; Lumbar Vertebrae; diagnostic imaging; Magnetic Resonance Imaging; methods; Outcome Assessment, Health Care; Safety; Single-Blind Method; Spinal Stenosis; therapy; Treatment Outcome; Visual Analog Scale; Randomized Controlled Trials as Topic; Equivalence Trials as Topic
UT PubMed:32756160
PM 32756160
DA 2020-08-07
ER

PT J
AU Kasozi, KI
   Niedbala, G
   Alqarni, M
   Zirintunda, G
   Ssempijja, F
   Musinguzi, SP
   Usman, IM
   Matama, K
   Hetta, HF
   Mbiydzenyuy, NE
   Batiha, GE
   Beshbishy, AM
   Welburn, SC
AF Kasozi, Keneth Iceland
   Niedbala, Gniewko
   Alqarni, Mohammed
   Zirintunda, Gerald
   Ssempijja, Fred
   Musinguzi, Simon Peter
   Usman, Ibe Michael
   Matama, Kevin
   Hetta, Helal F.
   Mbiydzenyuy, Ngala Elvis
   Batiha, Gaber El-Saber
   Beshbishy, Amany Magdy
   Welburn, Susan Christina
TI Bee Venom-A Potential Complementary Medicine Candidate for SARS-CoV-2 Infections
SO FRONTIERS IN PUBLIC HEALTH
LA English
DT Review
DE bee venom; complementary medicine and alternative medicine; SARS-CoV-2 (2019-nCoV); pharmokinetics of bee poison; COVID-19 and complementary medicine; bee venom in clinical trials
ID phospholipase a(2); in-vitro; melittin; cells; covid-19; pain; immunotherapy; acupuncture; model; epidemiology
AB Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is characterized by severe cytokine storm syndrome following inflammation. SARS-CoV-2 directly interacts with angiotensin-converting enzyme 2 (ACE-2) receptors in the human body. Complementary therapies that impact on expression of IgE and IgG antibodies, including administration of bee venom (BV), have efficacy in the management of arthritis, and Parkinson's disease. A recent epidemiological study in China showed that local beekeepers have a level of immunity against SARS-CoV-2 with and without previous exposure to virus. BV anti-inflammatory properties are associated with melittin and phospholipase A2 (PLA2), both of which show activity against enveloped and non-enveloped viruses, including H1N1 and HIV, with activity mediated through antagonist activity against interleukin-6 (IL-6), IL-8, interferon-gamma (IFN-gamma), and tumor necrosis factor-alpha (TNF-alpha). Melittin is associated with the underexpression of proinflammatory cytokines, including nuclear factor-kappa B (NF-kappa B), extracellular signal-regulated kinases (ERK1/2), and protein kinase Akt. BV therapy also involves group III secretory phospholipase A(2) in the management of respiratory and neurological diseases. BV activation of the cellular and humoral immune systems should be explored for the application of complementary medicine for the management of SARS-CoV-2 infections. BV "vaccination" is used to immunize against cytomegalovirus and can suppress metastases through the PLA2 and phosphatidylinositol-(3,4)-bisphosphate pathways. That BV shows efficacy for HIV and H1NI offers opportunity as a candidate for complementary therapy for protection against SARS-CoV-2.
C1 [Kasozi, Keneth Iceland; Welburn, Susan Christina] Univ Edinburgh, Coll Med & Vet Med, Infect Med, Deanery Biomed Sci, Edinburgh, Midlothian, Scotland.
   [Kasozi, Keneth Iceland; Musinguzi, Simon Peter] Kabale Univ, Sch Med, Kabale, Uganda.
   [Niedbala, Gniewko] Poznan Univ Life Sci, Fac Environm Engn & Mech Engn, Dept Biosyst Engn, Poznan, Poland.
   [Alqarni, Mohammed] Taif Univ, Coll Pharm, Dept Pharmaceut Chem, At Taif, Saudi Arabia.
   [Zirintunda, Gerald] Busitema Univ, Fac Agr & Anim Sci, Arapai Campus, Soroti, Uganda.
   [Ssempijja, Fred; Usman, Ibe Michael] Kampala Int Univ, Fac Biomed Sci, Western Campus, Bushenyi, Uganda.
   [Matama, Kevin] Kampala Int Univ, Sch Pharm, Dept Clin Pharm & Pharm Practice, Western Campus, Bushenyi, Uganda.
   [Hetta, Helal F.] Assiut Univ, Fac Med, Dept Med Microbiol & Immunol, Assiut, Egypt.
   [Mbiydzenyuy, Ngala Elvis] Copperbelt Univ, Michael Chilufya Sata Sch Med, Dept Basic Med Sci, Ndola, Zambia.
   [Batiha, Gaber El-Saber] Damanhour Univ, Fac Vet Med, Dept Pharmacol & Therapeut, Damanhour, Egypt.
   [Beshbishy, Amany Magdy] Obihiro Univ Agr & Vet Med, Natl Res Ctr Protozoan Dis, Obihiro, Hokkaido, Japan.
   [Welburn, Susan Christina] Zhejiang Univ, Sch Med, Univ Edinburgh Inst, Haining, Peoples R China.
C3 University of Edinburgh; Kabale University; Poznan University of Life Sciences; Taif University; Busitema University; Egyptian Knowledge Bank (EKB); Assiut University; Copperbelt University; Egyptian Knowledge Bank (EKB); Damanhour University; Obihiro University of Agriculture & Veterinary Medicine; Zhejiang University
RP Kasozi, KI; Welburn, SC (corresponding author), Univ Edinburgh, Coll Med & Vet Med, Infect Med, Deanery Biomed Sci, Edinburgh, Midlothian, Scotland.; Kasozi, KI (corresponding author), Kabale Univ, Sch Med, Kabale, Uganda.; Niedbala, G (corresponding author), Poznan Univ Life Sci, Fac Environm Engn & Mech Engn, Dept Biosyst Engn, Poznan, Poland.; Batiha, GE (corresponding author), Damanhour Univ, Fac Vet Med, Dept Pharmacol & Therapeut, Damanhour, Egypt.; Welburn, SC (corresponding author), Zhejiang Univ, Sch Med, Univ Edinburgh Inst, Haining, Peoples R China.
EM kicelandy@gmail.com; gniewko@up.poznan.pl; gaberbatiha@gmail.com; sue.welburn@ed.ac.uk
FU Zhejiang University Education Foundation Emergency Research Fund; Global Challenges Research Fund; University of Edinburgh
CR Abd El-Wahed AA, 2018, STUD NAT PROD CHEM, V60, P459, DOI 10.1016/B978-0-444-64181-6.00013-9
   Abusabbah M, 2016, J ENTOMOL ZOOL STUD, V4, P23
   Al-Samie MAMA, 2012, INT J ADV RES TECHNO, V1, P1
   Almunia C, 2013, PLOS ONE, V8, P0, DOI 10.1371/journal.pone.0067645
   Alvarez-Fischer D, 2013, PLOS ONE, V8, P0, DOI 10.1371/journal.pone.0061700
   An HJ, 2014, INT J MOL MED, V34, P1341, DOI 10.3892/ijmm.2014.1933
   An WW, 2004, ACTA PHARMACOL SIN, V25, P1502
   Unknown -, 2019, FRONT IMMUNOL, V0, P0
   Unknown -, 2020, AAPS J, V0, P0
   Antonicelli L, 2002, CURR OPIN ALLERGY CL, V2, P341, DOI 10.1097/00130832-200208000-00008
   Babon A, 2005, FEBS LETT, V579, P1658, DOI 10.1016/j.febslet.2005.02.019
   BACHMAYER H, 1972, J INSECT PHYSIOL, V18, P1515, DOI 10.1016/0022-1910(72)90230-2
   Baek YH, 2006, BRAIN RES, V1073, P305, DOI 10.1016/j.brainres.2005.12.086
   Balozet L, 1971, CONTRIBUTORS THIS VO, V3, P1
   Beck BF, 1981, BEE VENOM THERAPY, V0, P238
   Bellinghausen I, 1997, EUR J IMMUNOL, V27, P1131, DOI 10.1002/eji.1830270513
   Bhalotia S, 2016, JOURNAL OF BASIC AND APPLIED ENGINEERING RESEARCH, V3, P96
   Bilò MB, 2009, CLIN EXP ALLERGY, V39, P1467, DOI 10.1111/j.1365-2222.2009.03324.x
   Block J, 2020, HIGH RISK COVID 19 P, V0, PP2020040013, DOI 10.20944/PREPRINTS202004.0013.V1
   Boens S, 2013, METHODS MOL BIOL, V1053, P271, DOI 10.1007/978-1-62703-562-0_16
   Bostanci N, 2012, FEMS MICROBIOL LETT, V333, P1, DOI 10.1111/j.1574-6968.2012.02579.x
   Bramwell VW, 2004, J DRUG TARGET, V11, P525, DOI 10.1080/10611860410001670080
   Brás NF, 2018, J PHYS CHEM B, V122, P3889, DOI 10.1021/acs.jpcb.8b01321
   Cao XT, 2020, NAT REV IMMUNOL, V20, P269, DOI 10.1038/s41577-020-0308-3
   Caramalho I, 2015, ALLERGY, V70, P1340, DOI 10.1111/all.12691
   Casewell NR, 2013, TRENDS ECOL EVOL, V28, P219, DOI 10.1016/j.tree.2012.10.020
   Chen J, 2016, NEUROSCI BULL, V32, P265, DOI 10.1007/s12264-016-0024-y
   Cherniack EP, 2018, TOXICON, V154, P74, DOI 10.1016/j.toxicon.2018.09.013
   Chirumbolo S, 2011, ALLERGY ASTHMA IMMUN, V3, P58, DOI 10.4168/aair.2011.3.1.58
   Cho HJ, 2010, J ETHNOPHARMACOL, V127, P662, DOI 10.1016/j.jep.2009.12.007
   Choi J, 2017, TOXINS, V9, P0, DOI 10.3390/toxins9110351
   Clerkin KJ, 2020, CIRCULATION, V141, P1648, DOI 10.1161/CIRCULATIONAHA.120.046941
   CONNOLLY TM, 1986, CELL, V46, P951, DOI 10.1016/0092-8674(86)90077-2
   Corman VM, 2020, EUROSURVEILLANCE, V25, P23, DOI 10.2807/1560-7917.ES.2020.25.3.2000045
   Cortegiani A, 2020, J CRIT CARE, V57, P279, DOI 10.1016/j.jcrc.2020.03.005
   Dams D, 2019, ADV EXP MED BIOL, V1148, P233, DOI 10.1007/978-981-13-7709-9_11
   Dawood AA, 2020, NEW MICROB NEW INFEC, V35, P0, DOI 10.1016/j.nmni.2020.100673
   de Haan CAM, 1998, J VIROL, V72, P6838, DOI 10.1128/JVI.72.8.6838-6850.1998
   Lima PRde, 2003, J. VENOM. ANIM. TOXINS INCL. TROP. DIS, V9, P149, DOI 10.1590/S1678-91992003000200002
   de Wit E, 2020, P NATL ACAD SCI USA, V117, P6771, DOI 10.1073/pnas.1922083117
   Duan K, 2020, P NATL ACAD SCI USA, V117, P9490, DOI 10.1073/pnas.2004168117
   Dunbar JP, 2019, CLIN TOXICOL, V57, P677, DOI 10.1080/15563650.2019.1578367
   Erzen R, 2012, ALLERGY, V67, P822, DOI 10.1111/j.1398-9995.2012.02817.x
   Fenard D, 1999, J CLIN INVEST, V104, P611, DOI 10.1172/JCI6915
   Garraud O, 2017, BMC IMMUNOL, V18, P0, DOI 10.1186/s12865-017-0207-y
   Ghosh R, 2020, MAYO CLIN PROC, V95, P1797, DOI 10.1016/j.mayocp.2020.05.027
   GOLDEN DBK, 1989, ALLERGY PROC, V10, P103, DOI 10.2500/108854189778960964
   Gu H, 2020, TOXINS, V12, P0, DOI 10.3390/toxins12030195
   Gu H, 2018, MOL MED REP, V18, P3711, DOI 10.3892/mmr.2018.9398
   Gupta T, 2020, INT IMMUNOPHARMACOL, V86, P0, DOI 10.1016/j.intimp.2020.106717
   Gurunathan S, 2013, INT J NANOMED, V8, P4399, DOI 10.2147/IJN.S51881
   Hauser RA, 2001, ALTERNATIVE AND COMPLEMENTARY THERAPIES, V7, P37, DOI https://doi.org/10.1089/107628001300000714
   HERMANN K, 1993, CLIN EXP ALLERGY, V23, P762, DOI 10.1111/j.1365-2222.1993.tb00364.x
   HOLTSBERG FW, 1995, BIOCHEM J, V309, P141, DOI 10.1042/bj3090141
   Hong JJ, 2019, MOLECULES, V24, P0, DOI 10.3390/molecules24091775
   Hossen MS, 2017, J CHEM-NY, V2017, P0, DOI 10.1155/2017/4035626
   Issa MF, 2019, MEAS SCI REV, V19, P101, DOI 10.2478/msr-2019-0016
   Jakob T, 2020, CURR ALLERGY ASTHM R, V20, P0, DOI 10.1007/s11882-020-00943-3
   Ji YP, 2020, LANCET GLOB HEALTH, V8, PE480, DOI 10.1016/S2214-109X(20)30068-1
   Jilek S, 2001, J IMMUNOL, V166, P3612, DOI 10.4049/jimmunol.166.5.3612
   Jilo NAK, 2016, ADVANCES IN LIFE SCIENCE AND TECHNOLOGY, V44, P18
   Johansen P, 2005, CLIN EXP ALLERGY, V35, P1591, DOI 10.1111/j.1365-2222.2005.02384.x
   Jung GB, 2018, BIOMED OPT EXPRESS, V9, P5703, DOI 10.1364/BOE.9.005703
   JUTEL M, 1995, J IMMUNOL, V154, P4187
   Kang CK, 2020, KOREAN J INTERN MED, V35, P782, DOI 10.3904/kjim.2020.157
   Karamitros CS, 2014, J BIOL CHEM, V289, P12962, DOI 10.1074/jbc.M113.545038
   Kim CMH, 2013, BIOTHERAPY - HISTORY, V0, P77, DOI 10.1007/978-94-007-6585-6_4
   Kim H, 2014, PLOS ONE, V9, P0, DOI 10.1371/journal.pone.0114726
   King TP, 2003, INT ARCH ALLERGY IMM, V131, P25, DOI 10.1159/000070431
   Klimek L, 2020, ALLERGY, V75, P1546, DOI 10.1111/all.14336
   Klok FA, 2020, THROMB RES, V191, P145, DOI 10.1016/j.thromres.2020.04.013
   Komi DEA, 2018, CLIN REV ALLERG IMMU, V54, P386, DOI 10.1007/s12016-017-8597-4
   LaFerla FM, 2007, NAT REV NEUROSCI, V8, P499, DOI 10.1038/nrn2168
   Lambeau G, 1999, TRENDS PHARMACOL SCI, V20, P162, DOI 10.1016/S0165-6147(99)01300-0
   Leandro LF, 2015, AN ACAD BRAS CIENC, V87, P147, DOI 10.1590/0001-3765201520130511
   Lee G, 2016, TOXINS, V8, P0, DOI 10.3390/toxins8020048
   Li GP, 2020, J AUTOIMMUN, V112, P0, DOI 10.1016/j.jaut.2020.102463
   Liu SJ, 2008, HEPATOLOGY, V47, P1964, DOI 10.1002/hep.22240
   Marichal T, 2013, IMMUNITY, V39, P963, DOI 10.1016/j.immuni.2013.10.005
   de Toledo LFM, 2018, REV SOC BRAS MED TRO, V51, P560, DOI 10.1590/0037-8682-0341-2017
   Mason RJ, 2020, EUR RESPIR J, V55, P0, DOI 10.1183/13993003.00607-2020
   Mehra MR, 2020, NEW ENGL J MED, V382, P0, DOI 10.1056/NEJMoa2007621
   Mehta P, 2020, LANCET, V395, P1033, DOI 10.1016/S0140-6736(20)30628-0
   Memariani H, 2020, EUR J CLIN MICROBIOL, V39, P5, DOI 10.1007/s10096-019-03674-0
   Mingomataj EÇ, 2012, J INVEST ALLERG CLIN, V22, P237
   Mizumoto K, 2020, EUROSURVEILLANCE, V25, P2, DOI 10.2807/1560-7917.ES.2020.25.10.2000180
   Moreno M, 2015, TOXINS, V7, P1126, DOI 10.3390/toxins7041126
   Mousavizadeh L, 2021, J MICROBIOL IMMUNOL, V54, P159, DOI 10.1016/j.jmii.2020.03.022
   Mozzini C, 2020, THROMB RES, V191, P26, DOI 10.1016/j.thromres.2020.04.031
   MULLER U, 1979, ALLERGY, V34, P369, DOI 10.1111/j.1398-9995.1979.tb02006.x
   Murakami M, 2017, CRIT REV IMMUNOL, V37, P121, DOI 10.1615/CritRevImmunol.v37.i2-6.20
   Okba NMA, 2017, CURR OPIN VIROL, V23, P49, DOI 10.1016/j.coviro.2017.03.007
   Organization WH, 2020, CORONAVIRUS DISEASE 2019 (COVID-19): SITUATION REPORT, V0, P0
   Oudit GY, 2003, TRENDS CARDIOVAS MED, V13, P93, DOI 10.1016/S1050-1738(02)00233-5
   OWEN MD, 1995, TOXICON, V33, P1181, DOI 10.1016/0041-0101(95)00054-P
   Palm NW, 2013, IMMUNITY, V39, P976, DOI 10.1016/j.immuni.2013.10.006
   Palm NW, 2012, NATURE, V484, P465, DOI 10.1038/nature11047
   Park S, 2015, IMMUN INFLAMM DIS, V3, P386, DOI 10.1002/iid3.76
   Pereira-Santos MC, 2008, CLIN EXP ALLERGY, V38, P291, DOI 10.1111/j.1365-2222.2007.02887.x
   Péterfi O, 2019, MOLECULES, V24, P0, DOI 10.3390/molecules24152778
   Putz T, 2006, CANCER IMMUNOL IMMUN, V55, P1374, DOI 10.1007/s00262-006-0143-9
   Quaresima V, 2020, EMBO MOL MED, V12, P0, DOI 10.15252/emmm.202012488
   Rady I, 2017, CANCER LETT, V402, P16, DOI 10.1016/j.canlet.2017.05.010
   Rajendiran C, 2012, J ASSOC PHYSICIANS INDIA, V60, P122
   Rawizza HE, 2019, J ANTIMICROB CHEMOTH, V74, P2707, DOI 10.1093/jac/dkz219
   Reber LL, 2017, J ALLERGY CLIN IMMUN, V140, P335, DOI 10.1016/j.jaci.2017.06.003
   Rizk JG, 2020, DRUGS, V80, P1267, DOI 10.1007/s40265-020-01367-z
   Rothan HA, 2020, J AUTOIMMUN, V109, P0, DOI 10.1016/j.jaut.2020.102433
   Roy A, 2021, INT J PEPT RES THER, V27, P129, DOI 10.1007/s10989-020-10073-z
   Saeed WSE, 2017, JOURNAL OF VACCINES AND VACCINATION, V8, P372, DOI 10.4172/2157-7560.1000372
   SCHUMACHER MJ, 1994, J ALLERGY CLIN IMMUN, V93, P831, DOI 10.1016/0091-6749(94)90373-5
   Seif F, 2017, CELL COMMUN SIGNAL, V15, P0, DOI 10.1186/s12964-017-0177-y
   Semuel Mokosuli Yermia, 2017, JOURNAL OF ENTOMOLOGY AND ZOOLOGY STUDIES, V5, P112
   Seo BK, 2017, TOXINS, V9, P0, DOI 10.3390/toxins9110361
   Shen L, 2020, J PHARMACOPUNCT, V23, P44, DOI 10.3831/KPI.2020.23.008
   SHKENDEROV S, 1982, TOXICON, V20, P317, DOI 10.1016/0041-0101(82)90234-3
   Soliman C, 2019, PLOS ONE, V14, P0, DOI 10.1371/journal.pone.0224028
   Soman NR, 2009, J CLIN INVEST, V119, P2830, DOI 10.1172/JCI38842
   Son DJ, 2007, PHARMACOL THERAPEUT, V115, P246, DOI 10.1016/j.pharmthera.2007.04.004
   Son DJ, 2007, J TOXICOL ENV HEAL A, V70, P1350, DOI 10.1080/15287390701428689
   South AM, 2020, AM J PHYSIOL-HEART C, V318, PH1084, DOI 10.1152/ajpheart.00217.2020
   Stahelin RV, 2016, BIOCHEM. LIPIDS, VSixth, P237, DOI 10.1016/B978-0-444-63438-2.00008-0
   Stoevesandt J, 2020, ALLERGY, V75, P535, DOI 10.1111/all.13945
   Stone KD, 2010, J ALLERGY CLIN IMMUN, V125, PS73, DOI 10.1016/j.jaci.2009.11.017
   Sun YR, 2018, SAUDI J BIOL SCI, V25, P213, DOI 10.1016/j.sjbs.2017.10.010
   Szulc P, 2013, BIOCHEMICAL MARKERS, V0, PP1573, DOI 10.1016/B978-0-12-415853-5.00067-4
   Taketomi Y, 2013, NAT IMMUNOL, V14, P554, DOI 10.1038/ni.2586
   Touret F, 2020, ANTIVIR RES, V177, P0, DOI 10.1016/j.antiviral.2020.104762
   Uddin M, 2016, J MICROBIOL, V54, P853
   Vetter RS, 1998, INT J DERMATOL, V37, P481, DOI 10.1046/j.1365-4362.1998.00455.x
   Vijay R, 2015, J EXP MED, V212, P1851, DOI 10.1084/jem.20150632
   Wang YM, 2020, LANCET, V395, P1569, DOI 10.1016/S0140-6736(20)31022-9
   Wehbe R, 2019, MOLECULES, V24, P0, DOI 10.3390/molecules24162997
   White J, 2010, GENDERED SCREEN: CANADIAN WOMEN FILMMAKERS, V0, P233
   Yang J, 2020, INT J INFECT DIS, V94, P91, DOI 10.1016/j.ijid.2020.03.017
   Yang W, 2020, TOXICON, V181, P69, DOI 10.1016/j.toxicon.2020.04.105
   Youngren-Ortiz SR, 2016, THESIS, V0, P0
   Zahirovic A, 2020, CLIN REV ALLERG IMMU, V58, P326, DOI 10.1007/s12016-019-08752-x
   Zhang S, 2018, TOXICON, V148, P64, DOI 10.1016/j.toxicon.2018.04.012
   Zhang Y, 2020, NEW ENGL J MED, V382, P0, DOI 10.1056/NEJMc2007575
   Zheng YY, 2020, NAT REV CARDIOL, V17, P259, DOI 10.1038/s41569-020-0360-5
NR 141
TC 39
Z9 45
U1 2
U2 28
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 
EI 2296-2565
J9 FRONT PUBLIC HEALTH
JI Front. Public Health
PD DEC 10
PY 2020
VL 8
IS 
BP 
EP 
DI 10.3389/fpubh.2020.594458
PG 14
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA PI7OX
UT WOS:000601276900001
PM 33363088
DA 2026-01-16
ER

PT J
AU Mao, JJ
   Liou, K
   Panageas, K
   Baser, RE
   Romero, SAD
   Li, QS
   Xiao, H
   Bao, T
   Kantoff, PW
AF Mao, Jun J.
   Liou, Kevin
   Panageas, Katherine
   Baser, Raymond E.
   Romero, Sally A. D.
   Li, Qing Susan
   Xiao, Han
   Bao, Ting
   Kantoff, Philip W.
TI Effects of electroacupuncture and auricular acupuncture for chronic pain in cancer survivors: The PEACE randomized controlled trial.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
C1 Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA.
   Univ Penn, Perelman Sch Med, Ctr Clin Epidemiol & Biostat, Philadelphia, PA USA.
   Mem Sloan Kettering Canc Ctr, Basking Ridge, NJ USA.
   Mem Sloan Kettering Canc Ctr, Dept Med, 1275 York Ave, New York, NY 10021 USA.
C3 Memorial Sloan Kettering Cancer Center; University of Pennsylvania; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center
FU Department of Defense U.S. National Institutes of Health
NR 0
TC 2
Z9 2
U1 0
U2 5
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2020
VL 38
IS 15
BP 
EP 
DI 
PG 2
WC Oncology
SC Oncology
GA NB2UL
UT WOS:000560368300429
DA 2026-01-16
ER

PT J
AU Li, D
   Yoo, JH
   Kim, SK
AF Li, Daxian
   Yoo, Ju Hyuk
   Kim, Sun Kwang
TI Long-Lasting and Additive Analgesic Effects of Combined Treatment of Bee Venom
SO Toxins
LA English
DT Journal Article
DE allodynia; bee venom acupuncture; combination therapy; paclitaxel; venlafaxine
AB Paclitaxel, a primary chemotherapeutic agent used to treat numerous solid  malignancies, is commonly associated with debilitating peripheral neuropathy.  However, a satisfactory gold-standard monotherapy for this neuropathic pain is  not currently available. A combination strategy of two or more medications with  different properties may achieve more beneficial effects than monotherapy. Thus,  we investigated the analgesic efficacies and spinal mechanisms of the combination  strategy, including bee venom acupuncture (BVA) and venlafaxine (VLX) against  paclitaxel-induced allodynia in mice. Four intraperitoneal infusions of  paclitaxel on alternating days (2 mg/kg/day) induced cold and mechanical  allodynia for at least 1 week as assessed using acetone and the von Frey hair  test, respectively. Co-treatment of BVA (1.0 mg/kg, s.c., ST36) with VLX (40  mg/kg, i.p.) at the medium dose produced a longer-lasting and additive effect  than each monotherapy at the highest dose (BVA, 2.5 mg/kg; VLX, 60 mg/kg). Spinal  pre-administration of idazoxan (α(2)-adrenergic receptor antagonist, 10 μg),  methysergide (mixed 5-HT(1)/5-HT(2) receptor antagonist, 10 μg), or MDL-72222  (5-HT(3) receptor antagonist, 10 μg) abolished this analgesia. These results  suggest that the combination therapy with BVA and VLX produces long-lasting and  additive analgesic effects on paclitaxel-induced allodynia, via the spinal  noradrenergic and serotonergic mechanism, providing a promising clinical  strategy.
C1 Department of Science in Korean Medicine, Graduate School, Kyung Hee University, Seoul 02447, Korea.
   Department of East-West Medicine, Graduate School, Kyung Hee University, Seoul 02447, Korea.
   Department of Science in Korean Medicine, Graduate School, Kyung Hee University, Seoul 02447, Korea.
   Department of East-West Medicine, Graduate School, Kyung Hee University, Seoul 
   Department of Physiology, College of Korean Medicine, Kyung Hee University, Seoul 02447, Korea.
NR 0
TC 0
SN 2072-665
EI 
J9 Toxins (Basel)
PD OCT 2
PY 2020
VL 12
IS 10
BP 
EP 
DI 10.3390/toxins12100620
PG 0
WC Acupuncture Therapy; Analgesics; pharmacology; Animals; Bee Venoms; administration & dosage; Combined Modality Therapy; Disease Models, Animal; Hyperalgesia; chemically induced; Male; Mice, Inbred C57BL; Paclitaxel; Pain Threshold; drug effects; Serotonin and Noradrenaline Reuptake Inhibitors; pharmacology; Spinal Cord; drug effects; Venlafaxine Hydrochloride; pharmacology
UT PubMed:32998357
PM 32998357
DA 2020-10-02
ER

PT J
AU Venkatasalu, MR
   Murang, ZR
   Ramasamy, DTR
   Dhaliwal, JS
AF Venkatasalu, Munikumar Ramasamy
   Murang, Zaidah Rizidah
   Ramasamy, Divya Thirumalai Rajam
   Dhaliwal, Jagjit Singh
TI Oral health problems among palliative and terminally ill patients: an integrated
SO BMC oral health
LA English
DT Journal Article
DE Cancer; Integrated review; Oral conditions; Oral diseases; Palliative; Terminally-ill
AB BACKGROUND: High incidence of treatable oral conditions has been reported among  palliative patients. However, a large proportion of palliative patients lose  their ability to communicate their sufferings. Therefore, it may lead to  under-reporting of oral conditions among these patients. This review  systematically synthesized the published evidence on the presence of oral  conditions among palliative patients, the impact, management, and challenges in  treating these conditions. METHODS: An integrative review was undertaken with  defined search strategy from five databases and manual search through key  journals and reference list. Studies which focused on oral conditions of  palliative patients and published between years 2000 to 2017 were included.  RESULTS: Xerostomia, oral candidiasis and dysphagia were the three most common  oral conditions among palliative patients, followed by mucositis, orofacial pain,  taste change and ulceration. We also found social and functional impact of having  certain oral conditions among these patients. In terms of management,  complementary therapies such as acupuncture has been used but not well explored.  The lack of knowledge among healthcare providers also posed as a challenge in  treating oral conditions among palliative patients. CONCLUSIONS: This review is  first in its kind to systematically synthesize the published evidence regarding  the impact, management and challenges in managing oral conditions among  palliative patients. Although there is still lack of study investigating  palliative oral care among specific group of patients such as patients with  dementia, geriatric or pediatric advanced cancer patients, this review has  however provided baseline knowledge that may guide health care professionals in  palliative settings.
C1 Pengiran Anak Puteri Rashidah Sa'adatul Bolkiah Institute of Health Sciences, Universiti Brunei Darussalam, Bandar Seri Begawan, Brunei Darussalam.
   Pengiran Anak Puteri Rashidah Sa'adatul Bolkiah Institute of Health Sciences, Universiti Brunei Darussalam, Bandar Seri Begawan, Brunei Darussalam.
   Pengiran Anak Puteri Rashidah Sa'adatul Bolkiah Institute of Health Sciences, Universiti Brunei Darussalam, Bandar Seri Begawan, Brunei Darussalam.
   Pengiran Anak Puteri Rashidah Sa'adatul Bolkiah Institute of Health Sciences, Universiti Brunei Darussalam, Bandar Seri Begawan, Brunei Darussalam.jagjit.dhaliwal@ubd.edu.bn.
NR 0
TC 0
SN 1472-683
EI 
J9 BMC Oral Health
PD MAR 20
PY 2020
VL 20
IS 1
BP 79
EP 79
DI 10.1186/s12903-020-01075-w
PG 0
WC Aged; Child; Humans; Mouth Diseases; etiology; Oral Health; Oral Ulcer; etiology; Palliative Care; methods; Terminally Ill; Xerostomia; etiology
UT PubMed:32188452
PM 32188452
DA 2020-03-20
ER

PT J
AU Chen, VE
   Greenberger, BA
   Shi, Z
   Gajjar, S
   Shi, WY
   Mourad, WF
   Yan, WS
AF Chen, Victor E.
   Greenberger, Benjamin A.
   Shi, Zheng
   Gajjar, Shefali
   Shi, Wenyin
   Mourad, Waleed F.
   Yan, Weisi
TI Post-mastectomy and post-breast conservation surgery pain syndrome: a review of etiologies, risk prediction, and trends in management
SO TRANSLATIONAL CANCER RESEARCH
LA English
DT Review
DE Etiology; detection; early predictor; acupuncture; narrative medicine
ID sentinel lymph-node; quality-of-life; inhibitor-induced arthralgia; neuropathic pain; persistent pain; axillary dissection; postoperative breast; american society; cancer-treatment; women
AB Postmastectomy pain syndrome (PMPS) or breast conservation surgery (BCS) pain syndrome could be long-term and lead to disability and impairment on body and social function. The pain syndromes are not uncommon in breast cancer patients. It can affect social, psychological, physical and behavioral aspects of a patient. Surgery, radiation, chemotherapy and psychological factors can all contribute to the development of pain syndromes. Axillary dissection is a strong predictor for pain development. Pain medications, ganglion blocks are typically given to the patient for management. Integrative medicine such as acupuncture and psychological management methods are promising modalities in the management arsenal. In this study, we summarized the up-to-date literature to elucidate the etiology, risk factors and management strategies for PMPS.
C1 [Chen, Victor E.; Greenberger, Benjamin A.; Gajjar, Shefali; Shi, Wenyin; Yan, Weisi] Thomas Jefferson Univ, Dept Radiat Oncol, Sidney Kimmel Med Coll, 501 South 54th St, Philadelphia, PA 19143 USA.
   [Chen, Victor E.; Greenberger, Benjamin A.; Gajjar, Shefali; Shi, Wenyin; Yan, Weisi] Thomas Jefferson Univ, Canc Ctr, Philadelphia, PA 19143 USA.
   [Shi, Zheng] Univ Texas Hlth Sci Ctr San Antonio, Dept Radiat Oncol, San Antonio, TX 78229 USA.
   [Mourad, Waleed F.] Univ Kentucky, Dept Radiat Oncol, Lexington, KY USA.
C3 Thomas Jefferson University; Thomas Jefferson University; University of Texas System; University of Texas at San Antonio; University of Kentucky
RP Yan, WS (corresponding author), Thomas Jefferson Univ, Dept Radiat Oncol, Sidney Kimmel Med Coll, 501 South 54th St, Philadelphia, PA 19143 USA.
EM Weisi.Yan@jefferson.edu
FU National Cancer Institute [UG1CA233341] Funding Source: NIH RePORTER; NCI NIH HHS [UG1 CA233341] Funding Source: Medline
CR Abbas DN, 2011, CLIN J PAIN, V27, P207, DOI 10.1097/AJP.0b013e3181fb1ef1
   Amr YM, 2010, CLIN J PAIN, V26, P381, DOI 10.1097/AJP.0b013e3181cb406e
   Andersen KG, 2011, J PAIN, V12, P725, DOI 10.1016/j.jpain.2010.12.005
   Bandos H, 2018, JNCI-J NATL CANCER I, V110, P0, DOI 10.1093/jnci/djx162
   Baron RH, 2007, ANN SURG ONCOL, V14, P1653, DOI 10.1245/s10434-006-9334-z
   Belfer I, 2013, J PAIN, V14, P1185, DOI 10.1016/j.jpain.2013.05.002
   Blanchard DK, 2003, ARCH SURG-CHICAGO, V138, P482, DOI 10.1001/archsurg.138.5.482
   Bredal IS, 2014, J PAIN SYMPTOM MANAG, V48, P852, DOI 10.1016/j.jpainsymman.2013.12.239
   Bruehl S, 2004, NEUROSCI BIOBEHAV R, V28, P395, DOI 10.1016/j.neubiorev.2004.06.004
   Burstein HJ, 2010, J CLIN ONCOL, V28, P3784, DOI 10.1200/JOP.000082
   Carpenter JS, 1999, CANCER PRACT, V7, P66, DOI 10.1046/j.1523-5394.1999.07208.x
   Cepeda MS, 2008, J PAIN SYMPTOM MANAG, V35, P623, DOI 10.1016/j.jpainsymman.2007.08.011
   De Oliveira GS, 2014, BREAST J, V20, P9, DOI 10.1111/tbj.12207
   Din OS, 2010, BREAST CANCER RES TR, V120, P525, DOI 10.1007/s10549-010-0757-7
   Donker M, 2014, LANCET ONCOL, V15, P1303, DOI 10.1016/S1470-2045(14)70460-7
   Ducic I, 2006, J AM COLL SURGEONS, V203, P304, DOI 10.1016/j.jamcollsurg.2006.05.018
   Eckhoff L, 2015, EUR J CANCER, V51, P292, DOI 10.1016/j.ejca.2014.11.024
   Eija K, 1996, PAIN, V64, P293, DOI 10.1016/0304-3959(95)00138-7
   Fassoulaki A, 2002, ANESTH ANALG, V95, P985, DOI 10.1097/00000539-200210000-00036
   Fenlon D, 2014, BMC CANCER, V14, P0, DOI 10.1186/1471-2407-14-467
   Friberg S, 2009, ACTA ONCOL, V48, P822, DOI 10.1080/02841860902824917
   Galecki J, 2006, ACTA ONCOL, V45, P280, DOI 10.1080/02841860500371907
   Gilbo P, 2018, ADV RADIAT ONCOL, V3, P265, DOI 10.1016/j.adro.2018.04.001
   Giuliano AE, 2011, JAMA-J AM MED ASSOC, V305, P569, DOI 10.1001/jama.2011.90
   Grover VK, 2009, J POSTGRAD MED, V55, P257, DOI 10.4103/0022-3859.58928
   Hershman DL, 2018, JAMA-J AM MED ASSOC, V320, P167, DOI 10.1001/jama.2018.8907
   Hille-Betz U, 2016, STRAHLENTHER ONKOL, V192, P8, DOI 10.1007/s00066-015-0899-y
   Hopwood P, 2010, LANCET ONCOL, V11, P231, DOI 10.1016/S1470-2045(09)70382-1
   Hoseinzade H, 2008, SHIRAZ E MEDICAL JOURNAL, V9, P88
   Jagsi R, 2015, JAMA ONCOL, V1, P918, DOI 10.1001/jamaoncol.2015.2590
   Jeong YJ, 2018, EVID-BASED COMPL ALT, V2018, P0, DOI 10.1155/2018/5367014
   Juhl AA, 2016, J BREAST CANCER, V19, P447, DOI 10.4048/jbc.2016.19.4.447
   Jung BF, 2003, PAIN, V104, P1, DOI 10.1016/S0304-3959(03)00241-0
   Kadmon I, 2017, ASIA-PAC J ONCOL NUR, V4, P89, DOI 10.4103/apjon.apjon_16_17
   KIRVELA O, 1992, REGION ANESTH, V17, P348, DOI 10.1136/rapm-00115550-199217060-00007
   Lancaster RB, 2016, CURR SURG REP, V4, P0, DOI 10.1007/s40137-016-0133-6
   Lötsch J, 2018, BREAST CANCER RES TR, V171, P399, DOI 10.1007/s10549-018-4841-8
   Lyman GH, 2014, J CLIN ONCOL, V32, P1365, DOI 10.1200/JCO.2013.54.1177
   McCann B, 2012, J PAIN, V13, P425, DOI 10.1016/j.jpain.2011.02.358
   Mejdahl MK, 2013, BMJ-BRIT MED J, V346, P0, DOI 10.1136/bmj.f1865
   Meretoja TJ, 2014, JAMA-J AM MED ASSOC, V311, P90, DOI 10.1001/jama.2013.278795
   Miaskowski C, 2014, EUR J ONCOL NURS, V18, P242, DOI 10.1016/j.ejon.2013.12.002
   Mols F, 2014, SUPPORT CARE CANCER, V22, P2261, DOI 10.1007/s00520-014-2255-7
   Nahm Nicole, 2018, ASIA PAC J CLIN ONCOL, V14, P374, DOI 10.1111/ajco.12845
   Nguyen JT, 2012, J PLAST RECONSTR AES, V65, P1199, DOI 10.1016/j.bjps.2012.04.003
   Niravath P, 2013, ANN ONCOL, V24, P1443, DOI 10.1093/annonc/mdt037
   Fabro EAN, 2012, BREAST, V21, P321, DOI 10.1016/j.breast.2012.01.019
   Patarica-Huber E, 2011, J BUON, V16, P40
   Peintinger F, 2003, BRIT J CANCER, V89, P648, DOI 10.1038/sj.bjc.6601150
   Peretti-Watel P, 2012, PAIN RES TREAT, V2012, P0, DOI 10.1155/2012/153060
   Rietman JS, 2003, EUR J SURG ONCOL, V29, P229, DOI 10.1053/ejso.2002.1403
   Romestaing P, 1997, J CLIN ONCOL, V15, P963, DOI 10.1200/JCO.1997.15.3.963
   Rosso R, 2000, ARCH PATHOL LAB MED, V124, P709
   Ryan JL, 2012, J INVEST DERMATOL, V132, P985, DOI 10.1038/jid.2011.411
   Schijven MP, 2003, EUR J SURG ONCOL, V29, P341, DOI 10.1053/ejso.2002.1385
   Shaitelman SF, 2015, JAMA ONCOL, V1, P931, DOI 10.1001/jamaoncol.2015.2666
   Shannon MT, 2011, J GEN INTERN MED, V26, P1217, DOI 10.1007/s11606-011-1702-0
   Smith HS, 2012, ANN PALLIAT MED, V1, P182, DOI 10.3978/j.issn.2224-5820.2012.10.13
   Steegers MA, 2008, J PAIN, V9, P813, DOI 10.1016/j.jpain.2008.04.001
   Stubblefield MD, 2006, ARCH PHYS MED REHAB, V87, PS96, DOI 10.1016/j.apmr.2005.12.017
   Swenson KK, 2002, ANN SURG ONCOL, V9, P745, DOI 10.1245/ASO.2002.02.007
   TASMUTH T, 1995, ANN ONCOL, V6, P453, DOI 10.1093/oxfordjournals.annonc.a059215
   Tasmuth T, 2002, EUR J PAIN-LONDON, V6, P17, DOI 10.1053/eujp.2001.0266
   Uchida K, 2009, PAIN PHYSICIAN, V12, P0
   Vrieling C, 2017, JAMA ONCOL, V3, P42, DOI 10.1001/jamaoncol.2016.3031
   Wang K, 2018, BREAST, V42, P113, DOI 10.1016/j.breast.2018.08.105
   WATSON CPN, 1992, PAIN, V51, P375, DOI 10.1016/0304-3959(92)90223-X
   Wijayasinghe N, 2014, REGION ANESTH PAIN M, V39, P272, DOI 10.1097/AAP.0000000000000101
   Winters L, 2010, CLIN J ONCOL NURS, V14, P379, DOI 10.1188/10.CJON.379-382
   Winters-Stone KM, 2012, CANCER-AM CANCER SOC, V118, P2288, DOI 10.1002/cncr.27465
   Wong L, 2001, ANN PLAS SURG, V46, P481, DOI 10.1097/00000637-200105000-00004
NR 71
TC 11
Z9 14
U1 0
U2 13
PU AME PUBLISHING COMPANY
PI SHATIN
PA FLAT-RM C 16F, KINGS WING PLAZA 1, NO 3 KWAN ST, SHATIN, HONG KONG 00000, PEOPLES R CHINA
SN 2218-676X
EI 2219-6803
J9 TRANSL CANCER RES
JI Transl. Cancer Res.
PD JAN 15
PY 2020
VL 9
IS 
BP S77
EP S85
DI 10.21037/tcr.2019.06.46
PG 9
WC Oncology
SC Oncology
GA KC8AO
UT WOS:000507394100010
PM 33828953
DA 2026-01-16
ER

PT J
AU Li, DX
   Yoo, JH
   Kim, SK
AF Li, Daxian
   Yoo, Ju Hyuk
   Kim, Sun Kwang
TI Long-Lasting and Additive Analgesic Effects of Combined Treatment of Bee Venom Acupuncture and Venlafaxine on Paclitaxel-Induced Allodynia in Mice
SO TOXINS
LA English
DT Article
DE bee venom acupuncture; venlafaxine; combination therapy; paclitaxel; allodynia
ID induced peripheral neuropathy; chronic pain; mouse model; combination; gabapentin; mechanisms; management; receptors; electroacupuncture; nociception
AB Paclitaxel, a primary chemotherapeutic agent used to treat numerous solid malignancies, is commonly associated with debilitating peripheral neuropathy. However, a satisfactory gold-standard monotherapy for this neuropathic pain is not currently available. A combination strategy of two or more medications with different properties may achieve more beneficial effects than monotherapy. Thus, we investigated the analgesic efficacies and spinal mechanisms of the combination strategy, including bee venom acupuncture (BVA) and venlafaxine (VLX) against paclitaxel-induced allodynia in mice. Four intraperitoneal infusions of paclitaxel on alternating days (2 mg/kg/day) induced cold and mechanical allodynia for at least 1 week as assessed using acetone and the von Frey hair test, respectively. Co-treatment of BVA (1.0 mg/kg, s.c., ST36) with VLX (40 mg/kg, i.p.) at the medium dose produced a longer-lasting and additive effect than each monotherapy at the highest dose (BVA, 2.5 mg/kg; VLX, 60 mg/kg). Spinal pre-administration of idazoxan (alpha(2)-adrenergic receptor antagonist, 10 mu g), methysergide (mixed 5-HT1/5-HT2 receptor antagonist, 10 mu g), or MDL-72222 (5-HT3 receptor antagonist, 10 mu g) abolished this analgesia. These results suggest that the combination therapy with BVA and VLX produces long-lasting and additive analgesic effects on paclitaxel-induced allodynia, via the spinal noradrenergic and serotonergic mechanism, providing a promising clinical strategy.
C1 [Li, Daxian; Kim, Sun Kwang] Kyung Hee Univ, Grad Sch, Dept Sci Korean Med, Seoul 02447, South Korea.
   [Yoo, Ju Hyuk; Kim, Sun Kwang] Kyung Hee Univ, Grad Sch, Dept East West Med, Seoul 02447, South Korea.
   [Kim, Sun Kwang] Kyung Hee Univ, Dept Physiol, Coll Korean Med, Seoul 02447, South Korea.
C3 Kyung Hee University; Kyung Hee University; Kyung Hee University
RP Kim, SK (corresponding author), Kyung Hee Univ, Grad Sch, Dept Sci Korean Med, Seoul 02447, South Korea.; Kim, SK (corresponding author), Kyung Hee Univ, Grad Sch, Dept East West Med, Seoul 02447, South Korea.; Kim, SK (corresponding author), Kyung Hee Univ, Dept Physiol, Coll Korean Med, Seoul 02447, South Korea.
EM lidaxian721@naver.com; impera27@naver.com; skkim77@khu.ac.kr
FU National Research Foundation of Korea (NRF) - Korea government [NRF-2017M3A9E4057926]
CR ARCHER T, 1986, EUR J PHARMACOL, V120, P295, DOI 10.1016/0014-2999(86)90470-X
   Beery AK, 2018, CURR OPIN BEHAV SCI, V23, P143, DOI 10.1016/j.cobeha.2018.06.016
   Boyette-Davis JA, 2018, PAIN MANAG, V8, P363, DOI 10.2217/pmt-2018-0020
   Cegielska-Perun K, 2013, PHARMACOLOGY, V91, P69, DOI 10.1159/000345035
   Chaparro LE, 2012, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD008943.pub2
   Chen J, 2010, PROG NEUROBIOL, V92, P151, DOI 10.1016/j.pneurobio.2010.06.006
   Cherniack EP, 2018, TOXICON, V154, P74, DOI 10.1016/j.toxicon.2018.09.013
   Choi J, 2017, TOXINS, V9, P0, DOI 10.3390/toxins9110351
   Choi S, 2019, TOXINS, V11, P0, DOI 10.3390/toxins11070396
   Deng YK, 2016, BMC ANESTHESIOL, V16, P0, DOI 10.1186/s12871-015-0150-5
   Dougherty PM, 2004, PAIN, V109, P132, DOI 10.1016/j.pain.2004.01.021
   Durand JP, 2005, ANTI-CANCER DRUG, V16, P587, DOI 10.1097/00001813-200506000-00015
   Eisenberg E, 2014, CURR PAIN HEADACHE R, V18, P0, DOI 10.1007/s11916-014-0463-y
   Finnerup NB, 2015, LANCET NEUROL, V14, P162, DOI 10.1016/S1474-4422(14)70251-0
   Folkesson A, 2010, SCAND J PAIN, V1, P91, DOI 10.1016/j.sjpain.2009.12.001
   Gilron I, 2005, NEW ENGL J MED, V352, P1324, DOI 10.1056/NEJMoa042580
   Gilron I, 2013, LANCET NEUROL, V12, P1084, DOI 10.1016/S1474-4422(13)70193-5
   Godoy MCM, 2004, EUR J PHARMACOL, V496, P93, DOI 10.1016/j.ejphar.2004.05.045
   Hache G, 2015, EUR J PAIN, V19, P322, DOI 10.1002/ejp.550
   Hajhashemi V, 2014, EUR J PHARMACOL, V738, P230, DOI 10.1016/j.ejphar.2014.04.046
   Hanna M, 2008, EUR J PAIN, V12, P804, DOI 10.1016/j.ejpain.2007.12.010
   Hershman DL, 2014, J ONCOL PRACT, V10, PE421, DOI 10.1200/JOP.2014.001776
   HYLDEN JLK, 1980, EUR J PHARMACOL, V67, P313, DOI 10.1016/0014-2999(80)90515-4
   Kawamura M, 1998, LIFE SCI, V62, P2181, DOI 10.1016/S0024-3205(98)00195-7
   Kerckhove N, 2017, FRONT PHARMACOL, V8, P0, DOI 10.3389/fphar.2017.00086
   Kim W, 2016, TOXINS, V8, P0, DOI 10.3390/toxins8020033
   Kus T, 2016, SUPPORT CARE CANCER, V24, P2085, DOI 10.1007/s00520-015-3009-x
   Lee JH, 2014, BMC COMPLEM ALTERN M, V14, P0, DOI 10.1186/1472-6882-14-471
   Li DX, 2019, INT J MOL SCI, V20, P0, DOI 10.3390/ijms20071652
   Li D, 2015, TOXINS, V7, P2422, DOI 10.3390/toxins7072422
   Lim BS, 2013, EVID-BASED COMPL ALT, V2013, P0, DOI 10.1155/2013/369324
   Liu ZY, 2002, NEUROSCIENCE, V112, P399, DOI 10.1016/S0306-4522(02)00038-6
   Lockwood SM, 2019, J NEUROPHYSIOL, V121, P96, DOI 10.1152/jn.00613.2018
   Lu KW, 2016, SCI REP-UK, V6, P0, DOI 10.1038/srep22123
   Mao JR, 2011, J PAIN, V12, P157, DOI 10.1016/j.jpain.2010.07.006
   Millan MJ, 2002, PROG NEUROBIOL, V66, P355, DOI 10.1016/S0301-0082(02)00009-6
   Moulin DE, 2014, PAIN RES MANAG, V19, P328
   NAKAGAWA I, 1990, ANESTHESIOLOGY, V73, P474, DOI 10.1097/00000542-199009000-00017
   Park JW, 2012, INTEGR CANCER THER, V11, P166, DOI 10.1177/1534735411413265
   Pedersen LH, 2005, PSYCHOPHARMACOLOGY, V182, P551, DOI 10.1007/s00213-005-0120-6
   Polomano RC, 2001, PAIN, V94, P293, DOI 10.1016/S0304-3959(01)00363-3
   Seo BK, 2017, TOXINS, V9, P0, DOI 10.3390/toxins9110361
   Starobova H, 2017, FRONT MOL NEUROSCI, V10, P0, DOI 10.3389/fnmol.2017.00174
   Trouvin AP, 2017, CLIN THER, V39, P1104, DOI 10.1016/j.clinthera.2017.05.347
   Wiesenfeld-Hallin Zsuzsanna, 2005, GEND MED, V2, P137, DOI 10.1016/S1550-8579(05)80042-7
   Yeo JH, 2016, J PAIN, V17, P298, DOI 10.1016/j.jpain.2015.10.018
   Yoon J, 2012, J ACUPUNCT MERIDIAN, V5, P156, DOI 10.1016/j.jams.2012.05.003
   Yoshimura M, 2006, J PHARMACOL SCI, V101, P107, DOI 10.1254/jphs.CRJ06008X
   Yoshimura M, 2017, PAIN, V158, PS85, DOI 10.1097/j.pain.0000000000000844
   Zeng YJ, 2018, LASER MED SCI, V33, P295, DOI 10.1007/s10103-017-2367-7
   Zhang S, 2018, TOXICON, V148, P64, DOI 10.1016/j.toxicon.2018.04.012
   Zuo CY, 2019, EVID-BASED COMPL ALT, V2019, P0, DOI 10.1155/2019/1807287
NR 52
TC 18
Z9 18
U1 2
U2 14
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
SN 
EI 2072-6651
J9 TOXINS
JI Toxins
PD OCT 15
PY 2020
VL 12
IS 10
BP 
EP 
DI 10.3390/toxins12100620
PG 12
WC Food Science & Technology; Toxicology
SC Food Science & Technology; Toxicology
GA OL6IT
UT WOS:000585441800001
PM 32998357
DA 2026-01-16
ER

PT J
AU Chen, JH
   Zhang, YX
   Li, XX
   Wan, Y
   Ji, XQ
   Wang, W
   Kang, XZ
   Yan, WP
   Fan, ZY
AF Chen, Jiheng
   Zhang, Yunxiao
   Li, Xiaoxi
   Wan, You
   Ji, Xinqiang
   Wang, Wei
   Kang, Xiaozheng
   Yan, Wanpu
   Fan, Zhiyi
TI Efficacy of transcutaneous electrical acupoint stimulation combined with general anesthesia for sedation and postoperative analgesia in minimally invasive lung cancer surgery: A randomized, double-blind, placebo-controlled trial
SO THORACIC CANCER
LA English
DT Article
DE Analgesia; general anesthesia; sedation; transcutaneous acupoint electrical stimulation; video-assisted thoracoscopic surgery
ID elderly-patients; pain; tolerance; electroacupuncture; acupuncture; modulation; recovery
AB Background Multimodal opioid-sparing analgesia is a key component of an enhanced recovery pathway after surgery that aims to improve postoperative recovery. Transcutaneous electrical acupoint stimulation (TEAS) is assumed to alleviate pain and anxiety and to modify the autonomic nervous system. This study aimed to determine the efficacy of TEAS for sedation and postoperative analgesia in lung cancer patients undergoing thoracoscopic pulmonary resection. Methods A total of 80 patients were randomized into two groups: the TEAS group and the sham TEAS combined with general anesthesia group. Postoperative pain levels at six, 24, 48 hours, and one month after surgery were measured using the visual analogue scale (VAS). Bispectral index (BIS) score during the TEAS prior to anesthetic induction, Observer's Assessment of Alertness/Sedation (OAAS) score, sufentanil consumption during postoperative patient-controlled intravenous analgesia (PCIA), number of total and effective attempts of PCIA pump use, and incidence of postoperative nausea and vomiting were recorded and analyzed statistically. Results Patients in the TEAS group had significantly lower VAS scores at six, 24, and 48 hours after surgery (P < 0.01); lower BIS scores at 10, 20, and 30 minutes before induction (P < 0.01); lower levels of postoperative sufentanil consumption; lower number of PCIA attempts and effective rates (P < 0.01); lower incidences of nausea at 0, six, 24, and 48 hours; and lower incidence of vomiting at 24 hours after surgery (P < 0.05). The postoperative OAAS scores were similar between the groups. Conclusions TEAS could be a feasible approach for sedation and postoperative analgesia in thoracoscopic pulmonary resection.
C1 [Chen, Jiheng; Zhang, Yunxiao; Li, Xiaoxi; Fan, Zhiyi] Peking Univ, Canc Hosp & Inst, Dept Anesthesiol, Key Lab Carcinogenesis & Translat Res,Minist Educ, 52 Fucheng Rd, Beijing 100142, Peoples R China.
   [Wan, You] Peking Univ, Neurosci Res Inst, Beijing, Peoples R China.
   [Wan, You] Peking Univ, Dept Neurobiol, Beijing, Peoples R China.
   [Wan, You] Minist Educ, Key Lab Neurosci, Beijing, Peoples R China.
   [Wan, You] Natl Hlth Commiss, Beijing, Peoples R China.
   [Ji, Xinqiang; Wang, Wei] Peking Univ, Canc Hosp & Inst, Minist Educ, Key Lab Carcinogenesis & Translat Res,Dept Med Re, Beijing, Peoples R China.
   [Kang, Xiaozheng; Yan, Wanpu] Peking Univ, Canc Hosp & Inst, Minist Educ, Key Lab Carcinogenesis & Translat Res,Dept Thorac, Beijing, Peoples R China.
C3 Peking University; Peking University; Peking University; Peking University; Peking University
RP Fan, ZY (corresponding author), Peking Univ, Canc Hosp & Inst, Dept Anesthesiol, Key Lab Carcinogenesis & Translat Res,Minist Educ, 52 Fucheng Rd, Beijing 100142, Peoples R China.
EM jihengchen@bjmu.edu.cn; 13911114196@163.com
FU Department of Science and Technology, Ministry of Science and Technology [National Key R&amp;D Program of China (2017YFC0907504), National Basic Research Development Program (973)] Funding Source: Medline; Beijing Municipal Administration of Hospitals [Youth Program Grant (QML20171106), Special Fund for Digestive System Multidisciplinar] Funding Source: Medline
CR Bai WY, 2018, J NEUROSURG ANESTH, V30, P337, DOI 10.1097/ANA.0000000000000460
   Batchelor TJP, 2019, EUR J CARDIO-THORAC, V55, P91, DOI 10.1093/ejcts/ezy301
   Chandran P, 2003, PAIN, V102, P195, DOI 10.1016/S0304-3959(02)00381-0
   DeSantana JM, 2008, ARCH PHYS MED REHAB, V89, P754, DOI 10.1016/j.apmr.2007.11.027
   DeSantana JM, 2010, PAIN, V148, P84, DOI 10.1016/j.pain.2009.10.011
   Han JS, 2003, TRENDS NEUROSCI, V26, P17, DOI 10.1016/S0166-2236(02)00006-1
   Huang S, 2017, J ANESTH, V31, P58, DOI 10.1007/s00540-015-2057-1
   Li HZ, 2019, CLIN INTERV AGING, V14, P1607, DOI 10.2147/CIA.S210751
   MacPherson H, 2010, PLOS MED, V7, P0, DOI 10.1371/journal.pmed.1000261
   McQuay H, 1999, LANCET, V353, P2229, DOI 10.1016/S0140-6736(99)03528-X
   Myles PS, 2017, BRIT J ANAESTH, V118, P424, DOI 10.1093/bja/aew466
   Tian JH, 1998, BRIT J PHARMACOL, V124, P21, DOI 10.1038/sj.bjp.0701788
   Wang H, 2014, BRIT J ANAESTH, V112, P1075, DOI 10.1093/bja/aeu001
   Wang XQ, 2010, J NEUROSURG ANESTH, V22, P128, DOI 10.1097/ANA.0b013e3181c9fbde
   Wick EC, 2017, JAMA SURG, V152, P691, DOI 10.1001/jamasurg.2017.0898
   Wong RHL, 2006, ANN THORAC SURG, V81, P2031, DOI 10.1016/j.athoracsur.2005.12.064
   Wu MS, 2016, PLOS ONE, V11, P0, DOI 10.1371/journal.pone.0150367
   Zhang Q, 2014, ANAESTHESIA, V69, P832, DOI 10.1111/anae.12639
NR 18
TC 48
Z9 62
U1 6
U2 40
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1759-7706
EI 1759-7714
J9 THORAC CANCER
JI Thorac. Cancer
PD APR 15
PY 2020
VL 11
IS 4
BP 928
EP 934
DI 10.1111/1759-7714.13343
PG 7
WC Oncology; Respiratory System
SC Oncology; Respiratory System
GA KY5PD
UT WOS:000522621100011
PM 32062864
DA 2026-01-16
ER

PT J
AU Zeng, JC
   Zhou, RJ
   Luo, ZK
   Zhang, N
   Liu, ZJ
   Lin, GH
AF Zeng, Jingchun
   Zhou, Runjin
   Luo, Zhenke
   Zhang, Na
   Liu, Zijun
   Lin, Guohua
TI Clinical evidence of acupuncture and related therapy in patients with cancer-pain A protocol for systematic review and meta-analysis
SO MEDICINE
LA English
DT Review
DE acupuncture and related therapy; cancer pain; high quality RCTs; protocol; protocol; systematic review
ID management; women
AB Background: Cancer pain (CP) is one of the common complications of cancer. During the treatment, oral medication, radiotherapy and chemotherapy bring certain adverse reactions to patients with CP; a safe way to treat this disease is necessary. Acupuncture and related therapies for CP with few side effects have been gradually accepted. But at present the evidence is insufficient, the related research is not thorough enough. The purpose of this study was to investigate the efficacy and safety of acupuncture and related therapies for CP. Methods: The Preferred Reporting Items for Systematic Review and Meta-Analysis Protocols (PRISMA-P) guidelines were used to design this protocol. The final study will also be conducted under the PRISMA guidelines for systematic reviews and meta-analysis. An electronic search will be conducted in Medline, Embase, and the Cochrane Central Register of Controlled Trials databases through January 2020. The search will be conducted in English. Risk of bias will be assessed by the Cochrane Collaboration tool and the collected evidence will be nar-ratively synthesized. We will also perform a meta-analysis to pool estimates from studies considered to be homogenous. Subgroup analyses will be based on intervention or overall bias. The strength of evidence will be evaluated by the Grading of Recommendations, Assessment, Development and Evaluation scale. Results: This systematic review will summarize high quality clinical evidence to assess and appraise the effectiveness and safety of acupuncture and related therapies for CP patients. Conclusion: The meta-analysis will assess evidence from randomized controlled trials of acupuncture and related therapies and CP types. INPLASY registration number: INPLASY202040129.
C1 [Zeng, Jingchun; Lin, Guohua] Guangzhou Univ Chinese Med, Dept Acupuncture, Affiliated Hosp 1, Guangzhou 510405, Peoples R China.
   [Zhou, Runjin; Luo, Zhenke; Zhang, Na; Liu, Zijun] Guangzhou Univ Chinese Med, Guangzhou, Peoples R China.
C3 Guangzhou University of Chinese Medicine; Guangzhou University of Chinese Medicine
RP Zeng, JC; Lin, GH (corresponding author), Guangzhou Univ Chinese Med, Dept Acupuncture, Affiliated Hosp 1, Guangzhou 510405, Peoples R China.
EM tcm_zjc@126.com; tcmlin-801@163.com
FU Chinese National Natural Science Foundation [81574061]; Guangdong Science and Technology Commission Foundation [2017A020213019]; Innovative Research Fund of the First Affiliated Hospital of Guangzhou University of Chinese Medicine [2019QN23]
CR Unknown -, 2009, BMJ-BRIT MED J, V6, Pe1000097, DOI 10.1136/bmj.b2535, 10.1371/journal.pmed.1000097, 10.1371/JOURNAL.PMED.1000097
   Unknown -, 2019, MEDICINE, V98, P0
   Carlson CL, 2016, J PAIN RES, V9, P515, DOI 10.2147/JPR.S97759
   Chao LF, 2009, BREAST CANCER RES TR, V118, P255, DOI 10.1007/s10549-009-0533-8
   Chen HY, 2013, BMC COMPLEM ALTERN M, V13, P0, DOI 10.1186/1472-6882-13-362
   Cheuk DKL, 2011, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD007849.pub2
   Chiu HY, 2017, EUR J CANCER CARE, V26, P0, DOI 10.1111/ecc.12457
   Crew KD, 2010, J CLIN ONCOL, V28, P1154, DOI 10.1200/JCO.2009.23.4708
   Deek J, 2011, COCHRANE HDB SYSTEMA, V0, P0
   Deng G, 2005, CA-CANCER J CLIN, V55, P109, DOI 10.3322/canjclin.55.2.109
   Dikmen HA, 2019, PAIN MANAG NURS, V20, P47, DOI 10.1016/j.pmn.2018.03.001
   Enblom A, 2012, ANN ONCOL, V23, P1353, DOI 10.1093/annonc/mdr402
   Fitzmaurice C, 2015, JAMA ONCOL, V1, P505, DOI 10.1001/jamaoncol.2015.0735
   Geue K, 2017, SCHMERZ, V31, P23, DOI 10.1007/s00482-016-0125-6
   Gralow J, 2007, J PAIN SYMPTOM MANAG, V33, P462, DOI 10.1016/j.jpainsymman.2007.01.001
   He YH, 2020, JAMA ONCOL, V6, P271, DOI 10.1001/jamaoncol.2019.5233
   He YH, 2017, BMJ OPEN, V7, P0, DOI 10.1136/bmjopen-2017-018494
   Hershman DL, 2018, JAMA-J AM MED ASSOC, V320, P167, DOI 10.1001/jama.2018.8907
   Higgins J, 2012, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.ED000049
   Hu CQ, 2016, EVID-BASED COMPL ALT, V2016, P0, DOI 10.1155/2016/1720239
   Induru RR, 2014, AM J HOSP PALLIAT ME, V31, P777, DOI 10.1177/1049909113508302
   Keskinbora K, 2007, J PAIN SYMPTOM MANAG, V34, P183, DOI 10.1016/j.jpainsymman.2006.11.013
   Kim YC, 2015, CANCER MED-US, V4, P1196, DOI 10.1002/cam4.471
   Laird B, 2008, EUR J CANCER, V44, P1078, DOI 10.1016/j.ejca.2008.03.022
   Li XM, 2017, SCI REP-UK, V7, P0, DOI 10.1038/srep39397
   Orwin RG, 1994, HDB RES SYNTHESIS, V0, P0
   Paley CA, 2015, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD007753.pub3
   Spencer K, 2018, BMJ-BRIT MED J, V360, P0, DOI 10.1136/bmj.k821
   Vallerand AH, 2007, PAIN, V132, P82, DOI 10.1016/j.pain.2007.01.029
   Vickers AJ, 2018, J PAIN, V19, P455, DOI 10.1016/j.jpain.2017.11.005
   Vickers AJ, 2001, LANCET ONCOL, V2, P226, DOI 10.1016/S1470-2045(00)00293-X
   Xie J, 2017, CHIN J CANCER, V36, P0, DOI 10.1186/s40880-016-0176-1
   Zhao Y, 2000, CONT ONCOLOGY, V0, P556
NR 33
TC 2
Z9 3
U1 0
U2 7
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0025-7974
EI 1536-5964
J9 MEDICINE
JI Medicine (Baltimore)
PD NOV 6
PY 2020
VL 99
IS 45
BP 
EP 
DI 10.1097/MD.0000000000023119
PG 5
WC Medicine, General & Internal
SC General & Internal Medicine
GA OP6AW
UT WOS:000588168200082
PM 33157988
DA 2026-01-16
ER

PT J
AU Iravani, S
   Motlagh, AHK
   Razavi, SZE
   Shahi, F
   Wang, J
   Hou, L
   Sun, WJ
   Fard, MRA
   Aghili, M
   Karimi, M
   Rezaeizadeh, H
   Zhao, BX
AF Iravani, Somayeh
   Kazemi Motlagh, Amir Hooman
   Emami Razavi, Seyede Zahra
   Shahi, Farhad
   Wang, Jing
   Hou, Li
   Sun, Wenjun
   Afshari Fard, Mohammad Reza
   Aghili, Mahdi
   Karimi, Mehrdad
   Rezaeizadeh, Hossein
   Zhao, Baixiao
TI Effectiveness of Acupuncture Treatment on Chemotherapy-Induced Peripheral Neuropathy: A Pilot, Randomized, Assessor-Blinded, Controlled Trial
SO PAIN RESEARCH & MANAGEMENT
LA English
DT Article
ID quality-of-life; clinical importance; cancer; pain; electroacupuncture; management; fatigue; patient
AB Objective. This pilot study aims to evaluate the effectiveness and safety of acupuncture in the treatment of chemotherapy-induced peripheral neuropathy (CIPN). Methods. This study was a pilot randomized controlled trial, which was conducted with cooperation between Beijing University of Chinese Medicine (BUCM), China, and Tehran University of Medical Science (TUMS), Iran. Forty participants with CIPN were randomly assigned (1 : 1) to receive twelve sessions of acupuncture (20 minutes each session over 4 weeks) or take one 300 mg tablet of vitamin B1 and three 300 mg capsules of gabapentin per day for 4 weeks, after which both groups were followed up for 4 weeks. The primary endpoint was CIPN symptom severity measured by the Numerical Rating Scale (NRS). The secondary endpoints included sensory neuropathy grade evaluated by the National Cancer Institute-Common Toxicity Criteria for Adverse Events (NCI-CTCAE), neurophysiological assessment of CIPN by the nerve conduction study (NCS), and the patient overall satisfaction with treatment. Safety was assessed at each visit. Results. The NRS and NCI-CTCAE sensory neuropathy grading scales decreased significantly over time in both groups (both P < 0.001), with a significantly higher reduction in the acupuncture group (P < 0.001 and P = 0.03, respectively). In addition, the acupuncture group showed a higher overall satisfaction with the treatment at the end of treatment and after 4 weeks follow-up, in comparison with the vit B1 and gabapentin group (P = 0.01 and P = 0.001, respectively). The NCS (except for the latency of the sural nerve) in the acupuncture group improved significantly (P < 0.05), while improvement in the vit B1 and gabapentin group was not observed (P > 0.05). Conclusion. Our study revealed that acupuncture, as a kind of traditional Chinese therapeutic method, is significantly effective and safe in the treatment of CIPN. Moreover, acupuncture is more effective than using vitamin B1 and gabapentin as the conventional treatment.
C1 [Iravani, Somayeh; Afshari Fard, Mohammad Reza] Beijing Univ Chinese Med, Sch Acupuncture Moxibust & Tuina, Beijing 100029, Peoples R China.
   [Kazemi Motlagh, Amir Hooman; Karimi, Mehrdad; Rezaeizadeh, Hossein] Univ Tehran Med Sci, Sch Persian Med, Tehran, Iran.
   [Emami Razavi, Seyede Zahra] Univ Tehran Med Sci, Imam Khomeini Hosp Complex, Dept Phys Med & Rehabil, Tehran, Iran.
   [Shahi, Farhad] Univ Tehran Med Sci, Canc Inst Res Ctr, Imam Khomeini Hosp Complex, Dept Hematol & Med Oncol, Tehran, Iran.
   [Wang, Jing; Hou, Li] Beijing Univ Chinese Med, Dongzhimen Hosp, Dept Hematol & Oncol, Beijing 100700, Peoples R China.
   [Sun, Wenjun] Beijing Univ Chinese Med, Dept Neurol, Affiliated Hosp 3, Beijing 100029, Peoples R China.
   [Aghili, Mahdi] Univ Tehran Med Sci, Dept Radiat Oncol, Radiat Oncol Res Ctr, Tehran, Iran.
   [Zhao, Baixiao] Beijing Univ Chinese Med, Sch Tradit Chinese Med, Beijing 100029, Peoples R China.
C3 Beijing University of Chinese Medicine; Tehran University of Medical Sciences; Tehran University of Medical Sciences; Tehran University of Medical Sciences; Beijing University of Chinese Medicine; Beijing University of Chinese Medicine; Tehran University of Medical Sciences; Beijing University of Chinese Medicine
RP Zhao, BX (corresponding author), Beijing Univ Chinese Med, Sch Tradit Chinese Med, Beijing 100029, Peoples R China.
EM iravani_somayeh@bucm.edu.cn; hooman_k@tums.ac.ir; zemamirazavi@gmail.com; fshahi@yahoo.com; jwang2936@126.com; houli1203@126.com; doctorsunwenjun@126.com; afsharimohammadreza@bucm.edu.cn; aghili@tums.ac.ir; mehrdadkarimi@yahoo.com; rezaeizadeh@sina.tums.ac.ir; baixiao100@vip.sina.com
FU National Natural Science Foundation of China [81874503]; Beijing University of Chinese Medicine; Tehran University of Medical Science
CR Abuaisha BB, 1998, DIABETES RES CLIN PR, V39, P115, DOI 10.1016/S0168-8227(97)00123-X
   Ahn Andrew C, 2007, ACUPUNCT MED, V25, P11
   Bakogeorgos M, 2017, EXPERT REV ANTICANC, V17, P1045, DOI 10.1080/14737140.2017.1374856
   Bao T, 2020, JAMA NETW OPEN, V3, P0, DOI 10.1001/jamanetworkopen.2020.0681
   Bao T, 2011, PAIN RES TREAT, V2011, P0, DOI 10.1155/2011/920807
   Cavaletti G, 2013, ANN ONCOL, V24, P454, DOI 10.1093/annonc/mds329
   Chien TJ, 2019, INTEGR CANCER THER, V18, P0, DOI 10.1177/1534735419886662
   Chiu HY, 2017, EUR J CANCER CARE, V26, P0, DOI 10.1111/ecc.12457
   DAlessandro EG, 2022, BMJ SUPPORT PALLIAT, V12, P64, DOI 10.1136/bmjspcare-2018-001542
   Dean-Clower E, 2010, INTEGR CANCER THER, V9, P158, DOI 10.1177/1534735409360666
   Deng B, 2016, EVID-BASED COMPL ALT, V2016, P0, DOI 10.1155/2016/2421876
   Donald GK, 2011, ACUPUNCT MED, V29, P230, DOI 10.1136/acupmed.2011.010025
   Dworkin RH, 2009, PAIN, V146, P238, DOI 10.1016/j.pain.2009.08.019
   Farrar JT, 2001, PAIN, V94, P149, DOI 10.1016/S0304-3959(01)00349-9
   Fradkin M, 2019, CURR MED CHEM, V26, P4698, DOI 10.2174/0929867326666190107163756
   Franconi G, 2013, EVID-BASED COMPL ALT, V2013, P0, DOI 10.1155/2013/516916
   Giorgi F, 1996, AM J CLIN ONCOL-CANC, V19, P394, DOI 10.1097/00000421-199608000-00016
   Goh YL, 2014, J ACUPUNCT MERIDIAN, V7, P331, DOI 10.1016/j.jams.2014.02.004
   Haddad NE, 2014, INTEGR CANCER THER, V13, P371, DOI 10.1177/1534735413520181
   Han JS, 2003, TRENDS NEUROSCI, V26, P17, DOI 10.1016/S0166-2236(02)00006-1
   Han XY, 2017, BMC CANCER, V17, P0, DOI 10.1186/s12885-016-3037-z
   Hershman DL, 2014, J CLIN ONCOL, V32, P1941, DOI 10.1200/JCO.2013.54.0914
   Hirayama Y, 2015, INT J CLIN ONCOL, V20, P866, DOI 10.1007/s10147-015-0810-y
   Jeong YJ, 2018, EVID-BASED COMPL ALT, V2018, P0, DOI 10.1155/2018/5367014
   Kim JH, 2013, TRIALS, V14, P0, DOI 10.1186/1745-6215-14-254
   Kim SY, 2016, EVID-BASED COMPL ALT, V2016, P0, DOI 10.1155/2016/9874207
   Langevin HM, 2001, FASEB J, V15, P2275, DOI 10.1096/fj.01-0015hyp
   Litscher G, 2002, LASER MED SCI, V17, P19, DOI 10.1007/s10103-002-8262-9
   Liu ZS, 2013, CHIN J INTEGR MED, V19, P58, DOI 10.1007/s11655-013-1191-y
   Mandiroglu S, 2014, ACUPUNCT MED, V32, P194, DOI 10.1136/acupmed-2013-010491
   Molassiotis A, 2007, COMPLEMENT THER MED, V15, P228, DOI 10.1016/j.ctim.2006.09.009
   Molassiotis A, 2019, INTEGR CANCER THER, V18, P0, DOI 10.1177/1534735419836501
   Park SB, 2013, CA-CANCER J CLIN, V63, P419, DOI 10.3322/caac.21204
   Phillips KD, 2004, J ALTERN COMPLEM MED, V10, P449, DOI 10.1089/1075553041323678
   Rostock M, 2013, EVID-BASED COMPL ALT, V2013, P0, DOI 10.1155/2013/349653
   Schroeder S, 2012, ACUPUNCT MED, V30, P4, DOI 10.1136/acupmed-2011-010034
   Seretny M, 2014, PAIN, V155, P2461, DOI 10.1016/j.pain.2014.09.020
   Shen JN, 2000, JAMA-J AM MED ASSOC, V284, P2755, DOI 10.1001/jama.284.21.2755
   Starobova H, 2017, FRONT MOL NEUROSCI, V10, P0, DOI 10.3389/fnmol.2017.00174
   Tong YQ, 2010, J ACUPUNCT MERIDIAN, V3, P95, DOI 10.1016/S2005-2901(10)60018-0
   Tsuchiya M, 2007, ANESTH ANALG, V104, P301, DOI 10.1213/01.ane.0000230622.16367.fb
   Vickers AJ, 2004, J CLIN ONCOL, V22, P1731, DOI 10.1200/JCO.2004.04.102
   Wong Raimond, 2006, ACUPUNCT MED, V24, P87
   Xiong ZF, 2016, WORLD J ACUPUNCT-MOX, V26, P20, DOI 10.1016/S1003-5257(17)30005-3
   Yao C, 2016, CURR ONCOL, V23, PE27, DOI 10.3747/co.23.2788
   Zhang C, 2010, J TRADIT CHIN MED, V30, P13, DOI 10.1016/S0254-6272(10)60003-9
   Zhang SQ, 2017, J TRADIT CHIN MED, V37, P179
NR 47
TC 46
Z9 53
U1 8
U2 36
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 1203-6765
EI 1918-1523
J9 PAIN RES MANAG
JI Pain Res. Manag.
PD JUN 29
PY 2020
VL 2020
IS 
BP 
EP 
DI 10.1155/2020/2504674
PG 11
WC Clinical Neurology
SC Neurosciences & Neurology
GA MQ2UU
UT WOS:000552753500002
PM 32676134
DA 2026-01-16
ER

PT J
AU Bossi, P
   Ghiani, M
   Argenone, A
   Depenni, R
AF Bossi, Paolo
   Ghiani, Massimo
   Argenone, Angela
   Depenni, Roberta
TI Is pain part of a systemic syndrome in head and neck cancer?
SO SUPPORTIVE CARE IN CANCER
LA English
DT Review
DE Head and neck cancer; Pain; Pain management; Multidisciplinary approach; Opioids
ID quality-of-life; placebo-controlled trial; pectin nasal spray; oral mucositis; double-blind; depression; fentanyl; association; management; fatigue
AB Head and neck cancers (HNC) represent 5% of all malignancies worldwide with about 180,000 cancer deaths per year. Patients with HNC are characterized by a systemic inflammatory state, generally associated with worse outcomes. Treatment-related toxicity is common among HNC patients and causes systemic consequences such as fatigue or cognitive dysfunction. The therapeutic treatments of HNC involve the release in circulation of inflammatory systemic mediators, whose effects trigger a vicious circle that may lead to functional and behavioral alterations. The areas of the head and neck are highly sensitive to pain. Literature data confirm that in HNC patients, pain is one of the most distressing symptoms across all the phases of treatment. Pain is associated with worse general conditions, depression, fatigue, impaired cognitive functions, and lower survival rate. The treatment of advanced HNC cases is multimodal and requires a multidisciplinary psycho-socio-pharmacological approach mediated by a team of experts. The pharmacological approach in management of HNC patients with pain is fundamental and involves the use of opioids, NSAIDs, steroids, or other drugs. Opioids in pain management therapy in patients with HNC could allow the pain level to be adequately monitored, thus improving quality of life. The integration of opioid and non-opioid therapy as well as non-pharmacological interventions is essential for the rehabilitation of physical, social, and psychological functions and to achieve pain control in patients with HNC. Opioid treatment is the mainstay for pain control, being used both for background and breakthrough cancer pain (BTcP) episodes. Fentanyl, easily absorbed and generally well tolerated, appears to be a possible choice due to its versatility. Non-pharmacological interventions, such as tailored yoga, physical exercise, and acupuncture, may have a role in pain management in patients with HNC.
C1 [Bossi, Paolo] ASST Spedali Civili Brescia, Med Oncol, Brescia, Italy.
   [Bossi, Paolo] Univ Brescia, Dept Med & Surg Specialties, Radiol Sci & Publ Hlth, Brescia, Italy.
   [Ghiani, Massimo] A Businco Hosp, Oncol Dept, Cagliari, Italy.
   [Argenone, Angela] Ist Nazl Tumori IRCCS G Pascale Fdn, Radiat Oncol Dept, Naples, Italy.
   [Depenni, Roberta] Univ Hosp Modena & Reggio Emilia, Oncol & Haematol Dept, Modena, Italy.
C3 Hospital Spedali Civili Brescia; University of Brescia; Universita di Modena e Reggio Emilia; Universita di Modena e Reggio Emilia Hospital
RP Bossi, P (corresponding author), ASST Spedali Civili Brescia, Med Oncol, Brescia, Italy.; Bossi, P (corresponding author), Univ Brescia, Dept Med & Surg Specialties, Radiol Sci & Publ Hlth, Brescia, Italy.
EM paolo.bossi@unibs.it
CR Adair M, 2018, INTEGR CANCER THER, V17, P774, DOI 10.1177/1534735417753540
   Al-Dasooqi N, 2009, CANCER CHEMOTH PHARM, V64, P1, DOI 10.1007/s00280-009-0984-y
   Allison RR, 2014, CANCER-AM CANCER SOC, V120, P1433, DOI 10.1002/cncr.28553
   Apkarian AV, 2004, J NEUROSCI, V24, P10410, DOI 10.1523/JNEUROSCI.2541-04.2004
   Bandieri E, 2016, J CLIN ONCOL, V34, P436, DOI 10.1200/JCO.2015.61.0733
   Barcellos-Hoff MH, 1998, RADIAT RES, V150, PS109, DOI 10.2307/3579813
   Bell BC, 2013, J PAIN RES, V6, P843, DOI 10.2147/JPR.S54788
   Bossi P, 2014, ORAL ONCOL, V50, P884, DOI 10.1016/j.oraloncology.2014.06.013
   Capuron L, 2003, BRAIN BEHAV IMMUN, V17, P0
   CAVAILLON JM, 1992, CIRC SHOCK, V0, P0
   Chang Andrew, 2015, J PAIN PALLIAT CARE PHARMACOTHER, V29, P247, DOI 10.3109/15360288.2015.1063560
   Chapman CR, 1999, LANCET, V353, P2233, DOI 10.1016/S0140-6736(99)01308-2
   Chua KSG, 1999, J PAIN SYMPTOM MANAG, V18, P193, DOI 10.1016/S0885-3924(99)00070-6
   Ciofi P, 2009, ENDOCRINOLOGY, V150, P5509, DOI 10.1210/en.2009-0584
   Clarkson Jan E, 2010, COCHRANE DATABASE SYST REV, V0, PPCD001973, DOI 10.1002/14651858.CD001973.pub4
   Cleeland CS, 2003, CANCER-AM CANCER SOC, V97, P2919, DOI 10.1002/cncr.11382
   Cohen E, 2008, CANCER NURS, V31, PE1, DOI 10.1097/01.NCC.0000305693.67131.7d
   Criswell T, 2003, ONCOGENE, V22, P5813, DOI 10.1038/sj.onc.1206680
   Dantzer R, 2004, EUR J PHARMACOL, V500, P399, DOI 10.1016/j.ejphar.2004.07.040
   Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1
   Denham JW, 2002, RADIOTHER ONCOL, V63, P129, DOI 10.1016/S0167-8140(02)00060-9
   Du MY, 2012, PROG NEURO-PSYCHOPH, V36, P11, DOI 10.1016/j.pnpbp.2011.09.014
   DUFTON BD, 1989, INT J PSYCHIAT MED, V19, P291, DOI 10.2190/JDJK-0795-5BFL-5N6K
   Elad S, 2020, CANCER-AM CANCER SOC, V126, P4423, DOI 10.1002/cncr.28592
   Enting RH, 2007, J PAIN SYMPTOM MANAG, V34, P523, DOI 10.1016/j.jpainsymman.2007.01.007
   Epstein JB, 2001, ORAL ONCOL, V37, P632, DOI 10.1016/S1368-8375(01)00005-7
   Giusti R, 2018, BRIT J PAIN, V12, P155, DOI 10.1177/2049463717736787
   Green CR, 2011, CANCER-AM CANCER SOC, V117, P1994, DOI 10.1002/cncr.25761
   Grond S, 1997, PAIN, V69, P191, DOI 10.1016/S0304-3959(96)03254-X
   Gustin SM, 2013, J PAIN, V14, P1642, DOI 10.1016/j.jpain.2013.08.005
   Haddad R, 2009, CANCER, V115, P4514, DOI 10.1002/cncr.24525
   Hart Robert P, 2003, CURR PAIN HEADACHE REP, V7, P116, DOI 10.1007/s11916-003-0021-5
   HESS R, 1972, EUR J CLIN PHARMACOL, V4, P137, DOI 10.1007/BF00561135
   Howren MB, 2013, J CONSULT CLIN PSYCH, V81, P299, DOI 10.1037/a0029940
   Illi J, 2012, CYTOKINE, V58, P437, DOI 10.1016/j.cyto.2012.02.015
   Jain MK, 2005, NAT REV DRUG DISCOV, V4, P977, DOI 10.1038/nrd1901
   Jemal Ahmedin Bray Freddie Center Melissa M, 2011, CA-CANCER J CLIN, V61, P90
   Jiang JR, 2019, J CLIN ONCOL, V37, P135, DOI 10.1200/JCO.18.00896
   Johansen-Berg H, 2008, CEREB CORTEX, V18, P1374, DOI 10.1093/cercor/bhm167
   Kestenbaum MG, 2014, PAIN MED, V15, P1129, DOI 10.1111/pme.12464
   Kim ES, 2015, KOREAN J PAIN, V28, P73, DOI 10.3344/kjp.2015.28.2.73
   Krysko DV, 2011, TRENDS IMMUNOL, V32, P157, DOI 10.1016/j.it.2011.01.005
   Kvillemo P, 2011, CANCER NURS, V34, P24, DOI 10.1097/NCC.0b013e3181e2d0df
   Laird BJA, 2016, J CLIN ONCOL, V34, P2769, DOI 10.1200/JCO.2015.65.7742
   Lalla RV, 2014, ORAL ONCOL, V50, P1098, DOI 10.1016/j.oraloncology.2014.08.001
   Li Y, 2008, J NEUROSCI, V28, P2814, DOI 10.1523/JNEUROSCI.5447-07.2008
   Logan RM, 2007, ORAL ONCOL, V43, P395, DOI 10.1016/j.oraloncology.2006.04.011
   Lopez G, 2018, J CANCER, V9, P3613, DOI 10.7150/jca.26527
   May A, 2008, PAIN, V137, P7, DOI 10.1016/j.pain.2008.02.034
   Mehanna HM, 2006, ARCH OTOLARYNGOL, V132, P27, DOI 10.1001/archotol.132.1.27
   Mejias NH, 2018, J INFLAMM-LOND, V15, P0, DOI 10.1186/s12950-018-0198-3
   Mirabile A, 2016, CRIT REV ONCOL HEMAT, V99, P100, DOI 10.1016/j.critrevonc.2015.11.010
   MOLE RH, 1953, BRIT J RADIOL, V26, P234, DOI 10.1259/0007-1285-26-305-234
   Moore R Andrew, 2009, COCHRANE DATABASE SYST REV, V0, PPCD007076, DOI 10.1002/14651858.CD007076.pub2
   MUSTIAN KM, 2013, EUR MED J ONCOL, V0, P0
   Paice JA, 2014, J CLIN ONCOL, V32, P1721, DOI 10.1200/JCO.2013.52.5196
   Pendergrass J C, 2018, INNOV CLIN NEUROSCI, V0, P0
   Pinquart M, 2010, PSYCHOL MED, V40, P1797, DOI 10.1017/S0033291709992285
   Rainville P, 1997, SCIENCE, V277, P968, DOI 10.1126/science.277.5328.968
   Rodriguez-Raecke R, 2009, J NEUROSCI, V29, P13746, DOI 10.1523/JNEUROSCI.3687-09.2009
   Rogers LQ, 2008, HEAD NECK-J SCI SPEC, V30, P1310, DOI 10.1002/hed.20873
   Rogers LQ, 2009, HEAD NECK-J SCI SPEC, V31, P994, DOI 10.1002/hed.21053
   ROSOW CE, 1987, DRUG ALCOHOL DEPEN, V20, P329, DOI 10.1016/0376-8716(87)90006-8
   Roxburgh CSD, 2014, BRIT J CANCER, V110, P1409, DOI 10.1038/bjc.2014.90
   Russi EG, 2014, MEDIAT INFLAMM, V2014, P0, DOI 10.1155/2014/518261
   Sarvizadeh Mostafa, 2015, ADV BIOMED RES, V4, P44, DOI 10.4103/2277-9175.151254
   Scharpf J, 2009, ARCH OTOLARYNGOL, V135, P789, DOI 10.1001/archoto.2009.107
   Schubert C, 2007, BRAIN BEHAV IMMUN, V21, P413, DOI 10.1016/j.bbi.2006.11.004
   Schug SA, 2017, DRUGS, V77, P747, DOI 10.1007/s40265-017-0727-z
   Sheline YI, 1999, J NEUROSCI, V19, P5034
   Shinn EH, 2016, PSYCHOSOM MED, V78, P38, DOI 10.1097/PSY.0000000000000256
   Srikrishna G, 2009, NEOPLASIA, V11, P615, DOI 10.1593/neo.09284
   Takase H, 2011, AURIS NASUS LARYNX, V38, P495, DOI 10.1016/j.anl.2010.12.012
   van Nieuwenhuizen AJ, 2018, SUPPORT CARE CANCER, V26, P1087, DOI 10.1007/s00520-017-3926-y
   Weber RJ, 2009, BRAIN BEHAV IMMUN, V23, P993, DOI 10.1016/j.bbi.2009.05.057
   Woolf CJ, 2000, SCIENCE, V288, P1765, DOI 10.1126/science.288.5472.1765
   Xiao CH, 2013, ORAL ONCOL, V49, P360, DOI 10.1016/j.oraloncology.2012.10.004
   Yang CA, 2015, J AUTOIMMUN, V61, P1, DOI 10.1016/j.jaut.2015.05.001
   Yennurajalingam S, 2013, J CLIN ONCOL, V31, P3076, DOI 10.1200/JCO.2012.44.4661
   Younger JW, 2011, PAIN, V152, P1803, DOI 10.1016/j.pain.2011.03.028
   Zeppetella G, 2015, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD004311.pub4
NR 81
TC 16
Z9 18
U1 0
U2 16
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0941-4355
EI 1433-7339
J9 SUPPORT CARE CANCER
JI Support. Care Cancer
PD FEB 15
PY 2020
VL 28
IS 2
BP 451
EP 459
DI 10.1007/s00520-019-05147-8
EA NOV 2019
PG 9
WC Oncology; Health Care Sciences & Services; Rehabilitation
SC Oncology; Health Care Sciences & Services; Rehabilitation
GA KW3FF
UT WOS:000495951700001
PM 31713692
DA 2026-01-16
ER

PT J
AU Sanaei, O
   Fernández-Esparrach, G
   De, La Serna-Higuera C
   Carrara, S
   Kumbhari, V
   El, Zein MH
   Ismail, A
   Ginès, A
   Sendino, O
   Montenegro, A
   Repici, A
   Rahal, D
   Brewer, Gutierrez OI
   Moran, R
   Yang, J
   Parsa, N
   Paiji, C
   Aghaie, Meybodi M
   Shin, EJ
   Lennon, AM
   Kalloo, AN
   Singh, VK
   Canto, MI
   Khashab, MA
AF Sanaei, Omid
   Fernández-Esparrach, Glòria
   De La Serna-Higuera, Carlos
   Carrara, Silvia
   Kumbhari, Vivek
   El Zein, Mohamad H
   Ismail, Amr
   Ginès, Angels
   Sendino, Oriol
   Montenegro, Andrea
   Repici, Alessandro
   Rahal, Daoud
   Brewer Gutierrez, Olaya I
   Moran, Robert
   Yang, Juliana
   Parsa, Nasim
   Paiji, Christopher
   Aghaie Meybodi, Mohamad
   Shin, Eun Ji
   Lennon, Anne Marie
   Kalloo, Anthony N
   Singh, Vikesh K
   Canto, Marcia Irene
   Khashab, Mouen A
TI EUS-guided 22-gauge fine needle biopsy versus single-incision with needle knife
SO Endoscopy international open
LA English
DT Journal Article
AB Background and study aims  EUS-FNA has suboptimal accuracy in diagnosing  gastrointestinal subepithelial tumors (SETs). EUS-guided 22-gauge fine needle  biopsy (EUS-FNB) and single-incision with needle knife (SINK) were proposed to  increase accuracy of diagnosis. This study aimed to prospectively compare the  diagnostic accuracy and safety of EUS-FNB with SINK in patients with upper  gastrointestinal SETs. Patients and methods  All adult patients referred for EUS  evaluation of upper gastrointestinal SETs ≥ 15 mm in size were eligible for  inclusion. Patients were randomized to undergo EUS-FNB or SINK. Lesions were  sampled with a 22-gauge reverse beveled core needle in the EUS-FNB group and by a  conventional needle-knife sphincterotome and biopsy forceps in the SINK  group. Patients were blinded to the technique used. The primary outcome was  diagnostic accuracy. Secondary outcomes included adverse events, histological  yield and procedure duration. Study enrollment was terminated early due to poor  recruitment. Results  A total of 56 patients (31 male (55.37 %); mean age,  67.41 ± 12.70 years) were randomized to either EUS-FNB (n = 26) or SINK (n = 30).  Technical success was 96.15 % and 96.66 %, respectively. The majority of lesions  were gastrointestinal stromal tumors (51.78 %). No significant difference was  found between EUS-FNB and SINK in terms of diagnostic accuracy for a malignant or  benign disease (76 % vs. 89.28 %, respectively; P  = 0.278). The rate of adverse  events (none severe) was also comparable (7.69 % vs. 10 %, respectively; P =   1.0) including two abdominal pain episodes in the EUS-FNB group compared to two  delayed bleeding (one requiring hospitalization and radiologic embolization) and  1 abdominal pain in the SINK group. Conclusion  EUS-FNB and SINK are equally  effective techniques for upper gastrointestinal SETs sampling. SINK can be  associated with mild to moderate delayed bleeding.
C1 Division of Gastroenterology and Hepatology, Johns Hopkins Medical Institution, Baltimore, Maryland, United States.
   Endoscopy Unit, Gastroenterology Department, ICMDiM, Hospital Clinic, University of Barcelona, Catalonia, Spain.
   Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, 
   Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Barcelona, Spain.
   Gastroenterology Department, Hospital Universitario Rio Hortega, Valladolid, Spain.
   Digestive Endoscopy Unit, Division of Gastroenterology, Humanitas Clinical and Research Center - IRCCS, Rozzano, Italy.
   Division of Gastroenterology and Hepatology, Johns Hopkins Medical Institution, Baltimore, Maryland, United States.
   Division of Gastroenterology and Hepatology, Johns Hopkins Medical Institution, Baltimore, Maryland, United States.
   Division of Gastroenterology and Hepatology, Johns Hopkins Medical Institution, Baltimore, Maryland, United States.
   Endoscopy Unit, Gastroenterology Department, ICMDiM, Hospital Clinic, University of Barcelona, Catalonia, Spain.
   Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, 
   Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Barcelona, Spain.
   Endoscopy Unit, Gastroenterology Department, ICMDiM, Hospital Clinic, University of Barcelona, Catalonia, Spain.
   Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, 
   Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Barcelona, Spain.
   Endoscopy Unit, Gastroenterology Department, ICMDiM, Hospital Clinic, University of Barcelona, Catalonia, Spain.
   Digestive Endoscopy Unit, Division of Gastroenterology, Humanitas Clinical and Research Center - IRCCS, Rozzano, Italy.
   Department of Pathology, Humanitas Clinical and Research Center, Rozzano, Italy.
   Division of Gastroenterology and Hepatology, Johns Hopkins Medical Institution, Baltimore, Maryland, United States.
   Division of Gastroenterology and Hepatology, Johns Hopkins Medical Institution, Baltimore, Maryland, United States.
   Division of Gastroenterology and Hepatology, Johns Hopkins Medical Institution, Baltimore, Maryland, United States.
   Division of Gastroenterology and Hepatology, Johns Hopkins Medical Institution, Baltimore, Maryland, United States.
   Division of Gastroenterology and Hepatology, Johns Hopkins Medical Institution, Baltimore, Maryland, United States.
   Division of Gastroenterology and Hepatology, Johns Hopkins Medical Institution, Baltimore, Maryland, United States.
   Division of Gastroenterology and Hepatology, Johns Hopkins Medical Institution, Baltimore, Maryland, United States.
   Division of Gastroenterology and Hepatology, Johns Hopkins Medical Institution, Baltimore, Maryland, United States.
   Division of Gastroenterology and Hepatology, Johns Hopkins Medical Institution, Baltimore, Maryland, United States.
   Division of Gastroenterology and Hepatology, Johns Hopkins Medical Institution, Baltimore, Maryland, United States.
   Division of Gastroenterology and Hepatology, Johns Hopkins Medical Institution, Baltimore, Maryland, United States.
   Division of Gastroenterology and Hepatology, Johns Hopkins Medical Institution, Baltimore, Maryland, United States.
NR 0
TC 0
SN 2196-973
EI 2364-372
J9 Endosc Int Open
PD MAR 3
PY 2020
VL 8
IS 3
BP E266
EP E273
DI 10.1055/a-1075-1900
PG 1
UT PubMed:32118100
PM 32118100
DA 2020-03-03
ER

PT J
AU Huang, XB
   Chen, YQ
   Xie, DY
   Chen, RX
AF Huang, Xian-Bao
   Chen, Yan-Qi
   Xie, Ding-Yi
   Chen, Ri-Xin
TI [Application of professor CHEN Ri-xin's academic thought "yang is often
SO Zhongguo zhen jiu = Chinese acupuncture & moxibustion
LA chi
DT Journal Article
DE CHEN Ri-xin; experience of famous doctor; heat-sensitive moxibustion; tumor; yang is often insufficient; yin is often surplus
AB Professor CHEN Ri-xin has explored the causes of the characteristics of TCM  syndromes in modern disease spectrum and pointed out that the TCM syndromes are  generally characterized by "yang is often insufficient, but yin is often  surplus". Based on the clinical experience and the understanding of TCM classics  and ancient literature on tumor, professor CHEN has proposed that TCM syndromes  of patients with advanced tumor are also generally characterized by "yang is  often insufficient, but yin is often surplus". The heat-sensitive moxibustion has  the functions of warming and nourishing yang-qi, eliminating dampness, warming  meridians and dispersing cold, activating blood circulation and clearing  collaterals, therefore tumor patients with deficiency syndrome (yang-deficiency,  qi-deficiency), cold syndrome, dampness syndrome, phlegm syndrome and  blood-stasis syndrome belonging to the indications of heat-sensitive moxibustion.  The heat-sensitive moxibustion has unique advantages in treating spleen-stomach  dysfunction after chemotherapy and radiotherapy, bone marrow suppression after  chemotherapy and radiotherapy, cancerous deficiency, cancerous pain, pleural  effusion, ascites, constipation, which has important clinical value in improving  the quality of life and prolonging the life time for patients with advanced  tumors.
C1 Affiliated Hospital of Jiangxi University of TCM, Nanchang 330006, China.
   College of Acupuncture-Moxibustion and Tuina, Jiangxi University of TCM.
   Affiliated Hospital of Jiangxi University of TCM, Nanchang 330006, China.
   Affiliated Hospital of Jiangxi University of TCM, Nanchang 330006, China.
NR 0
TC 0
SN 
EI 0255-293
J9 Zhongguo Zhen Jiu
PD JAN 14
PY 2020
VL 40
IS 1
BP 79
EP 83
DI 10.13703/j.0255-2930.20190701-k0003
PG 4
WC Hot Temperature; Humans; Medicine, Chinese Traditional; Moxibustion; Neoplasms; therapy; Quality of Life
UT PubMed:31930904
PM 31930904
DA 2020-01-14
ER

PT J
AU Bloch, AS
   Bloch, PJ
   Dahmen, A
   Xu, R
   Sherman, Z
   Ledbetter, CK
   Wake, RW
   West, J
   Patterson, AL
AF Bloch, Aaron S
   Bloch, Paul J
   Dahmen, Aaron
   Xu, Raymond
   Sherman, Zachary
   Ledbetter, Christopher K
   Wake, Robert W
   West, Jim
   Patterson, Anthony L
TI Acupuncture for Analgesia During Transurethral Resection of Bladder Tumor.
SO Journal of endourology case reports
LA English
DT Journal Article
DE acupuncture; analgesia; bladder cancer; transurethral surgery
AB Background: Acupuncture has been widely studied, and theories regarding its  analgesic mechanism of action have been proposed. It has been used for procedural  analgesia; however, no reports of its use in urologic surgery have been reported.  In this case report, we demonstrate how acupuncture can be used as an alternative  to general anesthesia for transurethral resection of bladder tumor (TURBT). This  may serve as an attractive option for bladder cancer patients with medical  comorbidities, which predispose them to high risk for general anesthesia. Case  Presentation: A 65-year-old Caucasian female with toxicant-induced loss of  tolerance (TILT) was found to have a bladder mass. TURBT was discussed, and in  light of her TILT syndrome, she elected to undergo the procedure with acupuncture  in lieu of general anesthesia for fear of an adverse reaction. Acupuncture was  performed by a trained practitioner with therapeutic needles placed in the ears,  hands, abdomen, and lower extremities bilaterally. She was subsequently taken to  the operating room where we performed a TURBT of a bladder tumor overlying the  left ureteral orifice. The procedure was generally well tolerated and the patient  experienced mild pain. There were no perioperative complications. The tumor was  estimated to be 3 cm in largest diameter, and a total of 8 g of aggregate tissue  was sent to our pathologists. Pathology analysis demonstrated adequate resection  with detrusor muscle present in the sample. The bladder tumor was low-grade  papillary urothelial cell carcinoma (Stage Ta). She has had tumor recurrence and  has undergone repeat TURBT, but to date, she is 22 months free of bladder cancer.  Conclusion: In this case report, we demonstrate that acupuncture is a safe and  effective alternative to general anesthesia for patients undergoing TURBT. Since  tobacco use is prevalent among bladder cancer patients, many of these individuals  have associated medical comorbidities, which predispose them to high risk with  general anesthesia. Therefore, acupuncture may serve as an attractive alternative  for certain patients in this population.
C1 Department of Urology, University of Tennessee Health Science Center, Memphis, Tennessee.
   Department of Urology, University of Tennessee Health Science Center, Memphis, Tennessee.
   Department of Urology, University of Tennessee Health Science Center, Memphis, Tennessee.
   Department of Urology, University of Tennessee Health Science Center, Memphis, Tennessee.
   Department of Urology, University of Tennessee Health Science Center, Memphis, Tennessee.
   Department of Urology, University of Tennessee Health Science Center, Memphis, Tennessee.
   Department of Urology, University of Tennessee Health Science Center, Memphis, Tennessee.
   Member Medical Anesthesia Group, Department of Anesthesiology, University of Tennessee Health Science Center, Memphis, Tennessee.
   Department of Urology, University of Tennessee Health Science Center, Memphis, Tennessee.
NR 0
TC 0
SN 2379-988
EI 2379-988
J9 J Endourol Case Rep
PD AUG 11
PY 2020
VL 5
IS 4
BP 184
EP 186
DI 10.1089/cren.2019.0026
PG 2
UT PubMed:32775660
PM 32775660
DA 2020-08-11
ER

PT J
AU Guo, X
   Zhao, YY
   Huang, F
   Li, SY
   Luo, M
   Wang, Y
   Zhang, JL
   Li, L
   Zhang, Y
   Jiao, Y
   Zhao, B
   Wang, JY
   Meng, H
   Zhang, ZJ
   Rong, PJ
AF Guo, Xiao
   Zhao, Yuanyuan
   Huang, Feng
   Li, Shaoyuan
   Luo, Man
   Wang, Yu
   Zhang, Jinling
   Li, Liang
   Zhang, Yue
   Jiao, Yue
   Zhao, Bin
   Wang, Junying
   Meng, Hong
   Zhang, Zhangjin
   Rong, Peijing
TI Effects of Transcutaneous Auricular Vagus Nerve Stimulation on Peripheral and Central Tumor Necrosis Factor Alpha in Rats with Depression-Chronic Somatic Pain Comorbidity
SO NEURAL PLASTICITY
LA English
DT Article
ID cholinergic antiinflammatory pathway; neuropathic pain; substance-p; neuropeptide; involvement; dysfunction; mechanisms; behavior
AB Depression and pain disorders share a high degree of comorbidity. Inflammatory mechanisms play an important role in the pathogenesis of depression-chronic somatic pain comorbidity. In this study, we investigated the effects of acupuncture on blood and brain regional tumor necrosis factor alpha (TNF-alpha) in rats with depression and chronic somatic pain comorbidity. Forty Sprague-Dawley rats were randomly divided into the following 4 groups with 10 each: control, model, model treated with transcutaneous auricular vagus nerve stimulation (taVNS), and model treated with electroacupuncture (EA). Chronic unpredictable mild stress (CUMS) with chronic constriction injury of the sciatic nerve (CCI) was used to produce depression and chronic somatic pain comorbidity in the latter 3 groups. The rats of the taVNS and EA groups received, respectively, taVNS and EA at ST 36 for 28 days. Pain intensity was measured using a mechanical withdrawal threshold and thermal stimulation latency once biweekly. Depressive behavior was examined using a sucrose preference test at baseline and the end of modeling and intervention. The level of plasma TNF-alpha and the expression of TNF-alpha in the prefrontal cortex (PFC), hippocampus, amygdala, and hypothalamus were measured. While CUMS plus CCI produced remarkable depression-like behavior and pain disorders, EA and taVNS significantly improved depression and reduced pain intensity. CUMS plus CCI also resulted in a significant increase in plasma TNF-alpha level and the expression in all brain regions examined compared to the intact controls. Both EA and taVNS interventions, however, suppressed the elevated level of TNF-alpha. These results suggest that EA and taVNS have antidepressant and analgesic effects. Such effects may be associated with the suppression of TNF-alpha-related neuroinflammation.
C1 [Guo, Xiao; Huang, Feng; Li, Shaoyuan; Luo, Man; Wang, Yu; Zhang, Jinling; Li, Liang; Zhang, Yue; Jiao, Yue; Zhao, Bin; Wang, Junying; Rong, Peijing] China Acad Chinese Med Sci, Inst Acupuncture & Moxibust, Beijing 100700, Peoples R China.
   [Guo, Xiao] China Acad Chinese Med Sci, Dept Sci Res Management, Beijing 100700, Peoples R China.
   [Zhao, Yuanyuan] Hebei Med Univ, Dept Psychiat, Hosp 1, Shijiazhuang 050031, Hebei, Peoples R China.
   [Huang, Feng] Capital Med Univ, Beijing Hosp Tradit Chinese Med, Beijing 100010, Peoples R China.
   [Meng, Hong] Beijing Technol & Business Univ, Key Lab Cosmet, China Natl Light Ind, Beijing 100048, Peoples R China.
   [Zhang, Zhangjin] Univ Hong Kong, LKS Fac Med, Sch Chinese Med, Hong Kong, Peoples R China.
C3 Institute of Acupuncture & Moxibustion, CACMS; China Academy of Chinese Medical Sciences; China Academy of Chinese Medical Sciences; Hebei Medical University; Capital Medical University; Beijing Technology & Business University; University of Hong Kong
RP Rong, PJ (corresponding author), China Acad Chinese Med Sci, Inst Acupuncture & Moxibust, Beijing 100700, Peoples R China.; Zhang, ZJ (corresponding author), Univ Hong Kong, LKS Fac Med, Sch Chinese Med, Hong Kong, Peoples R China.
EM zhangzj@hku.hk; drrongpj@163.com
FU National Basic Research Program of China [2018YFC1705800]; International Cooperation Project of Traditional Chinese Medicine in China Academy of Chinese Medical Sciences [GH2017-07]; Guangdong Province Higher Vocational Colleges and Schools Pearl River Scholar Funded Scheme (2018) [A1-AFD018181Z3905]; Beijing Key Laboratory of Plant Resources Research and Development; Beijing Technology and Business University Innovation [PRRD-2016-ZD2]; Fundamental Research Funds for Beijing Municipal Science & Technology Commission [Z161100002616003]; Joint Sino-German Research Project [GZ1236]
CR Unknown -, 2013, THESIS, V0, P0
   Bortolato B, 2015, CURR NEUROPHARMACOL, V13, P558, DOI 10.2174/1570159X13666150630171433
   Bravo L, 2012, ANESTHESIOLOGY, V117, P613, DOI 10.1097/ALN.0b013e3182657b3e
   Burke NN, 2015, MOD TR PHARMACOPSYCH, V30, P36, DOI 10.1159/000435931
   Burke NN, 2015, BEHAV BRAIN RES, V278, P193, DOI 10.1016/j.bbr.2014.09.044
   Cao BY, 2016, J TRADIT CHIN MED, V36, P768
   Chang CT, 2019, INT J MOL SCI, V20, P0, DOI 10.3390/ijms20071596
   Doan L, 2015, NEURAL PLAST, V2015, P0, DOI 10.1155/2015/504691
   Du JY, 2017, NEURAL PLAST, V2017, P0, DOI 10.1155/2017/3728752
   Felger JC, 2013, NEUROSCIENCE, V246, P199, DOI 10.1016/j.neuroscience.2013.04.060
   Fishbain DA, 2014, PAIN MED, V15, P1522, DOI 10.1111/pme.12448
   Gao Yong-Hui, 2018, ZHEN CI YAN JIU, V43, P537, DOI 10.13702/j.1000-0607.170450
   Geng Y, 2017, EVID-BASED COMPL ALT, V2017, P0
   Hsu HC, 2014, SCI WORLD J, V0, P0, DOI DOI 10.1155/2014/129875
   Johnson MB, 2017, FRONT CELL NEUROSCI, V10, P0, DOI 10.3389/fncel.2016.00296
   Kong J, 2018, FRONT PSYCHIATRY, V9, P0, DOI 10.3389/fpsyt.2018.00020
   Kox M, 2012, PLOS ONE, V7, P0, DOI 10.1371/journal.pone.0034431
   Liang Hai-xia, 2008, CHINESE PHARMACOLOGICAL BULLETIN, V24, P555
   Lin CH, 2014, J AFFECT DISORDERS, V166, P173, DOI 10.1016/j.jad.2014.03.039
   Liu D, 2018, ARTHRITIS RES THER, V20, P0, DOI 10.1186/s13075-018-1759-9
   Lu XX, 2017, MED SCI MONITOR, V23, P6072, DOI 10.12659/MSM.907628
   Mashaghi A, 2016, CELL MOL LIFE SCI, V73, P4249, DOI 10.1007/s00018-016-2293-z
   Rijavec N, 2012, PSYCHIAT DANUB, V24, P346
   [荣培晶 Rong Peijing], 2019, 中医杂志 JOURNAL OF TRADITIONAL CHINESE MEDICINE, V60, P295
   Sheng JY, 2017, NEURAL PLAST, V2017, P0, DOI 10.1155/2017/9724371
   Shiozawa P, 2014, ARQ NEURO-PSIQUIAT, V72, P542
   Song Q, 2014, AFR J TRADIT COMPLEM, V11, P469, DOI 10.4314/ajtcam.v11i2.35
   Sun H, 2003, J CLIN ACUPUNCTURE M, V19, P47
   Sun Hua, 2010, ZHONGGUO ZHEN JIU, V30, P195
   Suvas S, 2017, J IMMUNOL, V199, P1543, DOI 10.4049/jimmunol.1601751
   Tu YH, 2018, BRAIN STIMUL, V11, P501, DOI 10.1016/j.brs.2018.01.006
   Walker AK, 2014, PHARMACOL REV, V66, P80, DOI 10.1124/pr.113.008144
   Wang H, 2015, EVID-BASED COMPL ALT, V2015, P0, DOI 10.1155/2015/787393
   Wang ZJ, 2018, J PSYCHIATR RES, V102, P123, DOI 10.1016/j.jpsychires.2017.12.018
   Wu YY, 2015, EVID-BASED COMPL ALT, V2015, P0, DOI 10.1155/2015/732845
   Yang M, 2013, J NANCHANG U, V53, P80
   Yang XH, 2017, NEUROPSYCH DIS TREAT, V13, P2727, DOI 10.2147/NDT.S150028
   [俞裕天 Yu Yutian], 2017, 世界科学技术：中医药现代化 MODERNIZATION OF TRADITIONAL CHINESE MEDICINE AND MATERIA MEDICA--WORLD SCIENCE AND TECHNOLOGY, V19, P462
   Zhao GM, 2015, YIXUE ZONGSHU, V21, P2890
   Zhao YX, 2012, EVID-BASED COMPL ALT, V2012, P0, DOI 10.1155/2012/627023
   Zhou DP, 2018, VIRULENCE, V9, P1364, DOI 10.1080/21505594.2018.1482179
NR 41
TC 38
Z9 43
U1 2
U2 29
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 2090-5904
EI 1687-5443
J9 NEURAL PLAST
JI Neural. Plast.
PD OCT 22
PY 2020
VL 2020
IS 
BP 
EP 
DI 10.1155/2020/8885729
PG 10
WC Neurosciences
SC Neurosciences & Neurology
GA OU6JL
UT WOS:000591632700001
PM 33144854
DA 2026-01-16
ER

PT J
AU Ali, U
   Apryani, E
   Ahsan, MZ
   Shoaib, RM
   Ahmad, KA
   Wang, YX
AF Ali, Usman
   Apryani, Evhy
   Ahsan, Muhammad Zaeem
   Shoaib, Rana Muhammad
   Ahmad, Khalil Ali
   Wang Yong-xiang
TI Acupuncture/Electroacupuncture as an Alternative in Current Opioid Crisis
SO CHINESE JOURNAL OF INTEGRATIVE MEDICINE
LA English
DT Article
DE analgesia; Chinese medicine; electroacupuncture; acupuncture; opioid crisis
ID neuropathic pain; postoperative pain; spinal microglia; m2 macrophages; cancer pain; rat model; electroacupuncture; acupuncture; receptor; epidemic
AB Opioid drugs are the first line of defense in severe pain but the adverse effects associated with opioids are considered as a serious issue worldwide. Acupuncture/electroacupuncture is a type of Chinese medicine therapy which is an effective analgesic therapy, well documented in animals and human studies. Electroacupuncture stimulation could release endogenous opioid peptides causing analgesia in a variety of pain models. It can be used as an alternative therapy to control the opioid crisis.
C1 [Ali, Usman; Apryani, Evhy; Ahsan, Muhammad Zaeem; Shoaib, Rana Muhammad; Ahmad, Khalil Ali; Wang Yong-xiang] Shanghai Jiao Tong Univ, Sch Pharm, Kings Lab, Shanghai 200240, Peoples R China.
C3 Shanghai Jiao Tong University
RP Wang, YX (corresponding author), Shanghai Jiao Tong Univ, Sch Pharm, Kings Lab, Shanghai 200240, Peoples R China.
EM yxwang@sjtu.edu.cn
CR An LX, 2014, AM J CHINESE MED, V42, P1099, DOI 10.1142/S0192415X14500682
   Badal S, 2018, PHARMACOL THERAPEUT, V184, P51, DOI 10.1016/j.pharmthera.2017.10.021
   Barlas P, 2006, PAIN, V122, P81, DOI 10.1016/j.pain.2006.01.012
   Baumann MH, 2018, NEUROPHARMACOLOGY, V134, P101, DOI 10.1016/j.neuropharm.2017.08.016
   Beggs S, 2012, NAT NEUROSCI, V15, P1068, DOI 10.1038/nn.3155
   Chan YY, 2014, AM J CHINESE MED, V42, P569, DOI 10.1142/S0192415X14500372
   Chen XM, 2015, BRIT J ANAESTH, V114, P150, DOI 10.1093/bja/aeu199
   Chiu HY, 2017, EUR J CANCER CARE, V26, P0, DOI 10.1111/ecc.12457
   Comachio J, 2015, TRIALS, V16, P0, DOI 10.1186/s13063-015-0850-7
   da Silva MD, 2015, MOL NEUROBIOL, V51, P19, DOI 10.1007/s12035-014-8790-x
   Dai Y, 2001, J PAIN, V2, P151, DOI 10.1054/jpai.2001.19964
   Fan AY, 2017, J INTEGR MED-JIM, V15, P411, DOI 10.1016/S2095-4964(17)60378-9
   Fan H, 2016, NEUROPHARMACOLOGY, V101, P98, DOI 10.1016/j.neuropharm.2015.09.010
   Froehlich JC, 1997, ALCOHOL HEALTH RES W, V21, P132
   Fu Taofang, 2017, ZHONGGUO ZHEN JIU, V37, P513, DOI 10.13703/j.0255-2930.2017.05.017
   Fukazawa Y, 2005, J PHARMACOL SCI, V99, P408, DOI 10.1254/jphs.FP0050502
   Gao R, 2018, SCI REP-UK, V8, P0, DOI 10.1038/s41598-018-24835-9
   Golianu B, 2014, MED ACUPUNCT, V26, P279, DOI 10.1089/acu.2014.1048
   Gong CZ, 2018, CHIN J INTEGR MED, V24, P323, DOI 10.1007/s11655-018-2989-z
   Gong NA, 2012, NEUROPHARMACOLOGY, V63, P460, DOI 10.1016/j.neuropharm.2012.04.030
   GRICHNIK KP, 1991, MT SINAI J MED, V58, P217
   Hill R, 2016, NEUROPSYCHOPHARMACOL, V41, P762, DOI 10.1038/npp.2015.201
   Hopton A, 2010, PAIN PRACT, V10, P94, DOI 10.1111/j.1533-2500.2009.00337.x
   Kaye AD, 2018, BEST PRAC RES-CL ANA, V32, P125, DOI 10.1016/j.bpa.2018.06.009
   Kivimäki M, 2014, MOL PSYCHIATR, V19, P149, DOI 10.1038/mp.2013.35
   Kong JT, 2018, J ALTERN COMPLEM MED, V24, P304, DOI 10.1089/acm.2018.0083
   Lee JH, 2013, CLIN J PAIN, V29, P172, DOI 10.1097/AJP.0b013e31824909f9
   Leng L, 2018, MEDICINE, V97, P0, DOI 10.1097/MD.0000000000011905
   Li S, 2013, CHIN J NAT MEDICINES, V11, P110, DOI 10.1016/S1875-5364(13)60037-0
   Li SS, 2017, INT J CLIN EXP MED, V10, P10565
   Liang QD, 2019, GEN PSYCHIAT, V32, P0, DOI 10.1136/gpsych-2018-100019
   Liang Y, 2016, ACUPUNCT MED, V34, P40, DOI 10.1136/acupmed-2015-010773
   Liao HY, 2017, SCI REP-UK, V7, P0, DOI 10.1038/s41598-017-16031-y
   Liu TT, 2009, CELL MOL NEUROBIOL, V29, P449, DOI 10.1007/s10571-008-9336-4
   Lucyk SN, 2017, ANN EMERG MED, V69, P91, DOI 10.1016/j.annemergmed.2016.08.445
   Macdonald A, 1993, ACUPUNCTURE IN MEDICINE, V11, P66, DOI 10.1136/AIM.11.2.66
   Madariaga-Mazón A, 2017, DRUG DISCOV TODAY, V22, P1719, DOI 10.1016/j.drudis.2017.07.002
   Mercadante S, 2018, CRIT REV ONCOL HEMAT, V122, P60, DOI 10.1016/j.critrevonc.2017.12.016
   Molsberger AF, 2010, PAIN, V151, P146, DOI 10.1016/j.pain.2010.06.036
   Moore RA, 2015, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD010794.pub2
   Morgan MM, 2011, BRIT J PHARMACOL, V164, P1322, DOI 10.1111/j.1476-5381.2011.01335.x
   Negus SS, 2018, TRENDS PHARMACOL SCI, V39, P327, DOI 10.1016/j.tips.2018.02.002
   Ouyang Ba-Si, 2010, ZHONGGUO ZHEN JIU, V30, P840
   Peirs C, 2016, SCIENCE, V354, P578, DOI 10.1126/science.aaf8933
   Saybolt MD, 2010, RESUSCITATION, V81, P42, DOI 10.1016/j.resuscitation.2009.09.016
   Sima L, 2016, EVID-BASED COMPL ALT, V2016, P0, DOI 10.1155/2016/8028474
   Sun Y, 2008, BRIT J ANAESTH, V101, P151, DOI 10.1093/bja/aen146
   Tejada MA, 2018, PHARMACOL RES, V131, P224, DOI 10.1016/j.phrs.2018.02.008
   Toroski M, 2018, J ACUPUNCT MERIDIAN, V11, P62, DOI 10.1016/j.jams.2018.01.003
   Vickers AJ, 2018, J PAIN, V19, P455, DOI 10.1016/j.jpain.2017.11.005
   Volkow ND, 2017, NEW ENGL J MED, V377, P391, DOI 10.1056/NEJMsr1706626
   Wang XQ, 2017, NEUROSCI LETT, V661, P84, DOI 10.1016/j.neulet.2017.09.057
   Wang Y, 2018, GEN PSYCHIAT, V31, P0, DOI 10.1136/gpsych-2018-000015
   Wang Y, 2018, BRAIN RES BULL, V137, P257, DOI 10.1016/j.brainresbull.2018.01.002
   West NA, 2015, DRUG ALCOHOL DEPEN, V149, P117, DOI 10.1016/j.drugalcdep.2015.01.027
   Wu JJ, 2018, BRAIN RES, V1690, P61, DOI 10.1016/j.brainres.2018.04.009
   Wu Xueqing, 2018, SHANGHAI ARCH PSYCHIATRY, V30, P188, DOI 10.11919/j.issn.1002-0829.218007
   Xue CCL, 2012, TRIALS, V13, P0, DOI 10.1186/1745-6215-13-169
   Yang BB, 2019, GEN PSYCHIAT, V32, P0, DOI 10.1136/gpsych-2019-100056
   Zhang R, 2018, BRAIN RES, V1678, P12, DOI 10.1016/j.brainres.2017.10.006
   Zhang ZD, 2012, ANESTH ANALG, V114, P879, DOI 10.1213/ANE.0b013e318246536d
   Zhao JG, 2017, ACUPUNCT MED, V35, P224, DOI 10.1136/acupmed-2016-011107
   Zhou YF, 2018, PURINERG SIGNAL, V14, P359, DOI 10.1007/s11302-018-9617-4
   Zhu Y, 2019, ANN PHYS REHABIL MED, V62, P297, DOI 10.1016/j.rehab.2018.09.010
NR 65
TC 24
Z9 28
U1 2
U2 46
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 1672-0415
EI 1993-0402
J9 CHIN J INTEGR MED
JI Chin. J. Integr. Med.
PD SEP 15
PY 2020
VL 26
IS 9
BP 643
EP 647
DI 10.1007/s11655-019-3175-7
EA OCT 2019
PG 5
WC Integrative & Complementary Medicine
SC Integrative & Complementary Medicine
GA NF2SH
UT WOS:000491940100002
PM 31630362
DA 2026-01-16
ER

PT J
AU Omura, Y
AF Omura, Yoshiaki
TI High Frequency Vibration of Worst Ear Lobule induced short period of Rapid Inhibition of any Cancer Activity including Advanced Terminal Cancers, Most Malignant Brain Tumor "Glioblastoma" as well as Cancer of Lung, Breast & Gastrointestinal Cancers particularly Pancreatic Cancer
SO ACUPUNCTURE & ELECTRO-THERAPEUTICS RESEARCH
LA English
DT Article
DE Bi-Digital O-Ring Test (BDORT); Ear lobules; Abnormally reduced Acetylcholine of brain; Optimal dose or overdose of medicine; drinks or food; Beneficial effect of optimal dose of Vitamin D-3 tablets &amp; Methylcobalamin; New Immune System on middle fingers; DNA mutations and cancer
ID adenoassociated virus; telomere length; vectors; glucose; promote; ring
AB While a visiting Professor at the University of Paris, VI (formerly Sorvonne) more than 40 years ago, the Author became very good friends with Dr. Paul Nogier who periodically gave seminars and workshops in Paris. After the author diagnosed his cervical problem & offered him simple help, Dr. Nogier asked the Author to present lectures and demonstrations on the effects of ear stimulation, namely the effects of acupuncture & electrical stimulation of the ear lobules. It is only now, in 2019 that we have discovered 2 - 5 minute high frequency stimulation of the car lobule inhibits cancer activity for 1- 4 hours post stimulation. Although the procedure is extremely simple. First take optimal dose of Vitamin D-3, which has the most essential 10 unique beneficial factors required for every human cell activity. Next, apply high frequency stimulation to car lobule while the worst ear lobule is held by all fingers with vibrator directly touching the surface of the worst ear lobule, preferably after patient repeatedly takes optimal dose of Vitamin D-3. When the worst ear lobule is held between thumb & index fingers and applying mechanical stimulation of 250 similar to 500 mechanical vibration/second for 2 similar to 5 minutes using an electrical vibrator, there is rapid disappearance of cancer activity in both the brain and rest of the body for short time duration 1 similar to 4 hours. The effect often increases by additional pressure by holding fingers. As of May 2019, the Author found that many people from various regions of the world developed early stages of multiple cancers. For evaluation of this study, U.S. patented Bi-Digital O-Ring Test (BDORT) was used which was developed by the Author while doing his Graduate experimental physics research at Colombia University. BDORT was found to be most essential for determining the beneficial effects as well as harmful effects of any substance or treatment. Using BDORT, Author was the first to recognize severe increasing mid-backache was an early sign of pancreatic cancer of President of New York State Board of Medicine after top pain specialists failed to detect the cause after 3 years of effort, while the BDORT showed early stages of cancer whereas conventional X-Ray of the pancreas did not show any cancer image until 2 months after Author detected with BDORT. For example, the optimal dose of the banana is usually about 2.0 - 2.5 millimeters cross section of the banana. A whole banana is more than 50 similar to 100 times the optimal dose. Any substance eaten in more than 25 times of its optimal dose becomes highly toxic and creates DNA mutations which can cause multiple malignancies in the presence of strong electro-magnetic field. With standard medication given by doctor, patients often become sick and they are unable to reduce body weight, unless medication is reduced or completely stopped. When the amount of zinc is very high, DNA often becomes unstable and multiple cancers can grow rapidly in the presence of strong electromagnetic field. Large amount of Vitamin C from regular orange or orange juice inhibit the most important Vitamin D3 effects. At least 3 kinds of low Vitamin C oranges will not inhibit Vitamin D3. Since B12 particularly methyl cobalamin which is a red small tablet is known to improve brain circulation very significantly we examined its effect within 20 seconds of oral intake we found the following very significant changes. Acetylcholine in both sides of the brain often increases over 4,500 ng. Longevity gene Sirtuin 1 level increases significantly for short time of few hours. Thymosin alpha 1 and Thymosin beta 4 both increase to over 1500 ng from 20 ng or less.
C1 [Omura, Yoshiaki] New York Med Coll, Family & Community Med, New York, NY USA.
   [Omura, Yoshiaki] Int Assoc Bidigital O Ring Test Med Soc, Yokohama, Kanagawa, Japan.
   [Omura, Yoshiaki] Int Coll Acupuncture & Electrotherapeut, New York, NY USA.
   [Omura, Yoshiaki] Heart Dis Res Fdn, Med Res, Brooklyn, NY USA.
C3 New York Medical College
RP Omura, Y (corresponding author), 800 Riverside Dr Suite 8-1, New York, NY 10032 USA.
EM icaet@yahoo.com
CR de Jesus BB, 2012, EMBO MOL MED, V4, P691, DOI 10.1002/emmm.201200245
   Büning H, 2008, J GENE MED, V10, P717, DOI 10.1002/jgm.1205
   Collado M, 2007, CELL, V130, P223, DOI 10.1016/j.cell.2007.07.003
   Flores I, 2005, SCIENCE, V309, P1253, DOI 10.1126/science.1115025
   Francis PT, 2005, CNS SPECTRUMS, V10, P6, DOI 10.1017/S1092852900014164
   Gao GP, 2002, P NATL ACAD SCI USA, V99, P11854, DOI 10.1073/pnas.182412299
   González-Suárez E, 2002, MOL CELL BIOL, V22, P7291, DOI 10.1128/MCB.22.20.7291-7301.2002
   Grossberg S, 2017, FRONT NEURAL CIRCUIT, V11, P0, DOI 10.3389/fncir.2017.00082
   Guarente L, 2006, NATURE, V444, P868, DOI 10.1038/nature05486
   Harley CB, 2011, REJUV RES, V14, P45, DOI 10.1089/rej.2010.1085
   Hemann MT, 2001, CELL, V107, P67, DOI 10.1016/S0092-8674(01)00504-9
   Hikosaka O, 2002, CURR OPIN NEUROBIOL, V12, P217, DOI 10.1016/S0959-4388(02)00307-0
   Jaskelioff M, 2011, NATURE, V469, P102, DOI 10.1038/nature09603
   Kuhlow D, 2010, AGING-US, V2, P650, DOI 10.18632/aging.100200
   Mas A, 2006, DIABETES, V55, P1546, DOI 10.2337/db05-1615
   Matsushita T, 1998, GENE THER, V5, P938, DOI 10.1038/sj.gt.3300680
   MATTHEWS DR, 1985, DIABETOLOGIA, V28, P412, DOI 10.1007/BF00280883
   OMURA Y, 1990, ACUPUNCTURE ELECTRO, V15, P217, DOI 10.3727/036012990816358135
   Omura Y, 1993, US PATENT, V0, Patent No. [5,188,107, 5188107]
   Omura Y, 2019, 9 INT C CARD DIS THE, V0, P0
   Omura Y, 2015, ACUPUNCTURE ELECTRO, V40, P297, DOI 10.3727/036012916X14533115160606
   Omura Y, 2010, ACUPUNCTURE ELECTRO, V35, P45, DOI 10.3727/036012910803860977
   Ornish D, 2008, LANCET ONCOL, V9, P1048, DOI 10.1016/S1470-2045(08)70234-1
   Sahin E, 2011, NATURE, V470, P359, DOI 10.1038/nature09787
   Schoeftner S, 2009, P NATL ACAD SCI USA, V106, P19387, DOI 10.1073/pnas.0909265106
   Tafuro S, 2009, CARDIOVASC RES, V83, P663, DOI 10.1093/cvr/cvp152
NR 26
TC 1
Z9 1
U1 0
U2 10
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 0360-1293
EI 2167-9010
J9 ACUPUNCTURE ELECTRO
JI Acupunct. Electro-Ther. Res.
PD JUN 15
PY 2020
VL 44
IS 3-4
BP 241
EP 249
DI 10.3727/036012920X15779969212982
PG 9
WC Integrative & Complementary Medicine; Neurosciences
SC Integrative & Complementary Medicine; Neurosciences & Neurology
GA KM0ZL
UT WOS:000513846500006
DA 2026-01-16
ER

PT J
AU Zhang, C
   Xia, C
   Zhang, X
   Li, W
   Miao, X
   Zhou, Q
AF Zhang, Chunpeng
   Xia, Chen
   Zhang, Xiaowen
   Li, Weimin
   Miao, Xuerong
   Zhou, Qinghui
TI Wrist-ankle acupuncture attenuates cancer-induced bone pain by regulating
SO Chinese medicine
LA English
DT Journal Article
DE Cancer pain; Descending modulation; Electroacupuncture; Wrist–ankle acupuncture
AB BACKGROUND: Cancer-induced bone pain (CIBP) presents a multiple-mechanism of  chronic pain involving both inflammatory and neuropathic pain, and its  pathogenesis is closely related to endogenous descending system of pain control.  However, the action mechanism underlying the effects of wrist-ankle acupuncture  (WAA) versus electroacupuncture (EA) on CIBP remains unknown. METHODS: Thirty-two  Wistar rats were divided into sham, CIBP, EA-treated and WAA-treated groups. CIBP  was induced in rats of the latter three groups. Time courses of weight and  mechanical hyperalgesia threshold (MHT) were evaluated. After 6 days of EA or WAA  treatment, the expressions of 5-hydroxytryotamine type 3A receptor (5-HT(3A)R)  and μ-opioid receptor (MOR) in rostral ventromedial medulla (RVM) and/or spinal  cord, as well as the levels of 5-HT, β-endorphin, endomorphin-1 and endomorphin-2  in RVM and spinal cord, were detected. RESULTS: Injection of cancer cells caused  decreased MHT, which was attenuated by EA or WAA (P < 0.05). WAA had a quicker  analgesic effect than EA (P < 0.05). No significant difference of MOR in RVM was  found among the four groups. EA or WAA counteracted the cancer-driven  upregulation of 5-HT(3A)R and downregulation of MOR in spinal cord (P < 0.05),  and upregulation of 5-HT and downregulation of endomorphin-1 in both RVM and  spinal cord (P < 0.05). β-endorphin and endomorphin-2 in RVM and spinal cord  decreased in CIBP group compared with sham group (P < 0.05), but EA or WAA showed  no significant effect on them, although a tendency of increasing effect was  observed. CONCLUSION: WAA, similar to EA, alleviated mechanical hyperalgesia in  CIBP rats by suppressing the expressions of 5-HT and 5-HT(3A)R, and increasing  the expressions of MOR and endomorphin-1 in RVM-spinal cord pathway of the  descending pain-modulating system. However, WAA produced a quicker analgesic  effect than EA, the mechanisms of which need further investigation.
C1 School of Traditional Chinese Medicine, Changhai Hospital, Naval Medical University, 168 Changhai Road, Shanghai, 200433 People's Republic of China.
   School of Traditional Chinese Medicine, Changhai Hospital, Naval Medical University, 168 Changhai Road, Shanghai, 200433 People's Republic of China.
   School of Traditional Chinese Medicine, Changhai Hospital, Naval Medical University, 168 Changhai Road, Shanghai, 200433 People's Republic of China.
   2Laboratory of Neuronal Network and Systems Biology, Shanghai Medical College, Fudan University, Shanghai, 200032 China. ISNI: 0000 0001 0125 2443. GRID:grid.8547.e
   Department of Anesthesiology, Eastern Hepatobiliary Surgery Hospital, Naval Medical University, 225 Changhai Road, Shanghai, 200433 People's Republic ofChina.
   School of Traditional Chinese Medicine, Changhai Hospital, Naval Medical University, 168 Changhai Road, Shanghai, 200433 People's Republic of China.
NR 0
TC 0
SN 1749-854
EI 1749-854
J9 Chin Med
PD FEB 12
PY 2020
VL 15
IS 
BP 13
EP 13
DI 10.1186/s13020-020-0289-y
PG 0
UT PubMed:32042305
PM 32042305
DA 2020-02-12
ER

PT J
AU Lohse, I
   Brothers, SP
AF Lohse, Ines
   Brothers, Shaun P.
TI Pathogenesis and Treatment of Pancreatic Cancer Related Pain
SO ANTICANCER RESEARCH
LA English
DT Review
DE Pancreatic cancer; pain; cancer treatment-induced pain; pancreatic cancer treatment; pancreatic cancer pain
ID celiac plexus block; perineural invasion; neural invasion; risk; chemotherapy; survival; neurotoxicity; hyperalgesia; innervation; acupuncture
AB Pancreatic cancer is often diagnosed due to the patient seeking medical attention for abdominal pain. It is among the most painful cancers, with pain severity strongly correlating with prognosis. Perineural invasion is a prominent feature of pancreatic cancer and often the first route of metastasis resulting in neuropathic pain. While surgical pain is present, it is generally short-lived; chemo- and radio-therapy associated side effect pain is often longer lasting and more difficult to manage. Treatment-induced mucositis in response to chemotherapy occurs throughout the GI tract resulting in infection-prone ulcers on the lip, buccal mucosa, palate or tongue. Cisplatin treatment is associated with axonal neuropathy in the dorsal root ganglion, although other large sensory fibers can be affected. Opioid-induced hyperalgesia can also emerge in patients. Along with traditional means to address pain, neurolytic celiac plexus block of afferent nociceptive fibers has been reported to be effective in 74% of patients. Moreover, as cancer treatments become more effective and result in improved survival, treatment-related side effects become more prevalent. Here, pancreatic cancer and treatment associated pain are reviewed along with current treatment strategies. Potential future therapeutic strategies to target the pathophysiology underlying pancreatic cancer and pain induction are also presented.
C1 [Lohse, Ines; Brothers, Shaun P.] Univ Miami, Miller Sch Med, Ctr Therapeut Innovat, Miami, FL 33136 USA.
   [Lohse, Ines; Brothers, Shaun P.] Univ Miami, Sylvester Comprehens Canc Ctr, Dept Psychiat & Behav Sci, Miami, FL USA.
   [Lohse, Ines; Brothers, Shaun P.] Univ Miami, Sylvester Comprehens Canc Ctr, Mol Therapeut Shared Resource, Miami, FL USA.
C3 University of Miami; University of Miami; University of Miami
RP Brothers, SP (corresponding author), Univ Miami, Miller Sch Med, Ctr Therapeut Innovat, Dept Psychiat & Behav Sci, 1501 NW 10th Ave,BRB 415, Miami, FL 33136 USA.
EM sbrothers@med.miami.edu
FU National Institutes of Health [R01NS092671, R01MH110441]; University of Miami Sylvester Comprehensive Cancer Center Molecular Therapeutics Shared Resource (MTSR); Jay Weiss Institute for Health Equity; Ryan Foundation; National Cancer Institute [P30CA240139] Funding Source: NIH RePORTER
CR Abrams DI, 2016, CURR ONCOL, V23, PS8, DOI 10.3747/co.23.3099
   Allen PJ, 2011, ANN SURG ONCOL, V18, P636, DOI 10.1245/s10434-010-1372-x
   Alsamarrai A, 2014, CLIN GASTROENTEROL H, V12, P1635, DOI 10.1016/j.cgh.2014.01.038
   Alvarado S, 2015, FRONT CELL NEUROSCI, V9, P0, DOI 10.3389/fncel.2015.00088
   Aprile G, 2015, WORLD J GASTROENTERO, V21, P11793, DOI 10.3748/wjg.v21.i41.11793
   Avritscher Elenir B C, 2004, SEMIN ONCOL NURS, V20, P3
   Bapat AA, 2011, NAT REV CANCER, V11, P695, DOI 10.1038/nrc3131
   Benyamin R, 2008, PAIN PHYSICIAN, V11, P0
   Bertholet J, 2019, CLIN TRANSL RAD ONCO, V16, P21, DOI 10.1016/j.ctro.2019.03.001
   Boldrini L, 2019, RADIAT ONCOL, V14, P0, DOI 10.1186/s13014-019-1275-3
   Bryant KL, 2020, NAT MED, V26, P982, DOI 10.1038/s41591-020-0947-8
   Carter GT, 2014, PHYS MED REH CLIN N, V25, P457, DOI 10.1016/j.pmr.2014.01.007
   Ceyhan GO, 2008, BIOCHEM BIOPH RES CO, V374, P442, DOI 10.1016/j.bbrc.2008.07.035
   Ceyhan GO, 2009, GASTROENTEROLOGY, V136, P177, DOI 10.1053/j.gastro.2008.09.029
   Chee NT, 2019, MOL CANCER, V18, P0, DOI 10.1186/s12943-019-0968-4
   Chen H, 2013, PANCREATOLOGY, V13, P594, DOI 10.1016/j.pan.2013.10.007
   Choi TY, 2012, SUPPORT CARE CANCER, V20, P1147, DOI 10.1007/s00520-012-1432-9
   Collins MA, 2012, J CLIN INVEST, V122, P639, DOI 10.1172/JCI59227
   Colvin LA, 2019, PAIN, V160, PS1, DOI 10.1097/j.pain.0000000000001540
   Cornman-Homonoff J, 2017, SEMIN INTERVENT RAD, V34, P376, DOI 10.1055/s-0037-1608861
   DHaese JG, 2014, WORLD J GASTROENTERO, V20, P9154, DOI 10.3748/wjg.v20.i27.9154
   Denk F, 2016, CELL REP, V15, P1771, DOI 10.1016/j.celrep.2016.04.063
   Denk F, 2014, NAT NEUROSCI, V17, P192, DOI 10.1038/nn.3628
   di Mola FF, 2008, LANGENBECK ARCH SURG, V393, P919, DOI 10.1007/s00423-007-0277-z
   Dobosz L, 2016, ANZ J SURG, V86, P756, DOI 10.1111/ans.13609
   Doehring A, 2011, EUR J PAIN, V15, P11, DOI 10.1016/j.ejpain.2010.06.004
   Donertas Basak, 2018, J EXP PHARMACOL, V10, P19, DOI 10.2147/jep.s162059
   Eibl G, 2005, PANCREAS, V31, P258, DOI 10.1097/01.mpa.0000175176.40045.0f
   Ernsting MJ, 2015, J CONTROL RELEASE, V206, P122, DOI 10.1016/j.jconrel.2015.03.023
   Fernandes R, 2016, SUPPORT CARE CANCER, V24, P1583, DOI 10.1007/s00520-015-2941-0
   Flak RV, 2019, SCAND J GASTROENTERO, V54, P252, DOI 10.1080/00365521.2019.1575465
   Furness JB, 2014, ADV EXP MED BIOL, V817, P39, DOI 10.1007/978-1-4939-0897-4_3
   Gamelin L, 2004, CLIN CANCER RES, V10, P4055, DOI 10.1158/1078-0432.CCR-03-0666
   Gil Z, 2010, J NATL CANCER I, V102, P107, DOI 10.1093/jnci/djp456
   Gill P, 2019, ENDOCR PATHOL, V0, P0
   Gunduz OH, 2017, J PAIN RES, V10, P2815, DOI 10.2147/JPR.S134775
   Gurbuz N, 2019, ANTICANCER RES, V39, P529, DOI 10.21873/anticanres.13144
   Hameed Mariam, 2010, CANCERS (BASEL), V3, P43, DOI 10.3390/cancers3010043
   Haney SL, 2019, ONCOGENE, V38, P5308, DOI 10.1038/s41388-019-0794-6
   Hanks GW, 2001, BRIT J CANCER, V84, P587, DOI 10.1054/bjoc.2001.1680
   Harirforoosh S, 2013, J PHARM PHARM SCI, V16, P821, DOI 10.18433/J3VW2F
   Harris Debra J, 2006, THER CLIN RISK MANAG, V2, P251, DOI 10.2147/tcrm.2006.2.3.251
   Harris DG, 2014, BRIT MED BULL, V110, P117, DOI 10.1093/bmb/ldu010
   JEMAL A, 2011, CA-CANCER J CLIN, V61, P134, DOI 10.3322/caac.20115
   Jiao L, 2009, ARCH INTERN MED, V169, P764, DOI 10.1001/archinternmed.2009.46
   Jing WQ, 2019, J IMMUNOTHER CANCER, V7, P0, DOI 10.1186/s40425-019-0573-5
   Kanat O, 2017, WORLD J CLIN ONCOL, V8, P329, DOI 10.5306/wjco.v8.i4.329
   Kapral M, 2017, MOLECULES, V22, P0, DOI 10.3390/molecules22101657
   Katsuda M, 2019, TRIALS, V20, P0, DOI 10.1186/s13063-019-3332-5
   Kirkegård J, 2017, AM J GASTROENTEROL, V112, P1366, DOI 10.1038/ajg.2017.218
   Larsson SC, 2005, BRIT J CANCER, V93, P1310, DOI 10.1038/sj.bjc.6602868
   Lindsay TH, 2005, PAIN, V119, P233, DOI 10.1016/j.pain.2005.10.019
   Liu Y, 2019, ONCOL REP, V41, P1521, DOI 10.3892/or.2019.6979
   Lohse I, 2017, ONCOTARGET, V8, P3064, DOI 10.18632/oncotarget.13619
   Lohse I, 2015, BRIT J CANCER, V113, P425, DOI 10.1038/bjc.2015.220
   Lohse Ines, 2018, ONCOTARGET, V9, P35448, DOI 10.18632/oncotarget.26234
   Lohse I, 2016, PLOS ONE, V11, P0, DOI 10.1371/journal.pone.0167272
   Lohse I, 2016, ONCOTARGET, V7, P33571, DOI 10.18632/oncotarget.9654
   Lohse I, 2014, CANCERS, V6, P459, DOI 10.3390/cancers6010459
   Lu WD, 2008, HEMATOL ONCOL CLIN N, V22, P631, DOI 10.1016/j.hoc.2008.04.005
   Malsy M, 2019, BMC BIOCHEM, V20, P0, DOI 10.1186/s12858-019-0105-4
   Matsushita Y, 2013, BRIT J PHARMACOL, V170, P991, DOI 10.1111/bph.12366
   McCarthy MW, 2018, EXPERT REV ANTI-INFE, V16, P849, DOI 10.1080/14787210.2018.1536546
   Mercadante S, 2003, J PAIN SYMPTOM MANAG, V26, P1140, DOI 10.1016/j.jpainsymman.2003.04.004
   MERCADANTE S, 1993, PAIN, V52, P187, DOI 10.1016/0304-3959(93)90130-H
   Meyer L, 2010, CELL MOL LIFE SCI, V67, P3017, DOI 10.1007/s00018-010-0372-0
   Montgomery GH, 2013, CA-CANCER J CLIN, V63, P31, DOI 10.3322/caac.21165
   Müller MW, 2008, AM J SURG, V195, P221, DOI 10.1016/j.amjsurg.2007.02.026
   Murakawa M, 2019, J CANCER, V10, P627, DOI 10.7150/jca.28660
   Niederberger E, 2017, NAT REV NEUROL, V13, P434, DOI 10.1038/nrneurol.2017.68
   Nienhuijs SW, 2012, PANCREAS, V41, P1063, DOI 10.1097/MPA.0b013e31824c3dbf
   Niu LZ, 2013, CRYOBIOLOGY, V66, P105, DOI 10.1016/j.cryobiol.2012.12.002
   Obazee O, 2019, INT J CANCER, V145, P686, DOI 10.1002/ijc.32127
   Oronsky B, 2018, TRANSL ONCOL, V11, P771, DOI 10.1016/j.tranon.2018.03.014
   Paulson AS, 2013, GASTROENTEROLOGY, V144, P1316, DOI 10.1053/j.gastro.2013.01.078
   Pei YY, 2019, SMALL, V15, P0, DOI 10.1002/smll.201900631
   Pour PM, 2003, PANCREAS, V26, P322, DOI 10.1097/00006676-200305000-00002
   Ray P, 2019, J CELL COMMUN SIGNAL, V0, P0
   Rodríguez-Caballero A, 2012, INT J ORAL MAX SURG, V41, P225, DOI 10.1016/j.ijom.2011.10.011
   Roeckel LA, 2016, NEUROSCIENCE, V338, P160, DOI 10.1016/j.neuroscience.2016.06.029
   Seicean A, 2014, WORLD J GASTROENTERO, V20, P110, DOI 10.3748/wjg.v20.i1.110
   Seufferlein T, 2012, ANN ONCOL, V23, P33, DOI 10.1093/annonc/mds224
   Singhal M, 2019, PLOS ONE, V14, P0, DOI 10.1371/journal.pone.0211711
   Sisignano M, 2019, NAT REV NEUROL, V10, P694
   Thibodeau ML, 2019, CSH MOL CASE STUD, V5, P0, DOI 10.1101/mcs.a003681
   van Mackelenbergh MG, 2019, CANCERS, V11, P0, DOI 10.3390/cancers11050588
   Varrassi G, 2018, PAIN THER, V7, P59, DOI 10.1007/s40122-018-0094-9
   Wawszczyk J, 2015, ACTA POL PHARM, V72, P895
   Wolfgang CL, 2013, CA-CANCER J CLIN, V63, P318, DOI 10.3322/caac.21190
   Wong GY, 2004, JAMA-J AM MED ASSOC, V291, P1092, DOI 10.1001/jama.291.9.1092
   Wood LD, 2019, GASTROENTEROLOGY, V0, P0
   Wu J, 2019, J ENZYM INHIB MED CH, V34, P420, DOI 10.1080/14756366.2018.1484734
   Zheng JL, 2017, NUTR REV, V75, P883, DOI 10.1093/nutrit/nux038
NR 93
TC 57
Z9 70
U1 7
U2 56
PU INT INST ANTICANCER RESEARCH
PI ATHENS
PA EDITORIAL OFFICE 1ST KM KAPANDRITIOU-KALAMOU RD KAPANDRITI, PO BOX 22, ATHENS 19014, GREECE
SN 0250-7005
EI 1791-7530
J9 ANTICANCER RES
JI Anticancer Res.
PD APR 15
PY 2020
VL 40
IS 4
BP 1789
EP 1796
DI 10.21873/anticanres.14133
PG 8
WC Oncology
SC Oncology
GA KY7DO
UT WOS:000522734400001
PM 32234867
DA 2026-01-16
ER

PT J
AU Lu, W
   Giobbie-Hurder, A
   Freedman, RA
   Shin, IH
   Lin, NU
   Partridge, AH
   Rosenthal, DS
   Ligibel, JA
AF Lu, Weidong
   Giobbie-Hurder, Anita
   Freedman, Rachel A
   Shin, Im Hee
   Lin, Nancy U
   Partridge, Ann H
   Rosenthal, David S
   Ligibel, Jennifer A
TI Acupuncture for Chemotherapy-Induced Peripheral Neuropathy in Breast Cancer
SO The oncologist
LA English
DT Journal Article
DE Acupuncture; Breast cancer survivors; Chemotherapy-induced peripheral neuropathy; Quality of life; Taxane
AB BACKGROUND: Chemotherapy-induced peripheral neuropathy (CIPN) is one of the most  debilitating long-term side effects in breast cancer survivors. We conducted a  randomized controlled pilot trial to assess the feasibility, safety, and effects  of an acupuncture intervention on CIPN in this population. PATIENTS AND METHODS:  Women with stage I-III breast cancer with grade 1 or higher CIPN after  taxane-containing adjuvant chemotherapy were randomized 1:1 to an immediate  acupuncture (IA) arm or to a waitlist control group (CG). Participants in the IA  arm received 18 sessions of acupuncture over 8 weeks, then received no additional  acupuncture. Patients in the CG arm received usual care over 8 weeks, followed by  nine sessions of acupuncture over 8 weeks. Measures including Patient  Neurotoxicity Questionnaire (PNQ), Functional Assessment of Cancer  Therapy-Neurotoxicity subscale (FACT-NTX), and Brief Pain Inventory-short form  (BPI-SF) were collected at baseline and at 4, 8, and 16 weeks after enrollment.  RESULTS: Forty women (median age, 54) were enrolled (20 to IA and 20 to CG), with  median time between completion of chemotherapy and enrollment of 14 months (range  1-92). At 8 weeks, participants in the IA arm experienced significant  improvements in PNQ sensory score (-1.0 ± 0.9 vs. -0.3 ± 0.6; p = .01), FACT-NTX  summary score (8.7 ± 8.9 vs. 1.2 ± 5.4; p = .002), and BPI-SF pain severity score  (-1.1 ± 1.7 vs. 0.3 ± 1.5; p = .03), compared with those in the CG arm. No  serious side effects were observed. CONCLUSION: Women with CIPN after adjuvant  taxane therapy for breast cancer experienced significant improvements in  neuropathic symptoms from an 8-week acupuncture treatment regimen. Additional  larger studies are needed to confirm these findings. IMPLICATIONS FOR PRACTICE:  Chemotherapy-induced peripheral neuropathy (CIPN) is a toxicity that often  persists for months to years after the completion of adjuvant chemotherapy for  early breast cancer. In a randomized pilot trial of 40 breast cancer survivors  with CIPN, an 8-week acupuncture intervention (vs. usual care) led to a  statistically and clinically significant improvement in subjective sensory  symptoms including neuropathic pain and paresthesia. Given the lack of effective  therapies and established safety profile of acupuncture, clinicians may consider  acupuncture as a treatment option for mild to moderate CIPN in practice.
C1 Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
   Division of Biostatistics, Department of Data Sciences, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
   Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
   Department of Medical Statistics and Informatics, School of Medicine at the Catholic University of Daegu, Daegu, Republic of Korea.
   Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
   Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
   Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
   Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
NR 0
TC 0
SN 1549-490
EI 1083-715
J9 Oncologist
PD APR 17
PY 2020
VL 25
IS 4
BP 310
EP 318
DI 10.1634/theoncologist.2019-0489
PG 8
WC Acupuncture Therapy; Antineoplastic Agents; adverse effects; Breast Neoplasms; drug therapy; Cancer Survivors; Child; Child, Preschool; Female; Humans; Infant; Peripheral Nervous System Diseases; chemically induced; Pilot Projects
UT PubMed:32297442
PM 32297442
DA 2020-04-17
ER

PT J
AU Liu, WL
   Qdaisat, A
   Lopez, G
   Narayanan, S
   Underwood, S
   Spano, M
   Reddy, A
   Guo, Y
   Yeung, SC
   Bruera, E
   Cohen, L
AF Liu, Wenli
   Qdaisat, Aiham
   Lopez, Gabriel
   Narayanan, Santhosshi
   Underwood, Susan
   Spano, Michael
   Reddy, Akhila
   Guo, Ying
   Yeung, Sai-Ching
   Bruera, Eduardo
   Cohen, Lorenzo
TI Association Between Acupoint Selection, Target Symptoms, and Traditional Chinese Medicine Diagnosis in Real-Time Clinical Practice in a Comprehensive Cancer Center
SO INTEGRATIVE CANCER THERAPIES
LA English
DT Article
DE acupuncture; acupuncture point selection; traditional Chinese medicine; integrative medicine; cancer; complementary health approaches
ID acupuncture
AB Background: Acupuncture intervention in actual practice is rarely reported and may be different from that applied in acupuncture research. Objectives: To review acupuncture practice in an integrative medicine clinic and characterize the association between targeted symptoms, traditional Chinese medicine (TCM) diagnosis, and acupoint selection. Methods: We reviewed outpatient acupuncture records from March 2016 to April 2018. Statistical analyses were applied to characterize referral symptoms and associated TCM diagnosis as well as acupoint selection. Results: The final analysis included 5393 acupuncture records (1264 patients). Twelve TCM diagnosis components were identified in the referral symptoms of pain, neuropathy, xerostomia, and hot flashes. Pain was associated with 78 different TCM diagnoses (combinations of TCM diagnosis components). Total of 217 different acupoints were used in the acupuncture treatments (1739) for neuropathy. The acupoint yintang was used in 73.8% of the visits for neuropathy, yet only in 26.5% (P < .001) of the treatments when patients had a TCM diagnosis of qi deficiency, qi stagnation, and blood stagnation. Similarly, both consistencies and variations were seen in acupoint selection with each targeted symptom and its associated TCM diagnoses. Conclusions: TCM diagnosis was not homogeneous among acupuncture treatments for a single referral symptom. In contrast to most of the research on acupuncture for symptom control, there were considerable variations in acupoint selection among treatments for the same symptom in a clinical setting. Future research is needed to examine the clinical relevance of a fixed intervention structure in acupuncture research and the value of individualized acupuncture treatment.
C1 [Liu, Wenli; Qdaisat, Aiham; Lopez, Gabriel; Narayanan, Santhosshi; Underwood, Susan; Spano, Michael; Reddy, Akhila; Guo, Ying; Yeung, Sai-Ching; Bruera, Eduardo; Cohen, Lorenzo] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.
C3 University of Texas System; UTMD Anderson Cancer Center
RP Liu, WL (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Palliat Care Rehabil & Integrat Med, 1515 Holcombe Blvd,Unit 1414, Houston, TX 77030 USA.
EM wenliliu@mdanderson.org
FU NIH through Cancer Center Support Grant [P30 CA016672]; Duncan Family Institute for Cancer Prevention and Risk Assessment; Richard E. Haynes Distinguished Professorship for Clinical Cancer Prevention at The University of Texas MD Anderson Cancer Center; National Cancer Institute [P30CA016672] Funding Source: NIH RePORTER
CR Unknown -, 2013, TRADITIONAL MED STRA, V0, P0
   Avis NE, 2017, MENOPAUSE, V24, P171, DOI 10.1097/GME.0000000000000735
   Bao T, 2014, INTEGR CANCER THER, V13, P396, DOI 10.1177/1534735414534729
   Birkeflet O, 2014, ACUPUNCT MED, V32, P325, DOI 10.1136/acupmed-2013-010473
   Brauer JA, 2010, J ALTERN COMPLEM MED, V16, P183, DOI 10.1089/acm.2009.0354
   Garcia MK, 2015, CANCER-AM CANCER SOC, V121, P3948, DOI 10.1002/cncr.29630
   Garcia MK, 2014, CURR ONCOL REP, V16, P0, DOI 10.1007/s11912-014-0418-9
   Johnson MI, 2010, ACUPUNCT MED, V28, P111, DOI 10.1136/aim.2010.002535
   Lesi G, 2016, J CLIN ONCOL, V34, P1795, DOI 10.1200/JCO.2015.63.2893
   Liu WL, 2019, INTEGR CANCER THER, V18, P0, DOI 10.1177/1534735419848494
   Liu ZS, 2016, ANN INTERN MED, V165, P761, DOI 10.7326/M15-3118
   MacPherson H, 2004, COMPLEMENT THER MED, V12, P38, DOI 10.1016/S0965-2299(03)00125-0
   MacPherson H, 2013, EVID-BASED COMPL ALT, V2013, P0, DOI 10.1155/2013/286048
   MacPherson H, 2010, PLOS MED, V7, P0, DOI 10.1371/journal.pmed.1000261
   Molassiotis A, 2012, J CLIN ONCOL, V30, P4470, DOI 10.1200/JCO.2012.41.6222
   Rostock M, 2013, EVID-BASED COMPL ALT, V2013, P0, DOI 10.1155/2013/349653
   Stuardi T, 2012, J ALTERN COMPLEM MED, V18, P1021, DOI 10.1089/acm.2011.0670
   White A, 2011, ACUPUNCT MED, V29, P247, DOI 10.1136/acupmed-2011-010100
   White A, 2009, ACUPUNCT MED, V27, P33, DOI 10.1136/aim.2008.000372
   Wiseman Nigel, 1996, FUNDAMENTALS CHINESE, V0, P0
NR 20
TC 11
Z9 11
U1 0
U2 9
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 1534-7354
EI 1552-695X
J9 INTEGR CANCER THER
JI Integr. Cancer Ther.
PD JUN 15
PY 2020
VL 19
IS 
BP 
EP 
DI 10.1177/1534735420928490
PG 7
WC Oncology; Integrative & Complementary Medicine
SC Oncology; Integrative & Complementary Medicine
GA LY8KB
UT WOS:000540776000001
PM 32508209
DA 2026-01-16
ER

PT J
AU Liang, Q
   Zhang, K
   Wang, SM
   Xu, X
   Liu, YQ
   Cui, SY
   Liu, LX
AF Liang, Qi
   Zhang, Ke
   Wang, Sumeng
   Xu, Xian
   Liu, Yiqian
   Cui, Shiyun
   Liu, Lingxiang
TI Acupuncture for Cancer Pain - An Adjuvant Therapy for Cancer Pain Relief
SO AMERICAN JOURNAL OF CHINESE MEDICINE
LA English
DT Article
DE Cancer Pain; Acupuncture; Pain Management; Review
ID oncology acupuncture; aromatase inhibitors; symptom management; neck dissection; joint symptoms; breast-cancer; electroacupuncture; women; arthralgia; safety
AB As current pain management methods cannot effectively control pain among cancer patients, acupuncture has developed as an adjuvant therapy for cancer pain relief. However, the efficacy of acupuncture in treating cancer pain remains controversial. Here, we briefly introduced the development of pain management, analgesic mechanisms, and acupuncture methods. Meanwhile, a comprehensive overview of acupuncture programs was provided in terms of different cancer types, sources, and degrees. Interestingly, acupuncture can treat both tumor-induced pain and therapy-induced pain well among cancer patients. We preliminarily summarized frequently-used acupoints for different types of cancer pain and found that needle retention time was mostly 30 min, and treatment cycle was two weeks. Additionally, clinicians consistently selected Ashi acupoint or bilateral Zusanli acupoint and combined multiple acupuncture methods for different degrees of cancer pain.
C1 [Liang, Qi; Zhang, Ke; Wang, Sumeng; Xu, Xian; Liu, Yiqian; Cui, Shiyun; Liu, Lingxiang] Nanjing Med Univ, Affiliated Hosp 1, Dept Oncol, 300 Guangzhou Rd, Nanjing 210029, Peoples R China.
C3 Nanjing Medical University
RP Liu, LX (corresponding author), Nanjing Med Univ, Affiliated Hosp 1, Dept Oncol, 300 Guangzhou Rd, Nanjing 210029, Peoples R China.
EM llxlau@163.com
FU National Natural Science Foundation of China [81472782]; National Key Research and Development Program: The key technology of palliative care and nursing for cancer patients [2017YFC1309201]
CR Unknown -, 1986, PAIN S, V3, P226
   Castel LD, 2013, CANCER-AM CANCER SOC, V119, P2375, DOI 10.1002/cncr.28016
   Chang VT, 2000, CANCER-AM CANCER SOC, V88, P1175, DOI 10.1002/(SICI)1097-0142(20000301)88:5<1175::AID-CNCR30>3.0.CO;2-N
   Chen A, 2017, SHANGHAI J TRADITION, V51, P16, DOI 10.16305/J.1007-1334.2017.06.005
   Chen H, 2013, PANCREATOLOGY, V13, P594, DOI 10.1016/j.pan.2013.10.007
   Chen Ji-Jun, 2017, CHINESE JOURNAL OF ZOOLOGY, V52, P668, DOI 10.13859/j.cjz.201704016
   Chen L, 2017, BREAST, V33, P132, DOI 10.1016/j.breast.2017.03.015
   Chen Zhong-jie, 2008, ZHONGGUO ZHEN JIU, V28, P392
   Chi YL, 2019, AM J CHINESE MED, V47, P1445, DOI 10.1142/S0192415X19500745
   Chiu HY, 2017, EUR J CANCER CARE, V26, P0, DOI 10.1111/ecc.12457
   Choi TY, 2012, SUPPORT CARE CANCER, V20, P1147, DOI 10.1007/s00520-012-1432-9
   Crew KD, 2007, J CLIN ONCOL, V25, P3877, DOI 10.1200/JCO.2007.10.7573
   Crew KD, 2010, J CLIN ONCOL, V28, P1154, DOI 10.1200/JCO.2009.23.4708
   Curtis E B, 1991, J PALLIAT CARE, V7, P25
   Dijkstra PU, 2001, HEAD NECK-J SCI SPEC, V23, P947, DOI 10.1002/hed.1137
   Donald GK, 2011, ACUPUNCT MED, V29, P230, DOI 10.1136/acupmed.2011.010025
   Dong LL, 2018, ORE GEOL REV, V100, P99, DOI 10.1016/j.oregeorev.2016.10.030
   DONNELLY S, 1995, SEMIN ONCOL, V22, P67
   Dou Z, 2004, ZHEJIANG J INTEGRATE, V14, P538
   Garcia MK, 2014, INTEGR CANCER THER, V13, P133, DOI 10.1177/1534735413510558
   Goudas LC, 2005, CANCER INVEST, V23, P182, DOI 10.1081/CNV-200050482
   Gu Y, 2017, ACTA CHIN MED, V32, P2307
   Guerard EJ, 2017, CANCER J, V23, P242, DOI 10.1097/PPO.0000000000000276
   Guo H, 2019, ELEC J GEN STOMATOL, V6, P172
   Han JS, 2004, NEUROSCI LETT, V361, P258, DOI 10.1016/j.neulet.2003.12.019
   Han JS, 2003, TRENDS NEUROSCI, V26, P17, DOI 10.1016/S0166-2236(02)00006-1
   Han XY, 2017, BMC CANCER, V17, P0, DOI 10.1186/s12885-016-3037-z
   He Y, 2019, BRIGHT CHIN MED, V34, P2689
   He Y, 2019, JAMA ONCOL, V6, P0
   Henry NL, 2012, J CLIN ONCOL, V30, P936, DOI 10.1200/JCO.2011.38.0261
   Hershman DL, 2018, JAMA-J AM MED ASSOC, V320, P167, DOI 10.1001/jama.2018.8907
   Hong J, 2010, CHIN ARCH TRADIT CHI, V28, P277
   Hu CQ, 2016, EVID-BASED COMPL ALT, V2016, P0, DOI 10.1155/2016/1720239
   [胡侠 Hu Xia], 2004, 中国针灸 CHINESE ACUPUNCTURE AND MOXIBUSTION, V24, P149
   Huang QF, 2019, J ACUPUNCT TUINA SCI, V17, P89, DOI 10.1007/s11726-019-1097-8
   Huang WJ, 2012, PLOS ONE, V7, P0, DOI 10.1371/journal.pone.0032960
   景年财, 2014, 中国老年学杂志 CHINESE JOURNAL OF GERONTOLOGY, V34, P5428
   KRAUSE HR, 1992, INT J ORAL MAX SURG, V21, P276
   Laird B, 2008, EUR J CANCER, V44, P1078, DOI 10.1016/j.ejca.2008.03.022
   Lao HH, 1999, WRIST ANKLE ACUPUNCT, V0, P1
   Lau CHY, 2016, MEDICINE, V95, P0, DOI 10.1097/MD.0000000000002901
   Lee J, 2014, INTEGR CANCER THER, V13, P211, DOI 10.1177/1534735413510025
   LEIPZIG B, 1983, AM J SURG, V146, P526, DOI 10.1016/0002-9610(83)90246-5
   Li Q, 2016, INT C NUMER SIMUL, V0, PP97, DOI 10.1109/NUSOD.2016.7547047
   Li X, 2018, J HEBEI MED, V40, P594
   Li XY, 2019, AM J CHINESE MED, V47, P1755, DOI 10.1142/S0192415X19500897
   Lin JG, 2018, AM J CHINESE MED, V46, P55, DOI 10.1142/S0192415X18500039
   LIU XF, 2013, J N CHIN MED, V45, P128
   Lu WD, 2018, HEMATOL ONCOL CLIN N, V32, P519, DOI 10.1016/j.hoc.2018.01.009
   Lu WD, 2013, CURR PAIN HEADACHE R, V17, P0, DOI 10.1007/s11916-013-0321-3
   Lu WD, 2010, CURR TREAT OPTION ON, V11, P141, DOI 10.1007/s11864-010-0126-0
   Lu XS, 1985, ZHONGGUO ZHEN JIU, V5, P43
   Luo JH, 2018, SHAANXI ZHONGYI, V39, P253
   Ma LS, 2017, WORLD CHIN MED, V12, P2847
   Ma S, 2017, MAGNETIC MOXIBUSTION, V0, P0
   Mao JJ, 2014, EUR J CANCER, V50, P267, DOI 10.1016/j.ejca.2013.09.022
   MAYER DJ, 1977, BRAIN RES, V121, P368, DOI 10.1016/0006-8993(77)90161-5
   Mehling WE, 2007, J PAIN SYMPTOM MANAG, V33, P258, DOI 10.1016/j.jpainsymman.2006.09.016
   Paice JA, 2016, J ONCOL PRACT, V12, P757, DOI 10.1200/JOP.2016.014837
   Paley CA, 2011, BMJ SUPPORT PALLIAT, V1, P51, DOI 10.1136/bmjspcare-2011-000022
   Patil S, 2016, CURR PAIN HEADACHE R, V20, P0, DOI 10.1007/s11916-016-0552-1
   Payne R, 1998, PROG PAIN RES MANAG, V12, P17
   Pfister DG, 2010, J CLIN ONCOL, V28, P2565, DOI 10.1200/JCO.2009.26.9860
   POMERANZ B, 1976, LIFE SCI, V19, P1757, DOI 10.1016/0024-3205(76)90084-9
   Portenoy RK, 1999, LANCET, V353, P1695, DOI 10.1016/S0140-6736(99)01310-0
   Shen L, 2014, J HEBEI TRADIT CHIN, V29, P35
   Silberstein M, 2009, J THEOR BIOL, V261, P637, DOI 10.1016/j.jtbi.2009.09.008
   Song J, 2013, J CHONGQING MED, V42, P3714
   Tang H, 2015, J SHANDONG MED, V55, P42
   Thompson LMA, 2015, J ACUPUNCT MERIDIAN, V8, P127, DOI 10.1016/j.jams.2015.04.002
   Wang C, 2019, J NEW CHIN MED, V51, P242, DOI 10.13457/J.CNKI.JNCM.2019.10.069
   Wang H, 2014, W J TRADIT CHIN MED, V27, P112
   Wang H, 2018, HENAN TRADIT. CHIN. MED., V38, P454, DOI 10.16367/J.ISSN.1003-5028.2018.03.0120
   Wang HY, 2018, AM J CHINESE MED, V46, P1387, DOI 10.1142/S0192415X18500738
   Wang JJ, 2008, ONCOLOGY-BASEL, V74, P13, DOI 10.1159/000143213
   Wang XM, 2012, EVID-BASED COMPL ALT, V2012, P0, DOI 10.1155/2012/704584
   Wei R, 2018, WORLD LATEST MED INF, V18, P32
   Wu Y, 2015, J HUBEI U TRADIT CHI, V17, P87
   Xu Xiao-Kang, 2012, ZHEN CI YAN JIU, V37, P155
   Xu Y, 2018, AM J CHINESE MED, V46, P997, DOI 10.1142/S0192415X18500520
   Zeng K, 2014, AM J CHINESE MED, V42, P289, DOI 10.1142/S0192415X14500190
   Zhang XC, 2002, COMMAD 2002 PROCEEDINGS, V0, P1
   Zhao ZQ, 2008, PROG NEUROBIOL, V85, P355, DOI 10.1016/j.pneurobio.2008.05.004
   Zhou DT, 2016, CLIN J TRADIT CHIN M, V28, P989
   Zhou J, 2017, CURR ONCOL, V24, PE1, DOI 10.3747/co.24.3296
   Zhou QH, 2002, WRIST ANKLE ACUPUNCT, V0, P1
   Zhou Y, 2012, SEEK MED ASK MED, V10, P453
   Zhou Y, 2007, J ACUPUNCT TUINA SCI, V5, P162, DOI 10.1007/s11726-007-0162-x
   Zia Farah Z, 2017, JOURNAL OF THE NATIONAL CANCER INSTITUTE MONOGRAPHS, V0, PP68, DOI 10.1093/jncimonographs/lgx005
NR 89
TC 23
Z9 25
U1 9
U2 89
PU WORLD SCIENTIFIC PUBL CO PTE LTD
PI SINGAPORE
PA 5 TOH TUCK LINK, SINGAPORE 596224, SINGAPORE
SN 0192-415X
EI 1793-6853
J9 AM J CHINESE MED
JI Am. J. Chin. Med.
PD JUN 15
PY 2020
VL 48
IS 8
BP 1769
EP 1786
DI 10.1142/S0192415X20500883
PG 18
WC Integrative & Complementary Medicine; Medicine, General & Internal
SC Integrative & Complementary Medicine; General & Internal Medicine
GA PQ9IY
UT WOS:000606856300003
PM 33300479
DA 2026-01-16
ER

PT J
AU Shi, GX
   Tu, JF
   Wang, TQ
   Yang, JW
   Wang, LQ
   Lin, LL
   Wang, Y
   Li, YT
   Liu, CZ
AF Shi, Guang-Xia
   Tu, Jian-Feng
   Wang, Tian-Qi
   Yang, Jing-Wen
   Wang, Li-Qiong
   Lin, Lu-Lu
   Wang, Yu
   Li, Yong-Ting
   Liu, Cun-Zhi
TI Effect of Electro-Acupuncture (EA) and Manual Acupuncture (MA) on Markers of
SO Journal of pain research
LA English
DT Journal Article
DE electro-acupuncture; inflammation; knee osteoarthritis; manual acupuncture
AB BACKGROUND: Inflammation plays a significant role in the pathogenesis of knee  osteoarthritis (KOA). Although both electro-acupuncture (EA) and manual  acupuncture (MA) are known to influence systemic inflammation, little is known  about the potential changes in inflammation as a working mechanism of EA and MA  in KOA. METHODS: Data from the Acupuncture for Knee Osteoarthritis Trial (ATKOA)  were used. Serum concentrations of inflammatory factors (tumor necrosis factor-α  (TNF-α), interleukin-1β (IL-1β), IL-6, IL-8, IL-18, IL-4, IL-10, IL-13, IL-15,  IL-17, monocyte chemotactic protein-1 (MCP-1), CC-chemokine ligand 5 (CCL5), and  cartilage degradation biomarkers (matrix metalloproteinase-1 MMP-1, MMP-3, MMP-13  and cartilage oligomeric matrix protein COMP)) were measured at baseline and  after 8 weeks of treatment. Clinical outcomes were valid and reliable  self-reported pain and function measures for osteoarthritis using the Western  Ontario and McMaster Universities Osteoarthritis Index (WOMAC) and visual  analogue scale (VAS) at baseline and post-treatment. RESULTS: Both 8-weeks EA and  MA significantly reduced pro-inflammatory cytokines (TNFα, IL-1β), and cartilage  degradation biomarkers (MMP-3, MMP-13) significantly increased the  anti-inflammatory cytokine IL-13 compared with pre-treatment (p<0.05). Further,  the reduction of TNF-α was more significant in EA when compared to MA (p=0.046).  While there was no significant difference between groups in cytokines IL-1β  (p=0.102), MMP-3 (p=0.113), MMP-13 (p=0.623) or IL-13 (p=0.935). Moreover, in  both EA and MA, the effect of acupuncture on the VAS and WOMAC function scale  after 8 weeks is clinically important, although no significant differences were  found between groups. CONCLUSION: Eight weeks of both EA and MA seem to provide  improvement in pain relief and function among individuals with mild to moderate  knee OA. This benefit is partly mediated by changes of major inflammatory factors  TNF-α, IL-1β and IL-13. TRIAL REGISTRATION: Controlled-Trials.com Identifier:  NCT03274713.
C1 Department of Acupuncture and Moxibustion, Beijing Hospital of Traditional Chinese Medicine Affiliated to Capital Medical University, Beijing, People'sRepublic of China.
   School of Acupuncture-Moxibustion and Tuina, Beijing University of Chinese Medicine, Beijing, People's Republic of China.
   School of Acupuncture-Moxibustion and Tuina, Beijing University of Chinese Medicine, Beijing, People's Republic of China.
   School of Acupuncture-Moxibustion and Tuina, Beijing University of Chinese Medicine, Beijing, People's Republic of China.
   School of Acupuncture-Moxibustion and Tuina, Beijing University of Chinese Medicine, Beijing, People's Republic of China.
   School of Acupuncture-Moxibustion and Tuina, Beijing University of Chinese Medicine, Beijing, People's Republic of China.
   Department of Acupuncture and Moxibustion, Beijing Hospital of Traditional Chinese Medicine Affiliated to Capital Medical University, Beijing, People'sRepublic of China.
   Department of Acupuncture and Moxibustion, Beijing Hospital of Traditional Chinese Medicine Affiliated to Capital Medical University, Beijing, People'sRepublic of China.
   School of Acupuncture-Moxibustion and Tuina, Beijing University of Chinese Medicine, Beijing, People's Republic of China.
NR 0
TC 0
SN 1178-709
EI 1178-709
J9 J Pain Res
PD SEP 10
PY 2020
VL 13
IS 
BP 2171
EP 2179
DI 10.2147/JPR.S256950
PG 8
UT PubMed:32904642
PM 32904642
DA 2020-09-10
ER

PT J
AU Xue, Y
   Dai, S
   Liang, J
   Ji, W
AF Xue, Yan
   Dai, Sailin
   Liang, Jiexian
   Ji, Wenjin
TI Effect of reactive oxygen species of the psoas major muscle in complete Freund's
SO Molecular pain
LA English
DT Journal Article
DE Lower limb pain; PBN; complete Freund’s adjuvant-induced inflammatory pain; psoas major muscle; reactive oxygen species
AB Lower limb pain is a common clinical disease that affects millions of people  worldwide. It is found in previous studies that reactive oxygen species is  closely related to neuropathic, cancer, chemotherapy, and inflammatory pain,  which can be relieved by reactive oxygen species scavengers. Furthermore,  acupuncture or electroacupuncture on the psoas major muscle has a great effect on  adjuvant-induced arthritis and lower back pain. In our study, we investigated the  function of reactive oxygen species scavengers locally injecting into the  ipsilateral psoas major muscle on complete Freund's adjuvant-induced inflammatory  pain. Our results demonstrated that in the development of complete Freund's  adjuvant-induced inflammatory pain, early local continuous application of  N-tert-Butyl-α-phenylnitrone (PBN, 1 and 5 mg/kg/0.2 ml) on the ipsilateral psoas  major muscle effectively reduced mechanical and cold hyperalgesia. However,  intraperitoneal injection of PBN (1 and 5 mg/kg) or local injection of PBN (1 and  5 mg/kg/0.2 ml) into contralateral psoas major muscle, ipsilateral quadratus  lumborum, and ipsilateral erector spinae showed limited effect. In the developed  inflammatory pain model, local injection of PBN into the ipsilateral psoas major  muscle also alleviated pain and paw edema. In addition, reactive oxygen species  level increased in ipsilateral psoas major muscle at seven days after complete  Freund's adjuvant injection. In general, PBN reduces complete Freund's  adjuvant-evoked inflammatory pain by inhibiting reactive oxygen species in the  psoas major muscle.
C1 Division of Anesthesiology, Department of Cardiovascular Surgery, Guangdong Institute of Cardiovascular, Guangdong Provincial People's Hospital, GuangdongAcademy of Medical Sciences, School of Medicine, South China University ofTechnology, Guangzhou, China.
   Department of Anesthesiology, Guangdong Provincial People's Hospital, Guangdong 
   Department of Anesthesiology, Fudan University Shanghai Cancer Center, Shanghai, China.
   Division of Anesthesiology, Department of Cardiovascular Surgery, Guangdong Institute of Cardiovascular, Guangdong Provincial People's Hospital, GuangdongAcademy of Medical Sciences, School of Medicine, South China University ofTechnology, Guangzhou, China.
   Department of Anesthesiology, Guangdong Provincial People's Hospital, Guangdong 
   Department of Anesthesiology, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, China.
NR 0
TC 0
SN 1744-806
EI 
J9 Mol Pain
PD JUN 20
PY 2020
VL 16
IS 
BP 1744806920929246
EP 1744806920929246
DI 10.1177/1744806920929246
PG 1
WC Animals; Cyclic N-Oxides; administration & dosage; Freund's Adjuvant; administration & dosage; Inflammation; complications; Injections, Intraperitoneal; Injections, Subcutaneous; Male; Muscles; pathology; Pain; complications; Pain Threshold; Rats, Sprague-Dawley; Reactive Oxygen Species; metabolism
UT PubMed:32552357
PM 32552357
DA 2020-06-20
ER

PT J
AU Tang, H
   Fan, H
   Luo, F
   Huang, L
   Liao, S
   Yu, W
   Chen, Y
   Chen, J
   Qin, X
AF Tang, Hongzhi
   Fan, Huaying
   Luo, Fei
   Huang, Li
   Liao, Shichuan
   Yu, Wenjing
   Chen, Yunbei
   Chen, Jiao
   Qin, Xuefei
TI Acupuncture improves postoperative symptoms of pigmented villonodular synovitis:
SO Medicine
LA English
DT Journal Article
AB BACKGROUND: Pigmented villonodular synovitis (PVNS) is a benign proliferative  disease of synovial joint, synovial sac and tendon sheath. PVNS is usually  treated by surgery, but postoperative joint dysfunction and pain will be  accompanied, which seriously affects the quality of life. The purpose of this  review is to evaluate the effectiveness and safety of this intervention in  patients with pain and dysfunction caused by postoperative symptoms of PVNS.  METHODS: We will search the EMBASE, the Cochrane Library, Ovid MEDLINE, PubMed,  Web of Science, Chinese Biomedical Literature Database (CBM), Chinese National  Knowledge Infrastructure (CNKI), Wanfang Database, the Chongqing VIP (VIP), the  US National Institute of Health, the NIH clinical registry Clinical Trials, the  ICTRP, and the Australian New Zealand Clinical Trials Registry and the Chinese  clinical registry, from their inception to 1st July 2020. Randomized controlled  trials that include patients with postoperative symptoms of pigmented  villonodular synovitis receiving acupuncture therapy versus a control group will  be included. The selection of studies, data extraction and risk of bias  assessment will be conducted by 2 independent researchers. A third review author  resolved disagreements. The dichotomous data will be presented as risk ratios  with 95% confidence intervals (CIs) and the continuous data will be presented as  weighted mean differences or standardized mean differences with 95% CIs. Evidence  quality will be evaluated using the GRADE system. RESULTS: The results will be  disseminated through a peer-reviewed journal publication. CONCLUSIONS: This  systematic review will provide updated evidence of various types of acupuncture  specifically focuses on its effectiveness and safety for patients' pain and  dysfunction caused by post-operation of pigmented villonodular synovitis. ETHICS  AND DISSEMINATION: Ethical approval is not necessary as this review will not  require data from individual patients. The results of this will be published  through peer-reviewed journal articles or conference presentations. REGISTRATION:  Open Science Framework (OSF). 2020, July 7. 10.17605/OSF.IO/CZW9P.
C1 Outpatient Department of Sichuan Orthopedic Hospital.
   The Acupuncture and Tuina School, The 3rd Teaching Hospital, Chengdu University of Traditional Chinese Medicine, Chengdu City, Sichuan Province, China.
   Outpatient Department of Sichuan Orthopedic Hospital.
   Outpatient Department of Sichuan Orthopedic Hospital.
   Outpatient Department of Sichuan Orthopedic Hospital.
   Outpatient Department of Sichuan Orthopedic Hospital.
   Outpatient Department of Sichuan Orthopedic Hospital.
   The Acupuncture and Tuina School, The 3rd Teaching Hospital, Chengdu University of Traditional Chinese Medicine, Chengdu City, Sichuan Province, China.
   Outpatient Department of Sichuan Orthopedic Hospital.
NR 0
TC 0
SN 1536-596
EI 0025-797
J9 Medicine (Baltimore)
PD SEP 3
PY 2020
VL 99
IS 33
BP e21748
EP e21748
DI 10.1097/MD.0000000000021748
PG 1
WC Acupuncture Therapy; Humans; Meta-Analysis as Topic; Pain, Postoperative; therapy; Synovitis, Pigmented Villonodular; rehabilitation; Systematic Reviews as Topic
UT PubMed:32872065
PM 32872065
DA 2020-09-03
ER

PT J
AU Liou, KT
   Trevino, KM
   Meghani, SH
   Li, QS
   Deng, G
   Korenstein, D
   Mao, JJ
AF Liou, Kevin T
   Trevino, Kelly M
   Meghani, Salimah H
   Li, Q Susan
   Deng, Gary
   Korenstein, Deborah
   Mao, Jun J
TI Fear of analgesic side effects predicts preference for acupuncture: a
SO Supportive care in cancer : official journal of the Multinational Association of
LA English
DT Journal Article
DE Acupuncture; Analgesics; Barriers; Cancer; Opioids; Pain management; Preference
AB PURPOSE: Approximately one in two cancer patients globally are under-treated for  pain. Opioids and other analgesics represent the mainstay of cancer pain  management; however, barriers to their use are well-documented. We evaluated  whether acupuncture would be a preferable treatment option among cancer patients  with attitudinal barriers to pharmacological pain management. METHODS: We  conducted a cross-sectional survey of cancer patients at a tertiary urban cancer  center and eleven suburban/rural hospitals in the Northeastern United States. We  assessed attitudinal barriers to pharmacological pain management with the  Barriers Questionnaire (BQ-13). The BQ-13 consists of two subscales: pain  management beliefs and analgesic side effects. We also asked patients whether  they prefer acupuncture, analgesics, or have no preference between these two  modalities for pain management. Covariates included sociodemographics, clinical  characteristics, and attitudes/beliefs about acupuncture. We used logistic  regression to examine the association between attitudinal barriers and  acupuncture preference. RESULTS: Among 628 patients, 197 (31.4%) preferred  acupuncture for pain management, 146 (23.3%) preferred analgesics, and 285  (45.4%) had no preference. The highest reported attitudinal barriers were fear of  addiction and fear of analgesic-associated constipation and nausea. Adjusting for  covariates, we found that attitudinal barriers related to fear of analgesic side  effects were significantly associated with acupuncture preference (adjusted odds  ratio [AOR] 1.45, 95% confidence interval [CI] 1.17-1.81), but barriers related  to pain management beliefs were not (AOR 1.17, 95% CI 0.91-1.51).  Attitudes/beliefs about acupuncture (i.e., greater expected benefits, fewer  perceived barriers, and more positive social norms) and female gender also  predicted acupuncture preference, whereas race and educational status did not.  CONCLUSION: Acupuncture may be a preferable treatment option among cancer  patients at risk of inadequately controlled pain due to fear of analgesic side  effects. Evidence-based integration of acupuncture and analgesics, guided by  patient treatment preferences, represents an essential aspect of patient-centered  care and has potential to address unmet cancer pain management needs.
C1 Integrative Medicine Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, 1429 First Avenue, New York, NY, 10021, USA. liouk@mskcc.org.
   Department of Medicine, Weill Cornell Medicine, New York, NY, USA. 
   Department of Psychiatry and Behavioral Sciences, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
   Department of Biobehavioral Health Sciences, School of Nursing, University of Pennsylvania, Philadelphia, PA, USA.
   Integrative Medicine Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, 1429 First Avenue, New York, NY, 10021, USA.
   Integrative Medicine Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, 1429 First Avenue, New York, NY, 10021, USA.
   Department of Medicine, Weill Cornell Medicine, New York, NY, USA.
   Department of Medicine and Center for Health Policy and Outcomes, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
   Integrative Medicine Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, 1429 First Avenue, New York, NY, 10021, USA.
   Department of Medicine, Weill Cornell Medicine, New York, NY, USA.
NR 0
TC 0
SN 1433-733
EI 0941-435
J9 Support Care Cancer
PD MAY 10
PY 2020
VL 29
IS 1
BP 427
EP 435
DI 10.1007/s00520-020-05504-y
PG 8
WC Acupuncture Therapy; methods; Analgesics; therapeutic use; Cross-Sectional Studies; Female; Humans; Male; Middle Aged; Neoplasms; complications; Pain; drug therapy; Pain Management; methods; United States
UT PubMed:32383073
PM 32383073
DA 2020-05-10
ER

PT J
AU Chen, J
   Zhang, Y
   Li, X
   Wan, Y
   Ji, X
   Wang, W
   Kang, X
   Yan, W
   Fan, Z
AF Chen, Jiheng
   Zhang, Yunxiao
   Li, Xiaoxi
   Wan, You
   Ji, Xinqiang
   Wang, Wei
   Kang, Xiaozheng
   Yan, Wanpu
   Fan, Zhiyi
TI Efficacy of transcutaneous electrical acupoint stimulation combined with general
SO Thoracic cancer
LA English
DT Journal Article
DE Analgesia; general anesthesia; sedation; transcutaneous acupoint electrical stimulation; video-assisted thoracoscopic surgery
AB BACKGROUND: Multimodal opioid-sparing analgesia is a key component of an enhanced  recovery pathway after surgery that aims to improve postoperative recovery.  Transcutaneous electrical acupoint stimulation (TEAS) is assumed to alleviate  pain and anxiety and to modify the autonomic nervous system. This study aimed to  determine the efficacy of TEAS for sedation and postoperative analgesia in lung  cancer patients undergoing thoracoscopic pulmonary resection. METHODS: A total of  80 patients were randomized into two groups: the TEAS group and the sham TEAS  combined with general anesthesia group. Postoperative pain levels at six, 24,  48 hours, and one month after surgery were measured using the visual analogue  scale (VAS). Bispectral index (BIS) score during the TEAS prior to anesthetic  induction, Observer's Assessment of Alertness/Sedation (OAAS) score, sufentanil  consumption during postoperative patient-controlled intravenous analgesia (PCIA),  number of total and effective attempts of PCIA pump use, and incidence of  postoperative nausea and vomiting were recorded and analyzed statistically.  RESULTS: Patients in the TEAS group had significantly lower VAS scores at six,  24, and 48 hours after surgery (P < 0.01); lower BIS scores at 10, 20, and  30 minutes before induction (P < 0.01); lower levels of postoperative sufentanil  consumption; lower number of PCIA attempts and effective rates (P < 0.01); lower  incidences of nausea at 0, six, 24, and 48 hours; and lower incidence of vomiting  at 24 hours after surgery (P < 0.05). The postoperative OAAS scores were similar  between the groups. CONCLUSIONS: TEAS could be a feasible approach for sedation  and postoperative analgesia in thoracoscopic pulmonary resection.
C1 Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education, Beijing), Department of Anesthesiology, Peking University CancerHospital and Institute, Beijing, China.
   Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education, Beijing), Department of Anesthesiology, Peking University CancerHospital and Institute, Beijing, China.
   Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education, Beijing), Department of Anesthesiology, Peking University CancerHospital and Institute, Beijing, China.
   Neuroscience Research Institute and Department of Neurobiology, Peking University and Key Laboratory of Neuroscience of the Ministry of Education and the NationalHealth Commission, Beijing, China.
   Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education, Beijing), Department of Medical Record Statistics, Peking UniversityCancer Hospital & Institute, Beijing, China.
   Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education, Beijing), Department of Medical Record Statistics, Peking UniversityCancer Hospital & Institute, Beijing, China.
   Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education, Beijing), The First Department of Thoracic Surgery, Peking UniversityCancer Hospital and Institute, Beijing, China.
   Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education, Beijing), The First Department of Thoracic Surgery, Peking UniversityCancer Hospital and Institute, Beijing, China.
   Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education, Beijing), Department of Anesthesiology, Peking University CancerHospital and Institute, Beijing, China.
NR 0
TC 0
SN 1759-771
EI 1759-770
J9 Thorac Cancer
PD FEB 18
PY 2020
VL 11
IS 4
BP 928
EP 934
DI 10.1111/1759-7714.13343
PG 6
WC Acupuncture Points; Adolescent; Adult; Aged; Anesthesia, General; methods; China; epidemiology; Double-Blind Method; Enhanced Recovery After Surgery; Female; Follow-Up Studies; Humans; Lung Neoplasms; pathology; Male; Middle Aged; Minimally Invasive Surgical Procedures; methods; Nausea; epidemiology; Pain, Postoperative; epidemiology; Prognosis; Vomiting; epidemiology; Young Adult
UT PubMed:32062864
PM 32062864
DA 2020-02-18
ER

PT J
AU Guo, J
   Pei, L
   Chen, L
   Chen, H
   Gu, D
   Xin, C
   Peng, Y
   Sun, J
AF Guo, Jing
   Pei, Lixia
   Chen, Lu
   Chen, Hao
   Gu, Dongmei
   Xin, Chen
   Peng, Yongjun
   Sun, Jianhua
TI Research Trends of Acupuncture Therapy on Cancer Over the Past Two Decades: A
SO Integrative cancer therapies
LA English
DT Journal Article
DE CiteSpace; VOSviewer; acupuncture therapy; bibliometric analysis; cancer
AB PURPOSE: Acupuncture has been used for managing cancer-related symptoms. However,  there are still few studies concerning the overall trends in acupuncture therapy  on cancer based on bibliometric analysis. This study aims to demonstrate the  current status and trends in this field over the past 2 decades. METHODS:  Articles were retrieved from the Web of Science from 2000 to 2019. CiteSpace was  used for co-authorship network of countries/institutions, dual-map analysis, and  detecting the keywords with citation bursts. VOSviewer was used to construct  networks based on co-authorship and co-citation analysis of authors, and  co-occurrence of keywords. RESULTS: A total of 927 articles and reviews were  included in the final analysis. The number of publications has steadily increased  with some fluctuations among years. The country and institution contributing most  to this field are the USA and Memorial Sloan Kettering Cancer Center. Mao JJ was  the most productive author and Molassiotis A ranked first in the cited authors.  The co-occurrence analysis revealed 5 clusters (including "clinical trials,"  "clinical studies on chemotherapy/radiation-induced symptoms," "CAM therapy for  cancer," "clinical studies on vasomotor symptoms," and "systematic reviews").  Most recent keyword bursts were "neuropathic pain," "arthralgia," "prevention,"  "supportive care," and "integrative medicine". CONCLUSIONS: The annual  publication output would increase rapidly in the next decade, which shows a  promising future in this research field. Future research hotspots would focus on  the role of acupuncture in neuropathic pain, arthralgia, prevention, supportive  care, and integrative medicine.
C1 The Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing, China.
   The Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing, China.
   The Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing, China.
   Nanjing University of Chinese Medicine, Nanjing, China.
   The Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing, China.
   The Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing, China.
   The Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing, China.
   The Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing, China.
NR 0
TC 0
SN 1552-695
EI 1534-735
J9 Integr Cancer Ther
PD NOV 5
PY 2020
VL 19
IS 
BP 1534735420959442
EP 1534735420959442
DI 10.1177/1534735420959442
PG 1
WC Acupuncture Therapy; Bibliometrics; Humans; Integrative Medicine; Neoplasms; therapy
UT PubMed:33143477
PM 33143477
DA 2020-11-05
ER

PT J
AU Chen, VE
   Greenberger, BA
   Shi, Z
   Gajjar, S
   Shi, W
   Mourad, WF
   Yan, W
AF Chen, Victor E
   Greenberger, Benjamin A
   Shi, Zheng
   Gajjar, Shefali
   Shi, Wenyin
   Mourad, Waleed F
   Yan, Weisi
TI Post-mastectomy and post-breast conservation surgery pain syndrome: a review of
SO Translational cancer research
LA English
DT Journal Article
DE Etiology; acupuncture; detection; early predictor; narrative medicine
AB Postmastectomy pain syndrome (PMPS) or breast conservation surgery (BCS) pain  syndrome could be long-term and lead to disability and impairment on body and  social function. The pain syndromes are not uncommon in breast cancer patients.  It can affect social, psychological, physical and behavioral aspects of a  patient. Surgery, radiation, chemotherapy and psychological factors can all  contribute to the development of pain syndromes. Axillary dissection is a strong  predictor for pain development. Pain medications, ganglion blocks are typically  given to the patient for management. Integrative medicine such as acupuncture and  psychological management methods are promising modalities in the management  arsenal. In this study, we summarized the up-to-date literature to elucidate the  etiology, risk factors and management strategies for PMPS.
C1 Department of Radiation Oncology, Sidney Kimmel Medical College & Cancer Center at Thomas Jefferson University, Philadelphia, PA, USA.
   Department of Radiation Oncology, Sidney Kimmel Medical College & Cancer Center at Thomas Jefferson University, Philadelphia, PA, USA.
   Department of Radiation Oncology, The University of Texas Health Science Center at San Antonio, San Antonio, TX, USA.
   Department of Radiation Oncology, Sidney Kimmel Medical College & Cancer Center at Thomas Jefferson University, Philadelphia, PA, USA.
   Department of Radiation Oncology, Sidney Kimmel Medical College & Cancer Center at Thomas Jefferson University, Philadelphia, PA, USA.
   Department of Radiation Oncology, University of Kentucky, Lexington, KY, USA.
   Department of Radiation Oncology, Sidney Kimmel Medical College & Cancer Center at Thomas Jefferson University, Philadelphia, PA, USA.
NR 0
TC 0
SN 2219-680
EI 2218-676
J9 Transl Cancer Res
PD JAN 1
PY 2020
VL 9
IS Suppl 1
BP S77
EP S85
DI 10.21037/tcr.2019.06.46
PG 1
UT PubMed:33828953
PM 33828953
DA 2020-01-01
ER

PT J
AU Chan, K
   Lui, L
   Yu, K
   Lau, K
   Lai, M
   Lau, W
   Ng, B
   Zhong, LLD
   Bian, ZX
AF Chan, Kaiyin
   Lui, Louisa
   Yu, Kaling
   Lau, Kwongwai
   Lai, Manchi
   Lau, Waiwai
   Ng, Bacon
   Zhong, Linda L D
   Bian, Zhao-Xiang
TI The efficacy and safety of electro-acupuncture for alleviating
SO Trials
LA English
DT Journal Article
DE Acupuncture; Chemotherapy-induced peripheral neuropathy; Colorectal cancer; Oxaliplatin
AB BACKGROUND: Colorectal cancer is the most common cancer in Hong Kong.  Oxaliplatin-based chemotherapy is a major first-line conventional therapy for  advanced and metastatic colorectal cancer. However, oxaliplatin causes  chemotherapy-induced peripheral neuropathy (CIPN). Acupuncture has long been used  to alleviate limb numbness in Chinese medicine. This study aims to examine the  efficacy and safety of acupuncture for alleviating CIPN in patients with  colorectal cancer in Hong Kong. METHODS/DESIGN: This is a single-blinded,  randomized, sham-controlled efficacy trial. Eighty-four eligible patients, who  are Hong Kong Chinese, aged ≥ 18 years, diagnosed with colorectal cancer and  undergoing oxaliplatin-based chemotherapy, will be randomized in a ratio of 1:1  to the electro-acupuncture group or the sham-controlled group. During a 12-week  treatment period, patients in the electro-acupuncture group will undergo  electro-acupuncture once a week from the first cycle of chemotherapy, while  patients in the control group will receive sham acupuncture, and the patients in  both groups will be followed up for 12 weeks. The primary outcome measure is the  Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity  (FACT/GOC-Ntx) questionnaire. The secondary outcome measures include numerical  rating scale (NRS) for numbness/pain, vibration and light touch sense test, the  European Organization for Research and Treatment of Cancer Quality of Life  Questionnaire-C30 (EORTC QLQ-C30) and Constitution of Chinese Medicine  Questionnaire (CCMQ). DISCUSSION: The study will compare electro-acupuncture with  sham acupuncture to explore the feasibility for electro-acupuncture in improving  symptoms caused by chemotherapy-induced peripheral neuropathy. TRIAL  REGISTRATION: Clinicaltrials.gov, NCT03582423. Registered on 11 July 2018.
C1 Yan Chai Hospital cum Hong Kong Baptist University Chinese Medicine Clinic cum Training and Research Centre, Ha Kwai Chung, Hong Kong SAR.
   Oncology Department of Princess Margaret Hospital, Kwai Chung, Hong Kong SAR.
   Yan Chai Hospital cum Hong Kong Baptist University Chinese Medicine Clinic cum Training and Research Centre, Ha Kwai Chung, Hong Kong SAR.
   Yan Chai Hospital cum Hong Kong Baptist University Chinese Medicine Clinic cum Training and Research Centre, Ha Kwai Chung, Hong Kong SAR.
   Yan Chai Hospital cum Hong Kong Baptist University Chinese Medicine Clinic cum Training and Research Centre, Ha Kwai Chung, Hong Kong SAR.
   Yan Chai Hospital cum Hong Kong Baptist University Chinese Medicine Clinic cum Training and Research Centre, Ha Kwai Chung, Hong Kong SAR.
   Chinese Medicine Department, Hong Kong Hospital Authority, Kowloon, Hong Kong SAR.
   Hong Kong Chinese Medicine Clinical Study Centre, Hong Kong Baptist University, Jockey Club School of Chinese Building, 7 Baptist Road, Kowloon Tong, Hong KongSAR. ldzhong@hkbu.edu.hk.
   School of Chinese Medicine, Hong Kong Baptist University, Jockey Club School of 
   Hong Kong Chinese Medicine Clinical Study Centre, Hong Kong Baptist University, Jockey Club School of Chinese Building, 7 Baptist Road, Kowloon Tong, Hong KongSAR. bzxiang@hkbu.edu.hk.
   School of Chinese Medicine, Hong Kong Baptist University, Jockey Club School of
NR 0
TC 0
SN 1745-621
EI 
J9 Trials
PD JAN 11
PY 2020
VL 21
IS 1
BP 58
EP 58
DI 10.1186/s13063-019-3972-5
PG 0
WC Antineoplastic Agents; adverse effects; Colorectal Neoplasms; drug therapy; Electroacupuncture; adverse effects; Humans; Outcome Assessment, Health Care; Peripheral Nervous System Diseases; chemically induced; Randomized Controlled Trials as Topic; Single-Blind Method
UT PubMed:31918748
PM 31918748
DA 2020-01-11
ER

PT J
AU Zhang, YP
   Hu, RX
   Han, M
   Lai, BY
   Liang, SB
   Chen, BJ
   Robinson, N
   Chen, K
   Liu, JP
AF Zhang, Ya-Peng
   Hu, Rui-Xue
   Han, Mei
   Lai, Bao-Yong
   Liang, Shi-Bing
   Chen, Bing-Jie
   Robinson, Nicola
   Chen, Kevin
   Liu, Jian-Ping
TI Evidence Base of Clinical Studies on Qi Gong: A Bibliometric Analysis
SO COMPLEMENTARY THERAPIES IN MEDICINE
LA English
DT Article
DE Qigong; Ba Duan Jin; Bibliometric Analysis; Clinical Study; Non-drug therapy
ID quality-of-life; qigong; individuals; exercises; disease; adults; impact
AB Objective: This bibliometric study aimed to systematically and comprehensively summarize the volume, breadth and evidence for clinical research on Qigong. And this bibliometric analysis also can provide the evidence of this field. Design: Bibliometric analysis. Methods: All types of primary and secondary studies on humans were included: systematic reviews, randomized clinical trials, non-randomized controlled clinical studies, case series and case reports. Chinese Biomedical Literature Database, China National Knowledge Infrastructure, Chinese Scientific Journal Database, Chinese Academic Conference Papers Database and Chinese Dissertation Database, PubMed and the Cochrane Library were searched from the date of inception to December 10, 2018. Bibliometric information, such as publication information, disease/condition, Qigong intervention and research results were extracted and analyzed. Results: A total of 886 clinical studies were identified: including 47 systematic reviews, 705 randomized clinical trials, 116 non-randomized controlled clinical studies, 12 case series and 6 case reports. The studies were conducted in 14 countries. The top 15 diseases/conditions studied were: diabetes, chronic obstructive pulmonary disease, hypertension, stroke, cervical spondylosis, lumbar disc herniation, insomnia, knee osteoarthritis, low back pain, and osteoporosis, Coronary heart disease, breast cancer, periarthritis of shoulder, depression, metabolic syndrome. Of the various Qigong exercises reported in these 886 clinical studies, Ba Duan Jin was the most frequently researched in 492 (55.5%) studies, followed by Health Qigong 107 (12.1%), Dao Yin Shu 85 (9.6%), Wu Qin Xi 67 (7.6%) and Yi Jin Jing 66 (7.4%). The most frequently used comparisons in randomized trials were maintaining normal way of life unchanged 149 (18.1%), the remaining controls included conventional treatment, mainly western medicine, Chinese herbal medicine, acupuncture, health education, psychological therapy, Yoga, Tai Chi and other non-drug therapy. The most frequently reported outcomes were physical function, quality of life, symptoms, pain and mental health indicators. Beneficial results from practicing Qigong were reported in 97% of studies. Conclusions: Qigong research publications have been increasing gradually. Reports on study types, participants, Qigong Intervention, and outcomes are diverse and inconsistent. There is an urgent need to develop a set of reporting standards for various interventions of Qigong. Further trials of high methodological quality with sufficient sample size and real world studies are needed to verify the effects of Qigong in health and disease management.
C1 [Zhang, Ya-Peng; Hu, Rui-Xue; Han, Mei; Liang, Shi-Bing; Robinson, Nicola; Liu, Jian-Ping] Beijing Univ Chinese Med, Ctr Evidence Based Chinese Med, Beijing 100029, Peoples R China.
   [Hu, Rui-Xue] China Acad Chinese Med Sci, Ctr Evidence Based Tradit Chinese Med, Inst Basic Res Clin Med, Beijing, Peoples R China.
   [Lai, Bao-Yong] Beijing Universal Chinese Med, Affiliated Hosp 3, Beijing 100029, Peoples R China.
   [Liang, Shi-Bing] Shanxi Univ Tradit Chinese Med, Coll Basic Med Sci, Taiyuan 030000, Peoples R China.
   [Chen, Bing-Jie] Beijing Univ Chinese Med, Coll Tradit Chinese Med, Beijing 100029, Peoples R China.
   [Robinson, Nicola] London South Bank Univ, Sch Hlth & Social Care, London SE1 0AA, England.
   [Chen, Kevin] Univ Maryland, Sch Med, Ctr Integrat Med, College Pk, MD 20742 USA.
   [Chen, Kevin] ShenZhen Univ, Fac Phys Educ, Shenzhen, Peoples R China.
   [Zhang, Ya-Peng; Hu, Rui-Xue; Han, Mei; Lai, Bao-Yong; Liang, Shi-Bing; Chen, Bing-Jie; Robinson, Nicola; Chen, Kevin; Liu, Jian-Ping] Guangzhou Med Univ, Inst Integrated Tradit Chinese Med & Western Med, Guangzhou, Peoples R China.
C3 Beijing University of Chinese Medicine; Institute of Basic Research In Clinical Medicine, CACMS; China Academy of Chinese Medical Sciences; Beijing University of Chinese Medicine; London South Bank University; University System of Maryland; University of Maryland College Park; Shenzhen University; Guangzhou Medical University
RP Liu, JP (corresponding author), Beijing Univ Chinese Med, Ctr Evidence Based Chinese Med, Beijing 100029, Peoples R China.; Liu, JP (corresponding author), Guangzhou Med Univ, Inst Integrated Tradit Chinese Med & Western Med, Guangzhou, Peoples R China.
EM zhangyapeng@bucm.edu.cn; ruixue_hu@bucm.edu.cn; hanmeizoujin@163.com; by_lai@126.com; zyi20126185@163.com; tian8388@163.com; nicky.robinson@lsbu.ac.uk; KChen@som.umaryland.edu; Liujp@bucm.edu.cn
FU key program of the National Natural Science Foundation of China [81830115]; Beijing University of Chinese Medicine [2016-ZXFZJJ-011]; Overseas Expertise Project, Ministry of Education of China [MS20080009]
CR Unknown -, 2003, MANAGEMENT CANC CHIN, V0, P0
   Unknown -, 2017, RES EVOLUTION HYDROL, V0, P0
   Unknown -, 2010, INTERNATIONAL STATISTICAL CLASSIFICATIONS OF DISEASES AND RELATED HEALTH PROBLEMS. 10TH REVISION VOL 2 INSTRUCTION MANUAL, V0, P0
   Bai ZG, 2015, AM J CHINESE MED, V43, P1525, DOI 10.1142/S0192415X15500871
   Bongi SM, 2012, CLIN EXP RHEUMATOL, V30, P0
   Chen DZ, 2016, J AM GERIATR SOC, V64, P1513, DOI 10.1111/jgs.14218
   Chen Kevin, 2002, INTEGR CANCER THER, V1, P345, DOI 10.1177/1534735402238187
   Chen Z, 2013, CANCER-AM CANCER SOC, V119, P1690, DOI 10.1002/cncr.27904
   Hartley L, 2015, COCHRANE DATABASE SY, V0, P0
   Kemp Carol A, 2004, J HOLIST NURS, V22, P351, DOI 10.1177/0898010104269313
   Kuan SC, 2012, BIOL RES NURS, V14, P139, DOI 10.1177/1099800411399645
   Li M, 2016, CHINESE MED MODERN D, V14, P49
   Li XS, 2008, THESIS, V0, P0
   Li Y, 2011, 9 NAT SPORTS SCI C 2, V0, P2
   Liu JY, 2006, J HLTH MANAGEMENT, V4, P1
   Liu TJ, 2016, TRADITIONAL CHINESE, V0, P2
   Liu TJ, 2005, QIGONG STUDY CHINESE, V0, P0
   Lynch M, 2012, ARTHRITIS RES THER, V14, P0, DOI 10.1186/ar3931
   Oh B, 2010, ANN ONCOL, V21, P608, DOI 10.1093/annonc/mdp479
   Song R, 2017, PARKINSONISM RELAT D, V41, P3, DOI 10.1016/j.parkreldis.2017.05.019
   Tang N, 2016, CHINESE MED MODERN D, V14, P111
   Tao J, 2017, SCI REP-UK, V7, P0, DOI 10.1038/srep41581
   Teut M, 2016, J PAIN, V17, P796, DOI 10.1016/j.jpain.2016.03.003
   Wang CX, 1994, CHIN J GERONTOL, V0, P90
   Wang CX, 1984, J TRADITIONAL CHINES, V0, P27
   Wang L, 2009, THESIS, V0, P0
   Wei X, 2015, MATURITAS, V82, P346, DOI 10.1016/j.maturitas.2015.08.013
   Xiao CM, 2015, J AM GERIATR SOC, V63, P1420, DOI 10.1111/jgs.13478
   Yang XM, 2009, J JIANGXI U TRADITIO, V21, P32
   [杨莹骊 Yang Yingli], 2019, 中医杂志 JOURNAL OF TRADITIONAL CHINESE MEDICINE, V60, P664
   Yu J, 2018, CHINESE MED MODERN D, V16, P56
   Zhang F, 2014, J PHYS THER SCI, V26, P881, DOI 10.1589/jpts.26.881
   ZHU GM, 2012, SHANGHAI J TRADITION, V46, P10
NR 33
TC 61
Z9 66
U1 16
U2 207
PU CHURCHILL LIVINGSTONE
PI EDINBURGH
PA JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE, LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND
SN 0965-2299
EI 1873-6963
J9 COMPLEMENT THER MED
JI Complement. Ther. Med.
PD MAY 15
PY 2020
VL 50
IS 
BP 
EP 
DI 10.1016/j.ctim.2020.102392
PG 8
WC Integrative & Complementary Medicine
SC Integrative & Complementary Medicine
GA LR4ZL
UT WOS:000535704900005
PM 32444061
DA 2026-01-16
ER

PT J
AU Lin, TY
   Hsieh, CL
AF Lin, Ting-Yen
   Hsieh, Ching-Liang
TI Clinical Applications of Bee Venom Acupoint Injection
SO TOXINS
LA English
DT Review
DE bee venom; acupoint injections; clinical application; pharmacological mechanism
ID spinal-cord-injury; acupuncture point; neuropathic pain; rheumatoid-arthritis; mechanical allodynia; repetitive treatment; functional recovery; parkinsons-disease; fos expression; shoulder pain
AB Bee venom is a complex natural mixture with various pharmaceutical properties. Among these properties, its peptides and enzymes have potential medical therapy for pain relief and inflammation. In clinical settings, this therapy has been used widely to treat diseases by injecting into acupoints. In this article, we have conducted various research from PubMed, Cochrane Library, and Clinical Key from inception of July 2020. The results revealed that bee venom therapy has been reported effective in anti-inflammatory, antiapoptosis, and analgesic effects. Moreover, bee venom acupuncture has been commonly used for clinical disorders such as Parkinson disease, neuropathic pain, Alzheimer disease, intervertebral disc disease, spinal cord injury, musculoskeletal pain, arthritis, multiple sclerosis, skin disease and cancer.
C1 [Lin, Ting-Yen; Hsieh, Ching-Liang] China Med Univ Hosp, Dept Chinese Med, Taichung 40447, Taiwan.
   [Hsieh, Ching-Liang] China Med Univ, Grad Inst Acupuncture Sci, Coll Chinese Med, Taichung 40402, Taiwan.
   [Hsieh, Ching-Liang] China Med Univ, Chinese Med Res Ctr, Taichung 40402, Taiwan.
C3 China Medical University Taiwan; China Medical University Hospital - Taiwan; China Medical University Taiwan; China Medical University Taiwan
RP Hsieh, CL (corresponding author), China Med Univ Hosp, Dept Chinese Med, Taichung 40447, Taiwan.; Hsieh, CL (corresponding author), China Med Univ, Grad Inst Acupuncture Sci, Coll Chinese Med, Taichung 40402, Taiwan.; Hsieh, CL (corresponding author), China Med Univ, Chinese Med Res Ctr, Taichung 40402, Taiwan.
EM u103030067@cmu.edu.tw; clhsieh@mail.cmuh.org.tw
FU Chinese Medicine Research Center of China Medical University; Featured Areas Research Center Program within the framework of the Taiwan Ministry of Education Higher Education Sprout Project [CMRC-CENTER-0]
CR Ahn YJ, 2016, J ETHNOPHARMACOL, V194, P774, DOI 10.1016/j.jep.2016.11.012
   AL-Atiyyat N, 2017, INT J PALLIAT NURS, V23, P13, DOI 10.12968/ijpn.2017.23.1.13
   Alvarez-Fischer D, 2013, PLOS ONE, V8, P0, DOI 10.1371/journal.pone.0061700
   An HJ, 2014, INT J MOL MED, V34, P1341, DOI 10.3892/ijmm.2014.1933
   Awada K, 2017, BIOMED PHARMACOTHER, V91, P295, DOI 10.1016/j.biopha.2017.04.065
   Baek H, 2020, TOXINS, V12, P0, DOI 10.3390/toxins12030198
   Baek H, 2018, SCI REP-UK, V8, P0, DOI 10.1038/s41598-018-35030-1
   Baek YH, 2006, BRAIN RES, V1073, P305, DOI 10.1016/j.brainres.2005.12.086
   Branas P, 2000, HEALTH TECHNOL ASSESS, V4, P1
   Cai M, 2015, TOXINS, V7, P846, DOI 10.3390/toxins7030846
   Cao HJ, 2015, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD009436.pub2
   Chen HS, 2010, BRAIN RES, V1355, P61, DOI 10.1016/j.brainres.2010.08.002
   Cherniack EP, 2018, TOXICON, V154, P74, DOI 10.1016/j.toxicon.2018.09.013
   Cho KH, 2018, EVID-BASED COMPL ALT, V2018, P0, DOI 10.1155/2018/3671542
   Cho SY, 2018, J ALTERN COMPLEM MED, V24, P25, DOI 10.1089/acm.2016.0250
   Cho SY, 2013, COMPLEMENT THER MED, V21, P155, DOI 10.1016/j.ctim.2013.02.001
   Cho SY, 2012, PARKINSONISM RELAT D, V18, P948, DOI 10.1016/j.parkreldis.2012.04.030
   Choi DC, 2010, NEUROBIOL DIS, V39, P272, DOI 10.1016/j.nbd.2010.04.003
   Choi HS, 2019, EVID-BASED COMPL ALT, V2019, P0, DOI 10.1155/2019/2345640
   Choi J, 2017, TOXINS, V9, P0, DOI 10.3390/toxins9110351
   Choi KE, 2014, TOXINS, V6, P2210, DOI 10.3390/toxins6082210
   Chung KS, 2015, EXP BIOL MED, V240, P1656, DOI 10.1177/1535370215590823
   Chung SJ, 2014, J MOV DISORD, V7, P84, DOI 10.14802/jmd.14012
   Conrad VJ, 2019, J ALTERN COMPLEM MED, V25, P845, DOI 10.1089/acm.2019.0121
   Darwish SF, 2013, PLOS ONE, V8, P0, DOI 10.1371/journal.pone.0079284
   de Souza RN, 2017, J ACUPUNCT MERIDIAN, V10, P204, DOI 10.1016/j.jams.2017.04.003
   Doo AR, 2012, BRAIN RES, V1429, P106, DOI 10.1016/j.brainres.2011.10.003
   Doo AR, 2010, NEUROL RES, V32, PS88, DOI 10.1179/016164109X12537002794282
   Doo KH, 2015, J ALTERN COMPLEM MED, V21, P598, DOI 10.1089/acm.2015.0078
   Huh JE, 2010, CANCER LETT, V292, P98, DOI 10.1016/j.canlet.2009.11.013
   Jeong YJ, 2012, FOOD CHEM TOXICOL, V50, P3996, DOI 10.1016/j.fct.2012.08.026
   Jung GB, 2018, BIOMED OPT EXPRESS, V9, P5703, DOI 10.1364/BOE.9.005703
   Kang H, 2014, J PHARMACOPUNCT, V17, P73
   Kang H, 2014, J PHARMACOPUNCT, V17, P18, DOI 10.3831/KPI.2014.17.012
   Kang SS, 2002, AM J CHINESE MED, V30, P73, DOI 10.1142/S0192415X02000089
   Kang SY, 2015, TOXINS, V7, P2571, DOI 10.3390/toxins7072571
   Kang SY, 2013, EVID-BASED COMPL ALT, V2013, P0, DOI 10.1155/2013/809062
   Kang SY, 2012, EVID-BASED COMPL ALT, V2012, P0, DOI 10.1155/2012/784713
   Kang SY, 2012, J PAIN, V13, P155, DOI 10.1016/j.jpain.2011.10.012
   Kang SY, 2011, BRAIN RES BULL, V86, P412, DOI 10.1016/j.brainresbull.2011.08.012
   Khalil WKB, 2015, NEUROCHEM INT, V80, P79, DOI 10.1016/j.neuint.2014.11.008
   Kim H, 2019, TOXINS, V11, P0, DOI 10.3390/toxins11070374
   Kim H, 2014, PLOS ONE, V9, P0, DOI 10.1371/journal.pone.0114726
   Kim JI, 2011, INT J NEUROSCI, V121, P209, DOI 10.3109/00207454.2010.548613
   Kim JD, 2010, J ACUPUNCT MERIDIAN, V3, P141, DOI 10.1016/S2005-2901(10)60029-5
   Kim KW, 2011, BRAIN RES BULL, V84, P61, DOI 10.1016/j.brainresbull.2010.10.002
   Kim KS, 2005, J ETHNOPHARMACOL, V99, P245, DOI 10.1016/j.jep.2005.02.025
   Kim MR, 2016, MEDICINE, V95, P0, DOI 10.1097/MD.0000000000003635
   Kim M, 2020, COMPLEMENT THER CLIN, V40, P0, DOI 10.1016/j.ctcp.2020.101179
   Kim SH, 2014, J PHARMACOPUNCT, V17, P7, DOI 10.3831/KPI.2014.17.031
   Kim W, 2016, TOXINS, V8, P0, DOI 10.3390/toxins8020033
   Kwon YB, 2004, MOL CELLS, V17, P329
   Kwon YB, 2002, LIFE SCI, V71, P191, DOI 10.1016/S0024-3205(02)01617-X
   Kwon YB, 2001, AM J CHINESE MED, V29, P187, DOI 10.1142/S0192415X01000228
   Kwon YB, 2001, NEUROSCI LETT, V308, P133, DOI 10.1016/S0304-3940(01)01989-9
   Kwon YB, 2001, PAIN, V90, P271, DOI 10.1016/S0304-3959(00)00412-7
   Lee G, 2016, MOLECULES, V21, P0, DOI 10.3390/molecules21050616
   Lee G, 2016, TOXINS, V8, P0, DOI 10.3390/toxins8020048
   Lee JD, 2004, AM J CHINESE MED, V32, P361, DOI 10.1142/S0192415X04002016
   Lee JH, 2014, BMC COMPLEM ALTERN M, V14, P0, DOI 10.1186/1472-6882-14-471
   Lee J, 2017, PLOS ONE, V12, P0, DOI 10.1371/journal.pone.0170972
   Lee JA, 2014, BMJ OPEN, V4, P0, DOI 10.1136/bmjopen-2014-006140
   Lee KH, 2016, J PHARMACOPUNCT, V19, P101, DOI 10.3831/KPI.2016.19.010
   Lee KH, 2015, J PHARMACOPUNCT, V18, P49, DOI 10.3831/KPI.2015.18.024
   Lee MJ, 2016, MOL NEUROBIOL, V53, P1977, DOI 10.1007/s12035-015-9131-4
   Lee MS, 2008, J PAIN, V9, P289, DOI 10.1016/j.jpain.2007.11.012
   Lee SH, 2012, J PHARMACOPUNCT, V15, P7, DOI 10.3831/KPI.2012.15.011
   Lee SM, 2003, J NEUROTRAUM, V20, P1017, DOI 10.1089/089771503770195867
   Lee WR, 2015, TOXINS, V7, P4758, DOI 10.3390/toxins7114758
   Lee WR, 2014, J INVEST DERMATOL, V134, P1922, DOI 10.1038/jid.2014.75
   Lee Y, 2018, EVID-BASED COMPL ALT, V2018, P0, DOI 10.1155/2018/2353280
   Li JH, 2010, AM J CHINESE MED, V38, P1039, DOI 10.1142/S0192415X10008457
   Lim BS, 2013, EVID-BASED COMPL ALT, V2013, P0, DOI 10.1155/2013/369324
   Lim C, 2014, J PHARMACOPUNCT, V17, P15, DOI 10.3831/KPI.2014.17.032
   Lim SM, 2015, J INTEGR MED-JIM, V13, P241, DOI 10.1016/S2095-4964(15)60178-9
   Liu CC, 2016, CANCER CHEMOTH PHARM, V78, P1113, DOI 10.1007/s00280-016-3160-1
   Moon DO, 2006, INT IMMUNOPHARMACOL, V6, P1796, DOI 10.1016/j.intimp.2006.07.027
   Nakamura M, 2003, EXP NEUROL, V184, P313, DOI 10.1016/S0014-4886(03)00361-3
   Park JE, 2019, EUR J INTEGR MED, V27, P121, DOI 10.1016/j.eujim.2019.03.001
   Roh DH, 2006, J PAIN, V7, P500, DOI 10.1016/j.jpain.2006.02.002
   Roh DH, 2004, J PAIN, V5, P297, DOI 10.1016/j.jpain.2004.05.003
   Seo BK, 2017, TOXINS, V9, P0, DOI 10.3390/toxins9110361
   Seo BK, 2014, TRIALS, V15, P0, DOI 10.1186/1745-6215-15-132
   Seo BK, 2013, TRIALS, V14, P0, DOI 10.1186/1745-6215-14-16
   SHARMA SV, 1993, ONCOGENE, V8, P939
   Shen L, 2020, J PHARMACOPUNCT, V23, P44, DOI 10.3831/KPI.2020.23.008
   Shin JS, 2016, J ALTERN COMPLEM MED, V22, P533, DOI 10.1089/acm.2014.0368
   Son DJ, 2007, PHARMACOL THERAPEUT, V115, P246, DOI 10.1016/j.pharmthera.2007.04.004
   Spence A, 2015, CURR OPIN IMMUNOL, V37, P11, DOI 10.1016/j.coi.2015.09.002
   Suh SJ, 2006, TOXICOL IN VITRO, V20, P1465, DOI 10.1016/j.tiv.2006.06.016
   Sur B, 2016, BMC COMPLEM ALTERN M, V16, P0, DOI 10.1186/s12906-016-1019-y
   Tsai LC, 2015, BIOMED RES INT, V2015, P0, DOI 10.1155/2015/363801
   Tu WC, 2008, TOXICON, V52, P318, DOI 10.1016/j.toxicon.2008.06.007
   Wehbe R, 2019, MOLECULES, V24, P0, DOI 10.3390/molecules24162997
   Yamasaki SC, 2015, TOXICON, V98, P75, DOI 10.1016/j.toxicon.2015.02.016
   Yang CY, 2010, ANN NUCL MED, V24, P455, DOI 10.1007/s12149-010-0380-z
   Yang EJ, 2011, J NEUROINFLAMM, V8, P0, DOI 10.1186/1742-2094-8-69
   Ye M, 2016, EXP MOL MED, V48, P0, DOI 10.1038/emm.2016.49
   Ye M, 2016, J NEUROINFLAMM, V13, P0, DOI 10.1186/s12974-016-0476-z
   Yeo JH, 2016, J PAIN, V17, P298, DOI 10.1016/j.jpain.2015.10.018
   Yoon H, 2015, BIOL PHARM BULL, V38, P710, DOI 10.1248/bpb.b14-00797
   Yoon J, 2012, J ACUPUNCT MERIDIAN, V5, P156, DOI 10.1016/j.jams.2012.05.003
   Yoon SY, 2018, J PAIN, V19, P1157, DOI 10.1016/j.jpain.2018.04.015
   Yoon SY, 2013, BIOL PHARM BULL, V36, P1787, DOI 10.1248/bpb.b13-00469
   Yoon SY, 2009, J PAIN, V10, P253, DOI 10.1016/j.jpain.2008.09.002
   Yun SP, 2010, J ALTERN COMPLEM MED, V16, P223, DOI 10.1089/acm.2009.7094-O
   Yune TY, 2007, J NEUROSCI, V27, P7751, DOI 10.1523/JNEUROSCI.1661-07.2007
   Zhang S, 2018, TOXICON, V148, P64, DOI 10.1016/j.toxicon.2018.04.012
NR 108
TC 35
Z9 39
U1 4
U2 28
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
SN 
EI 2072-6651
J9 TOXINS
JI Toxins
PD OCT 15
PY 2020
VL 12
IS 10
BP 
EP 
DI 10.3390/toxins12100618
PG 25
WC Food Science & Technology; Toxicology
SC Food Science & Technology; Toxicology
GA OM8ZN
UT WOS:000586305400001
PM 32992601
DA 2026-01-16
ER

PT J
AU Du, SS
   Yang, T
   Qiang, S
   Lin, Z
AF Shanshan, Du
   Yang, Tingting
   Qiang, Sun
   Lin, Zhang
TI RETRACTED: Molecular mechanism of electroacupuncture treatment on oxaliplatin-induced peripheral neurotoxicity in rats (Retracted article. See vol. 21, 2023)
SO EUROPEAN JOURNAL OF INFLAMMATION
LA English
DT Article; Retracted Publication
DE electroacupuncture; molecular mechanism; oxaliplatin; peripheral neurotoxicity
ID metastatic colorectal-cancer; expression; neuropathy; cold; proteins; pain
AB Oxaliplatin (L-OHP) has been widely used in the treatment of various tumors, especially in colorectal cancer. The mechanism of peripheral neurotoxicity induced by L-OHP (OIPN) is unclear and current therapeutic options only serve to alleviate the symptoms rather than prevent OIPN. To observe the effects of electroacupuncture (EA) stimulation on OIPN in rats, rats were randomly divided into the control group, OIPN model group, and OIPN + EA group. To establish OIPN rat models, a single intraperitoneal injection with 10 mg/kg L-OHP in the OIPN model rats. Rats in the control group received a single intraperitoneal injection with 0.9% lactose. From the third day after establishing OIPN models, the rats were treated with EA. Cold allodynia and heat sensitivity were assessed using the acetone drop and the Hargreaves method, respectively. Pathological changes in nerves were detected using hematoxylin and eosin (H&E) staining and transmission electron microscopy. Related mRNA and protein expression levels were measured by real-time polymerase chain reaction (PCR) and western blotting from 14 days after establishing OIPN models. Our results showed that L-OHP significantly increased the sensitivity to cold allodynia and nervous injury, which were ameliorated after EA treatment. The expression of glucocorticoid receptor alpha (GR-alpha) and B-cell lymphoma 2 (Bcl-2) was significantly decreased and that of Bax was significantly increased in sciatic nerve of OIPN model rats compared with control rats. However, EA treatment significantly inhibited L-OHP-induced protein expressions in rats. Moreover, compared with the control rats, the nucleus NF-kappa Bp65 levels were significantly increased, while the cytoplasm NF-kappa Bp65 levels were significantly decreased, which were reversed by EA treatment. In conclusion, EA treatment may reduce peripheral neurotoxicity induced by L-OHP through regulating related protein expression.
C1 [Shanshan, Du; Yang, Tingting; Lin, Zhang] Community Hlth Serv Ctr Minhang Dist, Dept Acupuncture & Traumatol, Shanghai, Peoples R China.
   [Qiang, Sun] Changzheng Hosp, Dept Gen Surg, Shanghai, Peoples R China.
C3 Naval Medical University
RP Lin, Z (corresponding author), Gumei Community Hlth Serv Ctr Minhang Dist, Dept Acupuncture & Traumatol, Shanghai 201102, Peoples R China.
EM skhmiv7529651@163.com
CR Areti A, 2014, REDOX BIOL, V2, P289, DOI 10.1016/j.redox.2014.01.006
   de Sena LSB, 2018, J ORAL PATHOL MED, V47, P788, DOI 10.1111/jop.12757
   Cavaletti G, 2002, ANTICANCER RES, V22, P4199
   Choi JW, 2015, AM J CHINESE MED, V43, P57, DOI 10.1142/S0192415X15500044
   Flatters SJL, 2004, PAIN, V109, P150, DOI 10.1016/j.pain.2004.01.029
   Hecht JR, 2015, CANCER MANAG RES, V7, P165, DOI 10.2147/CMAR.S61408
   Ihara K, 2016, ONCOL REP, V35, P1349, DOI 10.3892/or.2015.4488
   Jin Ze, 2011, ZHONGGUO ZHEN JIU, V31, P613
   Kelly H, 2005, J CLIN ONCOL, V23, P4553, DOI 10.1200/JCO.2005.17.749
   Kim JH, 2013, TRIALS, V14, P0, DOI 10.1186/1745-6215-14-254
   Kolb NA, 2016, JAMA NEUROL, V73, P860, DOI 10.1001/jamaneurol.2016.0383
   Li Q, 2014, EVID-BASED COMPL ALT, V2014, P0, DOI 10.1155/2014/158987
   Li QW, 2007, J ACUPUNCT TUINA SCI, V5, P10
   Manni L, 2011, DIABETOLOGIA, V54, P1900, DOI 10.1007/s00125-011-2117-5
   McKeage MJ, 2001, BRIT J CANCER, V85, P1219, DOI 10.1054/bjoc.2001.2024
   Moon HJ, 2014, J PHYSIOL SCI, V64, P151, DOI 10.1007/s12576-013-0297-0
   Ogawa K, 2013, EVID-BASED COMPL ALT, V2013, P0, DOI 10.1155/2013/928129
   Park JH, 2010, BRAIN RES, V1322, P24, DOI 10.1016/j.brainres.2010.02.001
   Park SB, 2011, PLOS ONE, V6, P0, DOI 10.1371/journal.pone.0018469
   Pereira V, 2014, PAIN, V155, P2534, DOI 10.1016/j.pain.2014.09.013
   Prenek L, 2017, APOPTOSIS, V22, P239, DOI 10.1007/s10495-016-1320-8
   Schulze C, 2011, CLIN COLORECTAL CANC, V10, P126, DOI 10.1016/j.clcc.2011.03.010
   Shao JP, 2018, LIFE SCI, V208, P268, DOI 10.1016/j.lfs.2018.07.026
   Sun XJ, 2018, LIFE SCI, V195, P33, DOI 10.1016/j.lfs.2018.01.006
   Tsutsumi K, 2014, NEUROSCI RES, V80, P86, DOI 10.1016/j.neures.2014.02.004
   Ursic K, 2018, BIOELECTROCHEMISTRY, V119, P161, DOI 10.1016/j.bioelechem.2017.09.009
   Waseem M, 2017, PLOS ONE, V12, P0, DOI 10.1371/journal.pone.0180953
   Xiao WH, 2012, NEUROSCIENCE, V203, P194, DOI 10.1016/j.neuroscience.2011.12.023
   Yerra VG, 2013, REDOX BIOL, V1, P394, DOI 10.1016/j.redox.2013.07.005
   Zhao W, 2008, NEUROCHEM RES, V33, P2214, DOI 10.1007/s11064-008-9677-x
   Zheng HE, 2011, EXP NEUROL, V232, P154, DOI 10.1016/j.expneurol.2011.08.016
NR 31
TC 1
Z9 1
U1 0
U2 11
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 1721-727X
EI 2058-7392
J9 EUR J INFLAMM
JI Eur. J. Inflamm.
PD OCT 15
PY 2020
VL 18
IS 
BP 
EP 
DI 10.1177/2058739220929149
PG 10
WC Immunology
SC Immunology
GA OG9PY
UT WOS:000582207900001
DA 2026-01-16
ER

PT J
AU de Matos, NMP
   Pach, D
   Xing, JJ
   Barth, J
   Beyer, LE
   Shi, XM
   Kern, A
   Lukic, N
   Ettlin, DA
   Brügger, M
   Witt, CM
AF de Matos, Nuno M. P.
   Pach, Daniel
   Xing, Jing Jing
   Barth, Jurgen
   Beyer, Lara Elena
   Shi, Xuemin
   Kern, Alexandra
   Lukic, Nenad
   Ettlin, Dominik A.
   Brugger, Mike
   Witt, Claudia M.
TI Evaluating the Effects of Acupuncture Using a Dental Pain Model in Healthy Subjects - A Randomized, Cross-Over Trial
SO JOURNAL OF PAIN
LA English
DT Article
DE Acupuncture; pain; toothache; nociception; Medicine; Chinese traditional
ID tension-type headache; postoperative pain; placebo analgesia; anxiety; predictors; optimism; osteoarthritis; associations; experience; outcm
AB Acupuncture is a complementary and nonpharmacological intervention that can be effective for the management of chronic pain in addition to or instead of medication. Various animal models for neuropathic pain, inflammatory pain, cancer-related pain, and visceral pain already exist in acupuncture research. We used a newly validated human pain model and examined whether acupuncture can influence experimentally induced dental pain. For this study, we compared the impact of manual acupuncture (real acupuncture), manual stimulation of a needle inserted at nonacupuncture points (sham acupuncture) and no acupuncture on experimentally induced dental pain in 35 healthy men who were randomized to different sequences of all 3 interventions in a within-subject design. BORG CR10 pain ratings and autonomic responses (electrodermal activity and heart rate variability) were investigated. An initial mixed model with repeated measures included preintervention pain ratings and the trial sequence as covariates. The results showed that acupuncture was effective in reducing pain intensity when compared to no acupuncture (beta = -.708, P = .002), corresponding to a medium Cohen's d effect size of .56. The comparison to the sham acupuncture revealed no statistically significant difference. No differences in autonomic responses between real and sham acupuncture were found during the intervention procedures. Perspective: This study established a dental pain model for acupuncture research and provided evidence that experimentally induced dental pain can be influenced by either real acupuncture or manual stimulation of needles at nonacupuncture points. The data do not support that acupoint specificity is a significant factor in reducing experimental pain. (C) 2020 THE AUTHORS. Published by Elsevier Inc. on behalf of the U.S Association forthe Study of Pain.
C1 [de Matos, Nuno M. P.; Pach, Daniel; Barth, Jurgen; Beyer, Lara Elena; Shi, Xuemin; Kern, Alexandra; Witt, Claudia M.] Univ Zurich, Inst Complementary & Integrat Med, Zurich, Switzerland.
   [de Matos, Nuno M. P.; Pach, Daniel; Barth, Jurgen; Beyer, Lara Elena; Shi, Xuemin; Kern, Alexandra; Witt, Claudia M.] Univ Hosp Zurich, Zurich, Switzerland.
   [de Matos, Nuno M. P.; Lukic, Nenad; Ettlin, Dominik A.; Brugger, Mike] Univ Zurich, Ctr Dent Med, Clin Craniomaxillofacial & Oral Surg, Zurich, Switzerland.
   [Brugger, Mike] Swiss Fed Inst Technol, Inst Biomed Engn, Zurich, Switzerland.
   [Brugger, Mike] Univ Zurich, Zurich, Switzerland.
   [Pach, Daniel; Witt, Claudia M.] Charite Univ Med Berlin, Berlin, Germany.
   [Pach, Daniel; Witt, Claudia M.] Humboldt Univ, Freie Univ Berlin, Berlin, Germany.
   [Pach, Daniel; Witt, Claudia M.] Berlin Inst Hlth, Inst Social Med Epidemiol & Hlth Econ, Berlin, Germany.
   [Xing, Jing Jing] Tianjin Univ Tradit Chinese Med, Teaching Hosp 1, Tianjin, Peoples R China.
   [Witt, Claudia M.] Univ Maryland, Sch Med Baltimore, Ctr Integrat Med, Baltimore, MD USA.
C3 University of Zurich; University of Zurich; University Zurich Hospital; University of Zurich; Swiss Federal Institutes of Technology Domain; ETH Zurich; University of Zurich; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Humboldt University of Berlin; Free University of Berlin; Humboldt University of Berlin; Free University of Berlin; Charite Universitatsmedizin Berlin; Berlin Institute of Health; Tianjin University of Traditional Chinese Medicine; University System of Maryland; University of Maryland Baltimore
RP Pach, D (corresponding author), Univ Zurich, Inst Complementary & Integrat Med, Zurich, Switzerland.; Pach, D (corresponding author), Univ Hosp Zurich, Zurich, Switzerland.
EM daniel.pach@uzh.ch
CR ALABSI M, 1991, PAIN, V46, P43, DOI 10.1016/0304-3959(91)90032-S
   Unknown -, 2011, J ACUPUNCT TUINA SCI, V0, P0
   Appelhans BM, 2008, BIOL PSYCHOL, V77, P174, DOI 10.1016/j.biopsycho.2007.10.004
   Barlas P, 2000, CLIN J PAIN, V16, P255, DOI 10.1097/00002508-200009000-00012
   Barth J, 2019, BMJ OPEN, V9, P0, DOI 10.1136/bmjopen-2018-026712
   Beissner F, 2012, NEUROIMAGE, V60, P653, DOI 10.1016/j.neuroimage.2011.12.045
   [卞金玲 Bian Jinling], 2003, 中国针灸 CHINESE ACUPUNCTURE AND MOXIBUSTION, V23, P287
   Birch S, 2017, J ALTERN COMPLEM MED, V23, P242, DOI 10.1089/acm.2016.0385
   Borg G, 1998, BORGS PERCEIVED EXERTION AND PAIN SCALES: HUMAN KINETICS, V0, P0, DOI DOI 10.1097/00005768-199809000-00018
   Bourdillon N, 2017, FRONT NEUROSCI-SWITZ, V11, P0, DOI 10.3389/fnins.2017.00456
   Brinkhaus B, 2006, ARCH INTERN MED, V166, P450
   Brügger M, 2012, J DENT RES, V91, P156, DOI 10.1177/0022034511431253
   Brügger M, 2011, FRONT HUM NEUROSCI, V5, P0, DOI 10.3389/fnhum.2011.00012
   BYERS MR, 1984, INT REV NEUROBIOL, V25, P39, DOI 10.1016/S0074-7742(08)60677-7
   Cacioppo JT, 2007, HANDBOOK OF PSYCHOPHYSIOLOGY, V0, P1, DOI 10.2277/ 0521844711
   Camm AJ, 1996, CIRCULATION, V93, P1043
   Chae Y, 2013, J PAIN, V14, P215, DOI 10.1016/j.jpain.2012.11.011
   Charron J, 2006, CLIN J PAIN, V22, P204, DOI 10.1097/01.ajp.0000161526.25374.e5
   Clarke Tainya C, 2015, NATL HEALTH STAT REPORT, V0, P1
   CORNWALL A, 1988, PAIN, V35, P105, DOI 10.1016/0304-3959(88)90282-5
   de Matos NMP, 2017, NEUROIMAGE, V162, P162, DOI 10.1016/j.neuroimage.2017.08.078
   De Pascalis V, 2002, PAIN, V96, P393, DOI 10.1016/S0304-3959(01)00485-7
   Dhond RP, 2007, J ALTERN COMPLEM MED, V13, P603, DOI 10.1089/acm.2007.7040
   Duschek S, 2007, INT J PSYCHOPHYSIOL, V65, P193, DOI 10.1016/j.ijpsycho.2007.03.012
   Ernst E, 1998, BRIT DENT J, V184, P443, DOI 10.1038/sj.bdj.4809654
   Ettlin DA, 2016, J NEUROPHYSIOL, V115, P1730, DOI 10.1152/jn.00917.2015
   Faul F, 2007, BEHAV RES METHODS, V39, P175, DOI 10.3758/BF03193146
   Fujita T, 2017, SCI REP-UK, V7, P0, DOI 10.1038/s41598-017-03542-x
   Goldman N, 2010, NAT NEUROSCI, V13, P883, DOI 10.1038/nn.2562
   Goodin BR, 2013, J PAIN, V14, P126, DOI 10.1016/j.jpain.2012.10.007
   Gutzeit A, 2013, EUR RADIOL, V23, P450, DOI 10.1007/s00330-012-2621-0
   Herman PM, 2012, BMJ OPEN, V2, P0, DOI 10.1136/bmjopen-2012-001046
   Huang WJ, 2012, PLOS ONE, V7, P0, DOI 10.1371/journal.pone.0032960
   Ip HYV, 2009, ANESTHESIOLOGY, V111, P657, DOI 10.1097/ALN.0b013e3181aae87a
   Jonas W, 2017, INTEGRATIVE APPROACH, V0, P0
   Kaptchuk TJ, 2002, ANN INTERN MED, V136, P374, DOI 10.7326/0003-4819-136-5-200203050-00010
   Karst M, 2000, PAIN, V88, P199, DOI 10.1016/S0304-3959(00)00315-8
   Kong J, 2005, J PAIN, V6, P55, DOI 10.1016/j.jpain.2004.10.005
   Kong J, 2007, J ALTERN COMPLEM MED, V13, P1059, DOI 10.1089/acm.2007.0524
   Langevin HM, 2018, J ALTERN COMPLEM MED, V24, P200, DOI 10.1089/acm.2017.0366
   Langevin HM, 2015, J ALTERN COMPLEM MED, V21, P113, DOI 10.1089/acm.2014.0186
   Langevin HM, 2011, EVID-BASED COMPL ALT, V2011, P0, DOI 10.1155/2011/180805
   Langevin HM, 2006, J CELL PHYSIOL, V207, P767, DOI 10.1002/jcp.20623
   Laux L, 1981, STATE TRAIT ANXIETY, V0, P0
   Leung A, 2014, MOL PAIN, V10, P0, DOI 10.1186/1744-8069-10-23
   Linde K, 2005, JAMA-J AM MED ASSOC, V293, P2118, DOI 10.1001/jama.293.17.2118
   Linde K, 2007, PAIN, V128, P264, DOI 10.1016/j.pain.2006.12.006
   Lumb BA, 2004, NEWS PHYSIOL SCI, V19, P22, DOI 10.1152/nips.01467.2003
   MacPherson H, 2001, BMJ-BRIT MED J, V323, P486, DOI 10.1136/bmj.323.7311.486
   Madsen C, 2018, MED ACUPUNCT, V30, P33, DOI 10.1089/acu.2017.1260
   Meier ML, 2015, J DENT RES, V94, P690, DOI 10.1177/0022034515572022
   Meier ML, 2014, FRONT HUM NEUROSCI, V8, P0, DOI 10.3389/fnhum.2014.00526
   Melchart D, 2005, BMJ-BRIT MED J, V331, P376, DOI 10.1136/bmj.38512.405440.8F
   Micalos PS, 2011, J ALTERN COMPLEM MED, V17, P57, DOI 10.1089/acm.2010.0040
   More Ari O, 2013, J CAFFEINE RES, V3, P143, DOI 10.1089/jcr.2013.0014
   Musial F, 2012, ACUPUNCT MED, V30, P21, DOI 10.1136/acupmed-2011-010094
   Nahman-Averbuch H, 2014, EUR J PAIN, V18, P47, DOI 10.1002/j.1532-2149.2013.00349.x
   Napadow V, 2008, J ALTERN COMPLEM MED, V14, P861, DOI 10.1089/acm.2008.SAR-3
   Nierhaus T, 2016, FRONT HUM NEUROSCI, V10, P0, DOI 10.3389/fnhum.2016.00404
   Nierhaus T, 2015, FRONT HUM NEUROSCI, V9, P0, DOI 10.3389/fnhum.2015.00074
   Pan PH, 2006, ANESTHESIOLOGY, V104, P417, DOI 10.1097/00000542-200603000-00007
   Price DD, 1999, PAIN, V83, P147, DOI 10.1016/S0304-3959(99)00081-0
   Rhudy JL, 2000, PAIN, V84, P65, DOI 10.1016/S0304-3959(99)00183-9
   Sawynok J, 2016, NEUROSCIENCE, V338, P1, DOI 10.1016/j.neuroscience.2015.10.031
   SCHEIER MF, 1985, HEALTH PSYCHOL, V4, P219, DOI 10.1037/0278-6133.4.3.219
   SCHEIER MF, 1994, J PERS SOC PSYCHOL, V67, P1063, DOI 10.1037/0022-3514.67.6.1063
   Sedan O, 2005, PAIN, V113, P354, DOI 10.1016/j.pain.2004.11.012
   SESSLE BJ, 1987, DENT CLIN N AM, V31, P595
   Shi X, 2013, SHI XM COMPREHENSIVE, V0, P0
   Sommer M, 2010, CLIN J PAIN, V26, P87, DOI 10.1097/AJP.0b013e3181b43d68
   Takano T, 2012, J PAIN, V13, P1215, DOI 10.1016/j.jpain.2012.09.012
   Tang Y, 2016, NEUROSCIENTIST, V22, P563, DOI 10.1177/1073858416654453
   Theysohn N, 2014, J ALTERN COMPLEM MED, V20, P893, DOI 10.1089/acm.2014.0105
   Vaughn Felicia, 2007, AORN J, V85, P589, DOI 10.1016/S0001-2092(07)60130-6
   Vickers AJ, 2018, J PAIN, V19, P455, DOI 10.1016/j.jpain.2017.11.005
   Vickers AJ, 2012, ARCH INTERN MED, V172, P1444, DOI 10.1001/archinternmed.2012.3654
   Wiesenfeld-Hallin Zsuzsanna, 2005, GEND MED, V2, P137, DOI 10.1016/S1550-8579(05)80042-7
   Witt C, 2005, LANCET, V366, P136, DOI 10.1016/S0140-6736(05)66871-7
   Witt CM, 2009, FORSCH KOMPLEMENTMED, V16, P91, DOI 10.1159/000209315
   Yin C, 2017, CURR OPIN ANESTHESIO, V30, P583, DOI 10.1097/ACO.0000000000000501
   Zhu SP, 2013, EVID-BASED COMPL ALT, V2013, P0, DOI 10.1155/2013/518784
   Zunhammer M, 2013, PAIN MED, V14, P843, DOI 10.1111/pme.12085
NR 82
TC 10
Z9 13
U1 1
U2 26
PU CHURCHILL LIVINGSTONE
PI EDINBURGH
PA JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE, LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND
SN 1526-5900
EI 1528-8447
J9 J PAIN
JI J. Pain
PD MAR-APR 15
PY 2020
VL 21
IS 3-4
BP 440
EP 454
DI 10.1016/j.jpain.2019.08.013
PG 15
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA MX7IM
UT WOS:000557894300017
PM 31521794
DA 2026-01-16
ER

PT J
AU Zeng, J
   Zhou, R
   Luo, Z
   Zhang, N
   Liu, Z
   Lin, G
AF Zeng, Jingchun
   Zhou, Runjin
   Luo, Zhenke
   Zhang, Na
   Liu, Zijun
   Lin, Guohua
TI Clinical evidence of acupuncture and related therapy in patients with
SO Medicine
LA English
DT Journal Article
AB BACKGROUND: Cancer pain (CP) is one of the common complications of cancer. During  the treatment, oral medication, radiotherapy and chemotherapy bring certain  adverse reactions to patients with CP; a safe way to treat this disease is  necessary. Acupuncture and related therapies for CP with few side effects have  been gradually accepted. But at present the evidence is insufficient, the related  research is not thorough enough. The purpose of this study was to investigate the  efficacy and safety of acupuncture and related therapies for CP. METHODS: The  Preferred Reporting Items for Systematic Review and Meta-Analysis Protocols  (PRISMA-P) guidelines were used to design this protocol. The final study will  also be conducted under the PRISMA guidelines for systematic reviews and  meta-analysis. An electronic search will be conducted in Medline, Embase, and the  Cochrane Central Register of Controlled Trials databases through January 2020.  The search will be conducted in English. Risk of bias will be assessed by the  Cochrane Collaboration tool and the collected evidence will be nar-ratively  synthesized. We will also perform a meta-analysis to pool estimates from studies  considered to be homogenous. Subgroup analyses will be based on intervention or  overall bias. The strength of evidence will be evaluated by the Grading of  Recommendations, Assessment, Development and Evaluation scale. RESULTS: This  systematic review will summarize high quality clinical evidence to assess and  appraise the effectiveness and safety of acupuncture and related therapies for CP  patients. CONCLUSION: The meta-analysis will assess evidence from randomized  controlled trials of acupuncture and related therapies and CP types. INPLASY  REGISTRATION NUMBER: INPLASY202040129.
C1 Department of Acupuncture, The First Affiliated Hospital, Guangzhou University of Chinese Medicine.
   Guangzhou University of Chinese Medicine, Guangzhou, People's Republic of China.
   Guangzhou University of Chinese Medicine, Guangzhou, People's Republic of China.
   Guangzhou University of Chinese Medicine, Guangzhou, People's Republic of China.
   Guangzhou University of Chinese Medicine, Guangzhou, People's Republic of China.
   Department of Acupuncture, The First Affiliated Hospital, Guangzhou University of Chinese Medicine.
NR 0
TC 0
SN 1536-596
EI 0025-797
J9 Medicine (Baltimore)
PD NOV 8
PY 2020
VL 99
IS 45
BP e23119
EP e23119
DI 10.1097/MD.0000000000023119
PG 1
WC Acupuncture Therapy; adverse effects; Cancer Pain; therapy; Humans; Research Design; Systematic Reviews as Topic; Treatment Outcome
UT PubMed:33157988
PM 33157988
DA 2020-11-08
ER

PT J
AU Saraswati, W
   Rosyiadi, MR
   Imandiri, A
AF Saraswati, Wita
   Rosyiadi, Mochammad Rizalul
   Imandiri, Ario
TI Electroacupuncture Versus Analgesics for Patients with Stage IIIB Cervical Cancer
SO Medical acupuncture
LA English
DT Journal Article
DE cancer pain; electroacupuncture; pain scale; paracetamol–codeine; quality of life; β-endorphin
AB Background: The prevalence of pain at advanced cervical cancer stages is  increasing. Existing World Health Organization recommendations for management  comprises a 3-step ladder of analgesic therapy but this still cannot address this  pain optimally. An alternative therapy used to reduce pain, acupuncture, is  almost without side-effects, is safe, and is easy to implement. This study  compared electroacupuncture (EA) versus paracetamol 500 mg +10-mg codeine therapy  for patients with stage-IIIB cervical cancer post cisplatin chemotherapy.  Materials and Methods: Participants were divided into 2 groups (treatment and  control groups). A quasiexperimental study was conducted using a nonequivalent  control group pretest-post-test design. Participants in the treatment group were  given EA for 30 minutes 10 times over 3 weeks, while participants in the control  group were given paracetamol 3 × 500 mg and codeine 3 × 10 mg orally every day  for 3 weeks. Statistical analysis used paired t-tests, a Wilcoxon test, an  independent t-test, or a Mann-Whitney-U test with P < 0.05. Results: Pretest and  post-test pain-scale levels were 5.39 ± 0.62 and 4.57 ± 0.88, respectively  (P < 0.001). Average endorphin-β levels at pretest and post-test were  571.80 ± 281.13 and 491.14 ± 272.14, respectively (P = 0.818). Median values of  quality of life at pretest and post-test were 681.75 (range: 503.80-915.20) and  635.25 (range: 538.20-781.20; P = 0.383), respectively. Conclusions: Pain-control  therapy using drugs or EA produces similar results. However, EA, subjectively,  produces improved pain-scale results better than pharmaceuticals.
C1 Department of Obstetrics and Gynecology, Faculty of Medicine, Universitas Airlangga Dr. Soetomo General Academic Hospital, Surabaya, Indonesia.
   Department of Obstetrics and Gynecology, Faculty of Medicine, Universitas Airlangga Dr. Soetomo General Academic Hospital, Surabaya, Indonesia.
   Department of Traditional Healer, Faculty of Vocations, Universitas Airlangga, Surabaya, Indonesia.
   The Traditional Poly Herbal Medicine, Universitas Airlangga Teaching Hospital,
NR 0
TC 0
SN 1933-659
EI 1933-658
J9 Med Acupunct
PD OCT 27
PY 2020
VL 32
IS 5
BP 293
EP 299
DI 10.1089/acu.2020.1425
PG 6
UT PubMed:33101574
PM 33101574
DA 2020-10-27
ER

PT J
AU Park, S
   Gu, JH
   Jang, HK
   Oh, MS
   Lee, EJ
   Jung, IC
AF Park, Sohyeon
   Gu, Ji-Hyang
   Jang, Hye-Kyoung
   Oh, Min-Seok
   Lee, Eun-Jung
   Jung, In Chul
TI Electroacupuncture for post-thoracotomy pain Protocol for a systematic review and meta-analysis
SO MEDICINE
LA English
DT Review
DE electroacupuncture; postoperative pain management thoracotomy
ID management
AB Background: Thoracotomy is a common surgical procedure used in cases such as trauma and cancer resection. It is an invasive procedure in which incisions are made in the chest wall to gain access to the chest. Therefore. it often produces intense postoperative pain. Electroacupuncture has been known for its analgesic effects in various conditions. including cases of postoperative pain. This protocol design is for a systematic review and meta-analysis to gather evidence and investigate the analgesic effects of electroacupuncture in pain after thoracotomy. Methods: The studies for the systematic review will be searched with keywords on the following 10 databases: PubMed. Cochrane Library (CENTRAL), EMBASE, MEDLINE, Google Scholar, CNKI, KoreaMed, KMBASE, KISS, and OASIS. The search will be done without language restrictions. Only the randomized controlled trials that meet the eligibility criteria will be finally included in the study. The quality of the study will be assessed using the Cochrane Collaborations" risk-of-bias tool, and Cochrane's software RevMan 5.3 will be used for meta-analysis. Results: The designed study will provide a systematic review and meta-analysis of the searched and randomized controlled trials that meet the eligibility criteria. Meta-analysis will be performed with pain scores as the main outcome measure, and they may also be performed with additional outcomes. The qualitative and quantitative data synthesis is expected to provide high quality evidence to judge the pain management effect of electroacupuncture for patients who underwent thoracotomy. Conclusion: The conclusion of this systematic review and meta-analysis will provide evidence to judge whether electroacupuncture is an effective analgesic treatment option for patients suffering with post-thoracotomy pain.
C1 [Park, Sohyeon] Daejeon Univ, Coll Korean Med, Daejeon, South Korea.
   [Gu, Ji-Hyang; Oh, Min-Seok; Lee, Eun-Jung] Daejeon Univ, Coll Korean Med, Dept Korean Rehabil Med, 62 Daehak Ro, Daejeon 34520, South Korea.
   [Jang, Hye-Kyoung] Daejeon Univ, Dunsan Korean Med Hosp, Clin Trial Ctr, Daejeon, South Korea.
   [Jung, In Chul] Daejeon Univ, Coll Korean Med, Dept Oriental Neuropsychiat, 62 Daehak Ro, Daejeon 34520, South Korea.
C3 Daejeon University; Daejeon University; Daejeon University; Daejeon University
RP Lee, EJ (corresponding author), Daejeon Univ, Coll Korean Med, Dept Korean Rehabil Med, 62 Daehak Ro, Daejeon 34520, South Korea.; Jung, IC (corresponding author), Daejeon Univ, Coll Korean Med, Dept Oriental Neuropsychiat, 62 Daehak Ro, Daejeon 34520, South Korea.
EM jungkahn@dju.kr; npjeong@dju.kr
FU Ministry of Health and Welfare, Republic of Korea [HI15C0006]
CR CHENG RSS, 1979, LIFE SCI, V25, P1957, DOI 10.1016/0024-3205(79)90598-8
   COOK TD, 1980, J PERS, V48, P449, DOI 10.1111/j.1467-6494.1980.tb02379.x
   DUTHIE DJR, 1987, BRIT J ANAESTH, V59, P61, DOI 10.1093/bja/59.1.61
   Gerner Peter, 2008, ANESTHESIOL CLIN, V26, P355, DOI 10.1016/j.anclin.2008.01.007
   Glare P, 2019, LANCET, V393, P1537, DOI 10.1016/S0140-6736(19)30352-6
   Maguire MF, 2006, EUR J CARDIO-THORAC, V29, P800, DOI 10.1016/j.ejcts.2006.02.002
   Meade MO, 1997, ANN INTERN MED, V127, P531, DOI 10.7326/0003-4819-127-7-199710010-00005
   NIDA, 2019, OV DEATH RAT, V0, P0
   Pussegoda K, 2017, SYST REV-LONDON, V6, P0, DOI 10.1186/s13643-017-0507-6
   Smith V, 2011, BMC MED RES METHODOL, V11, P0, DOI 10.1186/1471-2288-11-15
   Somogyi AA, 2007, CLIN PHARMACOL THER, V81, P429, DOI 10.1038/sj.clpt.6100095
   WILSON GT, 1983, J CONSULT CLIN PSYCH, V51, P54, DOI 10.1037/0022-006X.51.1.54
NR 12
TC 3
Z9 3
U1 0
U2 9
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0025-7974
EI 1536-5964
J9 MEDICINE
JI Medicine (Baltimore)
PD FEB 15
PY 2020
VL 99
IS 9
BP 
EP 
DI 10.1097/MD.0000000000019312
PG 4
WC Medicine, General & Internal
SC General & Internal Medicine
GA LD2LY
UT WOS:000525865600058
PM 32118757
DA 2026-01-16
ER

PT J
AU Zhao, Q
   Zheng, S
   Delaney, GP
   Moylan, E
   Agar, MR
   Koh, ES
   Lai, H
   Birling, Y
   Zhang, GS
   Wang, K
   Ma, Y
   Zhu, X
AF Zhao, Qi
   Zheng, Suyang
   Delaney, Geoff P
   Moylan, Eugene
   Agar, Meera R
   Koh, Eng-Siew
   Lai, Hezheng
   Birling, Yoann
   Zhang, George Shengxi
   Wang, Kang
   Ma, Yong
   Zhu, Xiaoshu
TI Acupuncture for Cancer Related Pain: Protocol for a Pragmatic Randomised
SO Integrative cancer therapies
LA English
DT Journal Article
DE acupuncture; cancer related pain; clinical trial; complementary and alternative medicine; pragmatic
AB BACKGROUND: Acupuncture has been proved effective for cancer related pain (CRP)  in China, America and some other countries. However, there is relative lack of  evidence to support the use of acupuncture for CRP in Australia. OBJECTIVES: To  assess the effectiveness and safety of acupuncture for management of CRP in a  real-world setting and to understand cancer patients' experience of undergoing  acupuncture for CRP. METHODS: A pragmatic randomised controlled trial will be  conducted in South Western Sydney Local Health District (SWSLHD) in NSW,  Australia. Adults with cancer related pain (n = 106) will be randomised in a 1:1  ratio to receive the acupuncture intervention up front versus after a wait list  period of 4 weeks. Pain level (by Numerical Rating Scale), analgesic use,  auricular acupressure frequency and adverse events will be assessed at baseline,  mid-treatment and post-treatment. Expectancy on trial outcome (by Credibility and  Expectancy questionnaire) will be assessed at baseline. The perspective of the  participants (by an interview) will be recorded after the last intervention.  EXPECTED OUTCOMES: We hypothesise that acupuncture will relieve cancer related  pain at mid-treatment and post-treatment. We also hypothesise that few adverse  events will be provoked by acupuncture. TRIAL REGISTRATION: Australia New-Zealand  Clinical Trial Registry (ACTRN12620000325909).
C1 Dongzhimen Hospital Affiliated to Beijing University of Chinese Medicine, Beijing, China.
   Chinese Medicine Centre, Western Sydney University, NSW, Australia.
   Chinese Medicine Centre, Western Sydney University, NSW, Australia.
   Nanjing University of Chinese Medicine, Nanjing, China.
   University of NSW, Australia.
   South Western Sydney Local Health District, NSW, Australia.
   South Western Sydney Local Health District, NSW, Australia.
   University of Technology Sydney, NSW, Australia.
   University of NSW, NSW, Australia.
   South Western Sydney Local Health District, NSW, Australia.
   Chinese Medicine Centre, Western Sydney University, NSW, Australia.
   Chinese Medicine Centre, Western Sydney University, NSW, Australia.
   Chinese Medicine Centre, Western Sydney University, NSW, Australia.
   Chinese Medicine Centre, Western Sydney University, NSW, Australia.
   Dongfang Hospital of Beijing University of Chinese Medicine, Beijing, China.
   Nanjing University of Chinese Medicine, Nanjing, China.
   Affiliated Hospital of Nanjing University of Chinese Medicine.
   Chinese Medicine Centre, Western Sydney University, NSW, Australia.
NR 0
TC 0
SN 1552-695
EI 1534-735
J9 Integr Cancer Ther
PD DEC 11
PY 2020
VL 19
IS 
BP 1534735420976579
EP 1534735420976579
DI 10.1177/1534735420976579
PG 1
WC Acupressure; Acupuncture Therapy; Adult; Analgesics; Cancer Pain; therapy; Humans; Neoplasms; therapy; Randomized Controlled Trials as Topic; Surveys and Questionnaires; Treatment Outcome; Pragmatic Clinical Trials as Topic
UT PubMed:33300382
PM 33300382
DA 2020-12-11
ER

PT J
AU Jacobson, KA
   Reitman, ML
AF Jacobson, Kenneth A
   Reitman, Marc L
TI Adenosine-Related Mechanisms in Non-Adenosine Receptor Drugs.
SO Cells
LA English
DT Review
DE CNS; adenosine receptor; cardiovascular system; inflammation; nucleoside transport; pain
AB Many ligands directly target adenosine receptors (ARs). Here we review the  effects of noncanonical AR drugs on adenosinergic signaling. Non-AR mechanisms  include raising adenosine levels by inhibiting adenosine transport (e.g.,  ticagrelor, ethanol, and cannabidiol), affecting intracellular metabolic pathways  (e.g., methotrexate, nicotinamide riboside, salicylate, and  5-aminoimidazole-4-carboxamide riboside), or undetermined means (e.g.,  acupuncture). However, other compounds bind ARs in addition to their canonical  'on-target' activity (e.g., mefloquine). The strength of experimental support for  an adenosine-related role in a drug's effects varies widely. AR knockout mice are  the 'gold standard' method for investigating an AR role, but few drugs have been  tested on these mice. Given the interest in AR modulation for treatment of  cancer, CNS, immune, metabolic, cardiovascular, and musculoskeletal conditions,  it is informative to consider AR and non-AR adenosinergic effects of approved  drugs and conventional treatments.
C1 Molecular Recognition Section, Laboratory of Bioorganic Chemistry, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD 20892, USA.
   Diabetes, Endocrinology and Obesity Branch, National Institute of Diabetes and Digestive and Kidney Diseases, NIH, Bethesda, MD 20892, USA.
NR 0
TC 0
SN 2073-440
EI 
J9 Cells
PD APR 17
PY 2020
VL 9
IS 4
BP 
EP 
DI 10.3390/cells9040956
PG 0
WC Animals; Humans; Mice; Pharmaceutical Preparations; chemistry; Receptors, Purinergic P1; metabolism; Signal Transduction
UT PubMed:32295065
PM 32295065
DA 2020-04-17
ER

PT J
AU Green, OJ
   Green, JP
   Carroll, PJ
AF Green, Olivia J.
   Green, Joseph P.
   Carroll, Patrick J.
TI The Perceived Credibility of Complementary and Alternative Medicine: A Survey of Undergraduate and Graduate Students
SO INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL HYPNOSIS
LA English
DT Article
ID united-states; therapeutic touch; back-pain; cancer; metaanalysis; hypnosis; benefits; prevalence; therapy; internet
AB The popularity of complementary and alternative medicine (CAM) appears to be increasing, especially among college students. We surveyed 146 undergraduate and graduate students with the CAM Health Belief Questionnaire and obtained credibility and frequency ratings for a select group of CAM therapies: yoga, meditation, massage, chiropractic medicine, biofeedback, hypnosis, acupuncture, spirituality/religion, therapeutic touch, the use of herbs/vitamins, and aromatherapy/essential oils. Graduate students held more favorable views about integrating CAM into conventional medical practice. Female students reported using a wider variety of therapies than male students. Spirituality/religion and herbs/vitamins were the most popular CAM approaches. Students rated yoga, meditation, and massage as being highly credible practices. They rated hypnosis and therapeutic touch low in credibility. We discuss hypnosis as an example of a therapy that suffers from poor public perception despite having a relatively strong evidentiary base.
C1 [Green, Olivia J.] Ohio State Univ, Dept Psychol, Columbus, OH 43210 USA.
   [Green, Joseph P.; Carroll, Patrick J.] Ohio State Univ, Dept Psychol, 4240 Campus Dr, Lima, OH 45804 USA.
C3 University System of Ohio; Ohio State University; University System of Ohio; Ohio State University
RP Green, JP (corresponding author), Ohio State Univ, Dept Psychol, 4240 Campus Dr, Lima, OH 45804 USA.
EM green.301@osu.edu
CR AJZEN I, 1974, HUM RELAT, V27, P1, DOI 10.1177/001872677402700101
   Unknown -, 2018, COMPLEMENTARY, V0, P0
   Arslan IO, 2012, HEALTHMED, V6, P2185
   Atsumi K, 2005, IEEE ENG MED BIOL, V24, P30, DOI 10.1109/MEMB.2005.1411345
   Bervoets DC, 2015, J PHYSIOTHER, V61, P106, DOI 10.1016/j.jphys.2015.05.018
   Bishop FL, 2011, PROSTATE CANCER P D, V14, P1, DOI 10.1038/pcan.2010.38
   Cassileth BR, 1999, CA-CANCER J CLIN, V49, P362, DOI 10.3322/canjclin.49.6.362
   Centers for Disease Control and Prevention, 2018, REP NAT CTR HLTH STA, V0, P0
   Chang HY, 2007, J ADV NURS, V58, P307, DOI 10.1111/j.1365-2648.2007.04291.x
   Chang HY, 2015, J CLIN NURS, V24, P1466, DOI 10.1111/jocn.12790
   CLARK PE, 1984, NURS RES, V33, P37
   Cole SW, 2015, PSYCHONEUROENDOCRINO, V62, P11, DOI 10.1016/j.psyneuen.2015.07.001
   College Board, 2019, AP PSYCH UPD 2019 20, V0, P0
   Coulter ID, 2018, SPINE J, V18, P866, DOI 10.1016/j.spinee.2018.01.013
   Cronk BC, 2002, BEHAV RES METH INS C, V34, P177, DOI 10.3758/BF03195440
   Dolnicar S, 2009, J TRAVEL RES, V47, P295, DOI 10.1177/0047287508326506
   EISENBERG DM, 1993, NEW ENGL J MED, V328, P246, DOI 10.1056/NEJM199301283280406
   Eisenberg DM, 1998, JAMA-J AM MED ASSOC, V280, P1569, DOI 10.1001/jama.280.18.1569
   Elkins G, 2016, HDB MED PSYCHOL HYPN, V0, P0, DOI DOI 10.1891/9780826124876
   Elkins G, 2007, INT J CLIN EXP HYP, V55, P275, DOI 10.1080/00207140701338621
   Ernst E, 2004, J MED ETHICS, V30, P156, DOI 10.1136/jme.2003.007021
   Ernst E, 1998, ARCH INTERN MED, V158, P2235, DOI 10.1001/archinte.158.20.2235
   Ernst E, 1998, CANCER-AM CANCER SOC, V83, P777, DOI 10.1002/(SICI)1097-0142(19980815)83:4<777::AID-CNCR22>3.0.CO;2-O
   Fredrickson BL, 2013, P NATL ACAD SCI USA, V110, P13684, DOI 10.1073/pnas.1305419110
   Gahche Jamie, 2011, NCHS DATA BRIEF, V0, P1
   Gosling SD, 2004, AM PSYCHOL, V59, P93, DOI 10.1037/0003-066X.59.2.93
   Green JP, 2014, PSYCHOLOGY OF CONSCIOUSNESS: THEORY, V0, P0
   Green JP, 2019, COGN BEH THER, V0, P0, DOI DOI 10.1002/9781119139676
   Green JP, 2017, INT J CLIN EXP HYP, V65, P308, DOI 10.1080/00207144.2017.1314740
   Hall HG, 2011, MIDWIFERY, V27, P817, DOI 10.1016/j.midw.2010.08.007
   Horneber M, 2012, INTEGR CANCER THER, V11, P187, DOI 10.1177/1534735411423920
   Hui KK, 2002, J ALTERN COMPLEM MED, V8, P507, DOI 10.1089/107555302760253711
   Iyioha I, 2011, EVID-BASED COMPL ALT, V2011, P0, DOI 10.1155/2011/389518
   Izzo AA, 2009, DRUGS, V69, P1777, DOI 10.2165/11317010-000000000-00000
   Jensen MP, 2017, NEUROSCI CONSCIOUS, V3, P0, DOI 10.1093/nc/nix004
   Joyce Paul, 2016, J COMPLEMENT INTEGR MED, V13, P333, DOI 10.1515/jcim-2014-0053
   Kessler RC, 2001, ANN INTERN MED, V135, P262, DOI 10.7326/0003-4819-135-4-200108210-00011
   Keyes CLM, 2012, AM J PUBLIC HEALTH, V102, P2164, DOI 10.2105/AJPH.2012.300918
   Kristoffersen AE, 2014, BMC COMPLEM ALTERN M, V14, P0, DOI 10.1186/1472-6882-14-463
   Lee J, 2016, SPRINGERPLUS, V5, P0, DOI 10.1186/s40064-016-2362-7
   Lie Desiree, 2004, BMC MED EDUC, V4, P2, DOI 10.1186/1472-6920-4-2
   Lynn SJ, 2019, WILEY ENCY HLTH PSYC, V0, P0
   Lynn SJ, 2010, HANDBOOK OF CLINICAL HYPNOSIS, V2nd, P0, DOI 10.2307/J.CTV1CHS5QJ.34
   Lynn SJ, 2019, INT J CLIN EXP HYP, V67, P475, DOI 10.1080/00207144.2019.1649541
   Martínez ME, 2012, JNCI-J NATL CANCER I, V104, P732, DOI 10.1093/jnci/djs195
   Martins N, 2010, SOUTH AFR BUS REV, V14, P77
   Merriam-Webster Incorporated, 2019, DICT MERR WEBST AM T, V0, P0
   Montgomery GH, 2000, INT J CLIN EXP HYP, V48, P138, DOI 10.1080/00207140008410045
   Musallam AB, 2011, COMPUT HUM BEHAV, V27, P1915, DOI 10.1016/j.chb.2011.04.016
   National Center for Complementary and Integrative Health, 2018, US COMPL ALT MED US, V0, P0
   Nowak ALV, 2008, AM J HEALTH EDUC, V39, P80, DOI 10.1080/19325037.2008.10599019
   Nowak ALV, 2015, J AM COLL HEALTH, V63, P362, DOI 10.1080/07448481.2015.1042878
   Ostwald M, 1962, LIB LIBERAL ARTS, V0, P0
   Peters RM, 1999, NURS SCI QUART, V12, P52, DOI 10.1177/08943189922106413
   Rosa L, 1998, JAMA-J AM MED ASSOC, V279, P1005, DOI 10.1001/jama.279.13.1005
   Schneider CraigD, 2003, BMC MED EDUC, V3, P1
   Sullivan MB, 2018, FRONT HUM NEUROSCI, V12, P0, DOI 10.3389/fnhum.2018.00067
   Tabish Syed Amin, 2008, INT J HEALTH SCI (QASSIM), V2, P0
   Tefikow S, 2013, CLIN PSYCHOL REV, V33, P623, DOI 10.1016/j.cpr.2013.03.005
   Ventola C Lee, 2010, P T, V35, P461
   WebMD, 2019, WHAT EX ALT MED, V0, P0
   *WHO, 2011, TRAD MED DEF, V0, P0
   Yamashita H, 2002, COMPLEMENT THER MED, V10, P84, DOI 10.1054/ctim.2002.0519
   Zick SM, 2004, ALTERN THER HEALTH M, V10, P50
NR 64
TC 6
Z9 8
U1 0
U2 13
PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND
SN 0020-7144
EI 1744-5183
J9 INT J CLIN EXP HYP
JI Int. J. Clin. Exp. Hypn.
PD JUL 2
PY 2020
VL 68
IS 3
BP 327
EP 347
DI 10.1080/00207144.2020.1756695
EA MAY 2020
PG 21
WC Psychology, Clinical; Psychiatry
SC Psychology; Psychiatry
GA ND5EP
UT WOS:000532222300001
PM 32364462
DA 2026-01-16
ER

PT J
AU Lu, WD
   Giobbie-Hurder, A
   Freedman, RA
   Shin, IH
   Lin, NU
   Partridge, AH
   Rosenthal, DS
   Ligibel, JA
AF Lu Weidong
   Giobbie-Hurder, Anita
   Freedman, Rachel A.
   Shin, Im Hee
   Lin, Nancy U.
   Partridge, Ann H.
   Rosenthal, David S.
   Ligibel, Jennifer A.
TI Acupuncture for Chemotherapy-Induced Peripheral Neuropathy in Breast Cancer Survivors: A Randomized Controlled Pilot Trial
SO ONCOLOGIST
LA English
DT Article
DE Acupuncture; Chemotherapy-induced peripheral neuropathy; Breast cancer survivors; Quality of life; Taxane
ID quality-of-life; functional assessment; weekly paclitaxel; clinical-trials; prevalence; oncology; women; management; symptoms; therapy
AB Background Chemotherapy-induced peripheral neuropathy (CIPN) is one of the most debilitating long-term side effects in breast cancer survivors. We conducted a randomized controlled pilot trial to assess the feasibility, safety, and effects of an acupuncture intervention on CIPN in this population. Patients and Methods Women with stage I-III breast cancer with grade 1 or higher CIPN after taxane-containing adjuvant chemotherapy were randomized 1:1 to an immediate acupuncture (IA) arm or to a waitlist control group (CG). Participants in the IA arm received 18 sessions of acupuncture over 8 weeks, then received no additional acupuncture. Patients in the CG arm received usual care over 8 weeks, followed by nine sessions of acupuncture over 8 weeks. Measures including Patient Neurotoxicity Questionnaire (PNQ), Functional Assessment of Cancer Therapy-Neurotoxicity subscale (FACT-NTX), and Brief Pain Inventory-short form (BPI-SF) were collected at baseline and at 4, 8, and 16 weeks after enrollment. Results Forty women (median age, 54) were enrolled (20 to IA and 20 to CG), with median time between completion of chemotherapy and enrollment of 14 months (range 1-92). At 8 weeks, participants in the IA arm experienced significant improvements in PNQ sensory score (-1.0 +/- 0.9 vs. -0.3 +/- 0.6; p = .01), FACT-NTX summary score (8.7 +/- 8.9 vs. 1.2 +/- 5.4; p = .002), and BPI-SF pain severity score (-1.1 +/- 1.7 vs. 0.3 +/- 1.5; p = .03), compared with those in the CG arm. No serious side effects were observed. Conclusion Women with CIPN after adjuvant taxane therapy for breast cancer experienced significant improvements in neuropathic symptoms from an 8-week acupuncture treatment regimen. Additional larger studies are needed to confirm these findings. Implications for Practice Chemotherapy-induced peripheral neuropathy (CIPN) is a toxicity that often persists for months to years after the completion of adjuvant chemotherapy for early breast cancer. In a randomized pilot trial of 40 breast cancer survivors with CIPN, an 8-week acupuncture intervention (vs. usual care) led to a statistically and clinically significant improvement in subjective sensory symptoms including neuropathic pain and paresthesia. Given the lack of effective therapies and established safety profile of acupuncture, clinicians may consider acupuncture as a treatment option for mild to moderate CIPN in practice.
C1 [Lu Weidong; Freedman, Rachel A.; Lin, Nancy U.; Partridge, Ann H.; Rosenthal, David S.; Ligibel, Jennifer A.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02215 USA.
   [Giobbie-Hurder, Anita] Dana Farber Canc Inst, Dept Data Sci, Div Biostat, Boston, MA 02115 USA.
   [Shin, Im Hee] Catholic Univ Daegu, Dept Med Stat & Informat, Sch Med, Daegu, South Korea.
C3 Harvard University; Harvard University Medical Affiliates; Dana-Farber Cancer Institute; Harvard University; Harvard University Medical Affiliates; Dana-Farber Cancer Institute; Catholic University of Daegu
RP Lu, WD (corresponding author), Dana Farber Canc Inst, Dept Med Oncol, Leonard P Zakim Ctr Integrat Therapies & Hlth Liv, 450 Brookline Ave, Boston, MA 02215 USA.
EM weidong_lu@dfci.harvard.edu
CR AARONSON NK, 1993, J NATL CANCER I, V85, P365, DOI 10.1093/jnci/85.5.365
   Bandos H, 2018, JNCI-J NATL CANCER I, V110, P0, DOI 10.1093/jnci/djx162
   Bao T, 2018, EUR J CANCER, V101, P12, DOI 10.1016/j.ejca.2018.06.008
   Bao T, 2016, BREAST CANCER RES TR, V159, P327, DOI 10.1007/s10549-016-3939-0
   Cella D, 2003, CANCER-AM CANCER SOC, V98, P822, DOI 10.1002/cncr.11578
   CELLA DF, 1993, J CLIN ONCOL, V11, P570, DOI 10.1200/JCO.1993.11.3.570
   Cleeland CS, 1994, ANNALS ACADEMY OF MEDICINE SINGAPORE, V23, P129
   Cocks K, 2008, EUR J CANCER, V44, P1793, DOI 10.1016/j.ejca.2008.05.008
   Ezzo J, 2005, J CLIN ONCOL, V23, P7188, DOI 10.1200/JCO.2005.06.028
   Franconi G, 2013, EVID-BASED COMPL ALT, V2013, P0, DOI 10.1155/2013/516916
   Garcia MK, 2014, J HEMATOL ONCOL, V7, P0, DOI 10.1186/1756-8722-7-41
   Gewandter JS, 2017, NEUROLOGY, V89, P859, DOI 10.1212/WNL.0000000000004272
   Han XY, 2017, BMC CANCER, V17, P0, DOI 10.1186/s12885-016-3037-z
   Hausheer FH, 2006, SEMIN ONCOL, V33, P15, DOI 10.1053/j.seminoncol.2005.12.010
   Hershman DL, 2018, JAMA-J AM MED ASSOC, V320, P167, DOI 10.1001/jama.2018.8907
   Hershman DL, 2014, J CLIN ONCOL, V32, P1941, DOI 10.1200/JCO.2013.54.0914
   Kolb NA, 2016, JAMA NEUROL, V73, P860, DOI 10.1001/jamaneurol.2016.0383
   Kuroi K, 2009, SUPPORT CARE CANCER, V17, P1071, DOI 10.1007/s00520-008-0550-x
   Li K, 2019, CURR ONCOL, V26, PE147, DOI 10.3747/co.26.4261
   MacPherson H, 2002, J ALTERN COMPLEM MED, V8, P85, DOI 10.1089/107555302753507212
   Majithia N, 2016, SUPPORT CARE CANCER, V24, P1439, DOI 10.1007/s00520-015-3063-4
   McCrary JM, 2017, SUPPORT CARE CANCER, V25, P3485, DOI 10.1007/s00520-017-3772-y
   Molassiotis A, 2019, INTEGR CANCER THER, V18, P0, DOI 10.1177/1534735419836501
   Norman GR, 2003, MED CARE, V41, P582, DOI 10.1097/00005650-200305000-00004
   OSOBA D, 1994, QUAL LIFE RES, V3, P353, DOI 10.1007/BF00451727
   Seretny M, 2014, PAIN, V155, P2461, DOI 10.1016/j.pain.2014.09.020
   Shimozuma K, 2012, SUPPORT CARE CANCER, V20, P3355, DOI 10.1007/s00520-012-1492-x
   Shimozuma K, 2009, SUPPORT CARE CANCER, V17, P1483, DOI 10.1007/s00520-009-0613-7
   Simon NB, 2017, QUAL LIFE RES, V26, P2763, DOI 10.1007/s11136-017-1635-0
   Smith EML, 2013, JAMA-J AM MED ASSOC, V309, P1359, DOI 10.1001/jama.2013.2813
   Tanabe Y, 2013, INT J CLIN ONCOL, V18, P132, DOI 10.1007/s10147-011-0352-x
   Visovsky Constance, 2007, CLIN J ONCOL NURS, V11, P901
   Winters-Stone KM, 2017, J CLIN ONCOL, V35, P2604, DOI 10.1200/JCO.2016.71.3552
   Wong K, 2013, SUPPORT CARE CANCER, V21, P1893, DOI 10.1007/s00520-013-1731-9
   Xu Wei-Ru, 2010, ZHONGGUO ZHEN JIU, V30, P457
NR 35
TC 115
Z9 145
U1 4
U2 49
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 1083-7159
EI 1549-490X
J9 ONCOLOGIST
JI Oncologist
PD APR 15
PY 2020
VL 25
IS 4
BP 310
EP 318
DI 10.1634/theoncologist.2019-0489
PG 9
WC Oncology
SC Oncology
GA LE4IN
UT WOS:000526683000010
PM 32297442
DA 2026-01-16
ER

PT J
AU Xu, LP
   Yang, SL
   Su, SQ
   Huang, BX
   Lan, XM
   Yao, RJ
AF Xu, Li-Ping
   Yang, Shi-Lai
   Su, Shao-Qing
   Huang, Bi-Xia
   Lan, Xin-Mei
   Yao, Ru-Jie
TI Effect of wrist-ankle acupuncture therapy combined with auricular acupuncture on
SO Complementary therapies in clinical practice
LA English
DT Journal Article
DE Auricular acupuncture; Cancer pain; Combine therapy; Wrist-ankle acupuncture therapy
AB BACKGROUND: Cancer pain affects the quality of life of cancer patients;  therefore, various methods exist for alleviating the adverse effects caused by  cancer pain. Nonpharmacological intervention is regarded as an important means of  auxiliary therapy for drug treatment, with acupuncture receiving the most  attention; However, there are numerous types of acupuncture therapies, including  acupuncture, wrist-ankle acupuncture (WAA) and auricular acupuncture (AA).  Previous studies have demonstrated that all types of acupuncture therapy can  alleviate cancer pain. However, the effects and pathways of different acupuncture  treatments are not similar, and it is unknown whether single therapy or  combination therapy has better analgesic effects. This study aimed to examine the  effect of WAA therapy combined with AA on cancer pain. DESIGN: A randomized  controlled trial. METHOD: A total of 160 patients were selected and randomly  divided into groups A, B, C and D, with 40 patients in each group. Group A  received conventional analgesia alone, with opioids administered based on the  World Health Organization (WHO) 3-tiered "cancer pain ladder". Group B received  WAA, in addition to the treatment received by group A. Group C received AA, in  addition to the treatment received by group A. Group D received WAA combined with  AA, in addition to the treatment received by group A. Analgesic effects and  analgesic drug use before and 3, 5 and 7 days after treatment were observed in  each group. RESULT: A total of 159 patients were included in the analysis. The  verbal rating scale (VRS) and numeric rating scale (NRS) scores for patients who  received mono-acupuncture therapy and combination therapy for 1 week were  significantly different from those of the control group. Combination therapy had  a stronger effect on the VRS score and a faster onset time, based on the NRS  score, and the patients who received combination therapy had reduced analgesic  drug use. CONCLUSION: WAA combined with AA can more quickly reduce pain symptoms  with more lasting analgesic effects and can effectively reduce analgesic drug  use.
C1 Nursing Department, The Third Affiliated People's Hospital of Fujian University of Traditional Chinese Medicine, Fuzhou, China. 
   School of Nursing, Quanzhou Medical College, Quanzhou, China. 
   People's Hospital Affiliated of Fujian University of Traditional Chinese Medicine, Fuzhou, China.
   The Third Affiliated People's Hospital of Fujian University of Traditional Chinese Medicine, Fuzhou, China.
   The Third Affiliated People's Hospital of Fujian University of Traditional Chinese Medicine, Fuzhou, China.
   The Third Affiliated People's Hospital of Fujian University of Traditional Chinese Medicine, Fuzhou, China.
EM 247872083@qq.com
NR 0
TC 0
SN 1873-694
EI 
J9 Complement Ther Clin Pract
PD MAY 8
PY 2020
VL 39
IS 
BP 101170
EP 101170
DI 10.1016/j.ctcp.2020.101170
PG 0
WC Acupuncture Therapy; methods; Acupuncture, Ear; methods; Adult; Aged; Aged, 80 and over; Analgesics; therapeutic use; Analgesics, Opioid; therapeutic use; Cancer Pain; drug therapy; Combined Modality Therapy; Female; Humans; Male; Middle Aged; Pain Management; methods
UT PubMed:32379695
PM 32379695
DA 2020-05-08
ER

PT J
AU Jang, S
   Kim, KH
AF Jang, Soobin
   Kim, Kyeong Han
TI Clinical Effectiveness and Adverse Events of Bee Venom Therapy: A Systematic Review of Randomized Controlled Trials
SO TOXINS
LA English
DT Review
DE bee venom; bee venom therapy; bee venom acupuncture; bee sting; efficacy; safety
ID adhesive capsulitis; acupuncture; pain; arthritis; physiotherapy; mechanism
AB Bee venom has been used to treat many diseases because of its anti-inflammatory and analgesic effects. However, the secretions of bee venom can also cause life-threatening adverse reactions. The objective of this paper was to review the clinical effectiveness of bee venom and adverse events induced by bee venom, regardless of the disease. Four electronic databases were searched in April 2020. The reference lists of the retrieved articles and previous review articles were also hand-searched. Randomized controlled trials (RCTs) using any type of bee venom other than live bee stings for the clinical treatment of any disease other than cancer were included. The studies were selected, the data were extracted, and the quality of the studies was assessed by two authors. Risk of bias was assessed using the Cochrane risk of bias standards. Twelve RCTs were included in this review-three on Parkinson's disease, four on arthralgia, four on musculoskeletal disorders, and one on polycystic ovary syndrome. The types of bee venom used were acupuncture injections, ultrasound gel, and an ointment. Six studies reported adverse events, and skin reactions such as pruritus and swelling were the most common. The large-scale clinical trials of bee venom therapy are needed to verify the statistical difference, and the reporting system for adverse events is also required to increase the safety of bee venom therapy.
C1 [Jang, Soobin] Korea Inst Oriental Med, Clin Med Div, Daejeon 34054, South Korea.
   [Kim, Kyeong Han] Woosuk Univ, Coll Korean Med, Dept Prevent Med, Jeonju 54986, Jeollabuk Do, South Korea.
C3 Korea Institute of Oriental Medicine (KIOM); Woosuk University
RP Kim, KH (corresponding author), Woosuk Univ, Coll Korean Med, Dept Prevent Med, Jeonju 54986, Jeollabuk Do, South Korea.
EM suebin@nate.com; solip922@hanmail.net
FU National Research Foundation of Korea [NRF-2019R1C1C1007573]
CR Ahn CB, 2001, J DONG EUI ORIENT ME, V5, P23
   Aufschnaiter A, 2020, TOXINS, V12, P0, DOI 10.3390/toxins12020066
   Baek YH, 2006, BRAIN RES, V1073, P305, DOI 10.1016/j.brainres.2005.12.086
   Cagnie B, 2003, PHYS THER, V83, P707, DOI 10.1093/ptj/83.8.707
   Castro HJ, 2005, ALLERGY ASTHMA PROC, V26, P470
   Chen HS, 2010, BRAIN RES, V1355, P61, DOI 10.1016/j.brainres.2010.08.002
   Chen J, 2010, PROG NEUROBIOL, V92, P151, DOI 10.1016/j.pneurobio.2010.06.006
   Chen SH, 2010, ARTHRITIS RES THER, V12, P0, DOI 10.1186/ar2926
   Cho SY, 2018, J ALTERN COMPLEM MED, V24, P25, DOI 10.1089/acm.2016.0250
   Cho SY, 2012, PARKINSONISM RELAT D, V18, P948, DOI 10.1016/j.parkreldis.2012.04.030
   Choi MS, 2013, CYTOKINE, V61, P256, DOI 10.1016/j.cyto.2012.10.005
   Conrad VJ, 2019, J ALTERN COMPLEM MED, V25, P845, DOI 10.1089/acm.2019.0121
   Cumpston M, 2019, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.ED000142
   Hartmann A, 2016, PLOS ONE, V11, P0, DOI 10.1371/journal.pone.0158235
   Heo DS, 2005, J ORIENT REHAB MED, V15, P171
   Kim SK, 2014, J PHYS THER SCI, V26, P1419, DOI 10.1589/jpts.26.1419
   Kim TaeHwa Kim TaeHwa, 2006, JOURNAL OF VETERINARY CLINICS, V23, P190
   권기록, 2001, JOURNAL OF PHARMACOPUNCTURE, V4, P127, DOI 10.3831/KPI.2001.4.3.127
   Koh PS, 2013, J SHOULDER ELB SURG, V22, P1053, DOI 10.1016/j.jse.2012.10.045
   Korean Pharmacopuncutre Institute, 2019, PHARM, V0, P0
   Kwon YB, 2002, LIFE SCI, V71, P191, DOI 10.1016/S0024-3205(02)01617-X
   박원, 2010, JOURNAL OF ACUPUNCTURE RESEARCH, V27, P105
   Lee G, 2016, TOXINS, V8, P0, DOI 10.3390/toxins8020048
   Lee JY, 2005, IN VIVO, V19, P801
   Lee MS, 2008, J PAIN, V9, P289, DOI 10.1016/j.jpain.2007.11.012
   Lim JA, 2005, J PHARMACOPUNCT, V20, P73, DOI 10.3831/KPI.2005.8.2.029
   Mohamed EA, 2016, INT J PHARMTECH RES, V9, P66
   Nitecka-Buchta A, 2014, BIOMED RES INT, V2014, P0, DOI 10.1155/2014/296053
   Park JE, 2019, EUR J INTEGR MED, V27, P121, DOI 10.1016/j.eujim.2019.03.001
   Park JH, 2015, PLOS ONE, V10, P0, DOI 10.1371/journal.pone.0126971
   Park JS, 2013, INT J DERMATOL, V52, P1519, DOI 10.1111/ijd.12161
   Park YC, 2014, J ALTERN COMPLEM MED, V20, P919, DOI 10.1089/acm.2014.0220
   Seo BK, 2017, TOXINS, V9, P0, DOI 10.3390/toxins9110361
   Shamseer L, 2015, BMJ-BRIT MED J, V349, P0, DOI 10.1136/bmj.g7647
   Shin BC, 2012, EUR J INTEGR MED, V4, PE271, DOI 10.1016/j.eujim.2012.02.005
   Son DJ, 2007, PHARMACOL THERAPEUT, V115, P246, DOI 10.1016/j.pharmthera.2007.04.004
   심우행, 2011, KOREAN JOURNAL OF DERMATOLOGY 대한피부과학회지, V49, P374
   Surh YJ, 2001, MUTAT RES-FUND MOL M, V480, P243, DOI 10.1016/S0027-5107(01)00183-X
   World Health Organization Regional Office for the Western Pacific (WPRO), 2007, WHO INT STAND TERM T, V0, P0
   Yang MS, 2008, ANN ALLERG ASTHMA IM, V100, P31, DOI 10.1016/S1081-1206(10)60401-2
   Yasin MM, 2018, JOURNAL OF APPLIED PHARMACEUTICAL SCIENCE, V8, P159, DOI 10.7324/japs.2018.8124
   유덕선, 2011, JOURNAL OF KOREAN MEDICINE REHABILITATION 한방재활의학과학회지, V21, P101
   Zhang S, 2018, TOXICON, V148, P64, DOI 10.1016/j.toxicon.2018.04.012
NR 43
TC 31
Z9 34
U1 1
U2 34
PU MDPI
PI BASEL
PA MDPI AG, Grosspeteranlage 5, CH-4052 BASEL, SWITZERLAND
SN 
EI 2072-6651
J9 TOXINS
JI Toxins
PD SEP 15
PY 2020
VL 12
IS 9
BP 
EP 
DI 10.3390/toxins12090558
PG 16
WC Food Science & Technology; Toxicology
SC Food Science & Technology; Toxicology
GA OF9BX
UT WOS:000581494500001
PM 32872552
DA 2026-01-16
ER

PT J
AU Jang, S
   Ko, Y
   Sasaki, Y
   Park, S
   Jo, J
   Kang, NH
   Yoo, ES
   Park, NC
   Cho, SH
   Jang, H
   Jang, BH
   Hwang, DS
   Ko, SG
AF Jang, Soobin
   Ko, Youme
   Sasaki, Yui
   Park, Sunju
   Jo, Junyoung
   Kang, Na-Hoon
   Yoo, Eun-Sil
   Park, Nam-Chun
   Cho, Seong Hee
   Jang, Heejea
   Jang, Bo-Hyoung
   Hwang, Deok-Sang
   Ko, Seong-Gyu
TI Acupuncture as an adjuvant therapy for management of treatment-related symptoms in breast cancer patients Systematic review and meta-analysis (PRISMA-compliant)
SO MEDICINE
LA English
DT Review
DE acupuncture; complementary and alternative medicine; electro-acupuncture; Korean medicine
ID controlled-trial; alternative medicine; vasomotor symptoms; double-blind; hot flashes; dual-center; women; complementary; electroacupuncture; chemotherapy
AB Background: Although randomized controlled trials have revealed the considerable effectiveness of acupuncture in breast cancer patients, there have been no studies exploring current acupuncture research trends for treatment induced various symptoms in breast cancer patients. This review evaluated the effectiveness of acupuncture for treatment-induced symptoms in breast cancer patients. Methods: We performed a systematic review and meta-analysis of the literature regarding acupuncture to treat symptoms associated with breast cancer therapies. The following databases were searched for relevant RCTs published before June 2018: MEDLINE, EMBASE, the Cochrane Library, AMED, CINAHL, OASIS, CNKI, and CiNii. Results: Among the 19,483 records identified, 835 articles remained after screening titles and abstracts. A total of 19 RCTs were included in this qualitative synthesis. Among the studies, 8 explored climacteric symptoms, 4 explored pain, 2 explored lymphedemas, 2 explored nausea and vomiting and 3 investigated miscellaneous symptoms. explored miscellaneous symptoms due to cancer treatments. Most of the studies reported that acupuncture can alleviate various symptoms of breast cancer treatment. However, there is a lack of evidence as to whether accupuncture can alleviate chemotherapy associated side effects Conclusions: Acupuncture may alleviate the treatment-related symptoms of breast cancer; however, further studies are necessary to obtain conclusive evidence of the effectiveness of acupuncture in treating breast cancer. Registration number: CRD42018087813
C1 [Jang, Soobin] Korea Inst Oriental Med, Div Clin Res, 1672 Yuseong Daero, Daejeon, South Korea.
   [Ko, Youme; Sasaki, Yui; Jang, Bo-Hyoung; Ko, Seong-Gyu] Kyung Hee Univ, Dept Prevent Med, Coll Korean Med, 26 Kyungheedae Ro, Seoul 02447, South Korea.
   [Park, Sunju; Hwang, Deok-Sang] Daejeon Univ, Dept Prevent Med, Coll Korean Med, 62 Daehak Ro, Daejeon, South Korea.
   [Jo, Junyoung] Korean Med, Dept Korean Obstet & Gynecol, Conmaul Hosp, 110 Seochojungang Ro, Seoul, South Korea.
   [Kang, Na-Hoon; Yoo, Eun-Sil; Park, Nam-Chun] Kyung Hee Univ, Grad Sch, Dept Clin Korean Med, 26 Kyungheedae Ro, Seoul, South Korea.
   [Cho, Seong Hee] Dong Shin Univ, Dept Obstet & Gynecol, Coll Korean Med, 185 Geonjae Ro, Naju Si, Jeollanam Do, South Korea.
   [Jang, Heejea] Soram Korean Med Hosp, Women Canc Ctr, 154-11 Samsung Dong, Seoul 06154, South Korea.
C3 Korea Institute of Oriental Medicine (KIOM); Kyung Hee University; Daejeon University; Kyung Hee University
RP Jang, BH (corresponding author), Kyung Hee Univ, Dept Prevent Med, Coll Korean Med, 26 Kyungheedae Ro, Seoul 02447, South Korea.; Hwang, DS (corresponding author), Daejeon Univ, Dept Prevent Med, Coll Korean Med, 62 Daehak Ro, Daejeon, South Korea.
EM bhjang@khu.ac.kr
FU Traditional Korean Medicine RAMP;D Program - Ministry of Health AMP; Welfare through the Korea Health Industry Development Institute (KHIDI) [HB16C0072]
CR Bao T, 2018, BREAST CANCER RES TR, V170, P77, DOI 10.1007/s10549-018-4743-9
   Bao T, 2014, CANCER-AM CANCER SOC, V120, P381, DOI 10.1002/cncr.28352
   Bao T, 2013, BREAST CANCER RES TR, V138, P167, DOI 10.1007/s10549-013-2427-z
   Beith JM, 2012, MED ACUPUNCT, V24, P241, DOI 10.1089/acu.2012.0876
   Chien TJ, 2019, INTEGR CANCER THER, V18, P0, DOI 10.1177/1534735419866910
   Chien TJ, 2017, PLOS ONE, V12, P0, DOI 10.1371/journal.pone.0180918
   Chien TJ, 2015, J ALTERN COMPLEM MED, V21, P251, DOI 10.1089/acm.2014.0083
   Crew KD, 2010, J CLIN ONCOL, V28, P1154, DOI 10.1200/JCO.2009.23.4708
   Campos MPD, 2011, J ALTERN COMPLEM MED, V17, P505, DOI 10.1089/acm.2010.0571
   Deng G, 2007, J CLIN ONCOL, V25, P5584, DOI 10.1200/JCO.2007.12.0774
   DiGianni LM, 2002, J CLIN ONCOL, V20, P34S, DOI 10.1200/JCO.2002.07.176
   Dong ST, 2014, J PAIN SYMPTOM MANAG, V48, P411, DOI 10.1016/j.jpainsymman.2013.10.027
   Ernst E, 2010, INT J CLIN PRACT, V64, P1350, DOI 10.1111/j.1742-1241.2010.02453.x
   Fitzmaurice C, 2017, JAMA ONCOL, V3, P524, DOI 10.1001/jamaoncol.2016.5688
   Frisk J, 2012, SUPPORT CARE CANCER, V20, P715, DOI 10.1007/s00520-011-1134-8
   Gerber B, 2006, BREAST CANCER RES TR, V95, P199, DOI 10.1007/s10549-005-9005-y
   Ginsburg O, 2017, LANCET, V389, P847, DOI 10.1016/S0140-6736(16)31392-7
   Giron PS, 2016, SUPPORT CARE CANCER, V24, P2491, DOI 10.1007/s00520-015-3054-5
   Greenlee H, 2016, BREAST CANCER RES TR, V156, P453, DOI 10.1007/s10549-016-3759-2
   [何佩珊 He Peishan], 2017, 中华中医药杂志 CHINA JOURNAL OF TRADITIONAL CHINESE MEDICINE AND PHARMACY, V32, P2805
   Hervik J, 2014, SPRINGERPLUS, V3, P0, DOI 10.1186/2193-1801-3-141
   Hervik J, 2009, BREAST CANCER RES TR, V116, P311, DOI 10.1007/s10549-008-0210-3
   2011, 1900, V343, V0, PPD5928, DOI 10.1136/BMJ.D5928
   Hou WZ, 2019, J OBSTET GYNAECOL RE, V45, P2307, DOI 10.1111/jog.14122
   Jiao J, 2015, J NURSES TRAIN (CHINESE), V30, P2221, DOI 10.16821/J.CNKI.HSJX.2015.24.005
   Joshi N, 2009, ACUPUNCTURE ELECTRO, V34, P165, DOI 10.3727/036012909803861022
   Kim TH, 2018, MEDICINE, V97, P0, DOI 10.1097/MD.0000000000011793
   Kwekkeboom KL, 2016, SEMIN ONCOL NURS, V32, P373, DOI 10.1016/j.soncn.2016.08.004
   Lesi G, 2016, J CLIN ONCOL, V34, P1795, DOI 10.1200/JCO.2015.63.2893
   Li Zhiping, 2015, ZHONGGUO ZHEN JIU, V35, P1010
   Liljegren A, 2012, BREAST CANCER RES TR, V135, P791, DOI 10.1007/s10549-010-1283-3
   Lin, 2015, CANC NURS, V0, P0
   Ma H, 2011, BMC COMPLEM ALTERN M, V2011, P1
   Nedstrand E, 2006, J PSYCHOSOM OBST GYN, V27, P193, DOI 10.1080/01674820600724797
   Oh B, 2013, ACUPUNCT MED, V31, P264, DOI 10.1136/acupmed-2012-010309
   Peng, 2020, JOURNAL OF NURSING ADMINISTRATION, V20, P195
   Schapira MM, 2014, SUPPORT CARE CANCER, V22, P1207, DOI 10.1007/s00520-013-2073-3
   Shamseer L, 2015, BMJ-BRIT MED J, V349, P0, DOI 10.1136/bmj.g7647
   Tong TS, 2018, MED SCI MONITOR, V24, P2919, DOI 10.12659/MSM.909712
   Walker EM, 2010, J CLIN ONCOL, V28, P634, DOI 10.1200/JCO.2009.23.5150
   Wang XL, 2018, J INF PROCESS SYST, V14, P600, DOI 10.3745/JIPS.04.0071
   Wong LYE, 2010, PATIENT PREFER ADHER, V4, P223
   Xue D, 2011, CHINESE J CANCER RES, V23, P74, DOI 10.1007/s11670-011-0074-7
   Zhan Jing, 2017, CHIN J WOMAN CHILD HEALTH RES, V28, P570
   Zhang, 2018, GUIDE CHINA MED, V16, P187
NR 45
TC 20
Z9 30
U1 2
U2 35
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0025-7974
EI 1536-5964
J9 MEDICINE
JI Medicine (Baltimore)
PD DEC 11
PY 2020
VL 99
IS 50
BP 
EP 
DI 10.1097/MD.0000000000021820
PG 14
WC Medicine, General & Internal
SC General & Internal Medicine
GA PZ6GU
UT WOS:000612838800003
PM 33327222
DA 2026-01-16
ER

PT J
AU Hao, J
   Zhu, X
   Bensoussan, A
AF Hao, Jie
   Zhu, Xiaoshu
   Bensoussan, Alan
TI Effects of Nonpharmacological Interventions in Chemotherapy-Induced Peripheral
SO Integrative cancer therapies
LA English
DT Review
DE chemotherapy-induced peripheral neuropathy; meta-analysis; nonpharmacological intervention; overview; systematic review
AB INTRODUCTION: Chemotherapy-induced peripheral neuropathy (CIPN) is one of the  prevalent and disabling side effects of cancer treatment. However, management  strategies for CIPN currently remain elusive, with treatment restricted to  neuropathic pain medications, supportive care, and chemotherapy dosing  adjustments. This overview explores evidence on the potential benefits and safety  of nonpharmacological interventions in preventing and treating CIPN in cancer  patients. METHODS: Seven databases were searched for systematic reviews of  randomized controlled trials (RCTs). The methodological quality of the selected  reviews was assessed by AMSTAR 2, and the quality of evidence was judged by  GRADE. Twenty-eight systematic reviews were considered eligible for this review.  RESULTS: It was found that nonpharmacological interventions (acupuncture,  exercise, herbal medicine, nutritional supplements) provided potential benefits  for patients with CIPN. Furthermore, Chinese herbal medicine, administered orally  or externally, significantly prevented and/or relieved the incidence and severity  of CIPN in comparison to control groups (no additional treatment, placebo, and  conventional western medicine). However, the quality of evidence and strength of  recommendations were compromised by the inconsistencies and imprecision of  included studies. The main concerns regarding the quality of systematic reviews  included the lack of sufficiently rigorous a priori protocols, and the lack of  protocol registration adopted in the included studies. CONCLUSIONS: Though  looking across reviews, Chinese herbal medicine appear generally effective in  CIPN, uncertainty remains about the effects of many other nonpharmacological  interventions. The evidence on what works was particularly compromised by  reporting and methodological limitations, which requires further investigation to  be more certain of their effects.
C1 Western Sydney University, Sydney, New South Wales, Australia.
   Western Sydney University, Sydney, New South Wales, Australia.
   Western Sydney University, Sydney, New South Wales, Australia.
NR 0
TC 0
SN 1552-695
EI 1534-735
J9 Integr Cancer Ther
PD SEP 3
PY 2020
VL 19
IS 
BP 1534735420945027
EP 1534735420945027
DI 10.1177/1534735420945027
PG 1
WC Acupuncture Therapy; Antineoplastic Agents; adverse effects; Humans; Meta-Analysis as Topic; Neoplasms; drug therapy; Peripheral Nervous System Diseases; chemically induced; Systematic Reviews as Topic
UT PubMed:32875921
PM 32875921
DA 2020-09-03
ER

PT J
AU Lee, JH
   Gang, J
   Yang, E
   Kim, W
   Jin, YH
AF Lee, Ji Hwan
   Gang, Juan
   Yang, Eunhee
   Kim, Woojin
   Jin, Young-Ho
TI Bee Venom Acupuncture Attenuates Oxaliplatin-Induced Neuropathic Pain by
SO Toxins
LA English
DT Journal Article
DE action potential; allodynia; bee venom acupuncture; oxaliplatin; voltage-gated sodium channel
AB Oxaliplatin is a third-generation platinum-based chemotherapeutic drug widely  used in colorectal cancer treatment. Although potent against this tumor, it can  induce cold and mechanical allodynia even after a single injection. The currently  used drugs to attenuate this allodynia can also cause unwanted effects, which  limit their use. Bee venom acupuncture (BVA) is widely used in Korean medicine to  treat pain. Although the effect of BVA on oxaliplatin-induced neuropathic pain  has been addressed in many studies, its action on dorsal root ganglia (DRG)  neurons has never been investigated. A single oxaliplatin injection (6 mg/kg,  intraperitoneally) induced cold and mechanical allodynia, and BVA (0.1 and 1  mg/kg, subcutaneous, ST36) dose-dependently decreased allodynia in rats. On  acutely dissociated lumbar 4-6 DRG neurons, 10 min application of oxaliplatin  (100 μM) shifted the voltage-dependence of sodium conductance toward negative  membrane potentials in A- but not C-fibers. The resting membrane potential  remained unchanged, but the action potential threshold decreased significantly  compared to that of the control (p < 0.05). However, 0.1 μg/mL of BVA  administration increased the lowered action potential threshold. In conclusion,  these results suggest that BVA may attenuate oxaliplatin-induced neuropathic pain  by altering the action potential threshold in A-fiber DRG neurons.
C1 Department of Physiology, College of Korean Medicine, Kyung Hee University, Seoul 02453, Korea.
   Department of Science in Korean Medicine, Graduate School, Kyung Hee University, 
   Department of East-West Medicine, Graduate School, Kyung Hee University, Seoul 02453, Korea.
   Department of Physiology, College of Medicine, Kyung Hee University, Seoul 02453, Korea.
   Department of Physiology, College of Korean Medicine, Kyung Hee University, Seoul 02453, Korea.
   Department of Science in Korean Medicine, Graduate School, Kyung Hee University, 
   Department of East-West Medicine, Graduate School, Kyung Hee University, Seoul 02453, Korea.
   Department of Physiology, College of Medicine, Kyung Hee University, Seoul 02453, Korea.
NR 0
TC 0
SN 2072-665
EI 
J9 Toxins (Basel)
PD DEC 2
PY 2020
VL 12
IS 12
BP 
EP 
DI 10.3390/toxins12120737
PG 0
WC Action Potentials; drug effects; Acupuncture Therapy; Animals; Antineoplastic Agents; therapeutic use; Bee Venoms; pharmacology; Disease Models, Animal; Dose-Response Relationship, Drug; Ganglia, Spinal; drug effects; Hyperalgesia; chemically induced; Neuralgia; chemically induced; Neurons; drug effects; Oxaliplatin; adverse effects; Rats; Rats, Sprague-Dawley; Voltage-Gated Sodium Channels; metabolism
UT PubMed:33255279
PM 33255279
DA 2020-12-02
ER

PT J
AU Han, Q
   Yang, L
   Huang, SY
   Yeung, JWF
   Chen, XH
   Xue, H
   Xu, LP
   Suen, LKP
AF Han, Qiong
   Yang, Liu
   Huang, Shuang-Yan
   Yeung, Jerry W. F.
   Chen, Xiao-Huan
   Xue, Hui
   Xu, Li-Ping
   Suen, Lorna K. P.
TI Effectiveness of auricular point therapy for cancer-related fatigue: A systematic review and meta-analysis
SO JOURNAL OF ADVANCED NURSING
LA English
DT Review
DE auricular point therapy; cancer-related fatigue; fatigue; meta-analysis; nursing; systematic review
ID randomized controlled-trial; alternative medicine; risk-factors; acupressure; survivors; pain; complementary; chemotherapy; acupuncture; disability
AB Aims To systemically review the efficacy and safety of auricular point therapy in patients with cancer-related fatigue. Design A systematic review and meta-analysis of randomized controlled trials. Data sources Eight electronic databases (PubMed, CENTRAL, Embase, CINAHL, Web of Science, China Biology Medicine, China National Knowledge Infrastructure and WanFang Data Knowledge Service Platform) were explored for randomized controlled trials from their inception to 1 December 2018. Review methods The risk of bias assessment tool was adopted in accordance with Cochrane Handbook 5.3.0. All included studies reported the effects on cancer-related fatigue as the primary outcome. Effect size was estimated using relative risk, standardized mean difference or mean difference with a corresponding 95% confidence interval. Review Manager 5.3 was used for meta-analysis. Results Six studies comprising 394 patients were included. The results of meta-analysis showed that auricular point therapy plus standard care produced more positive effects on cancer-related fatigue and quality of life than standard care alone. It could significantly improve the role, emotional, cognitive, and social functions of patients with cancer-related fatigue. Conclusions Auricular point therapy may be a safe therapy to relieve cancer-related fatigue and enhance the quality of life of patients with cancer. However, the evidence was inconclusive due to limitations on the quantity and quality of included studies. Rigorously designed randomized controlled trials should be conducted to verify the results. Impact Auricular point therapy is a simple and safe therapeutic approach that may alleviate cancer-related fatigue of common complications in patients with cancer and it is worth promoting in the community, family, and hospital. Moreover, the research findings can provide suggestions and inspiration for nurses and researchers to implement the proposal, which is conducive to design more rigorous and high-quality randomized controlled trials.
C1 [Han, Qiong; Yang, Liu; Huang, Shuang-Yan; Xue, Hui] Fujian Univ Tradit Chinese Med, Sch Nursing, 1 Qiu Yang Rd, Fuzhou, Fujian, Peoples R China.
   [Yeung, Jerry W. F.; Suen, Lorna K. P.] Hong Kong Polytech Univ, Sch Nursing, Hong Kong, Peoples R China.
   [Chen, Xiao-Huan] Fujian Prov Hosp, Fuzhou, Peoples R China.
   [Xu, Li-Ping] Fujian Univ Tradit Chinese Med, Affiliated Peoples Hosp 3, Fuzhou, Peoples R China.
C3 Fujian University of Traditional Chinese Medicine; Hong Kong Polytechnic University; Fujian Provincial Hospital; Fujian University of Traditional Chinese Medicine
RP Yang, L (corresponding author), Fujian Univ Tradit Chinese Med, Sch Nursing, 1 Qiu Yang Rd, Fuzhou, Fujian, Peoples R China.
EM yangliu@fjtcm.edu.cn
CR Abrahams HJG, 2016, ANN ONCOL, V27, P965, DOI 10.1093/annonc/mdw099
   Unknown -, 1990, REPORT OF THE WORKING GROUP ON AURICULAR ACUPUNCTURE NOMENCLATURE, V0, P0
   Atkinson TM, 2017, JAMA ONCOL, V3, P738, DOI 10.1001/jamaoncol.2016.3328
   Behringer K, 2016, J CLIN ONCOL, V34, P4329, DOI 10.1200/JCO.2016.67.7450
   Bohlius J, 2014, BRIT J CANCER, V111, P33, DOI 10.1038/bjc.2014.171
   Bower JE, 2014, NAT REV CLIN ONCOL, V11, P597, DOI 10.1038/nrclinonc.2014.127
   Bower JE, 2014, J CLIN ONCOL, V32, P1840, DOI 10.1200/JCO.2013.53.4495
   Bower JE, 2011, J CLIN ONCOL, V29, P3517, DOI 10.1200/JCO.2011.36.1154
   DING JX, 2017, TODAY NURSE, V7, P98
   DRAGER DL, 2015, COCHRANE DB SYST REV, V5, P0
   Eghbali M, 2016, COMPLEMENT THER CLIN, V24, P189, DOI 10.1016/j.ctcp.2016.06.006
   Escalante CP, 2014, CANCER J, V20, P8, DOI 10.1097/PPO.0000000000000018
   Feng CX, 1994, CHINESE AURICULAR THERAPY, V0, P0
   Garner BK, 2018, MED ACUPUNCT, V30, P262, DOI 10.1089/acu.2018.1294
   Guan ZX, 2002, AURICULAR THERAPY, V0, P0
   Higgins J, 2011, COCHRANE COLLABORATI, V0, P0
   Hoffmann TC, 2014, BMJ-BRIT MED J, V348, P0, DOI 10.1136/bmj.g1687
   Huang DY, 2014, COMPUT SPEECH LANG, V28, P392, DOI 10.1016/j.csl.2013.06.002
   Janelsins MC, 2011, CLIN BREAST CANCER, V11, P161, DOI 10.1016/j.clbc.2011.03.013
   Jones JM, 2016, J CANCER SURVIV, V10, P51, DOI 10.1007/s11764-015-0450-2
   Kapoor A, 2015, SOUTH ASIAN J CANCER, V4, P21, DOI 10.4103/2278-330X.149942
   Kreissl S, 2016, LANCET ONCOL, V17, P1453, DOI 10.1016/S1470-2045(16)30093-6
   Kua KP, 2017, PLOS ONE, V12, P0, DOI 10.1371/journal.pone.0172289
   Larkey LK, 2015, ANN BEHAV MED, V49, P165, DOI 10.1007/s12160-014-9645-4
   Lee S, 2019, APPL NURS RES, V45, P12, DOI 10.1016/j.apnr.2018.11.005
   LI WY, 2004, CHINESE ACUPUNCTURE, V9, P28
   LIN YZ, 2014, ZHEJIANG PREVENTIVE, V26, P796
   Linde K, 2010, BMC MED, V8, P0, DOI 10.1186/1741-7015-8-75
   Marom T, 2016, MEDICINE, V95, P1, DOI 10.1097/MD.0000000000002695
   *NAT STAND INF SHA, 2008, GBT137342008 NAT STA, V0, P0
   Ni XS, 2019, SUPPORT CARE CANCER, V27, P3701, DOI 10.1007/s00520-019-04911-0
   Nilsson I, 2015, J NEUROSURG ANESTH, V27, P42, DOI 10.1097/ANA.0000000000000089
   Oleson T, 2014, AURICULOTHERAPY MANUAL: CHINESE AND WESTERN SYSTEMS OF EAR ACUPUNCTURE, V0, P0
   Parkin DM, 2005, CA-CANCER J CLIN, V55, P74, DOI 10.3322/canjclin.55.2.74
   Ruela LD, 2018, REV ESC ENFERM USP, V52, P0, DOI 10.1590/S1980-220X2017040503402
   Shan QH, 1996, AURICULAR-POINT-PRESSING THERAPY, V0, P0
   SHEN QP, 2009, CLIN OBSERVATION MEC, V0, P38
   Shin J, 2018, WESTERN J NURS RES, V40, P67, DOI 10.1177/0193945916680362
   Stein DJ, 2017, GASTROENTEROL CLIN N, V46, P875, DOI 10.1016/j.gtc.2017.08.015
   Tan J, 2014, EVID-BASED COMPL ALT, V0, P0, DOI DOI 10.1155/2014/506758
   Tan JY, 2015, PLOS ONE, V10, P0, DOI 10.1371/journal.pone.0132989
   TAN JY, 2014, EVID-BASED COMPL ALT, V2014, P0
   TIAN XX, 2018, CHINESE J PHYS, V20, P1108
   Vadiraja HS, 2017, INDIAN J PALLIAT CAR, V23, P247, DOI 10.4103/IJPC.IJPC_95_17
   WANG JZ, 2013, ZHEJIANG J TRADITION, V8, P618
   WANG XQ, 2016, J NURS MANAGE, V16, P562
   YANG JL, 2016, W TRADITIONAL CHINES, V29, P108
   Yeh CH, 2016, CANCER NURS, V39, P402, DOI 10.1097/NCC.0000000000000303
   YENNU S, 2016, J CLIN ONCOL, V34, P0
   YU LF, 2012, GEN NURSING, V10, P2689
   Zhang QT, 2018, COMMUN BIOL, V1, P0, DOI 10.1038/s42003-018-0154-z
   ZHAO JJ, 2016, J LIAONING U TRADITI, V18, P82
   Zick SM, 2016, JAMA ONCOL, V2, P1470, DOI 10.1001/jamaoncol.2016.1867
   Zou C, 2015, PLOS ONE, V10, P0, DOI 10.1371/journal.pone.0122724
NR 55
TC 26
Z9 28
U1 1
U2 38
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0309-2402
EI 1365-2648
J9 J ADV NURS
JI J. Adv. Nurs.
PD AUG 15
PY 2020
VL 76
IS 8
BP 1924
EP 1935
DI 10.1111/jan.14375
EA MAY 2020
PG 12
WC Nursing
SC Nursing
GA QI1VW
UT WOS:000534285900001
PM 32428970
DA 2026-01-16
ER

PT J
AU Zhou, J
   Jin, Y
   Ma, R
   Song, H
   Chen, Q
   Chai, Y
   Liang, Y
   Zhou, Y
   Fang, J
AF Zhou, Jie
   Jin, Ying
   Ma, Ruijie
   Song, Hongyun
   Chen, Qin
   Chai, Yueyang
   Liang, Yi
   Zhou, You
   Fang, Jianqiao
TI Electroacupuncture Alleviates Experimental Chronic Inflammatory Pain by
SO Evidence-based complementary and alternative medicine : eCAM
LA English
DT Journal Article
AB BACKGROUND: Both experimental and clinical studies have shown that  electroacupuncture (EA) administration ameliorates chronic inflammatory pain  (CIP). However, the multifaceted mechanism underlying the effects of EA on CIP is  poorly understood. In this study, the mRNA transcriptome was used to study  various therapeutic targets of EA. METHODS: Using RNA-sequencing, protein-coding  mRNA expression profiles of the L4-L5 dorsal root ganglion (DRG) were examined in  the control (CN), complete Freund's adjuvant- (CFA-) induced CIP, and EA-treated  CIP groups. A series of bioinformatics analyses was performed; "EA-reversed  upregulated genes with CIP" (up-DEGs) and "EA-reversed downregulated genes with  CIP" (down-DEGs) were identified. Thereafter, based on up-DEGs and down-DEGs,  biological functions and signaling pathways were enriched using gene ontology  (GO) and Kyoto encyclopedia of genes and genomes (KEGG) pathway analyses.  RESULTS: In total, 189 DEGs were identified, including 134 up- and 55 down-DEGs,  which were enriched in arachidonic acid metabolism (rno00590), glutamatergic  synapse (rno04724), serotonergic synapse (rno04726), FoxO signaling pathway  (rno04068), insulin signaling pathway (rno04910), amyotrophic lateral sclerosis  (rno05014), cholinergic synapse (rno04725), ECM-receptor interaction (rno04512),  and choline metabolism in cancer (rno05231). CONCLUSION: We identified a few GOs,  pathways, and genes that could play key roles in the amelioration of CIP by EA.  Hence, this study may provide a theoretical basis for CIP amelioration by EA.
C1 The Third Affiliated Hospital of Zhejiang Chinese Medical University, 219 Moganshan Road, Xihu District, Hangzhou City, Zhejiang Province 310005, China.
   Department of Rehabilitation in Traditional Chinese Medicine, The Second Affiliated Hospital of Zhejiang University School of Medicine, No. 88, JiefangRd,Hangzhou City, Zhejiang Province 310000, China.
   The Third Affiliated Hospital of Zhejiang Chinese Medical University, 219 Moganshan Road, Xihu District, Hangzhou City, Zhejiang Province 310005, China.
   Department of Rehabilitation in Traditional Chinese Medicine, The Second Affiliated Hospital of Zhejiang University School of Medicine, No. 88, JiefangRd,Hangzhou City, Zhejiang Province 310000, China.
   The Third Affiliated Hospital of Zhejiang Chinese Medical University, 219 Moganshan Road, Xihu District, Hangzhou City, Zhejiang Province 310005, China.
   Department of Emergency Medicine, The Second Affiliated Hospital of Zhejiang University School of Medicine, No. 88, JiefangRd, Hangzhou City, ZhejiangProvince 310000, China.
   The Third Clinical Medical College, Zhejiang Chinese Medical University, 548 Binwen Road, Binjiang District, Hangzhou City, Zhejiang Province 310053, China.
   Department of Rehabilitation in Traditional Chinese Medicine, The Second Affiliated Hospital of Zhejiang University School of Medicine, No. 88, JiefangRd,Hangzhou City, Zhejiang Province 310000, China.
   The Third Clinical Medical College, Zhejiang Chinese Medical University, Key Laboratory of Acupuncture and Neurology of Zhejiang Province, Hangzhou 310053,China.
NR 0
TC 0
SN 1741-428
EI 1741-427
J9 Evid Based Complement Alternat Med
PD FEB 28
PY 2020
VL 2020
IS 
BP 7061972
EP 7061972
DI 10.1155/2020/7061972
PG 0
UT PubMed:32104194
PM 32104194
DA 2020-02-28
ER

PT J
AU Gao, X
   Zhang, SN
AF Gao, Xin
   Zhang, Shi-Nian
TI [Clinical observation of filiform fire needling on moderate and severe pain in
SO Zhongguo zhen jiu = Chinese acupuncture & moxibustion
LA chi
DT Journal Article
DE advanced cancer; analgesia; filiform fire needling; numerical rating scales (NRS); pain
AB OBJECTIVE: To evaluate the clinical effect of filiform fire needling on moderate  and severe pain in advanced cancer. METHODS: A total of 66 patients with moderate  and severe pain in advanced cancer were randomly divided into an observation  group (34 cases, 4 cases dropped off) and a control group (32 cases, 2 cases  dropped off). The two groups were treated with oral analgesics continuously for 4  weeks. The moderate pain patients was given bucinnazine hydrochloride tablets  (starting at 30 mg, once every 6 hours, increasing by 30%-50% until the titration  volume was reached), and the severe pain patients were given oxycodone  hydrochloride sustained-release tablets (starting at 20 mg every 12 hours and  increasing by 25%-50% until the titration volume was reached). The observation  group was cooperated with filiform fire needling at ashi point, Zusanli (ST 36),  Liangqiu (ST 34), Qihai (CV 6), Guanyuan(CV 4), Quchi (LI 11) and Waiguan (TE 5)  once every other day for 4 weeks. The changes of numerical rating scales (NRS)  scores were observed in both groups before and after treatment, and the amount of  analgesics and the incidence of adverse reactions were recorded. The clinical  effects in the two groups were evaluated. RESULTS: The effective rate was 90.0%  (27/30) in the observation group, which was higher than 66.7% (20/30) in the  control group (P<0.05). After treatment, the NRS scores of both groups were lower  than those before treatment (P<0.05), and the reducing degree in the observation  group was larger than that in the control group (P<0.05). The average dosage of  bunarizine hydrochloride tablets and oxycodone hydrochloride sustained release  tablets to titration volume in the observation group was less than that in the  control group (P<0.05). The incidence of adverse reactions was 23.3% (28/120) in  the observation group, which was lower than 44.2% (53/120) in the control group  (P<0.05). CONCLUSION: Filiform fire needling can alleviate pain symptoms of  patients with moderate and severe pain in advanced cancer, reduce the amount of  analgesics, and decrease the incidence of adverse reactions.
C1 Graduate School of Nanjing University of Chinese Medicine, Nanjing 210046, Jiangsu Province, China.
   Massage Department of Jiangsu Provincial Hospital of TCM.
NR 0
TC 0
SN 
EI 0255-293
J9 Zhongguo Zhen Jiu
PD JUN 17
PY 2020
VL 40
IS 6
BP 601
EP 4
DI 10.13703/j.0255-2930.20190531-k0001
PG -597
WC Acupuncture Points; Acupuncture Therapy; Analgesics; therapeutic use; Cancer Pain; therapy; Humans; Neoplasms; complications; Oxycodone; therapeutic use; Pain Management; Piperazines; therapeutic use; Treatment Outcome
UT PubMed:32538009
PM 32538009
DA 2020-06-17
ER

PT J
AU Dilaveri, CA
   Croghan, IT
   Mallory, MJ
   Dion, LJ
   Fischer, KM
   Schroeder, DR
   Martinez-Jorge, J
   Nguyen, MT
   Fokken, SC
   Bauer, BA
   Wahner-Roedler, DL
AF Dilaveri, Christina A
   Croghan, Ivana T
   Mallory, Molly J
   Dion, Liza J
   Fischer, Karen M
   Schroeder, Darrell R
   Martinez-Jorge, Jorys
   Nguyen, Minh-Doan T
   Fokken, Shawn C
   Bauer, Brent A
   Wahner-Roedler, Dietlind L
TI Massage Compared with Massage Plus Acupuncture for Breast Cancer Patients
SO Journal of alternative and complementary medicine (New York, N.Y.)
LA English
DT Journal Article
DE acupuncture; integrative therapy; massage; stress
AB Objectives: Integrative therapies have been incorporated increasingly into health  and wellness in the United States in recent decades. Their potential benefits are  under evaluation in various situations, including pain and symptom relief for  cancer patients and survivors. This pilot study evaluated whether combining two  integrative complementary approaches augments a patient's benefit by reducing  postoperative stress, pain, anxiety, muscle tension, and fatigue compared with  one integrative complementary approach alone. Design: Patients undergoing  autologous tissue breast reconstruction were randomly assigned to one of two  postoperative complementary alternative therapies for three consecutive days. All  participants were observed for up to 3 months. Subjects: Forty-two participants  were recruited from January 29, 2016 to July 11, 2018. Interventions: Twenty-one  participants were randomly assigned to massage alone and 21 to massage and  acupuncture. Outcome measures: Stress, anxiety, relaxation, nausea, fatigue,  pain, and mood (score 0-10) were measured at enrollment before surgery and  postoperative days 1, 2, and 3 before and after the intervention. Patient  satisfaction was evaluated. Results: Stress decreased from baseline for both  Massage-Only Group and Massage+Acupuncture Group after each treatment  intervention. Change in stress score from baseline decreased significantly more  in the Massage-Only Group at pretreatment and posttreatment (p = 0.03 and  p = 0.04). After adjustment for baseline values, change in fatigue, anxiety,  relaxation, nausea, pain, and mood scores did not differ between groups. When  patients were asked whether they would recommend the study, 100% (19/19) of  Massage-Only Group and 94% (17/18) of Massage+Acupuncture Group responded yes  (p = 0.49). Conclusion: No additive beneficial effects were observed with  addition of acupuncture to massage for pain, anxiety, relaxation, nausea,  fatigue, and mood. Combined massage and acupuncture was not as effective in  reducing stress as massage alone, although both groups had significant stress  reduction. These findings indicate a need for larger studies to explore these  therapies further.
C1 Division of General Internal Medicine, Mayo Clinic, Rochester, MN, USA.
   Division of General Internal Medicine, Mayo Clinic, Rochester, MN, USA.
   Department of Health Sciences Research, Mayo Clinic, Rochester, MN, USA.
   Department of Medicine Clinical Research Office, Mayo Clinic, Rochester, MN, USA.
   Division of General Internal Medicine, Mayo Clinic, Rochester, MN, USA.
   Division of General Internal Medicine, Mayo Clinic, Rochester, MN, USA.
   Department of Health Sciences Research, Mayo Clinic, Rochester, MN, USA.
   Department of Health Sciences Research, Mayo Clinic, Rochester, MN, USA.
   Division of Plastic and Reconstructive Surgery, Mayo Clinic, Rochester, MN, USA.
   Division of Plastic and Reconstructive Surgery, Mayo Clinic, Rochester, MN, USA.
   Division of General Internal Medicine, Mayo Clinic, Rochester, MN, USA.
   Department of Medicine Clinical Research Office, Mayo Clinic, Rochester, MN, USA.
   Division of General Internal Medicine, Mayo Clinic, Rochester, MN, USA.
   Division of General Internal Medicine, Mayo Clinic, Rochester, MN, USA.
NR 0
TC 0
SN 1557-770
EI 1075-553
J9 J Altern Complement Med
PD JUL 17
PY 2020
VL 26
IS 7
BP 602
EP 609
DI 10.1089/acm.2019.0479
PG 7
WC Acupuncture Therapy; Adult; Affect; Aged; Anxiety; etiology; Breast Neoplasms; complications; Combined Modality Therapy; Fatigue; etiology; Female; Humans; Massage; Middle Aged; Nausea; etiology; Pain; etiology; Pain Management; Patient Satisfaction; Pilot Projects; Postoperative Care; methods; Postoperative Period; Plastic Surgery Procedures; adverse effects; Relaxation; Stress, Psychological; etiology
UT PubMed:32673082
PM 32673082
DA 2020-07-17
ER

PT J
AU Li, Y
   Wu, F
   Wei, JZ
   Lao, LX
   Shen, XY
AF Li, Yuan
   Wu, Fan
   Wei, Jianzi
   Lao, Lixing
   Shen, Xueyong
TI Laser Moxibustion Alleviates Knee Osteoarthritis Pain by Inhibiting Spinal Microglial Activation-Mediated Neuroinflammation in Rats
SO PHOTOBIOMODULATION PHOTOMEDICINE AND LASER SURGERY
LA English
DT Article
DE laser moxibustion; knee osteoarthritis pain; neuroinflammation; glial activation
ID monosodium iodoacetate model; central sensitization; acupuncture
AB Background: Central sensitization driven by glial activation-mediated neuroinflammation is recognized as a key mechanism in pain processing. Laser moxibustion using low-intensity laser irradiation of corresponding acupoints significantly relieves knee osteoarthritis (KOA) pain. However, the underlying mechanism of its effects on KOA pain is still not completely understood. Objective: In this study, we aimed to investigate whether laser moxibustion could alleviate KOA pain by inhibiting spinal glial activation and proinflammatory cytokines upregulation in monosodium iodoacetate (MIA)-induced KOA pain in rats. Materials and methods: Sprague-Dawley rats were divided randomly into three groups: Saline + Sham Laser, MIA + Laser, and MIA + Sham Laser. A 10.6 mu m laser was used to irradiate ST35 (Dubi) for 10 min once every 2 days for a total of seven applications. The paw withdrawal mechanical threshold and weight-bearing distribution were performed to evaluate the nociceptive behaviors. Spinal expressions of microglial marker, ionized calcium binding adaptor molecule-1 (Iba-1); astrocyte marker, glial fibrillary acidic protein (GFAP); pro-inflammatory cytokines, tumor necrosis factor-alpha (TNF-alpha), interleukin-1 beta (IL-1 beta), and interleukin-6 (IL-6) were measured 14 days after MIA injection. Results: The results showed that laser moxibustion significantly reversed the MIA-induced mechanical hyperalgesia and weight-bearing difference up to 14 days compared with MIA + Sham Laser group (p < 0.05 or p < 0.01). Moreover, both the protein level and immunofluorescence intensity of Iba-1 in the ipsilateral spinal cord dorsal horn were markedly decreased in the MIA + Laser group than those in the MIA + Sham Laser group (p < 0.01). However, there was no significant difference in the expression of GFAP between groups (p > 0.05). In addition, laser moxibustion decreased the upregulation of TNF-alpha, IL-1 beta, and IL-6 compared with the MIA + Sham Laser group (p < 0.01). Conclusions: This study demonstrated that laser moxibustion at ST35 significantly alleviated MIA-induced KOA pain through inhibition of the microglial activation-mediated neuroinflammation, at least partially, by suppressing the production of proinflammatory cytokines, which may provide a potential analgesic target for KOA pain relief.
C1 [Li, Yuan; Wu, Fan; Wei, Jianzi; Lao, Lixing; Shen, Xueyong] Shanghai Univ Tradit Chinese Med, Sch Acupuncture Moxibust & Tuina, Room 9415,1200 Cailun Rd, Shanghai 201203, Peoples R China.
   [Lao, Lixing] Univ Hong Kong, Sch Chinese Med, Hong Kong, Peoples R China.
   [Shen, Xueyong] Shanghai Res Ctr Acupuncture & Meridian, Shanghai, Peoples R China.
C3 Shanghai University of Traditional Chinese Medicine; University of Hong Kong
RP Shen, XY (corresponding author), Shanghai Univ Tradit Chinese Med, Sch Acupuncture Moxibust & Tuina, Room 9415,1200 Cailun Rd, Shanghai 201203, Peoples R China.
EM snowysh@hotmail.com
FU National Natural Science Foundation of China [2015CB554505]; Shanghai Key Laboratory of Acupuncture Mechanism and Acupoint function [14DZ2260500]; Shanghai University of Traditional Chinese Medicine Budget Research Project [18LK010]; Li Yuan's Postgraduate Innovation Ability Project [A1-N192050102040105]
CR Adaes S, 2017, MOL PAIN, V13, P0, DOI 10.1177/1744806916688219
   Al Rashoud AS, 2014, PHYSIOTHERAPY, V100, P242, DOI 10.1016/j.physio.2013.09.007
   Bai FH, 2019, EVID-BASED COMPL ALT, V2019, P0, DOI 10.1155/2019/7493286
   Chen QL, 2019, J NEUROSCI, V39, P2065, DOI 10.1523/JNEUROSCI.2552-18.2019
   Combe R, 2004, NEUROSCI LETT, V370, P236, DOI 10.1016/j.neulet.2004.08.023
   Dieppe PA, 2005, LANCET, V365, P965, DOI 10.1016/S0140-6736(05)71086-2
   Fernihough J, 2004, PAIN, V112, P83, DOI 10.1016/j.pain.2004.08.004
   Guo CJ, 2004, GLIA, V48, P259, DOI 10.1002/glia.20079
   Gwilym SE, 2009, ARTHRIT RHEUM-ARTHR, V61, P1226, DOI 10.1002/art.24837
   Hannan MT, 2000, J RHEUMATOL, V27, P1513
   Helianthi DR, 2016, ACTA MED INDONES, V48, P114
   Hendiani JA, 2003, J PAIN, V4, P203, DOI 10.1016/S1526-5900(03)00557-1
   Hermanns H, 2008, NEUROSCI LETT, V445, P214, DOI 10.1016/j.neulet.2008.09.012
   Ji RR, 2018, ANESTHESIOLOGY, V129, P343, DOI 10.1097/ALN.0000000000002130
   Ji RR, 2013, PAIN, V154, PS10, DOI 10.1016/j.pain.2013.06.022
   Kelly S, 2013, OSTEOARTHR CARTILAGE, V21, P1327, DOI 10.1016/j.joca.2013.07.002
   Kelly S, 2012, OSTEOARTHR CARTILAGE, V20, P305, DOI 10.1016/j.joca.2012.01.002
   Latremoliere A, 2009, J PAIN, V10, P895, DOI 10.1016/j.jpain.2009.06.012
   Lee Y, 2011, MOL PAIN, V7, P0, DOI 10.1186/1744-8069-7-39
   Lin CZ, 2020, LASER MED SCI, V35, P1085, DOI 10.1007/s10103-019-02892-4
   Liu LL, 2019, LASER MED SCI, V34, P263, DOI 10.1007/s10103-018-2581-y
   Lockwood SM, 2019, OSTEOARTHR CARTILAGE, V27, P712, DOI 10.1016/j.joca.2018.12.017
   Mohammed N, 2018, J COMPLEMENT INTEGR, V15, P0
   Park JE, 2010, COMPLEMENT THER MED, V18, P215, DOI 10.1016/j.ctim.2010.07.001
   Peat G, 2001, ANN RHEUM DIS, V60, P91, DOI 10.1136/ard.60.2.91
   Sagar DR, 2011, MOL PAIN, V7, P0, DOI 10.1186/1744-8069-7-88
   Shen D, 2019, PHOTOBIOMODULATION P, V37, P151, DOI 10.1089/photob.2018.4570
   Shen XY, 2009, LASER MED SCI, V24, P129, DOI 10.1007/s10103-007-0536-9
   Shih RH, 2015, FRONT MOL NEUROSCI, V8, P0, DOI 10.3389/fnmol.2015.00077
   Song GM, 2016, MEDICINE, V95, P0, DOI 10.1097/MD.0000000000002790
   Watkins LR, 2001, TRENDS NEUROSCI, V24, P450, DOI 10.1016/S0166-2236(00)01854-3
   Wu F, 2012, BMC COMPLEMENT AL S1, V12, P0
   Wu F, 2014, EVID-BASED COMPL ALT, V2014, P0, DOI 10.1155/2014/754304
   Yu DC, 2013, PLOS ONE, V8, P0, DOI 10.1371/journal.pone.0054516
   Zhao L, 2014, ARTHRITIS RES THER, V16, P0, DOI 10.1186/ar4590
   Zhao L, 2010, PHOTOMED LASER SURG, V28, P351, DOI 10.1089/pho.2009.2511
NR 36
TC 9
Z9 12
U1 0
U2 16
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 
EI 2578-5478
J9 PHOTOBIOMOD PHOTOMED
JI Photobiomodulation Photomed. Laser Surg.
PD APR 1
PY 2020
VL 38
IS 4
BP 237
EP 243
DI 10.1089/photob.2019.4744
EA JAN 2020
PG 7
WC Surgery
SC Surgery
GA LE4IX
UT WOS:000509226300001
PM 31976816
DA 2026-01-16
ER

PT J
AU Venkatasalu, MR
   Murang, ZR
   Ramasamy, DTR
   Dhaliwal, JS
AF Venkatasalu, Munikumar Ramasamy
   Murang, Zaidah Rizidah
   Ramasamy, Divya Thirumalai Rajam
   Dhaliwal, Jagjit Singh
TI Oral health problems among palliative and terminally ill patients: an integrated systematic review
SO BMC ORAL HEALTH
LA English
DT Review
DE Oral conditions; Oral diseases; Palliative; Terminally-ill; Cancer; Integrated review
ID cancer-treatment; older-adults; care; mucositis; end; hospice; pain
AB Background High incidence of treatable oral conditions has been reported among palliative patients. However, a large proportion of palliative patients lose their ability to communicate their sufferings. Therefore, it may lead to under-reporting of oral conditions among these patients. This review systematically synthesized the published evidence on the presence of oral conditions among palliative patients, the impact, management, and challenges in treating these conditions. Methods An integrative review was undertaken with defined search strategy from five databases and manual search through key journals and reference list. Studies which focused on oral conditions of palliative patients and published between years 2000 to 2017 were included. Results Xerostomia, oral candidiasis and dysphagia were the three most common oral conditions among palliative patients, followed by mucositis, orofacial pain, taste change and ulceration. We also found social and functional impact of having certain oral conditions among these patients. In terms of management, complementary therapies such as acupuncture has been used but not well explored. The lack of knowledge among healthcare providers also posed as a challenge in treating oral conditions among palliative patients. Conclusions This review is first in its kind to systematically synthesize the published evidence regarding the impact, management and challenges in managing oral conditions among palliative patients. Although there is still lack of study investigating palliative oral care among specific group of patients such as patients with dementia, geriatric or pediatric advanced cancer patients, this review has however provided baseline knowledge that may guide health care professionals in palliative settings.
C1 [Venkatasalu, Munikumar Ramasamy; Murang, Zaidah Rizidah; Ramasamy, Divya Thirumalai Rajam; Dhaliwal, Jagjit Singh] Univ Brunei Darussalam, Pengiran Anak Puteri Rashidah Saadatul Bolkiah In, Bandar Seri Begawan, Brunei.
C3 University Brunei Darussalam
RP Dhaliwal, JS (corresponding author), Univ Brunei Darussalam, Pengiran Anak Puteri Rashidah Saadatul Bolkiah In, Bandar Seri Begawan, Brunei.
EM jagjit.dhaliwal@ubd.edu.bn
FU Universiti Brunei Darussalam [UBD/OAVCRI/CRGWG (014)/171001]
CR Amódio J, 2014, CLINICS, V69, P706, DOI 10.6061/clinics/2014(10)10
   Unknown -, 2017, CHECKLIST FOR ANALYTICAL CROSS SECTIONAL STUDIES, V0, P0
   Barker GJ, 2005, SUPPORT CARE CANCER, V13, P32, DOI 10.1007/s00520-004-0691-5
   Bogaardt H, 2015, DYSPHAGIA, V30, P145, DOI 10.1007/s00455-014-9590-1
   Chen X, 2015, J AM GERIATR SOC, V63, P375, DOI 10.1111/jgs.13240
   Chen X, 2013, J AM DENT ASSOC, V144, P1234, DOI 10.14219/jada.archive.2013.0051
   Chung J P, 2000, SPEC CARE DENTIST, V20, P12, DOI 10.1111/j.1754-4505.2000.tb00004.x
   Davies AN, 2006, ORAL ONCOL, V42, P698, DOI 10.1016/j.oraloncology.2005.11.010
   Ezenwa MO, 2016, SUPPORT CARE CANCER, V24, P4769, DOI 10.1007/s00520-016-3328-6
   Fischer DJ, 2014, SUPPORT CARE CANCER, V22, P803, DOI 10.1007/s00520-013-2037-7
   Gligorov J, 2011, INT J RADIAT ONCOL, V80, P532, DOI 10.1016/j.ijrobp.2010.02.006
   Kvalheim SF, 2016, GERODONTOLOGY, V33, P522, DOI 10.1111/ger.12198
   Lagman R, 2017, AM J HOSP PALLIAT ME, V34, P645, DOI 10.1177/1049909116643927
   Lalla Rajesh V, 2008, DENT CLIN NORTH AM, V52, P61, DOI 10.1016/j.cden.2007.10.002
   Liberati Alessandro, 2009, PLOS MED, V6, Pe1000100, DOI 10.1371/journal.pmed.1000100
   Ling IS, 2011, SUPPORT CARE CANCER, V19, P1343, DOI 10.1007/s00520-010-0955-1
   Matsuo K, 2016, SUPPORT CARE CANCER, V24, P157, DOI 10.1007/s00520-015-2759-9
   Meidell L, 2009, INT J PALLIAT NURS, V15, P12, DOI 10.12968/ijpn.2009.15.1.37947
   Mercadante S, 2015, SUPPORT CARE CANCER, V23, P3249, DOI 10.1007/s00520-015-2720-y
   Miller M, 2001, CANCER NURS, V24, P241, DOI 10.1097/00002820-200108000-00001
   Momo K, 2017, SUPPORT CARE CANCER, V25, P2997, DOI 10.1007/s00520-017-3817-2
   Mulk BS, 2014, J CLIN DIAGN RES, V8, PZE1, DOI 10.7860/JCDR/2014/8898.4427
   Nakajima N, 2017, AM J HOSP PALLIAT ME, V34, P430, DOI 10.1177/1049909116633063
   Ohno T, 2016, SUPPORT CARE CANCER, V24, P19, DOI 10.1007/s00520-015-2734-5
   Qutob AF, 2013, SUPPORT CARE CANCER, V21, P1113, DOI 10.1007/s00520-012-1633-2
   Rohr Y, 2010, INT J PALLIAT NURS, V16, P439, DOI 10.12968/ijpn.2010.16.9.78638
   Rydholm Marareta, 2002, INT J PALLIAT NURS, V8, P318
   Saini R, 2009, INDIAN J PALLIAT CAR, V15, P26, DOI 10.4103/0973-1075.53508
   Tebidze N, 2017, TRANSLATIONAL AND CLINICAL MEDICINE - GEORGIAN MEDICAL JOURNAL, V0, PP20, DOI 10.29088/tcm-gmj.2017.20
   Velten DB, 2017, BMC ORAL HEALTH, V17, P0, DOI 10.1186/s12903-016-0331-8
   Whittemore R, 2005, J ADV NURS, V52, P546, DOI 10.1111/j.1365-2648.2005.03621.x
   Wilberg P, 2012, SUPPORT CARE CANCER, V20, P3115, DOI 10.1007/s00520-012-1441-8
NR 33
TC 45
Z9 62
U1 1
U2 14
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1472-6831
EI 
J9 BMC ORAL HEALTH
JI BMC Oral Health
PD MAR 18
PY 2020
VL 20
IS 1
BP 
EP 
DI 10.1186/s12903-020-01075-w
PG 11
WC Dentistry, Oral Surgery & Medicine
SC Dentistry, Oral Surgery & Medicine
GA KW9DT
UT WOS:000521484200002
PM 32188452
DA 2026-01-16
ER

PT J
AU Yang, YL
   Wen, J
   Hong, JY
AF Yang, Yulan
   Wen, Jian
   Hong, Jianyun
TI The Effects of Auricular Therapy for Cancer Pain: A Systematic Review and Meta-Analysis
SO EVIDENCE-BASED COMPLEMENTARY AND ALTERNATIVE MEDICINE
LA English
DT Review
ID point acupressure; management; undertreatment; dysmenorrhea; acupuncture; prevalence; relief; adults
AB Objective. This study aims to systematically assess the efficacy and safety of auricular therapy for cancer pain. Methods. A systematic search was conducted using PubMed, EMBASE, Cochrane library databases, CNKI, VIP, WanFang Data, and CBM for randomized controlled trials (RCTs). Review Manager 5.3 was used for meta-analysis. Results. Of the 275 screened studies, nine RCTs involving 783 patients with cancer pain were systematically reviewed. Compared with drug therapy, auricular therapy plus drug therapy has significant advantages both in the effective rate for pain relief (RR = 1.40; 95% CI 1.22, 1.60; P<0.00001) and adverse effects rate (RR = 0.46; 95% CI 0.37, 0.58; P<0.00001). And the result revealed that auricular acupuncture had superior pain-relieving effects as compared with sham auricular acupuncture (SMD = -1.45; 95% CI -2.80, -0.09; P=0.04). However, the analysis indicated no difference on the effective rate for pain relief between auricular therapy and drug therapy (RR = 1.24; 95% CI 0.71, 2.16; P=0.46). Conclusion. Our meta-analysis indicated that auricular therapy is effective and safe for the treatment of cancer pain, and auricular therapy plus drug therapy is more effective than drug therapy alone, whether in terms of pain relief or adverse reactions. However, the included RCTs had some methodological limitations; future large, rigor, and high-quality RCTs are still needed to confirm the benefits of auricular therapy on cancer pain.
C1 [Yang, Yulan; Hong, Jianyun] Maoming Peoples Hosp, Dept Acupuncture, Maoming, Guangdong, Peoples R China.
   [Wen, Jian] Maoming Peoples Hosp, Dept Oncol, Maoming, Guangdong, Peoples R China.
RP Yang, YL (corresponding author), Maoming Peoples Hosp, Dept Acupuncture, Maoming, Guangdong, Peoples R China.
EM leleyangyulan@163.com; wenjian218@163.com; hongjianyunmm@sina.cn
FU High-Level Hospital Construction Research Project of Maoming People's Hospital
CR Alimi D, 2003, J CLIN ONCOL, V21, P4120, DOI 10.1200/JCO.2003.09.011
   Unknown -, 1986, CANC PAIN REL, V0, P0
   Bao YJ, 2014, EVID-BASED COMPL ALT, V2014, P0, DOI 10.1155/2014/170396
   Bardia A, 2006, J CLIN ONCOL, V24, P5457, DOI 10.1200/JCO.2006.08.3725
   Cha NH, 2016, J NURS SCHOLARSHIP, V48, P508, DOI 10.1111/jnu.12238
   Chen M, 2013, IEEE NETWORK, V27, P8, DOI 10.1109/MNET.2013.6574659
   Cherny NI, 2000, CA-CANCER J CLIN, V50, P70, DOI 10.3322/canjclin.50.2.70
   Deandrea S, 2008, ANN ONCOL, V19, P1985, DOI 10.1093/annonc/mdn419
   Fallon M, 2018, ANN ONCOL, V29, P166, DOI 10.1093/annonc/mdy152
   Goertz CMH, 2006, MIL MED, V171, P1010, DOI 10.7205/MILMED.171.10.1010
   Greco MT, 2014, J CLIN ONCOL, V32, P4149, DOI 10.1200/JCO.2014.56.0383
   Haumann J, 2017, CURR OPIN SUPPORT PA, V11, P99, DOI 10.1097/SPC.0000000000000261
   He X-D, 2019, CHINESE COMMUNITY DO, V35, P90
   HIGGINS JP, 2017, COCHRANE HANDBOOK FO, V2, P2017
   Horrigan BJ, 2008, EXPLORE-NY, V4, P228, DOI 10.1016/j.explore.2008.04.007
   Hou PW, 2015, EVID-BASED COMPL ALT, V2015, P0, DOI 10.1155/2015/495684
   Hozo Stela Pudar, 2005, BMC MED RES METHODOL, V5, P13, DOI 10.1186/1471-2288-5-13
   Jiang Y-M, 2019, J GUANGZHOU U TRADIT, V36, P1961
   Karcioglu O, 2018, AM J EMERG MED, V36, P707, DOI 10.1016/j.ajem.2018.01.008
   LEWIS S M, 1990, JOURNAL OF BURN CARE AND REHABILITATION, V11, P322, DOI 10.1097/00004630-199007000-00010
   Luo DH, 2018, STAT METHODS MED RES, V27, P1785, DOI 10.1177/0962280216669183
   Ruela LD, 2018, REV ESC ENFERM USP, V52, P0, DOI 10.1590/S1980-220X2017040503402
   Scarborough BM, 2018, CA-CANCER J CLIN, V68, P182, DOI 10.3322/caac.21453
   Wang H, 2016, INT J DAMAGE MECH, V25, P4, DOI 10.1177/1056789514565933
   Wang J, 2015, YUNNAN J TRADIT CHIN MED, V36, P43, DOI 10.16254/j.cnki.53-1120/r.2015.02.027
   Wang MC, 2009, J ALTERN COMPLEM MED, V15, P235, DOI 10.1089/acm.2008.0164
   Wei S, 2016, CHIN MANIPULATION RE, V7, P24
   Ye XX, 2019, EVID-BASED COMPL ALT, V2019, P0, DOI 10.1155/2019/2979780
   Yeh CH, 2017, ONCOL NURS FORUM, V44, P476, DOI 10.1188/17.ONF.476-487
   Yeh CH, 2015, PAIN MANAG NURS, V16, P285, DOI 10.1016/j.pmn.2014.08.005
   Yeh CH, 2014, EVID-BASED COMPL ALT, V2014, P0, DOI 10.1155/2014/934670
   Yeh ML, 2013, J ALTERN COMPLEM MED, V19, P313, DOI 10.1089/acm.2011.0665
   Zhao HJ, 2015, COMPLEMENT THER CLIN, V21, P68, DOI 10.1016/j.ctcp.2015.03.006
NR 34
TC 33
Z9 41
U1 1
U2 20
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 1741-427X
EI 1741-4288
J9 EVID-BASED COMPL ALT
JI Evid.-based Complement Altern. Med.
PD MAY 25
PY 2020
VL 2020
IS 
BP 
EP 
DI 10.1155/2020/1618767
PG 10
WC Integrative & Complementary Medicine
SC Integrative & Complementary Medicine
GA LY5AM
UT WOS:000540541100001
PM 32565846
DA 2026-01-16
ER

PT J
AU Lei, Y
   Duan, YY
   Wang, JS
   Yu, XD
   Deng, S
   Liu, RJ
   Si, HM
   Li, JM
   Zhang, B
AF Lei, Yi
   Duan, Yunyun
   Wang, Jisheng
   Yu, Xudong
   Deng, Sheng
   Liu, Ruijia
   Si, Hongmei
   Li, Jiameng
   Zhang, Bao
TI A randomized controlled trial for acupuncture combined with conventional therapy in the treatment of pain caused by prostate cancer Study protocol clinical trial (SPIRIT compliant)
SO MEDICINE
LA English
DT Article
DE acupuncture; prostate cancer; protocol; randomized controlled trial
ID analgesia
AB Introduction: Prostate cancer refers to an epithelial malignant tumor that occurs in the prostate area. In recent years, with the improvement of people's living standards, the incidence of prostate cancer has gradually increased, which has greatly affected people's life and health and quality of life. Acupuncture has its unique advantages in treating cancer pain. We will evaluate the efficacy and safety of acupuncture and moxibustion in the treatment of pain caused by prostate cancer using a clinical randomized parallel control method. Methods/design: This pragmatic randomized controlled trial will recruit 120 patients who are diagnosed with prostate cancer. Simple randomization to conventional drug treatment with a 1:1 allocation ratio will be used. Based on the patient's pain location and the primary lesion, the acupuncture needle insertion position was determined according to the principle of local selection of acupoints. All participants will continue to receive conventional drug treatment. Discussion: This trial may provide evidence regarding the clinical effectiveness, safety, and cost-effectiveness of acupuncture for pain caused by prostate cancer.
C1 [Lei, Yi; Duan, Yunyun; Zhang, Bao] Shaanxi Univ Chinese Med, Affiliated Hosp 2, Xianyang 712000, Shaanxi, Peoples R China.
   [Wang, Jisheng; Yu, Xudong; Deng, Sheng; Liu, Ruijia; Si, Hongmei; Li, Jiameng] Beijing Univ Chinese Med, Grad Sch, Beijing, Peoples R China.
   [Wang, Jisheng; Yu, Xudong; Deng, Sheng; Si, Hongmei; Li, Jiameng] Beijing Univ Chinese Med, Dongzhimen Hosp, Dept Androl, Beijing, Peoples R China.
   [Liu, Ruijia] Beijing Univ Chinese Med, Dongzhimen Hosp, Fist Dept Neurol, Beijing, Peoples R China.
C3 Shaanxi University of Chinese Medicine; Beijing University of Chinese Medicine; Beijing University of Chinese Medicine; Beijing University of Chinese Medicine
RP Zhang, B (corresponding author), Shaanxi Univ Chinese Med, Affiliated Hosp 2, Xianyang 712000, Shaanxi, Peoples R China.
EM xlht3943@sina.com
FU Current Graduate Program 2019, Dongzhimen Hospital Affiliated to Being University of Chinese Medicine [2019-JYB-XS-152]
CR Andre TA, 2016, J ACUPUNCT MERIDIAN, V9, P0
   Unknown -, 2013, CHINA CANC, V0, P0
   Unknown -, 2016, CHIN SOC INTEGR TRAD, V0, P0
   Unknown -, 2013, CANC PROGR, V0, P0
   de Valois B, 2015, EUR J INTEGR MED, V7, P0
   Del Rosario Rodriguez V, 2018, EUR UROL S, V17, P0
   LANGELAND E, 2013, QUAL LIFE RES S1, V22, P0
   Lin LL, 2016, CELL TRANSPLANT, V25, P621, DOI 10.3727/096368916X690872
   Manzano A, 2014, J CLIN NURS, V23, P1877, DOI 10.1111/jocn.12447
   Patrick D, 2013, EUR UROL S, V12, P0
   Sauer CM, 2018, CRIT REV ONCOL HEMAT, V132, P66, DOI 10.1016/j.critrevonc.2018.09.013
   Shen XL, 2016, J UROLOGY, V195, P1397, DOI 10.1016/j.juro.2015.11.056
   Slavík H, 2014, NEW BIOTECHNOL, V31, PS106, DOI 10.1016/j.nbt.2014.05.1867
   Xu Jianfeng, 2010, J UROL, V183, P0
   Zou Jian-Fei, 2010, XI BAO YU FEN ZI MIAN YI XUE ZA ZHI, V26, P1252
NR 15
TC 5
Z9 5
U1 3
U2 20
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0025-7974
EI 1536-5964
J9 MEDICINE
JI Medicine (Baltimore)
PD APR 15
PY 2020
VL 99
IS 14
BP 
EP 
DI 10.1097/MD.0000000000019609
PG 5
WC Medicine, General & Internal
SC General & Internal Medicine
GA LC0GC
UT WOS:000525008200029
PM 32243384
DA 2026-01-16
ER

PT J
AU Mazzei, LG
   Bergamaschi, CC
   Silva, MT
   Barberato, Filho S
   Fulone, I
   Moura, MDG
   Guimaraes, C
   Lopes, LC
AF Mazzei, Lauren Giustti
   Bergamaschi, Cristiane de Cássia
   Silva, Marcus Tolentino
   Barberato Filho, Silvio
   Fulone, Izabela
   Moura, Mariana Del Grossi
   Guimaraes, Caio
   Lopes, Luciane Cruz
TI Use of IMMPACT domains in clinical trials of acupuncture for chronic pain: A
SO PloS one
LA English
DT Journal Article
AB Acupuncture is one of the therapeutic resources used for the management of  chronic pain. Variability in outcome measurements in randomized clinical trials  of non-oncologic chronic pain (RCT-NOCP) generates inconsistencies in determining  effects of treatments. The objective of this survey was to assess the adherence  to the recommendations made by the Initiative on Methods, Measurement, and Pain  Assessment in Clinical Trials (IMMPACT) in the measurement of RCT-NOCP of  acupuncture. This methodological research made a systematic search for eligible  studies from different sources of information. Eligible studies included those  with number of patients ≥100, who randomized and allocated patients with chronic  non-oncologic pain to be treated with acupuncture or with "sham" acupuncture, or  non-acupuncture. This research included the recommendations for IMMPACT in the  measurement of RCT-NOCP: presence of outcomes pain, physical function, emotional  state and improvement perception of patient, the source of the outcome  information pain and the tools used to measure such domains. From a total of  1,386 studies, 24 were included in this survey. Eleven studies presented low risk  of bias. Pain outcome was measured in 23 studies, physical function in 22  studies, emotional state in 14 studies and improvement perception of patient in  one study. As for the pain outcome, the patient was the information source in 50%  of the studies. The measurement tools recommended for IMMPACT were included in  eight studies (35%) that evaluated pain, one study that evaluated the emotional  state (7%), and one study that evaluated the improvement perception and  satisfaction of patient. It was observed that studies which did not adhere to the  recommendations had more favorable results for acupuncture in the outcome pain.  This study concludes that randomized clinical trials that used acupuncture to  manage chronic pain failed to adhere to IMMPACT recommendations. Clinical  societies and IMMPACT do not share the same recommendations. This fact reflects  in the diversity of outcomes and instruments adopted in the studies, making it  difficult to compare the results.
C1 Pharmaceutical Sciences Graduate Program, University of Sorocaba, Sorocaba, State of São Paulo, Brazil.
   Pharmaceutical Sciences Graduate Program, University of Sorocaba, Sorocaba, State of São Paulo, Brazil.
   Pharmaceutical Sciences Graduate Program, University of Sorocaba, Sorocaba, State of São Paulo, Brazil.
   Pharmaceutical Sciences Graduate Program, University of Sorocaba, Sorocaba, State of São Paulo, Brazil.
   Pharmaceutical Sciences Graduate Program, University of Sorocaba, Sorocaba, State of São Paulo, Brazil.
   Pharmaceutical Sciences Graduate Program, University of Sorocaba, Sorocaba, State of São Paulo, Brazil.
   Pharmaceutical Sciences Graduate Program, University of Sorocaba, Sorocaba, State of São Paulo, Brazil.
   Pharmaceutical Sciences Graduate Program, University of Sorocaba, Sorocaba, State of São Paulo, Brazil.
NR 0
TC 0
SN 1932-620
EI 
J9 PLoS One
PD APR 17
PY 2020
VL 15
IS 4
BP e0231444
EP e0231444
DI 10.1371/journal.pone.0231444
PG 1
WC Acupuncture Analgesia; methods; Adult; Aged; Chronic Pain; therapy; Female; Humans; Male; Middle Aged; Pain Measurement; methods; Randomized Controlled Trials as Topic; methods; Surveys and Questionnaires
UT PubMed:32298300
PM 32298300
DA 2020-04-17
ER

PT J
AU Yang, Y
   Wen, J
   Hong, J
AF Yang, Yulan
   Wen, Jian
   Hong, Jianyun
TI The Effects of Auricular Therapy for Cancer Pain: A Systematic Review and
SO Evidence-based complementary and alternative medicine : eCAM
LA English
DT Review
AB OBJECTIVE: This study aims to systematically assess the efficacy and safety of  auricular therapy for cancer pain. METHODS: A systematic search was conducted  using PubMed, EMBASE, Cochrane library databases, CNKI, VIP, WanFang Data, and  CBM for randomized controlled trials (RCTs). Review Manager 5.3 was used for  meta-analysis. RESULTS: Of the 275 screened studies, nine RCTs involving 783  patients with cancer pain were systematically reviewed. Compared with drug  therapy, auricular therapy plus drug therapy has significant advantages both in  the effective rate for pain relief (RR = 1.40; 95% CI 1.22, 1.60; P < 0.00001)  and adverse effects rate (RR = 0.46; 95% CI 0.37, 0.58; P < 0.00001). And the  result revealed that auricular acupuncture had superior pain-relieving effects as  compared with sham auricular acupuncture (SMD = -1.45; 95% CI -2.80, -0.09;  P=0.04). However, the analysis indicated no difference on the effective rate for  pain relief between auricular therapy and drug therapy (RR = 1.24; 95% CI 0.71,  2.16; P=0.46). CONCLUSION: Our meta-analysis indicated that auricular therapy is  effective and safe for the treatment of cancer pain, and auricular therapy plus  drug therapy is more effective than drug therapy alone, whether in terms of pain  relief or adverse reactions. However, the included RCTs had some methodological  limitations; future large, rigor, and high-quality RCTs are still needed to  confirm the benefits of auricular therapy on cancer pain.
C1 Department of Acupuncture, Maoming People's Hospital, Maoming, Guangdong, China.
   Department of Oncology, Maoming People's Hospital, Maoming, Guangdong, China.
   Department of Acupuncture, Maoming People's Hospital, Maoming, Guangdong, China.
NR 0
TC 0
SN 1741-428
EI 1741-427
J9 Evid Based Complement Alternat Med
PD JUN 23
PY 2020
VL 2020
IS 
BP 1618767
EP 1618767
DI 10.1155/2020/1618767
PG 0
UT PubMed:32565846
PM 32565846
DA 2020-06-23
ER

PT J
AU Liu, J
   Huang, Z
   Zhang, GH
AF Liu, Jing
   Huang, Zheng
   Zhang, Gen-Hong
TI [Involvement of NF-κB signal pathway in acupuncture treatment of patients with
SO Zhen ci yan jiu = Acupuncture research
LA chi
DT Journal Article
DE Acupuncture; Inflammatory factor; NF-κB signaling pathway; Rheumatoid arthritis
AB OBJECTIVE: To observe the effect of acupuncture on nuclear factor  kappa-B(NF-κB)signaling pathway in patients with rheumatoid arthritis (RA), so as  to explore the mechanism of acupuncture in the treatment of RA. METHODS: A total  of 120 RA patients admitted to the Xinyu Hospital of Traditional Chinese Medicine  in Jiangxi Province from June 2018 to June 2019 were selected and randomly  divided into a control group and a treatment group, with 60 cases in each group.  The patients in the control group received oral administration of Methotrexate,  (10-15) mg/time, once a week, for a total of 10 weeks. On the basis of oral  administration of Methotrexate, patients in the treatment group were treated with  acupuncture at Quchi(LI11), Zusanli(ST36), Taichong(LR3), Hegu(LI4),  Shenshu(BL23), Geshu(BL17) and Dazhui(GV14) once daily. The treatment was  conducted 6 consecutive times as a course for 10 courses. The serum C-reactive  protein (CRP) and erythrocyte sedimentation rate (ESR), pain visual analog scale  (VAS) score, number of swollen joints, and morning stiffness time before and  after treatment were compared between the two groups. The expression levels of  inflammatory related factors and NF-κB p65 protein in the synovial fluid were  detected by enzyme-linked immunosorbent assay and Western blot separately.  RESULTS: After treatment, both groups had significant decrease in CRP, ESR, VAS  score, number of swollen joints and morning stiffness time, levels of NF-κB p65  protein, tumor necrosis factor-α (TNF-α), interleukin-1β (IL-1β), and IL-6  (P<0.05) in the joint fluid, and increase in transforming growth factor-β (TGF-β)  and IL-10 (P<0.05). After treatment, compared with the control group, CRP, ESR,  VAS score and morning stiffness time, and the levels of NF-κB p65, TNF-α, IL-1β  and IL-6 in the treatment group were down-regulated (P<0.05), while the level of  TGF-β was up-regulated (P<0.05). The treatment group had a higher total effective  rate than the control group［85.0%(51/60) vs 75.0%(45/60), P<0.05］. CONCLUSION:  Acupuncture can inhibit the expression of NF-κB signaling pathway in RA patients,  regulate the levels of related inflammatory factors, and thus improve the  symptoms of RA patients.
C1 Department of Acupuncture and Moxibustion, Xinyu Hospital of Traditional Chinese Medicine, Xinyu 338025, Jiangxi Province, China.
   Department of Acupuncture and Moxibustion, Xinyu Hospital of Traditional Chinese Medicine, Xinyu 338025, Jiangxi Province, China.
   Department of Acupuncture and Moxibustion, Xinyu Hospital of Traditional Chinese Medicine, Xinyu 338025, Jiangxi Province, China.
NR 0
TC 0
SN 
EI 1000-060
J9 Zhen Ci Yan Jiu
PD DEC 4
PY 2020
VL 45
IS 11
BP 914
EP 9
DI 10.13702/j.1000-0607.190848
PG -905
WC Acupuncture Therapy; Arthritis, Rheumatoid; genetics; Humans; Methotrexate; NF-kappa B; genetics; Signal Transduction
UT PubMed:33269836
PM 33269836
DA 2020-12-04
ER

PT J
AU Lei, Y
   Duan, Y
   Wang, J
   Yu, X
   Deng, S
   Liu, R
   Si, H
   Li, J
   Zhang, B
AF Lei, Yi
   Duan, Yunyun
   Wang, Jisheng
   Yu, Xudong
   Deng, Sheng
   Liu, Ruijia
   Si, Hongmei
   Li, Jiameng
   Zhang, Bao
TI A randomized controlled trial for acupuncture combined with conventional therapy
SO Medicine
LA English
DT Journal Article
AB INTRODUCTION: Prostate cancer refers to an epithelial malignant tumor that occurs  in the prostate area. In recent years, with the improvement of people's living  standards, the incidence of prostate cancer has gradually increased, which has  greatly affected people's life and health and quality of life. Acupuncture has  its unique advantages in treating cancer pain. We will evaluate the efficacy and  safety of acupuncture and moxibustion in the treatment of pain caused by prostate  cancer using a clinical randomized parallel control method. METHODS/DESIGN: This  pragmatic randomized controlled trial will recruit 120 patients who are diagnosed  with prostate cancer. Simple randomization to conventional drug treatment with a  1:1 allocation ratio will be used. Based on the patient's pain location and the  primary lesion, the acupuncture needle insertion position was determined  according to the principle of local selection of acupoints. All participants will  continue to receive conventional drug treatment. DISCUSSION: This trial may  provide evidence regarding the clinical effectiveness, safety, and  cost-effectiveness of acupuncture for pain caused by prostate cancer. TRIAL  REGISTRATION: ClinicalTrials.gov, ChiCTR2000029801, Registered on 14 February  2020.
C1 The Second Affiliated Hospital of Shaanxi University of Chinese Medicine, Xianyang, Shaanxi.
   The Second Affiliated Hospital of Shaanxi University of Chinese Medicine, Xianyang, Shaanxi.
   Graduate School of Beijing University of Chinese Medicine.
   Department of Andrology.
   Graduate School of Beijing University of Chinese Medicine.
   Department of Andrology.
   Graduate School of Beijing University of Chinese Medicine.
   Department of Andrology.
   Graduate School of Beijing University of Chinese Medicine.
   The Fist Department of Neurology, Dongzhimen Hospital, Beijing University of 
   Graduate School of Beijing University of Chinese Medicine.
   Department of Andrology.
   Graduate School of Beijing University of Chinese Medicine.
   Department of Andrology.
   The Second Affiliated Hospital of Shaanxi University of Chinese Medicine, Xianyang, Shaanxi.
NR 0
TC 0
SN 1536-596
EI 0025-797
J9 Medicine (Baltimore)
PD APR 4
PY 2020
VL 99
IS 14
BP e19609
EP e19609
DI 10.1097/MD.0000000000019609
PG 1
WC Acupuncture Therapy; methods; Aged; Cancer Pain; etiology; Cost-Benefit Analysis; Humans; Male; Middle Aged; Moxibustion; methods; Pain Management; methods; Pain Measurement; Prostatic Neoplasms; complications; Randomized Controlled Trials as Topic; Treatment Outcome; Pragmatic Clinical Trials as Topic
UT PubMed:32243384
PM 32243384
DA 2020-04-04
ER

PT J
AU Ludwick, A
   Corey, K
   Meghani, S
AF Ludwick, Allison
   Corey, Kristin
   Meghani, Salimah
TI Racial and Socioeconomic Factors Associated with the Use of Complementary and Alternative Modalities for Pain in Cancer Outpatients: An Integrative Review
SO PAIN MANAGEMENT NURSING
LA English
DT Review
ID african-americans; medicine use; united-states; care; survivors; acupuncture; management; attitudes; adherence; beliefs
AB Objectives: Racial and ethnic disparities in pain management are widely documented in the United States. The 2016 Centers for Disease Control and Prevention (CDC) guidelines for opioid prescribing have generated new imperatives for using complementary and alternative medicine approaches (CAM) to manage chronic pain, including cancer pain. This review's purpose was to explore the prevalence of CAM use for cancer-related pain among racial and ethnic minorities and to organize these findings according to the CAM modalities proposed by the National Center for Complementary and Integrative Health (NCCIH). Design: An integrative review of the literature published between 2007 and 2017. Data Sources: PubMed and SCOPUS databases (2007-2017). Review/Analysis Methods: Articles were included if they engaged in explicit analysis of racial or ethnic differences in CAM use for cancer pain in the outpatient setting, yielding 13 articles for final analysis. Results and Conclusions: Overall, CAM use for any modality ranged from 51% to 83%. Mind-body therapies were reported most, and energy therapies the least. Differences in CAM use were most often attributable to socioeconomic status (SES), with those of higher SES associated with greater use of practitioner-assisted CAM therapies and those of lower SES with greater use of free therapies. This difference has implications for achieving adequate and consistent pain relief among subgroups of patients with cancer. This review also identifies a literature gap regarding racial/ethnic disparities in access to CAM for cancer pain, and a need for validated measures to assess CAM use. (C) 2019 American Society for Pain Management Nursing. Published by Elsevier Inc. All rights reserved.
C1 [Ludwick, Allison; Corey, Kristin; Meghani, Salimah] Univ Penn, Sch Nursing, Fagin Hall 337,418 Curie Blvd, Philadelphia, PA 19104 USA.
C3 University of Pennsylvania
RP Ludwick, A (corresponding author), Univ Penn, Sch Nursing, Fagin Hall 337,418 Curie Blvd, Philadelphia, PA 19104 USA.
EM ludwicka@upenn.edu
FU National Institute of Nursing Research, National Institutes of Health [R01NR017853]; Ruth L. Kirschstein National Research Service Award training program Individualized Care for At Risk Older Adults at the University of Pennsylvania - National Institute of Nursing Research [T32NR009356]; National Institute of Nursing Research [R01NR017853, T32NR009356] Funding Source: NIH RePORTER
CR Abbasi J, 2016, JAMA-J AM MED ASSOC, V316, P2343, DOI 10.1001/jama.2016.15029
   Anderson KC, 2000, CANCER, V88, P1929, DOI 10.1002/(SICI)1097-0142(20000415)88:8<1929::AID-CNCR23>3.3.CO;2-U
   Bao T, 2018, ACUPUNCT MED, V36, P80, DOI 10.1136/acupmed-2017-011435
   Bardia A, 2006, J CLIN ONCOL, V24, P5457, DOI 10.1200/JCO.2006.08.3725
   Barnes Patricia M, 2008, NATL HEALTH STAT REPORT, V0, P1
   Bauml J, 2014, SUPPORT CARE CANCER, V22, P2465, DOI 10.1007/s00520-014-2220-5
   Bauml JM, 2015, CANCER-AM CANCER SOC, V121, P2431, DOI 10.1002/cncr.29173
   Buck HG, 2012, J HOLIST NURS, V30, P107, DOI 10.1177/0898010111423420
   Cheville AL, 2014, J CLIN ONCOL, V32, P1691, DOI 10.1200/JCO.2013.53.6680
   Dowell Deborah, 2016, JAMA, V315, P1624, DOI 10.15585/mmwr.rr6501e1
   Fisch MJ, 2016, JAMA ONCOL, V2, P862, DOI 10.1001/jamaoncol.2016.0854
   Gansler T, 2008, CANCER-AM CANCER SOC, V113, P1048, DOI 10.1002/cncr.23659
   Hamilton AS, 2013, INTEGR CANCER THER, V12, P225, DOI 10.1177/1534735412449733
   Hawker S, 2002, QUAL HEALTH RES, V12, P1284, DOI 10.1177/1049732302238251
   Jones D, 2018, INTEGR CANCER THER, V17, P371, DOI 10.1177/1534735417735892
   Jones RA, 2007, ONCOL NURS FORUM, V34, P359, DOI 10.1188/07.ONF.359-364
   Judson PL, 2017, INTEGR CANCER THER, V16, P96, DOI 10.1177/1534735416660384
   Lee RT, 2014, J CLIN ONCOL, V32, P4095, DOI 10.1200/JCO.2014.55.8676
   MacPherson H, 2017, PAIN, V158, P784, DOI 10.1097/j.pain.0000000000000747
   McCaffrey AM, 2007, J GEN INTERN MED, V22, P1500, DOI 10.1007/s11606-007-0302-5
   McDermott CL, 2012, SUPPORT CARE CANCER, V20, P65, DOI 10.1007/s00520-010-1055-y
   Meghani SH, 2018, JAMA ONCOL, V4, P1323, DOI 10.1001/jamaoncol.2018.1574
   Meghani SH, 2016, JAMA ONCOL, V2, P1243, DOI 10.1001/jamaoncol.2016.2185
   Meghani SH, 2015, PAIN MED, V16, P2222, DOI 10.1111/pme.12829
   Meghani SH, 2015, J PAIN, V16, P825, DOI 10.1016/j.jpain.2015.05.009
   Meghani SH, 2014, J CLIN ONCOL, V32, P2773, DOI 10.1200/JCO.2013.54.7992
   Meghani SH, 2013, BMC MED INFORM DECIS, V13, P0, DOI 10.1186/1472-6947-13-118
   Meghani SH, 2012, PAIN MED, V13, P150, DOI 10.1111/j.1526-4637.2011.01310.x
   Meghani SH, 2011, PAIN MED, V12, P634, DOI 10.1111/j.1526-4637.2011.01074.x
   Nahin RL, 2007, BMC PUBLIC HEALTH, V7, P0, DOI 10.1186/1471-2458-7-217
   Ni HY, 2002, MED CARE, V40, P353, DOI 10.1097/00005650-200204000-00011
   Owens B, 2009, J HOLIST NURS, V27, P167, DOI 10.1177/0898010108330801
   Paley CA, 2011, BMJ SUPPORT PALLIAT, V1, P51, DOI 10.1136/bmjspcare-2011-000022
   Paley CA, 2011, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD007753.pub2
   Rhee YO, 2012, J IMMIGR MINOR HEALT, V14, P1045, DOI 10.1007/s10903-012-9582-x
   Richardson MA, 2000, J CLIN ONCOL, V18, P2505, DOI 10.1200/JCO.2000.18.13.2505
   Rosen JE, 2013, THYROID, V23, P1238, DOI 10.1089/thy.2012.0495
   Sohl SJ, 2014, SUPPORT CARE CANCER, V22, P927, DOI 10.1007/s00520-013-2040-z
   Standish LJ, 2017, INTEGR CANCER THER, V16, P85, DOI 10.1177/1534735416649034
   Stein KD, 2009, CANCER-AM CANCER SOC, V115, P4397, DOI 10.1002/cncr.24591
   Whittemore R, 2005, J ADV NURS, V52, P546, DOI 10.1111/j.1365-2648.2005.03621.x
   Wong-Kim E, 2007, J HEALTH CARE POOR U, V18, P118, DOI 10.1353/hpu.2007.0123
NR 44
TC 24
Z9 27
U1 1
U2 6
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1524-9042
EI 1532-8635
J9 PAIN MANAG NURS
JI Pain Manag. Nurs.
PD APR 15
PY 2020
VL 21
IS 2
BP 142
EP 150
DI 10.1016/j.pmn.2019.08.005
PG 9
WC Nursing
SC Nursing
GA KU7GS
UT WOS:000519882200004
PM 31928745
DA 2026-01-16
ER

PT J
AU Fink, J
   Burns, J
   Perez, Moreno AC
   Kram, JJF
   Armstrong, M
   Chopp, S
   Maul, SJ
   Conway, N
AF Fink, Jennifer
   Burns, John
   Perez Moreno, Ana Christina
   Kram, Jessica J F
   Armstrong, Melissa
   Chopp, Sara
   Maul, Scott J
   Conway, Nancy
TI A Quality Brief of an Oncological Multisite Massage and Acupuncture Therapy
SO Journal of alternative and complementary medicine (New York, N.Y.)
LA English
DT Journal Article
DE acupuncture treatment; cancer-related symptoms; massage treatment
AB Objectives: Cancer treatment can present its own physical and mental challenges  resulting in symptoms such as fatigue, stress, pain, nausea, and vomiting. Aurora  Health Care is a large health system with 19 cancer centers. Integrative  therapies such as acupuncture and massage have demonstrated success in reducing  cancer-related symptoms and side effects to conventional cancer treatment and  improving patient outcomes. In 2018, 15 of the 19 Aurora Cancer Clinics embedded  a replicable Integrative Cancer Care closed model to provide adjuvant therapies  for the best patient outcomes. This quality improvement study aimed to explore if  the replicable integrative care model could demonstrate consistent outcomes for  massage and acupuncture therapies aimed at symptom reduction across multiple  oncology clinics. Design: Aurora Cancer Care and Aurora Integrative Medicine  designed a reproducible integrative therapy service model to be embedded into the  Aurora Cancer Centers. Integrative therapies within the cancer centers allow  patients easy access to care before, during, or after their cancer treatment. In  2018, 15 of the 19 cancer clinics had integrative therapies available to patients  with cancer. This model required unified operations, onboarding, training,  competency, and clinical oversight to achieve consistent processes for consistent  outcomes. Furthermore, these innovative models prioritized the following: patient  access (easy and affordable); service delivery (consistent and operationalized);  clinical outcomes (effective and meaningful); and caliber of clinician (competent  and confident). Aurora Health Care employs massage therapists (Mts) and  acupuncturists (Ats). This employment model allows for standards and program  model adherence. To achieve competent and confident clinician's, MT or AT must  complete a cancer treatment-focused competency training program relative to their  respective profession and adherence to practice standards outlined. The training  program is built on evidence-based practice, observation, direct demonstration,  return demonstration, mentorship, and ongoing quality review by clinical leaders.  Aurora's Integrative Cancer Care closed model of care is accessible to patients  through philanthropic funds secured to underwrite the free service of MT provided  during infusion treatments. Funds also provided three free AT sessions. Ongoing  acupuncture therapies were provided at a low-cost group acupuncture fee at $25.00  per treatment. Acupuncture is available in group format and provided either  before or after chemotherapy treatment. The free services were intended to  introduce the concept of integrative therapies as a viable adjuvant option with  conventional cancer care. As this model incorporates a mix of philanthropic  funding and low-cost fees to offset the cost of the therapy provider, it is  referred to as a "closed model" or accessible only to those patients under the  care of an Aurora Cancer specialist. In 2018, 15 Aurora Cancer Clinics offered  massage and 11 Aurora Cancer Clinics offered acupuncture. Patients who  self-selected integrative therapies via system-employed Mts and Ats were surveyed  pre/post acupuncture and MT treatments using a visual analog scale about their  perceived levels of pain, stress, nausea, and neuropathy. The staff integrative  clinicians collected data from patients, and post-treatment data were compiled by  the Department of Integrative Medicine. Settings/Location: Aurora Cancer Centers  are embedded within Aurora hospitals or free-standing clinics located throughout  Wisconsin. In 2018, 15 cancer clinic locations embedded Mts, and 11 cancer clinic  locations embedded Ats. Subjects: Oncology patients. Interventions: Clinical  competencies were developed and applied to address indications,  contraindications, and oncology-specific procedures to ensure that consistent  quality of therapies was provided across sites. In 2018, Ats delivered 4367 Ats  across 11 locations and Mts delivered 4197 Mts across 15 locations. During this  study, the number of treatments provided was tracked versus episodic care.  Outcome Measures: Pre/post AT and MT pain, stress, nausea, and neuropathy scores  were recorded (0 [least] to 10 [worst]) and compared using paired t-tests.  Results: Pre/post AT scores for pain, neuropathy, stress, and nausea were all  significantly different (p < 0.001). For AT, there was a reported decrease in  pain, stress, and neuropathy of 61.7%, 68.8%, and 47.9%, respectively. Pre/post  MT scores for pain, neuropathy, nausea, and stress were also significantly  different (p < 0.001). MT was greater at reducing stress and pain, 42.5% and  34.4%, respectively. Conclusions: Across 15 cancer clinics, both AT and MT  treatments consistently and significantly reduced cancer-related side effects.  These findings highlight the value of conducting a larger randomized-controlled  trial to further assess the impact of Oncological Multisite Massage and  Acupuncture Therapy on cancer-related symptoms across multiple oncologic clinics.
C1 Department of Health Informatics and Administration, University of Wisconsin-Milwaukee, Milwaukee, WI, USA.
   Department of Integrative Medicine, Aurora Health Care, Aurora Sinai Medical Center, Milwaukee, WI, USA.
   Aurora Research Institute, Aurora Health Care, Milwaukee, WI, USA.
   Aurora UW Medical Group and Center for Urban Population Health, Aurora Health Care, Aurora Sinai Medical Center, Milwaukee, WI, USA.
   Department of Integrative Medicine, Aurora Health Care, Aurora Sinai Medical Center, Milwaukee, WI, USA.
   Department of Health Informatics and Administration, University of Wisconsin-Milwaukee, Milwaukee, WI, USA.
   Department of Oncology, Aurora Health Care, Milwaukee, WI, USA.
   Department of Integrative Medicine, Aurora Health Care, Aurora Sinai Medical Center, Milwaukee, WI, USA.
NR 0
TC 0
SN 1557-770
EI 
J9 J Altern Complement Med
PD SEP 15
PY 2020
VL 26
IS 9
BP 820
EP 824
DI 10.1089/acm.2019.0371
PG 4
WC Acupuncture; Acupuncture Therapy; Ambulatory Care Facilities; Humans; Integrative Medicine; Integrative Oncology; Massage; Medical Oncology; Nausea; etiology; Neoplasms; complications; Pain; etiology; Pain Management; Palliative Care; Peripheral Nervous System Diseases; etiology; Program Evaluation; Stress, Psychological; etiology; Surveys and Questionnaires; Treatment Outcome; Vomiting
UT PubMed:32924553
PM 32924553
DA 2020-09-15
ER

PT J
AU Chien, TJ
   Liu, CY
   Fang, CJ
   Kuo, CY
AF Chien, T. -J.
   Liu, C. -Y.
   Fang, C. -J.
   Kuo, C. -Y.
TI The maintenance effect of acupuncture on breast cancer-related menopause symptoms: a systematic review
SO CLIMACTERIC
LA English
DT Review
DE Acupuncture; breast cancer; hot flushes; menopause symptom; systematic review
ID hot flashes; vasomotor symptoms; hormone-therapy; applied relaxation; skin-conductance; controlled-trial; joint pain; women; electroacupuncture; metaanalysis
AB Background: Acupuncture has been used for many breast cancer treatment-related problems, but how long the effect lasts is unknown. This meta-analysis aims to evaluate how long the effect of acupuncture on breast cancer-related hot flushes and menopause symptoms lasts. Methods: The research design followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses Statement, without language restrictions. Seven databases from inception through February 2019 were accessed; only randomized clinical trials (RCTs) that examined the maintenance effect of acupuncture on hot flushes or menopause symptoms after treatment were included. Cochrane criteria were followed and RevMan 5.2 software was used to analyze trials. Results: In total, 943 patients from 13 RCTs were analyzed. The meta-analysis showed that acupuncture had no significant long-term maintenance effect on the frequency or severity of hot flushes (p?=?0.29; p?=?0.34), but had a significant 3-month maintenance effect of ameliorating menopause symptoms at 3 months after treatment ended (p?=?0.001). No adverse events were reported. Conclusions: Acupuncture significantly alleviated menopause symptoms for at least 3 months, but not hot flushes. Breast cancer patients concerned about the adverse effects of hormone therapy could consider acupuncture as an alternative. Additional acupuncture at 3 months after the initial treatment course could be considered. A large-scale study may help to define the optimal guideline for this issue.
C1 [Chien, T. -J.] Taipei City Hosp, Dept Internal Med, Div Hematooncol, Branch Zhong Zhou & Jen Ai, Taipei, Taiwan.
   [Chien, T. -J.; Liu, C. -Y.; Kuo, C. -Y.] Natl Yang Ming Univ, Inst Tradit Med, Taipei, Taiwan.
   [Liu, C. -Y.] Chang Gung Univ, Coll Med, Sch Tradit Chinese Med, Taoyuan, Taiwan.
   [Liu, C. -Y.] China Med Univ, Sch Chinese Med, Taichung, Taiwan.
   [Liu, C. -Y.] Flourish Tradit Chinese Med Clin, Taipei, Taiwan.
   [Fang, C. -J.] Natl Cheng Kung Univ, Med Lib, Tainan, Taiwan.
   [Fang, C. -J.] Natl Cheng Kung Univ, Natl Cheng Kung Univ Hosp, Coll Med, Dept Secretariat, Tainan, Taiwan.
C3 Taipei City Hospital; National Yang Ming Chiao Tung University; Chang Gung University; China Medical University Taiwan; National Cheng Kung University; National Cheng Kung University; National Cheng Kung University Hospital
RP Chien, TJ (corresponding author), Taipei City Hosp, Dept Internal Med, Div Hematooncol, Branch Zhong Zhou & Jen Ai, Taipei, Taiwan.
EM silence021@gmail.com
FU Ministry of Science and Technology - MOST, Taiwan [107-2635-B-532-003-]
CR Bäcker M, 2008, CLIN J PAIN, V24, P106, DOI 10.1097/AJP.0b013e318159f95e
   Bahr DE, 2014, PHYSIOL MEAS, V35, P95, DOI 10.1088/0967-3334/35/2/95
   Bao T, 2014, CANCER-AM CANCER SOC, V120, P381, DOI 10.1002/cncr.28352
   Bokmand S, 2013, BREAST, V22, P320, DOI 10.1016/j.breast.2012.07.015
   Bonta IL, 2002, MED HYPOTHESES, V58, P221, DOI 10.1054/mehy.2001.1425
   Borud E, 2010, AUTON NEUROSCI-BASIC, V157, P57, DOI 10.1016/j.autneu.2010.04.004
   CHEN CH, 1979, AM J CHINESE MED, V7, P183, DOI 10.1142/S0192415X79000155
   Chen HY, 2019, AM J CHINESE MED, V47, P1, DOI 10.1142/S0192415X19500010
   Chen L, 2017, BREAST, V33, P132, DOI 10.1016/j.breast.2017.03.015
   Chen YP, 2016, J CANCER RES THER, V12, P535, DOI 10.4103/0973-1482.172716
   Chien TJ, 2017, PLOS ONE, V12, P0, DOI 10.1371/journal.pone.0180918
   Chien TJ, 2015, J ALTERN COMPLEM MED, V21, P251, DOI 10.1089/acm.2014.0083
   Chiu HY, 2016, CANCER NURS, V39, P228, DOI 10.1097/NCC.0000000000000278
   Chiu HY, 2015, MENOPAUSE, V22, P234, DOI 10.1097/gme.0000000000000260
   Chlebowski RT, 2019, MENOPAUSE, V26, P578, DOI 10.1097/GME.0000000000001283
   Choi TY, 2017, INTEGR CANCER THER, V16, P135, DOI 10.1177/1534735416664172
   COUZI RJ, 1995, J CLIN ONCOL, V13, P2737, DOI 10.1200/JCO.1995.13.11.2737
   Deng G, 2007, J CLIN ONCOL, V25, P5584, DOI 10.1200/JCO.2007.12.0774
   Filshie Jacqueline, 2005, ACUPUNCT MED, V23, P171
   Fisher WI, 2016, MENOPAUSE, V23, P1222, DOI 10.1097/GME.0000000000000685
   Freedman RR, 2014, J STEROID BIOCHEM, V142, P115, DOI 10.1016/j.jsbmb.2013.08.010
   Frisk J, 2008, CLIMACTERIC, V11, P166, DOI 10.1080/13697130801958709
   Frisk J, 2012, SUPPORT CARE CANCER, V20, P715, DOI 10.1007/s00520-011-1134-8
   Fu HY, 2018, LIFE SCI, V197, P109, DOI 10.1016/j.lfs.2018.02.005
   Gao Z, 2013, J TRADIT CHIN MED, V33, P1
   Oyarzún MFG, 2017, GYNECOL ENDOCRINOL, V33, P418, DOI 10.1080/09513590.2017.1290076
   Goodwin PJ, 1999, J CLIN ONCOL, V17, P2365, DOI 10.1200/JCO.1999.17.8.2365
   Gorodeski EZ, 2012, MENOPAUSE, V19, P382, DOI 10.1097/gme.0b013e31824c7a3b
   Hershman DL, 2018, JAMA-J AM MED ASSOC, V320, P2270, DOI 10.1001/jama.2018.16744
   Hershman DL, 2018, JAMA-J AM MED ASSOC, V320, P167, DOI 10.1001/jama.2018.8907
   Hervik J, 2014, SPRINGERPLUS, V3, P0, DOI 10.1186/2193-1801-3-141
   Hervik J, 2009, BREAST CANCER RES TR, V116, P311, DOI 10.1007/s10549-008-0210-3
   Hesse T, 2016, ACUPUNCT MED, V34, P14, DOI 10.1136/acupmed-2015-010852
   Higgins JP GS, 2011, COCHRANE HDB SYSTEMA, V4, P9.5.2, DOI 10.1002/9780470712184
   Huang HP, 2016, NEURAL REGEN RES, V11, P465, DOI 10.4103/1673-5374.179060
   Iseki C, 2014, CASE REP NEUROL MED, V2014, P0, DOI 10.1155/2014/953109
   Jadad AR, 1996, CONTROL CLIN TRIALS, V17, P1, DOI 10.1016/0197-2456(95)00134-4
   Lee HJ, 2009, J EXP CLIN CANC RES, V28, P0, DOI 10.1186/1756-9966-28-102
   Lee SH, 2017, MEDICINE, V96, P0, DOI 10.1097/MD.0000000000005836
   Lesi G, 2016, J CLIN ONCOL, V34, P1795, DOI 10.1200/JCO.2015.63.2893
   LI QQ, 2013, EVID BASED COMPL ALT, V2013, P0
   Liberati A, 2009, PLOS MED, V62, Pe1, DOI 10.1371/journal.pmed.1000100
   Liljegren A, 2012, BREAST CANCER RES TR, V135, P791, DOI 10.1007/s10549-010-1283-3
   Lu LY, 2017, TRIALS, V18, P0, DOI 10.1186/s13063-017-2188-9
   Mao JJ, 2015, J CLIN ONCOL, V33, P3615, DOI 10.1200/JCO.2015.60.9412
   Moher D, 2009, PLOS MED, V6, P0, DOI 10.1371/journal.pmed.1000097
   Nedstrand E, 2005, CLIMACTERIC, V8, P243, DOI 10.1080/13697130500118050
   Nedstrand E, 2006, J PSYCHOSOM OBST GYN, V27, P193, DOI 10.1080/01674820600724797
   Pachman DR, 2013, MENOPAUSE, V20, P1164, DOI 10.1097/GME.0b013e31828cec53
   Pan YQ, 2018, INTEGR CANCER THER, V17, P602, DOI 10.1177/1534735418786801
   Schneider H P, 2000, CLIMACTERIC, V3, P50, DOI 10.3109/13697130009167599
   SONIA B, 2012, EUR J INTEGR MED, V4, P49
   Thakur A, 2016, J ACUPUNCT MERIDIAN, V9, P109, DOI 10.1016/j.jams.2016.01.016
   Usichenko TI, 2016, CLIN J PAIN, V32, P82, DOI 10.1097/AJP.0000000000000222
   Walker EM, 2010, J CLIN ONCOL, V28, P634, DOI 10.1200/JCO.2009.23.5150
   Wanchai A, 2010, CLIN J ONCOL NURS, V14, P431, DOI 10.1188/10.CJON.E45-E55
   Wang Xu, 2018, ZHONGGUO ZHEN JIU, V38, P1347, DOI 10.13703/j.0255-2930.2018.12.024
   Wang XR, 2015, FREE RADICAL BIO MED, V89, P1077, DOI 10.1016/j.freeradbiomed.2015.10.426
   Xiao Bin, 2014, ZHONGGUO ZHEN JIU, V34, P956
   Yu JS, 2013, INT REV NEUROBIOL, V111, P125, DOI 10.1016/B978-0-12-411545-3.00006-7
   Zhu W, 2018, NEUROSCIENCE, V379, P281, DOI 10.1016/j.neuroscience.2018.03.029
   2006, 1900, V12, V0, P11
NR 62
TC 15
Z9 19
U1 0
U2 18
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 1369-7137
EI 1473-0804
J9 CLIMACTERIC
JI Climacteric
PD MAR 3
PY 2020
VL 23
IS 2
BP 130
EP 139
DI 10.1080/13697137.2019.1664460
EA OCT 2019
PG 10
WC Obstetrics & Gynecology
SC Obstetrics & Gynecology
GA KI1HZ
UT WOS:000490441400001
PM 31612733
DA 2026-01-16
ER

PT J
AU Dymackova, R
   Kazda, T
   Slavik, M
   Selingerova, I
   Slampa, P
   Slama, O
AF Dymackova, Radana
   Kazda, Tomas
   Slavik, Marek
   Selingerova, Iveta
   Slampa, Pavel
   Slama, Ondrej
TI Acupuncture in the treatment of acute toxicity during and after head and neck
SO Biomedical papers of the Medical Faculty of the University Palacky, Olomouc,
LA English
DT Journal Article
DE acupuncture; cancer; head and neck; radiotherapy; toxicity
AB AIMS: The aim of this investigator-initiated prospective randomized open-label  single institutional trial is to evaluate the role of acupuncture in the  treatment of acute skin and mucosal toxicity, xerostomia, and perception of  taste, pain, and nausea related to curative and adjuvant (chemo)radiotherapy of  head and neck cancer. This paper reports pilot data of the first 30 enrolled  patients. METHODS: Patients were randomized to undergo standard of care  radiotherapy ± chemotherapy and support care defined by our institutional  standard operating procedures alone or in the combination with acupuncture which  was initiated with the first signs of any toxicity. RESULTS: Fifteen patients  were enrolled in both arms and all finished the treatment as planned.The median  pain was significantly lower in the acupuncture arm (median 1.6 points vs. 2.5  points on a 10-item Likert scale; P=0.035) as well as duration of acute pain  (median 31 days vs. 54 days; P=0.031). Patients with acupuncture had  significantly shorter duration of acute skin (median 44 days vs. 109 days;  P<0.001) and mucosal toxicity (median 34 days vs. 109 days; P<0.001) with no  difference in grading of toxicity (median grade 1.6 vs. 1.5; P=0.701 and median  grade 1.4 vs. 1.6; P=0.204 for skin and mucosa, respectively). No significant  difference was found for other toxicity domains, with the exception of salivation  toxicity which was significantly lower in acupuncture arm (median grade 1.3 vs.  1.7; P=0.048). CONCLUSION: In this interim analysis, acupuncture leads to lower  pain andfaster disappearance of skin and mucosal toxicity after  (chemo)radiotherapy of head and neck cancer. Description and validation of  acupuncture using scientific approaches will further enhance acceptance of this  method by both patients and health care providers. TRIAL REGISTRATION:  Clinicaltrials.gov - NCT03751566.
C1 Department of Radiation Oncology, Faculty of Medicine, Masaryk University, Kamenice 5, 625 00 Brno, Czech Republic.
   Department of Radiation Oncology, Masaryk Memorial Cancer Institute, Zluty kopec 
   Department of Radiation Oncology, Faculty of Medicine, Masaryk University, Kamenice 5, 625 00 Brno, Czech Republic.
   Department of Radiation Oncology, Masaryk Memorial Cancer Institute, Zluty kopec 
   Department of Radiation Oncology, Faculty of Medicine, Masaryk University, Kamenice 5, 625 00 Brno, Czech Republic.
   Department of Radiation Oncology, Masaryk Memorial Cancer Institute, Zluty kopec 
   Regional Center for Applied Molecular Oncology (RECAMO), Masaryk Memorial Cancer Institute, Zluty kopec 7, 656 53 Brno, Czech Republic.
   Department of Radiation Oncology, Faculty of Medicine, Masaryk University, Kamenice 5, 625 00 Brno, Czech Republic.
   Department of Radiation Oncology, Masaryk Memorial Cancer Institute, Zluty kopec 
   Department of Comprehensive Cancer Care, Faculty of Medicine, Masaryk University, Kamenice 5, 625 00 Brno, Czech Republic.
   Department of Comprehensive Cancer Care, Masaryk Memorial Cancer Institute, Zluty
NR 0
TC 0
SN 1804-752
EI 
J9 Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub
PD JUL 1
PY 2020
VL 164
IS 4
BP 454
EP 460
DI 10.5507/bp.2020.021
PG 6
WC Acupuncture Therapy; methods; Aged; Czech Republic; Female; Head and Neck Neoplasms; radiotherapy; Humans; Male; Middle Aged; Prospective Studies; Radiotherapy; adverse effects; Skin; radiation effects; Skin Diseases; etiology
UT PubMed:32597419
PM 32597419
DA 2020-07-01
ER

PT J
AU Dymackova, R
   Kazda, T
   Slavik, M
   Selingerova, I
   Slampa, P
   Slama, O
AF Dymackova, Radana
   Kazda, Tomas
   Slavik, Marek
   Selingerova, Iveta
   Slampa, Pavel
   Slama, Ondrej
TI Acupuncture in the treatment of acute toxicity during and after head and neck cancer radiotherapy: Interim analysis of randomized prospective open-label trial
SO BIOMEDICAL PAPERS-OLOMOUC
LA English
DT Article
DE acupuncture; head and neck; cancer; radiotherapy; toxicity
ID radiation-induced xerostomia; prevention
AB Aims. The aim of this investigator-initiated prospective randomized open-label single institutional trial is to evaluate the role of acupuncture in the treatment of acute skin and mucosal toxicity, xerostomia, and perception of taste, pain, and nausea related to curative and adjuvant (chemo)radiotherapy of head and neck cancer. This paper reports pilot data of the first 30 enrolled patients. Methods. Patients were randomized to undergo standard of care radiotherapy +/- chemotherapy and support care defined by our institutional standard operating procedures alone or in the combination with acupuncture which was initiated with the first signs of any toxicity. Results. Fifteen patients were enrolled in both arms and all finished the treatment as planned.The median pain was significantly lower in the acupuncture arm (median 1.6 points vs. 2.5 points on a 10-item Likert scale; P=0.035) as well as duration of acute pain (median 31 days vs. 54 days; P=0.031). Patients with acupuncture had significantly shorter duration of acute skin (median 44 days vs. 109 days; P<0.001) and mucosal toxicity (median 34 days vs. 109 days; P<0.001) with no difference in grading of toxicity (median grade 1.6 vs. 1.5; P=0.701 and median grade 1.4 vs. 1.6; P=0.204 for skin and mucosa, respectively). No significant difference was found for other toxicity domains, with the exception of salivation toxicity which was significantly lower in acupuncture arm (median grade 1.3 vs. 1.7; P=0.048). Conclusion. In this interim analysis, acupuncture leads to lower pain andfaster disappearance of skin and mucosal toxicity after (chemo)radiotherapy of head and neck cancer. Description and validation of acupuncture using scientific approaches will further enhance acceptance of this method by both patients and health care providers.
C1 [Dymackova, Radana; Kazda, Tomas; Slavik, Marek; Slampa, Pavel] Masaryk Univ, Fac Med, Dept Radiat Oncol, Kamenice 5, Brno 62500, Czech Republic.
   [Dymackova, Radana; Kazda, Tomas; Slavik, Marek; Slampa, Pavel] Masaryk Mem Canc Inst, Dept Radiat Oncol, Zluty Kopec 7, Brno 65653, Czech Republic.
   [Selingerova, Iveta] Masaryk Mem Canc Inst, Reg Ctr Appl Mol Oncol RECAMO, Zluty Kopec 7, Brno 65653, Czech Republic.
   [Slama, Ondrej] Masaryk Univ, Fac Med, Dept Comprehens Canc Care, Kamenice 5, Brno 62500, Czech Republic.
   [Slama, Ondrej] Masaryk Mem Canc Inst, Dept Comprehens Canc Care, Zluty Kopec 7, Brno 65653, Czech Republic.
C3 Masaryk University; Masaryk Memorial Cancer Institute; Masaryk Memorial Cancer Institute; Masaryk University; Masaryk Memorial Cancer Institute
RP Kazda, T (corresponding author), Masaryk Univ, Fac Med, Dept Radiat Oncol, Kamenice 5, Brno 62500, Czech Republic.; Kazda, T (corresponding author), Masaryk Mem Canc Inst, Dept Radiat Oncol, Zluty Kopec 7, Brno 65653, Czech Republic.
EM tomas.kazda@mou.cz
FU Ministry of Health of the Czech Republic [15-33590A]; MH CZ-DRO (MMCI) [00209805]; project MSMT -NPU I [LO1413]
CR Brizhik L, 2019, J ACUPUNCT MERIDIAN, V12, P29, DOI 10.1016/j.jams.2018.06.009
   Chan ATC, 2012, ANN ONCOL, V23, P83, DOI 10.1093/annonc/mds266
   Chan MWC, 2017, SCI REP-UK, V7, P0, DOI 10.1038/s41598-017-03272-0
   Dymackova R, 2014, KLIN ONKOL, V27, P291
   Braga FDF, 2011, BRAZ ORAL RES, V25, P180
   Gregoire V, 2010, ANN ONCOL, V21, Pv184, DOI 10.1093/annonc/mdq185
   Meng ZQ, 2012, CANCER-AM CANCER SOC, V118, P3337, DOI 10.1002/cncr.26550
   Niu X, 2013, AFR J TRADIT COMPLEM, V10, P550, DOI 10.4314/ajtcam.v10i3.25
   Santuray RT, 2018, TRENDS CANCER, V4, P385, DOI 10.1016/j.trecan.2018.03.006
   Wang XP, 2018, J CANCER RES THER, V14, PS600, DOI 10.4103/0973-1482.183174
NR 10
TC 10
Z9 11
U1 0
U2 7
PU PALACKY UNIV, MEDICAL FAC
PI OLOMOUC
PA CENTRAL LIBRARY, HNEVOTINSKA 3, OLOMOUC, 00000, CZECH REPUBLIC
SN 1213-8118
EI 1804-7521
J9 BIOMED PAP
JI Biomed. Pap-Olomouc
PD DEC 15
PY 2020
VL 164
IS 4
BP 454
EP 460
DI 10.5507/bp.2020.021
PG 7
WC Engineering, Biomedical; Medicine, Research & Experimental
SC Engineering; Research & Experimental Medicine
GA PO1ST
UT WOS:000604951200014
PM 32597419
DA 2026-01-16
ER

PT J
AU Zhang, CP
   Xia, C
   Zhang, XW
   Li, WM
   Miao, XR
   Zhou, QH
AF Zhang, Chunpeng
   Xia, Chen
   Zhang, Xiaowen
   Li, Weimin
   Miao, Xuerong
   Zhou, Qinghui
TI Wrist-ankle acupuncture attenuates cancer-induced bone pain by regulating descending pain-modulating system in a rat model
SO CHINESE MEDICINE
LA English
DT Article
DE Wrist-ankle acupuncture; Electroacupuncture; Cancer pain; Descending modulation
ID ventromedial medulla; murine model; receptor; electroacupuncture; expression; mu; hyperalgesia; mechanisms; analgesia; endomorphin-1
AB Background Cancer-induced bone pain (CIBP) presents a multiple-mechanism of chronic pain involving both inflammatory and neuropathic pain, and its pathogenesis is closely related to endogenous descending system of pain control. However, the action mechanism underlying the effects of wrist-ankle acupuncture (WAA) versus electroacupuncture (EA) on CIBP remains unknown. Methods Thirty-two Wistar rats were divided into sham, CIBP, EA-treated and WAA-treated groups. CIBP was induced in rats of the latter three groups. Time courses of weight and mechanical hyperalgesia threshold (MHT) were evaluated. After 6 days of EA or WAA treatment, the expressions of 5-hydroxytryotamine type 3A receptor (5-HT3AR) and mu-opioid receptor (MOR) in rostral ventromedial medulla (RVM) and/or spinal cord, as well as the levels of 5-HT, beta-endorphin, endomorphin-1 and endomorphin-2 in RVM and spinal cord, were detected. Results Injection of cancer cells caused decreased MHT, which was attenuated by EA or WAA (P < 0.05). WAA had a quicker analgesic effect than EA (P < 0.05). No significant difference of MOR in RVM was found among the four groups. EA or WAA counteracted the cancer-driven upregulation of 5-HT3AR and downregulation of MOR in spinal cord (P < 0.05), and upregulation of 5-HT and downregulation of endomorphin-1 in both RVM and spinal cord (P < 0.05). beta-endorphin and endomorphin-2 in RVM and spinal cord decreased in CIBP group compared with sham group (P < 0.05), but EA or WAA showed no significant effect on them, although a tendency of increasing effect was observed. Conclusion WAA, similar to EA, alleviated mechanical hyperalgesia in CIBP rats by suppressing the expressions of 5-HT and 5-HT3AR, and increasing the expressions of MOR and endomorphin-1 in RVM-spinal cord pathway of the descending pain-modulating system. However, WAA produced a quicker analgesic effect than EA, the mechanisms of which need further investigation.
C1 [Zhang, Chunpeng; Xia, Chen; Zhang, Xiaowen; Zhou, Qinghui] Naval Med Univ, Sch Tradit Chinese Med, Changhai Hosp, 168 Changhai Rd, Shanghai 200433, Peoples R China.
   [Li, Weimin] Fudan Univ, Shanghai Med Coll, Lab Neuronal Network & Syst Biol, Shanghai 200032, Peoples R China.
   [Miao, Xuerong] Naval Med Univ, Dept Anesthesiol, Eastern Hepatobiliary Surg Hosp, 225 Changhai Rd, Shanghai 200433, Peoples R China.
C3 Naval Medical University; Fudan University; Naval Medical University
RP Zhou, QH (corresponding author), Naval Med Univ, Sch Tradit Chinese Med, Changhai Hosp, 168 Changhai Rd, Shanghai 200433, Peoples R China.; Miao, XR (corresponding author), Naval Med Univ, Dept Anesthesiol, Eastern Hepatobiliary Surg Hosp, 225 Changhai Rd, Shanghai 200433, Peoples R China.
EM miaoxr@smmu.edu.cn; qinghui2016@163.com
FU National Natural Science Foundation of China [81373756]
CR Unknown -, 2005, CHIN J INTEGRATED TR, V0, P0
   Bee LA, 2007, NEUROSCIENCE, V147, P786, DOI 10.1016/j.neuroscience.2007.05.004
   Calejesan AA, 2000, EUR J PAIN, V4, P83, DOI 10.1053/eujp.1999.0158
   [曹菲 CAO Fei], 2009, 中华麻醉学杂志 CHINESE JOURNAL OF ANESTHESIOLOGY, V29, P992
   CHAPLAN SR, 1994, J NEUROSCI METH, V53, P55, DOI 10.1016/0165-0270(94)90144-9
   CLEMENTJONES V, 1980, LANCET, V2, P946
   Coleman RE, 2006, CLIN CANCER RES, V12, P6243S, DOI 10.1158/1078-0432.CCR-06-0931
   Colvin L, 2008, EUR J CANCER, V44, P1083, DOI 10.1016/j.ejca.2008.03.001
   De Marco R, 2016, CURR TOP MED CHEM, V16, P141, DOI 10.2174/1568026615666150817103635
   DIXON WJ, 1980, ANNU REV PHARMACOL, V20, P441, DOI 10.1146/annurev.pa.20.040180.002301
   Donovan-Rodriguez T, 2006, NEUROSCI LETT, V393, P237, DOI 10.1016/j.neulet.2005.09.073
   [杜俊英 Du Junying], 2014, 中华中医药杂志 CHINA JOURNAL OF TRADITIONAL CHINESE MEDICINE AND PHARMACY, V29, P1454
   Dubin AE, 1999, J BIOL CHEM, V274, P30799, DOI 10.1074/jbc.274.43.30799
   Falk S, 2014, J CLIN ONCOL, V32, P1647, DOI 10.1200/JCO.2013.51.7219
   Fallon M, 2016, J CLIN ONCOL, V34, P550, DOI 10.1200/JCO.2015.63.8221
   Fernandes C, 2016, NUCL MED BIOL, V43, P150, DOI 10.1016/j.nucmedbio.2015.11.004
   Foley Kathleen M, 2004, J NATL CANCER INST MONOGR, V0, P103
   Gong JH, 1998, FEBS LETT, V439, P152, DOI 10.1016/S0014-5793(98)01362-3
   Hackler L, 1997, PEPTIDES, V18, P1635, DOI 10.1016/S0196-9781(97)00259-3
   Han JS, 2004, NEUROSCI LETT, V361, P258, DOI 10.1016/j.neulet.2003.12.019
   Han JS, 2003, TRENDS NEUROSCI, V26, P17, DOI 10.1016/S0166-2236(02)00006-1
   Han Z, 1999, NEUROSCI LETT, V274, P75, DOI 10.1016/S0304-3940(99)00670-9
   [胡侠 Hu Xia], 2004, 中国针灸 CHINESE ACUPUNCTURE AND MOXIBUSTION, V24, P149
   Huang ZX, 2014, PAIN, V155, P783, DOI 10.1016/j.pain.2014.01.011
   Hurley RW, 2003, NEUROSCIENCE, V118, P789, DOI 10.1016/S0306-4522(03)00041-1
   Jia Wang-Hua, 2016, ZHEN CI YAN JIU, V41, P225
   Koyyalagunta D, 2012, PAIN PHYSICIAN, V15, P0
   Lao LX, 2004, BRAIN RES, V1020, P18, DOI 10.1016/j.brainres.2004.01.092
   Liang FR, 2001, SHANGHAI J ACUPUNCT, V20, P37
   Liang Y, 2018, INTEGR CANCER THER, V17, P401, DOI 10.1177/1534735417728335
   Lin JG, 2008, AM J CHINESE MED, V36, P635, DOI 10.1142/S0192415X08006107
   Lin WF, 2016, EXP THER MED, V12, P3369, DOI 10.3892/etm.2016.3793
   Ling CQ, 2017, WRIST ANKLE ACUPUNCT, V0, P1
   Mansikka H, 2004, ANESTHESIOLOGY, V100, P912, DOI 10.1097/00000542-200404000-00022
   Mantyh WG, 2010, NEUROSCIENCE, V171, P588, DOI 10.1016/j.neuroscience.2010.08.056
   Mao-Ying QL, 2006, BIOCHEM BIOPH RES CO, V345, P1292, DOI 10.1016/j.bbrc.2006.04.186
   Mase H, 2011, NEUROSCI RES, V70, P35, DOI 10.1016/j.neures.2011.01.003
   Matthes HWD, 1996, NATURE, V383, P819, DOI 10.1038/383819a0
   Meuser Thomas, 2001, PAIN, V93, P247, DOI 10.1016/S0304-3959(01)00324-4
   Millan MJ, 2002, PROG NEUROBIOL, V66, P355, DOI 10.1016/S0301-0082(02)00009-6
   Morales R, 1998, J COMP NEUROL, V402, P385
   Ossipov MH, 2000, ANN NY ACAD SCI, V909, P12
   Ossipov MH, 2010, J CLIN INVEST, V120, P3779, DOI 10.1172/JCI43766
   Paxinos G, 1998, RAT BRAIN IN STEREOTAXIC COORDINATES, V0, P0
   Schwei MJ, 1999, J NEUROSCI, V19, P10886, DOI 10.1523/JNEUROSCI.19-24-10886.1999
   Shenoy PA, 2016, FRONT PHARMACOL, V7, P0, DOI 10.3389/fphar.2016.00286
   Suzuki R, 2004, BRAIN RES, V1019, P68, DOI 10.1016/j.brainres.2004.05.108
   Urban MO, 1999, P NATL ACAD SCI USA, V96, P7687, DOI 10.1073/pnas.96.14.7687
   Wang XW, 2012, MOL BRAIN, V5, P0, DOI 10.1186/1756-6606-5-21
   Wu ZS, 2015, ACTA PHARMACOL SIN, V36, P1024, DOI 10.1038/aps.2015.35
   Yamamoto J, 2008, NEUROSCIENCE, V151, P843, DOI 10.1016/j.neuroscience.2007.11.025
   Zeng K, 2014, AM J CHINESE MED, V42, P289, DOI 10.1142/S0192415X14500190
   Zhang CP, 2017, CHINA PATENT, V0, Patent No. [CN 201621273938.1, 201621273938]
   Zhang RX, 2008, EUR J PAIN, V12, P870, DOI 10.1016/j.ejpain.2007.12.006
   Zhang RX, 2007, ANESTH ANALG, V105, P1482, DOI 10.1213/01.ane.0000284705.34629.c5
   Zhang XM, 2002, PROCEEDINGS FIFTEENTH INTERNATIONAL SYMPOSIUM ON MATHEMATICAL THEORY OF NETWORKS AND SYSTEMS, V0, P1
   Zhang Y, 2011, BRAIN RES, V1395, P38, DOI 10.1016/j.brainres.2011.04.037
   Zhang ZD, 2012, ANESTH ANALG, V114, P879, DOI 10.1213/ANE.0b013e318246536d
   Zhou QH, 2005, J ZHEJIANG COLL TRAD, V29, P53
NR 60
TC 21
Z9 30
U1 5
U2 27
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1749-8546
EI 
J9 CHIN MED-UK
JI Chin. Med.
PD FEB 4
PY 2020
VL 15
IS 1
BP 
EP 
DI 10.1186/s13020-020-0289-y
PG 13
WC Integrative & Complementary Medicine; Pharmacology & Pharmacy
SC Integrative & Complementary Medicine; Pharmacology & Pharmacy
GA KL8BY
UT WOS:000513643700001
PM 32042305
DA 2026-01-16
ER

PT J
AU Ranieri, G
   Laface, C
   Fazio, V
   De Ceglia, D
   Macina, F
   Gisone, V
   Porcelli, M
   Vinciarelli, G
   Carella, C
   Molinari, P
   Laricchia, G
   Laforgia, M
   Cosmo, DG
AF Ranieri, G.
   Laface, C.
   Fazio, V
   De Ceglia, D.
   Macina, F.
   Gisone, V
   Porcelli, M.
   Vinciarelli, G.
   Carella, C.
   Molinari, P.
   Laricchia, G.
   Laforgia, M.
   Cosmo, D. Gadaleta
TI Local treatment with deep percutaneous electrochemotherapy of different tumor lesions: pain relief and objective response results from an observational study
SO EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES
LA English
DT Article
DE Deep percutaneous electrochemotherapy; Pain relief; Local disease control; Adrenal metastasis; Malignant pleural mesothelioma; Uterine leiomyosarcoma; Male mUllerian tumor
ID standard operating procedures; breast-cancer; hepatocellular-carcinoma; radiofrequency ablation; antitumor effectiveness; european research; metastases; head; electroporation; recurrence
AB OBJECTIVE: The aim of this investigation focuses on the evaluation of the efficacy of deep-seated Electrochemotherapy (ECT) in terms of pain relief and local objective response. in pre-treated patients with neither further available pharmacological treatments nor eligible for surgery. PATIENTS AND METHODS: Deep percutaneous ECT has been performed in 20 patients subjected to systemic anaesthesia. Bleomycin was administrated intravenously before the application of the electrical pulses on the target area, employing multiple single needles depending on the size and location of the target tumor. RESULTS: Pain assessment based on Visual Analogue Scale showed significant pain relief one month after treatment in all patients, reducing from 7.5 to 3 as a median value (p-value at Wilcoxon test <0.001). Local symptom-free survival median value was 5.5 months. At the first follow-up (1-2 months), a local disease control rate (LDCR) was observed in 19/20 (95%) patients: complete responses in 2 (10%), partial responses in 8 (40%) and stable disease in 9 (45%). Local progression-free survival median value was 5.7 months. Overall, no major adverse effects were observed. CONCLUSIONS: Our study indicates that deep percutaneous ECT can produce a significant pain reduction and a high LDCR in different tumor lesions, for anatomical site or histotype. In particular, ECT has demonstrated to be effective in various histotypes and deep-seated tumor lesions never treated before by this approach giving a new chance to physicians for reducing oncological pain in patients not eligible to other therapeutic routes. The innovative peculiarity of our study was the successful application of deep percutaneous ECT on adrenal metastasis, malignant pleural mesothelioma, uterine leiomyosarcoma and the uncommon case of a male mullerian tumor.
C1 [Ranieri, G.] IRCCS Ist Tumori G Paolo II, Intervent & Med Oncol Unit, Bari, Italy.
   IRCCS Ist Tumori G Paolo II, Pharm Unit, Bari, Italy.
RP Ranieri, G (corresponding author), IRCCS Ist Tumori G Paolo II, Intervent & Med Oncol Unit, Bari, Italy.
EM giroran@tiscali.it
CR Bertino G, 2016, EUR J CANCER, V63, P41, DOI 10.1016/j.ejca.2016.05.001
   Bianchi G, 2016, WORLD J SURG, V40, P3088, DOI 10.1007/s00268-016-3627-6
   Cadossi R, 2017, HDB ELECTROPORATION, V0, P0
   Campana LG, 2012, BRIT J SURG, V99, P821, DOI 10.1002/bjs.8749
   Campana LG, 2012, BREAST CANCER RES TR, V134, P1169, DOI 10.1007/s10549-012-2095-4
   Campana LG, 2014, BRIT J ORAL MAX SURG, V52, P957, DOI 10.1016/j.bjoms.2014.08.004
   Cornelis FH, 2019, CARDIOVASC INTER RAD, V42, P1806, DOI 10.1007/s00270-019-02316-4
   Curatolo P, 2012, ANN SURG ONCOL, V19, P192, DOI 10.1245/s10434-011-1860-7
   Deodhar A, 2011, AM J ROENTGENOL, V196, PW330, DOI 10.2214/AJR.10.4490
   Djokic M, 2018, EJSO-EUR J SURG ONC, V44, P651, DOI 10.1016/j.ejso.2018.01.090
   Edhemovic I, 2014, J SURG ONCOL, V110, P320, DOI 10.1002/jso.23625
   Eichhorn JH, 2002, AM J SURG PATHOL, V26, P1243, DOI 10.1097/00000478-200210000-00001
   Fini M, 2010, J BONE JOINT SURG BR, V92B, P1614, DOI 10.1302/0301-620X.92B11.24664
   Gadaleta C, 2004, J CHEMOTHERAPY, V16, P86, DOI 10.1080/1120009X.2004.11782394
   Gadaleta C, 2004, AM J ROENTGENOL, V183, P361, DOI 10.2214/ajr.183.2.1830361
   Gadaleta CD, 2013, RADIOLOGY, V267, P627, DOI 10.1148/radiol.12120198
   Gasljevic G, 2017, PLOS ONE, V12, P0, DOI 10.1371/journal.pone.0180709
   Gehl J, 2018, ACTA ONCOL, V57, P874, DOI 10.1080/0284186X.2018.1454602
   Granata V, 2014, EUR J INFLAMM, V12, P467, DOI 10.1177/1721727X1401200308
   Kanthan R, 2010, WORLD J SURG ONCOL, V8, P0, DOI 10.1186/1477-7819-8-60
   Kos B, 2015, RADIOL ONCOL, V49, P234, DOI 10.1515/raon-2015-0031
   Kunte C, 2017, BRIT J DERMATOL, V176, P1475, DOI 10.1111/bjd.15340
   Latini A, 2012, DERMATOL THER, V25, P214, DOI 10.1111/j.1529-8019.2012.01437.x
   Llovet JM, 2020, J HEPATOL, V72, P288, DOI 10.1016/j.jhep.2019.09.026
   Longo F, 2019, ORAL ONCOL, V92, P77, DOI 10.1016/j.oraloncology.2019.03.016
   Mali B, 2005, JOURNAL OF MEDICAL ENGINEERING & TECHNOLOGY, V29, P288, DOI 10.1080/03091900512331332591
   Mali B, 2013, EJSO-EUR J SURG ONC, V39, P4, DOI 10.1016/j.ejso.2012.08.016
   Mali B, 2015, BIOMED ENG ONLINE, V14, P0, DOI 10.1186/1475-925X-14-S3-S5
   Marty M, 2006, EJC SUPPL, V4, P3, DOI 10.1016/j.ejcsup.2006.08.002
   Matthiessen LW, 2012, ACTA ONCOL, V51, P713, DOI 10.3109/0284186X.2012.685524
   Miklavcic D, 2012, MED BIOL ENG COMPUT, V50, P1213, DOI 10.1007/s11517-012-0991-8
   Miklavcic D, 2015, BIOMED ENG ONLINE, V14, P0, DOI 10.1186/1475-925X-14-S3-I1
   Miklavcic D, 2014, BIOMED ENG ONLINE, V13, P0, DOI 10.1186/1475-925X-13-29
   Mir LM, 2006, EJC SUPPL, V4, P14, DOI 10.1016/j.ejcsup.2006.08.003
   ORLOWSKI S, 1988, BIOCHEM PHARMACOL, V37, P4727, DOI 10.1016/0006-2952(88)90344-9
   Pavliha D, 2012, BIOELECTROCHEMISTRY, V87, P265, DOI 10.1016/j.bioelechem.2012.01.007
   Plaschke CC, 2017, EUR J CANCER, V87, P172, DOI 10.1016/j.ejca.2017.10.008
   Quaglino P, 2015, ACTA ONCOL, V54, P298, DOI 10.3109/0284186X.2014.992546
   SERSA G, 1995, CANCER RES, V55, P3450
   Sersa G, 2012, CANCER TREAT REV, V38, P379, DOI 10.1016/j.ctrv.2011.07.006
   Spratt DE, 2014, J CLIN ONCOL, V32, P3144, DOI 10.1200/JCO.2014.55.4634
   Tarantino L, 2018, EJSO-EUR J SURG ONC, V44, P1603, DOI 10.1016/j.ejso.2018.06.025
   Tarantino L, 2017, WORLD J GASTROENTERO, V23, P906, DOI 10.3748/wjg.v23.i5.906
   Valpione S, 2014, ANN ONCOL S4, V25, P0
   Wang CM, 2018, MEDICINE, V97, P0, DOI 10.1097/MD.0000000000012903
   Williamson JM, 2016, ANN R COLL SURG ENGL, V98, P26
   Yarmush ML, 2014, ANNU REV BIOMED ENG, V16, P295, DOI 10.1146/annurev-bioeng-071813-104622
NR 47
TC 11
Z9 13
U1 0
U2 1
PU VERDUCI PUBLISHER
PI ROME
PA VIA GREGORIO VII, ROME, 186-00165, ITALY
SN 1128-3602
EI 
J9 EUR REV MED PHARMACO
JI Eur. Rev. Med. Pharmacol. Sci.
PD JUN 15
PY 2020
VL 24
IS 14
BP 7764
EP 7775
DI 10.26355/eurrev_202007_22279
PG 12
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA MU7XP
UT WOS:000555882500021
PM 32744703
DA 2026-01-16
ER

PT J
AU Kako, J
   Kajiwara, K
   Kobayashi, M
AF Kako, Jun
   Kajiwara, Kohei
   Kobayashi, Masamitsu
TI Could acupuncture be a treatment option for cancer patients with attitudinal
SO Supportive care in cancer : official journal of the Multinational Association of
LA English
DT Letter
C1 Division of Nursing Science, Graduate School of Biomedical and Health Sciences, Hiroshima University, 1-2-3, Kasumi, Minami-ku, Hiroshima, 734-8553, Japan.jkako-tky@umin.ac.jp.
   Japanese Red Cross Kyushu International College of Nursing, Munakata, Japan.
   Faculty of Nursing, National Defense Medical College, Tokorozawa, Japan.
NR 0
TC 0
SN 1433-733
EI 
J9 Support Care Cancer
PD AUG 25
PY 2020
VL 29
IS 1
BP 3
EP 3
DI 10.1007/s00520-020-05712-6
PG 0
WC Acupuncture Therapy; Cancer Pain; drug therapy; Humans; Neoplasms; complications; Pain; drug therapy; Pain Management
UT PubMed:32833095
PM 32833095
DA 2020-08-25
ER

PT J
AU Childress, MA
   Stuek, SJ
AF Childress, Marc A
   Stuek, Samantha Jayne
TI Neck Pain: Initial Evaluation and Management.
SO American family physician
LA English
DT Review
AB Neck pain is a common presenting symptom in the primary care setting and causes  significant disability. The broad differential diagnosis requires an efficient  but global assessment; therefore, emphasis is typically placed on red flags that  can assist in the early recognition and treatment of more concerning diagnoses,  such as traumatic injuries, infection, malignancy, vascular emergencies, and  other inflammatory conditions. The critical element in appropriate diagnosis and  management of these conditions is an accurate patient history. Physical  examination findings complement and refine diagnostic cues from the history but  often lack the specificity to be of value independently. Diagnostic tools such as  imaging and electrodiagnostic tests have variable utility, especially in chronic  or degenerative conditions. Treatment of mechanical or nonneuropathic neck pain  includes short-term use of medications and possibly injections. However,  long-term data for these interventions are limited. Acupuncture and other  complementary and alternative therapies may be helpful in some cases. Advanced  imaging and surgical evaluation may be warranted for patients with worsening  neurologic function or persistent pain.
C1 Virginia Commonwealth University Fairfax Family Practice, Fairfax, VA, USA.
   Virginia Commonwealth University Fairfax Family Practice, Fairfax, VA, USA.
NR 0
TC 0
SN 1532-065
EI 
J9 Am Fam Physician
PD AUG 1
PY 2020
VL 102
IS 3
BP 150
EP 156
DI 
PG 6
WC Adult; Aged; Aged, 80 and over; Curriculum; Diagnostic Tests, Routine; standards; Education, Medical, Continuing; Female; Guidelines as Topic; Humans; Male; Medical History Taking; standards; Middle Aged; Neck Pain; diagnosis
UT PubMed:32735440
PM 32735440
DA 2020-08-01
ER

PT J
AU Lin, TY
   Hsieh, CL
AF Lin, Ting-Yen
   Hsieh, Ching-Liang
TI Clinical Applications of Bee Venom Acupoint Injection.
SO Toxins
LA English
DT Journal Article
DE acupoint injections; bee venom; clinical application; pharmacological mechanism
AB Bee venom is a complex natural mixture with various pharmaceutical properties.  Among these properties, its peptides and enzymes have potential medical therapy  for pain relief and inflammation. In clinical settings, this therapy has been  used widely to treat diseases by injecting into acupoints. In this article, we  have conducted various research from PubMed, Cochrane Library, and Clinical Key  from inception of July 2020. The results revealed that bee venom therapy has been  reported effective in anti-inflammatory, antiapoptosis, and analgesic effects.  Moreover, bee venom acupuncture has been commonly used for clinical disorders  such as Parkinson disease, neuropathic pain, Alzheimer disease, intervertebral  disc disease, spinal cord injury, musculoskeletal pain, arthritis, multiple  sclerosis, skin disease and cancer.
C1 Department of Chinese Medicine, China Medical University Hospital, Taichung 40447, Taiwan.
   Department of Chinese Medicine, China Medical University Hospital, Taichung 40447, Taiwan.
   Graduate Institute of Acupuncture Science, College of Chinese Medicine, China 
   Chinese Medicine Research Center, China Medical University, Taichung 40402, Taiwan.
NR 0
TC 0
SN 2072-665
EI 
J9 Toxins (Basel)
PD OCT 1
PY 2020
VL 12
IS 10
BP 
EP 
DI 10.3390/toxins12100618
PG 0
WC Acupuncture Points; Acupuncture Therapy; adverse effects; Animals; Bee Venoms; administration & dosage; Disease Models, Animal; Humans; Injections; Treatment Outcome
UT PubMed:32992601
PM 32992601
DA 2020-10-01
ER

PT J
AU Shi, K
   Tang, Y
   He, F
   Xiao, X
   Zhang, J
   Jin, Y
   Wang, Y
   Zhang, Q
AF Shi, Kejin
   Tang, Ying
   He, Fengyi
   Xiao, Xiao
   Zhang, Jiayuan
   Jin, Yuxia
   Wang, Yunxia
   Zhang, Qi
TI The maintenance effect of acupuncture on the side effects of breast cancer
SO Medicine
LA English
DT Journal Article
AB BACKGROUND: Breast cancer is common among women throughout the world and  endocrine therapy is an established part of its treatment. But, unfortunately,  this has also resulted in intolerable side effects affecting the quality of life.  Acupuncture has been widely used to treat endocrine-related side effects in  patients with breast cancer, but how long its effect can be maintained has not  been published. The systematic review is designed to evaluate the maintenance  efficacy of acupuncture for related side effects after breast cancer endocrine  therapy. METHODS AND ANALYSIS: We will search for the following databases:  PubMed, Embase, Cochrane Library, Web of Science, including China National  Knowledge Infrastructure (CNKI), WanFang Data, Technology Periodical Database  (VIP), and China Biology Medicine (CBM) from inception to May 2020. Two reviewers  will search these databases, collect all articles, and assess the quality of  studies separately, and there will be no limitations on language. The primary  outcomes will be assessed using acupuncture for endocrine-related hot flashes and  joint pain duration (1 month, 3 months, 6 months). Measurement tools include the  Kupperman index, Brief Pain Inventory Short Form (BPI-SF), the Western Ontario  and McMaster Universities Osteoarthritis Index (WOMAC), the Brief Pain  Inventory-Short (BPI-SF). We will use RevMan V.5.3 for meta-analysis and employ  the Grading of Recommendations Assessment, Development and Evaluation System to  assess the quality of evidence. RESULTS: This systematic review will evaluate the  maintenance efficacy of acupuncture on the side effects of breast cancer  endocrine therapy. CONCLUSION: This study will provide high-quality current  evidence of how long its effect can be maintained after acupuncture for related  side effects after breast cancer endocrine therapy. ETHICS AND DISSEMINATION:  Ethical committee approval is not required for this systematic review as patient  data will not be collected. This study will help to inform doctors and  researchers on the duration of acupuncture treatment for endocrine-related hot  flashes and joint pain. The results will be published in a peer-reviewed journal  and will be disseminated in relevant conferences. INPLASY REGISTRATION NUMBER:  INPLASY202040024.
C1 Chengdu university of traditional Chinese medicine, Chengdu, Sichuan province, China.
NR 0
TC 0
SN 1536-596
EI 0025-797
J9 Medicine (Baltimore)
PD JUN 17
PY 2020
VL 99
IS 24
BP e20567
EP e20567
DI 10.1097/MD.0000000000020567
PG 1
WC Acupuncture Therapy; Antineoplastic Agents, Hormonal; adverse effects; Arthralgia; chemically induced; Breast Neoplasms; drug therapy; Hot Flashes; chemically induced; Humans; Meta-Analysis as Topic; Systematic Reviews as Topic
UT PubMed:32541483
PM 32541483
DA 2020-06-17
ER

PT J
AU Pu, JK
   Wong, SC
   So, KH
   Tsang, AC
   Li, LF
AF Pu, Jenny Kan-Suen
   Wong, Sanna Ching-Shan
   So, Karen Hoi-Ting
   Tsang, Anderson Chun-On
   Li, Lai-Fung
TI Acupuncture as Part of Iatrogenic Facial Nerve Palsy Rehabilitation-First Report.
SO World neurosurgery
LA English
DT Journal Article
DE Acoustic; Acupuncture therapy; Facial paralysis; Neuroma; Postoperative complications
AB BACKGROUND: Facial paresis is one of the complications after treatment for  vestibular schwannoma (VS). Acupuncture has been used for Bell palsy but not in  iatrogenic facial paresis. The objective of this study is to measure the efficacy  of using acupuncture for iatrogenic facial nerve palsy and patients'  satisfaction. METHODS: This is a single-center retrospective study with patients  from 2007-2019 received treatment for newly diagnosed or recurrent VS. Some  patients who suffered facial paresis after surgery had self-initiated  acupuncture. All patients who had facial paresis were included. Their facial  nerve status before and immediately after surgery, postoperative 6 months and 12  months, were recorded. Those who received acupuncture also answered 6- and  12-month patient satisfaction surveys over the phone. Adverse effects were also  assessed. RESULTS: There were 123 patients in this period. Of these, 29 patients  had iatrogenic facial paresis and 23 of them received acupuncture. There was  significant improvement of facial paresis for the acupuncture group compared with  the nonacupuncture group at 6 and 12 months. More than 80% of patients who  received acupuncture were satisfied. They had motor improvement and experienced  less pain and tightness. No adverse effects were reported. CONCLUSIONS:  Acupuncture for postresection VS facial paresis seemed to speed up its recovery.  Both patients' recovery and satisfaction were good after acupuncture, and it  seemed to be a safe procedure in trained hands.
C1 Division of Neurosurgery, Department of Surgery, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Queen Mary Hospital, Hong Kong, Hong Kong.
   Division of Neurosurgery, Department of Surgery, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Queen Mary Hospital, Hong Kong, Hong Kong.
   Division of Neurosurgery, Department of Surgery, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Queen Mary Hospital, Hong Kong, Hong Kong.
   Division of Neurosurgery, Department of Surgery, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Queen Mary Hospital, Hong Kong, Hong Kong.
   Division of Neurosurgery, Department of Surgery, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Queen Mary Hospital, Hong Kong, Hong Kong.
EM llfrandom@gmail.com
NR 0
TC 0
SN 1878-876
EI 
J9 World Neurosurg
PD MAY 21
PY 2020
VL 140
IS 
BP e343
EP e347
DI 10.1016/j.wneu.2020.05.079
PG 1
WC Acupuncture Therapy; methods; Adult; Aged; Facial Nerve Injuries; etiology; Facial Paralysis; etiology; Female; Humans; Iatrogenic Disease; Male; Middle Aged; Neuroma, Acoustic; therapy; Neurosurgical Procedures; adverse effects; Radiotherapy; adverse effects; Retrospective Studies
UT PubMed:32434036
PM 32434036
DA 2020-05-21
ER

PT J
AU Zhang, F
   Zhou, H
   Ding, SY
   Zhang, D
   Lian, DS
   Chen, XL
   Wang, C
AF Zhang, Feng
   Zhou, Hao
   Ding, Songyi
   Zhang, Da
   Lian, Daoshi
   Chen, Xingliang
   Wang, Chao
TI Efficacy and safety of acupuncture for recurrent aphthous stomatitis: a systematic review protocol
SO BMJ OPEN
LA English
DT Review
DE pain management; health & safety; protocols & guidelines
ID cancer
AB Introduction Recurrent aphthous stomatitis (RAS) is a distressing symptom. There are many ways to treat RAS, such as pudilan anti-inflammatory oral liquid and doxycycline and laser therapy, but these take a long time to produce positive effects and compliance is low. Previous reviews of acupuncture treatment for RAS has been growing, but a systematic review is not available. To assess the efficacy and safety of acupuncture for the management of RAS. Methods and analysis The following databases will be searched from their inception to 1 February 2020: PubMed, Embase, Cochrane Library, CINAHL, Chinese Biomedical Literature Database, VIP Database for Chinese Technical Periodicals, China National Knowledge Infrastructure and Wanfang. The randomised controlled trials in English or Chinese associated with acupuncture for patients with RAS will be included. Eligible study conference abstracts and reference lists of manuscripts will also be searched. Two reviewers will select the studies, extract data independently. The Cochrane risk of bias tool will be used to assess the risk of bias for the studies. According to heterogeneity testing, data will be synthesised using a random-effects model. A meta-analysis will be performed using Rev Man V.5.3.5 statistical software for each outcome. Subgroup analysis and sensitivity analysis are planned according to clinical evidence. Mean difference or standardised mean difference for continuous data and risk ratio for dichotomous data will be calculated. Ethics and dissemination No ethical approval is required. This protocol will not involve individual patient information and endangering participant rights. The results will be reported in a peer-reviewed journal or disseminated in relevant conferences. OSF registration number DOI 10.17605/OSF.IO/QASUY.
C1 [Zhang, Feng; Lian, Daoshi; Chen, Xingliang; Wang, Chao] Chengdu Univ Tradit Chinese Med, Acupuncture & Tuina Sch, Chengdu, Peoples R China.
   [Zhou, Hao; Ding, Songyi; Zhang, Da; Wang, Chao] Sichuan Integrat Med Hosp, Subhlth Ctr, Chengdu, Peoples R China.
C3 Chengdu University of Traditional Chinese Medicine
RP Wang, C (corresponding author), Chengdu Univ Tradit Chinese Med, Acupuncture & Tuina Sch, Chengdu, Peoples R China.; Wang, C (corresponding author), Sichuan Integrat Med Hosp, Subhlth Ctr, Chengdu, Peoples R China.
EM wangchaotcm@126.com
FU administration science and technology project of traditional Chinese medicine of Sichuan provincial [2018LC001]; emphasis science and technology department of Sichuan Science and technology department [2018SZ0408];  [2020100]
CR Akintoye Sunday O, 2014, DENT CLIN NORTH AM, V58, P281, DOI 10.1016/j.cden.2013.12.002
   Altenburg A, 2007, J EUR ACAD DERMATOL, V21, P1019, DOI 10.1111/j.1468-3083.2007.02393.x
   Bulut N, 2015, J BUON, V20, P1276
   Chen Yan-ming, 2006, ZHONGGUO ZHEN JIU, V26, P103
   Eisen D, 2001, CUTIS, V68, P201
   El-Wakeel NM, 2019, J INVESTIG CLIN DENT, V10, P0, DOI 10.1111/jicd.12437
   Giammarinaro Enrica, 2019, J CONTEMP DENT PRACT, V20, P1249, DOI 10.5005/jp-journals-10024-2709
   Habibzadeh S, 2021, J DERMATOL TREAT, V32, P361, DOI 10.1080/09546634.2019.1654597
   Jin YG, 2017, PPAR RES, V2017, P1
   Joseph RM, 2016, SEMIN ARTHRITIS RHEU, V46, P133, DOI 10.1016/j.semarthrit.2016.03.001
   Krisdapong S, 2012, QUAL LIFE RES, V21, P71, DOI 10.1007/s11136-011-9925-4
   Nayir E, 2015, J BUON, V20, P1606
   Piacentini M, 2019, J CLIN PHARM THER, V44, P838, DOI 10.1111/jcpt.13022
   Sami AS, 2021, J MATERN-FETAL NEO M, V34, P1055, DOI 10.1080/14767058.2019.1623872
   Ship JA, 2000, QUINTESSENCE INT, V31, P95
   Stehlikova Z, 2019, MICROORGANISMS, V7, P0, DOI 10.3390/microorganisms7120636
   Stokowski R, 2015, PRENATAL DIAG, V35, P1243, DOI 10.1002/pd.4686
   Sun N, 2020, BMJ OPEN, V10, P0, DOI 10.1136/bmjopen-2019-034290
   Yildirimyan N, 2019, ORAL HLTH PREV DENT, V17, P465, DOI 10.3290/j.ohpd.a42736
   Zhang F, 2020, MEDICINE, V99, P0, DOI 10.1097/MD.0000000000018900
   Zhou PR, 2017, J AM DENT ASSOC, V148, P17, DOI 10.1016/j.adaj.2016.08.025
NR 21
TC 2
Z9 2
U1 1
U2 17
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 2044-6055
EI 
J9 BMJ OPEN
JI BMJ Open
PD JUN 15
PY 2020
VL 10
IS 10
BP 
EP 
DI 10.1136/bmjopen-2020-037603
PG 5
WC Medicine, General & Internal
SC General & Internal Medicine
GA OI5DD
UT WOS:000583298100001
PM 33033019
DA 2026-01-16
ER

PT J
AU Xu, H
   Fan, YY
   Meng, XZ
   Luan, J
   Guan, H
   Su, XL
   Xu, LX
   Lu, DP
AF Xu, Hao
   Fan, Yingying
   Meng, Xiangzhong
   Luan, Jing
   Guan, Hua
   Su, Xianli
   Xu, Lixian
   Lu, Dominic P.
TI Use of Acupoint Stimulation to Regulate Perioperative Stress-Induced Immunosuppression
SO ACUPUNCTURE & ELECTRO-THERAPEUTICS RESEARCH
LA English
DT Article
DE Acupuncture stimulation; Immunosuppression; Perioperative period; Postoperative recovery; Stress response
ID acupuncture; immune; electroacupuncture; anesthesia; endorphin
AB The stress response can be triggered during the perioperative period by tension, fear, anesthesia, surgical trauma, and various postoperative adverse stimuli, leading to significant changes in the endocrine, metabolic, and immune systems of patients. In particular, immunosuppression induced by the stress response has adverse effects on the postoperative recovery of patients. As acupuncture stimulation-related technologies have been rapidly developed and applied in recent years, a number of basic and clinical studies have confirmed that acupoint stimulation can regulate the immune system via local, neurological, and endocrine pathways. Moreover, acupoint stimulation treatment has also been shown to reduce the adverse effects of immunosuppression by affecting the release of various cytokines, such as interleukin (IL) 1, IL-2, IL-4, IL-6, IL-10, IFN-gamma, and tumor necrosis factor (TNF) beta, immunoglobulins, complement proteins, and T cell markers such as CD3, CD4, and CD4/CD8 via the regulation of macrophages, neutrophils, NK cells, and endogenous opioids. In addition, acupuncture stimulation treatment during the perioperative period can also significantly decrease the amount of anesthetic required for anesthesia, effectively reduce nausea and vomiting, relieve post-operative pain, and accelerate the recovery of physiological functions. Therefore, acupuncture stimulation treatment has shown important potential for clinical applications.
C1 [Xu, Hao; Su, Xianli] Xian Med Univ, Inst Basic Med Sci, Xian, Peoples R China.
   [Fan, Yingying; Meng, Xiangzhong; Luan, Jing; Guan, Hua; Xu, Lixian] Fourth Mil Med Univ, Dept Anesthesiol, Sch Stomatol, Xian, Peoples R China.
   [Lu, Dominic P.] Univ Penn, Oral & Maxillofacial Surg, Philadelphia, PA 19104 USA.
C3 Xi'an Medical University; Air Force Medical University; University of Pennsylvania
RP Su, XL (corresponding author), Xian Med Univ, Inst Basic Med Sci, Xian, Peoples R China.; Xu, LX (corresponding author), Fourth Mil Med Univ, Dept Anesthesiol, Sch Stomatol, Xian, Peoples R China.
EM 20867934@qq.com; xlx116@fmmu.edu.cn
CR Abali AE, 2015, BURNS, V41, P833, DOI 10.1016/j.burns.2014.10.028
   Aoki E, 2005, IN VIVO, V19, P495
   BIANCHI M, 1991, AM J CHINESE MED, V19, P101, DOI 10.1142/S0192415X91000168
   Bing Z, 2016, ACUPUNCTURE RES, V41, P388
   Burleson GR, 2018, METHODS MOL BIOL, V1803, P199, DOI 10.1007/978-1-4939-8549-4_13
   Cabioglu MT, 2008, AM J CHINESE MED, V36, P25, DOI 10.1142/S0192415X08005552
   Chang JS, 2016, ACUPUNCTURE ELECTRO, V41, P79, DOI 10.3727/036012916X14666839504550
   Chen Y, 2014, NEUROL SCI, V35, P215, DOI 10.1007/s10072-013-1481-y
   da Silva MD, 2015, MOL NEUROBIOL, V51, P19, DOI 10.1007/s12035-014-8790-x
   Ding SS, 2014, QJM-INT J MED, V107, P341, DOI 10.1093/qjmed/hct196
   Du Ke-Bing, 2013, FOREST SCIENCE AND PRACTICE, V15, P1, DOI 10.1007/s11632-013-0101-5
   Fan Wen-Chao, 2012, ZHONGGUO ZHEN JIU, V32, P715
   Gliedt JA, 2015, J ACUPUNCT MERIDIAN, V8, P264, DOI 10.1016/j.jams.2014.12.004
   Gu Chen-yi, 2004, ZHONGGUO ZHONG XI YI JIE HE ZA ZHI, V24, P973
   Hideaki W, 2015, ACUPUNCT MED, V33, P451, DOI 10.1136/acupmed-2015-010784
   Huang S, 2017, J ANESTH, V31, P58, DOI 10.1007/s00540-015-2057-1
   icottg M, 2017, CHINESE ACUPUNCTURE, V37, P483
   Jaillon S, 2013, SEMIN IMMUNOPATHOL, V35, P377, DOI 10.1007/s00281-013-0374-8
   Karst M, 2003, COMPLEMENT THER MED, V11, P4, DOI 10.1016/S0965-2299(02)00117-6
   Kavoussi B, 2007, INTEGR CANCER THER, V6, P251, DOI 10.1177/1534735407305892
   KHO HG, 1990, ACTA ANAESTH SCAND, V34, P563, DOI 10.1111/j.1399-6576.1990.tb03146.x
   Li Jia, 2009, ZHONGGUO ZHEN JIU, V29, P905
   Li Q, 2018, METHODS MOL BIOL, V1803, P231, DOI 10.1007/978-1-4939-8549-4_15
   Liu LT, 2016, ACUPUNCTURE ELECTRO, V41, P107, DOI 10.3727/036012916X14666839504631
   LUNDEBERG T, 1991, NEUROSCI LETT, V128, P161, DOI 10.1016/0304-3940(91)90251-N
   Mayor D, 2013, ACUPUNCT MED, V31, P409, DOI 10.1136/acupmed-2013-010324
   Mo YJ, 2018, MOL GENET GENOMICS, V293, P463, DOI 10.1007/s00438-017-1401-6
   Pomorska DK, 2014, MINI-REV MED CHEM, V14, P1148
   Qiang W, 2015, CHINESE J ANESTHESIO, V35, P6
   Shen Hua, 2012, ZHONGGUO ZHONG XI YI JIE HE ZA ZHI, V32, P1607
   Shengzhe S, 2017, PROGR MODERN BIOMEDI, V17, P1659
   Wang NK, 2018, ONCOL LETT, V15, P189, DOI 10.3892/ol.2017.7262
   Wang YP, 2014, PLOS ONE, V9, P0, DOI 10.1371/journal.pone.0101303
   Wenxue H, 2006, CHINESE MED EQUIPMEN, V27, P52
   Xiangdong P, 2016, CHINA ACUPUNCT MOXIBUSTION, V36, P613
   Yu JS, 2013, INT REV NEUROBIOL, V111, P125, DOI 10.1016/B978-0-12-411545-3.00006-7
   Zhang Bing-ru, 2006, ZHONGGUO ZHEN JIU, V26, P625
   ZHANG K, 2018, EVID-BASED COMPL ALT, V2018, P0, DOI 10.1155/2018/9260630
   Zhang Shuang-yan, 2011, ZHONGGUO ZHEN JIU, V31, P513
NR 39
TC 1
Z9 1
U1 0
U2 19
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 0360-1293
EI 2167-9010
J9 ACUPUNCTURE ELECTRO
JI Acupunct. Electro-Ther. Res.
PD JUN 15
PY 2020
VL 44
IS 3-4
BP 203
EP 212
DI 10.3727/036012920X15779969212946
PG 10
WC Integrative & Complementary Medicine; Neurosciences
SC Integrative & Complementary Medicine; Neurosciences & Neurology
GA KM0ZL
UT WOS:000513846500003
DA 2026-01-16
ER

PT J
AU Ginex, PK
   Hanson, BJ
   LeFebvre, KB
   Lin, YF
   Moriarty, KA
   Maloney, C
   Vrabel, M
   Morgan, RL
AF Ginex, Pamela K.
   Hanson, Brian J.
   LeFebvre, Kristine B.
   Lin, Yufen
   Moriarty, Kerri A.
   Maloney, Christine
   Vrabel, Mark
   Morgan, Rebecca L.
TI Management of Opioid-Induced and Non-Opioid-Related Constipation in Patients With Cancer: Systematic Review and Meta-Analysis
SO ONCOLOGY NURSING FORUM
LA English
DT Review
DE constipation; symptom management; opioid-induced constipation; cancer; opioids
ID chronic idiopathic constipation; randomized phase-iii; double-blind; subcutaneous methylnaltrexone; oral methylnaltrexone; noncancer pain; parallel-group; efficacy; placebo; chemotherapy
AB PROBLEM IDENTIFICATION: A systematic review and meta-analysis was conducted to inform the development of national clinical practice guidelines on the management of cancer constipation. LITERATURE SEARCH: PubMed(R), Wiley Cochrane Library, and CINAHL(R) were searched for studies published from May 2009 to May 2019. DATA EVALUATION: Two investigators independently reviewed and extracted data from eligible studies. The Cochrane Collaboration risk-of-bias tool was used, and the GRADE (Grading of Recommendations Assessment, Development and Evaluation) approach was used to assess the certainty of the evidence. SYNTHESIS: For patients with cancer and opioid-induced constipation, moderate benefit was found for osmotic or stimulant laxatives; small benefit was found for methylnaltrexone, naldemedine, and electroacupuncture. For patients with cancer and non-opioid-related constipation, moderate benefit was found for naloxegol, prucalopride, lubiprostone, and linaclotide; trivial benefit was found for acupuncture. IMPLICATIONS FOR PRACTICE: Effective strategies for managing opioid-induced and non-opioid-related constipation in patients with cancer include lifestyle, pharmacologic, and complementary approaches.
C1 [Ginex, Pamela K.; LeFebvre, Kristine B.; Moriarty, Kerri A.; Maloney, Christine; Vrabel, Mark] Oncol Nursing Soc, Pittsburgh, PA 15275 USA.
   [Hanson, Brian J.] Univ Minnesota, Vet Affairs Healthcare, Minneapolis, MN USA.
   [Lin, Yufen] Duke Univ, Sch Nursing, Durham, NC USA.
   [Morgan, Rebecca L.] McMaster Univ, Dept Hlth Res Methods Evidence & Impact, Hamilton, ON, Canada.
C3 University of Minnesota System; University of Minnesota Twin Cities; Duke University; McMaster University
RP Ginex, PK (corresponding author), Oncol Nursing Soc, Pittsburgh, PA 15275 USA.
EM pginex@ons.org
FU Oncology Nursing Society
CR Amankwah J, 2015, ONCOL NURS FORUM, V42, P0
   Benyamin R, 2008, PAIN PHYSICIAN, V11, P0
   Bharucha AE, 2013, GASTROENTEROLOGY, V144, P211, DOI 10.1053/j.gastro.2012.10.029
   Bull J, 2015, FIXED DOSE SUBCUTANE, V18, P593, DOI 10.1089/jpm.2014.0362
   Camilleri M, 2014, NEUROGASTROENT MOTIL, V26, P1386, DOI 10.1111/nmo.12417
   Chey WD, 2014, NEW ENGL J MED, V370, P2387, DOI 10.1056/NEJMoa1310246
   Clemens KE, 2013, CURR OPIN SUPPORT PA, V7, P183, DOI 10.1097/SPC.0b013e32835f1e17
   Costilla VC, 2014, CLIN GERIATR MED, V30, P107, DOI 10.1016/j.cger.2013.10.001
   Cryer B, 2014, PAIN MED, V15, P1825, DOI 10.1111/pme.12437
   Da NL, 2015, EVID-BASED COMPL ALT, V2015, P0, DOI 10.1155/2015/670963
   Davies A, 2020, SUPPORT CARE CANCER, V28, P23, DOI 10.1007/s00520-019-05016-4
   DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2
   Downing GM, 2007, J PAIN SYMPTOM MANAG, V34, P513, DOI 10.1016/j.jpainsymman.2007.01.014
   Ford AC, 2011, GUT, V60, P209, DOI 10.1136/gut.2010.227132
   Forootan M, 2018, MEDICINE, V97, P0, DOI 10.1097/MD.0000000000010631
   Freedman MD, 1997, J CLIN PHARMACOL, V37, P904, DOI 10.1002/j.1552-4604.1997.tb04264.x
   Gaertner J, 2015, J CLIN GASTROENTEROL, V49, P9, DOI 10.1097/MCG.0000000000000246
   Guyatt GH, 2011, J CLIN EPIDEMIOL, V64, P1311, DOI 10.1016/j.jclinepi.2011.06.004
   Hale M, 2017, LANCET GASTROENTEROL, V2, P555, DOI 10.1016/S2468-1253(17)30105-X
   Hanai A, 2016, BREAST CANCER RES TR, V155, P99, DOI 10.1007/s10549-015-3652-4
   Hanson B, 2019, GASTROENTEROLOGY, V156, P229, DOI 10.1053/j.gastro.2018.08.018
   Higgins Julian P T, 2011, BMJ, V343, Pd5928, DOI 10.1136/bmj.d5928
   Jamal MM, 2015, AM J GASTROENTEROL, V110, P725, DOI 10.1038/ajg.2015.106
   Katakami N, 2018, ANN ONCOL, V29, P1461, DOI 10.1093/annonc/mdy118
   Katakami N, 2017, J CLIN ONCOL, V35, P3859, DOI 10.1200/JCO.2017.73.0853
   Katakami N, 2017, J CLIN ONCOL, V35, P1921, DOI 10.1200/JCO.2016.70.8453
   Kaur V, 2017, J ONCOL PRACT, V13, PE91, DOI 10.1200/JOP.2016.013797
   Lacy BE, 2015, PLOS ONE, V10, P0, DOI 10.1371/journal.pone.0134349
   Larkin PJ, 2018, ANN ONCOL, V29, P111, DOI 10.1093/annonc/mdy148
   Lee HY, 2018, BMC COMPLEM ALTERN M, V18, P0, DOI 10.1186/s12906-018-2243-4
   Lembo AJ, 2011, NEW ENGL J MED, V365, P527, DOI 10.1056/NEJMoa1010863
   Lembo AJ, 2010, GASTROENTEROLOGY, V138, P886, DOI 10.1053/j.gastro.2009.12.050
   Liberati Alessandro, 2009, PLOS MED, V6, Pe1000100, DOI 10.1371/journal.pmed.1000100
   Liu YQ, 2015, CHIN J INTEGR MED, V21, P697, DOI 10.1007/s11655-014-2009-x
   Liu ZS, 2016, ANN INTERN MED, V165, P761, DOI 10.7326/M15-3118
   Mari A, 2020, KOREAN J FAM MED, V41, P139, DOI 10.4082/kjfm.18.0182
   Martin Bradley C, 2006, MANAG CARE INTERFACE, V19, P43
   McCormick D, 2019, AM J MANAG CARE, V25, P0
   McGraw T, 2016, CLIN EXP GASTROENTER, V9, P0, DOI 10.2147/CEG.S111693
   McMillan Susan C, 2004, CANCER CONTROL, V11, P3
   McMillan Susan C, 2013, ONCOL NURS FORUM, V40, PE92, DOI 10.1188/13.ONF.E92-E100
   Mearin Fermin, 2016, GASTROENTEROLOGY, V0, P0, DOI DOI 10.1053/j.gastro.2016.02.031
   Michna E, 2011, J PAIN, V12, P554, DOI 10.1016/j.jpain.2010.11.008
   Mori T, 2013, J PHARMACOL EXP THER, V347, P91, DOI 10.1124/jpet.113.204313
   Nakajima A, 2019, J GASTROENTEROL, V54, P792, DOI 10.1007/s00535-019-01581-x
   National Comprehensive Cancer Network, 2020, NCCN CLIN PRACT ONC, V0, P0
   Nelson AD, 2017, GUT, V66, P1611, DOI 10.1136/gutjnl-2016-311835
   Paré P, 2014, CAN J GASTROENTEROL, V28, P549, DOI 10.1155/2014/631740
   Portenoy RK, 2008, J PAIN SYMPTOM MANAG, V35, P458, DOI 10.1016/j.jpainsymman.2007.12.005
   Rauck R, 2017, PAIN PRACT, V17, P820, DOI 10.1111/papr.12535
   Rauck RL, 2019, J PAIN RES, V12, P139, DOI 10.2147/JPR.S170086
   Reville B, 2009, PRIMARY CARE, V36, P781, DOI 10.1016/j.pop.2009.07.010
   Rhondali W, 2013, J PAIN SYMPTOM MANAG, V45, P23, DOI 10.1016/j.jpainsymman.2012.01.009
   Rithirangsriroj K, 2015, GYNECOL ONCOL, V136, P82, DOI 10.1016/j.ygyno.2014.10.025
   SHEA BJ, 2017, BMJ-BRIT MED J, V358, P0, DOI 10.1136/BMJ.14008
   Shen Q, 2018, WESTERN J NURS RES, V40, P874, DOI 10.1177/0193945917701128
   Shin J, 2018, WESTERN J NURS RES, V40, P67, DOI 10.1177/0193945916680362
   Slatkin Neal, 2009, J SUPPORT ONCOL, V7, P39
   Sloots CEJ, 2010, DIGEST DIS SCI, V55, P2912, DOI 10.1007/sio620-010-1229-y
   Speed C, 2010, HEALTH TECHNOL ASSES, V14, P1, DOI 10.3310/hta14520
   Spierings ELH, 2016, PAIN PRACT, V16, P985, DOI 10.1111/papr.12347
   Tarumi Y, 2013, J PAIN SYMPTOM MANAG, V45, P2, DOI 10.1016/j.jpainsymman.2012.02.008
   Thomas J, 2008, NEW ENGL J MED, V358, P2332, DOI 10.1056/NEJMoa0707377
   Tomich JL, 2019, CIN-COMPUT INFORM NU, V37, P551, DOI 10.1097/CIN.0000000000000598
   Webster L, 2014, ALIMENT PHARM THER, V40, P771, DOI 10.1111/apt.12899
   Webster L, 2018, PAIN PRACT, V18, P505, DOI 10.1111/papr.12640
   Webster L, 2013, PAIN, V154, P1542, DOI 10.1016/j.pain.2013.04.024
   Webster LR, 2018, J PAIN RES, V11, P2509, DOI 10.2147/JPR.S160625
   Webster LR, 2018, PAIN MED, V19, P1195, DOI 10.1093/pm/pnx212
   Webster LR, 2018, PAIN, V159, P987, DOI 10.1097/j.pain.0000000000001174
   Webster LR, 2017, PAIN MED, V18, P2350, DOI 10.1093/pm/pnw325
   WU J, 2014, MEDICINE, V93, P0, DOI 10.1097/MD0000000000000284
   Wu X, 2017, EVID-BASED COMPL ALT, V2017, P0, DOI 10.1155/2017/1428943
   Zheng H, 2018, NEUROGASTROENT MOTIL, V30, P0, DOI 10.1111/nmo.13307
NR 74
TC 9
Z9 11
U1 1
U2 31
PU ONCOLOGY NURSING SOC
PI PITTSBURGH
PA 125 ENTERPRISE DR, PITTSBURGH, PA 15275 USA
SN 0190-535X
EI 1538-0688
J9 ONCOL NURS FORUM
JI Oncol. Nurs. Forum
PD NOV 15
PY 2020
VL 47
IS 6
BP E211
EP E224
DI 10.1188/20.ONF.E211-E224
PG 14
WC Oncology; Nursing
SC Oncology; Nursing
GA OI2WH
UT WOS:000583144900003
PM 33063777
DA 2026-01-16
ER

PT J
AU Djaali, W
   Simadibrata, CL
   Nareswari, I
AF Djaali, Wahyuningsih
   Simadibrata, Christina Lanny
   Nareswari, Irma
TI Acupuncture Therapy in Post-Radiation Head-and-Neck Cancer with Dysgeusia.
SO Medical acupuncture
LA English
DT Journal Article
DE acupuncture; dysgeusia; head-and-neck cancer; radiation therapy
AB Background: Radiation therapy for head-and-neck cancer can cause side-effects,  including pain, nausea, vomiting, sensory disorders such as anosmia and  dysgeusia, dysphagia, xerostomia, hot flashes, fatigue, sleep disorders, and even  anxiety and depression disorders. Therapies using acupuncture are now being  adopted at cancer therapy centers. Acupuncture has been clinically proven to  reduce the side-effects of cancer therapies, thus, resulting in better quality of  life. Case: A 65-year-old man was diagnosed with stage I laryngeal squamous-cell  carcinoma (SCC), and had missing taste and pain on swallowing (visual analogue  scale [VAS]: 4) after undergoing 30 sessions of radiation therapy for  head-and-neck cancer with a total radiation dose of 60 Gy. He received  acupuncture at: body points (LI 4 Hegu, LR 3 Taichong, ST 36 Zusanli, SP 6  Sanyinjiao, and ST 40 Fenglong); the Battlefield Acupuncture points of the ear  (Cingulate Gyrus, Thalamus, Zero Point, Shen Men, and Omega 2); and on the wrist  area (according to a balance method). Acupuncture therapy was given 2 times a  week, for 45-minute sessions. Results: After 12 acupuncture sessions, he had  improvement in taste function and pain reduction from VAS 4 to VAS 1. This  improvement likely occurred due to acupuncture's anti-inflammatory effects  through anti-inflammatory mediator secretion, an antipain effect through  ß-endorphin secretion, and nerve-cell regeneration through neurotropic factors'  secretion. Conclusions: Routine acupuncture therapy can reduce dysgeusia and pain  in postradiated patients with head-and-neck cancer. Acupuncture can be a  therapeutic choice for patients with post-radiation head-and-neck cancer  toxicity.
C1 Universitas Negeri Jakarta, East Jakarta, Jakarta, Indonesia.
   Department of Medical Acupuncture, Faculty of Medicine, Universitas 
   Department of Medical Acupuncture, Faculty of Medicine, Universitas Indonesia/RSUPN Dr. Cipto Mangunkusumo, Central Jakarta, Jakarta, Indonesia.
   Department of Medical Acupuncture, Faculty of Medicine, Universitas Indonesia/RSUPN Dr. Cipto Mangunkusumo, Central Jakarta, Jakarta, Indonesia.
NR 0
TC 0
SN 1933-659
EI 1933-658
J9 Med Acupunct
PD JUL 1
PY 2020
VL 32
IS 3
BP 157
EP 162
DI 10.1089/acu.2020.1410
PG 5
UT PubMed:32595823
PM 32595823
DA 2020-07-01
ER

PT J
AU Huang, W
   Long, W
   Xiao, J
   Zhao, G
   Yu, T
AF Huang, Wei
   Long, Wenfei
   Xiao, Jianbin
   Zhao, Gaofeng
   Yu, Tingyu
TI Effect of electrically stimulating acupoint, Zusanli (ST 36), on patient's
SO Journal of traditional Chinese medicine = Chung i tsa chih ying wen pan
LA English
DT Journal Article
DE Colorectal neoplasms; Laparoscopes; Randomized controlled trial; Recovery of function; Transcutaneous electric nerve stimulation
AB OBJECTIVE: To investigate the effect of transcutaneous electrical acupoint  stimulation (TEAS) on enhanced recovery after surgery (ERAS) in laparoscopic  colorectal cancer resection and its clinical significance. METHODS: Sixty-four  patients undergoing laparoscopic colorectal resection were randomly divided into  two groups, the control group (group A) and the TEAS group (group B). Patients in  the TEAS group received electroacupuncture stimulation of bilateral Zusanli (ST  36) at 30 min before anesthesia to the end of surgery. The patients in the  control group were not given the stimulation. Perioperative anesthesia management  of the two groups were performed according to the ERAS guidelines, and  postoperative patient-controlled intravenous analgesia (PCIA) was used. The  amount of remifentanil used in the two groups was observed and recorded, and the  visual analogue scale (VAS) of the 4, 12, 24 and 48 h after surgery in the two  groups was recorded. Moreover, postoperative anal exhaust time, postoperative  feeding time, postoperative first ambulation time and postoperative hospital stay  length were compared between the two groups. RESULTS: Compared with group A, the  VAS score of group B decreased significantly at 48 h after operation (P < 0.05).  The postoperative anal exhaust time in group B was significantly shorter than  that of group A (P < 0.05). There was no significant difference between the two  groups with regards to remifentanil consumption, postoperative feeding time,  postoperative first ambulation time and postoperative hospital stay (all P >  0.05). CONCLUSION: TEAS can promote the recovery of postoperative  gastrointestinal function and reduce the pain intensity 48 h after surgery, thus  satisfying the need of early postoperative analgesia.
C1 Department of Anesthesiology, Guangdong Provincial Hospital of Chinese Medicine, Guangzhou 510000, China.
   Department of Anesthesiology, Guangdong Provincial Hospital of Chinese Medicine, Guangzhou 510000, China.
   Department of Anesthesiology, Guangdong Provincial Hospital of Chinese Medicine, Guangzhou 510000, China.
   Department of Anesthesiology, Guangdong Provincial Hospital of Chinese Medicine, Guangzhou 510000, China.
   Second Clinical Medical College, Guangzhou University of Chinese Medicine, Guangzhou 510000, China.
NR 0
TC 0
SN 2589-451
EI 
J9 J Tradit Chin Med
PD MAR 19
PY 2020
VL 39
IS 3
BP 433
EP 439
DI 
PG 6
WC Acupuncture Points; Aged; Colorectal Neoplasms; surgery; Humans; Laparoscopy; Middle Aged; Recovery of Function; physiology; Transcutaneous Electric Nerve Stimulation
UT PubMed:32186016
PM 32186016
DA 2020-03-19
ER

PT J
AU Jang, A
   Brown, C
   Lamoury, G
   Morgia, M
   Boyle, F
   Marr, I
   Clarke, S
   Back, M
   Oh, B
AF Jang, Andrew
   Brown, Chris
   Lamoury, Gillian
   Morgia, Marita
   Boyle, Frances
   Marr, Isobel
   Clarke, Stephen
   Back, Michael
   Oh, Byeongsang
TI The Effects of Acupuncture on Cancer-Related Fatigue: Updated Systematic Review and Meta-Analysis
SO INTEGRATIVE CANCER THERAPIES
LA English
DT Review
DE acupuncture; cancer; fatigue; cancer related fatigue
ID breast-cancer; psychological distress; chronic pain; management; interventions; acupressure; therapy; trial
AB Background Several studies have identified fatigue as one of the major symptoms experienced during and after cancer treatment. However, there are limited options to manage cancer related fatigue (CRF) with pharmacological interventions. Several acupuncture studies suggested that acupuncture has a positive impact on CRF. This review aims to assess the evidence of acupuncture for the treatment of CRF. Method Electronic database searches were conducted on 4 English databases (Medline, PubMed, Embase, and ScienceDirect). Search keywords were; "acupuncture" and "cancer," or "cancer related fatigue." Studies published as full text randomized controlled trials (RCTs) in English were included. Estimates of change in fatigue cores were pooled using a random effects meta-analysis where randomized comparisons were available for true acupuncture versus sham acupuncture and true acupuncture versus usual care. The quality of original papers were assessed using the Cochrane Collaboration's tool for assessing risk of bias (ROB). Results Nine RCTs were selected for review with a total of 809 participants and a range of 13 to 302 participants within the studies. Six RCTs reported significant improvement of CRF for the acupuncture intervention compared to the control groups. Pooled estimates suggest Brief Fatigue Inventory scores are 0.93 points lower 95% CI (-1.65, -0.20) in true acupuncture versus sham acupuncture and 2.12 points lower 95% C (-3.21, -1.04) in true acupuncture versus usual care. Six studies had low risk of bias (ROB) and 3 studies had a moderate ROB predominantly in blinding of participants, blinding of assessors and incomplete data outcomes. Among the 9 RCTs, 2 studies have reported the occurrence of minor adverse effects (spot bleeding and bruising) related to acupuncture treatment. No serious adverse reactions related to acupuncture were reported. Conclusion The current literature review suggests that acupuncture has therapeutic potential in management of CRF for cancer survivors. Promotion of acupuncture in cancer care to manage CRF may improve the quality of life of cancer survivors.
C1 [Jang, Andrew; Brown, Chris; Lamoury, Gillian; Morgia, Marita; Marr, Isobel; Clarke, Stephen; Back, Michael; Oh, Byeongsang] Royal North Shore Hosp, St Leonards, NSW, Australia.
   [Brown, Chris; Lamoury, Gillian; Boyle, Frances; Clarke, Stephen; Back, Michael; Oh, Byeongsang] Univ Sydney, Sydney, NSW, Australia.
   [Lamoury, Gillian; Morgia, Marita; Boyle, Frances; Back, Michael; Oh, Byeongsang] Mater Hosp, Sydney, NSW, Australia.
C3 Royal North Shore Hospital; University of Sydney
RP Oh, B (corresponding author), Univ Sydney, Sydney Med Sch, Sydney, NSW 2005, Australia.
EM byeong.oh@sydney.edu.au
CR Unknown -, 2011, EVID BASED COMPLEMEN, V0, P0
   Balk Judith, 2009, J SOC INTEGR ONCOL, V7, P4
   Brown LF, 2009, PSYCHOSOMATICS, V50, P440, DOI 10.1176/appi.psy.50.5.440
   Cheng CS, 2017, SUPPORT CARE CANCER, V25, P3807, DOI 10.1007/s00520-017-3812-7
   Deng G, 2013, SUPPORT CARE CANCER, V21, P1735, DOI 10.1007/s00520-013-1720-z
   Edmond SN, 2019, PAIN REP, V4, P0, DOI 10.1097/PR9.0000000000000655
   Escalante CP, 2009, J GEN INTERN MED, V24, P412, DOI 10.1007/s11606-009-1056-z
   Finnegan-John J, 2013, INTEGR CANCER THER, V12, P276, DOI 10.1177/1534735413485816
   Fukuda S, 2016, BIOL PSYCHOL, V118, P88, DOI 10.1016/j.biopsycho.2016.05.005
   Glaus A, 1996, EUR J CANCER CARE (ENGL), V5, P8, DOI 10.1111/j.1365-2354.1996.tb00247.x
   Groenvold M, 2007, BREAST CANCER RES TR, V105, P209, DOI 10.1007/s10549-006-9447-x
   Higgins Julian P T, 2011, BMJ, V343, Pd5928, DOI 10.1136/bmj.d5928
   Johnston MF, 2011, BMC COMPLEM ALTERN M, V11, P0, DOI 10.1186/1472-6882-11-49
   Kuchinski Anne-Marie, 2009, MEDSURG NURS, V18, P174
   Ling WM, 2014, ONCOL NURS FORUM, V41, P581, DOI 10.1188/14.ONF.581-592
   Mao JJ, 2014, CANCER-AM CANCER SOC, V120, P3744, DOI 10.1002/cncr.28917
   Minton O, 2010, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD006704.pub3
   Molassiotis A, 2013, ANN ONCOL, V24, P1645, DOI 10.1093/annonc/mdt034
   Molassiotis A, 2007, COMPLEMENT THER MED, V15, P228, DOI 10.1016/j.ctim.2006.09.009
   Molassiotis A, 2012, J CLIN ONCOL, V30, P4470, DOI 10.1200/JCO.2012.41.6222
   Posadzki P, 2013, SUPPORT CARE CANCER, V21, P2067, DOI 10.1007/s00520-013-1765-z
   Prell T, 2019, FRONT NEUROL, V10, P0, DOI 10.3389/fneur.2019.00195
   Richardson PG, 2010, J NATL COMPR CANC NE, V8, P0
   Saligan LN, 2012, BRAIN BEHAV IMMUN, V26, P830, DOI 10.1016/j.bbi.2012.05.004
   Smith C, 2013, ACUPUNCT MED, V31, P9, DOI 10.1136/acupmed-2012-010228
   Vickers AJ, 2004, J CLIN ONCOL, V22, P1731, DOI 10.1200/JCO.2004.04.102
   Vickers AJ, 2012, ARCH INTERN MED, V172, P1444, DOI 10.1001/archinternmed.2012.3654
   Wanchai A, 2011, CLIN J ONCOL NURS, V15, P203, DOI 10.1188/11.CJON.203-214
   Witt CM, 2012, BMC COMPLEM ALTERN M, V12, P0, DOI 10.1186/1472-6882-12-148
   World Health Organization, 1995, GUID CLIN RES AC, V0, P0
   Wu CX, 2019, WORLDV EVID-BASED NU, V16, P102, DOI 10.1111/wvn.12352
   Xu YL, 2018, EUR REV MED PHARMACO, V22, P8519, DOI 10.26355/eurrev_201812_16553
   Zeng YC, 2014, INTEGR CANCER THER, V13, P193, DOI 10.1177/1534735413510024
   Zhang Y, 2018, SUPPORT CARE CANCER, V26, P415, DOI 10.1007/s00520-017-3955-6
NR 34
TC 35
Z9 45
U1 1
U2 22
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 1534-7354
EI 1552-695X
J9 INTEGR CANCER THER
JI Integr. Cancer Ther.
PD SEP 15
PY 2020
VL 19
IS 
BP 
EP 
DI 10.1177/1534735420949679
PG 10
WC Oncology; Integrative & Complementary Medicine
SC Oncology; Integrative & Complementary Medicine
GA NY4VJ
UT WOS:000576388900001
PM 32996339
DA 2026-01-16
ER

PT J
AU Aljawadi, MH
   Khoja, AT
   AlOtaibi, AD
   Alharbi, KT
   Alodayni, MA
   AlMetwazi, MS
   Arafah, A
   Al-Shammari, SA
   Khoja, TA
AF Aljawadi, Mohammad H.
   Khoja, Abdullah T.
   AlOtaibi, Azzam D.
   Alharbi, Khalid Turki
   Alodayni, Muhannad Abdulwahed
   AlMetwazi, Mansour S.
   Arafah, Azher
   Al-Shammari, Sulaiman A.
   Khoja, Tawfik A.
TI The Utilization of Complementary and Alternative Medicine among Saudi Older Adults: A Population-Based Study
SO EVIDENCE-BASED COMPLEMENTARY AND ALTERNATIVE MEDICINE
LA English
DT Article
ID patient-physician relationship; subjective cognitive decline; quality-of-life; herbal medicines; cancer-patients; united-states; breast-cancer; drug-interactions; chronic diseases; controlled-trial
AB Background. Complementary and alternative medicine (CAM) is an integral part of patients' therapeutic experience worldwide. Among Saudi older adults, less is known about CAM utilization. Objectives. To determine the prevalence, patterns, and factors associated with CAM utilization among SOA. Methods. In the Saudi National Survey for Elderly Health (SNSEH), subjects were asked about CAM use during the last twelve months before the interview. CAM use was defined as any use of herbal products, acupuncture, bloodletting, cauterization, medical massage, bones manual manipulation, honey, or religious rituals. Demographic characteristics included gender, age, marital status, region, educational level, and residence area. In addition, multiple comorbidities were included as possible factors that may be associated with CAM use. Multivariable logistic regression was used to explore factors associated with CAM utilization. All statistical analyses were done using STATA v.14. Results. Out of 2946 respondents, 50.4% were males, the mean age was 70.3 +/- 8.3 years, and 70% were illiterate. CAM use was prevalent (62.5%). The most common CAM types were herbal products (25.4%), acupuncture (21.2%), bloodletting (12%), honey (9.5%), cauterization (7.4%), medical massage and bones manual manipulation (4%), and traditional bone setting (2.1%). In the multivariable regression, age, gender, and marital status did not have an impact on the odds of using CAM. Subjects from rural areas were 2.92 times more likely to use CAM compared with subjects in urban areas (OR = 2.92; 95%CI: 2.28-3.75). Subjects with metabolic disorders (OR = 0.50; 95% CI: 0.42-0.60) or kidney disease were less likely to use CAM (OR = 0.30; 95%CI: 0.14-0.64). About pain, CAM is used more in neck pain (OR = 1.69; 95%CI: 1.30-2.21) and also used in back pain (OR = 1.22; 95%CI: 1.03-1.46). Conclusions. CAM use was very prevalent among SOA. Clinicians and pharmacists must ask about CAM use among older adults as many of CAM may interact with patients medications.
C1 [Aljawadi, Mohammad H.; AlMetwazi, Mansour S.; Arafah, Azher] King Saud Univ, Coll Pharm, Dept Clin Pharm, Riyadh, Saudi Arabia.
   [Khoja, Abdullah T.] Al Imam Muhammad Ibn Saud Islamic Univ IMSIU, Coll Med, Publ Hlth Dept, Riyadh, Saudi Arabia.
   [Khoja, Abdullah T.] Al Imam Muhammad Ibn Saud Islamic Univ IMSIU, Coll Med, Family Med Dept, Riyadh, Saudi Arabia.
   [AlOtaibi, Azzam D.] Al Imam Muhammad Ibn Saud Islamic Univ IMSIU, Coll Med, Dept Med, Riyadh, Saudi Arabia.
   [Alharbi, Khalid Turki] Prince Sultan Mil Med City, Pharm Serv, Riyadh, Saudi Arabia.
   [Alodayni, Muhannad Abdulwahed] Imam Muhammad Ibn Saud Islamic Univ, Coll Med, Riyadh, Saudi Arabia.
   [Al-Shammari, Sulaiman A.] King Saud Univ, Coll Med, Dept Family & Community Med, Riyadh, Saudi Arabia.
   [Khoja, Tawfik A.] Hlth Ministers Council Cooperat Council States, Riyadh, Saudi Arabia.
C3 King Saud University; Imam Mohammad Ibn Saud Islamic University (IMSIU); Imam Mohammad Ibn Saud Islamic University (IMSIU); Imam Mohammad Ibn Saud Islamic University (IMSIU); Prince Sultan Military Medical City; Imam Mohammad Ibn Saud Islamic University (IMSIU); King Saud University
RP Aljawadi, MH (corresponding author), King Saud Univ, Coll Pharm, Dept Clin Pharm, Riyadh, Saudi Arabia.
EM maljawadi@ksu.edu.sa
FU Deanship of Scientific Research at King Saud University [RG-1441-476]
CR AALEN O, 1978, ANN STAT, V6, P701, DOI 10.1214/aos/1176344247
   Abuelgasim KA, 2018, BMC COMPLEM ALTERN M, V18, P0, DOI 10.1186/s12906-018-2150-8
   Al Bedah AMN, 2016, J ALTERN COMPLEM MED, V22, P768, DOI 10.1089/acm.2016.0193
   Al-Eidi S, 2016, J INTEGR MED-JIM, V14, P187, DOI 10.1016/S2095-4964(16)60244-3
   Al-Faris EA, 2008, ANN SAUDI MED, V28, P4
   Al-Ghamdi S, 2017, BMC COMPLEM ALTERN M, V17, P0, DOI 10.1186/s12906-017-1714-3
   Al-Ramahi R, 2015, BMC COMPLEM ALTERN M, V15, P0, DOI 10.1186/s12906-015-0764-7
   Al-Zahim AA, 2013, SAUDI J GASTROENTERO, V19, P75, DOI 10.4103/1319-3767.108477
   AlBedah A, 2015, J ALTERN COMPLEM MED, V21, P504, DOI 10.1089/acm.2015.0065
   AlBedah AM, 2015, J CUTAN MED SURG, V19, P527, DOI 10.1177/1203475415607170
   AlBedah Abdullah M, 2015, ASIAN PAC J CANCER PREV, V16, P6799, DOI 10.7314/apjcp.2015.16.15.6799
   AlBedah AM, 2013, J ALTERN COMPLEM MED, V19, P918, DOI 10.1089/acm.2013.0162
   AlBedah AMN, 2013, ANN SAUDI MED, V33, P282, DOI 10.5144/0256-4947.2013.282
   AlGhamdi KM, 2015, J CUTAN MED SURG, V19, P570, DOI 10.1177/1203475415584867
   Anderegg MD, 2016, HYPERTENSION, V68, P1314, DOI 10.1161/HYPERTENSIONAHA.116.08043
   Ariff Kamil M, 2006, AUST J RURAL HEALTH, V14, P2, DOI 10.1111/j.1440-1584.2006.00747.x
   Armishaw J, 1999, ARCH DIS CHILD, V81, P133, DOI 10.1136/adc.81.2.133
   Astin JA, 1998, JAMA-J AM MED ASSOC, V279, P1548, DOI 10.1001/jama.279.19.1548
   Astin JA, 2000, J GERONTOL A-BIOL, V55, P0
   Awortwe C, 2018, BRIT J CLIN PHARMACO, V84, P679, DOI 10.1111/bcp.13490
   Ayele AA, 2017, COMPLEMENT THER MED, V35, P115, DOI 10.1016/j.ctim.2017.10.006
   Barnes Patricia M, 2004, ADV DATA, V0, P1
   Barnes Patricia M, 2008, NATL HEALTH STAT REPORT, V0, P1
   Beedie C, 2018, BRIT J SPORT MED, V52, P817, DOI 10.1136/bjsports-2017-097747
   Chang CM, 2019, J ETHNOPHARMACOL, V236, P70, DOI 10.1016/j.jep.2019.02.042
   Chang EY, 2006, AM J SURG, V192, P471, DOI 10.1016/j.amjsurg.2006.05.013
   Cherniack E Paul, 2008, COMPLEMENT THER CLIN PRACT, V14, P116, DOI 10.1016/j.ctcp.2007.11.002
   Clairet AL, 2019, MED ONCOL, V36, P0, DOI 10.1007/s12032-019-1267-z
   Clarke Tainya C, 2015, NATL HEALTH STAT REPORT, V0, P1
   Cordier W, 2012, PHARM BIOL, V50, P443, DOI 10.3109/13880209.2011.611145
   del Mundo WFB, 2002, FAM MED, V34, P206
   EISENBERG DM, 1993, NEW ENGL J MED, V328, P246, DOI 10.1056/NEJM199301283280406
   Elolemy Ahmed Tawfik, 2012, OMAN MED J, V27, P20, DOI 10.5001/omj.2012.04
   Ernst E, 2000, B WORLD HEALTH ORGAN, V78, P252
   FISHER P, 1994, BRIT MED J, V309, P107, DOI 10.1136/bmj.309.6947.107
   Foster DF, 2000, J AM GERIATR SOC, V48, P1560, DOI 10.1111/j.1532-5415.2000.tb03864.x
   Gronnesby J K, 1996, LIFETIME DATA ANAL, V2, P315, DOI 10.1007/BF00127305
   Hafner-Blumenstiel Verena, 2011, THER UMSCH, V68, P54, DOI 10.1024/0040-5930/a000120
   He D, 1997, PREV MED, V26, P208, DOI 10.1006/pmed.1996.0125
   Huiart L, 2013, PLOS ONE, V8, P0, DOI 10.1371/journal.pone.0081677
   Hussain MS, 2011, AFR J TRADIT COMPLEM, V8, P152, DOI 10.4314/ajtcam.v8i5S.8
   Hwang AY, 2017, J FAM PRACTICE, V66, P0
   Hwang SW, 2008, J THORAC ONCOL, V3, P942, DOI 10.1097/JTO.0b013e3181803f1e
   Innes KE, 2017, J ALZHEIMERS DIS, V56, P899, DOI 10.3233/JAD-160867
   Innes KE, 2016, J ALZHEIMERS DIS, V52, P1277, DOI 10.3233/JAD-151106
   Innes KE, 2016, COMPLEMENT THER MED, V26, P98, DOI 10.1016/j.ctim.2016.03.002
   Izzo AA, 2009, DRUGS, V69, P1777, DOI 10.2165/11317010-000000000-00000
   Jan MM, 2009, SAUDI MED J, V30, P682
   Javed F, 2008, J LARYNGOL OTOL, V122, P116, DOI 10.1017/S0022215107000011
   Jazieh AR, 2012, J ALTERN COMPLEM MED, V18, P1045, DOI 10.1089/acm.2011.0266
   Johnson SB, 2018, JAMA ONCOL, V4, P1375, DOI 10.1001/jamaoncol.2018.2487
   Johnson SB, 2018, JNCI-J NATL CANCER I, V110, P0, DOI 10.1093/jnci/djx145
   Abad MJ, 2010, CURR DRUG METAB, V11, P171
   Kamel FO, 2017, COMPLEMENT THER CLIN, V29, P207, DOI 10.1016/j.ctcp.2017.10.007
   Kessler RC, 2001, ANN INTERN MED, V135, P262, DOI 10.7326/0003-4819-135-4-200108210-00011
   Khoja AT, 2017, SAUDI PHARM J, V0, P0
   Kulchaitanaroaj P, 2017, J HYPERTENS, V35, P178, DOI 10.1097/HJH.0000000000001126
   Landin J, 2008, INT J GERIATR PSYCH, V23, P1163, DOI 10.1002/gps.2046
   Liang Ni-Cheng, 2017, AM J RESPIR CRIT CARE MED, V195, PP21, DOI 10.1164/rccm.19511p21
   Lin HW, 2018, J FORMOS MED ASSOC, V117, P235, DOI 10.1016/j.jfma.2017.04.017
   Linetzky B, 2017, J DIABETES, V9, P596, DOI 10.1111/1753-0407.12443
   Linus-Lojikip S, 2019, COMPLEMENT THER CLIN, V37, P73, DOI 10.1016/j.ctcp.2019.09.001
   Mariampillai JE, 2017, BLOOD PRESSURE, V26, P133, DOI 10.1080/08037051.2016.1277129
   Mbada CE, 2015, BMC COMPLEM ALTERN M, V15, P0, DOI 10.1186/s12906-015-0695-3
   Meurk C, 2013, HEALTH PLACE, V20, P75, DOI 10.1016/j.healthplace.2012.12.005
   Mohammad Y, 2015, BMC COMPLEM ALTERN M, V15, P0, DOI 10.1186/s12906-015-0623-6
   Mohieldin A, 2017, J CANCER EDUC, V32, P314, DOI 10.1007/s13187-015-0973-2
   Moran JM, 2017, BMC COMPLEM ALTERN M, V17, P0, DOI 10.1186/s12906-017-1629-z
   Neiberg RH, 2011, J ALTERN COMPLEM MED, V17, P363, DOI 10.1089/acm.2009.0157
   NELSON W, 1972, TECHNOMETRICS, V14, P945, DOI 10.2307/1267144
   Nguyen D, 2014, RURAL REMOTE HEALTH, V14, P0
   Persons AAoR, 2007, COMPL ALT MED WHAT P, V0, P0
   Posadzki P, 2016, COMPLEMENT THER MED, V29, P141, DOI 10.1016/j.ctim.2016.09.019
   Public IoMUCotUoCaAMbtA, 2005, COMPL ALT MED US, V0, P0
   Rakovitch E, 2005, BREAST CANCER RES TR, V90, P139, DOI 10.1007/s10549-004-3779-1
   Ramos FL, 2014, INT J CHRONIC OBSTR, V9, P139, DOI 10.2147/COPD.S38938
   Roumeliotis GA, 2017, PLAST SURG-CHIR PLAS, V25, P275, DOI 10.1177/2292550317716126
   Saydah SH, 2006, J ALTERN COMPLEM MED, V12, P805, DOI 10.1089/acm.2006.12.805
   Schnabel K, 2014, BMC GERIATR, V14, P0, DOI 10.1186/1471-2318-14-38
   Shumer G, 2014, BMC COMPLEM ALTERN M, V14, P0, DOI 10.1186/1472-6882-14-360
   Singh Vimal, 2004, BMC COMPLEMENT ALTERN MED, V4, P3, DOI 10.1186/1472-6882-4-3
   Smith SM, 2016, J AM SOC HYPERTENS, V10, P307, DOI 10.1016/j.jash.2016.01.010
   Sood A, 2006, NICOTINE TOB RES, V8, P767, DOI 10.1080/14622200601004109
   Statistics GAo, 2018, POP EST, V0, P0
   Sturman MT, 2008, NEUROLOGY, V70, P360, DOI 10.1212/01.wnl.0000285081.04409.bb
   Sullivan A, 2015, INTEGR CANCER THER, V14, P350, DOI 10.1177/1534735415580679
   Thomas K, 2004, J PUBLIC HEALTH, V26, P152, DOI 10.1093/pubmed/fdh139
   Tindle HA, 2005, ALTERN THER HEALTH M, V11, P42
   Turkmenoglu FP, 2016, COMPLEMENT THER CLIN, V23, P46, DOI 10.1016/j.ctcp.2016.03.004
   Waite NR, 1998, BRIT J GEN PRACT, V48, P1487
   Wang SH, 2016, BMC COMPLEM ALTERN M, V16, P0, DOI 10.1186/s12906-016-1337-0
   Weeger S, 2017, DISABIL REHABIL, V39, P468, DOI 10.3109/09638288.2016.1146360
   Williams AM, 2011, BMC COMPLEM ALTERN M, V11, P0, DOI 10.1186/1472-6882-11-47
   Xue CCL, 2007, J ALTERN COMPLEM MED, V13, P643, DOI 10.1089/acm.2006.6355
   Zeller T, 2013, J CANCER RES CLIN, V139, P357, DOI 10.1007/s00432-012-1336-6
   Zeng LF, 2015, PHYTOTHER RES, V29, P1843, DOI 10.1002/ptr.5481
NR 96
TC 17
Z9 25
U1 0
U2 16
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 1741-427X
EI 1741-4288
J9 EVID-BASED COMPL ALT
JI Evid.-based Complement Altern. Med.
PD AUG 7
PY 2020
VL 2020
IS 
BP 
EP 
DI 10.1155/2020/4357194
PG 14
WC Integrative & Complementary Medicine
SC Integrative & Complementary Medicine
GA NE8SE
UT WOS:000562874700003
PM 32831865
DA 2026-01-16
ER

PT J
AU Zhang, RY
   Zhu, BF
   Wang, LK
   Song, Y
   Zhao, JG
   Guo, Y
   Zhao, L
   Chen, S
AF Zhang, Rong yi
   Zhu, Ben Fan
   Wang, Li kui
   Song, Yang
   Zhao, Jia Gui
   Guo, Yan
   Zhao, Long
   Chen, Shi
TI Electroacupuncture alleviates inflammatory pain via adenosine suppression and its mediated substance P expression
SO ARQUIVOS DE NEURO-PSIQUIATRIA
LA English
DT Article
DE Electroacu puncture; Chronic Pain; Adenosine; Substance P
ID adenosine-a1-receptors mediate; hyperalgesia; receptors; opioids; alpha; mice
AB Background: Acupuncture has been widely used for alleviating pain. However, its mechanisms remain largely enigmatic. Objective: In the present study, we focused on whether the analgesic effect of electroacupuncture is related to its regulation on adenosine and substance P expression. Methods: We established chronic inflammatory pain model in rats through a single injection of Complete Freund's Adjuvant, and then we treated animals using dailyelectroacupuncture.We applied seven bilateralsessions of electroacu puncture (ST36 and BL60, 0.5 to 1.5 mA, initialstrength of 0.5 mA, increased by 0.5 mA every 10 minutes, for 30 minutes per session, one section per day) to Complete Freund's Adjuvant rats for seven days. The analgesic effect of electroacupuncture was evaluated by measuring paw withdrawal threshold in rats that received mechanical and thermal stimulation. Results: Daily electroacupuncture stimulation effectively increased paw withdrawal threshold in Complete Freund's Adjuvant rats. Electroacupuncture increased the adenosine level in zusanli.Afurtherstudyshowed that electroacu puncture could decrease substance P, neurokinin-1 receptor,tumor necrosis factor-alpha, interleukin-1 beta, interleukin-6 and CD68 levels in dorsal root ganglion. Interestingly, direct injection of adenosine A1 or substance P receptor antagonists, or dorsal nerve root transection could significantly impair electroacupuncture induced analgesic actions in Complete Freund's Adjuvant rats could and reduce the levels of substance P neurokinin-1 receptor, tumor necrosis factor-alpha, interleukin-1 beta, interleukin-6 and CD68. Finally, we confirmed that direct injection of adenosine A1 receptor agonist replicated the analgesic effect of electroacupuncture. Conclusion: Our results indicate regulation of adenosine-mediated substance Psecretion.Substance P-mediated pathway may be involved in the analgesia process by electroacupuncture in rats.
C1 [Zhang, Rong yi; Zhu, Ben Fan; Wang, Li kui; Song, Yang; Zhao, Jia Gui; Guo, Yan; Zhao, Long; Chen, Shi] Anhui Med Univ, Affiliated Hosp 1, Dept Pain Management, Hefei, Anhui, Peoples R China.
C3 Anhui Medical University
RP Zhang, RY (corresponding author), Anhui Med Univ, Affiliated Hosp 1, Dept Pain Management, Hefei, Anhui, Peoples R China.
EM rongyizha@163.com
FU National Natural Science Foundation of Anhui province [1808085MH310]; Grants of the Scientific Research of BoshiKeYan (BSKY) from the First Affiliated Hospital of Anhui Medical University [3101005001249]
CR Azzolina A, 2003, BBA-MOL CELL RES, V1643, P75, DOI 10.1016/j.bbamcr.2003.09.003
   Essawy SS, 2013, EUR REV MED PHARMACO, V17, P1857
   Fan AY, 2017, CHIN J INTEGR MED, V23, P83, DOI 10.1007/s11655-017-2800-6
   Fang JQ, 2013, MOL PAIN, V9, P0, DOI 10.1186/1744-8069-9-13
   Gao F, 2018, BRAIN BEHAV IMMUN, V67, P91, DOI 10.1016/j.bbi.2017.08.004
   Garrido-Suárez BB, 2009, BRAIN RES BULL, V79, P339, DOI 10.1016/j.brainresbull.2009.04.014
   Goldman N, 2010, NAT NEUROSCI, V13, P883, DOI 10.1038/nn.2562
   Henschke N, 2015, MAYO CLIN PROC, V90, P139, DOI 10.1016/j.mayocp.2014.09.010
   Huang C, 2004, BRAIN RES BULL, V63, P99, DOI 10.1016/j.brainresbull.2004.01.006
   Landry BW, 2015, PM&R, V7, PS295, DOI 10.1016/j.pmrj.2015.09.006
   Liao HY, 2017, SCI REP-UK, V7, P0, DOI 10.1038/srep42531
   Liu YJ, 2018, EVID-BASED COMPL ALT, V2018, P0, DOI 10.1155/2018/9102107
   OConnor TM, 2004, J CELL PHYSIOL, V201, P167, DOI 10.1002/jcp.20061
   Park JH, 2010, BRAIN RES, V1322, P24, DOI 10.1016/j.brainres.2010.02.001
   Patil S, 2016, CURR PAIN HEADACHE R, V20, P0, DOI 10.1007/s11916-016-0552-1
   Pinho-Ribeiro FA, 2017, TRENDS IMMUNOL, V38, P5, DOI 10.1016/j.it.2016.10.001
   Richards CJ, 2017, ORTHOP CLIN N AM, V48, P433, DOI 10.1016/j.ocl.2017.06.002
   SANTICIOLI P, 1993, EUR J PHARMACOL, V231, P139, DOI 10.1016/0014-2999(93)90695-E
   Schäfers M, 2003, PAIN, V104, P579, DOI 10.1016/S0304-3959(03)00115-5
   Sjolund KF, 1997, ANESTH ANALG, V85, P627, DOI 10.1097/00000539-199709000-00025
   Sommer C, 1999, NEUROSCI LETT, V270, P25, DOI 10.1016/S0304-3940(99)00450-4
   TAIWO YO, 1990, NEUROSCIENCE, V38, P757, DOI 10.1016/0306-4522(90)90068-F
   Webster Lynn R, 2016, ANESTHESIOL CLIN, V34, P341, DOI 10.1016/j.anclin.2016.01.002
   Xiang XN, 2019, INT J MOL SCI, V20, P0, DOI 10.3390/ijms20133248
   Yang Y, 2013, EXP THER MED, V6, P459, DOI 10.3892/etm.2013.1152
   Zylka MJ, 2011, TRENDS MOL MED, V17, P188, DOI 10.1016/j.molmed.2010.12.006
NR 26
TC 27
Z9 30
U1 2
U2 12
PU ASSOC ARQUIVOS NEURO- PSIQUIATRIA
PI SAO PAULO SP
PA PR AMADEU AMARAL 47/33, 01327-010 SAO PAULO SP, BRAZIL
SN 0004-282X
EI 1678-4227
J9 ARQ NEURO-PSIQUIAT
JI Arq. Neuro-Psiquiatr.
PD OCT 15
PY 2020
VL 78
IS 10
BP 617
EP 623
DI 10.1590/0004-282X20200078
PG 7
WC Neurosciences; Psychiatry
SC Neurosciences & Neurology; Psychiatry
GA OR2AN
UT WOS:000589277400004
PM 33146290
DA 2026-01-16
ER

PT J
AU Cheung, DST
   Yeung, WF
   Chau, PH
   Lam, TC
   Yang, M
   Lai, K
   Ip, CY
   Lao, L
   Lin, CC
AF Cheung, Denise Shuk Ting
   Yeung, Wing Fai
   Chau, Pui Hing
   Lam, Tai Chung
   Yang, Mingxiao
   Lai, Kithelia
   Ip, Chun Yat
   Lao, Lixing
   Lin, Chia-Chin
TI Patient-centred, self-administered acupressure for Chinese advanced cancer
SO European journal of cancer care
LA English
DT Journal Article
DE acupressure; advanced cancer; fatigue; insomnia; pain; traditional Chinese medicine
AB OBJECTIVES: To evaluate the feasibility and potential effects of patient-centred  self-administered acupressure for alleviating fatigue and co-occurring symptoms  among Chinese advanced cancer patients receiving treatment. METHODS: Thirty  advanced cancer patients who screened positive for moderate/severe fatigue with  symptoms of insomnia and/or pain were recruited from a hospital in Hong Kong.  They were randomly assigned (1:1) to receive a 4-week patient-centred  self-administered acupressure intervention or health education. Fatigue (primary  outcome) and secondary outcomes (sleep quality, pain, fatigue-sleep  disturbance-pain symptom cluster severity, anxiety, depression and quality of  life) were measured by questionnaires and actigraphy. RESULTS: Twenty-four  participants (80%) completed the study. Adherence to self-administered  acupressure practice was satisfactory, with all retained participants attending  all sessions and 90.9% practising acupressure daily. All completers rated the  class as very enjoyable or quite enjoyable. Fatigue, pain, symptom cluster  severity, anxiety, depression and quality of life appeared to improve from  baseline to post-intervention in the intervention group. Among these outcomes,  only the between-group difference in anxiety post-intervention was significant.  The group × time interaction effect was nonsignificant for all outcomes.  CONCLUSIONS: Patient-centred self-administered acupressure appears to be feasible  and acceptable among advanced cancer patients. A fully powered trial is warranted  to confirm the intervention effect.
C1 School of Nursing, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, China.
   School of Nursing, The Hong Kong Polytechnic University, Hong Kong, China.
   School of Nursing, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, China.
   Department of Clinical Oncology, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, China.
   School of Chinese Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, China.
   Department of Clinical Oncology, Queen Mary Hospital, Hong Kong, China.
   Department of Clinical Oncology, Queen Mary Hospital, Hong Kong, China.
   School of Chinese Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, China.
   Virginia University of Integrative Medicine, Virginia, United States.
   School of Nursing, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, China.
   Alice Ho Miu Ling Nethersole Charity Foundation Professor in Nursing, Hong Kong, 
   School of Nursing, College of Nursing, Taipei Medical University, Taiwan.
NR 0
TC 0
SN 1365-235
EI 
J9 Eur J Cancer Care (Engl)
PD SEP 9
PY 2020
VL 31
IS 5
BP e13314
EP e13314
DI 10.1111/ecc.13314
PG 1
WC Acupressure; China; Fatigue; etiology; Humans; Neoplasms; complications; Pain; Pilot Projects; Quality of Life; Syndrome
UT PubMed:32896014
PM 32896014
DA 2020-09-09
ER

PT J
AU Du, JY
   Chen, F
   Jiang, B
   Fu, TF
   Fang, JQ
   Liang, Y
AF Du, Jun Ying
   Chen, Feng
   Jiang, Bin
   Fu, Tao Fang
   Fang, Jian Qiao
   Liang, Yi
TI [Bone-edge electroacupuncture relieves pain by regulating expression of GRK5,
SO Zhen ci yan jiu = Acupuncture research
LA chi
DT Journal Article
DE G protein­coupled receptor kinase (GRK5); Bone­edge acupoint; Electroacupuncture analgesia; Locus coeruleus; Morphine tolerance; PKCα; β­arrestin 2
AB OBJECTIVE: To observe the effect of bone-edge electroacupuncture (EA)  intervention on mechanical pain threshold (PT) and expression of G  protein-coupled receptor kinase (GRK5), β-arrestin 2, total and phosphorylated  PKC alpha (p-PKCα) proteins in the locus coeruleus (LC) of rats with bone cancer  pain induced morphine tolerance, so as to reveal its partial central mechanisms  underlying pain relief. METHODS: Forty SD rats were randomly divided into 5  groups, namely sham bone cancer, bone cancer pain, morphine tolerance, bone-edge  EA, and sham EA (n＝ 8 rats in each group). The bone cancer with morphine  tolerance model was established by intramedullary injection of MRMT-1 cells into  the tibial cavity, and then intraperitoneal injection of morphine hydrochloride  injection. After successful establishment of morphine tolerance model, the  bone-edge EA (2 Hz/100 Hz，0.5－1.5 mA) was applied to bilateral "Zusanli" (ST36)  and "Kunlun" (BL60) for 30 min, once a day for 7 days, after inserting the  needle-tip to the tibial bone surface. The ipsilateral mechanical paw withdrawal  thresholds (PWTs) were detected dynamically. The expression levels of GRK5,  β-arrestin 2, PKCα and p-PKCα in the LC area were measured by Western blot.  RESULTS: The PWTs of bone cancer pain rats were decreased on day 10 after  inoculation of cancer cells (P<0.01). After i．p. of morphine for 11 days, no  analgesic effect and pain tolerance appeared (P>0.05). The PWTs were  significantly increased in the bone-edge EA intervention group (P<0.01), not in  the sham EA group (P>0.05). In comparison with the sham bone cancer group, the  expression of GRK5 protein in morphine tolerance group was significantly  decreased (P<0.01); compared with morphine tolerance group, the expression of  GRK5 protein in bone-edge EA group was increased(P<0.01). In comparison with the  sham bone cancer group, the expression of β-arrestin 2 and p-PKCα in bone cancer  group significantly increased (P<0.01). After the intervention, the increased  β-arrestin 2 and p-PKCα expressions were reversed in the bone-edge EA group  (P<0.01); compared with morphine tolerance group and sham EA group, the  expression of PKCα protein was decreased(P<0.01). CONCLUSION: Bone-edge EA can  effectively relieve morphine tolerance in bone cancer pain rats, which may be  related to its functions in up-regulating GRK5 protein and down-regulating  β-arrestin 2, PKCα and p-PKCα proteins in LC.　.
C1 The Third Clinical Medical College, Zhejiang Chinese Medical University, Key Laboratory of Acupuncture and Neurology of Zhejiang Province, Hangzhou 310053,China.
   The Second Clinical Medical College, Zhejiang Chinese Medical University, Hangzhou 310053
   The First Affiliated Hospital of Jiaxing College, Jiaxing314001, Zhejiang Province.
   The First Affiliated Hospital of Jiaxing College, Jiaxing 314001, Zhejiang Province.
   The Third Clinical Medical College, Zhejiang Chinese Medical University, Key Laboratory of Acupuncture and Neurology of Zhejiang Province, Hangzhou 310053,China.
   The Third Clinical Medical College, Zhejiang Chinese Medical University, Key Laboratory of Acupuncture and Neurology of Zhejiang Province, Hangzhou 310053,China.
   The Third Clinical Medical College, Zhejiang Chinese Medical University, Key Laboratory of Acupuncture and Neurology of Zhejiang Province, Hangzhou 310053,China.
NR 0
TC 0
SN 
EI 1000-060
J9 Zhen Ci Yan Jiu
PD MAR 8
PY 2020
VL 45
IS 2
BP 87
EP 92
DI 10.13702/j.1000-0607.1900036
PG 5
WC Acupuncture Points; Animals; Bone Neoplasms; Cancer Pain; Electroacupuncture; G-Protein-Coupled Receptor Kinase 5; Locus Coeruleus; Morphine; Protein Kinase C-alpha; Rats; Rats, Sprague-Dawley; beta-Arrestin 2
UT PubMed:32144916
PM 32144916
DA 2020-03-08
ER

PT J
AU Hack, CC
   Häberle, L
   Brucker, SY
   Janni, W
   Volz, B
   Loehberg, CR
   Hartkopf, AD
   Walter, CB
   Baake, G
   Fridman, A
   Malter, W
   Wuerstlein, R
   Harbeck, N
   Hoffmann, O
   Kuemmel, S
   Martin, B
   Thomssen, C
   Graf, H
   Wolf, C
   Lux, MP
   Bayer, CM
   Rauh, C
   Almstedt, K
   Gass, P
   Heindl, F
   Brodkorb, T
   Willer, L
   Lindner, C
   Kolberg, HC
   Krabisch, P
   Weigel, M
   Steinfeld-Birg, D
   Kohls, A
   Brucker, C
   Schulz,
   Fischer, G
   Pelzer,
   Rack, B
   Beckmann, MW
   Fehm, T
   Rody, A
   Maass, N
   Hein, A
   Fasching, PA
   Nabieva, N
AF Hack, C. C.
   Haeberle, L.
   Brucker, S. Y.
   Janni, W.
   Volz, B.
   Loehberg, C. R.
   Hartkopf, A. D.
   Walter, C-B
   Baake, G.
   Fridman, A.
   Malter, W.
   Wuerstlein, R.
   Harbeck, N.
   Hoffmann, O.
   Kuemmel, S.
   Martin, B.
   Thomssen, C.
   Graf, H.
   Wolf, C.
   Lux, M. P.
   Bayer, C. M.
   Rauh, C.
   Almstedt, K.
   Gass, P.
   Heindl, F.
   Brodkorb, T.
   Willer, L.
   Lindner, C.
   Kolberg, H-C
   Krabisch, P.
   Weigel, M.
   Steinfeld-Birg, D.
   Kohls, A.
   Brucker, C.
   Schulz, V
   Fischer, G.
   Pelzer, V
   Rack, B.
   Beckmann, M. W.
   Fehm, T.
   Rody, A.
   Maass, N.
   Hein, A.
   Fasching, P. A.
   Nabieva, N.
TI Complementary and alternative medicine and musculoskeletal pain in the first year of adjuvant aromatase inhibitor treatment in early breast cancer patients
SO BREAST
LA English
DT Article
DE Breast cancer; Endocrine therapy/treatment; Aromatase inhibitors; Letrozole; Integrative medicine; Complementary and alternative medicine; Arthralgia; Myalgia
ID postmenopausal women; induced arthralgia; endocrine therapy; controlled trial; free survival; symptoms; tamoxifen; acupuncture; personality; anastrozole
AB Background: Patients with breast cancer (BC) show strong interest in complementary and alternative medicine (CAM), particularly for adverse effects of adjuvant endocrine treatment - e.g., with letrozole. Letrozole often induces myalgia/limb pain and arthralgia, with potential noncompliance and treatment termination. This analysis investigated whether CAM before aromatase inhibitor (AI) therapy is associated with pain development and the intensity of AI-induced musculoskeletal syndrome (AIMSS) during the first year of treatment. Patients and methods: The multicenter phase IV PreFace study evaluated letrozole therapy in post-menopausal, hormone receptor-positive patients with early BC. Patients were asked about CAM use before, 6 months after, and 12 months after treatment started. They recorded pain every month for 1 year in a diary including questions about pain and numeric pain rating scales. Data were analyzed for patients who provided pain information for all time points. Results: Of 1396 patients included, 901 (64.5%) had used CAM before AI treatment. Throughout the observation period, patients with CAM before AI treatment had higher pain values, for both myalgia/limb pain and arthralgia, than non-users. Pain increased significantly in both groups over time, with the largest increase during the first 6 months. No significant difference of pain increase was noted regarding CAM use. Conclusions: CAM use does not prevent or improve the development of AIMSS. Pain intensity was generally greater in the CAM group. Therefore, because of the risk of non-compliance and treatment discontinuation due to the development of higher pain levels, special attention must be paid to patient education and aftercare in these patients. (C) 2020 The Author(s). Published by Elsevier Ltd.
C1 [Hack, C. C.; Haeberle, L.; Volz, B.; Loehberg, C. R.; Lux, M. P.; Bayer, C. M.; Rauh, C.; Almstedt, K.; Gass, P.; Heindl, F.; Brodkorb, T.; Willer, L.; Beckmann, M. W.; Hein, A.; Fasching, P. A.; Nabieva, N.] Friedrich Alexander Univ Erlangen Nuremberg, Erlangen Univ Hosp, Comprehens Canc Ctr Erlangen EMN, Dept Gynecol, Erlangen, Germany.
   [Haeberle, L.] Erlangen Univ Hosp, Dept Gynecol, Biostat Unit, Erlangen, Germany.
   [Brucker, S. Y.; Hartkopf, A. D.; Walter, C-B; Fehm, T.] Univ Tubingen, Dept Gynecol, Tubingen, Germany.
   [Janni, W.; Rack, B.] Ulm Univ Hosp, Dept Gynecol, Ulm, Germany.
   [Loehberg, C. R.] St Theresien Hosp, Nurnberg, Germany.
   [Baake, G.] Oncol Med Practice Pinneberg, Pinneberg, Germany.
   [Fridman, A.; Malter, W.; Wuerstlein, R.; Harbeck, N.] Univ Cologne Hosp, Breast Ctr, Dept Obstet & Gynecol, Cologne, Germany.
   [Fridman, A.] Evangelisches Krankenhaus Kalk, Cologne, Germany.
   [Wuerstlein, R.; Harbeck, N.] Univ Munich LMU, Breast Ctr, Dept Gynecol & Obstet, Munich, Germany.
   [Fridman, A.] Univ Munich LMU, CCC Munich, Munich, Germany.
   [Hoffmann, O.] Essen Univ Hosp, Dept Gynecol, Essen, Germany.
   [Kuemmel, S.] Evang Huyssens Stiftung Knappschaft GmbH, Breast Unit, Essen Mitte Clin, Essen, Germany.
   [Martin, B.] Tuttlingen Clin, Tuttlingen, Germany.
   [Thomssen, C.] Martin Luther Univ Halle Wittenberg, Dept Gynecol, Halle, Saale, Germany.
   [Graf, H.] Helios Clin Meiningen, Meiningen, Germany.
   [Wolf, C.] Ulm Med Ctr, Ulm, Germany.
   [Almstedt, K.] Mainz Univ Hosp, Dept Gynecol, Mainz, Germany.
   [Lindner, C.] Agaplesion Diakonie Clin Hamburg, Hamburg, Germany.
   [Kolberg, H-C] Marienhosp Bottrop, Dept Gynecol & Obstet, Bottrop, Germany.
   [Krabisch, P.] Klinikum Chemnitz gGmbH, Dept Gynecol, Chemnitz, Germany.
   [Weigel, M.] Leopoldina Hosp Schweinfurt, Dept Gynecol, Schweinfurt, Germany.
   [Steinfeld-Birg, D.] Gynecol Onocol Practice Steinfeld Birg, Augsburg, Germany.
   [Kohls, A.] Protestant Cty Hosp Ludwigsfelde Teltow, Ludwigsfelde Teltow, Germany.
   [Brucker, C.] Paracelsus Med Univ, Nuremberg Gen Hosp, Dept Gynecol & Obstet, Nurnberg, Germany.
   [Schulz, V] Gynecol Practice Abts Partner, Kiel, Germany.
   [Fischer, G.] Mittweida Hosp gGmbH, Mittweida, Germany.
   [Pelzer, V] GFO Clin Bonn, Dept Gynecol, Bonn, Germany.
   [Fehm, T.] Heinrich Heine Univ Dusseldorf, Dept Gynecol, Dusseldorf, Germany.
   [Rody, A.] Schleswig Holstein Univ Hosp, Dept Gynecol, Campus Lubeck, Schleswig Holstein, Germany.
   [Maass, N.] Schleswig Holstein Univ Hosp, Dept Gynecol, Campus Kiel, Schleswig Holstein, Germany.
C3 University of Erlangen Nuremberg; University of Erlangen Nuremberg; Eberhard Karls University of Tubingen; Ulm University; University of Cologne; University of Munich; University of Munich; University of Duisburg Essen; Kliniken Essen-Mitte; Martin Luther University Halle Wittenberg; University Hospital Mainz; St. Marien Hospital; Chemnitz Clinic; Heinrich Heine University Dusseldorf
RP Fasching, PA (corresponding author), Erlangen Univ Hosp, Dept Gynecol, Univ Str 21-23, D-91054 Erlangen, Germany.; Fasching, PA (corresponding author), Univ Breast Ctr Franconia, Univ Str 21-23, D-91054 Erlangen, Germany.; Fasching, PA (corresponding author), European Metropolitan Area Nuremberg CCC ER EMN, Comprehens Canc Ctr Erlangen, Univ Str 21-23, D-91054 Erlangen, Germany.; Fasching, PA (corresponding author), Friedrich Alexander Univ Erlangen Nuremberg, Univ Str 21-23, D-91054 Erlangen, Germany.
EM peter.fasching@uk-erlangen.de
CR Bao T, 2013, BREAST CANCER RES TR, V138, P167, DOI 10.1007/s10549-013-2427-z
   Baum M, 2002, LANCET, V359, P2131
   Beckwée D, 2017, SUPPORT CARE CANCER, V25, P1673, DOI 10.1007/s00520-017-3613-z
   Briot K, 2010, BREAST CANCER RES TR, V120, P127, DOI 10.1007/s10549-009-0692-7
   Burstein HJ, 1999, NEW ENGL J MED, V340, P1733, DOI 10.1056/NEJM199906033402206
   Chen L, 2017, BREAST, V33, P132, DOI 10.1016/j.breast.2017.03.015
   Chirgwin JH, 2016, J CLIN ONCOL, V34, P2452, DOI 10.1200/JCO.2015.63.8619
   Colleoni M, 2011, J CLIN ONCOL, V29, P1117, DOI 10.1200/JCO.2010.31.6455
   Crew KD, 2010, J CLIN ONCOL, V28, P1154, DOI 10.1200/JCO.2009.23.4708
   Davidson R, 2005, PSYCHO-ONCOLOGY, V14, P187, DOI 10.1002/pon.834
   DiGianni LM, 2002, J CLIN ONCOL, V20, P34S, DOI 10.1200/JCO.2002.07.176
   Dowsett M, 2015, LANCET, V386, P1341, DOI 10.1016/S0140-6736(15)61074-1
   Fremd C, 2017, ARCH GYNECOL OBSTET, V295, P1239, DOI 10.1007/s00404-017-4348-2
   Galantino ML, 2012, EXPLORE-NY, V8, P40, DOI 10.1016/j.explore.2011.10.002
   Hack CC, 2017, INTEGR CANCER THER, V16, P165, DOI 10.1177/1534735416668575
   Hadji P, 2014, ANN ONCOL, V25, P372, DOI 10.1093/annonc/mdt513
   Hadji P, 2013, ANN ONCOL, V24, P1505, DOI 10.1093/annonc/mds653
   Henry NL, 2012, J CLIN ONCOL, V30, P936, DOI 10.1200/JCO.2011.38.0261
   Hershman DL, 2015, J CLIN ONCOL, V33, P1910, DOI 10.1200/JCO.2014.59.5595
   Honda K, 2005, PREV MED, V40, P46, DOI 10.1016/j.ypmed.2004.05.001
   Horneber M, 2012, INTEGR CANCER THER, V11, P187, DOI 10.1177/1534735411423920
   Irwin ML, 2015, J CLIN ONCOL, V33, P1104, DOI 10.1200/JCO.2014.57.1547
   Jacobsen PB, 2015, PSYCHO-ONCOLOGY, V24, P1578, DOI 10.1002/pon.3756
   Johnson SB, 2018, JAMA ONCOL, V4, P1375, DOI 10.1001/jamaoncol.2018.2487
   Lash BW, 2011, J CLIN ONCOL, V29, P0, DOI 10.1200/jco.2011.29.15_suppl.e19725
   Lohrisch CA, 2011, J CLIN ONCOL, V29, P0, DOI 10.1200/jco.2011.29.15_suppl.636
   Lombard JM, 2016, SUPPORT CARE CANCER, V24, P2139, DOI 10.1007/s00520-015-3001-5
   Möbus V, 2017, GEBURTSH FRAUENHEILK, V77, P1079, DOI 10.1055/s-0043-119542
   Molassiotis A, 2005, ANN ONCOL, V16, P655, DOI 10.1093/annonc/mdi110
   Moschèn R, 2001, SUPPORT CARE CANCER, V9, P267, DOI 10.1007/s005200000208
   Nabieva N, 2018, ANN ONCOL, V29, P186, DOI 10.1093/annonc/mdx630
   OConnor Casey, 2016, HAND (N Y), V11, P295, DOI 10.1177/1558944715620798
   Peppone LJ, 2015, BREAST CANCER RES TR, V150, P597, DOI 10.1007/s10549-015-3351-1
   Prieto-Alhambra D, 2011, BREAST CANCER RES TR, V125, P869, DOI 10.1007/s10549-010-1075-9
   Roberts K, 2017, CRIT REV ONCOL HEMAT, V111, P66, DOI 10.1016/j.critrevonc.2017.01.010
   Scharl A, 2016, GEBURTSH FRAUENHEILK, V76, P516, DOI 10.1055/s-0042-106389
   Sirois FM, 2008, J ALTERN COMPLEM MED, V14, P1151, DOI 10.1089/acm.2007.0801
   Stearns V, 2015, J CLIN ONCOL, V33, P265, DOI 10.1200/JCO.2014.57.6926
   Templeton AJ, 2013, BMC CANCER, V13, P0, DOI 10.1186/1471-2407-13-153
   Thorne C, 2007, CURR ONCOL, V14 Suppl 1, PS11, DOI 10.3747/co.2007.152
   Thürlimann B, 2005, NEW ENGL J MED, V353, P2747
   Toivonen KI, 2018, INTEGR CANCER THER, V17, P785, DOI 10.1177/1534735417753539
   Untch M, 2017, GEBURTSH FRAUENHEILK, V77, P633, DOI 10.1055/s-0043-111601
NR 43
TC 7
Z9 7
U1 1
U2 13
PU CHURCHILL LIVINGSTONE
PI EDINBURGH
PA JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE, LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND
SN 0960-9776
EI 1532-3080
J9 BREAST
JI Breast
PD APR 15
PY 2020
VL 50
IS 
BP 11
EP 18
DI 10.1016/j.breast.2019.12.017
PG 8
WC Oncology; Obstetrics & Gynecology
SC Oncology; Obstetrics & Gynecology
GA KU6HI
UT WOS:000519815500002
PM 31958661
DA 2026-01-16
ER

PT J
AU Lee, JH
   Cho, TJ
   Park, MG
   Kim, JH
   Song, SK
   Park, SY
   Sunwoo, YY
   Lee, I
   Park, TY
AF Lee, Jin-Hyun
   Cho, Tae Jin
   Park, Min Geun
   Kim, Ji-Hoon
   Song, Sung Kyu
   Park, Shin-Young
   Sunwoo, Yun-Young
   Lee, Ilkyun
   Park, Tae-Yong
TI Clinical study on concurrent use of electro-acupuncture or Chuna manual therapy
SO Medicine
LA English
DT Journal Article
AB INTRODUCTION: Chemotherapy-induced peripheral neuropathy (CIPN) is one of the  major side effects of chemotherapy. Its main symptoms are pain, paresthesia, and  numbness. However, the mechanisms underlying the development of CIPN remain  unclear and standard treatments have not been established. Recently, there has  been a growing interest in various approaches to overcome the limitations of the  existing treatments. This study aims to evaluate the efficacy and safety of the  concurrent use of two complementary and alternative therapies: electroacupuncture  (EA) and Chuna manual therapy (CMT), with pregabalin, which is the conventional  pharmacotherapy for neuropathic pain. METHODS/DESIGN: This is an open-label,  parallel, assessor-blinded randomized controlled trial, which includes 90  patients with colorectal and breast cancer, who developed CIPN. After a 2-week  preparation period, the patients are divided into three groups (pregabalin  administration group, pregabalin + EA treatment group, and pregabalin + CMT  treatment group), treated for approximately 5 weeks and followed-up 4 weeks after  treatment. The primary outcome is assessed using the Functional Assessment of  Cancer Therapy/Gynecologic Oncology Group Neurotoxicity subscale score (version  4.0) and the secondary outcome is measured using the Quality of Life  Questionnaire-CIPN 20-Item Scale (version 3.0) and the quality of life  questionnaire (version 3.0) developed by the European Organisation for Research  and Treatment of Cancer. Moreover, exploratory efficacy and safety evaluations  will be conducted based on the chemotherapy-completion rate and nerve conduction  studies.
C1 Institute for Integrative Medicine, Catholic Kwandong University International St. Mary's Hospital.
   Department of Emergency Medicine.
   Department of Surgery, Catholic Kwandong University International St. Mary's Hospital, Catholic Kwandong University College of Medicine.
   Department of Surgery, Catholic University of Korea, Incheon St. Mary's Hospital.
   Department of Surgery, Catholic Kwandong University International St. Mary's Hospital, Catholic Kwandong University College of Medicine.
   Department of Surgery, Catholic Kwandong University International St. Mary's Hospital, Catholic Kwandong University College of Medicine.
   Iksoodang Korean Medical Clinic, Incheon, South Korea.
   Department of Emergency Medicine.
   Institute for Integrative Medicine, Catholic Kwandong University International St. Mary's Hospital.
NR 0
TC 0
SN 1536-596
EI 0025-797
J9 Medicine (Baltimore)
PD FEB 6
PY 2020
VL 99
IS 3
BP e18830
EP e18830
DI 10.1097/MD.0000000000018830
PG 1
WC Acupuncture Therapy; Analgesics; therapeutic use; Antineoplastic Agents; adverse effects; Humans; Musculoskeletal Manipulations; Peripheral Nervous System Diseases; chemically induced; Pregabalin; therapeutic use; Randomized Controlled Trials as Topic; Research Design
UT PubMed:32011497
PM 32011497
DA 2020-02-06
ER

PT J
AU Turawa, EB
   Musekiwa, A
   Rohwer, AC
AF Turawa, Eunice B
   Musekiwa, Alfred
   Rohwer, Anke C
TI Interventions for preventing postpartum constipation.
SO The Cochrane database of systematic reviews
LA English
DT Journal Article
AB BACKGROUND: Postpartum constipation, with symptoms, such as pain or discomfort,  straining, and hard stool, is a common condition affecting mothers. Haemorrhoids,  pain at the episiotomy site, effects of pregnancy hormones, and haematinics used  in pregnancy can increase the risk of postpartum constipation. Eating a  high-fibre diet and increasing fluid intake are usually encouraged. Although  laxatives are commonly used in relieving constipation, the effectiveness and  safety of available interventions for preventing postpartum constipation should  be ascertained. This is an update of a review first published in 2015.  OBJECTIVES: To evaluate the effectiveness and safety of interventions for  preventing postpartum constipation. SEARCH METHODS: We searched Cochrane  Pregnancy and Childbirth's Trials Register, and two trials registers  ClinicalTrials.gov, the WHO International Clinical Trials Registry Platform  (ICTRP) (7 October 2019), and screened reference lists of retrieved trials.  SELECTION CRITERIA: We considered all randomised controlled trials (RCTs)  comparing any intervention for preventing postpartum constipation versus another  intervention, placebo, or no intervention in postpartum women. Interventions  could include pharmacological (e.g. laxatives) and non-pharmacological  interventions (e.g. acupuncture, educational and behavioural interventions).  Quasi-randomised trials and cluster-RCTs were eligible for inclusion; none were  identified. Trials using a cross-over design were not eligible. DATA COLLECTION  AND ANALYSIS: Two review authors independently screened the results of the search  to select potentially relevant trials, extracted data, assessed risk of bias, and  the certainty of the evidence, using the GRADE approach. We did not pool results  in a meta-analysis, but reported them per study. MAIN RESULTS: We included five  trials (1208 postpartum mothers); three RCTs and two quasi-RCTs. Four trials  compared a laxative with placebo; one compared a laxative plus a bulking agent  versus the same laxative alone, in women who underwent surgical repair of third  degree perineal tears. Trials were poorly reported, and four of the five trials  were published over 40 years ago. We judged the risk of bias to be unclear for  most domains. Overall, we found a high risk of selection and attrition bias.  Laxative versus placebo We included four trials in this comparison. Two of the  trials examined the effects of laxatives that are no longer used; one has been  found to have carcinogenic properties (Danthron), and the other is not  recommended for lactating women (Bisoxatin acetate); therefore, we did not  include their results in our main findings. None of the trials included in this  comparison assessed our primary outcomes: pain or straining on defecation,  incidence of postpartum constipation, or quality of life; or many of our  secondary outcomes. A laxative (senna) may increase the number of women having  their first bowel movement within 24 hours after delivery (risk ratio (RR) 2.90,  95% confidence interval (CI) 2.24 to 3.75; 1 trial, 471 women; low-certainty  evidence); may have little or no effect on the number of women having their first  bowel movement on day one after delivery (RR 0.94, 95% CI 0.72 to 1.22; 1 trial,  471 women; very low-certainty evidence); may reduce the number of women having  their first bowel movement on day two (RR 0.23, 95% CI 0.11 to 0.45; 1 trial, 471  women; low-certainty evidence); and day three (RR 0.05, 95% CI 0.00 to 0.89; 1  trial, 471 women; low-certainty evidence); and may have little or no effect on  the number of women having their first bowel movement on day four after delivery  (RR 0.22, 95% CI 0.03 to 1.87; 1 trial, 471 women; very low-certainty evidence),  but some of the evidence is very uncertain. Adverse effects were poorly reported.  Low-certainty evidence suggests that the laxative (senna) may increase the number  of women experiencing abdominal cramps (RR 4.23, 95% CI 1.75 to 10.19; 1 trial,  471 women). Very low-certainty evidence suggests that laxatives taken by the  mother may have little or no effect on loose stools in the baby (RR 0.62, 95% CI  0.16 to 2.41; 1 trial, 281 babies); or diarrhoea (RR 2.46, 95% CI 0.23 to 26.82;  1 trial, 281 babies). Laxative plus bulking agent versus laxative only Very  low-certainty evidence from one trial (147 women) suggests no evidence of a  difference between these two groups of women who underwent surgical repair of  third degree perineal tears; only median and range data were reported. The trial  also reported no evidence of a difference in the incidence of postpartum  constipation (data not reported), but did not report on quality of life. Time to  first bowel movement was reported as a median (range); very low-certainty  evidence suggests little or no difference between the two groups. A laxative plus  bulking agent may increase the number of women having any episode of faecal  incontinence during the first 10 days postpartum (RR 1.81, 95% CI 1.01 to 3.23; 1  trial, 147 women; very low-certainty evidence). The trial did not report on  adverse effects of the intervention on babies, or many of our secondary outcomes.  AUTHORS' CONCLUSIONS: There is insufficient evidence to make general conclusions  about the effectiveness and safety of laxatives for preventing postpartum  constipation. The evidence in this review was assessed as low to very  low-certainty evidence, with downgrading decisions based on limitations in study  design, indirectness and imprecision. We did not identify any trials assessing  educational or behavioural interventions. We identified four trials that examined  laxatives versus placebo, and one that examined laxatives versus laxatives plus  stool bulking agents. Further, rigorous trials are needed to assess the  effectiveness and safety of laxatives during the postpartum period for preventing  constipation. Trials should assess educational and behavioural interventions, and  positions that enhance defecation. They should report on the primary outcomes  from this review: pain or straining on defecation, incidence of postpartum  constipation, quality of life, time to first bowel movement after delivery, and  adverse effects caused by the intervention, such as: nausea or vomiting, pain,  and flatus.
C1 Division of Health Systems and Public Health, Department of Global Health, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town,South Africa.
   South African Medical Research Council, Burden of Disease Research Unit, Cape 
   Centre for Evidence-based Health Care, Division of Epidemiology and Biostatistics, Faculty of Medicine and Health Sciences, Stellenbosch University,Cape Town, South Africa.
   Centre for Evidence-based Health Care, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa.
NR 0
TC 0
SN 1469-493
EI 
J9 Cochrane Database Syst Rev
PD AUG 8
PY 2020
VL 8
IS 8
BP CD011625
EP CD011625
DI 10.1002/14651858.CD011625.pub3
PG 1
WC Adult; Constipation; prevention & control; Defecation; Dietary Fiber; adverse effects; Female; Humans; Laxatives; adverse effects; Perineum; injuries; Postpartum Period; Puerperal Disorders; prevention & control; Randomized Controlled Trials as Topic; Time Factors
UT PubMed:32761813
PM 32761813
DA 2020-08-08
ER

PT J
AU Park, S
   Gu, JH
   Jang, HK
   Oh, MS
   Lee, EJ
   Jung, IC
AF Park, Sohyeon
   Gu, Ji-Hyang
   Jang, Hye-Kyoung
   Oh, Min-Seok
   Lee, Eun-Jung
   Jung, In Chul
TI Electroacupuncture for post-thoracotomy pain: Protocol for a systematic review
SO Medicine
LA English
DT Journal Article
AB BACKGROUND: Thoracotomy is a common surgical procedure used in cases such as  trauma and cancer resection. It is an invasive procedure in which incisions are  made in the chest wall to gain access to the chest. Therefore, it often produces  intense postoperative pain. Electroacupuncture has been known for its analgesic  effects in various conditions, including cases of postoperative pain. This  protocol design is for a systematic review and meta-analysis to gather evidence  and investigate the analgesic effects of electroacupuncture in pain after  thoracotomy. METHODS: The studies for the systematic review will be searched with  keywords on the following 10 databases: PubMed, Cochrane Library (CENTRAL),  EMBASE, MEDLINE, Google Scholar, CNKI, KoreaMed, KMBASE, KISS, and OASIS. The  search will be done without language restrictions. Only the randomized controlled  trials that meet the eligibility criteria will be finally included in the study.  The quality of the study will be assessed using the Cochrane Collaborations'  risk-of-bias tool, and Cochrane's software RevMan 5.3 will be used for  meta-analysis. RESULTS: The designed study will provide a systematic review and  meta-analysis of the searched and randomized controlled trials that meet the  eligibility criteria. Meta-analysis will be performed with pain scores as the  main outcome measure, and they may also be performed with additional outcomes.  The qualitative and quantitative data synthesis is expected to provide high  quality evidence to judge the pain management effect of electroacupuncture for  patients who underwent thoracotomy. CONCLUSION: The conclusion of this systematic  review and meta-analysis will provide evidence to judge whether  electroacupuncture is an effective analgesic treatment option for patients  suffering with post-thoracotomy pain. PROSPERO REGISTRATION NUMBER:  CRD42019142157.
C1 College of Korean Medicine.
   Department of Korean Rehabilitation Medicine, College of Korean Medicine, Daejeon University, Dong-Gu.
   Clinical Trial Center, Dunsan Korean Medicine Hospital of Daejeon University, Seo-Gu Daejeon.
   Department of Korean Rehabilitation Medicine, College of Korean Medicine, Daejeon University, Dong-Gu.
   Department of Korean Rehabilitation Medicine, College of Korean Medicine, Daejeon University, Dong-Gu.
   Department of Oriental Neuropsychiatry, College of Korean Medicine, Daejeon University, Dong-Gu, Daejeon, Republic of Korea.
NR 0
TC 0
SN 1536-596
EI 0025-797
J9 Medicine (Baltimore)
PD MAR 3
PY 2020
VL 99
IS 9
BP e19312
EP e19312
DI 10.1097/MD.0000000000019312
PG 1
WC Electroacupuncture; methods; Humans; Pain, Postoperative; therapy; Systematic Reviews as Topic; Thoracotomy; adverse effects
UT PubMed:32118757
PM 32118757
DA 2020-03-03
ER

PT J
AU Chen, T
   Zhang, WW
   Chu, YX
   Wang, YQ
AF Chen, Teng
   Zhang, Wen Wen
   Chu, Yu-Xia
   Wang, Yan-Qing
TI Acupuncture for Pain Management: Molecular Mechanisms of Action
SO AMERICAN JOURNAL OF CHINESE MEDICINE
LA English
DT Article
DE Manual Acupuncture; Electroacupuncture; Pain Modulation; Glial Cells; Review
ID relieves neuropathic pain; flick test depends; muscle blood-flow; electroacupuncture analgesia; inflammatory pain; spinal-cord; rat model; manual acupuncture; 100-hz electroacupuncture; anti-hyperalgesia
AB Acupuncture reduces pain by activating specific areas called acupoints on the patient's body. When these acupoints are fully activated, sensations of soreness, numbness, fullness, or heaviness called De qi or Te qi are felt by clinicians and patients. There are two kinds of acupuncture, manual acupuncture and electroacupuncture (EA). Compared with non-acupoints, acupoints are easily activated on the basis of their special composition of blood vessels, mast cells, and nerve fibers that mediate the acupuncture signals. In the spinal cord, EA can inhibit glial cell activation by down-regulating the chemokine CX3CL1 and increasing the anti-inflammatory cytokine interleukin-10. This inhibits P38 mitogenactivated protein kinase and extracellular signal-regulated kinase pathways, which are associated with microglial activation of the C-Jun N-terminal kinase signaling pathway and subsequent astrocyte activation. The inactivation of spinal microglia and astrocytes mediates the immediate and long-term analgesic effects of EA, respectively. A variety of pain-related substances released by glial cells such as the proinflammatory cytokines tumor necrosis factor alpha, interleukin-1 beta, interleukin-6, and prostaglandins such as prostaglandins E2 can also be reduced. The descending pain modulation system in the brain, including the anterior cingulated cortex, the periaqueductal gray, and the rostral ventromedial medulla, plays an important role in EA analgesia. Multiple transmitters and modulators, including endogenous opioids, cholecystokinin octapeptide, 5-hydroxytryptamine, glutamate, noradrenalin, dopamine, gamma-aminobutyric acid, acetylcholine, and orexin A, are involved in acupuncture analgesia. Finally, the "Acupuncture thorn" strategy is introduced to help clinicians achieve better analgesic effects, and a newly reported acupuncture method called acupoint catgut embedding, which injects sutures made of absorbable materials at acupoints to achieve longterm effects, is discussed.
C1 Fudan Univ, Dept Integrat Med & Neurobiol, Brain Sci Collaborat Innovat Ctr,State Key Lab Me, Sch Basic Med Sci,Inst Integrat Med,Inst Brain Sc, Shanghai, Peoples R China.
   Fudan Univ, MOE Frontiers Ctr Brain Sci, Shanghai, Peoples R China.
C3 Fudan University; Fudan University
RP Chu, YX; Wang, YQ (corresponding author), Fudan Univ, Sch Basic Med Sci, Dept Integrat Med & Neurobiol, 130 Dongan Rd, Shanghai 200032, Peoples R China.
EM yuxiachu@fudan.edu.cn; wangyanqing@shmu.edu.cn
FU National Natural Science Funds of China [81971056, 31600852, 81771202, 81873101]; Innovative Research Team of High-level Local Universities in Shanghai; National Key R&D Program of China [2017YFB0403803]
CR Abraham TS, 2011, J CHEM NEUROANAT, V41, P129, DOI 10.1016/j.jchemneu.2011.01.001
   Chang S, 2019, FRONT NEUROSCI-SWITZ, V13, P0, DOI 10.3389/fnins.2019.00110
   Chen SP, 2016, BEHAV BRAIN FUNCT, V12, P0, DOI 10.1186/s12993-016-0096-x
   Chen XY, 2014, SCI REP-UK, V4, P0, DOI 10.1038/srep06482
   Chen YH, 2018, P NATL ACAD SCI USA, V115, P0
   Cheng LL, 2012, EVID-BASED COMPL ALT, V2012, P0, DOI 10.1155/2012/476457
   Choi DC, 2012, EXP NEUROL, V236, P268, DOI 10.1016/j.expneurol.2012.05.014
   Chu D, 2011, INT J COLORECTAL DIS, V26, P569, DOI 10.1007/s00384-010-1087-2
   Cui WQ, 2019, J PAIN, V20, P0
   Cui X, 2018, J PAIN RES, V11, P483, DOI 10.2147/JPR.S152015
   da Silva JRML, 2013, EVID-BASED COMPL ALT, V2013, P0
   Dai WJ, 2019, EVID-BASED COMPL ALT, V2019, P0, DOI 10.1155/2019/8413576
   Dimitrov N, 2017, ROM J MORPHOL EMBRYO, V58, P961
   Du KR, 2017, ANESTH ANALG, V125, P662, DOI 10.1213/ANE.0000000000001857
   Feng XM, 2012, BMC COMPLEM ALTERN M, V12, P0, DOI 10.1186/1472-6882-12-225
   Fusumada Kazutoshi, 2007, OKAJIMAS FOLIA ANATOMICA JAPONICA, V84, P1, DOI 10.2535/ofaj.84.1
   Gao ZS, 2014, EVID-BASED COMPL ALT, V2014, P0, DOI 10.1155/2014/659268
   Gim GT, 2011, BRAIN RES BULL, V86, P403, DOI 10.1016/j.brainresbull.2011.09.010
   Ho SC, 2008, AM J CHINESE MED, V36, P493, DOI 10.1142/S0192415X0800593X
   Hsiao SH, 2008, J ACUPUNCT MERIDIAN, V1, P42, DOI 10.1016/S2005-2901(09)60006-6
   Hu ML, 2016, EVID-BASED COMPL ALT, V2016, P0, DOI 10.1155/2016/3840202
   Huang C, 2008, NEUROCHEM RES, V33, P2107, DOI 10.1007/s11064-008-9721-x
   Huang C, 2007, BRAIN RES BULL, V71, P447, DOI 10.1016/j.brainresbull.2006.11.008
   Huang CP, 2019, EVID-BASED COMPL ALT, V2019, P0, DOI 10.1155/2019/6784735
   Huang Meng, 2010, ZHEN CI YAN JIU, V35, P99
   Inoue M, 2008, EVID-BASED COMPL ALT, V5, P133, DOI 10.1093/ecam/nem050
   Ji LL, 2017, CHIN J INTEGR MED, V23, P786, DOI 10.1007/s11655-016-2606-y
   Ji RR, 2016, SCIENCE, V354, P572, DOI 10.1126/science.aaf8924
   Jin LM, 2014, EVID-BASED COMPL ALT, V2014, P0, DOI 10.1155/2014/987365
   Jung TG, 2010, ACTA HISTOCHEM, V112, P127, DOI 10.1016/j.acthis.2008.09.009
   Kagitani F, 2010, AUTON NEUROSCI-BASIC, V157, P2, DOI 10.1016/j.autneu.2010.03.004
   Kim HNYR, 2012, EVID-BASED COMPL ALT, V2012, P0, DOI 10.1155/2012/643973
   Kim SJ, 2013, KOREAN J PHYSIOL PHA, V17, P505, DOI 10.4196/kjpp.2013.17.6.505
   Kim W, 2013, EVID-BASED COMPL ALT, V2013, P0, DOI 10.1155/2013/436913
   Lee JY, 2013, PLOS ONE, V8, P0, DOI 10.1371/journal.pone.0073948
   Lee YS, 2013, MOL MED REP, V8, P1130, DOI 10.3892/mmr.2013.1633
   Li C, 2016, ANESTH ANALG, V122, P1654, DOI 10.1213/ANE.0000000000001212
   LI DF, 2013, EVID-BASED COMPL ALT, V2013, P0, DOI 10.1155/2013/739078
   Li HP, 2019, J PAIN RES, V12, P1259, DOI 10.2147/JPR.S191900
   LI YR, 1984, SCI SIN B-CHEM B A M, V27, P1273
   Li YQ, 2007, WORLD J GASTROENTERO, V13, P709, DOI 10.3748/wjg.v13.i5.709
   Li YH, 2019, J PAIN RES, V12, P2663, DOI 10.2147/JPR.S205987
   Liang LL, 2010, NEUROCHEM RES, V35, P1780, DOI 10.1007/s11064-010-0244-x
   Liang Y, 2016, ACUPUNCT MED, V34, P40, DOI 10.1136/acupmed-2015-010773
   Liang YP, 2019, SMALL, V15, P0, DOI 10.1002/smll.201900046
   Lin JG, 2008, AM J CHINESE MED, V36, P635, DOI 10.1142/S0192415X08006107
   Liu HR, 2009, NEUROCHEM RES, V34, P1914, DOI 10.1007/s11064-009-9972-1
   Liu JL, 2010, CHIN J INTEGR MED, V16, P315, DOI 10.1007/s11655-010-0503-3
   Liu L, 2016, EVID-BASED COMPL ALT, V2016, P0, DOI 10.1155/2016/1846296
   Lundeberg T, 2013, ACUPUNCT MED, V31, P7, DOI 10.1136/acupmed-2013-010313
   Mi WL, 2008, BRAIN RES BULL, V77, P98, DOI 10.1016/j.brainresbull.2008.04.008
   Moon HJ, 2014, J PHYSIOL SCI, V64, P151, DOI 10.1007/s12576-013-0297-0
   Munro G, 1998, BRAIN RES, V780, P190, DOI 10.1016/S0006-8993(97)01137-2
   Murotani T, 2010, BRAIN RES, V1306, P62, DOI 10.1016/j.brainres.2009.09.117
   Nagaoka S, 2016, ACUPUNCT MED, V34, P229, DOI 10.1136/acupmed-2015-010959
   Park JH, 2010, BRAIN RES, V1322, P24, DOI 10.1016/j.brainres.2010.02.001
   Pei P, 2019, ACUPUNCT MED, V37, P47, DOI 10.1136/acupmed-2017-011410
   Pu L, 2012, EVID-BASED COMPL ALT, V2012, P1
   Qiao LN, 2019, J PAIN RES, V12, P405, DOI 10.2147/JPR.S180165
   Qiao LN, 2017, ACUPUNCT MED, V35, P276, DOI 10.1136/acupmed-2016-011177
   REZAYAT M, 1994, EUR J PHARMACOL, V254, P21, DOI 10.1016/0014-2999(94)90365-4
   Seo BK, 2013, RHEUMATOL INT, V33, P1177, DOI 10.1007/s00296-012-2502-5
   Shi TF, 2011, NEUROCHEM RES, V36, P129, DOI 10.1007/s11064-010-0281-5
   Shinbara H, 2017, ACUPUNCT MED, V35, P284, DOI 10.1136/acupmed-2016-011152
   Shou Y, 2013, EVID-BASED COMPL ALT, V2013, P0, DOI 10.1155/2013/393460
   Silva JRT, 2011, J PAIN, V12, P51, DOI 10.1016/j.jpain.2010.04.008
   Silva ML, 2013, LIFE SCI, V93, P742, DOI 10.1016/j.lfs.2013.09.012
   Silva ML, 2010, EUR J PAIN, V14, P249, DOI 10.1016/j.ejpain.2009.05.007
   Su TF, 2011, MOL PAIN, V7, P0, DOI 10.1186/1744-8069-7-98
   Sun S, 2006, EXP NEUROL, V198, P294, DOI 10.1016/j.expneurol.2005.11.011
   Tan LH, 2019, EVID-BASED COMPL ALT, V2019, P0, DOI 10.1155/2019/4213928
   Tang Q, 2016, EVIDENCE-BASED COMPLEMENTARY AND ALTERNATIVE MEDICINE, V2016, P0, DOI 10.1155/2016/9068257
   TSURUOKA M, 1987, AM J CHINESE MED, V15, P139, DOI 10.1142/S0192415X87000187
   Wang GB, 2011, PEPTIDES, V32, P713, DOI 10.1016/j.peptides.2010.12.006
   Wang JY, 2018, BMC COMPLEM ALTERN M, V18, P0, DOI 10.1186/s12906-018-2134-8
   Wang JY, 2012, CHIN J INTEGR MED, V18, P699, DOI 10.1007/s11655-012-1059-1
   Wang WS, 2014, J NEUROSCI RES, V92, P1703, DOI 10.1002/jnr.23451
   Wu ML, 2015, J CHEM NEUROANAT, V68, P14, DOI 10.1016/j.jchemneu.2015.06.002
   Xu GY, 2009, NEUROGASTROENT MOTIL, V21, P0, DOI 10.1111/j.1365-2982.2009.01354.x
   Xu QL, 2013, NEURAL REGEN RES, V8, P218, DOI 10.3969/j.issn.1673-5374.2013.03.003
   Yan Q, 2011, EXP TOXICOL PATHOL, V63, P151, DOI 10.1016/j.etp.2009.11.002
   Yang CX, 2010, NEUROMODULATION, V13, P93, DOI 10.1111/j.1525-1403.2009.00247.x
   Yen CM, 2019, INT J MOL SCI, V20, P0, DOI 10.3390/ijms20184471
   Yin N, 2018, EVID-BASED COMPL ALT, V2018, P0, DOI 10.1155/2018/3524279
   Yoo YC, 2011, YONSEI MED J, V52, P1016, DOI 10.3349/ymj.2011.52.6.1016
   Yoshimoto K, 2006, TOHOKU J EXP MED, V208, P321, DOI 10.1620/tjem.208.321
   Yu XJ, 2009, CONNECT TISSUE RES, V50, P110, DOI 10.1080/03008200802471856
   Zeng J, 2016, NEUROSCI LETT, V620, P38, DOI 10.1016/j.neulet.2016.03.041
   Zeng Y, 2006, BRAIN RES, V1097, P90, DOI 10.1016/j.brainres.2006.03.123
   Zeng YJ, 2014, EVID-BASED COMPL ALT, V2014, P0, DOI 10.1155/2014/659343
   Zhang D, 2008, EXPLORE-NY, V4, P170, DOI 10.1016/j.explore.2008.02.002
   Zhang MX, 2018, ARQ NEURO-PSIQUIAT, V76, P736, DOI 10.1590/0004-282X20180128
   Zhang Y, 2012, EUR J PAIN, V16, P170, DOI 10.1016/j.ejpain.2011.07.002
   Zhang YM, 2013, CHIN J INTEGR MED, V19, P132, DOI 10.1007/s11655-013-1353-6
   Zhang Y, 2011, NEUROCHEM RES, V36, P1785, DOI 10.1007/s11064-011-0495-1
   Zhang Y, 2011, BRAIN RES, V1395, P38, DOI 10.1016/j.brainres.2011.04.037
   Zhang Y, 2012, NEUROSCI LETT, V530, P12, DOI 10.1016/j.neulet.2012.09.050
   Zhao ZQ, 2008, PROG NEUROBIOL, V85, P355, DOI 10.1016/j.pneurobio.2008.05.004
   Zyloney CE, 2010, MOL PAIN, V6, P0, DOI 10.1186/1744-8069-6-80
NR 100
TC 157
Z9 191
U1 10
U2 116
PU WORLD SCIENTIFIC PUBL CO PTE LTD
PI SINGAPORE
PA 5 TOH TUCK LINK, SINGAPORE 596224, SINGAPORE
SN 0192-415X
EI 1793-6853
J9 AM J CHINESE MED
JI Am. J. Chin. Med.
PD JUN 15
PY 2020
VL 48
IS 4
BP 793
EP 811
DI 10.1142/S0192415X20500408
PG 19
WC Integrative & Complementary Medicine; Medicine, General & Internal
SC Integrative & Complementary Medicine; General & Internal Medicine
GA MA3GI
UT WOS:000541805400003
PM 32420752
DA 2026-01-16
ER

PT J
AU Li, DX
   Chung, G
   Kim, SK
AF Li, Daxian
   Chung, Geehoon
   Kim, Sun Kwang
TI The Involvement of Central Noradrenergic Pathway in the Analgesic Effect of Bee Venom Acupuncture on Vincristine-Induced Peripheral Neuropathy in Rats
SO TOXINS
LA English
DT Article
DE chemotherapy-induced peripheral neuropathy; vincristine; bee venom acupuncture; spinal wide dynamic range neuron; locus coeruleus; adrenergic receptor
ID locus-ceruleus neurons; dorsal-horn; spinal-cord; phospholipase a(2); mouse model; pain model; mechanisms; inhibition; electroacupuncture; stimulation
AB Vincristine is a vinca alkaloid anti-mitotic drug with a broad spectrum of effects on solid and hematologic cancers. The major dose-limiting factor of this anti-cancer regimen is painful peripheral neuropathy. However, no gold-standard analgesic option has been used clinically. In this study, we investigated the effects and mechanism of bee venom acupuncture (BVA) to alleviate peripheral neuropathic pain induced by repeated intraperitoneal infusions of vincristine (1 mg/kg/day, days 1-5 and 8-12) in rats. Subcutaneous injection with bee venom (BV, 1.0 mg/kg) at the ST36 acupoint ameliorated cold and mechanical hypersensitivity (i.e., aberrant withdrawal responses in acetone drop and von Frey hair tests, respectively). In vivo extracellular recording demonstrated that BVA inhibited cutaneous cold (acetone) and mechanical (brush, press, and pinch) stimuli-elicited abnormal hyperexcitation of the spinal wide dynamic range (WDR) neurons in vincristine-treated rats. In addition, the microinjection of lidocaine into the ipsilateral locus coeruleus or the antagonism of the spinal alpha(2)-adrenergic receptors clearly reversed the effects of BVA on cold and mechanical hypersensitivity, indicating a vital role of the descending noradrenergic modulation in analgesia. These findings suggest that BVA could be a potential therapeutic option for vincristine-induced peripheral neuropathy.
C1 [Li, Daxian; Kim, Sun Kwang] Kyung Hee Univ, Grad Sch, Dept Sci Korean Med, Seoul 02447, South Korea.
   [Chung, Geehoon; Kim, Sun Kwang] Kyung Hee Univ, Coll Korean Med, Dept Physiol, Seoul 02447, South Korea.
   [Kim, Sun Kwang] Kyung Hee Univ, Grad Sch, Dept East West Med, Seoul 02447, South Korea.
C3 Kyung Hee University; Kyung Hee University; Kyung Hee University
RP Kim, SK (corresponding author), Kyung Hee Univ, Grad Sch, Dept Sci Korean Med, Seoul 02447, South Korea.; Kim, SK (corresponding author), Kyung Hee Univ, Coll Korean Med, Dept Physiol, Seoul 02447, South Korea.; Kim, SK (corresponding author), Kyung Hee Univ, Grad Sch, Dept East West Med, Seoul 02447, South Korea.
EM lidaxian721@naver.com; geehoon.chung@khu.ac.kr; skkim77@khu.ac.kr
FU National Research Foundation of Korea (NRF) - Korean government [NRF-2017M3A9E4057926]
CR Aufschnaiter A, 2020, TOXINS, V12, P0, DOI 10.3390/toxins12020066
   Baek YH, 2006, BRAIN RES, V1073, P305, DOI 10.1016/j.brainres.2005.12.086
   Baron R, 2006, NAT CLIN PRACT NEURO, V2, P95, DOI 10.1038/ncpneuro0113
   Baron R, 2010, LANCET NEUROL, V9, P807, DOI 10.1016/S1474-4422(10)70143-5
   Boyette-Davis JA, 2018, PAIN MANAG, V8, P363, DOI 10.2217/pmt-2018-0020
   Brightwell JJ, 2009, NEUROSCIENCE, V160, P174, DOI 10.1016/j.neuroscience.2009.02.023
   Cherniack EP, 2018, TOXICON, V154, P74, DOI 10.1016/j.toxicon.2018.09.013
   Choi J, 2017, TOXINS, V9, P0, DOI 10.3390/toxins9110351
   Choi S, 2019, TOXINS, V11, P0, DOI 10.3390/toxins11070396
   Choi S, 2017, J PHYSIOL SCI, V67, P431, DOI 10.1007/s12576-016-0505-9
   CHOI Y, 1994, PAIN, V59, P369, DOI 10.1016/0304-3959(94)90023-X
   Chung ES, 2015, J IMMUNOL, V195, P4853, DOI 10.4049/jimmunol.1500386
   Chung G, 2017, SCI REP-UK, V7, P0, DOI 10.1038/s41598-017-09991-8
   CLARK FM, 1991, BRAIN RES, V538, P231, DOI 10.1016/0006-8993(91)90435-X
   De la Calle JL, 2002, BRAIN RES BULL, V59, P245, DOI 10.1016/S0361-9230(02)00866-3
   Dougherty PM, 2007, J PAIN SYMPTOM MANAG, V33, P166, DOI 10.1016/j.jpainsymman.2006.08.006
   EZE OBL, 2016, J PHARM CHEM BIOL SCI, V4, P48
   Flatters SJL, 2004, PAIN, V109, P150, DOI 10.1016/j.pain.2004.01.029
   Gwak YS, 2006, J NEUROTRAUM, V23, P1111, DOI 10.1089/neu.2006.23.1111
   Hickey L, 2014, J NEUROSCI, V34, P4148, DOI 10.1523/JNEUROSCI.4835-13.2014
   Jaggi AS, 2017, N-S ARCH PHARMACOL, V390, P1087, DOI 10.1007/s00210-017-1426-8
   Kerckhove N, 2017, FRONT PHARMACOL, V8, P0, DOI 10.3389/fphar.2017.00086
   Kim W, 2016, TOXINS, V8, P0, DOI 10.3390/toxins8020033
   Le Bars D, 2008, THE SENSES: A COMPREHENSIVE REFERENCE, V5, P331, DOI 10.1016/B978-012370880-9.00167-5
   Lee C, 2019, J IMMUNOTHER CANCER, V7, P0, DOI 10.1186/s40425-019-0610-4
   Li DX, 2020, TOXINS, V12, P0, DOI 10.3390/toxins12100620
   Li DX, 2019, INT J MOL SCI, V20, P0, DOI 10.3390/ijms20071652
   Li D, 2015, TOXINS, V7, P2422, DOI 10.3390/toxins7072422
   Lin TY, 2020, TOXINS, V12, P0, DOI 10.3390/toxins12100618
   Liu SJ, 2008, HEPATOLOGY, V47, P1964, DOI 10.1002/hep.22240
   Llorca-Torralba M, 2016, NEUROSCIENCE, V338, P93, DOI 10.1016/j.neuroscience.2016.05.057
   Lu KW, 2016, SCI REP-UK, V6, P0, DOI 10.1038/srep22123
   Ma WY, 2003, BRAIN RES, V970, P110, DOI 10.1016/S0006-8993(03)02293-5
   Millan MJ, 2002, PROG NEUROBIOL, V66, P355, DOI 10.1016/S0301-0082(02)00009-6
   Moon DO, 2006, INT IMMUNOPHARMACOL, V6, P1796, DOI 10.1016/j.intimp.2006.07.027
   Mora E, 2016, AM J CANCER RES, V6, P2416
   Muto Y, 2012, BRIT J PHARMACOL, V166, P1047, DOI 10.1111/j.1476-5381.2011.01820.x
   Nazemi S, 2015, CLIN EXP PHARMACOL P, V42, P772, DOI 10.1111/1440-1681.12414
   Patel R, 2019, EUR J PAIN, V23, P183, DOI 10.1002/ejp.1300
   Paxinos G, 1998, RAT BRAIN IN STEREOTAXIC COORDINATES, V0, P0
   Pertovaara A, 2006, HAND CLINIC, V81, P179, DOI 10.1016/S0072-9752(06)80017-5
   REN K, 1990, J NEUROPHYSIOL, V64, P1098, DOI 10.1152/jn.1990.64.4.1098
   Renn CL, 2011, MOL PAIN, V7, P0, DOI 10.1186/1744-8069-7-29
   Roh DH, 2004, J PAIN, V5, P297, DOI 10.1016/j.jpain.2004.05.003
   Safari MS, 2009, PHARMACOL BIOCHEM BE, V92, P629, DOI 10.1016/j.pbb.2009.03.002
   Seo BK, 2017, TOXINS, V9, P0, DOI 10.3390/toxins9110361
   Soliman C, 2019, PLOS ONE, V14, P0, DOI 10.1371/journal.pone.0224028
   Song Z, 2013, NEUROSCIENCE, V253, P426, DOI 10.1016/j.neuroscience.2013.09.006
   Starobova H, 2017, FRONT MOL NEUROSCI, V10, P0, DOI 10.3389/fnmol.2017.00174
   Viisanen H, 2007, NEUROSCIENCE, V146, P1785, DOI 10.1016/j.neuroscience.2007.03.016
   Weng HR, 2003, PAIN, V103, P131, DOI 10.1016/S0304-3959(02)00445-1
   Yin CS, 2008, RES VET SCI, V84, P159, DOI 10.1016/j.rvsc.2007.04.004
   Yoshimura M, 2006, J PHARMACOL SCI, V101, P107, DOI 10.1254/jphs.CRJ06008X
   You HJ, 2003, BRAIN RES, V960, P235, DOI 10.1016/S0006-8993(02)03895-7
   Yu LL, 2019, J PAIN RES, V12, P231, DOI 10.2147/JPR.S182876
   Zajaczkowska R, 2019, INT J MOL SCI, V20, P0, DOI 10.3390/ijms20061451
   Zeng YJ, 2018, LASER MED SCI, V33, P295, DOI 10.1007/s10103-017-2367-7
   Zhang S, 2018, TOXICON, V148, P64, DOI 10.1016/j.toxicon.2018.04.012
   Zhang S, 2018, J PAIN RES, V11, P505, DOI 10.2147/JPR.S152550
   Zheng FY, 2011, NEUROSCIENCE, V176, P447, DOI 10.1016/j.neuroscience.2010.12.052
   ZIMMERMANN M, 1983, PAIN, V16, P109, DOI 10.1016/0304-3959(83)90201-4
   Zuo CY, 2019, EVID-BASED COMPL ALT, V2019, P0, DOI 10.1155/2019/1807287
NR 62
TC 22
Z9 23
U1 1
U2 15
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
SN 
EI 2072-6651
J9 TOXINS
JI Toxins
PD DEC 15
PY 2020
VL 12
IS 12
BP 
EP 
DI 10.3390/toxins12120775
PG 16
WC Food Science & Technology; Toxicology
SC Food Science & Technology; Toxicology
GA PK5WY
UT WOS:000602516100001
PM 33291335
DA 2026-01-16
ER

PT J
AU Li, YF
   Xing, X
   Shi, X
   Yan, PJ
   Chen, YJ
   Li, MX
   Zhang, WY
   Li, XX
   Yang, KH
AF Li, Yanfei
   Xing, Xin
   Shi, Xiue
   Yan, Peijing
   Chen, Yajing
   Li, Meixuan
   Zhang, Weiyi
   Li, Xiuxia
   Yang, Kehu
TI The effectiveness of music therapy for patients with cancer: A systematic review and meta-analysis
SO JOURNAL OF ADVANCED NURSING
LA English
DT Review
DE cancer; music therapy; nursing; pain; quality of life; supportive care; systematic review
ID quality-of-life; medicine 5-element music; reporting characteristics; methodological quality; pain; anxiety; interventions; chemotherapy; acupuncture; depression
AB Aims To assess the effectiveness of music therapy on the quality of life, anxiety, depression and pain of patients with cancer. Design Systematic review. Data Sources Five electronic databases were searched in September 2018 for randomized controlled trials evaluating music therapy for patients with cancer. Review Methods The quality of the studies was assessed using the risk of bias tool recommended by the Cochrane Handbook Version 5.1.0 and the Revman version 5.3 software was used to perform the meta-analysis. The outcomes were overall quality of life, anxiety, depression and pain. Results A total of 19 trials evaluating 1,548 patients were included in this study, of which 765 were in the control group and 783 in the experimental group. Compared with standard care, music therapy can significantly increase the score of the overall quality of life in patients with cancer. In addition, music therapy was found to be more effective for decreasing the score of anxiety, depression and pain. Conclusion Music therapy can improve the overall quality of life of patients with cancer, with an observed optimal intervention duration of 1-2 months. Meanwhile, anxiety, depression and pain are improved as well. Nevertheless, high-quality trials are still needed to further determine the effects of music intervention in supportive cancer care.
C1 [Li, Yanfei; Chen, Yajing; Li, Meixuan; Zhang, Weiyi; Li, Xiuxia; Yang, Kehu] Lanzhou Univ, Evidence Based Social Sci Res Ctr, Sch Publ Hlth, Lanzhou, Peoples R China.
   [Li, Yanfei; Li, Meixuan; Zhang, Weiyi; Li, Xiuxia; Yang, Kehu] Key Lab Evidence Based Med & Knowledge Translat G, Lanzhou, Peoples R China.
   [Xing, Xin; Yang, Kehu] Lanzhou Univ, Evidence Based Med Ctr, Sch Basic Med Sci, Lanzhou, Peoples R China.
   [Shi, Xiue] Res Inst Evidence Based Rehabil Med Gansu Prov, Lanzhou, Peoples R China.
   [Shi, Xiue] Gansu Prov Hosp Rehabil Ctr, Lanzhou, Peoples R China.
   [Yan, Peijing; Yang, Kehu] Gansu Prov Hosp, Inst Clin Res & Evidence Based Med, Lanzhou, Peoples R China.
C3 Lanzhou University; Lanzhou University
RP Yang, KH (corresponding author), Lanzhou Univ, Sch Basic Med Sci, Lanzhou 730000, Peoples R China.; Li, XX (corresponding author), Lanzhou Univ, Sch Publ Hlth, Lanzhou 730000, Peoples R China.
EM lixiuxia@lzu.edu.cn; kehuyangebm2006@126.com
FU Fundamental Research Funds for the Central Universities: Evidence Based Social Science Research [18LZUJBWZX006, 2019jbkyjc002]; China Medical Board Open Project Funding: Tracking and Evaluating Quality (TEQ) of Rural Health Services in NW China: Tool kits for rural clinic quality management and capacity building [CMB#17-279]; Special Fund for Soft Science in Gansu Province: Study on the Measures to Improve the Quality of Rural Health Services in Gansu Province [18CX1ZA043]
CR Alcantara-Silva TR, 2018, INTEGR CANCER THER, V17, P628, DOI 10.1177/1534735418757349
   Archie P, 2013, SUPPORT CARE CANCER, V21, P2609, DOI 10.1007/s00520-013-1841-4
   Bieligmeyer S, 2018, COMPLEMENT THER MED, V40, P171, DOI 10.1016/j.ctim.2018.03.002
   Bradt J, 2010, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD007169.pub2
   Bultz BD, 2006, PSYCHO-ONCOLOGY, V15, P93, DOI 10.1002/pon.1022
   Burns DS, 2001, J MUSIC THER, V38, P51, DOI 10.1093/jmt/38.1.51
   Burrai F, 2014, HOLIST NURS PRACT, V28, P301, DOI 10.1097/HNP.0000000000000041
   Chen C, 2017, J TRADIT CHIN MED, V37, P64
   Dvorak AbbeyL, 2012, DISSERTATION ABSTRACTS INTERNATIONAL, V72, P4366, DOI 10.17077/etd.3zbutejc
   Gao YY, 2019, J PAIN SYMPTOM MANAG, V57, P319, DOI 10.1016/j.jpainsymman.2018.10.504
   Ge L, 2018, J CLIN EPIDEMIOL, V93, P45, DOI 10.1016/j.jclinepi.2017.10.012
   Geretsegger M, 2017, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD004025.pub4
   Hanser Suzanne B, 2006, J SOC INTEGR ONCOL, V4, P116, DOI 10.2310/7200.2006.014
   Hilliard RE, 2003, J MUSIC THER, V40, P113, DOI 10.1093/jmt/40.2.113
   Holland JC, 2010, J NATL COMPR CANC NE, V8, P448, DOI 10.6004/jnccn.2010.0034
   Huang ST, 2010, INT J NURS STUD, V47, P1354, DOI 10.1016/j.ijnurstu.2010.03.008
   Jasemi M, 2016, INDIAN J PALLIAT CAR, V22, P455, DOI 10.4103/0973-1075.191823
   Keenan A, 2015, ONCOL NURS FORUM, V42, PE368, DOI 10.1188/15.ONF.E368-E375
   Kern P, 2017, J MUSIC THER, V54, P255, DOI 10.1093/jmt/thx011
   Li XM, 2011, BREAST CANCER RES TR, V128, P411, DOI 10.1007/s10549-011-1533-z
   Li XX, 2015, HEALTH POLICY, V119, P503, DOI 10.1016/j.healthpol.2014.09.002
   Li XX, 2017, PAIN PRACT, V17, P1066, DOI 10.1111/papr.12555
   Li-hau L, 2016, MEDICAL INNOVATION OF CHINA, V13, P97, DOI 10.3969/j.issn.1674-4985.2016.17.027
   Liao J, 2013, CHIN J INTEGR MED, V19, P736, DOI 10.1007/s11655-013-1593-5
   Arruda MALB, 2016, J PALLIAT MED, V19, P943, DOI 10.1089/jpm.2015.0528
   Lin MF, 2011, J CLIN NURS, V20, P988, DOI 10.1111/j.1365-2702.2010.03525.x
   Ma L, 2013, CURR ONCOL, V20, PE554, DOI 10.3747/co.20.1651
   Makhlouf SM, 2020, J CANCER EDUC, V35, P214, DOI 10.1007/s13187-019-01548-9
   McCarter K, 2018, BMJ OPEN, V8, P0, DOI 10.1136/bmjopen-2017-017959
   Nightingale CL, 2013, INTEGR CANCER THER, V12, P393, DOI 10.1177/1534735413485817
   Ostermann T, 2012, BMC COMPLEMENTARY AND ALTERNATIVE MEDICINE, V12, P327, DOI 10.1186/1472-6882-12-S1-P327
   Revicki DA, 2000, QUAL LIFE RES, V9, P887, DOI 10.1023/A:1008996223999
   [孙凤英 Sun Fengying], 2015, 护理学杂志 JOURNAL OF NURSING SCIENCE, V30, P35
   Tao WW, 2016, J PAIN SYMPTOM MANAG, V51, P728, DOI 10.1016/j.jpainsymman.2015.11.027
   Thanh NN, 2010, J PEDIATR ONCOL NURS, V27, P146, DOI 10.1177/1043454209355983
   Tsai HF, 2014, CANCER NURS, V37, PE35, DOI 10.1097/NCC.0000000000000116
   Tuinmann G, 2017, PSYCHO-ONCOLOGY, V26, P377, DOI 10.1002/pon.4142
   Wan Y, 2009, CHIN NURS RES, V23, P1172
   Warth M, 2014, BMC PALLIAT CARE, V13, P0, DOI 10.1186/1472-684X-13-60
   Weatherall M, 2017, POSTGRAD MED J, V93, P696, DOI 10.1136/postgradmedj-2017-135034
   Xiao-hong Y, 2008, CHINESE J PRACTICAL, V0, PP11, DOI 10.3760/cma.j.issn.1672-7088.2008.06.005
   Yao L, 2016, J CLIN EPIDEMIOL, V74, P73, DOI 10.1016/j.jclinepi.2016.01.003
   Zhai W, 2017, WORLD CHINESE JOURNAL OF DIGESTOLOGY, V25, P388, DOI 10.11569/wcjd.v25.i4.388
   Zhang JM, 2012, SUPPORT CARE CANCER, V20, P3043, DOI 10.1007/s00520-012-1606-5
NR 44
TC 94
Z9 110
U1 2
U2 90
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0309-2402
EI 1365-2648
J9 J ADV NURS
JI J. Adv. Nurs.
PD MAY 15
PY 2020
VL 76
IS 5
BP 1111
EP 1123
DI 10.1111/jan.14313
EA FEB 2020
PG 13
WC Nursing
SC Nursing
GA KY6DS
UT WOS:000514250700001
PM 32017183
DA 2026-01-16
ER

PT J
AU Liang, Q
   Zhang, K
   Wang, S
   Xu, X
   Liu, Y
   Cui, S
   Liu, L
AF Liang, Qi
   Zhang, Ke
   Wang, Sumeng
   Xu, Xian
   Liu, Yiqian
   Cui, Shiyun
   Liu, Lingxiang
TI Acupuncture for Cancer Pain - An Adjuvant Therapy for Cancer Pain Relief.
SO The American journal of Chinese medicine
LA English
DT Review
DE Acupuncture; Cancer Pain; Pain Management; Review
AB As current pain management methods cannot effectively control pain among cancer  patients, acupuncture has developed as an adjuvant therapy for cancer pain  relief. However, the efficacy of acupuncture in treating cancer pain remains  controversial. Here, we briefly introduced the development of pain management,  analgesic mechanisms, and acupuncture methods. Meanwhile, a comprehensive  overview of acupuncture programs was provided in terms of different cancer types,  sources, and degrees. Interestingly, acupuncture can treat both tumor-induced  pain and therapy-induced pain well among cancer patients. We preliminarily  summarized frequently-used acupoints for different types of cancer pain and found  that needle retention time was mostly 30 min, and treatment cycle was two weeks.  Additionally, clinicians consistently selected Ashi acupoint or bilateral Zusanli  acupoint and combined multiple acupuncture methods for different degrees of  cancer pain.
C1 Department of Oncology, The First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, P. R. China.
   Department of Oncology, The First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, P. R. China.
   Department of Oncology, The First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, P. R. China.
   Department of Oncology, The First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, P. R. China.
   Department of Oncology, The First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, P. R. China.
   Department of Oncology, The First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, P. R. China.
   Department of Oncology, The First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, P. R. China.
NR 0
TC 0
SN 1793-685
EI 
J9 Am J Chin Med
PD DEC 11
PY 2020
VL 48
IS 8
BP 1769
EP 1786
DI 10.1142/S0192415X20500883
PG 17
WC Female; Humans; Male; Acupuncture Analgesia; methods; Breast Neoplasms; complications; Cancer Pain; etiology; Combined Modality Therapy; Lung Neoplasms; complications; Pain, Postoperative; etiology; Stomach Neoplasms; complications; Neoplasms; complications
UT PubMed:33300479
PM 33300479
DA 2020-12-11
ER

PT J
AU Carlson, LE
   Reed, EN
   Landmann, J
   Oberoi, D
   Piedalue, KAL
   Faris, PD
AF Carlson, Linda E.
   Reed, Erica N.
   Landmann, Jessa
   Oberoi, Devesh
   Piedalue, Katherine-Ann L.
   Faris, Peter D.
TI GROUP VERSUS INDIVIDUAL ACUPUNCTURE (AP) FOR CANCER PAIN: A RANDOMIZED NON-INFERIORITY TRIAL
SO ANNALS OF BEHAVIORAL MEDICINE
LA English
DT Meeting Abstract
C1 [Carlson, Linda E.; Reed, Erica N.; Oberoi, Devesh] Univ Calgary, Calgary, AB, Canada.
   [Landmann, Jessa] Vive Integrat Hlth Grp, Calgary, AB, Canada.
   [Piedalue, Katherine-Ann L.] Cumming Sch Med, Calgary, AB, Canada.
   [Faris, Peter D.] Alberta Hlth Serv, Calgary, AB, Canada.
C3 University of Calgary; Alberta Health Services (AHS); University of Calgary
EM lcarlso@ucalgary.ca
NR 0
TC 0
Z9 0
U1 0
U2 0
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0883-6612
EI 1532-4796
J9 ANN BEHAV MED
JI Ann. Behav. Med.
PD MAY 15
PY 2020
VL 54
IS 
BP S496
EP S496
DI 
PG 1
WC Psychology, Multidisciplinary
SC Psychology
GA MG8ED
UT WOS:000546262401215
DA 2026-01-16
ER

PT J
AU Chen, J
   Liu, QF
   Xiong, J
   Lu, LB
   Zhu, SY
   Zhong, ZY
   Tang, GH
   Zhou, XC
   Guo, H
   Chen, ZJ
AF Chen, Jun
   Liu, Qifang
   Xiong, Jun
   Lu, Lunbin
   Zhu, Siyuan
   Zhong, Zhiying
   Tang, Genhua
   Zhou, Xingchen
   Guo, Han
   Chen, Zhijun
TI Effect of fire needle for ganglion cysts A protocol of systematic review and meta-analysis of randomized controlled trials
SO MEDICINE
LA English
DT Article
DE acupuncture; fire needle; ganglion cysts; protocol; systematic review; tendon sheath
ID hand
AB Background: Ganglion cysts (GCs) are tumor-like lesions that often occur in the soft tissues, which are mostly caused by the degeneration of mucin produced by the joint capsule and tendon sheath on the carpal dorsal joints of extremities. GCs may appear asymptomatic as benign tumors, but some patients also seek treatment because of the pain caused by these fluid-filled cysts. As a kind of complementary and alternative therapy, there have been some studies published in China which have proved that the fire needle has a better therapeutic effect on ganglion cyst. The purpose of this systematic review is to evaluate the efficacy of fire needle in the treatment of GCs. Methods: PubMed, EMBASE, the Cochrane Library, Chinese National Knowledge Infrastructure, Chinese VIP Information, Wanfang Database, and Chinese Biomedical Literature Database were searched by 2 reviewers from the inception until August 2020. The original study that randomised control trials of fire needle for GCs will be selected and is not limited by country or language. In addition, researches in progress, the reference lists and the citation lists of identified publications will be retrieved similarly. Study selection, data extraction, and assessment of the quality will be performed independently by 2 reviewers who have been trained prior to data extraction. A meta-analysis will be conduct if the quantity and quality of the original studies included are satisfactory; otherwise, a descriptive analysis will be conducted. Review Manager V5.4: (The Nordic Cochrane Centre, The Cochrane Collaboration, Copenhagen, Denmark) software will be using for data synthesis and assessment the risk of bias according by Cochrane Handbook. Result: This study will provide a comprehensive review of current evidence for the treatment of fire needle on GCs. Conclusion: The conclusion of this study will provide a judging basis that whether the treatment of GCs with fire needle is effective. INPLASY registration number: INPLASY202080032
C1 [Chen, Jun; Lu, Lunbin; Zhu, Siyuan; Zhong, Zhiying; Tang, Genhua] Jiangxi Univ Tradit Chinese Med, Nanchang, Jiangxi, Peoples R China.
   [Liu, Qifang] Jiangxi Univ Tradit Chinese Med, Nanchang Hosp 1, Nanchang, Jiangxi, Peoples R China.
   [Xiong, Jun; Zhou, Xingchen; Guo, Han; Chen, Zhijun] Jiangxi Univ Tradit Chinese Med, Affiliated Hosp, 445 Bayi Ave, Nanchang 330009, Jiangxi, Peoples R China.
C3 Jiangxi University of Traditional Chinese Medicine; Jiangxi University of Traditional Chinese Medicine; Jiangxi University of Traditional Chinese Medicine; Affiliated Hospital of Jiangxi University of Traditional Chinese Medicine
RP Xiong, J (corresponding author), Jiangxi Univ Tradit Chinese Med, Affiliated Hosp, 445 Bayi Ave, Nanchang 330009, Jiangxi, Peoples R China.
EM xiongjun196071@163.com
FU Project of Jiangxi University of Traditional Chinese Medicine 1050 youth talent project [:5141900101]; National Natural Science Foundation [:81573835]; distinguished Young Talents Plan of Jiangxi Province [20171BCB23093]; Natural Science Youth Foundation Key Projects of Jiangxi Province [20192ACB21007]
CR Unknown -, 2009, BMJ-BRIT MED J, V6, Pe1000097, DOI 10.1136/bmj.b2535, 10.1371/journal.pmed.1000097, 10.1371/JOURNAL.PMED.1000097
   Atkins D, 2004, BMJ-BRIT MED J, V328, P1490
   Chen PY, 2011, J MED IMAGING, V21, P1734
   DU X, 2018, J CLIN ACUPUNCT MOXI, V34, P1
   Ebrahim S, 2013, J CLIN EPIDEMIOL, V66, P1014, DOI 10.1016/j.jclinepi.2013.03.014
   Giard MC, 2015, RHEUMATOL INT, V35, P597, DOI 10.1007/s00296-014-3120-1
   Higgins J, 2019, COCHRANE HANDBOOK FOR SYSTEMATIC REVIEWS OF INTERVENTIONS, V0, P0, DOI DOI 10.1002/9781119536604.CH17
   Higgins JP, 2011, ASSESSING RISK BIAS, V0, P187
   Li SL, 2019, ANN PLAS SURG, V82, P577, DOI 10.1097/SAP.0000000000001584
   Liang Teresa, 2013, HSS J, V9, P270, DOI 10.1007/s11420-013-9345-9
   Luo Y, 2019, EVID-BASED COMPL ALT, V2019, P0, DOI 10.1155/2019/8797056
   Nahra ME, 2011, OPERATIVE TECHNIQUES, V3, P3010
   Soren A, 1966, CLIN ORTHOP RELAT RES, V48, P173
   Tang ZH, 2017, SINGAP MED J, V58, P714, DOI 10.11622/smedj.2016147
   Wang LP, 2019, EVID-BASED COMPL ALT, V2019, P0, DOI 10.1155/2019/3513179
   Xueyong Z, 1990, NEW ROUTINE DIAGNOSI, V0, P0
   ZUBOWICZ VN, 1987, J HAND SURG-AM, V12A, P618, DOI 10.1016/S0363-5023(87)80221-6
NR 17
TC 2
Z9 2
U1 1
U2 5
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0025-7974
EI 1536-5964
J9 MEDICINE
JI Medicine (Baltimore)
PD OCT 9
PY 2020
VL 99
IS 41
BP 
EP 
DI 10.1097/MD.0000000000022602
PG 5
WC Medicine, General & Internal
SC General & Internal Medicine
GA OC6DZ
UT WOS:000579245800061
PM 33031314
DA 2026-01-16
ER

PT J
AU Zhou, J
   Jin, Y
   Ma, RJ
   Song, HY
   Chen, Q
   Chai, YY
   Liang, Y
   Zhou, Y
   Fang, JQ
AF Zhou, Jie
   Jin, Ying
   Ma, Ruijie
   Song, Hongyun
   Chen, Qin
   Chai, Yueyang
   Liang, Yi
   Zhou, You
   Fang, Jianqiao
TI Electroacupuncture Alleviates Experimental Chronic Inflammatory Pain by Inhibiting Calcium Voltage-Gated Channel-Mediated Inflammation
SO EVIDENCE-BASED COMPLEMENTARY AND ALTERNATIVE MEDICINE
LA English
DT Article
ID dorsal-root ganglia; neuronal apoptosis; rna-seq; expression analysis; rat model; involvement; activation; hyperalgesia; receptors; analgesia
AB Background. Both experimental and clinical studies have shown that electroacupuncture (EA) administration ameliorates chronic inflammatory pain (CIP). However, the multifaceted mechanism underlying the effects of EA on CIP is poorly understood. In this study, the mRNA transcriptome was used to study various therapeutic targets of EA. Methods. Using RNA-sequencing, protein-coding mRNA expression profiles of the L4-L5 dorsal root ganglion (DRG) were examined in the control (CN), complete Freund's adjuvant- (CFA-) induced CIP, and EA-treated CIP groups. A series of bioinformatics analyses was performed; "EA-reversed upregulated genes with CIP" (up-DEGs) and "EA-reversed downregulated genes with CIP" (down-DEGs) were identified. Thereafter, based on up-DEGs and down-DEGs, biological functions and signaling pathways were enriched using gene ontology (GO) and Kyoto encyclopedia of genes and genomes (KEGG) pathway analyses. Results. In total, 189 DEGs were identified, including 134 up- and 55 down-DEGs, which were enriched in arachidonic acid metabolism (rno00590), glutamatergic synapse (rno04724), serotonergic synapse (rno04726), FoxO signaling pathway (rno04068), insulin signaling pathway (rno04910), amyotrophic lateral sclerosis (rno05014), cholinergic synapse (rno04725), ECM-receptor interaction (rno04512), and choline metabolism in cancer (rno05231). Conclusion. We identified a few GOs, pathways, and genes that could play key roles in the amelioration of CIP by EA. Hence, this study may provide a theoretical basis for CIP amelioration by EA.
C1 [Zhou, Jie; Ma, Ruijie; Chen, Qin] Zhejiang Chinese Med Univ, Affiliated Hosp 3, 219 Moganshan Rd, Hangzhou 310005, Zhejiang, Peoples R China.
   [Jin, Ying; Song, Hongyun; Zhou, You] Zhejiang Univ, Sch Med, Affiliated Hosp 2, Dept Rehabil Tradit Chinese Med, 88,JiefangRd, Hangzhou 310000, Zhejiang, Peoples R China.
   [Chai, Yueyang] Zhejiang Univ, Sch Med, Affiliated Hosp 2, Dept Emergency Med, 88,JiefangRd, Hangzhou 310000, Zhejiang, Peoples R China.
   [Liang, Yi] Zhejiang Chinese Med Univ, Clin Med Coll 3, 548 Binwen Rd, Hangzhou 310053, Zhejiang, Peoples R China.
   [Fang, Jianqiao] Zhejiang Chinese Med Univ, Key Lab Acupuncture & Neurol Zhejiang Prov, Clin Med Coll 3, Hangzhou 310053, Zhejiang, Peoples R China.
C3 Zhejiang Chinese Medical University; Zhejiang University; Zhejiang University; Zhejiang Chinese Medical University; Zhejiang Chinese Medical University
RP Fang, JQ (corresponding author), Zhejiang Chinese Med Univ, Key Lab Acupuncture & Neurol Zhejiang Prov, Clin Med Coll 3, Hangzhou 310053, Zhejiang, Peoples R China.
EM fangjianqiao7532@163.com
FU Natural Science Foundation of Zhejiang Province [LQ18H270001]; Innovation Fund for Youth of Zhejiang Chinese Medical University [KC201947]
CR Alvarez-Garcia O, 2018, AGING CELL, V17, P0, DOI 10.1111/acel.12800
   Ashburner M, 2000, NAT GENET, V25, P25, DOI 10.1038/75556
   Borghi SM, 2019, J NEUROINFLAMM, V16, P0, DOI 10.1186/s12974-019-1496-2
   Fang JQ, 2013, EUR J INFLAMM, V11, P375, DOI 10.1177/1721727X1301100208
   Fang JQ, 2014, BMC COMPLEM ALTERN M, V14, P0, DOI 10.1186/1472-6882-14-285
   Fang JQ, 2013, MOL PAIN, V9, P0, DOI 10.1186/1744-8069-9-13
   Ferreira ML, 2017, BEST PRACT RES CL RH, V31, P192, DOI 10.1016/j.berh.2017.08.006
   Gagliese L, 2018, PROG NEURO-PSYCHOPH, V87, P207, DOI 10.1016/j.pnpbp.2017.09.022
   Han JS, 2011, PAIN, V152, PS41, DOI 10.1016/j.pain.2010.10.012
   Hu F, 2019, FASEB J, V33, P668, DOI 10.1096/fj.201800382RR
   Jackson T, 2016, ANESTH ANALG, V123, P739, DOI 10.1213/ANE.0000000000001389
   Ji RR, 1995, J NEUROSCI, V15, P8156
   Kim D, 2015, NAT METHODS, V12, P357, DOI 10.1038/NMETH.3317
   Mao JR, 2002, J NEUROSCI, V22, P7650
   Matsubara T, 2011, EVID-BASED COMPL ALT, V2011, P0, DOI 10.1155/2011/543291
   Mi WL, 2008, BRAIN RES BULL, V77, P98, DOI 10.1016/j.brainresbull.2008.04.008
   Mi WL, 2011, J PAIN, V12, P974, DOI 10.1016/j.jpain.2011.03.002
   Mortazavi A, 2008, NAT METHODS, V5, P621, DOI 10.1038/nmeth.1226
   Nikolayeva O, 2014, METHODS MOL BIOL, V1150, P45, DOI 10.1007/978-1-4939-0512-6_3
   Pertea M, 2016, NAT PROTOC, V11, P1650, DOI 10.1038/nprot.2016.095
   Pertea M, 2015, NAT BIOTECHNOL, V33, P290, DOI 10.1038/nbt.3122
   Robinson MD, 2010, GENOME BIOL, V11, P0, DOI 10.1186/gb-2010-11-3-r25
   Robinson MD, 2010, BIOINFORMATICS, V26, P139, DOI 10.1093/bioinformatics/btp616
   Scholz J, 2005, J NEUROSCI, V25, P7317, DOI 10.1523/JNEUROSCI.1526-05.2005
   Shan S, 2007, NEUROBIOL DIS, V26, P558, DOI 10.1016/j.nbd.2007.02.007
   Wang DM, 2015, J PHARMACOL EXP THER, V354, P431, DOI 10.1124/jpet.115.225672
   Wang F, 2018, BLOOD, V131, P2929, DOI 10.1182/blood-2017-10-813576
   Wang JY, 2016, EVID-BASED COMPL ALT, V2016, P0, DOI 10.1155/2016/8403064
   Wu GW, 2019, CHIN J INTEGR MED, V25, P677, DOI 10.1007/s11655-018-2916-8
   Xu Y, 2018, AM J CHINESE MED, V46, P997, DOI 10.1142/S0192415X18500520
   Yu GC, 2012, OMICS, V16, P284, DOI 10.1089/omi.2011.0118
   Zhao XY, 2019, SCI TOTAL ENVIRON, V646, P1047, DOI 10.1016/j.scitotenv.2018.07.363
NR 33
TC 7
Z9 9
U1 2
U2 12
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 1741-427X
EI 1741-4288
J9 EVID-BASED COMPL ALT
JI Evid.-based Complement Altern. Med.
PD FEB 10
PY 2020
VL 2020
IS 
BP 
EP 
DI 10.1155/2020/7061972
PG 10
WC Integrative & Complementary Medicine
SC Integrative & Complementary Medicine
GA LD5YY
UT WOS:000526107500001
PM 32104194
DA 2026-01-16
ER

PT J
AU Deng, G
AF Deng, Gary
TI Acupuncture As a Potential Opioid-Sparing Pain Management Intervention for
SO Medical acupuncture
LA English
DT Journal Article
DE acupuncture; chemotherapy; opioids; pain; symptom management
AB Background: High-symptom burdens, including pain, are associated with high-dose  chemotherapy. Objective: We conducted a pilot study to evaluate how acupuncture  may affect symptom burden and use of pain medication. Design: This is a  randomized sham acupuncture (SA) controlled trial. Setting: An academic cancer  center. Patients: Patients were with multiple myeloma undergoing autologous  hematopoietic stem cell transplantation. Intervention: Once daily acupuncture for  5 days after high-dose chemotherapy. Main Outcome Measures: M. D. Anderson  Symptom Inventory (MDASI), opioid use. Results: Compared with SA, true  acupuncture reduced nausea, poor appetite, and drowsiness, and use of opioids in  opioid-naive patients. Randomizations: Yes. Blinding: Investigators and study  participants were blinded. Conclusion: Further study of acupuncture in a larger  trial is warranted for its effect on reducing opioid use and symptom burdens  during high-dose chemotherapy. Registration: NCT01811862.
C1 Integrative Medicine Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
NR 0
TC 0
SN 1933-659
EI 1933-658
J9 Med Acupunct
PD DEC 29
PY 2020
VL 32
IS 6
BP 394
EP 395
DI 10.1089/acu.2020.1494
PG 1
UT PubMed:33362896
PM 33362896
DA 2020-12-29
ER

PT J
AU Chen, J
   Liu, Q
   Xiong, J
   Lu, L
   Zhu, S
   Zhong, Z
   Tang, G
   Zhou, X
   Guo, H
   Chen, Z
AF Chen, Jun
   Liu, Qifang
   Xiong, Jun
   Lu, Lunbin
   Zhu, Siyuan
   Zhong, Zhiying
   Tang, Genhua
   Zhou, Xingchen
   Guo, Han
   Chen, Zhijun
TI Effect of fire needle for ganglion cysts: A protocol of systematic review and
SO Medicine
LA English
DT Journal Article
AB BACKGROUND: Ganglion cysts (GCs) are tumor-like lesions that often occur in the  soft tissues, which are mostly caused by the degeneration of mucin produced by  the joint capsule and tendon sheath on the carpal dorsal joints of extremities.  GCs may appear asymptomatic as benign tumors, but some patients also seek  treatment because of the pain caused by these fluid-filled cysts. As a kind of  complementary and alternative therapy, there have been some studies published in  China which have proved that the fire needle has a better therapeutic effect on  ganglion cyst. The purpose of this systematic review is to evaluate the efficacy  of fire needle in the treatment of GCs. METHODS: PubMed, EMBASE, the Cochrane  Library, Chinese National Knowledge Infrastructure, Chinese VIP Information,  Wanfang Database, and Chinese Biomedical Literature Database were searched by 2  reviewers from the inception until August 2020. The original study that  randomised control trials of fire needle for GCs will be selected and is not  limited by country or language. In addition, researches in progress, the  reference lists and the citation lists of identified publications will be  retrieved similarly. Study selection, data extraction, and assessment of the  quality will be performed independently by 2 reviewers who have been trained  prior to data extraction. A meta-analysis will be conduct if the quantity and  quality of the original studies included are satisfactory; otherwise, a  descriptive analysis will be conducted. Review Manager V5.4: (The Nordic Cochrane  Centre, The Cochrane Collaboration, Copenhagen, Denmark) software will be using  for data synthesis and assessment the risk of bias according by Cochrane  Handbook. RESULT: This study will provide a comprehensive review of current  evidence for the treatment of fire needle on GCs. CONCLUSION: The conclusion of  this study will provide a judging basis that whether the treatment of GCs with  fire needle is effective. INPLASY REGISTRATION NUMBER: INPLASY202080032.
C1 Jiangxi University of Traditional Chinese Medicine.
   Nanchang First Hospital.
   The Affiliated Hospital of Jiangxi University of Traditional Chinese Medicine, Nanchang, China.
   Jiangxi University of Traditional Chinese Medicine.
   Jiangxi University of Traditional Chinese Medicine.
   Jiangxi University of Traditional Chinese Medicine.
   Jiangxi University of Traditional Chinese Medicine.
   The Affiliated Hospital of Jiangxi University of Traditional Chinese Medicine, Nanchang, China.
   The Affiliated Hospital of Jiangxi University of Traditional Chinese Medicine, Nanchang, China.
   The Affiliated Hospital of Jiangxi University of Traditional Chinese Medicine, Nanchang, China.
NR 0
TC 0
SN 1536-596
EI 0025-797
J9 Medicine (Baltimore)
PD OCT 9
PY 2020
VL 99
IS 41
BP e22602
EP e22602
DI 10.1097/MD.0000000000022602
PG 1
WC Acupuncture Therapy; Ganglion Cysts; therapy; Humans; Meta-Analysis as Topic; Randomized Controlled Trials as Topic; Systematic Reviews as Topic
UT PubMed:33031314
PM 33031314
DA 2020-10-09
ER

PT J
AU Hao, J
   Zhu, XS
   Bensoussan, A
AF Hao, Jie
   Zhu, Xiaoshu
   Bensoussan, Alan
TI Effects of Nonpharmacological Interventions in Chemotherapy-Induced Peripheral Neuropathy: An Overview of Systematic Reviews and Meta-Analyses
SO INTEGRATIVE CANCER THERAPIES
LA English
DT Review
DE overview; systematic review; meta-analysis; nonpharmacological intervention; chemotherapy-induced peripheral neuropathy
ID double-blind; vitamin-e; electroacupuncture; management; complementary; balance; pain; gabapentin; expression; prevention
AB Introduction: Chemotherapy-induced peripheral neuropathy (CIPN) is one of the prevalent and disabling side effects of cancer treatment. However, management strategies for CIPN currently remain elusive, with treatment restricted to neuropathic pain medications, supportive care, and chemotherapy dosing adjustments. This overview explores evidence on the potential benefits and safety of nonpharmacological interventions in preventing and treating CIPN in cancer patients. Methods: Seven databases were searched for systematic reviews of randomized controlled trials (RCTs). The methodological quality of the selected reviews was assessed by AMSTAR 2, and the quality of evidence was judged by GRADE. Twenty-eight systematic reviews were considered eligible for this review. Results: It was found that nonpharmacological interventions (acupuncture, exercise, herbal medicine, nutritional supplements) provided potential benefits for patients with CIPN. Furthermore, Chinese herbal medicine, administered orally or externally, significantly prevented and/or relieved the incidence and severity of CIPN in comparison to control groups (no additional treatment, placebo, and conventional western medicine). However, the quality of evidence and strength of recommendations were compromised by the inconsistencies and imprecision of included studies. The main concerns regarding the quality of systematic reviews included the lack of sufficiently rigorous a priori protocols, and the lack of protocol registration adopted in the included studies. Conclusions: Though looking across reviews, Chinese herbal medicine appear generally effective in CIPN, uncertainty remains about the effects of many other nonpharmacological interventions. The evidence on what works was particularly compromised by reporting and methodological limitations, which requires further investigation to be more certain of their effects.
C1 [Hao, Jie; Zhu, Xiaoshu; Bensoussan, Alan] Western Sydney Univ, Sydney, NSW, Australia.
C3 Western Sydney University
RP Zhu, XS (corresponding author), Western Sydney Univ, Locked Bag 1797, Penrith, NSW 2751, Australia.
EM xiaoshuzhuwesternsydney@gmail.com
FU Western Sydney University Research Training Scheme [UWS18405473]; China Scholarship Council Higher Degree (Doctor of Philosophy) Program [CSC201506550006]
CR Unknown -, 2010, SURGERY, V0, P0, DOI DOI 10.1016/J.SURG.2009.06.030
   Unknown -, 2015, MOD J INTEGR TRADIT, V0, P0
   Unknown -, 2008, J JIANGXI U TRADITIO, V0, P0
   Unknown -, 2003, STRENGTH POWER SPORT, V0, P0
   Argyriou AA, 2017, NAT REV NEUROL, V13, P492, DOI 10.1038/nrneurol.2017.88
   Ben-Arye E, 2012, SUPPORT CARE CANCER, V20, P557, DOI 10.1007/s00520-011-1121-0
   Brami C, 2016, CRIT REV ONCOL HEMAT, V98, P325, DOI 10.1016/j.critrevonc.2015.11.014
   Brayall P, 2018, REHABIL ONCOL, V36, P161, DOI 10.1097/01.REO.0000000000000111
   Chen S, 2018, THESIS, V0, P0
   Cheng XL, 2017, FRONT PHARMACOL, V8, P0, DOI 10.3389/fphar.2017.00344
   Coste TC, 2003, DIABETES, V52, P2578, DOI 10.2337/diabetes.52.10.2578
   Deng B, 2016, CHIN ARCH TRADIT CHI, V34, P20, DOI 10.13193/j.issn.1673-7717.2016.01.005
   Deng B, 2016, EVID-BASED COMPL ALT, V2016, P0, DOI 10.1155/2016/2421876
   Derksen TME, 2017, EVID-BASED COMPL ALT, V2017, P0, DOI 10.1155/2017/7916031
   Duregon F, 2018, CRIT REV ONCOL HEMAT, V121, P90, DOI 10.1016/j.critrevonc.2017.11.002
   Eum S, 2013, INT J VITAM NUTR RES, V83, P101, DOI 10.1024/0300-9831/a000149
   Franconi G, 2013, EVID-BASED COMPL ALT, V2013, P0, DOI 10.1155/2013/516916
   Fusumada Kazutoshi, 2007, OKAJIMAS FOLIA ANATOMICA JAPONICA, V84, P1, DOI 10.2535/ofaj.84.1
   Gerbi A, 1999, J NUTR, V129, P207, DOI 10.1093/jn/129.1.207
   Gewandter JS, 2017, NEUROLOGY, V89, P859, DOI 10.1212/WNL.0000000000004272
   Gladman SJ, 2012, J NEUROSCI, V32, P563, DOI 10.1523/JNEUROSCI.3371-11.2012
   He B, 2013, J LIAONING U TRADIT, V15, P146, DOI 10.13194/j.jlunivtcm.2013.06.148.heb.055
   Hershman DL, 2014, J CLIN ONCOL, V32, P1941, DOI 10.1200/JCO.2013.54.0914
   Hoshino N, 2018, INT J CLIN ONCOL, V23, P434, DOI 10.1007/s10147-017-1229-4
   Hsiang SW, 2011, AM J CHINESE MED, V39, P1207, DOI 10.1142/S0192415X11009500
   Huang HP, 2016, WSPOLCZESNA ONKOL, V20, P237, DOI 10.5114/wo.2016.61567
   Huang KS, 2011, EVID-BASED COMPL ALT, V2011, P1, DOI 10.1093/ecam/nep115
   Hunter J, 2018, BMC COMPLEM ALTERN M, V18, P0, DOI 10.1186/s12906-018-2209-6
   Ji Y, 2016, THESIS, V0, P0
   Kautio AL, 2008, J PAIN SYMPTOM MANAG, V35, P31, DOI 10.1016/j.jpainsymman.2007.02.043
   Kim BJ, 1997, INTERNATIONAL JOURNAL OF COSMETIC SCIENCE, V19, P299, DOI 10.1046/j.1467-2494.1997.171726.x
   Kuriyama A, 2018, SUPPORT CARE CANCER, V26, P1051, DOI 10.1007/s00520-017-4028-6
   Li K, 2019, CURR ONCOL, V26, PE147, DOI 10.3747/co.26.4261
   Li Q, 2019, EVID-BASED COMPL ALT, V2019, P0, DOI 10.1155/2019/2346583
   Liberati Alessandro, 2009, PLOS MED, V6, Pe1000100, DOI 10.1371/journal.pmed.1000100
   Liu YW, 2010, BIOCHEM BIOPH RES CO, V399, P49, DOI 10.1016/j.bbrc.2010.07.037
   Liu YH, 2018, INTEGR CANCER THER, V18, P0, DOI 10.1177/1534735418817833
   Mannelli LD, 2017, SCI REP-UK, V7, P0, DOI 10.1038/srep42021
   Mannelli LDC, 2015, PLANTA MED, V81, P1045, DOI 10.1055/s-0035-1546117
   Manni L, 2011, DIABETOLOGIA, V54, P1900, DOI 10.1007/s00125-011-2117-5
   Mao Z, 2017, MODERN CHIN WESTERN MED, V26, P4027, DOI 10.3969/j.issn.1008-8849.2017.36.011
   MILLER AB, 1981, CANCER, V47, P207, DOI 10.1002/1097-0142(19810101)47:1<207::AID-CNCR2820470134>3.0.CO;2-6
   NIWA Y, 1986, INFLAMMATION, V10, P79, DOI 10.1007/BF00916043
   Noh H, 2018, EVID-BASED COMPL ALT, V2018, P0, DOI 10.1155/2018/6194184
   Oh PJ, 2018, J KOREAN ACAD NURS, V48, P123, DOI 10.4040/jkan.2018.48.2.123
   Öztürk G, 2004, TOXICOL APPL PHARM, V196, P169, DOI 10.1016/j.taap.2003.12.006
   Pachman DR, 2014, CURR TREAT OPTION ON, V15, P567, DOI 10.1007/s11864-014-0303-7
   Park JH, 2010, BRAIN RES, V1322, P24, DOI 10.1016/j.brainres.2010.02.001
   Rao RD, 2008, CANCER, V112, P2802, DOI 10.1002/cncr.23482
   Rao RD, 2007, CANCER-AM CANCER SOC, V110, P2110, DOI 10.1002/cncr.23008
   Robson LG, 2010, NEUROBIOL AGING, V31, P678, DOI 10.1016/j.neurobiolaging.2008.05.027
   Rossi E, 2018, J ALTERN COMPLEM MED, V24, P933, DOI 10.1089/acm.2018.0143
   Schloss JM, 2013, CLIN NUTR, V32, P888, DOI 10.1016/j.clnu.2013.04.007
   SCHRODER S, 2013, EVID-BASED COMPL ALT, V2013, P0, DOI 10.1155/2013/423713
   Seretny M, 2014, PAIN, V155, P2461, DOI 10.1016/j.pain.2014.09.020
   Shalom-Sharabi I, 2017, J CANCER RES CLIN, V143, P2535, DOI 10.1007/s00432-017-2509-0
   Shea BJ, 2017, BMJ-BRIT MED J, V358, P0, DOI 10.1136/bmj.j4008
   Shi Y, 2015, MANUAL CLIN ONCOLOGY, V6th, P0
   Silva JRT, 2011, J PAIN, V12, P51, DOI 10.1016/j.jpain.2010.04.008
   Staff NP, 2017, ANN NEUROL, V81, P772, DOI 10.1002/ana.24951
   Streckmann F, 2014, SPORTS MED, V44, P1289, DOI 10.1007/s40279-014-0207-5
   Sung HJ, 2004, PROTEOMICS, V4, P2805, DOI 10.1002/pmic.200300821
   Taube W, 2008, ACTA PHYSIOL, V193, P101, DOI 10.1111/j.1748-1716.2008.01850.x
   Taube W, 2007, ACTA PHYSIOL, V189, P347, DOI 10.1111/j.1748-1716.2007.01665.x
   Tian J, 2013, CHIN J EXP TRADIT MED FORM, V19, P325, DOI 10.11653/SYFJ2013220325
   Tsavaris N, 2008, PAIN MED, V9, P1209, DOI 10.1111/j.1526-4637.2007.00325.x
   Vickers A, 1998, CONTROL CLIN TRIALS, V19, P159, DOI 10.1016/S0197-2456(97)00150-5
   Wang QY, 2015, MOD DIGESTION INTERV, V20, P387
   Wei XC, 2016, SHANDONG MED J, V56, P77
   [魏晓晨 Wei Xiaochen], 2016, 中国实验方剂学杂志 CHINESE JOURNAL OF EXPERIMENTAL TRADITIONAL MEDICAL FORMULAE, V22, P186
   [魏晓晨 Wei Xiaochen], 2016, 中国现代应用药学 CHINESE JOURNAL OF MODERN APPLIED PHARMACY, V33, P476
   Xing GG, 2007, EXP NEUROL, V208, P323, DOI 10.1016/j.expneurol.2007.09.004
   Yan Y, 2018, JIANGXI TRADIT CHIN MED, V49, P61
   Yang LN, 2018, J BASIC CHIN MED, V24, P1101
   Yee P, 2010, INVEST OPHTH VIS SCI, V51, P1755, DOI 10.1167/iovs.09-3792
   Zhang AC, 2020, NUTR REV, V78, P323, DOI 10.1093/nutrit/nuz054
NR 77
TC 16
Z9 18
U1 2
U2 16
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 1534-7354
EI 1552-695X
J9 INTEGR CANCER THER
JI Integr. Cancer Ther.
PD SEP 15
PY 2020
VL 19
IS 
BP 
EP 
DI 10.1177/1534735420945027
PG 23
WC Oncology; Integrative & Complementary Medicine
SC Oncology; Integrative & Complementary Medicine
GA NM2FC
UT WOS:000567916900001
PM 32875921
DA 2026-01-16
ER

PT J
AU Yu, ML
   Qian, JJ
   Fu, SP
   Chen, JY
   Zheng, YW
   Lu, ZG
   Lu, SF
AF Yu, Mei-Ling
   Qian, Jia-Jia
   Fu, Shu-Ping
   Chen, Jia-Ying
   Zheng, Yu-Wen
   Lu, Zhi-Gang
   Lu, Sheng-Feng
TI Acupuncture for Cancer-Induced Bone Pain in Animal Models: A Systemic Review and
SO Evidence-based complementary and alternative medicine : eCAM
LA English
DT Review
AB BACKGROUND: Cancer-induced bone pain (CIBP) is a highly prevalent symptom, which  afflicts vast majority of patients who suffer from cancer. The current treatment  options failed to achieve satisfactory effect and the side effects were  prominent. Recent randomized controlled trials (RCTs) of animal demonstrate the  benefit of acupuncture for CIBP. We sought to determine if the pooled data from  available RCTs supports the use of acupuncture for CIBP. METHODS: A literature  search for randomized controlled trials was conducted in six electronic databases  from inception to May 31, 2019. Meta-analysis was performed with Review Manager  5.3 software; the publication bias was assessed by Stata 12.0 software. We used  random effects model for pooling data because heterogeneity is absolute among  studies to some extent. RESULTS: Twenty-four trials were included in the review,  of which 12 trials provided detailed data for meta-analyses. Preliminary evidence  indicates that compared to wait list/sham group, acupuncture was effective on  increasing paw withdrawal threshold (PWT) and paw withdrawal latency (PWL).  Compared to medicine, acupuncture was less effective on PWT, but as effective as  medicine on PWL. Acupuncture can reinforce medicine's effect on PWT and PWL.  Compared to the control group, acupuncture was superior to increase body weight  (BW), decrease spinal cord glial fibrillary acidic protein (GFAP), and  interleukin-1β (IL-1β). Furthermore, some studies showed acupuncture delay or  partially reverse morphine tolerance. Three studies found acupuncture has no  effect on PWT, but 2 of them found acupuncture could enhance small dose of  Celebrex's effect on CIBP. CONCLUSIONS: Acupuncture was superior to wait  list/sham acupuncture on increasing PWT and has no less effect on increasing PWL  compared to medicine; acupuncture improved the efficacy of drugs, increased the  CIBP animals' body weight, and decreased their spinal cord GFAP and IL-1β.  High-quality studies are necessary to confirm the results.
C1 First Clinical Medical College, Nanjing University of Chinese Medicine, Nanjing 210023, China.
   Acupuncture and Rehabilitation College, Nanjing University of Chinese Medicine, 
   First Clinical Medical College, Nanjing University of Chinese Medicine, Nanjing 210023, China.
   Acupuncture and Rehabilitation College, Nanjing University of Chinese Medicine, 
   Key Laboratory of Acupuncture and Medicine Research of Ministry of Education, Nanjing University of Chinese Medicine, Nanjing 210023, China.
   Acupuncture and Rehabilitation College, Nanjing University of Chinese Medicine, Nanjing 210023, China.
   Acupuncture and Rehabilitation College, Nanjing University of Chinese Medicine, Nanjing 210023, China.
   First Clinical Medical College, Nanjing University of Chinese Medicine, Nanjing 210023, China.
   College of Pharmacy, Nanjing University of Chinese Medicine, Nanjing 210023, 
   Key Laboratory of Acupuncture and Medicine Research of Ministry of Education, Nanjing University of Chinese Medicine, Nanjing 210023, China.
NR 0
TC 0
SN 1741-428
EI 1741-427
J9 Evid Based Complement Alternat Med
PD AUG 18
PY 2020
VL 2020
IS 
BP 5606823
EP 5606823
DI 10.1155/2020/5606823
PG 0
UT PubMed:32802130
PM 32802130
DA 2020-08-18
ER

PT J
AU Li, D
   Sun, RR
   Li, QL
   Ma, Q
   Zeng, YL
   Jia, XZ
   Wang, J
AF Li, Dan
   Sun, Rui-Rui
   Li, Qing-Ling
   Ma, Qiang
   Zeng, Yong-Lei
   Jia, Xue-Zhao
   Wang, Jing
TI [Acupuncture combined with opioid drugs on moderate and severe cancer pain: a
SO Zhongguo zhen jiu = Chinese acupuncture & moxibustion
LA chi
DT Journal Article
DE acupuncture; cancer pain; opioid drugs; randomized controlled trial (RCT)
AB OBJECTIVE: To explore the clinical therapeutic effect of acupuncture combined  with opioid drugs on moderate and severe cancer pain. METHODS: A total of 60  patients with cancer were randomized into an observation group and a control  group, 30 cases in each group. Oxycodonehydrochloride prolonged-release tablet  was taken orally in the control group. On the basis of the control group,  acupuncture was applied at Hegu (LI 4), Neiguan (PC 6), Zusanli (ST 36),  Sanyinjiao (SP 6), etc. Corresponding back-shu points, xi-cleft points and ashi  points were selected additionally according to primary viscera and pain sites in  the observation group. The treatment was given once a day for 2 weeks.  Symptomatic and supportive treatment were implanted, and no other antalgic  measures were given during the trial. The daily dosage of opioid drug and the  adverse reactions were recorded in both groups. Karnofsky performance status  (KPS) and quality of life (QOL) scale scores were compared before and after  treatment. Numerical rating scale (NRS) score was calculated to evaluate the  clinical therapeutic effect. RESULTS: Compared before treatment, the daily dosage  of opioid drugs after treatment was obviously reduced in the observation group  (P<0.01), and was obviously increased in the control group (P<0.05). The dosage  of opioid drugs after treatment in the observation group was much less than the  control group (P<0.01). After treatment, the KPS and QOL scores were increased in  both groups (P<0.01), and the scores in the observation group were superior to  the control group (P<0.01, P<0.05). The analgesic effective rate was 90.0%  (27/30) in the observation group, which was superior to 76.7% (23/30) in the  control group (P<0.05). The adverse reactions rate in the observation group was  lower than the control group (P<0.01). CONCLUSION: Acupuncture combined with  opioid drugs can effectively relieve the cancer pain, improve the performance  status and quality of life in cancer patients, reduce the dosage of opioid drugs  and adverse reactions rate.
C1 Guoyitang Department of Anhui University of CM, Hefei 230038, China.
   Third Affiliated Hospital of Anhui University of CM.
   Graduate School of Anhui University of CM.
   Graduate School of Anhui University of CM.
   Second Affiliated Hospital of Anhui University of CM.
   College of TCM, Anhui University of CM, Hefei 230038.
   College of TCM, Anhui University of CM, Hefei 230038.
NR 0
TC 0
SN 
EI 0255-293
J9 Zhongguo Zhen Jiu
PD APR 10
PY 2020
VL 40
IS 3
BP 257
EP 61
DI 10.13703/j.0255-2930.20190311-k0001
PG -196
WC Acupuncture Points; Acupuncture Therapy; Analgesics, Opioid; therapeutic use; Cancer Pain; therapy; Humans; Neoplasms; physiopathology; Quality of Life; Treatment Outcome
UT PubMed:32270637
PM 32270637
DA 2020-04-10
ER

PT J
AU Deng, G
   Giralt, S
   Chung, DJ
   Landau, H
   Siman, J
   Li, QS
   Lapen, K
   Mao, JJ
AF Deng, Gary
   Giralt, Sergio
   Chung, David J.
   Landau, Heather
   Siman, Jonathan
   Li, Qing S.
   Lapen, Kaitlyn
   Mao, Jun J.
TI Reduction of Opioid Use by Acupuncture in Patients Undergoing Hematopoietic Stem Cell Transplantation: Secondary Analysis of a Randomized, Sham-Controlled Trial
SO PAIN MEDICINE
LA English
DT Article
DE Pain Management; Acupuncture; Opioids; Cancer Pain
ID oral mucositis; multiple-myeloma; cancer-treatment; symptom burden; pain; efficacy; surgery
AB Objective. To evaluate acupuncture as a nonpharmacologic intervention for pain management in patients undergoing hematopoietic stem cell transplantation (HSCT). Methods. Adult patients with multiple myeloma undergoing high-dose melphalan chemotherapy and autologous peripheral blood HSCT were randomized to receive either true (TA) or sham acupuncture (SA) once daily for five days starting on the day after chemotherapy. Use of pain medications and pain scores were assessed at baseline and at days 5, 15, and 30 after transplantation. Results. Among 60 evaluable subjects, the SA group (vs TA) had greater than five times odds of increasing pain medication use from baseline. Among patients who were opioid nonusers at baseline, all 15 patients in the TA group remained free from opioid use at the end of the study. In contrast, 20% of those in the SA group (four of the 20 patients) started to use opioids after chemotherapy and stem cell infusion (day 5) and 40% (eight of the 20) had become opioid users by day 30 after HSCT (Fisher exact test P= 0.006). Among patients who were taking opioids at baseline, 14% in the TA group vs 10% in the SA group increased opioid intake at day 5, and 21% (TA) vs 30% (SA) at day 30 (P= 0.86). Conclusions. Acupuncture appears to significantly reduce the need for pain medications during HSCT and the number of post-HSCT opioid users among baseline opioid nonusers. It warrants further studies as an opioid-sparing intervention for pain in HSCT patients.
C1 [Deng, Gary; Li, Qing S.; Mao, Jun J.] Mem Sloan Kettering Canc Ctr, Integrat Med Serv, New York, NY 10021 USA.
   [Giralt, Sergio; Chung, David J.; Landau, Heather] Mem Sloan Kettering Canc Ctr, Adult Bone Marrow Transplantat Serv, New York, NY 10021 USA.
   [Siman, Jonathan] Seattle Canc Care Alliance, Seattle, WA USA.
   [Lapen, Kaitlyn] Univ Illinois, Sch Med, Chicago, IL USA.
C3 Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Seattle Cancer Care Alliance; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital
RP Deng, G (corresponding author), Mem Sloan Kettering Canc Ctr, Dept Med, 1429 First Ave, New York, NY 10021 USA.
EM dengg@mskcc.org
FU Gateway for Cancer Research grant; MSK Translational Research and Integrative Medicine Grant; National Institutes of Health/National Cancer Institute (NIH/NCI) Cancer Center Support Grant [P30 CA008748]; AC Israel Foundation; Byrne Fund; National Cancer Institute [P30CA008748] Funding Source: NIH RePORTER
CR Cheng KKF, 2007, EUR J ONCOL NURS, V11, P36, DOI 10.1016/j.ejon.2006.03.004
   Cheng KKF, 2010, SUPPORT CARE CANCER, V18, P1477, DOI 10.1007/s00520-009-0771-7
   Chou R, 2017, ANN INTERN MED, V166, P493, DOI 10.7326/M16-2459
   Cleeland CS, 2000, CANCER-AM CANCER SOC, V89, P1634, DOI 10.1002/1097-0142(20001001)89:7<1634::AID-CNCR29>3.0.CO;2-V
   CLEMENTJONES V, 1980, LANCET, V2, P946
   Deng G, 2018, SUPPORT CARE CANCER, V26, P657, DOI 10.1007/s00520-017-3881-7
   Edlund MJ, 2014, CLIN J PAIN, V30, P557, DOI 10.1097/AJP.0000000000000021
   Gorin SS, 2012, J CLIN ONCOL, V30, P539, DOI 10.1200/JCO.2011.37.0437
   Jones D, 2013, J HEMATOL ONCOL, V6, P0, DOI 10.1186/1756-8722-6-13
   Kaptchuk TJ, 2002, ANN INTERN MED, V136, P374, DOI 10.7326/0003-4819-136-5-200203050-00010
   Kashiwazaki H, 2012, SUPPORT CARE CANCER, V20, P933, DOI 10.1007/s00520-011-1164-2
   Kushner JA, 2008, J CAN DENT ASSOC, V74, P59
   LAO LX, 1995, ORAL SURG ORAL MED O, V79, P423, DOI 10.1016/S1079-2104(05)80121-0
   Lao LX, 1999, ARCH OTOLARYNGOL, V125, P567, DOI 10.1001/archotol.125.5.567
   Liao HY, 2017, SCI REP-UK, V7, P0, DOI 10.1038/s41598-017-16031-y
   Otti A, 2012, FORSCH KOMPLEMENTMED, V19, P197, DOI 10.1159/000341928
   Paice JA, 2016, J CLIN ONCOL, V34, P3325, DOI 10.1200/JCO.2016.68.5206
   Raber-Durlacher Judith E, 2004, SUPPORT CANCER THER, V1, P219, DOI 10.3816/SCT.2004.n.014
   Sawynok J, 2016, NEUROSCIENCE, V338, P1, DOI 10.1016/j.neuroscience.2015.10.031
   SYRJALA KL, 1995, PAIN, V63, P189, DOI 10.1016/0304-3959(95)00039-U
   SYRJALA KL, 1992, PAIN, V48, P137, DOI 10.1016/0304-3959(92)90049-H
   Wang SM, 2008, ANESTH ANALG, V106, P602, DOI 10.1213/01.ane.0000277493.42335.7b
   Wang XS, 2014, CLIN CANCER RES, V20, P1366, DOI 10.1158/1078-0432.CCR-13-2442
NR 23
TC 15
Z9 22
U1 1
U2 10
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 1526-2375
EI 1526-4637
J9 PAIN MED
JI Pain Med.
PD MAR 15
PY 2020
VL 21
IS 3
BP 636
EP 642
DI 10.1093/pm/pnz190
PG 7
WC Anesthesiology; Medicine, General & Internal
SC Anesthesiology; General & Internal Medicine
GA LS6CO
UT WOS:000536469900022
PM 31498394
DA 2026-01-16
ER

PT J
AU Yang, P
   Wang, YC
   Xiao, YC
   Ma, QL
   Ma, RH
   Mi, J
   Hui, JR
AF Yang, Pu
   Wang, Yuanchun
   Xiao, Yingchun
   Ma, Qiaolin
   Ma, Runhong
   Mi, Jing
   Hui, Jianrong
TI Acupuncture for opioid-induced constipation Protocol for a systematic review and meta-analysis
SO MEDICINE
LA English
DT Review
DE acupuncture; opioid-induced constipation; meta-analysis; systematic review; protocol
ID management; pathophysiology; diagnosis
AB Background: Opioid-induced constipation (OIC) is one of the most common complications of analgesic therapy for cancer pain patients who suffer moderate to severe pain. Acupuncture as an effective treatment in constipation has been widely applied. But its efficacy has not been assessed systematically. Thus, the purpose of this study is to provide a protocol to explore the efficacy and safety of acupuncture for OIC. Methods: Randomized Controlled Trials (RCTs) of acupuncture treatment for OIC in 4 Chinese electronic databases (China National Knowledge Infrastructure, Chinese Biological and Medical Database, China Scientific Journal Database, Wan-Fang Data) and 3 English electronic databases (PubMed, Embase, Cochrane Library) will be searched from their inception to September 31, 2020. RevMan 5.3 software and Stata 14.0 software will be used for meta-analysis, EndNote X9.2 and Cochrane Risk of Bias Tool will be used for literature screening and quality assessment. Results: This study will present an assessment of the efficacy and safety of acupuncture treatment for OIC patients through summarize high-quality clinical evidence. Conclusion: The conclusion of our systematic review and meta-analysis may provide evidence of whether acupuncture treatment is beneficial to patients with OIC. INPLASY registration number: INPLASY2020100026.
C1 [Yang, Pu; Xiao, Yingchun; Ma, Qiaolin; Ma, Runhong; Mi, Jing; Hui, Jianrong] Shaanxi Univ Chinese Med, Sch Acupuncture Moxibust & Tuina, Xian, Peoples R China.
   [Wang, Yuanchun] Shaanxi Univ Chinese Med, Affiliated Hosp, Xianyang, Shaanxi, Peoples R China.
C3 Shaanxi University of Chinese Medicine; Shaanxi University of Chinese Medicine
RP Hui, JR (corresponding author), Shaanxi Univ Chinese Med, Xixian New Area, 1 Shi Ji Ave, Xian, Shaanxi, Peoples R China.
EM jrjianrong99@163.com
FU Science and Technology Project of Shaanxi Provincial Administration of Traditional Chinese Medicine
CR Bandieri E, 2016, J CLIN ONCOL, V34, P436, DOI 10.1200/JCO.2015.61.0733
   Cai H, 2019, J INT MED RES, V47, P6337, DOI 10.1177/0300060519874539
   Crockett S, 2019, GASTROENTEROLOGY, V156, P228, DOI 10.1053/j.gastro.2018.10.044
   Crockett SD, 2019, GASTROENTEROLOGY, V156, P218, DOI 10.1053/j.gastro.2018.07.016
   Farmer AD, 2019, UNITED EUR GASTROENT, V7, P7, DOI 10.1177/2050640618818305
   Farmer AD, 2018, LANCET GASTROENTEROL, V3, P203, DOI 10.1016/S2468-1253(18)30008-6
   Gaertner J, 2015, J CLIN GASTROENTEROL, V49, P9, DOI 10.1097/MCG.0000000000000246
   Hutson JM, 2015, PEDIATR SURG INT, V31, P445, DOI 10.1007/s00383-015-3681-4
   Kumar L, 2014, GASTROENT RES PRACT, V2014, P0, DOI 10.1155/2014/141737
   Larkin PJ, 2018, ANN ONCOL, V29, P111, DOI 10.1093/annonc/mdy148
   Lu WD, 2013, CURR PAIN HEADACHE R, V17, P0, DOI 10.1007/s11916-013-0321-3
   Mesía R, 2019, CURR TREAT OPTION ON, V20, P0, DOI 10.1007/s11864-019-0686-6
   Müller-Lissner S, 2017, PAIN MED, V18, P1837, DOI 10.1093/pm/pnw255
   Prichard, 2016, BR J NURS, V25, P0
   Prichard David, 2016, BR J NURS, V25, PS4, DOI 10.12968/bjon.2016.25.10.s4
   Rao VL, 2019, JAMA-J AM MED ASSOC, V322, P2241, DOI 10.1001/jama.2019.15852
   Sera L, 2018, AM J HOSP PALLIAT ME, V35, P330, DOI 10.1177/1049909117705379
   Wang XJ, 2019, AM J PHYSIOL-GASTR L, V316, PG797, DOI 10.1152/ajpgi.00018.2018
   Webster LR, 2015, PAIN MED, V16, PS16, DOI 10.1111/pme.12911
   Wiffen PJ, 2017, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD012637.pub2
   Zhang Feng-Li, 2009, ZHONGGUO ZHONG XI YI JIE HE ZA ZHI, V29, P922
   Zhu HD, 2018, INTEGR CANCER THER, V17, P437, DOI 10.1177/1534735417734910
   Zhu XW, 2016, ACUPUNCT MED, V34, P194, DOI 10.1136/acupmed-2015-010897
NR 23
TC 2
Z9 2
U1 1
U2 14
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0025-7974
EI 1536-5964
J9 MEDICINE
JI Medicine (Baltimore)
PD DEC 4
PY 2020
VL 99
IS 49
BP 
EP 
DI 10.1097/MD.0000000000023352
PG 4
WC Medicine, General & Internal
SC General & Internal Medicine
GA PZ6GR
UT WOS:000612838500051
PM 33285714
DA 2026-01-16
ER

PT J
AU Yu, ML
   Wei, RD
   Zhang, T
   Wang, JM
   Cheng, Y
   Qin, FF
   Fu, SP
   Lu, ZG
   Lu, SF
AF Yu, Mei-ling
   Wei, Rui-de
   Zhang, Tao
   Wang, Jun-meng
   Cheng, Yu
   Qin, Fen-fen
   Fu, Shu-ping
   Lu, Zhi-gang
   Lu, Sheng-feng
TI Electroacupuncture Relieves Pain and Attenuates Inflammation Progression Through Inducing IL-10 Production in CFA-Induced Mice
SO INFLAMMATION
LA English
DT Article
DE electroacupuncture treatment; analgesia; IL-10; regulatory T cells; pro-inflammatory cytokines; CFA-induced mice
ID tumor-necrosis-factor; nlrp3 inflammasome; neuropathic pain; macrophage; acupuncture; activation; therapy; injury; cells; interleukin-1-beta
AB The therapeutic effect of electroacupuncture (EA) on inflammatory pain has been well recognized clinically, but the mechanism is unclear. Interleukin-10 (IL-10), which is produced by regulatory T (Treg) cell, is a key anti-inflammatory cytokine for relieving inflammatory pain. Therefore, the aim of this study is to investigate whether EA could inhibit CFA-induced pain and attenuate inflammation progression by regulating the activation of immunocyte and inducing the expression of IL-10. In this study, mice were treated with EA (2/100 Hz, 2 mA) for five consecutive days after 1 day of CFA injection. The behavioral tests were measured and analyzed after the daily EA treatment; then, hind paw, spinal cord, and spleen tissues were prepared for assessment. The results showed that EA treatment significantly increased the mechanical threshold and thermal latency after CFA injection and boosted the expression of IL-10 in paw and spinal cord tissues. EA treatment promoted Treg cells; suppressed macrophage and neutrophils cells; reduced the expression of IL-1 beta, NLRP3, and TNF-alpha; and ultimately relieved inflammatory pain. The findings suggested that the analgesic and anti-inflammatory effect of EA treatment could be partially associated with suppression of pro-inflammatory cytokines mediated by induction of IL-10.
C1 [Yu, Mei-ling; Lu, Zhi-gang] Nanjing Univ Chinese Med, Clin Med Coll 1, Nanjing, Peoples R China.
   [Yu, Mei-ling; Zhang, Tao; Cheng, Yu; Qin, Fen-fen; Fu, Shu-ping; Lu, Zhi-gang; Lu, Sheng-feng] Nanjing Univ Chinese Med, Minist Educ, Key Lab Acupuncture & Med Res, Nanjing, Peoples R China.
   [Wei, Rui-de] Nanjing Univ Chinese Med, Sch Med & Holist Integrat Med, Nanjing, Peoples R China.
   [Wang, Jun-meng] Chengdu Univ Tradit Chinese Med, Acupuncture & Tuina Sch, Chengdu, Sichuan, Peoples R China.
C3 Nanjing University of Chinese Medicine; Nanjing University of Chinese Medicine; Nanjing University of Chinese Medicine; Chengdu University of Traditional Chinese Medicine
RP Lu, ZG; Lu, SF (corresponding author), Nanjing Univ Chinese Med, Minist Educ, Key Lab Acupuncture & Med Res, Nanjing, Peoples R China.
EM Luzg@njucm.edu.cn; lushengfeng@njucm.edu.cn
FU National Natural Science Foundation of China [81774210, 81574062]; "SixMajor Talent Summit" of Jiangsu Province [YY-033]; Jiangsu Province "333 High-level Talents Cultivating Project" (2016); "Qing Lan Project" of Jiangsu Province; Nursing Priority Academic Program Development of Jiangsu Higher Education Institutions [2019YSHL046]
CR Abderrazak A, 2015, REDOX BIOL, V4, P296, DOI 10.1016/j.redox.2015.01.008
   Aich A, 2015, INT J MOL SCI, V16, P29069, DOI 10.3390/ijms161226151
   Azizzadeh Faranak, 2017, IRANIAN BIOMEDICAL JOURNAL, V21, P114, DOI 10.18869/acadpub.ibj.21.2.114
   Baral P, 2019, NAT REV IMMUNOL, V19, P433, DOI 10.1038/s41577-019-0147-2
   Chatterjea D, 2015, MOL IMMUNOL, V63, P38, DOI 10.1016/j.molimm.2014.03.001
   Chen G, 2017, NAT NEUROSCI, V20, P917, DOI 10.1038/nn.4571
   Cunha TM, 2008, J LEUKOCYTE BIOL, V83, P824, DOI 10.1189/jlb.0907654
   da Silva MD, 2015, MOL NEUROBIOL, V51, P19, DOI 10.1007/s12035-014-8790-x
   Davis BK, 2011, ANNU REV IMMUNOL, V29, P707, DOI 10.1146/annurev-immunol-031210-101405
   Duffy SS, 2019, J NEUROSCI, V39, P2326, DOI 10.1523/JNEUROSCI.1815-18.2019
   Dunster JL, 2016, WIRES SYST BIOL MED, V8, P87, DOI 10.1002/wsbm.1320
   Fan XC, 2018, FRONT MOL NEUROSCI, V11, P0, DOI 10.3389/fnmol.2018.00085
   Fang JQ, 2018, LIFE SCI, V200, P69, DOI 10.1016/j.lfs.2018.03.028
   Gao F, 2018, BRAIN BEHAV IMMUN, V67, P91, DOI 10.1016/j.bbi.2017.08.004
   Ghasemlou N, 2015, P NATL ACAD SCI USA, V112, PE6808, DOI 10.1073/pnas.1501372112
   Held M, 2019, PAIN, V160, P2316, DOI 10.1097/j.pain.0000000000001623
   Huang DX, 2019, INFLAMMATION, V42, P895, DOI 10.1007/s10753-018-0944-y
   Hussein SZ, 2013, PLOS ONE, V8, P0, DOI 10.1371/journal.pone.0072365
   Inglis JJ, 2005, ARTHRITIS RES THER, V7, PR807, DOI 10.1186/ar1743
   Ip WKE, 2017, SCIENCE, V356, P513, DOI 10.1126/science.aal3535
   JEONG JH, 2015, PLOS ONE, V10, P0
   Jin Richard M, 2018, IMMUNOHORIZONS, V2, P142, DOI 10.4049/immunohorizons.1800024
   Kim CF, 2011, J PAIN, V12, P370, DOI 10.1016/j.jpain.2010.08.003
   Kobayashi Y, 2015, J BIOL CHEM, V290, P12603, DOI 10.1074/jbc.M115.636506
   Kong J, 2005, J PAIN, V6, P55, DOI 10.1016/j.jpain.2004.10.005
   Kosek E, 2016, PAIN, V157, P1382, DOI 10.1097/j.pain.0000000000000507
   Kwon JY, 2018, SCI REP-UK, V8, P0, DOI 10.1038/s41598-018-32206-7
   Li SF, 2016, BIOMED PHARMACOTHER, V79, P159, DOI 10.1016/j.biopha.2016.01.036
   Liu ZS, 2017, JAMA-J AM MED ASSOC, V317, P2493, DOI 10.1001/jama.2017.7220
   Marchetti C, 2019, J CARDIOVASC PHARM, V74, P285, DOI 10.1097/FJC.0000000000000718
   McCarson Kenneth E, 2015, CURR PROTOC PHARMACOL, V70, P0, DOI 10.1002/0471141755.ph0504s70
   Meng JB, 2018, BIOMED RES INT, V2018, P0, DOI 10.1155/2018/8293594
   Meng JB, 2018, MEDICINE, V97, P0, DOI 10.1097/MD.0000000000010555
   Milligan ED, 2012, NEUROMODULATION, V15, P520, DOI 10.1111/j.1525-1403.2012.00462.x
   Mueller M, 2003, LAB INVEST, V83, P175, DOI 10.1097/01.LAB.0000056993.28149.BF
   Parameswaran N, 2010, CRIT REV EUKAR GENE, V20, P87, DOI 10.1615/CritRevEukarGeneExpr.v20.i2.10
   Park JY, 2018, J INFLAMM RES, V11, P227, DOI 10.2147/JIR.S141198
   Paulsen O, 2017, PLOS ONE, V12, P0, DOI 10.1371/journal.pone.0177620
   Pedersen JL, 2000, DAN MED BULL, V47, P168
   Penatti A, 2017, ARTHRITIS RES THER, V19, P0, DOI 10.1186/s13075-017-1305-1
   Perrin FE, 2005, BRAIN, V128, P854, DOI 10.1093/brain/awh407
   Pinho-Ribeiro FA, 2017, TRENDS IMMUNOL, V38, P5, DOI 10.1016/j.it.2016.10.001
   Planells-Cases R, 2005, PFLUG ARCH EUR J PHY, V451, P151, DOI 10.1007/s00424-005-1423-5
   Plunkett JA, 2001, EXP NEUROL, V168, P144, DOI 10.1006/exnr.2000.7604
   Purdy M, 2016, ANTICANCER RES, V36, P3005
   Qin FF, 2019, FRONT PHARMACOL, V10, P0, DOI 10.3389/fphar.2019.00359
   Ren K, 2009, BRAIN RES REV, V60, P57, DOI 10.1016/j.brainresrev.2008.12.020
   Rose S, 2012, CYTOM PART A, V81A, P343, DOI 10.1002/cyto.a.22012
   Schuh CD, 2014, PAIN, V155, P545, DOI 10.1016/j.pain.2013.12.006
   Sharma A, 2019, INT REV IMMUNOL, V38, P183, DOI 10.1080/08830185.2019.1621310
   Shutov LP, 2016, J NEUROSCI, V36, P5055, DOI 10.1523/JNEUROSCI.3249-15.2016
   Slotkin JR, 2016, SPINE, V41, PE441, DOI 10.1097/BRS.0000000000001309
   Su TF, 2012, EUR J PAIN, V16, P624, DOI 10.1002/j.1532-2149.2011.00055.x
   Tanaka A, 2017, CELL RES, V27, P109, DOI 10.1038/cr.2016.151
   Tanaka T, 2014, CSH PERSPECT BIOL, V6, P0, DOI 10.1101/cshperspect.a016295
   Vanderwall AG, 2018, BRAIN BEHAV IMMUN, V69, P91, DOI 10.1016/j.bbi.2017.11.004
   Vardeh D, 2016, J PAIN, V17, PT50, DOI 10.1016/j.jpain.2016.03.001
   Vickers AJ, 2018, J PAIN, V19, P455, DOI 10.1016/j.jpain.2017.11.005
   Vickers AJ, 2012, ARCH INTERN MED, V172, P1444, DOI 10.1001/archinternmed.2012.3654
   von Banchet GS, 2009, PAIN, V145, P151, DOI 10.1016/j.pain.2009.06.002
   Wang ZG, 2017, INFLAMMATION, V40, P422, DOI 10.1007/s10753-016-0487-z
   Xiang HC, 2019, J NEUROINFLAMM, V16, P0, DOI 10.1186/s12974-019-1411-x
   Zazueta-Favela D, 2019, IMMUNOPHARM IMMUNOT, V41, P463, DOI 10.1080/08923973.2019.1641114
   Zhang JH, 2006, CHINESE MED J-PEKING, V119, P930, DOI 10.1097/00029330-200606010-00009
   Zhang JM, 2007, INT ANESTHESIOL CLIN, V45, P27, DOI 10.1097/AIA.0b013e318034194e
   Zhou YM, 2013, NAT COMMUN, V4, P0, DOI 10.1038/ncomms3399
   Zhu LQ, 2018, J IMMUNOL RES, V2018, P0, DOI 10.1155/2018/5201759
NR 67
TC 43
Z9 55
U1 4
U2 30
PU SPRINGER/PLENUM PUBLISHERS
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0360-3997
EI 1573-2576
J9 INFLAMMATION
JI Inflammation
PD AUG 15
PY 2020
VL 43
IS 4
BP 1233
EP 1245
DI 10.1007/s10753-020-01203-2
EA MAR 2020
PG 13
WC Cell Biology; Immunology
SC Cell Biology; Immunology
GA MO5ES
UT WOS:000520907000001
PM 32198725
DA 2026-01-16
ER

PT J
AU Liu, W
   Qdaisat, A
   Lopez, G
   Narayanan, S
   Underwood, S
   Spano, M
   Reddy, A
   Guo, Y
   Yeung, SC
   Bruera, E
   Cohen, L
AF Liu, Wenli
   Qdaisat, Aiham
   Lopez, Gabriel
   Narayanan, Santhosshi
   Underwood, Susan
   Spano, Michael
   Reddy, Akhila
   Guo, Ying
   Yeung, Sai-Ching
   Bruera, Eduardo
   Cohen, Lorenzo
TI Association Between Acupoint Selection, Target Symptoms, and Traditional Chinese
SO Integrative cancer therapies
LA English
DT Journal Article
DE acupuncture; acupuncture point selection; cancer; complementary health approaches; integrative medicine; traditional Chinese medicine
AB Background: Acupuncture intervention in actual practice is rarely reported and  may be different from that applied in acupuncture research. Objectives: To review  acupuncture practice in an integrative medicine clinic and characterize the  association between targeted symptoms, traditional Chinese medicine (TCM)  diagnosis, and acupoint selection. Methods: We reviewed outpatient acupuncture  records from March 2016 to April 2018. Statistical analyses were applied to  characterize referral symptoms and associated TCM diagnosis as well as acupoint  selection. Results: The final analysis included 5393 acupuncture records (1264  patients). Twelve TCM diagnosis components were identified in the referral  symptoms of pain, neuropathy, xerostomia, and hot flashes. Pain was associated  with 78 different TCM diagnoses (combinations of TCM diagnosis components). Total  of 217 different acupoints were used in the acupuncture treatments (1739) for  neuropathy. The acupoint yintang was used in 73.8% of the visits for neuropathy,  yet only in 26.5% (P < .001) of the treatments when patients had a TCM diagnosis  of qi deficiency, qi stagnation, and blood stagnation. Similarly, both  consistencies and variations were seen in acupoint selection with each targeted  symptom and its associated TCM diagnoses. Conclusions: TCM diagnosis was not  homogeneous among acupuncture treatments for a single referral symptom. In  contrast to most of the research on acupuncture for symptom control, there were  considerable variations in acupoint selection among treatments for the same  symptom in a clinical setting. Future research is needed to examine the clinical  relevance of a fixed intervention structure in acupuncture research and the value  of individualized acupuncture treatment.
C1 The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
   The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
   The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
   The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
   The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
   The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
   The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
   The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
   The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
   The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
   The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
NR 0
TC 0
SN 1552-695
EI 1534-735
J9 Integr Cancer Ther
PD JUN 9
PY 2020
VL 19
IS 
BP 1534735420928490
EP 1534735420928490
DI 10.1177/1534735420928490
PG 1
WC Acupuncture; Acupuncture Points; Acupuncture Therapy; Hot Flashes; Humans; Medicine, Chinese Traditional; Neoplasms; diagnosis
UT PubMed:32508209
PM 32508209
DA 2020-06-09
ER

PT J
AU Tang, QL
   Zhang, K
AF Tang, Qilin
   Zhang, Kai
TI Association of Acupuncture and Acupressure With Improved Cancer Pain
SO JAMA ONCOLOGY
LA English
DT Letter
ID breast-cancer
C1 [Tang, Qilin] Hebei Univ Chinese Med, Sch Basic Med Sci, 3 Xingyuan Rd, Shijiazhuang 050200, Hebei, Peoples R China.
   [Zhang, Kai] Tianjin Gong An Hosp, Dept Acupuncture & Moxibust, 78 Nanjing Rd, Tianjin 300042, Peoples R China.
C3 Hebei University of Chinese Medicine
RP Tang, QL (corresponding author), Hebei Univ Chinese Med, Sch Basic Med Sci, 3 Xingyuan Rd, Shijiazhuang 050200, Hebei, Peoples R China.; Zhang, K (corresponding author), Tianjin Gong An Hosp, Dept Acupuncture & Moxibust, 78 Nanjing Rd, Tianjin 300042, Peoples R China.
EM tqilin123@126.com; coolzhangkai@163.com
CR Chen L, 2017, BREAST, V33, P132, DOI 10.1016/j.breast.2017.03.015
   Farrar JT, 2000, CLIN J PAIN, V16, PS106, DOI 10.1097/00002508-200006001-00018
   He YH, 2020, JAMA ONCOL, V6, P271, DOI 10.1001/jamaoncol.2019.5233
   Hershman DL, 2018, JAMA-J AM MED ASSOC, V320, P167, DOI 10.1001/jama.2018.8907
   Nasser Mona, 2020, AM J PUBLIC HEALTH, V110, P753, DOI 10.2105/AJPH.2020.305609
NR 5
TC 3
Z9 4
U1 0
U2 7
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 2374-2437
EI 2374-2445
J9 JAMA ONCOL
JI JAMA Oncol.
PD JUN 15
PY 2020
VL 6
IS 6
BP 938
EP 938
DI 10.1001/jamaoncol.2020.0616
PG 1
WC Oncology
SC Oncology
GA MA6QT
UT WOS:000542037700033
PM 32324212
DA 2026-01-16
ER

